

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization.
International Bureau



(43) International Publication Date
12 July 2001 (12.07.2001)

PCT

(10) International Publication Number
WO 01/49721 A2

(51) International Patent Classification⁷: **C07K 14/195**,
C12N 15/31, G01N 33/68, C12Q 1/68, A61K 48/00,
38/16, G01N 33/50

Robert, E. [US/US]; 105 Corine Drive, Pennington,
NJ 08543 (US). **THANASSI, Jane, A.** [US/US]; 552
Woodhouse Avenue, Wallingford, CT 06492 (US).

(21) International Application Number: PCT/US00/35604

(74) Agents: **SHER, Audrey**; Bristol-Myers Squibb Company,
P.O. Box 4000, Lawrenceville-Princeton Road, Princeton,
NJ 08543-4000 et al. (US).

(22) International Filing Date:

29 December 2000 (29.12.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/174,089 30 December 1999 (30.12.1999) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): **BRIS-
TOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box
4000, Lawrenceville-Princeton Road, Princeton, NJ 08543-
4000 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DOUGHERTY,**
Thomas, J. [US/US]; 791 Ives Row, Cheshire, CT 06410
(US). **PUCCI, Michael, J.** [US/US]; 182 Stocking Brook
Road, Kensington, CT 06037 (US). **DOUGHERTY,**
Brian, A. [US/US]; 10 Rosemary Lane, Killingworth,
CT 06419 (US). **DAVISON, Daniel, B.** [US/US]; 37
Marks Court, Branford, CT 06405 (US). **BRUCCOLERI,**

Published:

— Without international search report and to be republished
upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/49721 A2

(54) Title: NOVEL BACTERIAL GENES AND PROTEINS THAT ARE ESSENTIAL FOR CELL VIABILITY AND THEIR
USES

(57) Abstract: The present invention provides novel bacterial genes and their encoded polypeptides thereof which are essential for
bacterial cell viability, and their uses.

NOVEL BACTERIAL GENES AND PROTEINS THAT ARE ESSENTIAL FOR CELL VIABILITY AND THEIR USES

5

10 Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

FIELD OF THE INVENTION

15

The present invention relates generally to nucleotide sequences, and polypeptides encoded by the sequences, that are essential for bacterial viability, and to methods of using the nucleotide and polypeptide sequences.

20 BACKGROUND OF THE INVENTION

Bacterial genera, such as *Streptococcus*, *Staphylococcus*, *Pseudomonas*, *Yersinia*, *Salmonella*, and *Enterobacter*, are the cause of numerous afflictions in humans and animals. Bacterial infection can lead to serious health conditions, including pneumonia, 25 osteomyelitis, meningitis, sinusitis, otitis, cystitis, and even food poisoning. Typically, these infections can be treated with standard antimicrobial agents such as antibiotics. However, the emergence of pathogenic bacterial strains that are resistant to antibiotics has risen alarmingly in the past two decades. This situation has created an urgent need for the development of new antimicrobial agents.

30

One strategy for developing new antimicrobial agents is to identify bacterial gene sequences that encode gene products that are essential for bacterial cell viability and

develop and/or identify agents which inhibit the function of the gene product. DNA sequencing technology has advanced from sequencing one gene at a time to sequencing entire genomes, the sum of all genes in an organism. With the recent arrival of bacterial genomic information, it is now possible to compare multiple bacterial genomes in an attempt to identify genes that encode conserved gene products. In this manner, one skilled in the art may identify a set of conserved bacterial genes, including a subset of genes that are essential for bacterial cell viability. The essential gene is then used as a starting point to develop therapeutic agents that inhibit or inactivate the product of the essential gene.

The availability of DNA sequence information for multiple microbial genomes is a recent development. The public release of the first complete genome, *Haemophilus influenzae* (Fleischmann, R.D., et al. 1995 *Science* 269:496-512), was followed in rapid succession by a number of public and private genome sequencing programs. Presently, some 20 completely sequenced bacterial genomes have been published, and over 100 other sequencing projects are underway (Blattner, F.R., et al., 1997 *Science* 277:1453-74; Ferretti, J.J., et al., 1997 *Adv Exp Med Biol* 418:961-963; Koonin, E.V., et al., 1996 *Methods Enzymol* 266:295-322). Analyses of these data indicate that approximately 46% of putative bacterial genes are of unknown function having no attributable function.

Others have pursued various strategies to identify bacterial genes that are essential for viability. These strategies include: identifying genes that are expressed by the bacteria when present in the infected host (Hensel, M., et al., 1995 *Science* 269:400-3), identifying essential genes by isolating temperature sensitive mutants (Schmid, M.B., et al., 1998 *Curr Opin Chem Biol* 2:529-34), and identifying genes in pathways known from prior physiological studies to be essential (Skarzynski, T. et al., 1996 *Structure* 1996 4:1465-74)

There continues to be a need to identify bacterial genes that encode gene products that are essential for cell viability, such as cell replication, growth, and survival. These genes and their encoded gene products can be used as a starting point towards identifying agents

that inhibit functions essential for cell viability, thereby causing bacterial cell stasis or death (e.g., antibacterial agents).

5 The present invention provides experimental identification of novel, conserved essential genes (*ceg*) from bacteria and their encoded protein products. The *ceg* genes are considered essential to cell viability because disruption of an endogenous *ceg* gene results in lethality of a bacterial cell (e.g., as determined by failure to recover viable chloramphenicol-resistant colonies, as described herein). Thus, the gene products encoded by these genes are potentially valuable targets for chemotherapeutic intervention
10 of bacterial infections.

The *ceg* nucleotide sequences of the invention were obtained by large-scale computational comparisons of multiple genome sequences to identify conserved protein coding regions, followed by gene disruption to identify *cegs*. The conservation of protein
15 sequences in many cases is believed to reflect the higher level conservation of common biochemical pathways essential for bacterial function and viability.

SUMMARY OF THE INVENTION

20 The acronyms "CEG" and "*ceg*" stand for Conserved Essential Gene. For convenience, the italicized term *ceg* refers herein to *ceg* nucleotide sequences. The capitalized term CEG refers herein to CEG polypeptide sequences.

Embodiments of the *ceg* nucleotide sequences and the CEG polypeptide sequences are
25 designated CFEs which stands for CEG For Expression. The CFEs are polypeptides resulting from expression of the *ceg* nucleotide sequence.

The present invention provides isolated nucleotide sequences of conserved essential genes from bacteria, designated *ceg*. The invention also provides recombinant nucleic
30 acid molecules including the *ceg* sequences of the invention, and methods of uses thereof. Examples of nucleic acid molecules having *ceg* sequences are described in SEQ ID

NOS.: 1-113. The invention further provides isolated polypeptides and recombinant polypeptides having the CEG sequences of the invention, and methods of uses thereof. Examples of polypeptides having CEG sequences are described in SEQ ID NOS.:114-226.

5

The *ceg* sequences of the present invention are DNA or RNA. Further, the invention includes nucleic acid molecules that are identical or nearly identical (e.g., similar) with the *ceg* sequences of the invention. The invention additionally provides polynucleotide sequences that hybridize under stringent conditions to the *ceg* sequences of the invention.

10 A further embodiment provides polynucleotide sequences which are complementary to the *ceg* sequences of the invention. Yet another embodiment provides *ceg* nucleic acid molecules that are labeled with a detectable marker. Another embodiment provides recombinant nucleic acid molecules, such as a vector or a fusion molecule, including the *ceg* sequences of the invention.

15

The present invention provides various *ceg* sequences, fragments thereof having essential gene activity, and related molecules such as antisense molecules, oligonucleotides, peptide nucleic acids (PNA), fragments, and portions thereof.

20 The present invention relates to the inclusion of the polynucleotides encoding CEG gene products, such as CEG polypeptides, in an expression vector which can be used to transform host cells or organisms. Such transgenic hosts are useful for the production of CEG gene products for the development of antibacterial agents such as antibiotics.

25 The invention further provides substantially purified CEG gene products, and uses thereof.

The invention also relates to pharmaceutical compositions comprising antisense molecules capable of disrupting expression of *ceg* sequences, agonists, antagonists or
30 inhibitors of CEG gene products, and antibodies reactive against the CEG polypeptides.

These compositions are useful for preventing the growth or survival of bacteria, for example, in the treatment of conditions associated with bacterial infections.

BRIEF DESCRIPTION OF THE FIGURES

5

Figure 1: A schematic representation of the gene disruption assay, as described in Example 3, *infra*. A) A recombinant vector undergoing homologous recombination with the host genome. B) The result of homologous recombination.

- 10 Figure 2: A schematic representation of the polarity test for operons, as described in Examples 2 and 3, *infra*. A) The recombinant vector undergoing homologous recombination with the host genome. B) Case 1: one possible result of homologous recombination; the downstream Gene B has an independent promoter. C) Case 2; another possible result of homologous recombination; the downstream Gene B does not have an independent promoter.
- 15

- Figure 3: Purification of 2CFE 75, as described in Example 6, *infra*. A) Fractionation profile of 2CFE 75 eluted from a Ni-NTA column. B) Gel electrophoresis of pooled fractions of CFE 75. C) Non-denaturing gel electrophoresis to determine oligo form of
- 20 2CFE 75.

Figure 4: Fractionation profile of 2CFE 3 eluted from a hydroxyapatite column, as described in Example 7, *infra*.

- 25 Figure 5: The biosynthesis pathway of Coenzyme A which starts with phosphorylation of pantothenate.

- Figure 6: Circular dichroism spectra of 2CFE 101 and 103, as described in Example 10, *infra*. A) Circular dichroism spectra of 2CFE 101 and 103 at 25 degrees C. B) Circular
- 30 dichroism thermal melt spectra of 2CFE 101 and 103 at a range of zero to 100 degrees C.

Figure 7: Circular dichroism spectra of aggregate and monomer pools of 2CFE 101 and 103, as described in Example 10, *infra*. A) Circular dichroism spectra of aggregate and monomer pools of 2CFE 101 and 103 at 25 degrees C. B) Circular dichroism thermal melt spectra of aggregate and monomer pools of 2CFE 101 and 103 at a range of zero to 100 degrees C.

5

Figure 8: Absorbance spectra of pantothenate-dependent production of ADP, as described in Example 10, *infra*.

Figure 9: The results of size exclusion chromatography and gel electrophoresis showing the oligomeric forms of 2CFE 21 and 39, as described in Example 11, *infra*. Lanes 1-6 contain 2CFE 21, lane 7 is a molecular weight marker, lanes 8-10 contain 2CFE 39.

Figure 10: Gel electrophoresis of a helicase reaction using 2CFE 21 and 39 and radiolabeled synthetic Holliday Junction template, as described in Example 11, *infra*. Lane 1 contains the synthetic Holliday Junction template; lane 2 contains the synthetic duplex; lane 3 contains a single-stranded template; lane 4 contains the helicase reaction using 2CFE 39; lane 5 contains the helicase reaction using 2CFE 21; lanes 6-8 contain the helicase reaction using 2CFE 39 and 21 at varying concentrations (e.g., 1, 2, and 3 μ M each); and lane 9 contains the helicase reaction using 2 μ M each 2CFE 39 and 21 in the presence of ethidium bromide.

20

Figure 11: A graph depicting the results of the helicase reaction which were monitored by measuring the unquenching of the Holliday Junction templates with time, as described in Example 11, *infra*.

25

Figure 12: Capillary electrophoresis results of 2CFE 8 with and without ssDNA, as described in Example 12, *infra*. A) Electropherogram of 2CFE 8 alone. B) Electropherogram of 2CFE 8 in the presence of a 32-nucleotide single-stranded oligomer.

Figure 13: Gel mobility shift assay of 2CFE 8, and 2CFE 8 in the presence of a single-stranded 32-mer, as described in Example 12, *infra*. A) An ethidium bromide-stained,

30

native, polyacrylamide gel containing 2CFE 8, and 2CFE 8 in the presence of a 32-mer. B) The same native, polyacrylamide gel stained with Coomassie.

Figure 14: The N-acetyl glucosamine pathway putatively mediated by 2CFE 3 and 2CFE 86, as described in Example 13, *infra*.

Figure 15: Capillary electrophoresis results of 2CFE 3 with and without putative substrates, as described in Example 13, *infra*. A) Electropherogram of 2CFE 3 with and without glucosamine-1-phosphate. B) Electropherogram of 2CFE 3 with and without D-glucose-1-phosphate. C) Electropherogram of 2CFE 3 alone, 2CFE 3 and glucose-1-phosphate, and 2CFE 3 and glucose-6-phosphate. D) Electropherogram of 2CFE 3 alone or in the presence of glucosamine-1-phosphate, glucosamine-6-phosphate, D-glucose, D(+) galactose, and α -D-glucose-1-phosphate.

Figure 16: Capillary electrophoresis results of FITC-derivitized 2CFE 3 polypeptide with and without D-glucosamine-6-phosphate (substrate) to produce the product D-glucosamine-1-phosphate, using laser-induced fluorescence, as described in Example 13, *infra*. Electropherogram of D-glucosamine-6-phosphate (putative substrate), 2CFE 3 reacted with D-glucosamine-6-phosphate, and the product glucosamine-1-phosphate.

Figure 17: Gel electrophoresis of 2CFE 86 eluted from an Ni-NTA column, as described in Example 13, *infra*.

Figure 18: HPLC analysis of a coupled reaction including 2CFE 3, 2CFE 86, and D-glucosamine-6-phosphate to produce the product, UDP-N-acetylglucosamine-1-phosphate (UDPAG), as described in Example 13, *infra*.

Figure 19: A fatty acid biosynthesis pathway.

Figure 20: Size exclusion chromatography to determine the molecular weight and oligomeric form of 2CFE 34, as described in Example 14, *infra*. Selected eluted samples were sized by gel electrophoresis.

- 5 Figure 21: Gel electrophoresis of 2CFE 41 eluted from a Ni-NTA column, as described in Example 15, *infra*.

Figure 22: Capillary electrophoresis results of 2CFE 40, 41, and 46, as described in Example 15, *infra*.

10

Figure 23: Depicts a schematic diagram of a ligand which binds 2CFE 34. The ligand is 2-phenyl-N-(3 carboxyl-4hydroxyphenyl) azabicyclo [4.3.0] nona-2, 8-diene.

- Figure 24: Depicts a schematic diagram of a ligand which binds 2CFE 43. The ligand is N-(3, 5-dinitrobenzyl)-7-trifluoromethyl benza diaza furanolactone.
- 15

Figure 25: Depicts a schematic diagram of a ligand which binds 2CFE 43. The ligand is 2-amino (N-para-methylphenyl sulfonamide)-3-phenylpropionic acid.

- 20 Figure 26: A nucleic acid sequence of 2CFE1 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 27: A nucleic acid sequence of 2CFE2 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25

Figure 28: A nucleic acid sequence of 2CFE3 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

- Figure 29: A nucleic acid sequence of 2CFE4 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.
- 30

Figure 30: A nucleic acid sequence of 2CFE5 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

- 5 Figure 31: A nucleic acid sequence of 2CFE6 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 32: A nucleic acid sequence of 2CFE7 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

10

Figure 33: A nucleic acid sequence of 2CFE8 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

- 15 Figure 34: A nucleic acid sequence of 2CFE9 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 35: A nucleic acid sequence of 2CFE10 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

- 20 Figure 36: A nucleic acid sequence of 2CFE11 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 37: A nucleic acid sequence of 2CFE12 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25

Figure 38: A nucleic acid sequence of 2CFE13 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

- 30 Figure 39: A nucleic acid sequence of 2CFE14 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 40: A nucleic acid sequence of 2CFE15 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

5 Figure 41: A nucleic acid sequence of 2CFE16 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 42: A nucleic acid sequence of 2CFE17 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

10 Figure 43: A nucleic acid sequence of 2CFE19 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 44: A nucleic acid sequence of 2CFE21 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

15

Figure 45: A nucleic acid sequence of 2CFE24 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

20 Figure 46: A nucleic acid sequence of 2CFE25 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 47: A nucleic acid sequence of 2CFE26 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25 Figure 48: A nucleic acid sequence of 2CFE27 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 49: A nucleic acid sequence of 2CFE28 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

30

Figure 50: A nucleic acid sequence of 2CFE29 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

5 Figure 51: A nucleic acid sequence of 2CFE30 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 52: A nucleic acid sequence of 2CFE31 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

10 Figure 53: A nucleic acid sequence of 2CFE32 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 54: A nucleic acid sequence of 2CFE33 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

15

Figure 55: A nucleic acid sequence of 2CFE34 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 56: A nucleic acid sequence of 2CFE35 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

20

Figure 57: A nucleic acid sequence of 2CFE36 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25 Figure 58: A nucleic acid sequence of 2CFE37 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 59: A nucleic acid sequence of 2CFE38 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

30

Figure 60: A nucleic acid sequence of 2CFE39 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

5 Figure 61: A nucleic acid sequence of 2CFE40 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 62: A nucleic acid sequence of 2CFE41 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

10 Figure 63: A nucleic acid sequence of 2CFE42 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

15 Figure 64: A nucleic acid sequence of 2CFE43 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 65: A nucleic acid sequence of 2CFE44 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

20 Figure 66: A nucleic acid sequence of 2CFE45 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 67: A nucleic acid sequence of 2CFE46 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25 Figure 68: A nucleic acid sequence of 2CFE47 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

30 Figure 69: A nucleic acid sequence of 2CFE48 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 70: A nucleic acid sequence of 2CFE49 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

5 Figure 71: A nucleic acid sequence of 2CFE50 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 72: A nucleic acid sequence of 2CFE51 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

10 Figure 73: A nucleic acid sequence of 2CFE52 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 74: A nucleic acid sequence of 2CFE53 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

15

Figure 75: A nucleic acid sequence of 2CFE54 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

20 Figure 76: A nucleic acid sequence of 2CFE55 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 77: A nucleic acid sequence of 2CFE56 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25 Figure 78: A nucleic acid sequence of 2CFE57 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 79: A nucleic acid sequence of 2CFE58 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

30

Figure 80: A nucleic acid sequence of 2CFE59 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

5 Figure 81: A nucleic acid sequence of 2CFE60 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 82: A nucleic acid sequence of 2CFE61 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

10 Figure 83: A nucleic acid sequence of 2CFE62 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 84: A nucleic acid sequence of 2CFE64 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

15 Figure 85: A nucleic acid sequence of 2CFE65 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 86: A nucleic acid sequence of 2CFE66 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

20 Figure 87: A nucleic acid sequence of 2CFE67 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25 Figure 88: A nucleic acid sequence of 2CFE68 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 89: A nucleic acid sequence of 2CFE69 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

30

Figure 90: A nucleic acid sequence of 2CFE70 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

5 Figure 91: A nucleic acid sequence of 2CFE71 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 92: A nucleic acid sequence of 2CFE72 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

10 Figure 93: A nucleic acid sequence of 2CFE75 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 94: A nucleic acid sequence of 2CFE76 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

15

Figure 95: A nucleic acid sequence of 2CFE78 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

20 Figure 96: A nucleic acid sequence of 2CFE79 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 97: A nucleic acid sequence of 2CFE80 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25 Figure 98: A nucleic acid sequence of 2CFE81 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 99: A nucleic acid sequence of 2CFE82 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

30

Figure 100: A nucleic acid sequence of 2CFE83 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

5 Figure 101: A nucleic acid sequence of 2CFE84 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 102: A nucleic acid sequence of 2CFE85 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

10 Figure 103: A nucleic acid sequence of 2CFE86 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 104: A nucleic acid sequence of 2CFE87 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

15

Figure 105: A nucleic acid sequence of 2CFE88 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

20 Figure 106: A nucleic acid sequence of 2CFE89 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 107: A nucleic acid sequence of 2CFE90 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25 Figure 108: A nucleic acid sequence of 2CFE91 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 109: A nucleic acid sequence of 2CFE92 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

30

Figure 110: A nucleic acid sequence of 2CFE94 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

5 Figure 111: A nucleic acid sequence of 2CFE95 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 112: A nucleic acid sequence of 2CFE96 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

10 Figure 113: A nucleic acid sequence of 2CFE97 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 114: A nucleic acid sequence of 2CFE99 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

15

Figure 115: A nucleic acid sequence of 2CFE101 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

20 Figure 116: A nucleic acid sequence of 2CFE102 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 117: A nucleic acid sequence of 2CFE103 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25 Figure 118: A nucleic acid sequence of 2CFE104 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 119: A nucleic acid sequence of 2CFE105 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

30

Figure 120: A nucleic acid sequence of 2CFE106 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

5 Figure 121: A nucleic acid sequence of 2CFE107 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 122: A nucleic acid sequence of 2CFE108 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

10 Figure 123: A nucleic acid sequence of 2CFE109 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 124: A nucleic acid sequence of 2CFE111 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

15

Figure 125: A nucleic acid sequence of 2CFE112 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 126: A nucleic acid sequence of 2CFE113 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

20

Figure 127: A nucleic acid sequence of 2CFE114 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

25 Figure 128: A nucleic acid sequence of 2CFE115 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 129: A nucleic acid sequence of 2CFE116 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

30

Figure 130: A nucleic acid sequence of 2CFE117 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000.

Figure 131: Schematic structures of alkyls which are ligands, for example, of 2CFE42.

5

DETAILED DESCRIPTION OF THE INVENTION

Definitions

10 All scientific and technical terms used in this application have meanings commonly used in the art unless otherwise specified. As used in this application, the following words or phrases have the meanings specified.

As used herein, a *ceg* nucleic acid molecule is said to be "isolated" when the nucleic acid
15 molecule is substantially separated from contaminant nucleic acid molecules that encode polypeptides other than CEGs. Additionally, isolated nucleic acid molecule refers to any RNA or DNA sequence obtained from a natural source, or constructed by recombinant methods, or synthesized. A skilled artisan can readily employ nucleic acid isolation procedures to obtain an isolated nucleic acid molecule having *ceg* sequences.

20

The term "*ceg*" includes all isolated forms of *ceg* nucleotide and CEG amino acid sequences disclosed herein. The *ceg* sequences encode gene products that have essential biological functions in bacterial cells, such as, for example, nucleotide biosynthesis, amino acid biosynthesis, DNA replication, RNA transcription, protein translation, DNA
25 recombination, DNA repair, biosynthesis of cofactors (e.g., Coenzyme A), biosynthesis of prosthetic groups, cellular processes (e.g., chaperones, cell division, and polypeptide secretion), energy metabolism (e.g., pentose phosphate pathway, glycolysis, gluconeogenesis), fatty acid biosynthesis, cell wall biosynthesis, and/or biosynthesis of purines, pyrimidines, nucleosides, and nucleotides. Accordingly, the gene products of the
30 *ceg* nucleotide sequences are required for viability of bacterial cells. The term "*ceg*" also includes variants having nucleotide sequence similarity to the disclosed *ceg* sequences,

including sequences isolated from various bacterial genera and species, allelic variants, mutant variants, and *ceg* variants that encode conservative and non-conservative amino acid substitutions. The present invention also provides for all *ceg* sequences generated by recombinant DNA technology, including complementary sequences, *ceg* sequences that
5 hybridize to the sequences of the invention at high stringency hybridization conditions, fusion genes comprising a *ceg* sequence, and codon usage variants.

The term "essential genes" refers to a nucleotide sequence that encodes a gene product having a function which is required for cell viability. The term "essential protein" refers
10 to a polypeptide that is encoded by an essential gene and has a function that is required for cell viability. Accordingly, a mutation that disrupts the function of the essential gene or essential proteins results in a loss of viability of cells harboring the mutation.

"Non-essential genes" or "non-essential proteins" refer to genomic information or the
15 protein(s) or RNAs encoded therefrom which, when disrupted by a mutation, do not result in a loss of viability of cells harboring said mutation under defined laboratory conditions.

As used herein, a nucleotide sequence is said to be "identical" to another reference
20 sequence when both nucleotide sequences are exactly alike.

As used herein, a nucleotide sequence is said to be "similar" to another reference sequence when a comparison of the two sequences shows that they have a low level of sequence differences. For example, two sequences are considered to be similar to each
25 other when the percentage of nucleotides that are shared between the two sequences is between about 70 % to 99.99% over the entire length of the two sequences.

As used herein an amino acid sequence is said to be "similar" to another reference sequence when a comparison of the two sequences shows that they have a low level of
30 sequence differences. For example, two sequences are considered to be similar to each

other when the percentage of amino acids that are shared between the two sequences may be between about 30% to 100% identity over the entire length of the two sequences.

5 As used herein, an "allele" or "allelic sequence" is an alternative form of the naturally-occurring *ceg* sequence. Alleles result from a mutation, that changes the nucleotide sequence, and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered.

10 "Substantially purified" as used herein means a specific isolated nucleic acid or protein, or fragment thereof, in which substantially all contaminants (i.e. substances that differ from said specific molecule) have been separated from said nucleic acid or protein.

15 In a host cell, an "endogenous" sequence as used herein means a nucleic acid sequence that is naturally-occurring and resides within the host genome.

In a host cell, an "exogenous" sequence as used herein means an isolated nucleic acid sequence that is introduced into the host cell, using any one of a variety of introduction methods, such as transfection, electroporation, cationic lipid or salt treatment methods.

20 "Knockout mutant" or "knockout mutation" as used herein refers to an *in vitro* engineered disruption of a region of endogenous chromosomal DNA (e.g., disruption of the genome), typically within a protein coding region. A knockout mutation can be generated by inserting an exogenous DNA sequence into the homologous endogenous sequence. A knockout mutation occurring in a protein coding region is expected to disrupt normal
25 expression of the protein coding region. This usually leads to loss of the function provided by the protein.

30 In order that the invention herein described may be more fully understood, the following description is set forth.

A) MOLECULES OF THE INVENTION

1.) CEG NUCLEIC ACID MOLECULES

- 5 The present invention provides isolated and recombinant *ceg* nucleic acid molecules and fragments thereof, and related molecules, such as sequences complementary to *ceg* sequences or a portion thereof, and those that hybridize to the nucleic acid molecules of the invention.
- 10 The *ceg* polynucleotide sequences, also referred to herein as nucleic acid molecules of the invention, are preferably in isolated form, including DNA, RNA, DNA/RNA hybrids, and related molecules, and fragments thereof. Specifically contemplated are genomic DNA, ribozymes, and antisense molecules, as well as nucleic acid molecules based on an alternative backbone or including alternative bases, whether derived from natural sources or
- 15 synthesized. Embodiments of particular *ceg* polynucleotide and amino acid sequences include, but are not limited to, the sequences described in Tables I and II (e.g., SEQ ID NOS:1-113, 114-226 and SEQ ID NOS: 227-339, 340-452, respectively). The *ceg* polynucleotide and amino acid sequences were designated *cfē* which stands for CEG For Expression.
- 20 Biological samples of the 2CFE nucleic acid molecules (e.g., SEQ ID NOS: 227-331) were deposited on December 20, 2000 with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209.

TABLE I

CFE Designation	SEQ. ID NO. (Nucleotide)	SEQ. ID NO. (Polypeptide)	POLARITY
CFE 1	1	114	+
CFE 2	2	115	-
CFE 3	3	116	-
CFE 4	4	117	+
CFE 5	5	118	-
CFE 6	6	119	+

TABLE I

CFE Designation	SEQ. ID NO. (Nucleotide)	SEQ. ID NO. (Polypeptide)	POLARITY
CFE 7	7	120	-
CFE 8	8	121	+
CFE 9	9	122	+
CFE 10	10	123	+
CFE 11	11	124	+
CFE 12	12	125	+
CFE 13	13	126	-
CFE 14	14	127	+
CFE 15	15	128	-
CFE 16	16	129	-
CFE 17	17	130	-
CFE 19	18	131	+
CFE 21	19	132	-
CFE 24	20	133	-
CFE 25	21	134	+
CFE 26	22	135	-
CFE 27	23	136	+
CFE 28	24	137	-
CFE 29	25	138	-
CFE 30	26	139	-
CFE 31	27	140	+
CFE 32	28	141	+
CFE 33	29	142	-
CFE 34	30	143	+
CFE 35	31	144	+
CFE 36	32	145	+
CFE 37	33	146	-
CFE 38	34	147	+
CFE 39	35	148	-
CFE 40	36	149	-
CFE 41	37	150	-
CFE 42	38	151	-
CFE 43	39	152	-
CFE 44	40	153	+
CFE 45	41	154	-
CFE 46	42	155	-

TABLE I

CFE Designation	SEQ. ID NO. (Nucleotide)	SEQ. ID NO. (Polypeptide)	POLARITY
CFE 47	43	156	-
CFE 48	44	157	
CFE 49	45	158	+
CFE 50	46	159	+
CFE 51	47	160	+
CFE 52	48	161	-
CFE 53	49	162	+
CFE 54	50	163	+
CFE 55	51	164	+
CFE 56	52	165	+
CFE 57	53	166	+
CFE 58	54	167	+
CFE 59	55	168	-
CFE 60	56	169	+
CFE 61	57	170	+
CFE 62	58	171	
CFE 63	59	172	
CFE 64	60	173	+
CFE 65	61	174	+
CFE 66	62	175	+
CFE 67	63	176	+
CFE 68	64	177	-
CFE 69	65	178	+
CFE 70	66	179	+
CFE 71	67	180	-
CFE 72	68	181	-
CFE 73	69	182	+
CFE 74	70	183	-
CFE 75	71	184	-
CFE 76	72	185	+
CFE 77	73	186	
CFE 78	74	187	+
CFE 79	75	188	-
CFE 80	76	189	-
CFE 81	77	190	+
CFE 82	78	191	

TABLE I

CFE Designation	SEQ. ID NO. (Nucleotide)	SEQ. ID NO. (Polypeptide)	POLARITY
CFE 83	79	192	-
CFE 84	80	193	-
CFE 85	81	194	-
CFE 86	82	195	-
CFE 87	83	196	-
CFE 88	84	197	-
CFE 89	85	198	+
CFE 90	86	199	+
CFE 91	87	200	-
CFE 92	88	201	-
CFE 93	89	202	+
CFE 94	90	203	+
CFE 95	91	204	+
CFE 96	92	205	+
CFE 97	93	206	-
CFE 98	94	207	-
CFE 99	95	208	+
CFE 100	96	209	-
CFE 101	97	210	-
CFE 102	98	211	+
CFE 103	99	212	-
CFE 104	100	213	+
CFE 105	101	214	-
CFE 106	102	215	-
CFE 107	103	216	-
CFE 108	104	217	+
CFE 109	105	218	-
CFE110	106	219	-
CFE 111	107	220	-
CFE 112	108	221	-
CFE 113	109	222	-
CFE 114	110	223	-
CFE 115	111	224	-
CFE 116	112	225	-
CFE 117	113	226	-

TABLE II

CFE Designation	SEQ. ID NO. (Nucleotide)	SEQ. ID NO. (Polypeptide)	FIGURE
2CFE 1			26
2CFE 2			27
2CFE 3			28
2CFE 4			29
2CFE 5			30
2CFE 6			31
2CFE 7			32
2CFE 8			33
2CFE 9			34
2CFE 10			35
2CFE 11			36
2CFE 12			37
2CFE 13			38
2CFE 14			39
2CFE 15			40
2CFE 16			41
2CFE 17			42
2CFE 19			43
2CFE 21			44
2CFE 24			45
2CFE 25			46
2CFE 26			47
2CFE 27			48
2CFE 28			49
2CFE 29			50
2CFE 30			51
2CFE 31			52
2CFE 32			53
2CFE 33			54
2CFE 34			55
2CFE 35			56
2CFE 36			57
2CFE 37			58
2CFE 38			59
2CFE 39			60

CFE Designation	SEQ. ID NO. (Nucleotide)	SEQ. ID NO. (Polypeptide)	FIGURE
2CFE 40			61
2CFE 41			62
2CFE 42			63
2CFE 43			64
2CFE 44			65
2CFE 45			66
2CFE 46			67
2CFE 47			68
2CFE 48			69
2CFE 49			70
2CFE 50			71
2CFE 51			72
2CFE 52			73
2CFE 53			74
2CFE 54			75
2CFE 55			76
2CFE 56			77
2CFE 57			78
2CFE 58			79
2CFE 59			80
2CFE 60			81
2CFE 61			82
2CFE 62			83
2CFE 64			84
2CFE 65			85
2CFE 66			86
2CFE 67			87
2CFE 68			88
2CFE 69			89
2CFE 70			90
2CFE 71			91
2CFE 72			92
2CFE 75			93
2CFE 76			94
2CFE 78			95
2CFE 79			96
2CFE 80			97

CFE Designation	SEQ. ID NO. (Nucleotide)	SEQ. ID NO. (Polypeptide)	FIGURE
2CFE 81			98
2CFE 82			99
2CFE 83			100
2CFE 84			101
2CFE 85			102
2CFE 86			103
2CFE 87			104
2CFE 88			105
2CFE 89			106
2CFE 90			107
2CFE 91			108
2CFE 92			109
2CFE 94			110
2CFE 95			111
2CFE 96			112
2CFE 97			113
2CFE 99			114
2CFE 101			115
2CFE 102			116
2CFE 103			117
2CFE 104			118
2CFE 105			119
2CFE 106			120
2CFE 107			121
2CFE 108			122
2CFE 109			123
2CFE 111			124
2CFE 112			125
2CFE 113			126
2CFE 114			127
2CFE 115			128
2CFE 116			129
2CFE 117			130

a) Variant *ceg* Nucleotide Sequences

5 The present invention also provides nucleic acid molecules having a nucleotide sequence substantially identical or similar to the *ceg* sequences (SEQ ID NOS: 1-113, 227-331) disclosed herein.

The present invention provides nucleotide sequences which are similar to SEQ ID NOS:1-113 and/or SEQ ID NOS:227-331. The present invention provides nucleotide
10 sequences which vary from SEQ ID NOS:1-113 or 227-331 by a range of about 1% to about 70%.

The present invention encompasses variations in polynucleotide sequences resulting from mutations and/or from transfer of genetic material from one cell to another (e.g.,
15 horizontal gene transfer or horizontal gene exchange).

The present invention also provides for variants of the polynucleotide *ceg* sequences disclosed herein, including variants isolated from naturally-occurring sources, those generated by recombinant DNA technology or other in vitro synthesis methodologies
20 (e.g., PCR). The variant polynucleotide sequences of the invention encode polypeptides that exhibit the biological activity of naturally-occurring CEG polypeptides, such as activity required for bacterial cell viability.

In general, for example, a variant of *ceg* polynucleotide sequences may encode a
25 polypeptide that differs by one or more amino acid substitutions. The variant may have conservative changes, wherein a substituted amino acid has similar structural or chemical properties, eg, replacement of leucine with isoleucine.

A polynucleotide sequence can encode conservative amino acid substitutions without
30 altering either the conformation or the function of the polypeptide. Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these

hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can alanine (A) and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK's of these two amino acid residues are not significant. Still other changes can be considered "conservative" in particular environments.

A variant may also have nonconservative changes, eg, replacement of a glycine with a tryptophan. Other variations may also include amino acid deletions or insertions, or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

Another type of *ceg* sequence variant includes naturally-occurring allelic variants of *ceg* which share significant similarity (e.g., between about 30- 99%) to the disclosed CEG polypeptide sequence. Allelic variants of the *ceg* sequences can encode conservative or non-conservative amino acid substitutions of the CEG polypeptide sequence herein described.

An example of allelic variants of *ceg* are mutant alleles of *ceg* polynucleotide sequences that encode a polypeptide having one or more changes in the polypeptide sequence, such as amino acid substitutions, deletions, insertions, frame shifts, or truncations. The mutant alleles of *ceg* may or may not encode a CEG polypeptide having the same biological functions as wild-type CEG proteins.

Variations in the bacterial genomic sequences can also arise from transfer of genetic material to another bacterial cell. The transfer of gene sequences can occur intraspecies or interspecies. Gene transfer can occur between bacterial cells which are members of the same or different populations. A population includes, but is not limited to, a serotype isolate, a clinical isolate, a naturally-occurring isolate, a strain, and a species. The transfer of genetic material can occur between cells within a population; for example transfer between serotype A to serotype A, or between *S. pneumoniae* and *S. pneumoniae*. The transfer of genetic material can occur between cells of different populations; for example, between serotype A to serotype B or *S. pneumoniae* and *S. mutans*.

Gene transfer can give rise to mutant or polymorphic variant genes sequences. In rare cases, gene transfer introduces new gene sequences that confer a new phenotype, such as antibiotic resistance. The transfer of genetic material includes transfer of large regions of genomic sequences which include partial gene sequences, whole single gene sequences, or multiple gene sequences. This mode of transfer can give rise to replacement of native whole gene sequences or introduction of new sequences in the recipient cell. This mode of transfer gives rise to mosaic gene sequences in the recipient cell.

The variation of genomic sequences resulting from gene transfer can be examined using molecular techniques, including: multilocus enzyme electrophoresis (Selander, R. K., et al., 1986 *Appl. Environ. Microbiol.* 51:837-884); and restriction endonuclease cleavage electrophoretic profiling (Coffey, T. J., et al., 1991 *Mol. Microbio.* 5:2255-2260); pulse-field gel electrophoresis fingerprinting (Bygraves, J. A. and Maiden, M. C. J. 1992 *J. Gen. Microbiol.* 138:523-531); and ribotyping (Stull, T. L., et al., 1988 *J. Infect. Dis.* 157:280-286). The degree of variation can vary greatly, and ranges from little or no variation as exemplified by gene sequences of *E. coli* (Caugant, d. A., et al., 1981 *Genetics* 98:467-490; Whittam, T. S., et al., 1983 *Mol. Biol. Evol.* 1:67-83; Souza, V., et al., 1992 *Proc. Natl. Acad. Sci. USA* 89:8389-8393) and *Salmonella* (Selander, R. K., et al., 1990 *Infect. Immun.* 58:2262-2275; Selander, R.K. and Smith, N. H. 1990 *Rev. Med. Microbiol.* 1:219-228; Smith, J. M., et al., 1993 *Proc. Natl. Acad. Sci. USA* 90:4384-

4388), to extensive gene transfer in *Neisseria gonorrhoeae* (Smith, J. M., et al., 1993 *Proc. Natl. Acad. Sci. USA* 90:4384-4388).

Gene transfer can be examined between various isolates of a particular microbial species which are antibiotic-sensitive or antibiotic-resistant (Coffey, T. J., et al., 1991 *Molec. Microbiol.* 5:2255-2260). Molecular biology techniques can be utilized to study the degree of transfer between populations, such as, for example, the degree of gene transfer between serotypes, isolates, strains, or species. The degree of transfer can be examined by comparing, for example, the penicillin binding proteins and numerous different loci which encode metabolic enzymes or capsular biosynthesis enzymes.

For example, intra-species, inter-serotype, gene transfer is possible (Coffey, T. J., et al., 1991 *supra*). Additionally, intraspecies gene transfer in *S. pneumoniae* (Coffey, T. J., et al., 1998 *Mol. Microbiol.* 27:73-83), *Vibrio cholerae* (Bik, E. M., et al., 1995 *EMBO J.* 14:209-216), and *Haemophilus influenzae* (Kroll, J. S. and Moxon, E. R. 1990 *J. Bacteriol.* 172: 1374-1379) are possible.

Interspecies gene transfer is also possible (Dowson, C. G., et al., 1989 *Proc. Natl. Acad. Sci. USA* 86:8842-8846; Laibl, G., et al., 1991 *Mol. Microbiol.* 5:1993-2002; Bourgoin, F., et al., 1999 *Gene* 233:151-161).

Variant gene sequences arising from gene transfer can be continually generated in transformable bacteria (e.g., transformation competent), such as *S. pneumoniae*. For example, the worldwide spread of varying degrees of antibiotic resistance has been documented and reviewed (Dowson, C. G., et al., 1994 *Trends Microbiol.* 2:361-366; Spratt, B. G. in *Bacterial Cell Wall*, eds Ghuyssen J-M. and Hakenbeck, R. 1994 pp. 517-534; and reviewed in Maiden, M. C. J. 1998 *Clinic. Infect. Dis.* 27 (Supplement 1) S12-S20). For example, variant gene sequence arising from gene transfer can be tracked using a marker gene such as the gene which encodes the penicillin binding protein (Barcus, V. A., et al., 1995 *FEMS Microbiol. Lett.* 126:299-303). At the nucleotide level, gene sequences encoding the penicillin binding proteins in susceptible and resistant

strains differ by about 14% to 23% (Hakenbeck, R. 1995 *Biochem. Pharmacol.* 50:1121-1127; Spratt, B. G. in *Bacterial Cell Wall*, eds Ghuysen J-M. and Hakenbeck, R. 1994 pp. 517-534; Spratt, B. G., et al., 1991 *Neisseria meningitidis* and *Streptococcus pneumoniae* eds. Camisi, J., et al., pp. 73-83; Coffey, T. J., et al., 1995 *Micro. Drug Resist.* 1:29-34).

5

The *ceg* nucleotide sequences can be isolated from various species of *Streptococcus* including *Streptococcus pneumoniae*. Additionally, the *ceg* sequences can be isolated from other Streptococcal species, including *S. mutans*, *S. pyogenes*, and *S. thermophila*. The *ceg* polynucleotide sequences can also be isolated from strains of other bacterial genera including, but not limited to, *Streptococcus*, *Escherichia*, *Bacillus*, *Pseudomonas*, *Yersinia*, *Salmonella*, and *Haemophilus*.

The present invention additionally provides isolated codon-usage variants that differ from the disclosed *ceg* nucleotide sequences, yet do not alter the predicted CEG polypeptide sequence or function. The codon-usage variants may be generated by recombinant DNA technology. Codons may be selected to optimize the level of production of the *ceg* transcript or CEG polypeptide in a particular prokaryotic or eukaryotic expression host, in accordance with the frequency of codon utilized by the host cell. Alternative reasons for altering the nucleotide sequence encoding a CEG polypeptide include the production of RNA transcripts having more desirable properties, such as an extended half-life or increased stability. A multitude of variant *ceg* nucleotide sequences that encode the respective CEG polypeptide may be isolated, as a result of the degeneracy of the genetic code. Accordingly, the present invention contemplates selecting every possible triplet codon to generate every possible combination of nucleotide sequences that encode the disclosed CEG polypeptides. This particular embodiment provides isolated nucleotide sequences that vary from the sequences as described in SEQ ID NOs.: 1-113 or 227-331, such that each variant nucleotide sequence encodes a polypeptide having sequence identity with the amino acid sequences, as described in SEQ ID NOs.: 114-226 or 332-436, respectively.

30

b) Complementary Sequences

5 The present invention includes polynucleotide sequences that are complementary to the sequences disclosed herein. The term "complementary" as used herein refers to the capacity of purine and/or pyrimidine nucleotides to associate through hydrogen bonding to form double stranded nucleic acid molecules. The following base pairs are related by complementarity: guanine and cytosine; adenine and thymine; and adenine and uracil. Complementary applies to all base pairs comprising at least two single-stranded nucleic
10 acid molecules.

c) Sequences Capable of Hybridizing

Another embodiment provides nucleic acid molecules that will hybridize to *ceg*
15 sequences under hybridization conditions. It is readily apparent to one skilled in the art that the stringency of the hybridization condition selected will depend upon the characteristics of the nucleic acid molecule to be hybridized, such as, the length, the degree of complementarity (e.g., exact or non-exact complementarity), the percent A/T content, and the objective of the hybridization experiment.

20 The hybridization procedure may be performed in low stringency hybridization conditions. Low stringency hybridization conditions will permit hybridization between two nucleic acid molecules that differ from exact complementarity by about 25% to 70%. Hybridization under standard high stringency conditions will occur between two
25 complementary nucleic acid molecules (e.g., 100% exact complementarity) or two complementary nucleic acid molecules that differ from exact complementarity by about 1% to about 70%.

The high stringency hybridization conditions that disfavor non-homologous base pairing
30 are well known in the art. Typically, high stringency hybridization conditions, includes but is not limited to, hybridizing at 50 °C to 65 °C in 5X SSPE, and washing at 50 °C to

65 °C in 0.5X SSPE. Typically, low stringency conditions, includes but is not limited to, hybridizing at 35 °C to 37 °C in 5X SSPE and 40% to 45% formamide and washing at 42 °C in 1-2X SSPE. The conditions and formulas for high stringency hybridization methods are well known in the art and can be readily obtained in *Molecular Cloning: A Laboratory Manual* (2nd edition, Sambrook, Fritsch, and Maniatis 1989, Cold Spring Harbor Press) or in *Short Protocols in Molecular Biology* (Ausubel, F. M., et al., 1989, John Wiley & Sons).

d) Fragments of *ceg* Sequences

10

The invention further provides nucleic acid molecules having fragments of the *ceg* sequences, such as a portion of the *ceg* sequence (e.g., SEQ ID NOS:1-113, 227-331) disclosed herein. The size of the fragment will be determined by its intended use. For example, the length of the fragment to be used as a nucleic acid probe or PCR primer is
15 chosen to obtain a relatively small number of false positives during probing or priming. Alternatively, a fragment of the *ceg* sequence may be used to construct a recombinant fusion gene having a *ceg* sequence fused to a non-*ceg* sequence.

The nucleic acid molecules, fragments thereof, and probes and primers of the present
20 invention are useful for a variety of molecular biology techniques including, for example, hybridization screens of libraries, or detection and quantification of mRNA transcripts as a means for analysis of gene transcription and/or expression. Preferably, the probes and primers are DNA. A probe or primer length of at least 15 base pairs is suggested by theoretical and practical considerations (Wallace, B. and Miyada, G. 1987
25 "Oligonucleotide Probes for the Screening of Recombinant DNA Libraries" in: *Methods in Enzymology*, 152:432-442, Academic Press). Other lengths of fragments, probes, or primers are possible and routine to determine.

The probes and primers of this invention can be prepared by methods well known to
30 those skilled in the art (Sambrook, et al. *supra*). In a preferred embodiment the probes

and primers are synthesized by chemical synthesis methods (ed: Gait, M. J. 1984 *Oligonucleotide Synthesis*, IRL Press, Oxford, England).

5 One embodiment of the present invention provides nucleic acid primers that are complementary to *ceg* sequences, which allow the specific amplification of nucleic acid molecules of the invention or of any specific parts thereof. Another embodiment provides nucleic acid probes that are complementary for selectively or specifically hybridizing to the *ceg* sequences or to any part thereof.

10 **e) Derivative Nucleic Acid Molecules**

The nucleic acid molecules of the invention include peptide nucleic acids (PNAs), or derivative molecules such as phosphorothioate, phosphotriester, phosphoramidate, and methylphosphonate, that specifically bind to single-stranded DNA or RNA in a base pair-
15 dependent manner (Zamecnik, P. C., et al., 1978 *Proc. Natl. Acad. Sci.* 75:280284; Goodchild, P. C., et al., 1986 *Proc. Natl. Acad. Sci.* 83:4143-4146).

PNA molecules comprise a nucleic acid oligomer to which an amino acid residue, such as lysine, and an amino group have been added. These small molecules, also designated
20 anti-gene agents, stop transcript elongation by binding to their complementary (template) strand of nucleic acid (Nielsen, P. E., et al., 1993 *Anticancer Drug Des* 8:53-63). For example, reviews of methods for synthesis of DNA, RNA, and their analogues can be found in: *Oligonucleotides and Analogues*, eds. F. Eckstein, 1991, IRL Press, New York; *Oligonucleotide Synthesis*, ed. M. J. Gait, 1984, IRL Press, Oxford, England.
25 Additionally, methods for antisense RNA technology are described in U. S. patents 5,194,428 and 5,110,802. A skilled artisan can readily obtain these classes of nucleic acid molecules using the herein described *ceg* polynucleotide sequences, see for example *Innovative and Perspectives in Solid Phase Synthesis* (1992) Egholm, et al. pp 325-328 or U. S. Patent No. 5,539,082.

30

f) RNA Molecules

5 The present invention provides RNA molecules that encode the predicted *ceg* gene products. In particular, the RNA molecules of the invention may be isolated full-length or partial mRNA molecules or RNA oligomers that encode CEG gene products. The RNA molecules of the invention include the nucleotide sequences encoding all or portions of CEGs.

10 The RNA molecules of the invention also include antisense RNA molecules, peptide nucleic acids (PNAs), or non-nucleic acid molecules such as phosphorothioate derivatives, that specifically bind to the sense strand of DNA or RNA in a base pair-dependent manner. A skilled artisan can readily obtain these classes of nucleic acid molecules using the herein described *ceg* sequences.

15

g) Labeled Nucleic Acid Molecules

The nucleic acid molecules having *ceg* sequences can be labeled with a detectable marker. Examples of a detectable marker include, but are not limited to, a radioisotope, a
20 fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator or an enzyme. Technologies for generating labeled DNA and RNA probes are well known in the art (See e.g. Sambrook et al., *supra*).

2.) RECOMBINANT NUCLEIC ACID MOLECULES

25

Also provided are recombinant nucleic acid molecules, such as recombinant DNA molecules (rDNAs) that comprise *ceg* sequences or fragments thereof. As used herein, a recombinant DNA molecule is a DNA molecule that has been subjected to molecular manipulation *in vitro*. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook
30 et al., *Molecular Cloning* (1989), *supra*.

a) Vectors

The nucleic acid molecules of the invention may be recombinant molecules each comprising the sequence, or portions thereof, of a *ceg* sequence linked to a non-*ceg* sequence. For example, the *ceg* sequence may be fused operatively to a vector to generate a recombinant molecule. The term vector includes, but is not limited to, plasmids, cosmids, and phagemids. A preferred vector includes an autonomously replicating vector comprising a replicon that directs the replication of the rDNA within the appropriate host cell. The preferred vectors can also include an expression control element, such as a promoter sequence, which enables transcription of the inserted *ceg* sequences and can be used for regulating the expression (e.g., transcription and/or translation) of an operably linked *ceg* sequence in an appropriate host cell such as *Escherichia coli*. Expression control elements are known in the art and include, but are not limited to, inducible promoters, constitutive promoters, secretion signals, enhancers, transcription terminators, and other transcriptional regulatory elements. Other expression control elements that are involved in translation are known in the art, and include the Shine-Dalgarno sequence, and initiation and termination codons. The preferred vector also includes at least one selectable marker gene that encodes a gene product that confers drug resistance such as resistance to ampicillin or tetracycline. The vector also comprises multiple endonuclease restriction sites that enable convenient insertion of exogenous DNA sequences.

The preferred vectors for generating *ceg* transcripts and/or the encoded CEG polypeptides are expression vectors which are compatible with prokaryotic host cells. Prokaryotic cell expression vectors are well known in the art and are available from several commercial sources. For example, a pET vectors (e.g., pET-21, Novagen Corp.) may be used to express CEG polypeptides in bacterial host cells.

b) Recombinant Vectors for Integration

5 The present invention provides recombinant vectors that may be used to integrate exogenously provided sequences into the genome of a host cell. The recombinant integration vectors of the present invention include a gene that encodes a selectable marker and *ceg* sequences; or fragments thereof. The integration vectors are used to integrate the *ceg* sequence into a target gene sequence that resides within the bacterial host genome (e.g., endogenous sequence), thereby disrupting the function of the target gene sequence within the bacterial cells. These integration vectors may be used in a gene
10 disruption assay to screen candidate *ceg* nucleotide sequences, in order to identify the candidate sequences that encode a gene product that is required for bacterial cell viability.

Accordingly, these recombinant integration vectors include candidate *ceg* sequences that
15 will be screened to determine if the candidate *ceg* sequences encode a gene product that is required for cell viability. The candidate *ceg* sequence that is included as part of the recombinant integration vector is the "exogenous" *ceg* sequence that is employed as the "disrupting" sequence in a gene disruption assay. The *ceg* sequence that resides within the host genome is the "endogenous" or "target" *ceg* sequence.

20 The integration event rarely occurs, for example, by non-homologous recombination in which a recombinant vector, that includes the exogenous *ceg* sequence, inserts the exogenous *ceg* sequence into a random location within the host genome. In a more preferred embodiment, the integration event inserts the exogenous *ceg* sequence into a
25 specific target site within the host genome. The targeted integration event can involve homologous recombination in which the integration vector, that includes the exogenous *ceg* sequence, inserts the exogenous *ceg* sequence into its homologous target *ceg* sequence that resides within the host's genome (e.g., the endogenous *ceg* sequence) (Figure 1). Further, the exogenous *ceg* sequence can be used as a disrupting sequence
30 whereby the homologous recombination event integrates the exogenous *ceg* sequence into the endogenous target *ceg* sequence resulting in disruption of the function of the

endogenous *ceg* sequence. For example, disrupting the function of the endogenous *ceg* sequence may result in the loss of bacterial cell viability.

5 An example of a recombinant vector that can be used as an integration vector in *S. pneumoniae* is the pEVP-3 vector (Jean-Pierre Claverys, et al. 1995 *Gene* 164: 123-128). The pEVP-3 vector integrates an exogenous sequence by homologous recombination involving a Campbell-type event (S. Adhya and A. Campbell 1970 *J. Mol. Biol.* 50:481-490). The pEVP-3 vector includes a replicon that functions only in gram-negative bacteria, such as *E. coli*. Therefore, the pEVP-3 vector cannot replicate in *S.*
10 *pneumoniae*. This vector also contains multiple cloning sites, and confers resistance to chloramphenicol in both a gram-negative and gram-positive bacteria, such as *S. pneumoniae*.

c) Fusion Gene Sequences

15

A fusion *ceg* gene is another example of a recombinant molecule of the invention. A fusion gene includes a *ceg* sequence operatively fused (e.g., linked) to a non-*ceg* sequence such as, for example, a tag sequence to facilitate isolation and/or purification of the expressed CEG gene product (Kroll, D.J., et al., 1993 *DNA Cell Biol* 12:441-53).

20

Alternatively, a recombinant fusion molecule has a *ceg* sequence of the invention fused to a *ceg* sequence isolated from a different microbial source. For example, the disclosed *ceg* sequences isolated from *S. pneumoniae* can be fused to a *ceg* sequence isolated from a different bacterial species.

25

3.) CEG PROTEINS AND POLYPEPTIDE MOLECULES

The invention additionally provides CEG proteins and peptide fragments thereof that are isolated or substantially purified. Embodiments of particular CEG amino acid sequences
30 are disclosed in Tables I and II (SEQ ID NOS:114-226 and SEQ ID NOS:332-436, respectively).

The present invention also includes polypeptides having sequence variations from the predicted CEG polypeptide sequences disclosed herein, including mutant variants, conservative substitution variants, and similar CEG polypeptides from other prokaryotic organisms. For convenience, such proteins are referred to herein as "CEG proteins",
5 "CEG polypeptides", or "proteins of the invention".

As used herein, CEG protein refers to a polypeptide having amino acid sequence identity or similarity to any one of the predicted amino acid sequences, as provided in SEQ ID NO.:
10 114-226 or 332-436. The variant CEG polypeptides can be allelic forms of CEG, such as mutant forms of CEG polypeptides. The present invention also provides conservative substitution-mutants of the CEG proteins that maintain functional activity of wild-type CEG (e.g., the CEG polypeptide is required for bacterial cell viability).

15 The CEG protein may be isolated from any source whether natural, synthetic, semi-synthetic, or recombinant. As used herein, "natural" refers to a polypeptide which is found in nature. Accordingly, the CEG proteins may be isolated from a prokaryotic organism, such as a bacterial strain including, but not limited to, *Streptococcus*, *Escherichia*, *Bacillus*, *Pseudomonas*, *Yersinia*, *Salmonella*, and *Streptomyces*. The CEG
20 proteins of the invention, and fragments thereof, can also be generated by recombinant methods or chemical synthesis methods.

The CEG polypeptides of the invention are essential for the viability of a bacterial cell. Further, the CEG polypeptides can exhibit at least any one of the following functions: a
25 pantothenate kinase, a Holliday Junction branch migration protein, a single stranded DNA binding protein, a phosphoglucosamine mutase, an acetyltransferase, an uridylyltransferase, a malonyl CoenzymeA:ACP transacylase, a 3-oxoacyl-ACP synthase II, a 3-oxoacyl-ACP reductase, a phosphomethylpyrimidine (HMP-P) kinase, a GTP binding protein, a ATP binding protein, or a 4-aminoimidazole carboxylase. Putative
30 functions can include, but are not limited to, sugar transferase, teichoic acid biosynthesis, ribosome recycling factor, response regulator, nicotinate phosphoribosyltransferase,

nitropropane dioxygenase, (3R)-hydroxymyristol acyl carrier protein dehydrase, sugar dehydrogenase, murein biosynthesis, cobalamin biosynthesis, ABC transporter, tRNA modification enzyme, arylsulfatase, 16S processing enzyme, tRNA methyl transferase, elongation factor P, signal recognition particle, protein export, undecaprenol kinase, SRP docking domain, diacyl glycerol kinase, dihydopicillinate reductase, HU-DNA binding protein, thiamine biosynthase, GreA transcription elongation factor, dTDP-L-rhamnose synthase, ATP-binding motif, ribose-5-p-3-epimerase-like activity, GTP pyrophosphokinase, acetyl-CoA carboxylase, O-sialoglycoprotein endopeptidase, glucosamine-fructose-6-phosphate aminotransferase, Strpn adhesion-associated ABC-permease, GTP pyrophosphokinase RelA, IMP dehydrogenase, DNA gyrase subunit B, acetyl-CoA carboxylase subunit AccD, phosphoglycerol kinase, acetyl-CoA carboxylase carbonyl transferase, phosphopanthetheine adenylyltransferase, oligopeptide transport permease subunit, translocation protein, perM permease, DNA pol III gamma and tau subunits, DNA pol III delta subunit, signal peptidase I, acetyl-coA carboxylase biotin carboxyl carrier protein, protein chain release factor-1, replicative DNA helicase, topoisomerase, pentapeptide-transferase, elongation factor G, spore coat polysaccharide biosynthesis protein C, protein release factor B, DNA polymerase III alpha subunit, phosphoprotein phosphatase, chaparonin, UDP-N-acetylmuramoylalanyl-D-glutamate-2, 6-diaminopimelate ligase, techuronic acid biosynthesis, UDP-glucose lipid carrier transferase, transcription termination factor, chromosome segregation factor, amino acid biosynthesis, HMG-CoA reductase, hypoxanthine-guanine phosphoribosyltransferase.


a) MODULATORS OF CEG POLYPEPTIDES

25 The invention provides compounds that modulate (e.g., activate or inhibit) the function of a CEG polypeptide. Such compounds can provide lead-compounds for developing drugs for diagnosing and/or treating conditions associated with bacterial infections. The modulator is a compound that may alter the function of the CEG polypeptide, such as activating or inhibiting the function of a CEG polypeptide. For example, the compound
30 can act as agonist, antagonist, partial agonist, partial antagonist, cytotoxic agents,


inhibitors of cell proliferation, and cell proliferation-promoting agents. The activity of the compound may be known, unknown or partially known.

5 Suitable ligands include, but are not limited to, diazalactones, *N*-protected amino acid, azabicyclodiene, and alkaloids.

An example of a diazalactone is:




An example of a *N*-protected amino acid is:







10

An example of an azabicyclodiene is:



Examples of alkaloids are:



5 B) METHODS FOR MAKING THE CEG PROTEINS AND POLYPEPTIDES

Recombinant methods are preferred if a high yield is desired. Recombinant methods involve expressing the cloned gene in a suitable host cell. For example, a host cell is introduced with an expression vector having the CEG sequence, then the host cell is cultured under conditions that permit *in vivo* production of the CEG protein. The recombinant vector can integrate the CEG sequence into the host genome. Alternatively, the CEG sequence can be maintained extra-chromosomally, as part of an autonomously replicating vector.

15 1. HOST-VECTOR SYSTEMS

The invention further provides a host-vector system comprising the vector, plasmid, phagemid, or cosmid comprising a *ceg* nucleotide sequence, or a fragment thereof, introduced into a suitable host cell. The host-vector system can be used to produce the

- CEG polypeptides encoded by the *ceg* nucleotide sequences. The host cell can be prokaryotic or eukaryotic. Examples of suitable prokaryotic host cells include bacteria strains from genera such as *Escherichia*, *Bacillus*, *Pseudomonas*, *Streptococcus*, and *Streptomyces*. Examples of suitable eukaryotic host cells include a yeast cell, a plant cell, or an animal cell, such as a mammalian cell. A preferred embodiment provides a host-vector system comprising the pET21 vector having a *ceg* sequence introduced into an *E. coli* λ DE3 lysogen which is useful, for example for the production of the CEG protein, herein designated CFE polypeptides and CFE proteins.
- 10 Introduction of the rDNA molecules of the present invention into an appropriate cell host is accomplished by well known methods that typically depend on the type of vector used and host system employed. For example, transformation of prokaryotic host cells by electroporation and salt treatment methods are typically employed, see for example, Cohen et al., 1972 *Proc Acad Sci USA* 69:2110; Maniatis, T., et al., 1989 *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- 15 Transformation of vertebrate cells with vectors containing rDNAs, electroporation, cationic lipid or salt treatment methods are typically employed, see, for example, Graham et al., 1973 *Virology* 52:456; Wigler et al., 1979 *Proc Natl Acad Sci USA* 76:1373-76.
- 20 Successfully transformed cells, i.e., cells that contain a rDNA molecule of the present invention, can be identified by well known techniques. For example, cells resulting from the introduction of a rDNA of the present invention can be selected and cloned to produce single colonies. Cells from those colonies can be harvested, lysed and their DNA content examined for the presence of the rDNA using a method such as that described by Southern, *J Mol Biol* (1975) 98:503, or Berent et al., *Biotech* (1985) 3:208, or the proteins produced
- 25 from the cell assayed via a biochemical assay or immunological method.
- Procaryotes are generally used as host cells for cloning and producing the products of exogenous DNA sequences. For example, the *Escherichia coli* K12 BL21 (λ DE3) (Novagen) is particularly useful for expression of foreign proteins. Other strains of *E. coli*, and bacilli such as *Bacillus subtilis*, Enterobacteriaceae such as *Salmonella*
- 30

typhimurium or *Serratia marcescans*, various *Pseudomonas*, *Streptococcus*, and *Streptomyces* species may also be employed as host cells in cloning and expressing the recombinant proteins of this invention.

- 5 In general terms, the production of recombinant CEG proteins may involve using a host/vector system, or other methods may be used. The host/vector system may employ the following steps.

10 A nucleic acid molecule is obtained that encodes a CEG protein or a fragment thereof, such as any one of the polynucleotides disclosed in SEQ ID NOs.: 1-113 or 227-331. The CEG-encoding nucleic acid molecule is preferably inserted into an expression vector in operable linkage with suitable expression control sequences, to generate an expression vector including the CEG-encoding sequence. The expression vector is introduced into a suitable host, by standard transformation methods, and the resulting transformed host is cultured
15 under conditions that allow the production of the CEG protein. For example, if expression of the CEG gene is under the control of an inducible promoter, then suitable growth conditions would include the appropriate inducer. The CEG protein (e.g., designated a CFE polypeptide or protein), so produced, is isolated from the growth medium or directly from the cells; recovery and purification of the protein may not be necessary in some
20 instances where some impurities may be tolerated. A skilled artisan can readily adapt an appropriate host/expression system known in the art for use with CEG-encoding sequences to produce a CEG protein (Cohen, et al., *supra*; Maniatis et al., *supra*).

25 Host cells harboring the nucleic acids disclosed herein are also provided by the present invention. A preferred host is *E. coli* strain BL21(λ DE3) transfected or transformed with a vector comprising a nucleic acid of the present invention. The invention also provides a host cell capable of expressing the *ceg* sequences described herein. The preferred host cell is any strain of *E. coli* that can accommodate high level expression of an exogenously introduced gene.

30

The proteins of the present invention can also be made by chemical synthesis. The principles of solid phase chemical synthesis of polypeptides are well known in the art and may be found in general texts relating to this area (Dugas, H. and Penney, C. 1981 *Bioorganic Chemistry*, pp 54-92, Springer-Verlag, New York). CEG polypeptides may
5 be synthesized by solid-phase methodology utilizing an Applied Biosystems 430A peptide synthesizer (Applied Biosystems, Foster City, Calif.) and synthesis cycles supplied by Applied Biosystems. Protected amino acids, such as t-butoxycarbonyl-protected amino acids, and other reagents are commercially available from many chemical supply houses.

10

The polypeptides of the invention exhibit properties of a CEG protein, such as, for example, the ability to elicit the generation of antibodies that specifically bind an epitope associated with CEG polypeptides. Accordingly, the CEG polypeptide, or any oligopeptide thereof, is capable of inducing a specific immune response in appropriate
15 animals or cells and binding with specific antibodies.

C) ANTIBODIES THAT RECOGNIZE AND BIND THE PROTEINS AND POLYPEPTIDES OF THE INVENTION

20 The invention further provides antibodies (e.g., polyclonal, monoclonal, chimeric, humanized, and human antibodies) that bind a CEG polypeptide. The most preferred antibodies will selectively bind a CEG polypeptide and will not bind (or will bind weakly) a non-CEG polypeptide. Antibodies that are particularly contemplated include monoclonal and polyclonal antibodies, as well as fragments thereof (e.g., recombinant proteins) which
25 include the antigen binding domain and/or one or more complement determining regions of these antibodies. These antibodies can be from any source, for example, rabbit, sheep, rat, dog, cat, pig, horse, mouse, and human.

The invention encompasses antibody fragments that specifically recognize a CEG
30 polypeptide. As used herein, an antibody fragment is defined as at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen binding region. Some of the constant region of the immunoglobulin may be included.

As will be understood by those skilled in the art, the regions or epitopes of a CEG polypeptide to which an antibody is directed may vary with the intended application. For example, antibodies intended for use in an immunoassay for the detection of membrane-bound CEG proteins on viable bacterial cells should be directed to an accessible epitope
5 on membrane-bound CEG proteins. Antibodies that recognize other epitopes may be useful for the identification of CEG protein within damaged or dying cells, for the detection of secreted CEG protein or fragments thereof.

10 Various methods for the preparation of antibodies are well known in the art. For example, antibodies may be prepared by immunizing a suitable mammalian host using a CEG protein, peptide, or fragment, in isolated or immunoconjugated form (Harlow, 1989 *Antibodies*, Cold Spring Harbor Press, NY). In addition, fusion proteins comprising CEG polypeptides may also be used, such as a CEG protein/GST-fusion protein. Cells expressing or overexpressing
15 a CEG polypeptide may also be used for immunizations. Similarly, any cell engineered to express CEG protein may be used. This strategy may result in the production of monoclonal antibodies with enhanced capacities for recognizing endogenous CEG protein.

The present invention contemplates chimeric antibodies that comprise a human and non-
20 human immunoglobulin portion. The antigen combining region (variable region) of a chimeric antibody can be derived from a prokaryotic source (e.g., bacteria) and the constant region of the chimeric antibody which confers biological effector function to the immunoglobulin can be derived from a eukaryotic source (e.g., human). The chimeric antibody should have the antigen binding specificity of the prokaryotic antibody
25 molecule and the effector function conferred by the eukaryotic antibody molecule.

In one example, the procedure used to produce chimeric antibodies can involve the following steps:

- 30 a) Identifying and cloning the correct immunoglobulin gene segment encoding the antigen binding portion of the antibody molecule. This gene segment is known as the VDJ, variable, diversity and joining regions for heavy chains or VJ, variable,

- joining regions for light chains or simply as the V or variable region. This gene regions may be in either the cDNA or genomic form;
- b) Cloning the gene segments encoding the constant region or desired part thereof;
 - c) Ligating the variable region with the constant region so that the complete chimeric antibody is encoded in a form that can be transcribed and translated;
 - d) Ligating this construct into a vector containing a selectable marker and gene control regions such as promoters, enhancers and poly(A) addition signals;
 - e) Amplifying this construct in bacteria;
 - f) Introducing this DNA into eukaryotic cells (transfection) most often mammalian lymphocytes;
 - g) Selecting for cells expressing the selectable marker;
 - h) Screening for cells expressing the desired chimeric antibody; and
 - k) Testing the antibody for appropriate binding specificity and effector functions.
- Chimeric antibodies of several distinct antigen binding specificities have been produced by protocols well known in the art, including anti-TNP antibodies (Boulianne et al., 1984 *Nature* 312:643); and anti-tumor antigen antibodies (Sahagan et al., 1986 *J. Immunol.* 137:1066). Likewise, several different effector functions have been achieved by linking new sequences to those encoding the antigen binding region. Examples of these include enzymes (Neuberger et al., 1984 *Nature* 312:604); immunoglobulin constant regions from another species and constant regions of another immunoglobulin chain (Sharon et al., 1984 *Nature* 309:364; Tan et al., 1985 *J. Immunol.* 135:3565-3567). Additionally, procedures for modifying antibody molecules and for producing chimeric antibody molecules using homologous recombination to target gene modification have been described (Fell et al., 1989 *Proc. Natl. Acad. Sci. USA* 86:8507-8511).

The predicted amino acid sequence of a CEG protein may be used to select specific regions of the CEG protein for generating antibodies. For example, hydrophobicity and hydrophilicity analyses of a CEG polypeptide may be used to identify hydrophobic and hydrophilic regions in the CEG protein. Regions of the CEG protein that show immunogenic structure, as well as other regions and domains, can readily be identified using

various other methods known in the art, such as Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schult or Jameson-Wolf analysis. Fragments that include the immunogenic regions are particularly suited for generating specific classes of antibodies.

- 5 Methods for preparing a protein for use as an immunogen and for preparing immunogenic conjugates of a protein with a carrier such as BSA, KLH, or other carrier proteins are well known in the art. In some circumstances, direct conjugation using, for example, carbodiimide reagents may be used; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, may be effective. Administration of a CEG
- 10 immunogen is conducted generally by injection over a suitable time period and with use of a suitable adjuvant, as is generally understood in the art. During the immunization schedule, titers of antibodies can be taken to determine adequacy of polyclonal antibody formation.

- While the polyclonal antisera produced in this way may be satisfactory for some
- 15 applications, for pharmaceutical compositions, monoclonal antibody preparations are preferred. Immortalized cell lines which secrete a desired monoclonal antibody may be prepared using the standard method of Kohler and Milstein (*Nature* 256: 495-497) or other techniques as described in *Monoclonal Antibodies; A Manual of Techniques*, CRC press, Inc., Boca Raton, Fla. (1987) ed. Zola. The immortalized cell lines secreting the desired
- 20 antibodies are screened by immunoassay in which the antigen is the CEG polypeptide having binding activity, or a fragment thereof. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either *in vitro* or by production in ascites fluid.

- 25 The desired monoclonal antibodies are then recovered from the culture supernatant or from the ascites supernatant. Fragments of the monoclonal antibodies of the invention or the polyclonal antisera (e.g., Fab, F(ab')₂, Fv fragments, fusion proteins) which contain the immunologically significant portion (i.e., a portion that recognizes and binds a CEG protein) can be used as antagonists, as well as the intact antibodies. Humanized antibodies directed
- 30 against a CEG polypeptide are also useful. The advantage of using humanized antibodies is that they are less immunogenic in humans. As used herein, a humanized antibody is an

- immunoglobulin molecule which is capable of binding to a CEG polypeptide and which comprises a FR region having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of non-human immunoglobulin or a sequence engineered to bind a CEG protein. Methods for humanizing
- 5 murine and other non-human antibodies by substituting one or more of the non-human antibody CDRs for corresponding human antibody sequences are well known (Jones et al., 1986 *Nature* 321: 522-525; Riechman et al., 1988 *Nature* 332: 323-327; Verhoeyen et al., 1988 *Science* 239: 1534-1536; Carter et al., 1993 *Proc. Natl. Acad. Sci. USA* 89: 4285; and Sims et al., 1993 *J. Immunol.* 151: 2296).
- 10 Use of immunologically reactive fragments, such as the Fab, Fab', or F(ab')₂ fragments is often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole immunoglobulin. Further, bi-specific antibodies specific for two or more epitopes may be generated using methods generally known in the art. Further,
- 15 antibody effector functions may be modified so as to enhance the therapeutic effect of the antibodies of the invention. For example, cysteine residues may be engineered into the Fc region, permitting the formation of interchain disulfide bonds and the generation of homodimers which may have enhanced capacities for internalization, ADCC and/or complement-mediated cell killing (Caron et al., 1992 *J. Exp. Med.* 176: 1191-1195; Shopes, 1992 *J. Immunol.* 148: 2918-2922). Homodimeric antibodies may also be
- 20 generated by cross-linking techniques known in the art (Wolff et al., *Cancer Res.* 53: 2560-2565). The invention also provides pharmaceutical compositions having the monoclonal antibodies or anti-idiotypic monoclonal antibodies of the invention.
- 25 The antibodies or fragments may also be produced, using current technology, by recombinant means. Regions that bind specifically to the desired regions of the CEG protein can also be produced in the context of chimeric or CDR grafted antibodies of multiple species origin. The invention includes an antibody, e.g., a monoclonal antibody which competitively inhibits the immunospecific binding of any of the monoclonal
- 30 antibodies of the invention to a CEG protein.

Alternatively, methods for producing fully human monoclonal antibodies, include phage display and transgenic methods, are known and may be used for the generation of human monoclonal antibodies (reviewed in: Vaughan et al., 1998 *Nature Biotechnology* 16: 535-539). For example, fully human monoclonal antibodies may be generated using cloning technologies employing large human Ig gene combinatorial libraries (i.e., phage display) (Griffiths and Hoogenboom, "Building an *in vitro* immune system: human antibodies from phage display libraries", in: *Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man*, Clark, M. (Ed.), Nottingham Academic, pp 45-64 (1993); Burton and Barbas, "Human Antibodies from combinatorial libraries" *Id.*, pp 65-82). Fully human monoclonal antibodies may also be produced using transgenic mice engineered to contain human immunoglobulin gene loci as described in PCT Patent Application WO98/24893, Jakobovits et al., published December 3, 1997 (see also, Jakobovits, 1998 *Exp. Opin. Invest. Drugs* 7: 607-614). This method avoids the *in vitro* manipulation required with phage display technology and efficiently produces high affinity, authentic human antibodies.

The antibody or fragment thereof of the invention may be labeled with a detectable marker or conjugated to a second molecule, such as a therapeutic agent (e.g., a cytotoxic agent) thereby resulting in an immunoconjugate. For example, the therapeutic agent includes, but is not limited to, an anti-tumor drug, a toxin, a radioactive agent, a cytokine, a second antibody or an enzyme. Further, the invention provides an embodiment wherein the antibody of the invention is linked to an enzyme that converts a prodrug into a cytotoxic drug.

Examples of cytotoxic agents include, but are not limited to ricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethiduum bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphtheria toxin, *Pseudomonas* exotoxin (PE) A, PE40, abrin, arbrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, and glucocorticoid and other chemotherapeutic agents, as well as radioisotopes such as ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Suitable detectable markers for diagnostic used include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme. Antibodies may also be conjugated to an anti-cancer pro-drug activating enzyme capable of converting the pro-drug to its active form. See, for example, U.S. Patent Nos. 4,952,394 and 5,716,990.

Additionally, a recombinant protein of the invention comprising the antigen-binding region of any of the monoclonal antibodies of the invention can be made. In such a situation, the antigen-binding region of the recombinant protein is joined to at least a functionally active portion of a second protein having therapeutic activity. The second protein can include, but is not limited to, an enzyme, lymphokine, oncostatin or toxin. Suitable toxins include those described above.

- Techniques for conjugating or joining therapeutic agents to antibodies are well known (Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in: *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56, Alan R. Liss, Inc. 1985; Hellstrom et al., "Antibodies For Drug Delivery", in: *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53, Marcel Dekker, Inc. 1987; Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in: *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", in: *Immunol. Rev.*, 62:119-58 (1982)). Techniques for joining detectable markers to antibodies are also known.

D) PHARMACEUTICAL COMPOSITIONS OF THE INVENTION

The invention includes pharmaceutical compositions for use in the treatment of microbial infections comprising a pharmaceutically effective amount of an anti-CEG antibody or a CEG polypeptide.

In one embodiment, the pharmaceutical compositions may comprise a CEG antibody, either unmodified, conjugated to a therapeutic agent (e.g., drug, toxin, enzyme or second antibody) or in a recombinant form (e.g., chimeric or bispecific). The compositions may additionally include other antibodies or conjugates (e.g., an antibody cocktail).

5

The pharmaceutical compositions also preferably include suitable carriers and adjuvants which include any material which when combined with the molecule of the invention (e.g., an anti-CEG antibody or a CEG protein) retains the molecule's activity and is non-reactive with the subject's immune systems. Examples of suitable carriers and adjuvants include, but are not limited to, human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate. Other examples include any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsion, and various types of wetting agents. Other carriers may also include sterile solutions, tablets including coated tablets and capsules. Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients. Compositions comprising such carriers are formulated by well known conventional methods. Such compositions may also be formulated within various lipid compositions, such as, for example, liposomes as well as in various polymeric compositions, such as polymer microspheres.

The pharmaceutical compositions of the invention can be administered using conventional modes of administration including, but not limited to, intravenous, intraperitoneal, oral, intralymphatic or administration directly into the tumor. Intravenous administration is preferred.

The pharmaceutical compositions of the invention may be in a variety of dosage forms which include, but are not limited to, liquid solutions or suspensions, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and

injectable or infusible solutions. The preferred form depends upon the mode of administration and the therapeutic application.

5 The CEG polypeptides and proteins of this invention are found in common pathogenic bacterial species such as *Streptococcus pneumoniae*. This organism causes upper respiratory tract infections. Thus, the peptides and proteins of this invention can be used as immunogens in subunit vaccines for vaccination against a pathogenic bacteria such as *Streptococcus pneumoniae*. Additionally, the *ceg* sequences of the invention can be used as DNA vaccines (U.S. Patent No. 5,736,524 and U.S. Patent No. 5,989,553).

10

The polypeptides and proteins of this invention can be formulated as univalent and multivalent vaccines. The protein can be mixed, conjugated or fused with other antigens, including B or T cell epitopes of other antigens.

15 Further, when a haptenic peptide of the proteins of the invention is used, (i.e., a peptide which reacts with cognate antibodies, but cannot itself elicit an immune response), it can be conjugated to an immunogenic carrier molecule. Conjugation to an immunogenic carrier can render the oligopeptide immunogenic. Examples of carrier molecules are tetanus toxin or toxoid, diphtheria toxin or toxoid and any mutant forms of these proteins
20 such as CRM.sub.197. Others include exotoxin A of *Pseudomonas*, the heat labile toxin of *E. coli* and rotaviral particles (including rotavirus and VP6 particles). Alternatively, a fragment or epitope of the carrier protein or other immunogenic protein can be used. For example, the happen can be coupled to a T cell epitope of a bacterial toxin.

25 In formulating the vaccine compositions with the CEG polypeptides or proteins of the invention, alone or in the various combinations described, the immunogen is adjusted to an appropriate concentration and formulated with any suitable vaccine adjuvant. Suitable adjuvants include, but are not limited to: surface active substances, e.g., hexadecylamine, octadecylamine, octadecyl amino acid esters, lysolecithin, dimethyl-
30 dioctadecylammonium bromide), methoxyhexadecylglycerol, and pluronic polyols; polyamines, e.g., pyran, dextran sulfate, poly IC, carbopol; peptides, e.g., muramyl

dipeptide, dimethylglycine, tuftsin; oil emulsions; and mineral gels, e.g., aluminum hydroxide, aluminum phosphate, etc. and immune stimulating complexes. The immunogen may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers.

5

The vaccines can be administered to a human or animal in a variety of ways. These include intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal routes of administration. Further, the vaccines can be live or inactivated vaccines.

10

The most effective mode of administration and dosage regimen for the compositions of this invention depends upon the severity and course of the disease, the patient's health and response to treatment and the judgment of the treating physician. Accordingly, the dosages of the compositions should be titrated to the individual patient.

15

E) USES OF THE MOLECULES OF THE INVENTION

1) MOLECULAR WEIGHT MARKERS

20 The nucleic acid molecules of the invention and their encoded proteins may be employed as molecular weight markers. For example, the molecular weight of each of the nucleic acid molecules having *ceg* sequences and their predicted polypeptides can be determined and can be used to compare against other gene sequences and proteins whose molecular weights are unknown.

25

2) DIAGNOSTICS

The nucleic acid molecules of the invention may be employed in diagnostic embodiments. For example, the presence of nucleotide sequences which are identical or
30 similar to the *ceg* sequences of the invention may be detected within a biological sample.

The biological sample may include blood, serum or a swab from nose, ear or throat, may be determined by means of a nucleic acid detection assay.

- 5 Nucleic acid probes or primers having sequences complementary to *ceg* sequences may be used in a hybridization assay to detect the presence of the sequences which are identical or similar to the *ceg* sequences of the invention in the biological samples. Typically, nucleic acids molecules obtained from a suitable biological sample are hybridized with labeled probes or primers. The resulting hybridized molecules are detected and resolved by methods well known in the art, such as Northern or Southern blotting, micro-array technology, or amplifying with PCR technology. Other hybridization techniques and systems are known that can be used in connection with the detection aspects of the invention, including diagnostic assays such as those described in Falkow et al., U.S. Pat. No. 4,358,535.
- 10
- 15 Examples of the PCR technology are disclosed in U.S. Patent Nos. 4,683,202 and 4,965,188 (incorporated herein by reference). Generally, nucleic acid molecules are obtained from a suitable biological source and contacted with two primers corresponding to the *ceg* sequences disclosed herein, under conditions which allow for hybridization and polymerization to occur. A pair of probes, one corresponding to the 5' flanking region and the other corresponding to the 3' flanking region, would be sufficient to detect the nucleic acid molecules of the invention in a biological sample and may be used to indicate the amount of bacteria present.
- 20

- Alternative methods of detecting nucleic acid molecules include, for example, in situ hybridization techniques, where a *ceg* probe is used to detect homologous sequences within one or more cells, such as cells within a clinical sample or even cells grown in tissue culture. As is well known in the art, the cells are prepared for hybridization by fixation, e.g. chemical fixation, and placed in conditions that allow for the hybridization of a detectable probe with nucleic acids located within the fixed cell.
- 25
- 30

The amount of *ceg* sequences present in a biological sample can be quantified and compared to the levels in a normal or "healthy" sample. For example, *ceg* sequences present in either increased or decreased levels, compared to the levels found in the control sample may indicate the presence of bacteria. This information is useful for diagnosis of a bacterial infection that requires treatment with an antibacterial agent.

Alternatively, the amount of CEG polypeptides present in a biological sample may be determined by means of an immunoassay. For example, labeled antibodies reactive against CEG polypeptides may be used in an immuno-reactive assay to detect the presence of CEG polypeptides in the biological samples.

3) SCREENING CANDIDATE CEG SEQUENCES

a) Gene Disruption Assay

The *ceg* nucleotide sequences of the invention can be used to identify nucleotide sequences which are identical or similar to the *ceg* sequences that are required for bacterial cell viability. For example, the *ceg* sequences can be used in a bacterial gene disruption assay to screen candidate nucleotide sequences to identify sequences required for bacterial cell viability.

The disruption assay can involve: introducing into a host cell a recombinant vector that is capable of integration into the host genome, where the recombinant vector includes a candidate sequence that putatively encodes a cell-viability gene product (e.g., the exogenous *ceg* sequence); the vector integrates the candidate sequence into a target sequence within the host's genome (e.g., the endogenous *ceg* sequence); and the host cell, so introduced, is screened for viability. The recombinant vector preferably includes a selectable marker so that the introduced host cell can be screened for viability in the presence of a selectable agent.

For example, Figure 1 shows a schematic representation of a gene disruption assay, within a bacterial host cell. In Figure 1A, the recombinant vector, pEVP3, includes the CAT gene (e.g., the selectable marker chloramphenicol acetyl transferase) and an internal region of the *ceg* disrupting sequence; the internal region excludes the 5' and 3' ends of the *ceg* sequence. The "X" in Figure 1 indicates the recombinant pEVP3 vector undergoing homologous recombination with the target sequence (e.g., within the host genome). In Figure 1B, the resolved pEVP3 vector that is integrated into the host genome, is shown. Left to right are the following elements: the native promoter of the target gene; a 5' partial copy of the target gene; the body of the integrated pEVP3 vector including the disrupting gene and CAT; and, a 3' partial copy of the target gene. Thus, integration of the pEVP3 vector via homologous recombination results in two partial gene duplications flanking the integrated vector. If the target gene is not essential for survival, it is possible to recover chloramphenicol-resistant colonies of *S. pneumoniae*. Failure to recover chloramphenicol resistant colonies, in the presence of the proper controls as described below, indicates that the target gene may be essential for cell viability.

More particularly, the gene disruption assay for screening candidate *ceg* sequences can involve the following steps. The recombinant pEVP-3 vector encoding CAT resistance and having a fragment of a candidate *ceg* sequence, can be introduced into transformation-competent *S. pneumoniae* cells by methods that are well-known in the art (Lee, M.S., et al., 1998 *Appl. Environ. Microbiol.* 64:4796-4802). The preferred size of the *ceg* fragment can be between about 200 to about 500 bp in length. It is advantageous that the candidate *ceg* sequence does not include the 5' and 3' ends that encode the N- and C-terminal ends of the CEG polypeptide. This insures that the inserted *ceg* fragment and the disrupted endogenous *ceg* gene sequence are not capable of expression of a full-length, functional *ceg* gene product. The transformation-competent cells can be obtained by performing the transformation step in the presence of a heptadecapeptide that induces competence for transformation of *S. pneumoniae* (Havarstein, L. S., et al., 1995 *Proc. Nat'l. Acad. Sci.* 92:11140-11144), such as the CSP-1 peptide. The CSP-1 can be naturally-derived or synthetic. Additionally, the transformation step can be optimized by performing the transformation when the cells have reached a density which is optimal for

transformation (e.g., 3×10^7 cells per ml.) (Havarstein, L. S. et al. *supra*). The recombinant vector can be introduced into the competent pneumococci and may undergo homologous recombination, whereby the candidate *ceg* fragment recombines with the corresponding endogenous *ceg* sequence, resulting in targeted integration of the vector into the pneumococcal genome and disruption of the endogenous *ceg*.

The transformed cells can be plated on or cultured in chloramphenicol-containing growth medium. The cells can be cultured under standard conditions, such as 37° C in 5% CO₂ for approximately 40 to 48 hours, for the purpose of selecting cells that carry the integrated vector.

Additionally, control samples can be run in parallel with the gene disruption assay, in order to determine whether the gene disruption procedure is working properly. For example, the control samples can be used to calibrate the gene disruption experiment so that disruption of a known non-essential bacterial gene results in an approximate number of colonies per plate. Similarly, the disruption of a known essential gene can be calibrated to yield only zero or one colony per plate. The appearance of one colony is due to the rare illegitimate recombination into a non-homologous sequence. In particular, a known non-essential gene such as the *lytA* gene (Tomasz, A., et al., 1988 *J. Bacteriol.* 170:5931-5934) can be used so that between about 70 to 100 chloramphenicol-resistant colonies will grow per plate. Similarly, the *ftsZ* gene (Lutkenhaus, J. F., et al., 1980 *J. Bacteriol.* 143:1281-1288), a known essential gene, can be used to yield zero or, rarely, one colony per plate. As is well known in the art, specific parameters that are involved in any given gene disruption assay can be adjusted to calibrate the desired number of plated cells in the control samples. Experimental parameters that can be adjusted include, but are not limited to, the *E. coli* strain used to propagate the vector/insert, the fragment length of the sequence to be integrated, the amount of recombinant integration vector used to transform the cells, use of transformation-competent cells, and plating density of the transformed cells.

30

The transformed cells carrying the recombinant integration vector that disrupts expression of an endogenous essential gene (e.g., the target *ceg* gene) can be identified, based on a selectable phenotype such as non-viability. For example, the cells that carry a disrupted non-essential gene will be viable and, due to the integration of pEVP3, will grow on chloramphenicol-containing medium. In contrast, cells that carry a disrupted essential gene will not grow (e.g., non-viable) on the chloramphenicol-containing medium. Thus, the transformed cells that do not grow under these selective conditions carry an endogenous gene sequence that is essential for cell viability which has been disrupted by an exogenous candidate fragment, thereby identifying a *ceg* sequence. Steps one through three may be repeated in order to confirm that the *ceg* sequences, so identified, are essential for cell viability.

b) Autolysin Assay

It is advantageous to perform additional steps to determine whether the homologous recombination events result in disruption of the intended target gene sequence. The *lytA* transformation control can be used to confirm that the transformation system is functioning properly. For example, a phenotypic test for autolysin activity (*lytA* gene product) can be performed to determine that the exogenous *lytA* fragment is correctly integrated into the *lytA* site within the host genome. This typically involves flooding the culture plates containing transformants carrying the integrated *lytA* control vector with a solution of detergent, such as 0.1% deoxycholate, which triggers cell lysis in *lytA*-intact cells (e.g., the cells that have not undergone homologous recombination). After about 5-10 minutes the colonies with intact *lytA* will appear ghost-like due to cell lysis, and the colonies with a disrupted *lytA* gene will appear intact.

c) Polarity Analysis

The *ceg* sequences that are confirmed to be essential for cell viability can be examined further by performing a polarity analysis to determine if the corresponding endogenous *ceg* sequence is organized in an operon. Polarity is an effect unique to prokaryotes and is

the result of the operon organization of bacterial genomes. Many bacterial genes are arranged in operons in which multiple genes are under the control of a single regulatory sequence (e.g., a promoter) and are transcribed into a single mRNA transcript. With respect to the orientation of multiple genes within an operon, the genes that are proximal to the regulatory sequence are said to be "upstream" genes and the genes that are distal are said to be "downstream" genes. For example, many operons contain genes encoding different proteins that catalyze discrete steps of a common biochemical pathway. Thus, any of the proteins that catalyze the steps of the pathway may be essential for cell viability.

5

The presence of operons in a bacterial host genome may influence the interpretations of the gene disruption results. For example, disruption of an upstream gene may be erroneously interpreted as affecting the expression of the disrupted gene but may, in fact, have expression effects on the intact downstream genes. Therefore, it is advantageous to perform a polarity analysis to determine if a *ceg* sequence is part of an operon.

10

A polarity analysis can involve performing an *in vivo* gene disruption procedure using, as the disrupting sequence, a *ceg* sequence that includes the entire *ceg* coding sequence region but lacking expression regulatory sequences. This differs from the gene disruption assay, which involves the central region of the *ceg* sequence. The polarity analysis involves gene duplication via homologous recombination. For example, the pEVP-3 vector having the entire coding region of a *ceg* sequence can be used for the polarity analysis (Figure 2 A). The polarity analysis will yield different results depending on the organization of the endogenous target sequence within the host genome.

15

20

For example, Figure 2 shows a schematic representation of the polarity test for operons, within a bacterial host cell. In Figure 2A, the recombinant vector, pEVP3, includes the CAT gene and the entire coding region of the *ceg* disrupting sequence. The "X" in Figure 2 indicates the recombinant pEVP3 vector undergoing homologous recombination with the target sequence. Two of the possible results of homologous recombination are shown in Figures 2 B and C.

25

30

In Figure 2 B, case 1, if the endogenous target sequence is not organized in an operon, the integration event may yield: a functional target sequence (e.g., it is capable of expression); a duplicate non-functional target sequence that lacks a promoter; and a functional downstream gene (e.g., Gene B) that is controlled by its own promoter. The cells carrying this type of integrated target sequence can be recovered as viable cells that grow in the presence of chloramphenicol; this condition is termed "polarity negative".

In Figure 2 C, case 2, if the target sequence is organized in an operon, then the integration event may yield an integration site that is similar to that described for case 1, including: a functional target sequence; and a duplicate non-functional target sequence which is not functional. However, this integration event may also yield a non-functional downstream gene (e.g., Gene B) because expression of this downstream gene is controlled by a promoter located upstream of the insertion site. The cells that carry this type of integrated target sequence will be non-viable; this condition is termed "polarity positive". Thus, the polarity analysis provides a method to determine whether integration of a recombinant vector into a target *ceg* sequence effects expression of downstream genes.

The *ceg* sequences disclosed herein (SEQ ID NOs.: 1-113, 227-331) encode gene products that are essential for viability in *S. pneumoniae*. Furthermore, many of these *ceg* sequences have been analyzed for the polarity effect and the results are presented in Table I. One subset of *ceg* sequences is classified as polarity negative (-), since the homologous recombination event did not effect the expression of downstream genes. Another subset of *ceg* sequences is classified as polarity positive (+), since the homologous recombination event did affect the expression of downstream genes. The *ceg* sequences that have not yet been classified as polarity positive or negative are indicated in Table I as a blank. For the *ceg* sequences that are classified as polarity positive, the genes downstream of the disrupted endogenous *ceg* sequences may or may not also be essential.

4) ASSAYS FOR IDENTIFYING CEG LIGANDS AND OTHER BINDING AGENTS

- The present invention provides screening methods for identifying agents that interact and/or bind to the CEG proteins of the invention, such as a ligand. An agent can be, for example, a natural product, a derived or synthetic chemical molecule, a polypeptide, a nucleic acid molecule, or a metal. The agents that interact with CEG proteins may cause bacterial cell death by disrupting the functions of CEG proteins, including, but not limited to, nucleotide biosynthesis, DNA replication, RNA transcription, protein translation, and/or cell wall biosynthesis. Accordingly, the present invention provides screening methods for identifying agents having antibacterial activity, such as agents that cause bacterial cell death by interacting with the CEG proteins. These antibacterial agents are useful for treating diseases and afflictions associated with bacterial infections.
- Various methods can be used to discover agents having antibacterial activity, as determined by the ability of the binding agent to bind to a CEG protein and disrupt the function of the CEG protein. These screening methods include whole cell *in vivo* assays as well as *in vitro* assays with cellular components.
- An *in vivo* screening method for identifying ligands that bind CEG polypeptides can be performed in a whole cell assay. A typical method may be the use of whole bacterial cells to assess the antibacterial properties based on cell growth or viability. These methods can include methods for measuring cell growth and/or viability, for example, by optical density or zones of growth (Koch, A. L. et al., 1970 *Anal. Biochem.* 38:252-259; Biemer, J. J. et al., 1973 *Ann. Clin. Lab. Sci.* 2:135-140; *Manual of Clinical Microbiology*, 7th edition, Murray, P. R. (ed), ASM Press), by growth inhibition in an agar assay (Murray, P. R., *supra*), or other means of detecting cell metabolism (Mychajlonka, M. et al., 1980 *Antimicrob. Agents Chemother.* 17:572-582), and are well known to those skilled in the art. In addition, there are molecular biology-based detection methods for use with whole bacterial cells, such as gene reporter assays, to monitor the effect of the ligand on specific targets (Slauch, J. M., et al., 1991 *Methods Enzymol.* 204:213-248). Examples of the reporter genes include, but are not limited to, beta-

galactosidase, alkaline phosphatase, luciferase, and green fluorescent protein. For example, one embodiment provides a reporter system that monitors inhibition of DNA synthesis by fusing a reporter such as beta-galactosidase (*lacZ*) to genes known to be upregulated by the cessation of DNA synthesis as a result of the binding of ligands to the DNA synthetic apparatus. (Shurvinton, C. E., et al., 1982 *Mol. Gen. Genetics* 185:352-355; Rosato, A., et al., 1998 *Antimicrob. Agents Chemother.* 42:1392-1396).

Alternatively, the yeast two-hybrid system (Fields, S. and Song, O. 1989, *Nature* 340:245-246) may be adapted to screen for ligands that bind CEG polypeptides. Generally, the yeast two-hybrid system is performed in a yeast host cell carrying a reporter gene, and is based on the modular nature of the GAL transcription factor which has a DNA binding domain and a transcriptional activation domain. The yeast two-hybrid system relies on the physical interaction between a recombinant polypeptide that comprises the GAL DNA binding domain and another recombinant polypeptide that comprises the GAL transcriptional activation domain. The physical interaction between the two recombinant polypeptides reconstitutes the transcriptional activity of the transcription factor, thereby causing expression of the reporter gene. Either of the recombinant polypeptides used in the two-hybrid system can be generated to include a CEG polypeptide sequence to screen for binding partners of CEG.

Another method uses the bacterial CEG proteins as the basis for *in vitro* assay systems to detect binding agents. Typically, the *in vitro* screening method comprises: a) generating the CEG protein of the invention, or membranes enriched in the CEG protein; b) exposing the CEG protein or membranes to a candidate agent; and c) detecting the interaction of the CEG protein with the agent by any suitable means. Additionally, the screening methods may be adapted to automated high-throughput procedures, such as PANDEX.RTM Baxter-Dade Diagnostics, allowing for efficient high-volume screening of candidate agents.

An alternative method for screening potential ligands involves an *in vitro* binding procedure. Typically, the CEG proteins of the invention can be produced using

recombinant DNA technology and host-vector systems as described herein. A candidate agent is introduced into a reaction vessel containing the CEG protein, or fragment thereof; the candidate agents may be detectable by methods such as, but not limited to, radioisotope or chemical labeling. Binding of the CEG protein by a candidate agent can
5 be determined by any suitable means, including, for example, quantifying bound label versus unbound label using any suitable method. Binding of a candidate agent may also be detected by methods similar to an alternative physical method disclosed in U.S. Patent No. 5,585,277. In this method, binding of a candidate agent to a protein is assessed by monitoring the ratio of folded protein to unfolded protein, for example by monitoring
10 sensitivity of the protein to a protease, or amenability to binding of the protein by a specific antibody against the folded state of the protein, or binding to chaperone protein, or by binding to any suitable surface.

The invention provides methods of identifying compounds that modulate (e.g., activate or
15 inhibit) the function of a CEG polypeptide. Essentially any compound can be used in the assays of the invention. The preferred compounds are those that are soluble in aqueous or organic solutions. It will be appreciated by those of skill in the art that there are many commercial suppliers of chemical compounds that can be used in the methods of the invention, including Sigma Chemical Co. (St. Louis, Mo.), Aldrich Chemical Co. (St.
20 Louis, Mo.), Sigma-Aldrich (St. Louis, Mo.), Fluka Chemika-Biochemica Analytika (Buchs, Switzerland), and the like.

The present invention provides methods for detecting compounds which are identified as modulators of CEG function. The methods of the invention can be performed using
25 isolated CEG polypeptides, or use whole cells expressing the CEG polypeptide. The steps of the method using isolated CEG polypeptides include: contacting the isolated CEG polypeptide with a candidate compound; and determining whether the function of the CEG polypeptide is altered. The steps of the method using whole cells include: contacting the whole cells with a candidate compound; and determining whether the cell
30 dies, indicating the compound inhibited the function of a CEG polypeptide.

The preferred methods of the invention provide high-throughput screening assays for identifying compounds which modulate the function of a CEG polypeptide. The high throughput methods permit screening of large libraries of compounds. For example the high throughput methods can use automated assay steps. The assays can be performed
5 in parallel on a solid support, as microtiter formats on microtiter plates in robotic assays are well known. A preferred embodiment of the methods includes adapting the methods to use microtiter plates or pico- nano- or micro-liter arrays. In high throughput assays it is desirable to run positive controls to ensure that the components of the assays are working properly.

10

The high throughput screening methods of the invention include providing a combinatorial library containing a large number of compounds (candidate modulator compounds) (Borman, S, C. & *E. News*, 1999, 70(10), 33-48). Such combinatorial chemical libraries can be screened in one or more assays to identify library members
15 (particular chemical species or subclasses) that exhibit the ability to modulate the function of the CEG polypeptide (Borman, S., *supra*; Dagani, R. C. & *E. News*, 1999, 70(10), 51-60). The compounds, so identified, can serve as lead-compounds or can themselves be used as potential or actual therapeutics.

20 A combinatorial chemical library is a collection of diverse chemical compounds generated by using either chemical synthesis or biological synthesis, to combine a number of chemical building blocks, such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide library, is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given
25 compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in
30 the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka, *Int. J. Pept. Prot. Res.*, 1991, 37:487-493 and

Houghton, et al., *Nature*, 1991, 354, 84-88). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to, peptoids (PCT Publication No. WO 91/19735); encoded peptides (PCT Publication WO 93/20242); random bio-oligomers (PCT Publication No. WO 92/00091); benzodiazepines (U.S. Pat. No. 5,288,514); diversomers, such as hydantoins, benzodiazepines and dipeptides (Hobbs, et al., *Proc. Nat. Acad. Sci. USA*, 1993, 90, 6909-6913); vinylogous polypeptides (Hagihara, et al., *J. Amer. Chem. Soc.* 1992, 114, 6568); nonpeptidal peptidomimetics with *beta*-D-glucose scaffolding (Hirschmann, et al., *J. Amer. Chem. Soc.*, 1992, 114, 9217-9218); analogous organic syntheses of small compound libraries (Chen, et al., *J. Amer. Chem. Soc.*, 1994, 116, 2661; Armstrong, et al. *Acc. Chem. Res.*, 1996, 29, 123-131); or small organic molecule libraries (see, e.g., benzodiazepines, Baum *C&E News*, 1993, Jan. 18, page 33,); oligocarbamates (Cho, et al., *Science*, 1993, 261, 1303); and/or peptidyl phosphonates (Campbell, et al., *J. Org. Chem.* 1994, 59, 658); nucleic acid libraries (see, Seliger, H et al., *Nucleosides & Nucleotides*, 1997, 16, 703-710); peptide nucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083); antibody libraries (see, e.g., Vaughn, et al., *Nature Biotechnology*, 1996, 14(3), 309-314 and PCT/US96/10287); carbohydrate libraries (see, e.g., Liang, et al., *Science*, 1996, 274, 1520-1522 and U.S. Pat. No. 5,593,853, Nilsson, UJ, et al., *Combinatorial Chemistry & High Throughput Screening*, 1999 2, 335-352; Schweizer, F; Hindsgaul, O. *Current Opinion In Chemical Biology*, 1999 3, 291-298); isoprenoids (U.S. Pat. No. 5,569,588); thiazolidinones and metathiazanones (U.S. Pat. No. 5,549,974); pyrrolidines (U.S. Pat. Nos. 5,525,735 and 5,519,134); morpholino compounds (U.S. Pat. No. 5,506,337); benzodiazepines (U.S. Pat. No. 5,288,514); and other similar art.

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem. Tech, Louisville Ky., Symphony, Rainin, Woburn, Mass., 433A Applied Biosystems, Foster City, Calif., 9050 Plus, Millipore, Bedford, Mass.). In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, Mo., ChemStar, Ltd., Moscow, RU, 3D Pharmaceuticals, Exton, Pa., Martek Bio sciences, Columbia, Md., etc.).

In the high throughput methods of the invention, several thousand different candidate compounds can be screened in a relatively short period of time. For example, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 100 to about 1500 different compounds. It is possible to assay many different plates per day; assay screens for up to about 6,000-20,000, and even up to about 100,000-1,000,000 different candidate modulator compounds are possible using the methods of the invention.

The following examples are presented to illustrate the present invention and to assist one of ordinary skill in making and using the same. The examples are not intended in any way to otherwise limit the scope of the invention.

EXAMPLE 1

The following provides a general description of how a list of candidate *ceg* sequences was generated. The list was generated by selecting candidate *ceg* gene sequences from a Concordance web engine using the method described in: Brucocoleri, R.E., Dougherty, T.J., Davison, D.B. (1998) "Concordance analysis of microbial genomes" in: *Nucleic Acids Res* 26:4482-4486.

Microbial Genomics CEG Discovery Process Summary.

Microbial Concordance Analysis

The entire genomic sequence data of various bacteria was acquired from several public and proprietary sequence database sources, including GTC (Genome Therapeutics Corporation), and TIGR (The Institute for Genomic Research).

Predicted ORFs from the genomic data were identified, translated, and stored. The desirable ORFs were at least 90 amino acid residues in length. Concordance analysis was performed among bacteria and various parameters were used to filter out genes with high similarity to eukaryotes.

5

Concordance Analysis

The entire genomic sequence of various Eubacteria was acquired from several public and private sources. The proprietary PathoGenome System from Genome Therapeutics Corporation, Waltham, MA, USA contributed data. Public data was obtained from
10 GenBank (<http://ncbi.nlm.nih.gov>), The Institute for Genomic Research (TIGR), the Yeast Proteome Database, from Proteome, Inc. of Beverly, MA, and the Sanger Center of the Medical Research Council of the United Kingdom (<http://www.sanger.ac.uk>). Additionally, the non-microbial sequence data used as a basis for comparison and data
15 subtraction was obtained from a proprietary database, including the LifeSeq Database from Incyte Pharmaceuticals, Palo Alto, CA.

Where required, Incyte nucleotide sequences were translated into protein sequences in all six possible reading frames. GTC supplied predicted protein sequences with their data. In
20 the case of other eubacterial nucleotide sequences, the program CRITICA (Badger, J. and Olsen, G., 1999 "CRITICA: coding region identification tool invoking comparative analysis" in: *Molecular Biology and Evolution* 16:512-524). The sequences were stored in flat files on a Unix computer system. Each predicted amino acid sequence had to be greater than 90 amino acids.

25

Each predicted protein sequence was compared to every other sequence (an "all-against-all" comparison). The program used was FASTA (Pearson, W.R., "Flexible sequence similarity searching with the FASTA3 program package." *Methods in Molecular Biology* 2000 132:185-219.) The parameters used were ktup=2, and all scores above the default
30 cutoff were kept. The output was processed and stored in a PostGres 95 database (<http://www.postgresql.org>). Graphical user interfaces, using web browser technology, were constructed to query the database.

A Concordance Analysis was performed on the data. The question used to generate the dataset was show all *Streptococcus pneumoniae* open reading frames with a similarity
5 greater than or equal to 30% overall protein sequence identity to both selected gram-positive and/or gram-negative bacteria in the database. The data was further required not to match yeast or human sequences at greater than 30% overall protein sequence similarity. The resulting dataset included a list of more than 400 conserved amino acid sequences having known or unknown function. The amino acid sequences having
10 unknown functions formed the basis of a list designated Conserved Unknown Reading Frames, or CURFs which is a subset of the total list of CEGs (e.g., CURFs includes known and unknown).

The resulting list of conserved genes (e.g., more than 400 sequences) was used as a basis
15 for selecting and screening bacterial gene sequences that are essential for cell viability. The Concordance system was designed to permit high-throughput identification of conserved gene sequences in the database. (Brucoleri, R, Dougherty, T, and Davison, D. 1998 "Concordance analysis of microbial genomes" *Nucleic Acids Res.* 26:4482-4486.)

20 Data Curation And Analysis

Exact N-terminal and C-terminal translational start sites of genes were identified by pairwise similarity searches, multiple sequence alignments. Ribosome binding sites, terminators, nearby genes, operons were identified.

25 The resulting list of conserved genes was used as a basis for selecting and screening bacterial gene sequences that are essential for cell viability. This Concordance system was designed to permit high throughput use of the conserved gene sequences contained on the list. A set of Knockout PCR primers were generated, based on the list of
30 conserved genes, for the purpose of use in the gene disruption procedure described below. The PCR primers were designed to amplify a central 300-500 bp region of the *ceg* (to prevent generation of a functional copy of the *ceg* gene following integration),

ordered electronically, the primers were placed in a 96-well format, and used in the gene disruption procedure as described below.

EXAMPLE 2

5

The following provides a description of the procedure to generate recombinant vectors of pEVP-3 having inserts of candidate *ceg* nucleotide sequences. The Knockout primers generated by the method described in Example 1 above were used to generate DNA fragments comprising candidate *ceg* sequences.

10

Genomic PCR Knockout Target Fragment Generation

96-well plate format were set up (36 μ l H₂O, 5 μ l 10 \times VentTM buffer, 1 μ l gene specific, knockout forward primer (0.5 μ g/ μ l), 1 μ l gene specific knockout reverse primer (0.5 μ g/ μ l), 0.5 μ l VentTM DNA polymerase (2000 U/ml New England Biolabs, Beverly, MA), 1.5 μ l each dNTPs (10mM; 6.0 μ l total), 0.5 μ l *S. pneumoniae* chromosomal DNA (0.5 μ g/ μ l), 50 μ l total volume/reaction):

The nucleotide sequences of the forward and reverse knockout primer pairs were generated from the nucleotide sequence information obtained from the Genomic Therapeutics Corporation database for *Streptococcus pneumoniae*. The primer pairs were each used in a PCR reaction to generate a unique internal (e.g., central region) fragment of the candidate gene targeted for knockout.

The PCR program was set in the PCR machine (Initial 95 °C - 5 minutes; 30 Cycles of: 95 °C - 1 minute, 58 °C - 1 minute, 72 °C - 30 seconds; Final, 72 °C - 10 minutes, 4 °C - hold indefinitely). 5 μ l of each reaction was run on an 0.8% agarose gel after purifying fragment over PCR purification kit (Qiagen) to visualize the fragments then ligation reactions were performed.

30

Ligation Reactions proceeded (set up in 96-well plate format (10.0 µl genomic PCR fragment (generated from step 2 above), 1.0 µl pEPV-3 SmaI-cut vector (1: 10 dilution of vector DNA at 50-100 ng/µl), 1.5 µl 10× ligation buffer (New England Biolabs™), 1.0 µl T4 DNA Ligase (New England Biolabs™ 400,000 U/ml), 1.5 µl ddH₂O, 15.0 µl total
5 reaction volume).

Reactions were allowed to incubate in 96-well plate at 14 °C overnight in the PCR machine. Transformations into *E. coli* for in vivo amplification were proceeded the following day.

10

The nucleotide sequences of the forward and reverse primer pairs used for the polarity test were generated in a similar manner, from the nucleotide sequence information obtained from the Genomic Therapeutics Corporation database for *Streptococcus pneumoniae*. The primer pairs were each used in a PCR reaction to generate a unique
15 fragment of the candidate gene targeted for the polarity test. The fragment generated for the polarity test included the entire *ceg* coding sequence region but lacking the expression regulatory sequences.

Transformation into *E. coli* (strain LE392):

20

The next day, 3 µl of above ligation mix was used per transformation reaction plus 50 µl LE392 competent cells. Reactions were set up in 96-well plate format; incubated on ice for 30 minutes; heat-shocked at 42° C for 90 seconds; and incubated on ice 2 minutes; 100 µl SOC media (Gibco BRL) was added; then incubated at 37° C on platform shaker
25 for 1 hour; plated on LB/chloramphenicol (13.0 µg/ml) agar plates for constructs overnight at 37° C with plates inverted and proceeded with colony PCR to confirm constructs. The universal primers flanking the insert site in pEVP-3 were used for PCR amplification.

30 The colony PCR involved the following. 96-well plate format was set up (36.5 µl H₂O, 0.5 µl pEPV3 forward primer (0.25 µg/µl), 0.5 µl pEPV3 reverse primer (0.25 µg/µl), 1.5

µl each (6.0 µl total) dNTPs (10 mM), 0.5 µl Vent™ DNA polymerase, 5 µl 10× Vent™ buffer, 1 µl of a 1:50 cell dilution, 50 µl total volume).

pEPV3 forward primer: 5' CATCAAGCTTATCGATACCGTCG 3' (SEQ ID NO:437)

5 pEPV3 reverse primer: 5' CACAGTAGTTCACCACTTTTCCC 3' (SEQ ID NO:438)

Colonies of *E. coli* LE392 were picked onto a master plate of LB + 13 µg/ml chloramphenicol (incubate throughout the day at 37° C) and then into 50 µl H₂O which has been placed into a 96-well plate. 1 µl of this dilution was used in above PCR reaction
10 (if the 96-well dilution plate is kept you will not need to prepare a master plate). Cultures for minipreps of plasmid candidates may be prepared directly from the cell dilutions.

The PCR program was run (95 °C - 5 minutes, 30 Cycles of: 95 °C - 1 minute, 58 °C - 1 minute, 72 °C - 30 seconds, 72 °C - 10 minutes, 4 °C - hold).

15

A 10 µl/ reaction was run on a 1.0 % TBE gel. A gel designed for 96 well plates and a multichannel pipettor were used to ease loading of the sample rows. The gel was run and stained with ethidium bromide. The positive clones were identified with appropriate molecular size insert(s), amplified by the flanking pEVP-3 primers.

20

Minipreps Of Plasmids To Identify Cells Carrying The Pevp-3 Vector With An Insert

The constructs that carried an insert were identified. The constructs having an insert were inoculated into a 5 ml LB/Cm culture, and incubated over night at 37 °C with
25 aeration. Miniprep plasmid DNA was prepared by a standard procedure. The miniprep DNA was digested with appropriate restriction enzymes to confirm the presence of the insert (enzymes flank SmaI site in pEVP-3) (10 µl miniprep DNA, 2 µl 10 × buffer, 1 µl XbaI, 1 µl XhoI, 6 µl ddH₂O, 20 µl total volume for digest).

To confirm the presence of an insert, the digest reactions were electrophoresed on an agarose gel and the gel was stained with ethidium bromide. The positive clones were used for the *S. pneumoniae* KNOCKOUTs procedure.

- 5 The confirmatory PCR reactions, using knock out-specific primers (quality control step) involved 35.5 μ l H₂O, 5 μ l 10 \times Vent™ buffer, 1 μ l knockout forward primer (0.5 μ g/ μ l), 1 μ l knockout reverse primer (0.5 μ g/ μ l), 0.5 μ l Vent™ (6.0 μ l total) DNA Polymerase (2000 U/ml), 1.5 μ l each dNTPs (10mM, 6.0 μ l total), 1.0 μ l miniprep DNA from test clone, 50 μ l total reaction volume. The PCR program was as follows: 95 °C for 5
10 minutes, 30 Cycles of: 95 °C for 1 minute, 60 °C for 1 minute, 72 °C for 30 seconds, 72 °C for 10 minutes, hold at 4 °C. The presence of the correct-sized insert was confirmed by agarose gel electrophoresis and ethidium bromide staining. The confirmed clones were used for the *S. pneumoniae* gene KNOCKOUT procedure. Glycerol stocks were made of all positive *E. coli* LE392 constructs and frozen at - 80 degrees C.

15

EXAMPLE 3

- The following provides a description of the high throughput gene disruption procedure used in *S. pneumoniae* strain (e.g., gene knockout procedure). The candidate *ceg*
20 fragments that were generated by the method described in Example 2 were used in the gene disruption procedure in order to identify *ceg* nucleotide sequences that are required for cell viability.

- Reactions were set up in a 1.5 ml eppendorf tubes or 96 well plate (1 μ g total of miniprep
25 pEVP-3 + insert DNA (usually 10 μ l of Qiagen miniprep DNA); then 200 μ l of *S. pneumoniae* (strain Rx-1) competent cells diluted 1:10 in competence media was added (1 ml of competence media = 980 μ l Todd Hewitt (Difco Laboratories) with 0.5% yeast extract, 20 μ l 10% BSA, 1 μ l 10 % CaCl₂, and 0.5 μ l (200 μ g/ml) Csp-1 competence peptide).

30

Controls were run with each KNOCKOUT experiment and involved 1 μ g pEPV3 *Lyt A* construct = positive control (non-essential), or 1 μ g pEPV3 *Fts Z* construct = negative control (essential). Then the 96 well plates and controls were incubated at 37 °C for 2.5 to 3 hours in 37 °C room without shaking. The 200 μ l of the samples were plated on
5 Todd Hewitt agar plates with 0.5% yeast extract and 2 μ g/ml chloramphenicol.

The samples were incubate over night at 37 °C in 5% CO₂ incubator. Control plates were checked for presence of colonies (pEVP-3::*lytA*) and no growth (pEVP-3::*ftsZ*). Plates were examined for growth (ca. 70-150 colonies) designating nonessentials and zero
10 colonies designating essential genes.

The polarity test was performed in a similar manner, using the polarity fragments described in Example 3.

15

EXAMPLE 4

The following provides a description of the autolysin procedure used to determine that the non-essential control samples of *S pneumoniae* contain a disrupted *lytA* gene.

20

Phenotypic Autolysin Test

The culture plates containing transformants carrying the *lytA* control vector were flooded
25 with 0.1% deoxycholate in H₂O. The plates were observed after 5-10 minutes. Plates with "ghosts" indicated intact *lytA* gene, or plates without "ghosts" indicated a disrupted *lytA* gene. The "ghost" phenomenon is due to detergent triggered autolysis of the cells, causing a gradual fading of the colonies.

30 The detergent treatment triggers the autolysin in *lytA* intact cells; it cannot trigger the autolysin (*lytA* gene product) in *lytA* disrupted cells. Colonies with intact *lytA* "ghost" in 5-10 minutes due to massive pneumococcal cell lysis.

EXAMPLE 5

The following provides a description of the procedure used to express the CEG proteins (e.g., designated CFE proteins) in *E. coli* cells.

CEG Protein Production

Full-length *ceg* gene were inserted into pET-21 expression vector using the *E. coli* BL21 λ DE3 expression system using the following method:

For each *ceg*, custom primers were used to insert N- and C- termini into vectors such that the 5' end (N-terminus of the CEG) is positioned properly for expression behind the T7 promoter and optimally placed with regard to the pET ribosome binding site. The pET vectors contain an *NdeI* site which allows positioning of ATG start site in the vector. In cases where the *ceg* sequence contains an internal *NdeI* site, blunt ligation of the *ceg* PCR fragment into the vector is accomplished via Klenow fill-in of the *NdeI* site. In many cases, primers were also designed such that the *ceg* 3' (C-terminus of the expressed protein) will contain an in-frame extension of 6X-histidine residues, encoded in the vector sequence of pET-21. The individual *cegs* were PCR amplified via custom designed primers as described above. Both *ceg* PCR and vector DNA were digested with appropriate restriction enzymes. The full-length *ceg* were ligated into the pET expression vector. The ligation mixture was transformed into competent *E. coli* BL21 λ DE3 cells and selected for transformants on LB agar with 50 μ g/ml ampicillin. Positive insert bearing clones were screened via minipreps of the plasmids and size analysis on 0.8% agarose gels, with detection by ethidium bromide staining, as above.

Protein Production

The proper reading frame of each *ceg* inserted into pET-21 is verified by DNA sequencing.

A small (2-5 ml) test culture of *E. coli* BL21 λ DE3 with the insert-bearing plasmid is tested for protein expression by IPTG induction of the expression vector for 1-2 hours. The expression is verified by SDS-Polyacrylamide Gel Electrophoresis analysis of a whole cell extract (SDS extract of 0.5-1 ml of cells treated at 100 °C for 5 minutes) to determine whether the protein is over-expressed and migrates at the correct predicted molecular weight.

The protein is overproduced and purified via the following method. A large scale (500-1000ml) culture of *E. coli* is grown to early logarithmic phase in broth (e.g., LB broth) and protein expression induced for 2 hours with IPTG (isopropyl-D-thiogalactoside). The cells are harvested by centrifugation (8000 X G; 15 minutes) and the cell pellets resuspended in 20 ml. of buffer. The cells are lysed by sonication, and the supernatant fluid centrifuged at low speed (5000 X G, 15 min.) to remove unbroken cells. The supernatant fluid, containing the over-expressed protein is subjected to Ni-NTA affinity column chromatography (Quiagen, Inc., Chatsworth, CA). The 6X-histidine residues linked at the C-terminal end of the CEG proteins permit rapid protein purification via selective binding to a Ni-NTA resin column. The protein-bound Ni-NTA resin was to remove contaminants, and the bound proteins subsequently eluted with imidazole and recovered. It is possible to upscale this procedure to larger volumes for higher yields of proteins.

EXAMPLE 6

The following provides a description of the methods used to purify all 2CEG polypeptides (e.g., 2CFE polypeptides #19-117; SEQ ID NOS:349-436) having a histidine tag at their C-terminal ends. The 2CEG polypeptides having the his-tags were produced by the methods described in Example 5, *supra*. As an example, results of purification of 2CFE 75 polypeptide are presented.

Production Of The CFE Polypeptides

The BL21λDE3 cells harboring recombinant pET-21 vectors carrying a 2CFE nucleotide sequence (SEQ ID NOS:244-331) were cultured in LB broth containing ampicillin.

- 5 When the A₆₀₀ reached approximately 0.6, protein production was induced by adding 1.0 mM of IPTG, the cells were cultured for an additional 2 hours. The cell pellet was collected by centrifugation, and the collected cell pellet was sonicated in Solution A (50 mM NaPO₄; 300 mM NaCl, pH 8.0). The sonicated cells were centrifuged at 10,000 RPM to remove the debris.

10

Purification Of The CFE Polypeptide

- The supernatant was diluted with Solution A, loaded onto a Ni-NTA column (Quiagen) equilibrated with Solution A; the column bed size was 2.5 x 25 cm, and the flow rate was approximately 3.0 ml/minute. The 2CFE protein was eluted using a linear gradient of imidazole, using 0-250 mM in 450 ml, flow rate approximately 3.0 ml/minute. The eluted samples were collected as 22 ml fractions per tube and the eluted samples were monitored using spectrophotometry. The amount of protein in the eluted fractions was estimated using the Bradford method (Bradford, M. M., 1976 *Anal. Biochem.* 72:248) and
- 15 the samples were run on an SDS-PAGE gel (Novex EC6008) (Figure 3 A). Fractions were selected for pooling based on the results of the SDS-PAGE gel. The pooled fractions were concentrated using a 10,000 MW Centricon (Amicon) to approximately 5 ml.

- 25 The 2CFE 75 polypeptide, a precipitate formed and was redissolved upon increasing the sample volume and removing the imidazole by repeated concentration in 50 mM Tris, 100 mM NaCl, pH 7.5. Varying amounts of the 2CFE 75 polypeptide were diluted in either 20 mM Tris, 20 mM KCl, pH 7.5 or 20 mM Tris, 20 mM MgCl₂, pH 7.5 at concentrations of 12, 24, or 36 ug/ml. The diluted samples were electrophoresed on an
- 30 SDS-PAGE gel under non-reducing conditions (Figure 3 B). The results of Figure 3 B suggests that 2CFE 75 forms a multimer.

EXAMPLE 7

The following provides a description of the methods used to purify CEG polypeptides that lack a histidine tag (e.g., 2CFE polypeptides #1-17; SEQ ID NOS:332-348). As an example, the results of purification of CFE 3 polypeptide are presented.

Purification of the CFE 3 Polypeptide

The 2CFE 3 polypeptide was produced using the large scale IPTG-induced method described in Example 5, *supra*. The 2CFE 3 (SEQ ID NO:334) polypeptide lacks a C-terminal histidine tag. The 2CFE 3 polypeptide was purified using a 2-column procedure. The 2CFE 3 polypeptide preparation was eluted from a 26/10 Q Sepharose column (Pharmacia) using a 0-1.0 M NaCl gradient, 2 ml/minute flow rate, and the gradient size was 1 liter. Then the 2CFE 3 polypeptide was eluted from a hydroxyapatite Bio-gel column (Bio-Rad) using a 5-200 mM potassium phosphate (pH 8.0) gradient, the flow rate was 0.3 ml/minute, and the gradient size was 300 ml. A sample of the 2CFE 3 preparation was run on a polyacrylamide gel (Figure 4).

EXAMPLE 8

The following provides a description of the size exclusion chromatography methods used to estimate the molecular weight and determine whether the CEG polypeptides oligomerize. The CFE polypeptide may oligomerize to form monomers, dimers, tetramers, hexameric rings, or other oligomeric forms.

Size exclusion chromatography was performed on all isolated 2CFE polypeptides #s 1-117 (e.g., SEQ ID NOS:332-436). This method was performed using various types of columns, depending on the particular 2CFE polypeptide tested.

The Biosil SEC-125 HPLC Gel Filtration column (BioRad Laboratories, Inc) was used, for example, to characterize CFE 8. The mobile phase was 0.2 M KH_2PO_4 , 0.9% NaCl pH 6.8.

- 5 The Phenomenex 600 x 7.5 mm Biosep SECS 3000 column was used, for example to characterize 2CFE 21 and 39. The mobile phase for size exclusion was 50 mM Na_2HPO_4 , pH 7.0 and 150 mM NaCl run at 1 ml/minute in a Gilson HPLC system, with protein detection at 280 nm.

10 EXAMPLE 9

The following provides a description of the computer-aided methods used to search for similarities between the amino acid sequences of the CEG polypeptides and sequences available through public and proprietary databases. In many cases, the function of the CEG polypeptides was suggested by the results of the similarity searches. The function of some of these CEG polypeptides has been confirmed by performing additional analyses. Table V provides a list of the suggested and confirmed functions of CEG polypeptides designated CFEs #1-117.

- 20 The putative function of the CFE polypeptides were determined using computer-aided bioinformatic approaches, including distant homologies, motif searching, or predictions based on statistical rules. For example, the distant homology approach involved pairwise or multiple sequence alignments, employing tools such as FASTA, and Psi-BLAST. The motif searching approach involved using sophisticated hidden Markov models. The approach based upon predictions of statistical rules involved prediction of transmembrane regions, coiled-coil, and other structural motifs. These approaches have been reviewed in *Computational Methods In Molecular Biology* 1998, eds. Salxber, S.L., Searls, D.B. Searls, and Kasif, S. , Elsevier, and in *Bioinformatics: A Practical Guide To The Analysis Of Genes And Proteins* 1998 eds Baxevanis, A. D. and Francis Ouellete, B.F. , Wiley-Interscience.

30

Global sequence similarity searches were performed using the amino acid sequences of all the conserved essential gene sequences (e.g., CFEs 1-117; SEQ ID NOS:114-226) to search against a non-redundant protein database using the BLAST2 algorithm (Altschul S.F., et al., 1997 *Nucleic Acids Res.* 25(17):3389-3402). In a similar search, similar
5 sequences were identified in the Concordance database using the "Neighbor" function (Brucoleri R. E., Dougherty T.J., Davison D.B. 1998 *Nucleic Acids Res.* 26(19):4482-4486). To determine if the predicted amino acid sequences were full length and in the proper reading frame, BLAST-type searching and CLUSTAL multiple sequence alignments (Higgins D.G., et al., 1996 *Methods Enzymol.* 266:383-402) were used.
10 Local sequence similarity searches were performed, by searching for Prosite (Hofmann K., et al., 1999 *Nucleic Acids Res.* 27(1):215-219) and Pfam motifs (Bateman A., et al., 2000 *Nucleic Acids Res.* 28(1):263-266). Additionally, the amino acid sequences of the CFEs were analyzed by performing protein threading analyses using the ProCeryon fold recognition program (Sippl, et al., 1992 *Proteins* 13:258-271; Sippl, J. 1993 *J. Comp.*
15 *Aided Mol. Design* 7:473-501; www.proceryon.com) and Geneformatics.

In bacteria, many operons include genes encoding different proteins that catalyze discrete steps of a common biochemical pathway. Therefore, the operon structures in *S. pneumoniae* was compared with that in other bacteria in order to predict the function of
20 CFE polypeptides.

Additionally, analysis of bacterial metabolic pathways were performed using Pathway Tools from DoubleTwist, based on the EcoCyc system (Karp P.D., et al., 1999 *Nucleic Acids Res.* 1999 27(1):55-58). This analysis was used to predict which CFEs mediate
25 various steps of the pathways.

When the sequence identity between a CFE polypeptide and the annotated database (e.g., SwissProt, Genbank) was low (e.g., sequence identity less than about 30%), a Protein Threading (e.g., fold recognition) method was used to predict similarities in the folded
30 protein structure of CFE polypeptides in the absence of a high level of sequence similarity with proteins in the databases (review by Teichmann, et al., 1999 *Current Opinion in*

Structural Biology 9:390-399). The Protein Threading method predicts the compatibility of a query sequence (e.g., CFE polypeptide sequences) with each of the folds in a library of known protein structures. The library of known protein structures as developed, maintained, and updated throughout the search process.

5

A list of potential structural folds, onto which each query was compatible, was generated for all CFE polypeptides (e.g., SEQ ID NOS:114-226). The fold assignments for each query were used to generate pairwise sequence alignments. The pairwise sequence alignments were used to generate protein models of the query polypeptide (e.g., CFE polypeptides).

10

The pairwise sequence alignments were also used to compare the position of critical residues of the structural template with the query polypeptide. The list of critical residues was generated by using multiple sequence alignments derived from a structural classification of proteins to generate a conservation profile which provided sequence-specific positions conserved across a homologous family of protein folds. Comparative modeling was used to search the model of the query polypeptide for the critical residues and determine whether the structural and functional motifs are conserved in the query protein. Conservation of structural and functional motifs permitted assignment of putative structure and function to a query polypeptide sequence.

20

The Protein Threading method was used to search for putative folded structure and function for all CFE polypeptides (SEQ ID NOS:114-226). The CFE polypeptides having significant sequence identity (e.g., more than 30%) to known proteins were assigned putative functions with a high level of confidence.

25

EXAMPLE 10

The following provides a description of the methods used to characterize purified, CFE 101 polypeptide. The 2CFE 101 polypeptide mediates the conversion of pantothenate to 4' phosphopantothenate, and is predicted to be a pantothenate kinase.

30

Computer-Aided Comparison

The computer-aided comparison, as described in Example 9 *supra*, suggests that the amino acid sequence of the CFE 101 polypeptide (SEQ ID NO:210) is 42% similar to the amino acid sequence of the *coaA* protein of *E. coli*. Thus, CFE 101 may be a pantothenate kinase, which mediates the conversion of pantothenate to 4' phosphopantothenate (Figure 5).

Circular Dichroism and Circular Dichroism Thermal Melt Analysis

10

Circular dichroism and circular dichroism melt methods were used to determine the folded structure of the expressed and isolated 2CFE polypeptides. For example, this method was used to characterize the folded structure of isolated 2CFE 101 (SEQ ID NO:421).

15

The starting concentration of the 2CFE 101 polypeptide was such that OD₂₀₅ was approximately 1.5, and the OD₂₈₀ was approximately 0.05 (e.g., 0.05 to 0.1 mg/ml). The starting concentration of 2CFE 101 was approximately 344 μ M in 50% glycerol, 50 mM Tris, 100 mM NaCl, 5 mM MgCl₂, 0.5 mM EDTA, at pH 7.5. The polypeptide was diluted to a final concentration of 7 μ M, as determined by absorbance at A₂₈₀, in 20 mM Na-phosphate, 100 mM KCl, at pH 7.0. The circular dichroism analysis was performed using quartz cuvettes, the instrumentation was from JASCO (Model J-720), the readings were performed at 25 degrees C (Figure 6 A). The band width was 1 nm, the sensitivity was 20 mdeg, the response was 0.25 seconds, the scan speed was 50 nm/minute, and the step was 0.5. The circular dichroism thermal melt analysis was performed at a range of between 0 and 100 degrees C (Figure 6 B). Additionally, the circular dichroism was performed comparing monomer and aggregate pools of 2CFE 101.

Size Exclusion Analyses

Size exclusion chromatography methods were performed using the Biosil SEC column, as described in Example 8 *supra*. The results suggest that the 2CFE 101 polypeptide
5 forms monomer (40,200 Da) and oligomers (194,000 Da). The specific activity of the monomer and oligomeric forms of 2CFE 101 were determined, as described below.

Biochemical Assays

10 The biochemical assays of the 2CFE 101 polypeptide was based on the PK/LDH coupled enzyme assays described by Vallari, D. S., et al. (1987 *J. Biol. Chem.* 262:2468-2471) and Song, W. -J., et al., (1994 *J. Biol. Chem.* 269:27051-27058).

Briefly, the assay was performed as follows. The reaction included: 885 μ l of 0.1 M
15 Tris-HCl (pH 7.6), 25 μ l NADH (14.1 mM), 20 μ l ATP (10.7 mM), 50 μ l phospho-enol-pyruvate (56 mM), 5 μ l LDH/PK (lactose dehydrogenase/PK; Sigma, catalog # P-0294, 60 U/ ml PK, 1050 U/ml LDH), 5 μ l of the 2CFE 101 polypeptide (9 mg/ml in 50 mM Tris-HCl, pH 7.5, 100 mM NaCl which was diluted to 4.5 mg/ml in 50% glycerol). The reaction was started by adding 10 μ l pantothenate (100 mM; Sigma, catalog # P2250).
20 The production of ADP in the reaction was monitored by measuring the absorbance at 340 nm. The results in Figure 8 show that the 2CFE 101 polypeptide mediates ADP production in the presence of pantothenate and ATP. The K_m of pantothenate ($n=4$) was 144 (± 16.5) μ M, the V_{max} of the 2CFE 101 polypeptide ($n=4$) was 2.04 (± 0.25) μ M min^{-1} mg^{-1} . The monomer form has a specific activity of approximately 1.7 μ M min^{-1} mg^{-1} .
25 The oligomeric form has a specific activity of 0.26 μ M min^{-1} mg^{-1} .

Alternatively, the 2CFE 101 polypeptide can be tested in an assay that monitors the conversion of pantothenate to 4'-phosphopantothenate. The same reaction described above can be used, except ^{14}C -labeled pantothenate is used. The reaction can be
30 monitored by measuring the amount of ^{14}C -labeled 4'-phosphopantothenate produced.

EXAMPLE 11

The following provides a description of the methods used to characterize purified, CFE 39 and CFE 21 polypeptides, carrying a C-terminal histidine 6-tag. The methods include
5 helicase reactions, in which synthetic Holliday Junction templates are resolved into duplex structures. In one method, helicase reaction was monitored using radiolabeled templates. In another method, the helicase assay was adapted for use in a high throughput assay employing fluorescence labeled templates.

10 Computer-Aided Comparison

The computer-aided comparison, as described in Example 9 *supra*, suggests that the CFE 39 polypeptide (SEQ ID NO: 148) is an RuvA homologue. The comparison also suggests that CFE 21 (SEQ ID NO:132) is an RuvB homologue.

15

Previous studies by Parsons and others have shown that RuvA and RuvB proteins, in *E. coli*, promote branch migration or movement of Holliday Junctions during genetic recombination and DNA repair (Parsons, C. A., et al., 1992 *Proc. Natl., Acad. Sci. USA* 89:5452-5456; Tsaneva, I. R., et al., 1993 *Proc. Natl., Acad. Sci. USA* 90:1315-1319;
20 Muller, B., et al., 1993 *J. Biol. Chem.* 268:17179-17184; Mitchell, A. H. and S. C. West 1996 *J. Biol. Chem.* 271:19497-19502; Parsons, C. A. and S. C. West 1993 *J. Molec. Biol.* 232:397-405; Tsaneva, I. R., et al., 1992 *Molec. Gen. Genet.* 235:1-10; Mitchell, A. H. and S. C. West 1994 *J. Molec. Biol.* 1994 243:208-215).

25 Size Exclusion Chromatography

Size exclusion chromatography was performed on 2CFE 39 (SEQ ID NO:366) and 2CFE 21 (SEQ ID NO:350) using the Phenomenex 600 x 7.5 mm Biosep SECS 3000 column, as described in Example 8 *supra*. Protein standards (BioRad) were used to calibrate the
30 column, including thyroglobulin (670,000 Da), gamma globulin (158,000 Da), ovalbumin (44,00 Da), myoglobin (17,00 Da), and B-12 (1350 Da).

The results indicate that 2CFE 39 (RuvA) forms tetramers and 2CFE 21 (RuvB) forms a hexameric ring structure. Selected eluted samples were electrophoresed on a polyacrylamide gel (Novagen) (Figure 9).

5

The Holliday Junction Analysis Using Radiolabeled Templates

The Holliday Junction analysis was performed using radiolabeled, synthetic, asymmetrical, Holliday Junction templates, as described in Hiom, K. and S. C. West
10 1995 *Cell* 80:787-793. The Holliday Junction templates were produced by annealing together four separate, single-stranded, oligonucleotide strands to form four-stranded structures (e.g., the Holliday Junction template). The Holliday Junction templates were reacted with the 2CFE 39 and 2CFE 21 polypeptides, in a helicase reaction, to test their ability to generate two duplex structures.

15

Producing the Synthetic Holliday Junction Templates

The asymmetrical Holliday Junction templates were produced by annealing the following oligonucleotide sequences:

20

Oligonucleotide strand 1:

5'-CCAGTGATCACATACGCTTTGCTAGGACATCTTGATATCAGCCCACGTT
CACCCGCCTACCAGTGCCACGTTGTATGCCACGTTGACC-3' (SEQ ID NO:438)

25 Oligonucleotide strand 2:

5'-GGGTCAACGTGGGCATACAACGTGGCACTGGTAGGCGGGTGAACGTGGG
CTGATATCAAGATGTCCATCTGTCCGTTCTATGACGT-3' (SEQ ID NO:439)

Oligonucleotide strand 3:

30 5'-AACGTCATAGATGAACGGACAGATCATGGTGCTTTTAAAGTCTAGAGAC
TATCGAGCATTAGTACCAGTATCGAATCCGTCTTGTC-3' (SEQ ID NO:440)

Oligonucleotide strand 4:

5'-TTTGACAAGACGGATTCGATACTGGTACTAATGCTCGATAGTCTCTAGAC
TTTAAAAGCACCATGTAGCAAAGCGTATGTGATCACTG-3' (SEQ ID NO:441)

5

Oligonucleotide strand 3 was labeled at the 5' end using approximately 300 ng of oligonucleotide strand 3, 1 μ l 10x Phosphate Buffer, 5 μ l 32 P ATP, 1 μ l T4 polynucleotide kinase (Gibco-BRL)), in a 10 μ l volume, and the reaction was performed at 37 degrees C for 30 minutes. The reaction was loaded onto a G50 column to remove the
10 unincorporated radiolabel. The final concentration of the radiolabeled oligonucleotide strand 3 was approximately 15 ng per μ l.

Approximately equimolar amounts of the four oligonucleotide strands were annealed (e.g., hybridized). The annealing reaction included: 5 μ l Annealing Buffer (200 mM
15 Tris-Cl pH 8.0, 100 mM MgCl₂, 1 M NaCl, 10 mM DTT); 450 ng of radiolabeled oligonucleotide strand 3; and 1000 ng each of oligonucleotide strands 1, 2, and 4; in 50 μ l total reaction volume. The control annealing reaction included: 5 μ l Annealing Buffer, 60 ng radiolabeled oligonucleotide strand 3; 1000 ng oligonucleotide strand 4; in 50 μ l total reaction volume. Annealing was performed at 95 degrees C for 5 minutes, 65
20 degrees C for 30 minutes, 42 degrees C for 30 minutes, and room temperature (e.g., between about 23 to 27 degrees C) for 30 minutes to generate the synthetic Holliday Junction templates. The synthetic Holliday Junction templates were gel or column-purified to remove the duplex and non-annealed products. As a control, oligonucleotide strands 3 and 4 were annealed to form duplex structures. The synthetic Holliday Junction
25 templates and duplex structures were stored at -20 degrees C.

CFE 39 and CFE 21: The Helicase Reaction Using Radiolabeled Templates

The helicase reaction was performed to determine whether 2CFE 39 and 2CFE 21
30 resolved the synthetic Holliday Junction templates into duplex structures. The helicase reaction was performed as follows. A 50 μ l total reaction volume included: 25 μ l of 2x

Reaction Buffer (50 mM Tris-Cl pH8.0, 30 mM MgCl₂, 2 mM ATP); 1 µl synthetic Holliday Junction template (36 ng); 2 µl 2CFE 39 (1 µM); and 2 µl 2CFE 21 (1 µM). The reaction was incubated at 37 degrees for 30 minutes. The reaction was stopped by adding 5 µl Stop Buffer (100 mM Tris-Cl pH 7.5, 5 mg/ml Proteinase-K, 5% SDS). The
5 stopped reaction was returned to 37 degrees C for 5 minutes. The helicase reaction was loaded onto and run on a non-denaturing, 12% PAGE, Tris-glycine gel.

The results shown in Figure 10, lanes 6, 7 and 8, indicate that the 2CFE 39 and 2CFE 21 polypeptides resolved the synthetic Holliday Junction templates into duplex structures.

10

CFE 39: The Helicase Reaction

It has been previously shown that *E. coli* RuvA binds to Holliday Junction templates (Parsons, C. A., et al., 1992 *Proc. Natl. Acad. Sci. USA* 89:5452-5456). The ability of *S.*
15 *pneumoniae* CFE 39 to bind to a Holliday Junction template can be tested by employing the helicase assay described herein. The results of the helicase assay can be monitored by performing a gel shift assay and/or capillary electrophoresis. The presence of a Holliday Junction template bound to 2CFE 39, which migrates more slowly than the Holliday Junction template alone, would indicate that *S. pneumoniae* 2CFE 39 binds to Holliday
20 Junction templates.

CFE 39 and CFE 21: Holliday Junction Analysis Using Fluorescent-Labeled Templates

The helicase reaction described herein was performed using Holliday Junction templates
25 having one oligonucleotide strand labeled with a fluorescent agent and another strand labeled with a quenching agent. The 5' fluorescent end and the 3' quenching end of the strands that make up the Holliday Junction templates are in proximity to each other, resulting in a non-fluorescent template. When the Holliday Junction templates are resolved into duplex structures, the fluorescent and quench ends are not in proximity to
30 each other, resulting in fluorescence.

The Holliday Junction templates used to perform this experiment comprised the following: the 5' end of oligonucleotide strand 1 was labeled with a fluorescein (e.g., the fluorescent agent), and the 3' end of oligonucleotide strand 4 was labeled with DABCYL (e.g., the quenching agent). The oligonucleotide strand 1 labeled with fluorescein and the
5 oligonucleotide strand 4 labeled with DABCYL were custom synthesized (Gibco-BRL Life Technologies, Inc.).

The fluorescein and DABCYL labeled oligonucleotides were annealed in a reaction, as described above, to generate synthetic Holliday Junction templates. The helicase reaction
10 was performed as described above. The results of the helicase reaction were monitored by measuring the unquenching of the Holliday Junction templates with time (Figure 11).

The helicase assay using Holliday Junction templates labeled with fluorescent-quenching agents can be adapted for use in high throughput analyses to test 2CFE 39, 2CFE 21, and
15 other polypeptides for their ability to resolve the templates into duplex structures.

EXAMPLE 12

The following provides a description of the methods used to characterize purified, CFE 8
20 polypeptide, which lacks a histidine tag. The CFE 8 is a putative DNA single-stranded binding protein.

Computer-Aided Comparison

25 The computer-aided comparison, as described in Example 9 *supra*, suggests that the CFE 8 polypeptide (SEQ ID NO:121) may be a single stand binding protein homologue, such as SSB.

Size Exclusion Chromatography

The 2CFE 8 polypeptide (SEQ ID NO:339) was characterized by size exclusion chromatography, using the Biosil SEC-125 HPLC Gel Filtration column as described in Example 8 *supra*. The chromatogram showed one peak corresponding to a molecular weight of approximately 89 kDa. Based on the nucleotide sequence, the predicted molecular weight of 2CFE 8 is 17,351 Da. In non-denaturing conditions, 2CFE 8 forms a multimer.

10 Binding Reaction

The 2CFE 8 polypeptide was reacted with a single-stranded oligonucleotide A. Briefly, the binding reaction included: 50 μ M of 2CFE 8 polypeptide, 50 μ M oligo strand A, 20 mM Tris/20 mM KCl pH 7.5. The binding reaction was performed at 37 degrees C, for 2 hours.

Oligonucleotide strand A:

5'-TTAGGGCCCGGGCTATCTTACAATCTCGTT-3' (SEQ ID NO:442)

20 Capillary Electrophoresis

The results of the binding reaction was monitored by capillary electrophoresis, following the methods described in "Handbook of Capillary Electrophoresis" 2nd Edition, 1997, ed. J. Landers.

25

Separation was performed using an uncoated capillary tube (360 μ m o.d., 50 μ m i.d., with a 50 cm effective separation length; Watrex International, Inc., Pittsford, NY) and 50 mM borate pH 9.3 as the mobile phase, at 25 kVolts, 20 minutes separation time.

30 The results indicate that 2CFE 8 alone elutes as a sharp peak, indicating little adsorption to the uncoated capillary wall (Figure 12 A). The shape of the peak and peak retention

time changed with 2CFE 8 in the presence of all oligonucleotides tested (Figure 12 B). As a negative control, MurB polypeptide (Pucci, M. J., L. F. Discotto, and T. J. Dougherty 1992 "Cloning and Identification of the Escherichia coli murB DNA sequence, which encodes UDP-N-acetylenolpyruvoylglucosamine reductase" *J. Bacteriol.* 174:1690-1693) was reacted with the same oligonucleotides. MurB reacted with or without the oligonucleotides showed no change in peak shape or retention time.

After capillary electrophoresis analyses, the 2CFE8 alone and 2CFE plus oligonucleotide samples were run on native polyacrylamide gels to determine whether the polypeptide was intact. The results indicate that in all cases, 2CFE 8 was intact and had not degraded with time or storage.

Mobility Shift Assays

The ability of 2CFE 8 polypeptide to bind oligonucleotide strand A was tested in a mobility shift assay.

The results indicate that 2CFE 8 binds single stranded oligonucleotides (Figure 13 A and B). In Figure 13 A, the gel was stained with ethidium bromide. The unbound oligonucleotides appear near the bottom of the gel, while the bound oligonucleotides appear near the middle. The same gel was stained with Coomassie (Figure 13 B), revealing that 2CFE 8 polypeptide bound to the oligonucleotide migrated further than unbound 2CFE 8, due to the change in charge carried by the oligonucleotide. Various ratios of 2CFE8:oligo were tested. The optimal binding ratio was 2:1.

The Effect of MgCl₂

The 2CFE 8 polypeptide precipitated in the presence of 5 mM MgCl₂. The precipitation was reversible by the addition of 1 μ M of the oligonucleotides tested. The observation indicates specific binding between 2CFE 8 polypeptide and the oligonucleotides tested.

Scintillation Proximity Assay

Scintillation proximity assay (SPA) methods can be used in a high throughput screening procedure to monitor, for example, a binding reaction. SPA utilizes beads (Amersham) which are coated on the surface with a particular compound or molecule. For example, the SPA bead may be coated with avidin to facilitate binding with any molecule having a biotin tag.

The binding reaction of the 2CFE 8 polypeptide and the oligonucleotide strand A can be monitored using SPA beads and a scintillation counter. The beads can be coated with avidin, the 2CFE 8 polypeptide can be tagged with biotin, and the oligonucleotide strand A can be radiolabeled.

EXAMPLE 13

The following provides a description of the methods used to characterize purified, 2CFE 3 (SEQ ID NO:334) and 2CFE 86 (SEQ ID NO:409) polypeptides.

The 2CFE 3 polypeptide catalyzes the conversion of D-glucosamine-6-phosphate to D-glucosamine-1-phosphate, indicating that 2CFE 3 mediates amino-sugar biosynthesis through the N-acetyl glucosamine pathway (Figure 14).

The 2CFE 86 polypeptide catalyzes the conversion of D-glucosamine-1-phosphate to N-acetylglucosamine-1-phosphate, and the conversion of N-acetylglucosamine-1-phosphate to UDP-N-acetylglucosamine-1-phosphate, which indicates that 2CFE 86 also mediates amino-sugar biosynthesis through the N-acetyl glucosamine pathway (Figure 14).

Computer-Aided Comparisons Of CFE 3

The computer-aided comparison, as described in Example 9 *supra*, suggested that the CFE 3 polypeptide (SEQ ID NO:116) is a phosphoglucosamine mutase, such as GlmM.

Purification of the CFE 3 Polypeptide

The 2CFE 3 polypeptide was produced using the large scale IPTG-induced method described in Example 5, *supra*. The 2CFE 3 polypeptide lacks a C-terminal histidine tag.

- 5 The 2CFE 3 polypeptide was purified using a 2-column procedure. The 2CFE 3 polypeptide preparation was eluted from a 26/10 Q Sepharose column (Pharmacia) using a 0-1.0 M NaCl gradient, 2 ml/minute flow rate, and the gradient size was 1 liter. Then the 2CFE 3 polypeptide was eluted from a hydroxyapatite Bio-gel column (Bio-Rad) using a 5-200 mM potassium phosphate (pH 8.0) gradient, the flow rate was 0.3
10 ml/minute, and the gradient size was 300 ml. A sample of the 2CFE 3 preparation was electrophoresed on an SDS polyacrylamide gel (Figure 4).

Affinity Capillary Electrophoresis of CFE 3

- 15 Affinity capillary electrophoresis methods were used to determine whether the 2CFE 3 polypeptide binds to various glucose derivatives. Binding was performed under equilibrium conditions, in which the sugars were dissolved in the running buffer and reacts with 2CFE 3 during separation in the column. The affinity capillary electrophoresis method used to analyze 2CFE 3 follows the methods described in
20 "Handbook of Capillary Electrophoresis" 2nd Edition, 1997, ed. J. Landers.

- Briefly, 2CFE 3 polypeptide was reacted with increasing amounts of various glucose derivatives (e.g., substrate) at 25, 30 and 37 degrees C. The glucose derivatives included UDP-glucose, glucose-1-phosphate, glucose-6-phosphate, glucosamine-1-phosphate, and
25 glucosamine-6-phosphate. The reaction included: 2CFE 3 polypeptide (2.0 mg/ml), separation buffer (25 mM Tris; 192 mM Glycine, pH 8.0; BupH Tris-Glycine Buffer Packs, Pierce). Separation was performed at 25 kVolts, separation time was 15 or 20 minutes.

- 30 The results shown in Figure 15 A indicate that at 25 degrees C, 2CFE 3 binds to D-glucose-1-phosphate in a dose-dependent manner, as the peak shape and/or the retention

time for 2CFE 3 changes in the presence of 100 and 500 μ M D-glucose-1-phosphate compared to unreacted 2CFE 3.

5 The results shown in Figure 15 B indicate that at 25 degrees C, 2CFE 3 binds to D-glucosamine-6-phosphate in a dose-dependent manner, as the peak shape and/or the retention time for 2CFE 3 changes in the presence of 100 and 500 μ M D-glucosamine-6-phosphate compared to unreacted 2CFE 3.

10 The results shown in Figure 15 C indicate that at 25 degrees C, the 2CFE 3 polypeptide also binds to glucose-6-phosphate.

A comparison of 2CFE 3 reacted with various glucose derivatives, at 30 degrees C, is shown in Figure 15 D. The results indicate that D-glucosamine-6-phosphate is a putative substrate for 2CFE 3, as this reaction exhibits the greatest change in peak shape and/or retention time.

CFE 3: Capillary Electrophoresis and Laser-Induced Fluorescence

20 In a further analysis of 2CFE 3 polypeptide, capillary electrophoresis was performed with laser-induced fluorescence in order to separate and detect interaction between the substrate (e.g., D-glucosamine-6-phosphate) and the product (e.g., D-glucosamine-1-phosphate) in a one dose, one time-point procedure.

25 The 2CFE 3 polypeptide was derivitized by reacting 10 mM FITC (fluorescein isothiocyanate dissolved in methanol; Calbiochem, San Diego, CA) with D-glucosamine-6-phosphate, at ambient temperature, in the dark, overnight. The FITC-derivatized 2CFE 3 polypeptide (2.0 mg/ml) was reacted with the substrate (D-glucosamine-6-phosphate and D-glucosamine-1-phosphate) for one hour.

30 Separation was performed using an uncoated capillary (360 μ m o.d., 50 μ m i.d., with a 50 cm effective separation length) and 50 mM borate (pH 9.3) as the mobile phase. The

argon-ion laser had an excitation wavelength of 488 nm and an emission filter of 520 nm (Beckman, Fullerton, CA). The results shown in Figure 16 indicate that 2CFE 3 binds and catalyzes the conversion of D-glucosamine-6-phosphate to D-glucosamine-1-phosphate.

5

Computer-Aided Comparison Of CFE 86

The comparison results, as described in Example 9 *supra*, suggested that the CFE 86 polypeptide (SEQ ID NO:195) is an acetyltransferase, such as GlmU which is a bifunctional enzyme in *E. coli*. It has been previously shown that, in *E. coli*, GlmU is a bifunctional protein having both the acetyltransferase and uridylyltransferase active sites (Mengin-Lecreulx, D. and J. van Heijennort 1994 *J. Bacteriol.* 176:5788-5795; Gehring, Al., et al., 1996 *Biochemistry* 35:579-585). The bifunctional enzyme catalyzes the conversion of D-glucosamine-1-phosphate to N-acetylglucosamine-1-phosphate (acetyltransferase), and catalyzes the conversion of N-acetylglucosamine-1-phosphate to UDP-N-acetylglucosamine-1-phosphate (uridylyltransferase). The K_m of the acetyltransferase and uridylyltransferase reactions has been previously calculated (Mengin-Lecreulx, D. and J. van Heijennort 1994 *supra*). Additionally, the crystal structure of GlmU from *E. coli* is known (Brown, K., et al., 1999 *EMBO J.* 18:4096-4107).

20

Purification of the CFE 86 Polypeptide

The 2CFE 86 polypeptide (SEQ ID NO:409) has a C-terminal histidine tag. The 2CFE 86 polypeptide was produced using the large scale IPTG-induced method described in Example 5, *supra*. The 2CFE 86 polypeptide was purified using the Ni-NTA affinity column method described in Example 6, *supra*. The eluted 2CFE 86 polypeptide was dialyzed against 50 mM Tris-Cl, 100 mM NaCl, 25% glycerol, pH 8.0. Samples of the purified 2CFE 86 polypeptide were electrophoresed on a polyacrylamide gel (Figure 17).

30

Coupling CFE 3 and CFE 86 to Produce UDPAG

A biochemical assay was performed, to determine whether 2CFE 3 and 2CFE 86 convert D-glucosamine-6-phosphate to UDP-N-acetylglucosamine-1-phosphate (e.g., UDPAG).

- 5 The 2CFE 3 and 2CFE 86 polypeptides were used in a coupled reaction based on the assays described in Jolly, L. P., et al., 1999 *Eur. J. Biochem.* 262:202-210.

A time-dependent and dose-dependent assay were performed. Briefly, the assay was performed in 96-well plates, each well including 100 µl volume. The assay included: 1
10 mM D-glucosamine-6-phosphate (Sigma); 0.7 mM D-glucosamine-1,6-diphosphate (Sigma); 1.2 mM acetyl-Coenzyme A (Sigma); and 5 mM uridine-5'-phosphate (Sigma); 3 mM MgCl₂ (Sigma); 50 mM Tris-Cl, pH 8.0 (Life Technologies). The reaction was started by adding 1 µg of 2CFE 3; and 10 µg of 2CFE 86. The reaction was performed at room temperature. The reaction was stopped at 0, 15, 30, and 65 minutes, by filtering out
15 the 2CFE polypeptides.

The results of the assay was monitored by HPLC (high pressure liquid chromatography) using an Optisil 10µ SAX column (250 x 4.6 mm), measuring at 262 nm, the mobile phase was 150 mM KH₂PO₄ (pH 3.5), and 1.5 ml/minute flow rate. The results shown in
20 Figure 18 show the time-dependent assay and indicate that HPLC detected the presence of UDPAG.

CFE 86: The Uridyltransferase Reaction

- 25 The 2CFE 86 polypeptide was tested in a uridyltransferase reaction, in which N-acetyl-D-glucosamine-1-phosphate and UTP produce UDP-N-acetylglucosamine. The uridyltransferase reaction was monitored using a malachite green/inorganic pyrophosphatase assay (e.g., malachite green-IPPAse assay) and/or monitored using HPLC. The malachite green-IPPAse assay was used to measure orthophosphate
30 production from digestion of the pyrophosphate liberated in the uridyltransferase reaction.

The malachite green reagent was prepared as follows. A 0.045 % solution of malachite green (Sigma; M9636) was prepared in water. A 4.2 % solution of ammonium molybdate (Mallinckrodt) was prepared in 4N HCl. The malachite green and ammonium molybdate were mixed in a 3:1 ratio, and stirred for about 20 minutes. The mixture was filtered, and stored at 4 degrees C. The inorganic pyrophosphatase (Sigma; I-2267) was diluted to 0.1 U/ μ l in 50 mM Tris/3mM MgCl₂ pH 8.0, and stored at 4 degrees C.

The uridylyltransferase reaction was performed in 96-well plates. The coupled reaction described herein was performed, in the presence of 2CFE 3 alone or 2CFE 3 and 2CFE 86, and included the addition of 0.5 U/well of the diluted inorganic pyrophosphate. The reaction was mixed for 5 minutes at room temperature. The reaction was stopped by the addition of 240 μ l/well of the malachite green reagent and 30 μ l/well of 34% sodium citrate, and the reaction was mixed. The results of the uridylyltransferase reaction was monitored by spectrophotometry at 660 nm.

The results of separate uridylyltransferase reactions were monitored by HPLC, using a Phenosphere-NEXT C18 column (250 x 4.6 mm). The mobile phases included A and B as follows: A) methanol/10 mM potassium phosphate pH 6.5 (0:100); and B) methanol/10 mM potassium phosphate pH 6.5 (40:60). The mobile phases were run under the following conditions: 100% mobile phase A for 5 minutes, to 100% mobile phase B in 3 minutes; and hold 100% mobile phase B for 9 minutes. The retention time for the UDPAG product is approximately 5.75 to 6.0 minutes.

The results three uridylyltransferase reactions, monitored by HPLC are summarized in Table III below.

TABLE III

<u>Purified CFE 86:</u>	<u>Specific Activity (nmol/min/μg):</u>
2CFE 86-1	3.1
2CFE 86-2	3.4
2CFE 86-3	3.1

5

The results of the uridylyltransferase reactions, monitored by HPLC or HPLC and Malachite Green IPPase assays are summarized in Table IV below.

10

TABLE IV

<u>Reaction:</u>	<u>K_m (μM):</u>	<u>Method:</u>
<u>Acetyltransferase reaction:</u>		
Glucosamine-1-P	94	HPLC
Acetyl-coA	150	HPLC
<u>Uridylyltransferase reaction:</u>		
N-acetylglucosamine-1-P	48	HPLC and MG/IPPase
UTP	79	HPLC

EXAMPLE 14

15

The following provides a description of the methods used to characterize various 2CFE polypeptides, including CFE 21, 34, 35, 39, and 90. The molecular weight of these 2CFE polypeptides were analyzed by size exclusion chromatography and gel electrophoresis. The 2CFE 34, 35, and 90 polypeptides putatively mediate fatty acid biosynthesis.

20

Computer-Aided Comparison

The computer-aided comparison, as described in Example 9 *supra*, suggests that CFE 34 (SEQ ID NO:143), CFE 35 (SEQ ID NO:144), and 90 (SEQ ID NO:199) are polypeptides which mediate a fatty acid biosynthesis pathway (Figure 19)

The comparison suggests that CFE 34 is a malonyl CoA:ACP transacylase, which catalyzes the reaction in which malonyl CoA and acyl carrier protein (ACP) are converted to malonyl-ACP and CoA. Thus, the CFE 34 polypeptide may be a homologue of *E. coli* FabD.

The comparison suggests that CFE 90 is a 3-oxoacyl-ACP synthase II (beta ketoacyl-ACP synthase II) which catalyzes the reaction in which malonyl-ACP is converted to beta aceto acetyl-ACP. Thus, the CFE 90 polypeptide may be a homologue of *E. coli* FabF.

The comparison suggests that CFE 35 is a 3-oxoacyl-ACP reductase (beta aceto acetyl ACP reductase) which catalyzes the reaction in which beta-keto-acetyl-ACP is converted to beta-hydroxy-acetyl-ACP. Thus, the CFE 35 polypeptide may be a homologue of *E. coli* FabG.

Size Exclusion Chromatography

The estimated molecular weights of 2CFE 34 (SEQ ID NO:361), 2CFE 35 (SEQ ID NO:362), and 2CFE 90 (SEQ ID NO:413) were determined using the Biosil SEC-125 HPLC Gel Filtration column as described in Example 8, *supra*.

The results suggest that 2CFE 34 polypeptide is a monomeric protein (33,093 Da), 2CFE 35 is a trimeric protein (25,758 Da; approximately 85%), and 2CFE 90 is a dimeric protein (43,930 Da). Selected eluted samples of 2CFE 34 were electrophoresed on a polyacrylamide gel (Figure 20).

Biochemical Assay: CFE 34

- The function of 2CFE 34 was determined by performing various biochemical reactions.
- 5 To determine whether 2CFE 34 catalyzes the conversion of malonyl-CoA to malonyl and CoA, the following reaction was performed.

- The biochemical reaction was performed in the presence of acyl carrier protein. The reaction included the following: 10 μM ^{14}C labeled malonyl-CoA, 20 μM ACP, 30 μM
- 10 2CFE 34 (e.g., FabD) in 20 mM Tris-Cl, pH 8.0 and 5 mM DTT in 300 μl volume. The reaction was performed at room temperature (e.g., approximately 24 degrees C) for 30 minutes. The reaction was terminated with the addition of 45 μl of 0.5% TFA. The labeled reaction was injected onto a MonoQ 5/5 column on a Gilson HPLC. Detection was performed by monitoring the radioactivity of the continuous flow-through of the
- 15 HPLC effluent. Chromatography was performed using a buffer gradient for column elution. Buffer A included 20 mM Tris-Cl, pH 8.3. Buffer B was the same as Buffer A and included 1 M NaCl. The program was held at 90% A, 10% B for 10 minutes followed by a linear ramp to a final mix of 50% of each Buffer A and B over 10 minutes.
- 20 The substrate (e.g., ^{14}C malonyl-CoA) eluted at 9.9 minutes, the product (e.g., ^{14}C malonyl-ACP) eluted at 14.3 minutes. The results indicate that CFE 34 catalyzes the conversion of malonyl-CoA and acyl carrier protein (ACP) to malonyl-ACP and CoA.

EXAMPLE 15

25

The following provides a description of the methods used to characterize CFE polypeptides 40, 41, and 46.

Computer-Aided Comparison

The computer-aided comparison, as described in Example 9 *supra*, suggests that the CFE 40 polypeptide (SEQ ID NO:149) is a phosphomethylpyrimidine (HMP-P) kinase
5 involved in thiamine biosynthesis.

The comparison, as described in Example 9 *supra*, suggests that the CFE 41 polypeptide (SEQ ID NO:150) has a GTP-binding motif and may be a protease.

10 The comparison, as described in Example 9 *supra*, suggests that the CFE 46 polypeptide (SEQ ID NO:155) has an ATP-binding motif.

Affinity Purification of CFE 41

15 The large-scale method described in Example 5 *supra* (e.g., IPTG-induced protein production) was used to prepare a sample of 2CFE 41 polypeptide (SEQ ID NO:368). The sample was affinity purified using the Ni-NTA method described in Example 6, *supra*. The eluted fractions were loaded onto and run on a 12% SDS-PAGE gel (Novex) (Figure 21).

20

Circular Dichroism and Circular Dichroism Thermal Melt Analysis

Circular dichroism and circular dichroism thermal melt methods were performed using JASCO instrumentation. The concentration of the isolated 2CFE 40 (SEQ ID NO:367)
25 was approximately 21 μ M, in a 0.1 cm pathlength cell at 210 nm. The circular dichroism spectrum suggests that this preparation of 2CFE 40 had mixed alpha and beta secondary structure. The circular dichroism thermal melt spectrum suggests that 2CFE 40 has a T_m of approximately 67 degrees C. The 2CFE 40 polypeptide precipitates at approximately the T_m .

The concentration of the isolated 2CFE 41 (SEQ ID NO:368) was approximately 70 μ M, in a 0.02 cm pathlength cell. The circular dichroism spectrum suggests that this preparation of 2CFE 41 had mixed alpha and beta secondary structure, with a greater
5 percentage of alpha structures. The circular dichroism thermal melt spectrum suggests that 2CFE 41 has a T_m of approximately 38 degrees C. The 2CFE 41 polypeptide precipitates at approximately the T_m .

The concentration of the isolated 2CFE 46 (SEQ ID NO:373) was approximately 23 μ M,
10 in a 0.1 cm pathlength cell at 280 nm. The circular dichroism spectrum suggests that this preparation of 2CFE 46 had mixed alpha and beta secondary structure. The circular dichroism thermal melt spectrum suggests that 2CFE 46 is highly stable at elevated temperatures. At 90 degrees C, the 2CFE 46 polypeptide exhibited only a 27% loss in signal and the polypeptide remained soluble.

15

Capillary Electrophoresis

Capillary electrophoresis was performed on samples of purified 2CFE 40, 41 and 46. The electropherograms of 2CFE 40, 41, and 46 are shown in Figure 22.

20

EXAMPLE 16

The following provides a description of methods that can be used to characterize CEG polypeptides (e.g., CFE polypeptides).

25

Computer-Aided Compilation

Computer-aided compilation of bacterial metabolic pathways may be analyzed using Pathway Tools from Doubletwise, based on the EcoCyc system (Karp P.D., et al., 1999
30 *Nucleic Acids Res.* 1999 27(1):55-58). This analysis may be used to predict which CFEs mediate various steps of the pathways. This information may be used in combination

with the results of a binding reaction which identifies a ligand or substrate that binds with a CFE polypeptide.

Identifying the Function of a CFE Polypeptide

5

The function of a CFE polypeptide may be identified by identifying a ligand or substrate which binds with the CFE polypeptide. The ligand or substrate may be identified using fractionation and affinity capillary electrophoresis methods. The following method is based upon the assumption that the bacterial cell lysate includes the ligand or substrate.

10

A bacterial host cells carrying an endogenous (e.g. native) CFE gene or carrying a recombinant vector which includes a CFE gene may be cultured so that the CFE polypeptide is produced by the cell. The cells may be ruptured in order to obtain the cell lysate. The cell lysate may be fractionated using HPLC technology. The HPLC fractions may be reacted with a CFE polypeptide in a binding reaction, and the binding reaction may be analyzed by affinity capillary electrophoresis methods. The ligand or substrate which reacts with the CFE polypeptide may be identified using mass spectrophotometry methods (in "Mass Spectrometry" 1990 eds. McCloskey, J. A., in *Methods in Enzymology* volume 193; Henion, J., et al., 1993 "Mass Spectrometric Investigations of Drug-Receptor Interactions" *Ther. Drug Monit.* 15:563-569; Loo, J. A., et al., 1999 "Application of Mass Spectrometry for Target Identification and Characterization" *Med. Res. Rev.* 19:307-319; Nguyen, D. N., et al., 1995 "Protein Mass Spectrometry: Applications to Analytical Biotechnology" *J. Chromatogr.* 705:21-45).

25 **EXAMPLE 17**

The following provides a description of nuclear magnetic resonance (NMR) spectroscopy methods that were used to characterize CFE polypeptides.

30 High resolution NMR spectroscopy was applied to ^{15}N -labeled, $^{13}\text{C}/^{15}\text{N}$ -labeled, $^2\text{H}/^{13}\text{C}/^{15}\text{N}$ -labeled, and type-specifically isotopically labeled CFE polypeptide samples

in the solution state for the following purposes: to assess various aspects of the structural state, e.g., foldedness, structural integrity; to refine a previously determined experimental structure of a close sequence homologue; to refine a homology-modeled structure; to assess the potential for a CFE polypeptide to bind small molecules; and to identify small-molecule pharmacophoric fragments that bind specifically to the CFE polypeptide ("Nuclear Magnetic Resonance" 1994 eds. James, T. L. in *Methods in Enzymology* volume 239).

The NMR analysis includes screening both a compound deck of approximately 4,500 commercially available, structurally and chemically diverse compounds (the small-molecule pharmacophore deck) and a compound deck of proprietary, known, anti-microbial compounds (anti-microbial deck) against the CFE polypeptides (i.e., target polypeptides) to determine, either based upon perturbations to the chemical shifts of the amide proton and/or nitrogen resonances, as measured from a two-dimensional proton-nitrogen heteronuclear single-quantum correlation spectrum (2D screening method), or based upon increases in the linewidth of the compound's proton resonance(s), as measured by a one-dimensional $T_{1\rho}$ spin-lock difference spectrum (1D screening method), both whether a compound binds to a CFE polypeptide and, in the case of the 2D screening method, where the compound binds on the CFE polypeptide.

Isotopic Labeling of CFE Polypeptides

BL21-DE3 *E. coli* bacteria are transformed with the CFE expression vectors. Expression takes place between 20°C and 37°C in minimal media containing [^{15}N]-ammonium sulfate as the sole nitrogen source and either glucose, [^2H] $_{13}$ -glucose, or [^{13}C] $_6$ -glucose as the sole carbon source. Glucose is used for preparing uniformly ^{15}N -labeled and $^2\text{H}/^{15}\text{N}$ -labeled CFE polypeptides. [^2H] $_{13}$ -glucose is used for preparing type-specifically $^1\text{H}/^{13}\text{C}$ -labeled, uniformly ^{15}N -labeled CFE polypeptides. [^{13}C] $_6$ -glucose is used for preparing $^{13}\text{C}/^{15}\text{N}$ -labeled CFE polypeptides. The minimal media is prepared in 100% H_2O for expressing both uniformly ^{15}N -labeled and uniformly $^{13}\text{C}/^{15}\text{N}$ -labeled CFE polypeptides; the minimal media is prepared in 95% D_2O (deuterium oxide) and 5% H_2O for expressing

both type-specifically $^1\text{H}/^{13}\text{C}$ -labeled, uniformly ^{15}N -labeled and just uniformly $^2\text{H}/^{15}\text{N}$ -labeled CFE polypeptides. In the case of type-specifically $^1\text{H}/^{13}\text{C}$ -labeled, uniformly ^{15}N -labeled CFE polypeptides, 40 mg/L of protonated and uniformly $^{13}\text{C}/^{15}\text{N}$ -labeled isoleucine, valine and leucine amino acids are added to the minimal media.

5

NMR Screening

Compounds in the anti-microbial deck are pre-dissolved to a target concentration of 16 mM in deuterated DMSO (dimethylsulfoxide) with each deck well containing only one
10 compound. Compounds in the small-molecule, pharmacophore deck are pre-dissolved in deuterated dmso to a target concentration of 50 mM in groups of 8, i.e., each deck well contains 8 unique compounds with each compound at a target concentration of 50 mM.

3.5 μL of compound is placed at the bottom of a well in a 96-well, screening plate. This
15 well will be referred to as the compound screening well. Each compound screening well contains solution from only one deck well. 166.5 μL of buffer is added to each compound screening well. 170 μL of a CFE polypeptide solution, initially at a concentration ranging from 200-300 μM , is added to each compound screening well; the contents of that well are then thoroughly mixed. The control screening well contains only 3.5 μL of deuterated
20 dmso. The screening plate is then centrifuged in a bucket rotor for 15 minutes at 3,500 rpm to insure that all particulate matter is at the bottom of the well.

The 2D screening method requires a single control screening well in which the compound solution consists only of deuterated DMSO. The 1D screening method requires a control
25 screening well for each compound screening well. In the case of the 1D screening method, the control screening well is prepared identically to the compound screening well except that the 170 μL of a CFE polypeptide solution is replaced by 170 μL of buffer.

The screening plate is covered with aluminum foil and placed onto a rack of a Gilson
30 liquid handler. The Gilson liquid handler, under computer control by the NMR host/data-acquisition software, is responsible for removing each sample from the screening plate,

injecting the sample into a high-resolution, $^1\text{H}/^{15}\text{N}$ double-resonance NMR flow-probe, removing the sample from the flow-probe, and dispensing it back into the screening plate well from which the sample was originally removed. NMR data are collected on the sample while the sample resides in the NMR flow-probe. The type of NMR data
5 collected depends upon whether the 2D or 1D screening method is being used.

Determining Structural Characteristics of a CFE Polypeptide

In assessing various aspects of the structural state of a CFE polypeptide, NMR was used
10 to provide the following information. The proton 1D spectra and proton-nitrogen 2D correlation NMR spectra were used to assess the overall foldedness of a CFE polypeptide without actually describing in detail that folded state. Unfolded and substantially misfolded proteins produced distinct signatures in these two types of NMR spectra.

15 The chemical shift of most protein nuclei in either the set $\{\text{H}_\text{N}, \text{H}_\alpha, \text{H}_\beta, \text{C}', \text{C}_\alpha, \text{C}_\beta, \text{N}\}$ or the set $\{\text{H}_\text{N}, \text{C}', \text{C}_\alpha, \text{C}_\beta, \text{N}\}$ for perdeuterated (e.g., ^2H -labeled) proteins were determined by procedures well known in the art that involve collecting up to 10 triple-resonance NMR data sets. The protein secondary structure was delineated as either helical, turn or extended (e.g., β -sheet) by measuring $\Delta(\delta_{\text{C}_\alpha} - \delta_{\text{C}_\beta})$, $\Delta\delta_{\text{C}'}$, and $\Delta\delta_{\text{H}_\alpha}$ where δ refers to the
20 chemical-shift value and Δ refers to the difference between chemical-shift values measured in this protein and those measured for the same residue type in a random-coil (unstructured), tetrameric peptide.

This secondary-structure profile was generated in approximately 2-3 weeks per protein.

25 The secondary-structure profile was used to confirm the functional identity of a protein. It was also used to refine the list of possible functional identities of folds, predicted by various computational techniques including fold recognition which is associated with a protein or polypeptide.

NMR was used to generate folds of proteins or polypeptides for which both no structure was known of a sequence homologue and no structural homologue was discernible in the PDB by fold recognition techniques.

5 Refining a Structural Model

Nuclear Overhauser (NOE) data were used to refine both homology-modeled structured and previously determined experimental structures of close sequence homologues. This process took approximately 2-3 weeks per structure.

10

The CFE 88 polypeptide was characterized by NMR analysis to establish its secondary structure. The NMR data was used to filter the computer-aided threading analysis. The NMR-determined secondary structure for CFE 88 suggested that CFE 88 is structurally similar to 4-aminoimidazole carboxylase.

15

The characteristics of other CFE polypeptides were analyzed by NMR methods. A computer-aided threading analysis revealed that the N-terminal domain of the protein EGA, which both binds and hydrolyzes GTP, was both structurally similar and sufficiently similar in sequence to CFE 52 to suggest that CFE 52 had a similar function.

20

The NMR data of CFE 103 suggests that this polypeptide is unfolded. Circular dichroism spectra, as a function of temperature, also indicated that CFE103 was unfolded.

The CFEs 2, 42, 43, 68 and 88 polypeptides were tested for their ability to bind potential
25 inhibitor molecules by screening both the anti-microbial deck and the small-molecule, pharmacophore deck. CFE 34 was tested for its ability to bind potential inhibitor molecules by screening the anti-microbial deck.

Characterizing Small-Molecule Binding

- NMR-based screening was used to measure binding against both the small-molecule, pharmacophore deck and the anti-microbial deck. Binding data from these screens
5 allowed assessment of the propensity of a protein to bind small molecules. The binding data was also used to identify sites on the protein which are capable of binding small molecules. The binding data was also used to identify common pharmacophores among the compounds which bind.
- 10 Reverse screening refers to a process whereby known anti-microbial compounds, the microbial target of which is unknown, are screened by a general method, e.g., binding as assessed by NMR, to find a physical interaction with polypeptide targets previously determined to be essential to the bacteria (i.e., the CFEs). The reverse screening method was used to determine which CFE polypeptides bind to which compounds in the anti-
15 microbial deck. The reverse screening method included the following. The compounds in a proprietary compound deck were screened for Minimal Inhibitory Concentration (e.g., MIC). The compounds exhibiting antimicrobial activity were designated active compounds. The CFE polypeptides were screened to determine which polypeptide bind to which active compounds. The CFE polypeptides which bound to the active
20 compound(s) were confirmed, where possible, i.e., in cases where an in-vitro assay was possible to construct, as being inhibited in their function as a polypeptide by the active compound(s) by examination of the inhibition profile of the compound(s) against the CFE polypeptides. For additional confirmation, the effect of the compound on the microorganism harboring the CFE polypeptide was monitored (e.g., whole cell assays).
25 The structure of the active compound was used as a basis to generate chemically-related compounds by iterative synthesis. The chemically-related compounds were tested in a screening assay for binding with CFE polypeptides. The active compounds and the chemically-related compounds of interest were the compounds which exhibited an increase in binding affinity for a CFE polypeptide and/or exhibited drug-like properties.

30

The results of the reverse screening are as follows. 127 compounds from the proprietary compound deck exhibited anti-microbial activity. 94 of these active compounds were selected based upon both lack of cytotoxicity and lack of excessive hydrophobicity. These 94 compounds were soluble to 16 mM in deuterated DMSO; these compounds
5 were also deemed to be sufficiently soluble in aqueous buffer for both the 2D and 1D NMR screening methods.

This subset of 94 compounds was used in an NMR-based screen to determine which compound binds to which CFE polypeptide. The CFE 42 polypeptide bound two
10 different compounds with K_d 's in the range of 0.2 to 1 mM; the CFE 43 polypeptide bound one compound with $K_d \sim 30$ -50 μ M; the CFE 34 polypeptide bound 13 compounds, one of which inhibited the polypeptide function with $IC_{50} < 10 \mu$ M.

The enzyme assay used to confirm the NMR results which suggested CFE 34 interaction
15 with the compounds included the following: 10 μ M 14 C-labeled malonyl CoA; 20 μ M ACP, 30 pM CFE 34; 20 mM Tris-Cl, pH 8.0; 5 mM DTT; in the presence of absence of 50 μ M of a compound solubilized at 40 mM in 100% DMSO and dilute 100-fold into 10% DMSO and further diluted 8-fold for a final concentration of 50 μ M in 1.25% DMSO. The reaction was performed at room temperature, the reaction was stopped with
20 the addition of TFA. Two hundred μ l of the reaction was injected onto a Mono Q 5/5 column. The chromatography conditions included: A) 20 mM Tris-Cl, pH 8.3; B) 20 mM Tris-Cl, pH 8.3, 1 M NaCl. Hold 10% B for 5 minutes, linear gradient from 10% B to 50%B in 10 minutes, back to 10% B in 1 minute, hold for 14 minutes to re-equilibrate. The reaction substrate (14 C- malonyl CoA) eluted at 9.9 minutes, the reaction product
25 (14 C-malonyl ACP) eluted at 14.3 minutes.

What is claimed is:

1. An isolated nucleic acid molecule encoding a polypeptide which is (1) essential for the viability of a bacterial cell and (2) has at least any one of the functions of a
5 pantothenate kinase, a Holliday Junction branch migration protein, a single
 stranded DNA binding protein, a phosphoglucosamine mutase, an
 acetyltransferase, an uridylyltransferase, a malonyl CoenzymeA:ACP transacylase,
 a 3-oxoacyl-ACP synthase II, a 3-oxoacyl-ACP reductase, a
 phosphomethylpyrimidine (HMP-P) kinase, a GTP binding protein, a ATP
10 binding protein, or a 4-aminoimidazole carboxylase.
2. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule
 is shown in SEQ ID NO:97 or Figure 115 and wherein the polypeptide is a
 pantothenate kinase.
- 15 3. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule
 is shown in SEQ ID NO:35, Figure 60, SEQ ID NO:19, or Figure 44, and wherein
 the polypeptide is a Holliday Junction branch migration protein.
- 20 4. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule
 is shown in SEQ ID NO:8 or Figure 33 and wherein the polypeptide is a single
 stranded DNA binding protein.
- 25 5. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule
 is shown in SEQ ID NO:3 or Figure 28 and wherein the polypeptide is a
 phosphoglucosamine mutase.
- 30 6. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule
 is shown in SEQ ID NO:82 or Figure 103 and wherein the polypeptide is a
 acetyltransferase.

7. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:82 or Figure 103 and wherein the polypeptide is a uridylyltransferase.
- 5 8. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:30 or Figure 55 and wherein the polypeptide is a malonyl CoenzymeA:ACP transacylase.
9. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:86 or Figure 107 and wherein the polypeptide is a 3-oxoacyl-ACP synthase II.
- 10 10. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:31 or Figure 56 and wherein the polypeptide is a 3-oxoacyl-ACP reductase.
- 15 11. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:36 or Figure 61 and wherein the polypeptide is a phosphomethylpyrimidine (HMP-P) kinase.
- 20 12. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:37, Figure 62, SEQ ID NO:48, or Figure 73, and wherein the polypeptide is a GTP binding protein.
- 25 13. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:42 or Figure 67 and wherein the polypeptide is a ATP binding protein.

14. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:84 or Figure 105 and wherein the polypeptide is a 4-aminoimidazole carboxylase.
- 5 15. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:48 or Figure 73 and wherein the polypeptide is a GTP binding protein.
- 10 16. An isolated nucleic acid molecule encoding a polypeptide which is essential for the viability of a bacterial cell, the nucleic acid molecule comprising a sequence shown in any one of SEQ ID NOS:1-113.
- 15 17. An isolated nucleic acid molecule encoding a polypeptide which is essential for the viability of a bacterial cell, the nucleic acid molecule comprising a sequence shown in any one of Figures 26-130.
18. An isolated nucleic acid molecule encoding any one of a polypeptide designated CFE 1-117 having the amino acid sequence shown in SEQ ID NO:114-226.
- 20 19. An isolated nucleic acid molecule comprising a nucleotide sequence which is complementary to the nucleotide sequence of claim 1, 16, 17 or 18.
20. The isolated nucleic acid molecule of claim 1, 16, 17 or 18 which is DNA or RNA.
- 25 21. The isolated nucleic acid molecule of claim 20, which is labeled with a detectable marker.
- 30 22. The isolated nucleic acid molecule of claim 21, wherein the detectable marker is selected from the group consisting of a radioisotope, a fluorescent compound, a

bioluminescent compound, a chemiluminescent compound, a metal chelator and an enzyme.

23. A vector comprising the nucleotide sequence of claim 1, 16, 17, or 18.

5

24. A host-vector system comprising the vector of claim 23, in a suitable host cell.

25. The host-vector system of claim 24, wherein the suitable host cell is selected from a group consisting of a yeast cell, a plant cell, and an animal cell.

10

26. The host-vector system of claim 24, wherein the suitable host cell is selected from a group consisting of an *Escherichia* cell, a *Bacillus* cell, a *Pseudomonas* cell, a *Streptococcus* cell, and a *Streptomyces* cell.

15

27. An isolated polypeptide which is essential for the viability of a bacterial cell comprising the amino acid sequence as shown in any one of SEQ. ID NOS: 114-226.

20

28. An isolated polypeptide which is essential for the viability of a bacterial cell encoded by the isolated nucleic acid molecule of claim 1, 16, 17, or 18.

29. The isolated polypeptide of claim 27 or 28 which is a fusion polypeptide.


25

30. A method for producing a polypeptide having the amino acid sequence of any one of SEQ ID NOS: 114-226 or a polypeptide encoded by the polynucleotide sequence as shown in any one of Figures 26-130, comprising:


- a) culturing the host-vector system of claim 24 under suitable conditions so as to produce the polypeptide; and
- b) recovering the polypeptide so produced.

30

31. A polypeptide produced by the method of claim 30.
32. A ligand which binds the polypeptide of claim 27 or 28.
- 5 33. The ligand of claim 32 which is an antibody or an immunologically active fragment thereof.
34. The ligand of claim 33, wherein the antibody is a monoclonal antibody.
- 10 35. The ligand of claim 32 which is a diazalactone.
36. The ligand of claim 35, wherein the diazalactone comprises the structure:




- 15 37. The ligand of claim 32 which is a *N*-protected amino acid.
38. The ligand of claim 37, wherein the *N*-protected amino acid comprises the structure:




- 20 39. The ligand of claim 32 which is an azabicyclodiene.

40. The ligand of claim 39, wherein the azabicyclodiene comprises the structure:




5 41. The ligand of claim 32 which is an alkaloid.

42. The ligand of claim 41, wherein the alkaloid comprises the structure:




10


43. The ligand of claim 41, wherein the alkaloid comprises the structure:




44. The ligand of claim 41, wherein the alkaloid comprises the structure:



5 45. The ligand of claim 41, wherein the alkaloid comprises the structure:



46. The ligand of claim 41, wherein the alkaloid comprises the structure:



5 47. A method for detecting the presence of the polypeptide of claim 27 or 28 in a sample, comprising contacting the sample with a ligand which binds the polypeptide and detecting the binding of the polypeptide with the ligand in the sample.


10 48. The method of claim 47, wherein the detecting comprises:
 a) contacting the sample with the ligand; and
 b) determining whether a polypeptide-ligand complex is so formed.

15 49. The method of claim 47, wherein the sample is a cell, a tissue, or a biological fluid.

50. The method of claim 47, wherein the sample is blood, serum, a swab from nose, a swab from ear, or a swab from throat.

20 51. The method of claim 47, wherein the ligand is a diazalactone.


52. The method of claim 51, wherein the diazalactone comprises the structure:



53. The method of claim 47, wherein the ligand is a *N*-protected amino acid.

5


54. The method of claim 53, wherein the *N*-protected amino acid comprises the structure:



55. The method of claim 47, wherein the ligand is an azabicyclodiene.

10


56. The method of claim 55, wherein the azabicyclodiene comprises the structure:



57. The ligand of claim 47 which is an alkaloid.


15

58. The ligand of claim 57, wherein the alkaloid comprises the structure:




5

59. The ligand of claim 57, wherein the alkaloid comprises the structure:




60. The ligand of claim 57, wherein the alkaloid comprises the structure:

10




61. The ligand of claim 57, wherein the alkaloid comprises the structure:



5

62. The ligand of claim 57, wherein the alkaloid comprises the structure:



10

63. A method for detecting the presence of a target nucleic acid molecule as shown in any one of SEQ ID NOS:1-113 in a sample, comprising contacting the sample with the complementary nucleic acid molecule of claim 19 and detecting the binding of the target nucleic acid molecule with the complementary nucleic acid molecule in the sample.


15

64. The method of claim 63, wherein the detecting comprises:
- a) contacting the sample with the complementary nucleic acid molecule; and
 - b) determining whether a complex comprising the target nucleic acid molecule and the complementary nucleic acid molecule is so formed.
65. The method of claim 63, wherein the sample is a cell, a tissue, or a biological fluid.
66. The method of claim 63, wherein the sample is blood, serum, a swab from nose, a swab from ear, or a swab from throat.
67. A pharmaceutical composition comprising the nucleic acid molecule of claim 1, 16, 17, or 18.
68. A pharmaceutical composition comprising the polypeptide of claim 27 or 28.
69. A pharmaceutical composition comprising the ligand of claim 32.
70. A method for determining whether a genomic nucleotide sequence of interest is essential for viability of a bacterial cell, comprising
- a. integrating an exogenous nucleotide sequence into the genomic nucleotide sequence of interest, wherein the exogenous nucleotide sequence comprises a portion of an open reading frame of the genomic nucleotide sequence of interest, and
 - b. determining whether the cell having the genomic nucleotide sequence of interest so integrated is viable.
71. The method of claim 70, wherein the portion of the open reading frame comprises about 200 to 500 base pairs in length.


- 5 72. The method of claim 70, wherein the exogenous nucleotide sequence further comprises a nucleotide sequence conferring a selectable phenotype to the cell having the genome so integrated.
73. The method of claim 70, wherein determining comprises selecting the cell having the genome so integrated in the presence of a selection agent.
- 10 74. The method of claim 73, wherein the selection agent is chloramphenicol.
75. A nucleotide sequence of interest which is essential for viability of a bacterial cell isolated by the method of claim 70.
- 15 76. A bacterial cell comprising an exogenous nucleotide sequence integrated into the genomic nucleotide sequence of interest, generated by the method of claim 70.
- 20 77. A method for determining whether a genomic nucleotide sequence of interest resides within an operon, comprising
- a) integrating an exogenous nucleotide sequence into the genomic nucleotide sequence of interest; and
 - b) determining whether the cell having the genomic nucleotide sequence of interest so integrated is viable, and wherein the exogenous nucleotide sequence lacks an expression regulatory sequence.
- 25 78. The method of claim 77, wherein the exogenous nucleotide sequence further comprises a nucleotide sequence conferring a selectable phenotype to the cell having the genome so integrated.
- 30 79. The method of claim 77, wherein determining comprises selecting the cell having the genome so integrated in the presence of a selection agent.

80. The method of claim 79, wherein the selection agent is chloramphenicol.
- 5 81. A method for inhibiting a function of a CEG polypeptide which is essential for viability of a bacterial cell, the method comprising contacting the CEG polypeptide with the ligand of claim 32 under suitable conditions thereby inhibiting the function of the CEG polypeptide.
- 10 82. The method of claim 81, wherein the function of the CEG polypeptide is selected from a group consisting of a pantothenate kinase, a Holliday Junction branch migration protein, a single stranded DNA binding protein, a phosphoglucosamine mutase, an acetyltransferase, an uridylyltransferase, a malonyl CoenzymeA:ACP transacylase, a 3-oxoacyl-ACP synthase II, a 3-oxoacyl-ACP reductase, a phosphomethylpyrimidine (HMP-P) kinase, a GTP binding protein, a ATP
- 15 binding protein, or a 4-aminoimidazole carboxylase.
83. The method of claim 81, wherein the CEG polypeptide is selected from a group consisting of CFE1-113.
- 20 84. The method of claim 81, wherein the CEG polypeptide is 2CFE 34 shown in Figure 55.
85. The method of claim 81, wherein the CEG polypeptide is 2CFE 43 shown in
- 25 Figure 64.


86. The method of claim 81, wherein the CEG polypeptide is 2CFE 34 shown in Figure 55 and the ligand is:



5 87. The method of claim 81, wherein the CEG polypeptide is 2CFE 43 shown in Figure 64 and the ligand is:



10 88. The method of claim 81, wherein the CEG polypeptide is 2CFE 43 shown in Figure 64 and the ligand is:




89. A method for identifying a ligand in a sample which specifically binds a CEG polypeptide, the method comprising:

- a) contacting the CEG polypeptide with the sample under suitable conditions so that a complex having the CEG polypeptide and the ligand is formed;
- b) recovering the complex so formed ; and
- c) separating the CEG polypeptide from the ligand in the complex and identifying the ligand so separated.

90. The method of claim 89, wherein the sample is a tissue or biological fluid.


91. The method of claim 89, wherein the ligand is an azabicyclodiene.

92. The method of claim 91, wherein the azabicyclodiene comprises the structure:




93. The method of claim 89, wherein the ligand is a diazalactone.

94. The method of claim 93, wherein the diazalactone comprises the structure:



95. The method of claim 89, wherein the ligand is a *N*-protected amino acid.


96. The method of claim 95, wherein the *N*-protected amino acid comprises the structure:



5


97. The method of claim 89, wherein the ligand is an alkaloid.

98. The ligand of claim 97, wherein the alkaloid comprises the structure:




10

99. The ligand of claim 97, wherein the alkaloid comprises the structure:




15

100. The ligand of claim 97, wherein the alkaloid comprises the structure:




101. The ligand of claim 97, wherein the alkaloid comprises the structure:

5



102. The ligand of claim 97, wherein the alkaloid comprises the structure:



Gene Disruption Assay




FIGURE 1

Polarity test for Operons





FIGURE 2

A.



B.




FIGURE 3




FIGURE 4





FIGURE 5

A.



B.





FIGURE 6

A.



B.




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 11




FIGURE 12




FIGURE 13

N-Acetyl Glucosamine Pathway




FIGURE 14




FIGURE 15

C:




FIGURE 15

D.




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18




FIGURE 19.




FIGURE 20




FIGURE 21




FIGURE 22




FIGURE 23




FIGURE 24




FIGURE 25

2 CFE1 "homologue of SEQ. ID NO. 1"

ATGATTATGCGAATTCCTTGCCGGTGGAACTGGCACACGCAATGGGGATCAGTAACCTTGCCAAAACAAT
 TTITAGAGCTAGGTGATCGACCTATTTTGATTACATACAATTGAAAAATTNGTCTTGGAGCCAAGTATTGAA
 AAAATTGTAGTTGGTGTTCATGGAGACTGGGTTTCTCATGCAGAAAGATCTTGTAGATAAATATCTTCTCT
 TTATAAGGAACGTATCATCATTACAAAGGGTGGTGTGACCGCAATACAAGTATTAAGAACATCATTGAA
 GCCATTGATGCTTATCGTCCGCTTACTCCAGAGGATATCGTTGTTACCCACGATTCTGTTCTGTCATTATT
 ACACCTTCCGATGATTACAGGACAATATCCAACCTTGCCCAAAATCATGACGCAAGTGGACACAGTGGTAGAA
 GCGGTTGATACTATCGTTGAAAGTACCAATGOTCAATTTATTACAGATATTCCAATCGTGCTCACTTTA
 TCAAGGACAAACACCTCAAAACATTCCGTTGCAAGGACCTTCAAGGACCTTTATGGATCTCTTCTGATGAA
 GAGAAAGAAATCTTGACAGATGCATGTAAATCTTTGTGATCAAGGAAAGATGTGGCTTTGCCAAA
 GGTGAATACTCAAACTCTGAAGATTACAACCGTAACAGATTGGAAGATTGCAAAAGTATGATTGAQAAA
 GACTAG

2 CFE2 "homologue of SEQ. ID NO. 2"

ATGGCTAACGTAATTATTGAAAAAGATAAAAAGAGAGAATGACCCATCTCACCAATCACTTGCTCGTGAAT
 TTGGTGTATCCGTGCTGGTCTGTCGCAATGCAAGCTTGCTTGACCGTGTACATGTAGAATACTATGGAGTC
 GAAACTCTCTTAACCAAATCGCTTCAATTACGATTCCAGAAGCGCGTGTGTTGTTGGTAACACCAATTTGA
 CAAGCTTCATTGAAAGACATCGACCGTGCTTGAACGCTTCTGATCTTGGTATCACACCGGCTAATGAC
 GGTCTGTGATTCGCTTGTATCCAGCTCTTACAGAAGAAACTCGTCTGACCTTGCTAAAAGAGTGA
 AQAAGGTCGGGAAAATGCTAAAGTGGCTGTCCGCAATATCCGTGCGCATGCTATGGACGAAGCTAAGA
 AACAAQAAAAGCAAAAGAAATCACTGAAGACGAATTGAAGACTCTTGAAAAAGATATTCAAAAAGTA
 ACAGACGATGTGTAAACACATCGACGACATGACTGCTAACAAAGAGAAAGAACTTTTGGAAAGTCTAA

2 CFE3 "homologue of SEQ. ID NO. 3"

ATGGGTAAATATTTGGGACTGATGGAGTCCGTGGAGAAGCTAACCTAGAGCTAACACCAGAATTAGCCT
 TTAACCTAGGACGTTTGGAGGCTATGTTCTTAGTCAACATGAAACGGAAGCCCGAAAAGTCTTTGTAGG
 ACCTGACACACGTATTTCAAGGGAAATGCTGGAATCGGCCCTTGGTGGCAGGTCTCCTTTCAGTAGGGATT
 CAGGTATACAACTTGGTGTCTTGCACACCAAGCAGTAGCTTACTTGGTTGAAACTGAAGGAGCAAGTG
 CCGGTGTCATGATTTCTGTAGCCACAACCCAGCCCTTGATAACGGAATCAAGTCTTTGCGGTGATGG
 CTTCAACTAGATGATGAAAAAGAGCAGAAATGGAAGCCTTGCTAGATGCTGAGGAAGACACTCTTCC
 TCTCCAACTGACAGAGGCTTAGGAATTTGGTAGATTATCCAGAAGGCTTGCGTAAGTATGAAGGATAC
 CTGTGTTCAACTGGAACCTCTTGTATGGAATGAAGGTTGCCCTTGGATACAGCTAATGAGCAGCTTCTAC
 CAGTGGCGGTCAAACTCTTGCAGACCTTGGTGCCCAATTGACGGTTATCGGGGAAACACCAAGACGCTCT
 AAGATCAACCTTAATGTTGTTCAACACATCCAGAAGCCCTTCAAGAAAGTGGTCAAAAGAAAGTGGGTCA
 GCTATGTTTGGGCTTTGATGGAGACAGTGACCGCTTGTATTGCTGTTGATGAGAATGGTGACATCGTCC
 ATGGTGCAAGATTATGTACATCATCGGAAATACCTTTCTAAAAAAGGACAATTGGCTCAAAATACAAT
 TGTGACAACCTGTTATGTCTAACCTTGGTTCCACAAGGCCTTGAATCGCGAAGGTATTAACAAGGCAGTT
 ACTGCAGTTGGTGACCGCTACGTTGTTGAAGAAATGAGAAAAATCAGGTTACAACCTTGGTGGTGAACAGT
 CTGGTCACGTTATCTGATGGATTACAATACCACAGGTGATGGTCAATTAATCAGCAGTTCAATTGACTAA
 AATCATGAAGGAACTGGTAAGAGCTTATCAGAGTTGGCGGCAGAAAGTAACGATTTATCCAAAAAATT
 AGTTAATATCCGAGTGGAAAACGTATGAAGGAAAAGGCCATGGAAAGTCCAGCTATCAAGGCCATCAT
 CGAGAAATGGAAGAAAGAAATGGCGGGAAACGGCCGTATCCTTGTTCGTCCAAAGTGGAAACAGAACCCCT
 CTTCGGTGTATGGCAGAAAGCGCTACAACAAGAAAGTAGACTACTATGTTGATACCATCACAGATGTA
 GTTCGTGCTGAAATTGGGATTGACTAA

2 CFE4 "homologue of SEQ. ID NO. 4"

2CFE 4 homologue of SEQ ID NO: 4

Fig. 29
 ATGAAAAAATACTAATTGTAGATGATGAGAAACCAATCTCGGATATTATCAAGTTTAAATGACCAAGG
 AAGGTTATGAAGTTGTAAGTCTTTAATGGTGGTGAAGCGCTAGAGCAATTTGAAGCAGAGCAACCAGA
 TATTATTCTCTGGATTGATGCTTCCAGAAATGATGGTTTGAAGTTGCTAAGACCATTCGTAAGACAA
 GCAATGCCCCATTCTTATGCTTTCAGCCAAAGATAGTGAATTTGATAAGGTTATCGGTTTGGAACTTGGG
 GCAGATGACTATGTAACGAAACCCCTTCTCCAATCGTGAGTTGCAGGCGCGTGTAAAGCTCTTCTGCGTC
 GTTCTCAACCTATGCCAGTAGATGGTCAGGAAGCAGATAGTAAACCTCAACCTATCCAAATTGGGGATT
 AGAAATTGTTCCAGACGCTACGTGGCTAAAAAATATGCGAAGAACTAGACTTAACCCATCGTGAAATT
 GAGCTTTGTATCATTTAGCACCGCATACAGGTCAAGTCATCACGCGGAAACACTTGCTTGAGACTGTCT
 GGGGTTATGACTATTTTGGTGATGTCCGCACAGTTGATGTGACTGTACGACGTCTGCGTGAGAAGATTGA
 AGATAAGCCGAGCCGACCAGATATATCTTGACGCGCCGTGGTGTAGGGTATTACATGAGAAATAATGCT
 TCA

2CFE 5 "homologue of SEQ. ID NO. 5"

Fig. 30
 ATGGAAGAAATTTCTGTATTGGTTGTGGAGCAACCATTTCAGACGACAGATAAGGCTGGTCTTGGTTTTA
 CCCCCAGTTGGCACTTGAAAAAGGTTTGGAGACTGGCGAAGTCTATTGCCAACGCTGTTCCGTCCTCG
 CCACTCAATGAAATCACAGATGTCCAGTTGACGGACGATGATTTCTCAAGCTCTTGCACGAGGTGGGA
 QACAGTGATGCTTTAGTGGTCAATGTCTATTGATATCTTTGATTAAATGGATCTGTATCCAGGTTTACC
 ACGTTTCTGTCGGGGCAATGATGTCTCTTGGTAGGAAATAAAAAAGATATCCTTCTAAGTCAGTTAAG
 TGTGTAAGATTAGCCAGTGGCTCATGAAACGTGCCCATGAAGAAAGGCTCTTCTGTCAGTGTGTCCTCC
 TAACCTTCAGCACAAAAATAAATATGCCATTAAAGGAATCATGATAAGATTGAACACTACCGTAAGGGCC
 GCGATGTCTATGTGGTGGTGTGACCAACGTGTGAAAAATCAACTCTAATCAATGCTATTATCCAAGAAAT
 CACGGGTGATCAGAATGTCTACTACTTACGCTTTCAGGGACAACCTTGGACAAAAATAGAGATTCCG
 CTGACGACGGATCTTATATTACGATACGCGGGGAATTATCCACCGCCACCAGATGGCTCACTACTGA
 CGGCCAAAAACCTCAAGTATGTCTAGTCTAAAAAGGAAATCAAGCCTAAGACCTATCAGCTTAATCTGA
 GCAAAACCTATTTTAAAGTGGTTTGGGACGCTTGACTTTATAGCAGGAGAAAAAGCAAGGATTTACTGCT
 TTCTTTGATAATGAAGCTCAAACTCCATCCTAGCAAGCTTGAAGGAGCTAGTGCTTTCTACGATAAGCACC
 TGGAACTCTTCTGACACCACCAAAATAGCAAGGAAAAAGAGATTCCCAAGGCTAGTCCAGCATGTCTT
 TACCATTAAAGATAAGACAGACCTAGTCATTTCAAGGCTAGGCTGGATTCTGTAAACAGGCATAGCAAAA
 GTCCGCTCTGGGCACCAGAAGGCGTCGCCGTCGTACACGAAAAAGCAATTATTTAA

2CFE 6 "homologue of SEQ. ID NO. 6"

Fig. 31
 ATGTATCAGATGATAGTTTGACATTGCACACGGACTTGTACCAGATCAACATGATGCAGGTTTACTTTO
 ACCAAGGGATTACAAATAAGAAAGCGGCTCTTTGAGGTGATTTCCGCCAACAGCCTTTTAAAGAACGGCTA
 TGGGTTTGTGAGGTTTGGAAAGAATTGTGAACATCTTGAAGACTTGGCTTTTTCAGATAGTGATATAG
 CCTTTTGGAGTCGCTTGGTTATCATGGGGCGTCTTGGATTACCTTCGCAATTTCAAGTTGGAGTTGACC
 GTTCTGTCGCCAAGAAGGGGATTGGTTTGTGTAATGAACCGATTGTGCAGGTGGAAGGACCTCTAG
 CCAATGTCAGTTGGTCGAAACGGCTCTTTGAACATCGTCAACTACCAGACCTTGGTGGCGGAGGCG
 AGCTCGATTGCTTGGTTATCGAAGATGAACCTTGTATGGAATTTGGGACACGTCGGGCTCAAGAAATG
 GATGCCGCCATCTGGGGAACACGGCAGCTGTGATTGGTGGCGCCAATGGAAACAGCAACGTCGTGCG
 GGTAAAGCTCTTTGACATTCTGTTTTGGGAACCCATGCCCATGCCCTGGTACAGGTTTATGGCAATGACTA
 TGAAGCTTTCAAGGCTTACGCTGCGACCCACAAAAATTTGTCTTCTTGTGATACCTATGACACCCCTTC
 GCACTCGGTGTACAGCTGCCATTTCAGGTGGCGCGTGGGTGATTAGATTAACTTTATGGGTGTGCG
 GATTGACTCTGGGATATTGCTTACATTTCTAAGAAAGTCCGTCAGCAACTGGACGAGGCTGGATTTACA
 GAGGCTAAGATTATGCTTCTAATGATTTGGACGAAAAATACTATCCTCAACCTCAAGATGCAAAAAGGCCA
 AGATTGATGCTGGGGCGTGGGTACCAAGCTGATTACAGCCTATGACCAGCCAGCTCTTGGGGCGGTTTA
 CAAGATTGTTGCAATCGAAGATGAAACTGGTCAGATGCGCAATACGATTAAGCTGTCTAATAATGCGGA
 AAAAGTGTCCAGCCAGGTAAGAAAGCAAGGTGTGGCGATTACCAAGTCTGAAAAAGGCAAGTCAGAAG
 GTGACTACATCACTTATGATGGTGTGGATATTAGCGACATGACAGAAATCAAGATGTTCCATCCGACCTA
 TACATAATCAAGAAAGCGGTCGTAATTTTGTATGCCGTTCTCTCTTGGTGGATATCTTCAAAAGAGGTA
 TATTAAGTTTACAACCTGCTAGTTTGAAGTACATTACAGGATTATGCCCGTAAGGAATTTGACAAAGTTGTGG
 GATGAGTATAAGCGTGTGCTCAATCCGACGACTATCCAGTGGATTGGCGCGTGATGTATGGCAAGATA
 AGATGGACTTGTGATAAGATGCGCAAGGAAGCCCTTGGTGAAGGAGAAGAAAGAAATGA

2CFE 7 "homologue of SEQ. ID NO. 7"

Fig. 32
 ATGGCTACTATTCAATGGTTTCTGGTGCATGTCTAAAGCGCGTCGACAGGTGCAGGAAAAATTTAAAT
 TTGTTGATTTTGTGACGATTTTATGATATGCACGCTTGCCTCTATCTAGTCAAAATCCTATGTTGACCAAG

2CFE 7 (contd)

Fig 32 (contd)

ATTGTTGGTGATAAAACCAAACTCTTGTATTTTAAACAAGGCCGACTTGGCTGATCCAGCAATGACCAAGG
 AATGGCGTCACTATTTTGAATCACAAGGAATCEAGACGCTAGCTATCAACTCCAAAGAGCAAGTGACTGT
 AAAAGTGTAAACAGATGCGGCCAAGAAGCTCATGGCTGATAAGATTGCTCGCCAGAAAGAACGTGGGAT
 TCAGATTGAAACCTTGGTACCATGATTATCGGGATTCCAAACGCTGGTAAATCCACTCTGTATGAACCGT
 TTGGCTGGTAAAAAGATTGCTGTTGTTGGAAACAAGCCAGGGGTACAAAAAGGTCAACAATGGCTTAAA
 ACCAAATAAGATCTGGAAATCTTGGATACACCGGGGATTCTCTGGCCTAAGTTTGAGGATGAAACTGTTG
 CACTTAAGTTGGCATTGACTGGAGCTATCAAGGATCAGTTGCTTCCATGGATGAGGTTACCATTTTTGGT
 ATCAATATTTCAAAGAACATTATCCAGAAAAGCTGGCTGAACGGCTTCAAACAAATGAAAAATTGAAGAA
 GAAGCCCTGTGTATTATATAGATATGACCCGCGCCCTCGGTTCCGTGATGACTATGACCGTTTATACAG
 TCTGTTGTGAAGGAAGTCCGTGATGGCAAACTCGGTAACCTATACCTTAGATACATTGGAAGACCTCGAT
 GGCAACGATTAA

Fig 33

2CFE8 "homologue of SEQ. ID NO. 8"

ATGATTAACAATGTTTACTTGTAGGGCGTATGACACGTGACGCTGAGTTGCGTTATACCCCATCAAAATG
 TAGCAGTTGCCACTTTACTCTTGCAGTAAACCGTACATTTAAGAGTCAAAATGGTGAACGTGAGGCTGA
 TTTATCAATGTCGTTATGTGGCGCCAAACAGGCTGAAAAATCTTGTAACTGGGCTAAAAAGGCTCACTT
 ATCGGGGTGACAGGTGCTATCCAGACTCGTAGTTACGATAACCAGCAAGGAGCAACGTGTCTACGTGACA
 CAGGTGCTGGCTGAGAAATTTCCAAATGTTGGAAAGCCGTAGTGTGCGTGAGGGTCACACAGGTGGAGCT
 TACTCTGACCAACTGCAAACTATTACGACCTACAAATTCAGTACCAAGACTTTTACGTAATGAAAAATC
 CATTTGAGCAACAAACCCATTGATATTTAGATGATGATTACCATTTCTAA

Fig 34

2CFE9 "homologue of SEQ. ID NO. 9"

ATGAAAACGCGTATTACAGAATTATTGAAGATTGACTATCCTATTTTCCAAGGAGGGATGGCTGGGTTG
 CTGATGTTGATTTGGCAGGGGCTGTTTCCAAGGCTGGAGGATTAGGAATTATCGGTGGGGGAAATGCCCC
 GAAAGAAGTTGTCAAGGCCAATATTGATAAAATCAAATCATTGACTGATAAAACCCCTTTGGGGTCAACATC
 ATGCTCTTATCTCCCTTTGTGGAAGATATCGTGGATCTCGTTATTGAAGAAGGTGTTAAAGTTGTCAAC
 AGGAGCGAGAAATCCAAGCAAGTATATGGAACGTTTCCATGAAAGCTGGGATAATCGTTATTCCTGTCTG
 CCTATGTTGCGTTTAGCTAAACGCTATGGAAGAAATCGGTGCGAGCGCTGTTATTGCAGAAGGAATGAAA
 GCTGGGGGGCATATCGGTAAATTAACAACCATGACCTTGGTGGCAGAGGTAGCEACAGCTGTATCTATTTC
 CTGTTATTGCTGCGAGGAGGAAATGCGGATGGTGAAAGGTGCTGCGGCTGGCTTTATGCTAGGTGAGAGGC
 TGTACAGGTGGGGACACGGTTTGTAGTTGCAAAAGAGTGAATGCCATCCAACTACAAGGAGAAAAAT
 TTAAAAAGCAAGGATATTGACACTACGATTTAGCTCAGCACTTTGGTCAATGCTGTTCTGCTATTAAAA
 ATCAGTTGACTAGAGATTTTGAAGTGGCTGAAAAAGATGCCTTAAAGCAGGAAGATCCTGATTTAGAAAT
 CTITGAACAAATGGGAGCAGGTGCCCTAGCCAAAGCAGTTGTTACCGGTGATGTGGAGGGTGGCTCTGTC
 ATGGCAGGTCAAAATCGCAGGGCTTGTCTTAAAGAAAGAACAGCTGAAGAAATCCTAAAAAGATTGTATT
 ACCGAGCCGCTAAGAAAATTCAGAAGGAAGCCTCTCGCTGGACAGGAGTTGTAAGAAATGACTAA

Fig 35

2CFE10 "homologue of SEQ. ID NO. 10"

ATGATCQATATTCAAGGAATCAAAGAAGCTCTTCCCCACCGTTATCCTATGCTTCTAGTGGACCGTGTCTT
 GGAAGTGAGCGAGGATACCATTTGTTGCTATCAAAAAATGTGACCATTAACGAACCTTTCTTAAACGGCCAC
 TTCTCTCAATACCCAGTTATGCCAGGTGTTCTGATTATGGAAGCCTTGGCGCAAACTGCTGGTGTGTTGGA
 GTTATCAAAACCTGAAAAATAAGGAAAACTGGTCTTTACGCTGGTATGGACAAGGTTAAGTTCAAGAA
 GCAAGTTGTACAGGGGACCAATTGGTTATGACAGCGACTTTTGTAAAAACGTCGTGGCACCATAAGCTGTG
 GTTGAACCAAAAGGCTGAAGTGGATGGCAAGCTTGCAGCCAGTGTATCCTTACTTTTCAATTGGGAACT
 AA

Fig 36

2CFE11 "homologue of SEQ. ID NO. 11"

ATGATTAATCAAATTTATCAACTAAGCCTAAGTTTATCAATGTCAAATATCAGGAAGAGGCTATTG
 ACCAAGAGAAATCATATCCTTATCCGTCCCAACTACATGGCTGTCTGTATGCGGATCAGCGTTACTATCA
 GGAAGAACGTGATCCCAAGATTTGAATAAAAGCTTCCAATGGCAATGATTACAGATCATGTGGAAC
 CGTCACTTCTGACCCGACCGGAACCTACGAGGTTGTGTCAAAAAGTTGTCATGATTECCAAATCAGTCTCT
 ATGACAGATGATGAAGAAATCTATGAAAACTACATGACAGGGACCCATTCTTGTCTAGTGGATTGATG
 GCTTATAGAGAGTTTGTCTCTCCCTAAAGATCGTGTGGTGGCTTATGATGCTATTGAAGATACGGTT
 GCAGGCATTACAGAGTTTGTGAGTGTGGGATGCACGCTATGAATCGTCTATTGACTCTTGTCTATGCA
 AGCGGGAGCGGATCGCCGTTATTGGAGATGGAAGTTTACGTTTGTGGTTGCCAATATTATCAACTATAC
 TTGCAAGAAAGCAGAGATTGTGGTTATTGGTCTATTGGGAAAAGTTGGAACCTCTCTCATTTGCCAAA

Fig. 36 (Contd.)

2 CFE 11 (Contd.)

GAATGCTATATTACGGATAATATTCCTGAAGATTGGCCTTTGACCATGCTTTGAATGTTGTGGTGGTGA
 TGGTACTGGACCAGCTATTAATGACTGTGATTCGCTACATTGCTCCTCAGGGAACGATTCTCATGATGGGA
 GTTAGCGAATATAAAGTCAATCTCAATACTCGCGATGCTTAGAAAAAGGCTTGATTTGGGTTGGGTCAT
 CTCGTTCTGGTCGCATTGATTTTGAAAAATGCTATCCAAATGATGGAAGTCAAGAAATTTGCCAATCGTCTT
 AAAAAATATCCTTTATCTAGAAGAAOCTGTAAGAGAAATIAAAGATATTCATCGTGTCTTTGCAACCGATT
 TAAACACAGCCTTTAAAAACAGTGTTTAAGTGGGAAGTATAA

Fig. 37

2 CFE12 "homologue of SEQ. ID NO. 12"

ATGAACITAAAACTACTTTGGGCTTCTTGCTGGGCGTCTTCCCACTTCGTTTTAAGCCGCTTTGGACG
 TGGAACTACGCTCCCAGGGAAGTCGCCCTTCAATTTGATAAAGATATTTTACAAAGCCTAGCTAAGAAC
 TACGAGATTGTGCTGTCACTGGAACAAATGGAAAAACCCGACAACTGCCCTCACTGTGCGGCATTTTAA
 AAGAGCTTTATGGTCAAGTTCTAACCAACCCAAAGCGGTGCCAACATGATTACAGGGATTGCAACAACCTT
 CCTAACAGCCAAATCTTCAAAAACCTGGGAAAAATATTGCCGCTCCTCGAAAAATTGACGAAGCCAGTCTATCT
 CGTATCTGTGACTATATCCAGCCTAGTCTTTTGTGCTTACTAAATATCTTCCGTGACCCAGATGGACCGTTTC
 CGTGAAATCTTATACTACCTATAACATGATATTGGATGCCATTGCAAAAGTTCCAACTGCTACTGTCTCTCT
 TAAAGGAGACAGTCCAETTTTCTACAAGCCAACTATTCCAAACCCCTATAGAGTATTTGGTTTTGACTTGG
 AAAAAGGACGAGCCCAACTGGCTCACTACAATACCGAAGGGATTCCTGTGCTGACTGCCAAGGCATCCT
 CAAATATGAGGCATAATACCTATGCAAACTTGGGTGCCTATATCTGTGAAGGTTGTGGATGTAAACGCTCT
 GATCTGACTATCGTTTGACAAAACCTGTTGAGTTGACCAACAATCGCTCTCGCTTTGTCATAGACGGCC
 AAGAATACGGTATCCAAATCGGCGGGCTCTATAATATCTATAACGCCCTAGCTGCTGTGGCCATCGCCCG
 TTTCTTAGGTGCGGATTGCAAACTCATCAAAACAGGGATTGACAAGAGCCGCTGTCTTTGGACGCCAA
 GAAACCTTTCTATCGGTGACAAGGAATGTACCCTTGTCTTGATTAAAAATCCAGTGGGTGCAACCCAAAG
 CTATCGAAATGATCAAACTAGCACCTTATCCATTAGCCTATCTGTCTCTCTTAAAGCCAACTATGCAGAT
 GGAATGACACTAGCTGGATCTGGGATGCAGACTTTGAACAAATCACTGACATGGACATTCCTGAAATCA
 AGCTGCGCGTGTTCGTCAATCTGAAATCGCTCGTCCGCTCCGAGTGACTGGCTATCCAGCTGAGAAAAAT
 CACTGAAACGAGTAATCTGGAGCAAGTTCTCAAGACCATTGAGAATCAAGACTGCAAGCATGCCTATATT
 CTGGCACTTATATGCCATGCTGGAATTTCTGTGAAGTGTGCTAGTCTGTCAGATTGTTAGAAAGGAGA
 TGAACCTAA

Fig. 38

2 CFE13 "homologue of SEQ. ID NO. 13"

ATGTTTATACTTCACTTTCTCCTCAAAAGATGGCAATTACCCCTATCAGCTCAACATTGCCCACTCTACGG
 AAATCTGATGAATACCTACGGGGACAATGGAAACATCCTCATGCTCAAGTATGTGGCTGAAAACTGGG
 AGCCCAATGTGACCGTTGACATCGTTTCTGCTCATGATGACTTTGATGAAAAATCACTACGACATCGCCTTTT
 TCGGTGCTGGTCAAGACTTTGAACAAAGTATCATTTGCAGACGACCTACCTGCTAAAAAAGAGAGCATTG
 ACACTACATCCAAAAACGACGGTGTAGTTCTGGCTATCTGCGGTGGTTTCCAACTATTGGGTCAATATTAT
 GTTGAAGCTTTCAGGAAAAACGTATCGAAGGGCTAGGGGTGATGGGACACTACACGCTCAACCAGACCAAT
 AACCGTTTATCGGTGACATCAAGATTCAAAATGAAGATTTCGATGAAACCTACTATGGATTGAAAAATC
 ACCAAGGCCGTACCTTCTCTGATGACCAAAAAACCGCTGGGACAGGTTGTCTATGGAAATGGAAACAA
 CGAAGAAAGGTGCGTGAAGGGGTTCAATTAAGAATGTCTTTGGTTCTACTTCCACGGGCCCTATCTCT
 TCTCGTAATGCCAATCTGGCTTATCGCCTAGTTACTACTGCCCTCAAGAAGAAATATGGTCAGGACATCC
 AACTCCCTGCTATGAGGATATCCTCAGCCAAGAAATCGCTGAAGAGTACAGTGACGCTCAAAAGCAAGG
 CTGACTTTTCTTAA

Fig. 39

2 CFE14

ATGAATGTAAAAAGAAATACAGAACTTGTTTTTGAGAAAGTTGCAGAGGCTAGTCTGAGTGTCTCATCGAG
 AGAGTGCTTCGGTCTCTGTCAATTGCAGTTATCAAGTATGTAGATGTACCGACAGCGGAAGCCTTCTCTCC
 GCTAGGTGTTTCATCATATCGGTGAAAAATCGTGTAGATAAGTTTCTGGAAAAATATGAAGCTTTAAAAGAT
 CGAGATCTGACTGGCATTGATTGGTACCTTCCAAAGACGTAAGGTGAAAGATGTCAATTCAATACGTTG
 ATTATTTCATGCTATTGGACTCAGTAAAGCTAGCAGGGGAAATTCAAAAAGAAAGTGACCGAGTCATCA
 AGTGTCTTCTGAAGTAAATATTCTAAAGAAAGAAACCAACACGGTTTTTTCGAGAGAGGAACTGCTGGA
 AATCTTGCCAGAGTTAGCCAGACTAGATAAGATTGAATATGTTGGTTAATGACGATGGCACCTTTTGAG
 GCTAGCAGTGACGAGTTGAAAGAGATTTTCAAGGCGGCCCAAGATTACAAAGAGAAATTCAGAGAAAA
 CAAATTCCAAATATGCCTATGACCGAGTTAAGTATGGGAATGAGTCGTGATTATAAAGAAAGCGATTCAAT
 TCGGTTCACCTTTGTTCTGATAGGTACATCATTTTAAAGTAG

2CFE15 "homologue of SEQ. ID NO. 15"

Fig 40
ATGGGAATTGCTCTAGAAAATGTGAATTTATATATCAAGAAGGTACTCCCTTAGCTTCAGCAGCTTTGTC
GGATGTTCTTTGACGATTGAAGATGGCTCTTATACAGCTTAAATTGGGCACACAGGTAGTGGTAAATCA
ACTATTTACAACTCTTAAATGGTTTATTGGTGCCAAAGTCAAGGAGGTGTGAGGGTTTTTGATACCTTAAT
CACTGACCTCTAAAAATAAAGATATTGCTCAAATTAGAAAACAGGTTGGCTTGGTATTTCAGTTTGGCT
GAAAATCAGATTTTTGAAGAAACGGTTTTGAAGGACGTTGCTTTTGGACCGCAAAATTTGGAGTTTCTG
AAGAGATGCTGTGAAGACTGCGCGTGAGAAAAGTGGCTGCTGGTTGGAATTGATGAATCACTTTTGTATCG
TAGTCCGTTTGGCTGTGAGGGGGACAAATGAGACGTTGCCATTGCAGGCATACCTGCCATGGAGCCA
TGTATATTAGTCTTAGATGAGCCAACAGCTGGTCTAGATCCTCTAGGGAGAAAAGAGTTGATGACCTGT
TCAAAAACTCCACCAGTCAGGGATGACCATCGTCTTGGTAACGCATTGATGGATGATGTTGCTGAATA
TCTAAATCAAGTCTATGTAATGGAAGGGGACGTTAGTAAAGGGGGGCAAAACCAAGTATGCTTTCA
AGACCTGTTTTATGGAAGAAAGTTCAAGTTGGGAGTACGTAAATACGGCCTTTTGTAAACGATTGGCT
GATAGAGGCGTGTCAATTAACGATTACCGATTAAAGATAGAGGAGTTCAAGGATCGCTAAATGGATAG

2CFE16 "homologue of SEQ. ID NO. 16"

Fig 41
ATGGATATTCATTTTATAGGAACGGGGGCTGGTCAGCCCTCTAAAGCCCGCAACGTTTCAAGTCTCGCCC
TGAACCTCTTGGATGAGATTAACGAAGTTTGGCTCTTGGACTGTGGAGAAAGGTACGCAAAATCGCATTCT
CGAAGCACAATTCGACCAGTAAGGTCAGCAAAATCTTTATTACCATCTGCATGGAGACCACATTTT
CGTTTCCAGGTTTCTTTCTAGCCGTGCTTTTCAGGCCAATGAAGAGCAGACAGATTGGGAAATCTACG
GACCTCAAGGAATCAAGTCATTTGTCTTAACAGCCTTCGTGTGTCAGGTTCTCGTCTGCCCTACCGCATT
CAITTCATGAOTTTGACCAAGATTCTCTGGGTAAAAATCTTGAAACCGATAAAATTCAGTGTGTATGCAGA
GGAGCTGGACCACACTATTTCTGTGTTGGCTATCGTGTATGCAAAAGGATCTAGAAGGGAGCGTGGAT
CGTGAATAACTCAAGGCTGCTGGTGTCCGTTCCGCCCGCTTTTGGTAAAAATCAAAAACGGCCAGGATC
TTGTTTGGAAAGCGGAACGTGAAATCAAGGCAGCAGACTATATCTCAGCGCCACGTCCAGGTAAAGATTAT
CACTATTTAGGAGACACTCGAAAAACGGGTGCCAOTGTGCGTCTGCTGTCAATGCAGATGCTCAGTT
CATGAGTCCAATTATGGCAAGGGTGTGAAAAAATGCTCGTAACCATGGTCACTCAACTAATATGCAAG
CTGCAGAAATAGCGGTAGAAAGCAGGTGCCAAACGCTCTACTCAACCATATCAGTGCCCGTTTCTCTC
AAAAGATATTAGCAAACTCAAGAAAGACGCTGCCACAAATTTTGAAAATGTCCATGTGGTCAAAAGACTTG
GAAGAAGTGGAAATCTAG

2CFE17 "homologue of SEQ. ID NO. 17"

Fig 42
ATGAGTAATATCAGTTTAAACAACACTTGGTGGTGTGCGTGAGAATGAAAAAATATGTACATTGCTGAAA
TTGGAGAGTCCATTTTGTTTGAATGTAGGGTTAAATATCTGAAAAATGAACAATTAGGGGTCCGATGT
GGTGATTCCAAACATGGATTACCTTTTGAATAAGCGACCGTATTGCTGGGGTTTCTTGACCCACGGGC
ATCCGATGCCATTGGTGTCTACCTTATCTCTTGGCAGAGGCTAAAGTTCTGTATTGGGTCTGAGTTG
ACCATTCAGTTGGCAAAGCTCTTTGTCAAAGGAAATGATGCCGTAAAGAAATTTAATGATTTCCATGTCA
TTGATGAGAATACGGAGATTGATTTGGTGGGACAGTGGTTTCTTCTTCCCTACGACTTACTCCGTTCCA
GAGATCTGGGAATTTGCTTGAAGACATCGGAAGGAAGCATCGTTTATACAGGTGACTTCAAATTTGACC
AAACCGCTAGTGAATCTTATGCAACTGATTTTGTCTGTTTGGCAGAGATTGGTCGTGACCGCGTCTGGC
TCTCTCAGTGATTGGGCCAATGCAGACAGCAATATTCAAGGTGGCTAGTGAAAGTGAAGTTAGGGATGAA
ATTACCCAAACTATTGCTGACTGGGAAGGTGATCATCGTTGCAGCTGTTTCCAGTAATCTTCTCGTAT
TGAAGCAATTTTACCGCTGCGGATAAAACAGGTCCGACGTATCGTCTGACAGGATTGATATTGAAAAT
ATGCTCCGACAGCGATTCTGCTTAAGAAGTTGTGTTAGCCAAACGAAATCTCTTGATTAAAGCCTAAAG
ATACTCTCGCTTTGAAGACCATGAGTTGATTATCTTGAAGACAGGTGATGGGTGAACCTATCAATGG
AGTTGCTAAGATGTCGATTGGTCCCATCGTTATGTAGAAATCAAGGATGGGGACCTGCTATATTGCT
ACCGCTCGCTTATTGCTAAAGAACCTTTGTTGCGCGTGTGGAAAAATATGATTTATCAGGCAGGTGGGG
TTGTGAAATTTGATTACCCAAAGTTTACATGTATCAGGGCACGGAAATGTGCGTGATTGGCAGCTGATGAT
CAATCTTTTGCACCTAAGTACCTCTTCCCTGTCCAAGGGGAGTATCGTGAGTTGGATGCTCACGCTAAG
GCTCCCATGGCAGTTGGGATGTTGCCAGAACGCATCTTCATTCTTAAAGGGGACGACCATGGCTTACG
AGATGCAAGACTTTGTTCCAGCTGATCGGTTTCCAGCAGGAGATATCTTGATGATGGGAATGCCATTGG
TGATGTTTGAAGATGTTGTTCTTCTGACCGTAAGCTTGTGTCAGAGGATGGAATTTTCATCGTGGCTATA
CAGTCAACCGTCTGTGAGAAGAAATTTGTGGCTAGAGCTCGTGTTCAGACCGCTGGATTGTTATCTTCA
GAAGAGTCCGCTATTTCTCCGTGAAAGTTTCAAGTTGATTAAACCAACCGGTAGAAGAGTATCTTCAAGG
AGATGACTTTGACTGGGCAGATCTCAAGGTAAGGTTCTGTGACAACTGACCAAGTACCTCTTTGATCAA
ACCAAGGTGCTCCAGCCATTTTACCAGTAGTCATGGAAGCAAAATAA

Fig. 43

Dr. F. H. 44

Sh. 24

18

Sh. 24

iga

2 CFE25 "homologue of SEQ. ID NO. 21"

ATGAAC TACITTAATGTTGGGAAAATCGTTAATACGCAGGGATTACAGGGTGAGATGCGAGTCTTGCTG
 TGAAGGATTTTGCAGAAGAACGGTTTAAAAAGGAGCTGAGCTGGCTTTGTTTGATGAAAAAGATCAGTT
 TGTCAAACAGTGACCATCGCTAGCCACCGTAAACAGAAGAACTTTGACATTATTAATTCAAAAGATATG
 TACCATATCAATACTATCGAAAAAGTACAAGGGATACAGTCTCAAGGTCGCTGAGGAAGATTTGAATGAC
 CTAGACGATGGTGAATTTTACTATCAGGAGATTATCGGTTTGGAAAGTCTATGAGGGTGATAGCTTGCTG
 GAAACATCAAGGAAATCCTGCAACCAAGGTGCTAATGATGTCTGGGTGGTCAAAACGAAAAGGCAACCGTG
 ATTGGCTTTTACCTTATATCCACCAGTGGTTCTCAATGTTGATATCCAAATAAACGGGTGATGTGGAA
 ATCTTAGAAGCGTTAGACGATGAAGATCTCGAGCACCACCACCACCACCTGA

2 CFE26 "homologue of SEQ. ID NO. 22"

ATGAAGATTGATATTTTAACCTCTTTCCAGAGATGTTTCTCCACTGGAGCACTCAATCGTTGAAAAGGC
 TCGAGAAAAAGGGCTCTTGGATATCCAGTATCAATTTTCGAGAAAAATGCTGAAAAGGCCCGTCATGTA
 GATGATGAGCCCTACGGAGGCGGTGAGGGCATGTTGCTCAGAGTACAACCTATTTTGGATTCTTTGATG
 CTATTGAAAAAGAAAAATCCGCGCGTTATTCTCTCGATCTGCTGGAAGCAGTTTGATCAGGCTTATGC
 TGAAGATTGGCTCAAGAGGAAGAGCTAATCTTTATCTGTGGGCACTATGAGGGTTATGATGAGCGCATT
 AAGACCTTGGTAACAGATGAGATTTCCCTAGGCGACTATGTTCTCACTGGTGGAGAATTGGCAGCTATGA
 CCGATTGATGCTACAGTTCGCTGATTCAGAAAGTATGGCAAGGAGTCTAGCCACCAAGATGATAG
 TTTTCTTCAGGCTTTTGAATATCCTCAGTACACAGCTCCCTATGATTATCGAGGCATGGTCTGCGCAAG
 ATGATTTGATGAGTGGTCACCATGAAAAAGATTCTGTCAGTGGCGATTGTACGAGAGTTTAAAGAAAACTA
 CGAGCGCAGGCGGATTTACTTGAACATTATCAACTGACAGTAGAAGAAGAAAAATGCTGGCAGAAAT
 CAAAGAAAAACAAAGAGCGGCGCACTCGAGCACCACCACCACCACCTGA

2 CFE27 "homologue of SEQ. ID NO. 23"

ATGATTCGAAGCAAGTAAATTAAGGCTGGTATGACCTTTGAAACAGCTGACGGCAAATTGATTGCGGTTT
 TGAAGCTAGTACACCAAAACAGGTAAAGGAAACACGATCATGCGTATGAAATTGCGTGATGTCCGTA
 CTGGTTTACATTTGACACAAGCTACCGTCCAGAGGAAAAATTTGAACAAGCTATTATCGAGACTGTCCC
 AGCTCAATACTTGTACAAAAATGGATGACACAGCATACTTCATGAATACAGAACTTATGACCAATACGAA
 ATCCCTGTAGTCAATGTTGAAACGAAATGCTTTACATCGTTGAAAACTCTGATGTGAAAATCCAATTCTA
 CGGAATGAAATGATCGGTGTACCGTTCTACTACTGTTGAGTTGACAGTTGCTGAAACTCAACCATCT
 ATGAAGGTGTACTGTTACAGGTTCTGTGTAACAGCAACGATGGAAGCTGGACTTGTCTGTAACCGTTC
 CAGACTTCATGGAAGCAGGACAAAACTCGTTATCAACACTGCAGAAGGAAGTACGTTTCTGTCGCT
 CGAGCAACCAACCACCACCACCTGA

2 CFE28 "homologue of SEQ. ID NO. 24"

ATGCAATTTGAAAOITTAACAGAACGTTTGCAGAACGTTTAAAAATCTACGTAAAAAGGAAAAATCT
 CTGAATCTGATGTCGAAGAGGCAACCAAGAAATTCGCTTGGCCCTGCTCGAGGCCGACGTTGCCCTTGCC
 TGTGTAAAGGACTTTATCAAGAAAGTTAGTGAGCGTGAGTGGGCGATGAGGTCATTGATACACTTAAT
 CCTGCCAACAAGATTATTAATTCGTTGATGAGGAACGACAGCCGTTTATGTTCTGATACGGCAGAAA
 TTATCAAGTCACTAAGATTCCAACCATCATGATGGTTGGTTTACAAGGGGCTGGTAAAAACAACCTT
 TGGTGGTAAATTGGCCAAACAACTCAAGAAAGAAAGAAATGCTCGTCTTTGATGGTTGCGGCGGATATT
 TATCGTCCAGCTGCCATTGAACAGCTTAAGACCTTGGGACAACAGATTGATGTGCTGCTTTGCACTTGG
 AAAGAAAGTACAGCTGTTGAGATTGTACGTCAAGGTTTGAAGCAAGCCCAAACTAATCATAAGCACTAT
 GTCTTGAATGATCTGCGGGTCTGTTGCAAGATTGATGAGCTCTCATGAATGAGCTTCTGTGATGTGAAAG
 CATGGGCTCAACCAAAATGAATCTTGTCTGCTGTTGATGCTATGATTGGTCAGGAAGCAGCAATGTTGC
 GCGTGATTTAATGCTCAGTTGGAAGTGAAGTGGGTCATCTTACCAAGATTGATGGCGATACTCGTGGT
 GGTGCTGCTGCTGCTGTTGCTCAGATTACTGGAAAAACCAATCAAGTTCACTGGTACAGGTGAAAAAGATTA
 CGGACATGAAACCTTCCACCCAGACCGCATGTCTAGCCGTATCCTTGGTATGGGGGATATGCTCACTTT
 GATTGAGAAAGCTTCTCAGGAATACGATGAACAAAAAGCCCTTGAATGGCTGAGAAAGATGCGCGAAAA
 CACTTTGATTTAATGATTCTATCGATCAATTAGATCAGGTGCAAAATATGGGGCCGATGGAAGACTTG
 CTCAGATGATTCAGGTATGGCCAAACATCCAGCCCTTCAAAACATGAAGGTGGATGAACCCAGATT
 GCTGTAACCGTGCCATTGTGTTCTGATGACACCTGAAGAGCGTGAAGAACCAAGATTGTTAAATGCCAA
 GCGTGGCGCTGATTTGCTGCTGTTCTGGAATACATTGCTGCAAGTCAATAAATTCATCAAGGACTTT
 AACAGGCTAAACAGCTCATGCAAGGTGTTATGCTGTTGGGATATGAATAAATGATGAAGCAAAATGGG
 ATTAATCAAAATAACCTTCTTAAAAATATGCCAAATATGGGAGGAATGGATATGCTGCGCTTGAAGGAA

2 CFE 28 (Contd.)

(Contd.)

Fig 49

TCATGGGACAAGGCGGTATGCCTGACTTATCAGCTCTCGGAGGAGCAGGAATGCCAGATATGAGCCAGA
TGTTCGTGGCGGTTTGAAGGTAATAATTGGTGAATTTGCCATGAAACAGTCCATGAAACGTATGGCTAA
CAAAATGAAGAAAGCGAAGAAGAAACGCAAGGCGGCCGCACTCGAGCACCACCACCACCACCTGA

2 CFE29 "homologue of SEQ. ID NO. 25"

Fig 50

ATGTACTTATTGAAATTTTAAATCTATCTTCTTCGGGATTGTTGAAGGAATTACGGAATGGTTGCCGAT
TTCCAGTACAGGTCACCTTGATTTAGCAGAGGAGTTTATCCAATACCAAAATCAAAATGAAGCCTTTATG
TCCATGTTAATGTCGTGATTCAGCTTGGTGCTATTTTAGCAGTTATGGTGATTTATTTTAAACAGCTCAAT
CCTTTTAAACCGACTAAGGACAAACAGGAAGTTCGTAAGACTTGGAGACTATGGTTGAAGGTCTTGATTG
CCACTTGGCTTTACTTGGTGCTTTAAATTTGATGATTGGTTTQATACCCACTTCCATAACATGGTTTCAG
TTGCTGTCTATGTTGATTATCTACGGGGTTGCCCTTCATCTATTTGGAAAAGCGCAATAAAGCGCGTGTATC
GAGCCAAGTGTAACAGAGTTGQACAAGCTTCTTATACGACCGCTTCTATATCGGACTCTTCCAAGTTCT
TGCTCTTTTACCAGGGACTAGCCGTCAGGTGCAACGATTGTCGGTGGTTTGTAAATGGAACCAAGTCGTT
CAGTTGTGAGAGAATTTACCTTCTATCTTGGGATTCCCGTTATGTTTGGAGCTAGTGCCTTAAAGATTTTC
AAATTGTGAAAGCCGGAGAATCTTQAGCTTTGGGCAATTGTTTTGCTCTTGGTCCGGATGGGAGTAG
CTTTTTCGGTCAGCATGGTGGCTATTGCTTCTTGACCAGCTATGTGAAAAAACACGACTTCACCTTTTT
GGTAAATACGGTATCGTGCTTGTAGTGTTTGCTACTTTACAGTTTGTCCGTTTATTGTACTCGAGCAC
CACCACCACCACCTGA

2 CFE30 "homologue of SEQ. ID NO. 26"

Fig 51

ATGGGATTATTTGACCGTCTATTTCGGAAAAAAGAAAGAACCTAAATCGAAGAAAGTTGTAAAAGAAAGCT
CTGAAAAATCTTGATTGTCTGAAGATGTTGATCCTACCTTCACAGAAAGTTGAGGAAGTTTCTCAGGAAG
AAGCAAGAGGTTGAAATTTGTAACAAGCTGTGTTCCAAGAAGAGGAAATCCAAGACACAGTTGAAAGAAA
GTCTGGATTTAGAGCCAGTTGTAGAAGTTTCTCAAAAAGAAAGTGAAGAATTTCCCACTCAGAAGAAGG
CAATAGTGAATTTCTAGAGACTATAGAAGAAAATAATTCTGAAGTTCTTGAACCAGAAAGGCCCTCAAGC
AGAAAGAAACCGTTCAGGAAAAATATGACCGCAGTCTTAAAGAAAACCTGACAGGTTTCGGTGCCTGATT
CAATGCTTCTTCTTAACTTCCGCTCTGTTGACGAAGAATTTTTCGAGGAAGTGAAGAAGTCTGATT
TGAGTGAATGTTGGTGTCCAAGTCGCTTCTAACTTAAACGGAAGAACTACGTTACGAAGCCAAAGCTTGA
TGCCAAAGAAACCTGATGCACTTCGTCGTGTCATCATTOGAGAAATGTTGTTGAGCTTTATGAAAAGGATGGT
AGCTACGATGAAAGCATCCACTTCCAAGATAAATGACAGTTATGCTCTTTGTTGGTGTGAATGGTGTG
GGAAAAACAATCTTATCGGAAAACTAGCCCAAGCTGTAACAAGCTGGTAAGAAGGTCATGCTGTTG
CAGCAGATACCTTCCGTGCGGGTGCAGTAGCTCAGCTAGCTGAATGGGGCCGACGAGTAGATGTTCCAGT
AGTAACCTGGACCTGAAAAAAGCTGATCCAGCCAGCGTGGTCTTTGATGGTATGGAACGTCCTGGCTGAA
GGTATCCTATTTCTCATGATTGATACTGCTGGTCTGCAAAATAAGGATAACCTTATGGCTGAGTTGG
AAAAGATTGGTGGTATTATCAAAAGCTTTGTGCAAGAACCAACATGAACCTTCTGGCACTTGAATGCA
TCAACAGGTCAAAATGCCCTAGTACAGGCCAAAGAAATTTTCAAAAATCACACCTTTAACGGGAATTTGTT
TGACTAAGATTGATGGAAGTCTCGAGGAGGTGTGGTTCTAGCCATTGCTGAAGAAGCAATATTCTCTGT
AAAATTGATTGGTTTTGGTGAAAAAATCGATGATATTGGAGAGTTTAACTCAGAAAACTTTATGAAAGGT
CTTTGCAAGGTTTAAATCGCGCCGCACTCGAGCACCACCACCACCACCTGA

2 CFE31 "homologue of SEQ. ID NO. 27"

Fig 52

ATGTATATTGAAATGGTAGATGAAAGTGTCAAGTTTCAAAAGAAATGTTGCAACAAACCCAAGAAATTT
TGAAATTTGCAGCCCAAAATTAAGGAAAGAAAGACAAAGGAGATGGCAGTCACTTTTGTGACCAATGAGC
GTAGTCAATGAATTAATCTGGAGTACCGTGACACCGACCGTCCGACAGATGTCAACAGCTTGAGTATAA
ACGAGAATTGGAATTTGCCCTTTGACGAAAGAGGATTTGCTTGAATTCAGAAATGGCAGAGATGATGTCT
GATTTGATGCTTATATTGGGGAATTGTTCACTCTATCGATAAGGCTCATGAGCAGGCCGAAGAATATG
GTACACCTTTTACCGTGAAGATGGGCTTCTTGGCAGTACACGGCTTTTACATATTAACGGCTATGATCAC
TATACTCGGAAGAAAGCGGAGATGTTGGTTTACAAGAAGAAATTTGACAGCCTATGACTCACA
AGCAACTCGAGCACCACCACCACCACCTGA

2 CFE32 "homologue of SEQ. ID NO. 28"

Fig 53

ATGAGTATTCGAGTAATTATTGCCGGTTTAAAGGGAAAGATGGGCCAGGCTGCTTGTGAGATGGTATTGA
CTGATCCAGACTTGGACTTGGTGGCAGTTTGGATCCTTTTGAATCTGAGTCAAGATGGCAAGGATTTCCCT
GTTTTCAGGATAAGGCTGATTAGCTGGTTTGAAGCGGATGTCTGGGTAGATTTTACTACTCCAGCTGT
TGCTTAAGAAAATACACGTTTGTCTTGAATAATGGCTTGTCTCCAGTAGTTGGAACGACTGGTTTCACGA

2CFE32

Fig 53 (contd.)

GTGAAGAAATTGCAGAGCTAAAAGAATTTCTCGTGCCCAAGACTTGGGTGGCCTGATTGCCCTAACTT
 TGCCTTGGGTGCTGTCTTACTCATGCAATTTGCGACGCGAGGCTGCCAAATAATTCCCAAATGTGGAGATTA
 TTGAGCTCCATCATGACAAGAAAAGGATGCTCCGAGTGGAACAGCCATTAAACAGCTGAAGTTGATGG
 CAQAGGTTTGAAGTCCATTGAGCAAGGCGCAGCAGATGAGGAAGAGCTGATTGCTGGTGTCTGGTGGT
 CTGACTTTGATGGTATGCGCATCCACTCAGTTTCGTTTGCCAGGCTTGGTAGCTCATCAAGAAGTCATCTTT
 GCGCAATCAGGGAGAAGGGTTGACCTCCGTCATGACTCCTATGATCGCATCTCCTTCATGACAGGAGTCA
 ATTGGGAATTAAAGAAGTTGTCAAGCGTCATGAGCTTGTCTATGGATTAGAACACTTATTACTCGAGCA
 CCAACCAACCACTGA

Fig 54

2CFE33 "homologue of SEQ. ID. NO. 29"

ATGGCAACAAACAAGATTTGATCGCTAAAGTAGCAGAAGCTACAGAATTGACTAAGAAAGACTCAGCA
 GCAGCATTTGAAGCTGTATTTGCAAGCAGTAGCTGACTATCTTGAGCTGGTGAAAAAGTTCAATTGATCG
 GTTTTGGTAACTTTGAAGTTGCTGAGCGTGCAAGACGTAAAGGTCGCAACCCACAACTGGTAAAGAAAT
 GACAAATTCAGCTTCTAAAGTACCAGCATTCAAAGCTGGTAAAGCTCTTAAAGACGCTGTAAACTCOAG
 CACCACCAACCACTGA

Fig 55

2CFE34 "homologue of SEQ. ID. NO. 30"

ATGACTAAAAAGCCTTTTATTGCTGGTCAAGGTGCCAGTATCTAGGGATGGGACGGGATTTCTATG
 ATCAATATCCGATTGTTAAAGAAACGATTGATCGAGCGAGTCAGGTGCTAGGTTATGATTTGCGTTATGT
 CATCGATACGGAAGAAGACAAACTCAATCAGACCCGCTATACGCAACCAAGCCATTCTAGCAGCTCGGTT
 CCTATCTACCGTTTATTGCAAGAAAAGGGCTATCAGCCTGATATGGTTGCTGGTTTGTCTTTGGAGAAAT
 CTCTGCTTGTGCGCAAGCGCGCCTTGGATTTTGAAGATGCGGTTGCTTGGTAGCTAAGCGTGGAGCC
 TATATGGAAGAAGCGGCTCCTGCTGACTCTGGCAAGATGGTAGCAGTTCTCAATACGCCAGTAGAGGTGA
 TTGAAGAAGCCTGTCAAAAAGCTTCTGAACCTTGGAGTGGTTACTCCAGCCAATATAACACACCTGCGACA
 AATCGTCAATTGCTGGAGAAGTGCTTGCAGTTGATCGAGCGGTGAACCTTTGCAAGAAGCAGGTGCCAAA
 CGCTTGATTCTCTTAAGGTGTCAGGTCCCTTTACACCTCTCTCCTTGAACCTGCTAGCCAGAAACTAGC
 TGAAGCTCTGCTCAGGTAAGTTTTCAGATTTTACTTGTCCCTAGTCGGCAATACAGAAGCTGCTGTGA
 TGCAAAAAGAGGACATTGCTCAGCTCTTGACGCGTCAGGTCAAGGAACCCGTTCTGTTTCTATGAAAGTAT
 TGGGTCATGGAAGAAGCAGGCATAAGCAACTTATCGAGATTGGAACCGGGAAAGTCTTGTGAGGTTT
 GTTAAAAAATGATCAAACTGCTCACTTAGCTCATGTGGAAGATCAAGCGAGTTTAGTAGCACTTTTAG
 AAAAACTCGAGCACCACCACCACCACCCTGA

Fig 56

2CFE35 "homologue of SEQ. ID. NO. 31" 35

ATGAAACTAGAAACATAAAAAATATCTTTATTACAGGTTCCGAGTCGTGGAATTGGTCTTGCCATCGCCACA
 AGTTTGTCAAGCAGGAGCCAACATTGTCTTAAACAGTCGTGGGGCAATCTCAGAAGAATTGCTGCTCA
 GTTTTCAAACTATGGTATCAAGGTGGTTCCCATTTCAAGAGATGTATCAGATTTTGCAGACGCTAAGCGT
 ATGATTCATCAAGCTATTGCAAGACTGGGTTCAAGTAGATGTTTGGTCAAGAAATGCAAGGATACCAAG
 ATACTCTTATGCTCAAGATGACAGAAGCAGATTTGAAAAAGTGCTCAAGGTCATCTGACTGGTGCCTT
 TATATGACAGAATCAGTCTTGAACCGATGATGAAGCCAGAGAGAGGCTGCTATCATTAATATGCTACT
 GTTGTGGTTTGTATGGGGAATATTGGTCAAGCTAACTATGCTGCTTCAAGGCTGGCTTGAATTGGCTTAC
 CAAGTCTGTGGCAGCGAGGTCGCTAGTCCGAATATACGAGTCAATGTGATTGCTCCAGGAATGATTGAG
 TCTGATATGACAGCTATCTTATCAGATAAGATTAAAGGAAGCTACACTAGCTCAGATTCCGATGAAGAAT
 TTGGGCAGGCAGAGCAGGTTGCAGATTGACAGTATTTTAGCAGGGCAAGATTATCTAATCTGGTCAAGT
 GATTGCCATTGATGGTGGCTTAAGTATGCTCGAGCACCACCACCACCACCCTGA

Fig 57

2CFE36 "homologue of SEQ. ID. NO. 32"

ATGGGAGTGAAAAAGAACTAAAGTTGACTAGTTTGCTAGGACTGTCTCTGTTAATCATGACAGCCTGTG
 CGACTAATGGGTAACCTAGCGATATTACAGCCGAATCGGCTGATTTTGGAGTAAATGGTTTACTTCTTT
 GCGGAAATCATTCGCTTTTATCGTTTGAATTAGTATCGGAGTGGGGATTATCTCTTTACCGTCTTGATT
 COTACAGTCTCTTGCCAGTCTTTCAGGTGCAAAATGGTGGCTTCTAGGAAAAATGCAGGAAGCTCAGCCAC
 GCAATTAAGGCGCTTCGAGAACAATATCCAGGTGCAAGATATGGAAGCAGAAACCAAACTAGAGCAGGAAA
 TGGCTAAAGTAATTAAGAAAAATGGGTGTCAGACAGTCAGACTCTCTTTGGCCGATTTTGATTGAGTGGC
 GGTATTTTGGCCCTGTCCAAGCCCTATCAAGAGTTGACTTTTAAAGACAGGTCAATTTCTTATGGATTA
 ACCTTGGTACTGTGGATACAACCTTGTCTTCCGATTTAGCAGCAGTATTCACCTTTTAAAGTACTTGG
 TTGTCCAACAAAGCTTTGTCTGAGCGAAATGGCGCTACGACTGCGATGATGATGGGATTCCAGTCTTGA
 TTTTATCTTTGACGTTTATGCGCCAGGTGGAGTCGCCCTATACTGGACAGTGTCTAATGCTTATCAAGTC

(Cont'd)
Fig 57

2 CFE 36

TTGCAAACTATTCTTGAATAATCCATTCAAGATTATCGCAGAGCGCGAGGCCGTAGTACAGGCACAAA
AAGATTGGAAAAATAGAAAAAGAAAAGCCAGAAAAAGGCTCAGAAAAAGAACTCGAGCACCACCAC
CACCACCACTGA

2 CFE37 "homologue of SEQ. ID NO. 33"

ATGAAGATTAGTAAAGGCACTTATTAATTATTCCATTCTTGATTCCCTACTTGCTTTTATCTATTTTGGGC
TGTATGTGGTCTATTTCGACCACCAAGTGCTATTTAATTGAAGAAGGCAAGAGCGCCTTGCAATTGGTTTCG
AAACCAAGGAATCTTTTGGATTGGTAGTTTGATACTGATTGCCCTAATTTATAAATTGAGACTAGATTTT
TGAGAAATGAGCGACTAATCAATTTAGTTATATTAATAGAAATGCTTTTATTGTTCTTGCTCGTTTATT
GOTATTTCAGTAAACCGGGCATAACGGTTGGATTTCGGTTGCAGGAGTAACTATTACGCCAGCTGAGTACT
TAAAAATCAATTATTATTGGTATTAGCTACCGATTCTCCAAACAGCAAGAAGAAATAGCTACTTATGA
TTTTCAAGTTTITGACTCAAAATCAATGGCTCCCCGTGCTTTAATGATTGGCGATTGCTTCTCCTAGTTCT
GATTGGAAGTTTGGGAATTTCCCTGATTTAGGAAATGCGACTATTTTAGTCTTGTTTCTGTTGATTATGT
ATACAGTTTAGTGGAAATCGCTTATCGCTGGTTTCAACCATTCTGGCGCTCGTATCTGCCGCTTCTGCTTTG
TCTTGAACCACTATCAGCCTAATCGGTGTTTGAGACCTTTTCAAAAATTTCCAGTATTTGGCTATGTAGCCAAA
CGCTTATAGTGCCTTTTAAATCTTTTGGCGATCGTCTGATGCAGGTCACCACTTACCTTATTTT
GCCATGTCAATGGTGGTTGGTTTGGTCTAGGTCTTGGAAACTCGATTGAAAAACGAGGTTATTTGCCAG
AAGCTCATAACAGACTTTGTCTTTTCTATCGTATTGAAAGAAATTTGGCTTTGTTGGTGCCAGTCTTATTTAG
CTCTCTTGTTTTTCATGATTTTGGCGATTATCTTGGTGGTATTTCGAGCGGAGAAATCCTTCAATGCCATGG
TTCCACTCGGTGTCGGAGGGAATGATGTTGGTTCAAGTATTTGTCAATATCGGAGGGATTTCGGGCTTGATT
CGATCTACAGGAGTAACCTTCCCTTCTTATCCAGGGTGAAATAGTCTTCTAGTCTTATCAGTGGCACT
ACCTTGTCTTAAATATTGATGCCAGTGA AAAACGCGCTAAGTTGTACCGAGAATTGGA AAAATCAACCA
ATGAAGCTTCTGTTGAAGCTCGAGCACCACCACCACCACCACTGA

Fig 58

2 CFE38 "homologue of SEQ. ID NO. 34"

ATGCTCGGAATTTTAACTTTATTCTGGTTTTCGGGAATTATGATGTTGTCACGAGTTCGGGCACTTCTA
CTTTGCCAAGAAATCAGGGATTTAGTACGTGAATTTGCCATCGGTATGGGACCTAAAAATTTTGTCTACA
TTGCCAAGGATGGAACGGCCTATACCATCGAATCTTGCTCTGGGTGGCTATGTCCGCATGGCCGGTTG
GGGTUATGATACAACCTGAAATCAAGACAGGAACGCCGTGTAGTTTGACACTTGCTGATGATGGTAAAGTT
AAAGGATCAATCTCTCAGGTAAAAAATGGATCAAAACAGCCCTCCCTATGCAGGTGACTCAGTTTGATT
TTGAAGACAAGCTCTTATCAAAAGGATTGGTTCTGGAAAGAAAGAAAAACATTTGCAGTGGATCAGGATGC
AACGGTTGTGGAAGCAGATGGTACTGAGGTTCCGATTGCACCTTTAGATGTTCAATATCAAAAATGCGACT
ATCTGGGGCAAACTGATTACCAATTTTGCAGGTCTATGAACAATTTTATCTTAGGTGCTGTTGTTTGTG
GGTTTAACTTTATGCAAGGTGGTGTGACAGATGTTGATACCAATCAGTTCCATATCATGCCCAAGGTG
CCTTGGCCAAAGGTAGGATACCAGAAACGGCACAATATACCAAGATTGGCTCACAAGGTTAGCAACT
GGCAAGGCTTGATCCAAGCTGTGGAAACAGAAACCAAGATAAGACGGCAACCGACTTTGGATGTGACTA
TTTCTGAAAAAGGGGAGTGACAAAACAGTCACGTGTACACCCGAAGATAGTCAAGGCTTACCTTCTAGG
TGTTCAACCGGGGTTAAGTCAGATTTTCTATCCATGTTTGTAGGTGGTTTACAACCTGCTGCTGACTCAO
CTCTCCCAATCTCTCAGCTCTGAAAAATCTGATTTCCAACCGGATTGAAACAAGTTGGGTGGACCTGTT
GCTATCTTTAAGGCAAGTAGTGATGCTGCTAAAAATGGAATTGAGAATATCTTGTACTCTTGGCAATGA
TTCCATCAATATTGGGATTTTAACTTTATCCGATTCCAGCTTGGATGGTGGTAAAGATTGTGCTCAAT
ATCTAGAAAGCCATCCGCCGCAACCAATGAAAAAGAAATTGAAACCTATGTACCTTGGCCGAGTG
GTGATCATGGTTGTCTTGATGATTGCTGTGACTTGAATGACATTATGCGACTCTTTTTAAGACTCGAGCA
CCACCACCACTGA

Fig 59

2 CFE39 "homologue of SEQ. ID NO. 35"

ATCTACCATATTTAAAAAGGAATCATTACCAAAATTACTGCCAAATACATTGTTCTTGAAACCAATGGTA
TTGGTTATATCTGTGATGTGGCCAATCCTTATGCCTATTACAGGTACGGTTAATCAGGAGGCTCAGATTAT
GTGATCAGGTTGTGCGTGAGGACGCCATTTGCTTTATGGAATTCGCTCAGAGGATGAGAAAAAGCTCT
TTCTAGTCTAATTTCCGTCTCTGGGATTGGTCTGTATCAGCTCTTGTCTATTATCGCTGCTGATGACAATG
CTGGCTTGGTTAAGCCATTGAAACCAAGAACATTACCTACTTGACCAAGTTCCCTAAAAATGGCAAGAA
AACAGCCAGCAAGATGCTGCTGGAATTTGGAAGGCAAGGTAGTAGTTGCAGGAGATGGCTTCTGCCAA
GGTCGCAAGTGAACCAAGTGTGAAAAACCAAGAAATTGGAAGGAACTATGGAAGCCATGTTGGCTCTGGG
CTACAAAGCAACAGAGCTCAAGAAAAATCAAGAAATTTTGAAGGAACGACAGATACAGCTGAGAACTA
TATCAAGTGGGCCCTTAAAAATGTTGGTCAAACTCGAGCACCACCACCACCACCACTGA

Fig 60

2 CFE40 "homologue of SEQ. ID NO. 36"

ATGAAAGAAATAATCGTATTTTACGACTTCTGGAAATGATATTTTATGTTGGTGGTGGACTGTCAGCTGATTT
 GGCTACCTATACCTTGAACGGCTTGCATGGGTTTGTAGCAGTGACTTGTGACAGCCCTGACAGAAAAA
 GGATTGGAAGTCTTTCCAAGTATGATACCATTTTCAACATGAATTAGATAGCTTGCCTGATGTGGAATT
 TGGGGGAATTAAGATTGGTCTTCTCCCTACTGTCAGTGTGGCTGAGAAGGCCTTGGACTTTATCAAAACA
 CCCCCGGAATACCTGTGGTGTGGATCCTGTCTTGGTCTGCAAGGAAACGCATGATGTAGCTGTCACTG
 AGCTCTGCCAAGAGTTGATTGCTTTTCCCTTATGTCAGTGTGATTACGCTAATCTCCAGAAAGCAGAA
 TTATTATCCGTCAGGAAATTAACCTTGGAAAGACATGAAACTGCAAGCAGAAATTCATGATTTTATG
 GAGCCGCAAGTCAATTATCAAGGGAGGCAATCGTCTTAGTCAGGACAAGGCTGTGGATGTCTTTTATGA
 TGGACAGACCTTTACTATCCTAGAAAATCCAGTTATCCAAGGCCAAAATGCTGGTGCAGGTTGACCTTT
 GCTCTAGCAATTGCCAGTCACTTGAATTAAGGTGATAAACTTTTCCAGCAGTAGAAAGCTTAAGGCTT
 TCGTTTATCGTGTATTGACACAAGCAGATCAGTATGGAGTAAGACAATATGAAGCAAAACAAAACAACC
 TCGAGCAACCAACCAACCACTGA

Fig 61

2 CFE41 "homologue of SEQ. ID NO. 37"

ATGATTGAAACGAGAAAAAAGAGGAGCGAGTCTGTGATTGGTGTGGAATTGCAGGGTATGGACAGT
 TTGACCTCTGCATGGAAGAAATTGGCTAGTTTAGCGAAAACGGCAGGGGAGTCTGTGATAGATAGCTACA
 GACAAAACGTTGAAAAATATGATTCCAAGACCTTCTGCGGCTCTGGTAAAGTTGGAAGAGATTGCGCTTAT
 GGTGGATGCAAGAAAGAAATCACTACTGTCATCGTCAACCAACCGTCTGACCCCAAGGCAGAAATGTCAATCTA
 GAGGAAGTCTCGGTGTTAAGGTCAATTGACCGTATGACGTTGATTGATATCTTTGCCATGCGGGCTCG
 AAGCCATGAAAGGAAGCTCCAAGTCCACCTAGCCCAACTCAAATACCTCTGCTCGCTGGTGGTGGTCA
 GGAATTATGCTCAGCCGTCAGGCAGGGGAAATTGGTTCCCGTGGTCTGGTGAAGGCCAACTGGAGCTG
 AACCTGCTGATCGTTCCCAATCAAATCACGGATATCGAGCGCCAGCTTAAGGTGGTTGAGAAAAATCGT
 GCGACTGTCAAGAAAAACGTTTGGAGTCTAGCACTTTAAGATTGGTTGATTGGTTATCTAATGCTG
 GAAAAATCACTATCATGAACATCTTGACCAAGTAAGACCCAGTATGAAGCAGATGAGCTCTTTGCCACTCT
 GGATGGGACAAACCAAGAGTATTCATCTGGGAGGCAACCTCCAAGTAACCTTGACAGATACCGTTGGCTTT
 ATCCAAGATTGCGGACAGAGTTGGTGTCCAGTTTCAAGTCAACCTTGGAAAGAAAGCAAGCATGTGGAGCT
 TTCTGGTTCATGTTATCGATGCTAGCAATCCTTACCACGAGGAGCATGAAAAAACGGTCTCTCCATCATG
 AAAGAAGCTGGACATGGAAGATATCTCACTTGACGCTTATAATAAAGCGGATTTGGTGGAGGATTTC
 CCGCTACCAAACGCCATATACCTCATTTCTGCAAGTGTGAGGACAGTCTGAAAACTTGAAGCATT
 ATTGCTAGATAAGATTAAGGAAATTTTGAAGCATTACCTGCGAGTGCTTTTCAAGTCTTACAAG
 ATTCATGATTAGAGAGTGTGCAATCTGGAAGAACGTGATTATCAGGAAGACGGCGAAGTGAATTACAG
 GCTACATTTCCGAGAAAAATAAATGGAGGTTAGAAGAAATTTATGACCTCGAGCACCACCACCACCA
 CTGA

Fig 62

2 CFE42 "homologue of SEQ. ID NO. 38"

ATGGCAAAAAACATATCCTATGACCCTTGAGGAAAAAGGAGAACTTGAAAAAGAAATTAGAAAGAAATG
 AAATTGCTTGGTCCGACCAGAAAGTGGTAGAACGCATTAAGATTGCCCGTTACATCGGTGATCTTTCAAGAA
 ACAGTGAAGTAAGCAAGCAGCTAAGGATGAACAAGCCTTTGTGGAAGGACAAATCTTAGCTTAGAAACAA
 AAACTCCGCTATGCTGAAATCGTCAATAGCGACGCAAGTGGCCAGGACGAAATAGCGATTGGTAAAAACA
 TCAACCATCCAAAGAAATTGGTGAGGACGAAAGAAAGTTTATATTATCGTAGGTTCACTGGTGGGATGC
 CTTTGCAGGTAAGGTTTCAAAATGAAAGCCCAATTGGGCAGGCCTTGATTGGCAAGAAAAACAGGTGACAC
 AGCAACCATTAACCGCCTGTTGGTAGCTATGATGTAAAAATCTTGAAGGTTGAAAAAACAGCCCTCGA
 GCACCACCACCACCACCTGA

Fig 63

2 CFE43 "homologue of SEQ. ID NO. 39"

ATGACCAAAATTAATGTTAGGCTTGGGAAATCCAGGGGATAAATATTTTGAACAAAAACACAATGTTGGTT
 TTAGTTGATTGATCAACTAGCGAAGAAACAGAAATGTCATTTTACACACGATAAGATATTTCAAGCTGA
 CCTAGCAATCTTTTCTAAATGGAAGAAAAATTTATCTGGTTAAACCAACGACCTTTATGAATGAAAGT
 GGAAGAGCAGTTCACTGCTTTATTAACCTTACTATGGTTTGGATATTGACGATTTACTTATCATTTACGATGA
 TCTTGACATGGAAGTTGGGAAATTCGTTAAGAGCAAAAGGCTCAGCAGGTGGTCATAATGGTATCAA
 GTCTATTATTCAACATATAGGAACTCAGGTCTTTAACCGTGTAAAGATTGGAATTGGAAGACCTAAAAAT
 GGTATGTCAGTTGTTCACTATGTTTGTAGTAAGTTGACAGGGATGATTATATCGGTATTTTACAGTCTAT
 TGACAAAGTTGACGATTCGTAAACTAGTATTTACAAGAGAAAAATTTGAGAAAAACAATGCAGAGGTA
 TAACCGACTCGAGCACCACCACCACCACCTGA

Fig 64

2 CFE44 "homologue of SEQ. ID NO. 40"

ATGATTTTAAATTACAGGGGCAAATGGCCAATTAGGAACGGAACCTCGCTATTATTGGATGAACGTAATG
AAGAATACGTGGCAGTAGATGTGGCTGAGATGGACATTACCGATGCAGAAATGGTTGAGAAAGTTTTTG
AAGAGGTGAACCGACTTTAGTCTACCACTGTGCAGCCTACACCGCTGTTGATGCAGCAGAGGATGAAO
GAAAAGAGTGGACTTCGCCATCAATGTGACGGGGACAAAAATGTGCAAAAGCATCTGAAAAGCATG
GTGCAACTCTAGTTTATATTTCTACGGACTATGTCTTTGACGGTAAGAAACCAGTTGGACAAGAGTGGOA
AGTTGATGACCGACCAGATCCACAGACAGAATATGGACGCACTAAGCGTATGGGGGAAGAGTTAGTTGA
GAAGCATGTGTCTAAATTTCTATATTATCCGTAAGCTTGAAGCTTTAACAGTTGTAAATGACCAGTACGGTCCGAC
TTGGAATCGTACCTTGGCTGAGTTTCATGACCTACCTAGCTGAAAATCGTAAGGAATTTGGTTATTAATCATT
TGTAAATGATGGCAGAGAAGACACAACATGOTATGATTTTGCAGTTGAAATTTTGAAGATACAGATGT
CGAAGTCAAGCCAGTAGATTCCAGTCAATTTCCAGCCAAAGCTAAACGTCCTAAACTCAACGATGAGC
GTGGCCAAAAGCCAAAGCTACTGGATTTGTTATTTCCAACTTGGCAAGATGCATTGCAAGAATTTTACAAAC
AAGAAATGAGACTCGAGCACCACCACCACCACCTGA

2 CFE45 "homologue of SEQ. ID NO. 41"

ATGAAACGTCTCTCGACTCTAGAGTCGATTATAGTTTGGCTCTTGCCAGTATTTTTCTACTGGTCACTCGGT
GTGGTGGTATCTATATAGCCGTAGTCAATGATTATCCCAATAATATCTGCCCATTTAGGGCAGCAGGT
CGCTGGATTGCTTGGGGCTTGTGATTGGTTTTGTGGTCTGCTCTTAATACAGAAATTTCTTTGGAAGG
TGACCCCTTTCTATATATTTAGGCTTGGGACTTATGATCTTGCCGATTGTAATTAATCCAAAGCTTAG
TTGCATCAACGGGTGCCAAAACTGGGTATCAATAAATGGAATTACCCTATTTCAACCGTCAGAATTTAT
GAAGATATCCTATATCCTCATGTTGGCTCGTGTCAATTGTCCAATTTACAAAGAAACATAAGGAATGGAGA
CGCACGGTTCGGCTGGACTTTTGTAAATTTCTGGATGATCTCTTACCATTCCAGTCTAGTTCTTTTA
GCACTTCAAAGTGAAGTGGGGACGGCTTTGGTTTTGTAGCCATTTTCTCAGGAATCGTTTTATTATCAGG
GGTTTGTGAAATTTATATCCAGTATTTGTGACTGCTGTAACAGGAGTTGCTGGTTCTTAGCTATCT
TTATTAGCAAGGACGGACGAGCTTTTCTTACCAGATTGGAATGCCGACCTACCAATCAATCGGATTTT
GGCTTGGCTCAATCCCTTTGAGTTTGGCCAAACAACGAGTTACCAGCAGGCTCAAGGGCAGATTGCCATT
GGGAATGGTGGCTTATTTTGTGAGGGATTTAATGCTTCGAATCTGCTTATCCAGTTCGAGAGTCAATAT
GATTTTACGGTTATTGACAGAGATTTTGGCTTATTTGGCTCTGTCTGGTTATGGCCCTCTATCTCATGTT
GATTTACCGTATGTTGAAGATTACTCTTAAATCAAATAACCAGTTCTACACTTATATTCCACAGGTTTGA
TTATGATGTTGCTCTTCCACATCTTTGAGAATATCGGTGCTGTGACTGGACTACTTCTTTGACGGGGATT
CCTTTGGCTTTTCAATTCGCAAGGGGATCAGCTATTATCAAGTAATCTGATTGGTGGTTGGTTTGTCTTATCG
ATGATTTACCAAGCTAATCTAGCTGAAGAAAGACGGGAAAGTCCCATTCAAACGGAAAAAGGTTGTA
TTAAAACAAATTAACCTCGAGCACCACCACCACCACCTGA

2 CFE46 "homologue of SEQ. ID NO. 42"

ATGGGAAAAATCATCGGAATCACTGGGGGAATTGCCTCAGGTAAGTCAACTGTGACAAATTTTCTAAGAC
AGCAAGGCTTCAAGCAGTGGATGCCGACGAGTCTGCCACCAACTACAGAAACCTGGTGGTCTGTT
TGAGGCTGTAGTACAGCACTTTGGGCAAGAAATCATTCTTGAAAAACGGAGAACTCAATCGCCCTCTCCTA
GCTAGTCTCATCTTTTCAAATCCTGAAGAGCAAAAAATGGTCTAATCAAATTCAGGGGAGATTATCCGTO
ACGAACCTGGCTACTTTGAGAGAACAGTTGGCTCAGACAGAAGAGATTTTCTCATGGATATTCCTTACT
TTTGTAGCAGGACTACAGCGATTGGTTTGTGAGACTTGGTTGGTCTATGTGGACCGAGATGCCCAAGTA
GAACGCTTAATGAAAAGGGACAGTTGTCCAAAGATGAAGCTGAGTCTCGTCTGGCAGCCAGTGGCCTT
TACAAAAAAGAAAGATTGGCCAGCCAGGTTCTTGATAATAATGGCAATCAGAACCCAGGTTCTTAATC
AAGTGCATATCTTCTTGAGGQAGGTAGGCAAGATGACAGAGATCTCGAGCACCACCACCACCACCT
GA

2 CFE47 "homologue of SEQ. ID NO. 43"

ATGAGAAAAATTTATTCAATGGTGGATTACCACTGCAAGGTGAAATCACTATTAGTGGTGGCTAAAAATA
GTGTCGTTCCTTAATTCAGCTATTATCTTGGCTGATGATGTGGTGACTTTGGATTGCGTTCCAGATATT
CGGATGTAGCGAGTCTTGTGCGAAATCATGGAATTGATGGGAGCTACTGTTAAGCGTTATGACGATGATTT
GGAGATTGACCAAGAGGTGTTCAAAATATTCCAATGCCTTATGGTAAATTAACAGTCTTCGTGCATCT
TACTATTTTATGGGAGCCTCTTAGGCGGTTTTGGTGAAGCGACAGTTGGTCTACCGGGAGGATGTGATCT
TGGTCTCGTCCGATTGACTTACACCTTAAGGCGTTGAAGCTATGGGTGCCACTGCTAGCTACGAGGGA
GATAACATGAAGTTATCTGCTAAAGATACAGGACTTCATGGTGCAAGTATTTACATGGATACGGTTAGTG
TGGGAGCAACGATTAATACGATGATTGCTGCGGTTAAAGCAAATGGTCTGACTATTATTGAAAAATGCAGC

2 CFE 47 (Contd.)

Fig 68 (Contd.)

CCGTGAACCTGAGATTATTGATGTAGCTACTCTCTTGAATAATATGGGTGCCCATATCCGTGGGGCAGGA
 ACTAATATCATCATTATTGATGGTGTGAAAGATTACATGGGACACGTCATCAGGTGATTCCAGACCGCA
 TTGAAGCTGGAAACATATATCTTTAGCTGCTGCAGTTGGTAAAGGAATTCGTATAAATAATGTTCTTTAC
 GAACACTGGAAAGGTTTGTGCTAAGTTGGAAGAAATGGGAGTGAGAATGACTGTATCTGAAGACAGC
 ATTTTGTCTGAGGAACAGTCTAATTTGAAAGCAATCAATATTAAGACAGCTCCTTACCCAGGCTTTGCAA
 CTGATTTGCAACAACCGCTTACCCCTCTTTTACTAAGAGCGAATGGTCGTGTACAATTGTGATACGATT
 TACGAAAAACGTGTAAATCATGTTTTTGAACAGCAAAAGATGGATGCGGATATTTGACAACAAATGGTC
 ATATTTGTACACGGGTGGACGTGATTACGTGGGCGCAGTGTTAAAGCGACCGACTTAAGAGCTGGGGC
 TGCACAGTGTATTGCTGGGCTTATGGCTGAAGGCAAACTGAAATTACCAATATCGAGTTTATCTTACGT
 GGTATTCTGATATTATCGAAAAATTACGTAATTTAGGAGCGGATATTAGACTGTGTGAGGATCTCGAGC
 ACCACCAACCACTGA

Fig 69

2 CFE48 "homologue of SEQ. ID NO. 44"

ATGTCAAGAAATTGAATTTTACCACATCTTTGATGACCATGGATTGTCACAAATTCAAAGAGCAGATTACTTT
 TTGAATGATAAAGTAGCATCTTATCATATCGATATTATGGATGGCCATTTTGTTCCTCAATATTACCTTGT
 CTCCTTGGTTCTATTCAAGAAGTTCAAAAAATTAGTGACACACCTTTATCAGTTTCATCTGATGGTCACAGAC
 CCAACCTTTTGGGTAGATCAAGTTCTCGATTACAAATGTGAGTATATTTGTATTTCATGCTGAAGTTCTGAA
 TGGTCTTGGCTTTCTGTTTGTATGATAAAATTCATGATGCAGGTCTAAAGGCTGGTGTGCTTAACTCTG
 AAACAGCTGTTTCTACAATCTTTCCCTACATTGATTTACTTGACAAAGTAACTATTATGACTGTAGATCCA
 GCTTTTGCAGGACAACGCTTTTGGAGTCTACCTTGTATAAAATCCAAGAACTCCATCAGCTTAGAGTTCA
 GAATCTTATCACTACATCATTTGAGATGGATGGTTCTTCGAGTCGTAAAGACTTTCAAACAAATTGATGTG
 GCAGGACAGATATTTATGTTATAGGTGCGAGTGGATTATTGGTTTGGATGACGATATTGGCAAAGCTT
 GCGATATCTGTTCTAGAGATTACGAAGAAATGACCGGAAAAACAATGCCAATCAAACCTCGAGCACCACC
 ACCACCACTGA

Fig 70

2 CFE49 "homologue of SEQ. ID NO. 45"

ATGAGAAATAATGGCTTTGACAGCAGGTATCGTTGGTTTGGCAAACGTTGGTAAATCAACACTATTTAATG
 CAATTACAAAAGCAGGAGCAGAGGCAGCAAACTACCCATTTGCGACTATTGATCCAAATGTTGGAATGG
 TGAAAGTTCCAGATGAACCGCTACAAAACTAACTGAAATGATAACTCCTAAAAAGACAGTTCCACAA
 CATTTGAATTTACAGATATTGCAGGGATTGTAAAAGGAGCTTCAAAGGAGAGGGCTAGGGAATAAAT
 TCTTGGCCAATATTTCGTGAAGTAGATGCGATTGTTCACGTAGTTCTGCTTTTGAATGATGAAAAATGTAATG
 CGGAGCAAGGACGTGAAGACGCTTTGTAGATCCACTTGCAGATATTGATACAATTAATCTGGAATTAA
 TTCTTGTGAGTTAGAATCAGTGAACAAACGATATGCGCGTGTAGAAAAATGACACGTACGCAAAAAAG
 ATAAAGAAATCAGTAGCAGAATTCAATGTTCTTCAAAGATTAAACCAGTCCTAGAAGACGGGAAATCAG
 CTGTAACCATTTGAATTAACAATGAGGAACAAAAGGTTGTCAAAGGTTCTTTCTTTTGGAGCTAAACC
 AGTTCTTTATGTAGCTAAATGTGGACGAGGATGTGTTTTCAGAACCTGACTCTATCGACTATGTCAAACAA
 ATTCTGAATTTGCAGCGACAGAAAAATGCTGAAGTAGTCTGTTATTTCTGCGCTGTGAGGAAGAAATTT
 CTGAATTTGATGATGAAGATAAAAAAGAGTTTCTTGAAGCCATTGGTTTGACAGAATCAGGTGTAGATAA
 GTTGACCGCTGCAGCTTACCACTTGTGTTGGATTGGGAACCTTACTTACAGCTGGTGAAGAAAGAGTTCCG
 GCTTGAACCTTCAAACGTGGTATGAAGGCTCCTCAAGCAGCTGGTATTATCCACTCAGACTTTGAAAAAG
 GCTTTATTCGTGCAATAACCATGTCTATGAAGATCTAGTGAAATATGGATCTGAAAAAGGCGTAAAAAGA
 AGGTGGACGCTTGGCTGAAGAAGGAAAAAGAAATATATCGTTCAAGATGGCGATATCATGGAATTCGCTTT
 AATGTCCTCGAGCACCACCACCACCACCTGA

Fig 71

2 CFE50 "homologue of SEQ. ID NO. 46"

ATCGAAATCGAAAAAACCAATCGTATGAATGCGCTCTTTGAATTTTATGCGCGCTTTTGACAGATAAGC
 AAATGAATTATATCGAGCTCTACTACGCTGATGATTACAGCCTTGCTGAAATTGCCGAGGAGTTCCGGTGT
 CACTCGTCAGGCTGTCTATGACAATATCAAGCGAACAGAAAAAGATTCTGGAAGATTATGAGATGAAAT
 GCACATGTACTCGGACTATATTGTCCGCAGTCAGATTTTGTATCAGATTTTGGAGCGCTATCCCAAGGATA
 ACTTCTTCAGGACGAGATAGAAATTTTAAACAGCATTGATAATAGAGAACTCGAGCACCACCACCACC
 ACCACTGA

Fig 72

2 CFE51 "homologue of SEQ. ID NO. 47"

ATGACCTTAGAATGGGAAGAATTTCTAGATCCTTACATTCAAGCTGTTGGTGAGTTAAAGATTAAACTTC
 GTGGTATTCGTAAGCAATATCGTAAGCAAAATAAGCATTCTCCAATTGAGTTTGTGACCGGTGAGTCAA
 GCCAATTGAGACATCAAAGAAAAATGGCTCGTCTGGCATTACTTATGCGACCTTGGAAACAGATTG

2 CFE 51 (contd)

Fig. 72 (contd)

CAGGATATTGCTGCTTACGTGTGATGGTTTCAGTTTGTAGATGACGTCAAGGAAGTAGTGGATATTTTGC
 ACAAGCGTCAGGATATGCGAATCATACAGGAGCGAGATTACATTACTCATAGAAAAGCATCAGGCTATC
 GTTCCATCATGTGGTAGTAGAATATACGGTTGATACCATCAATGGAGCTAAGACTATTTTGGCAGAAAT
 TCAAAATCGTACTTTGGCCATGAATTTCTGGGCAACGATAGAACATTCTCTCAACTACAAGTACCAAGGG
 GATTTGCCAGATGAGATTAAAGAGCGACTGGAAATTACAGCTAGAATCGCCATCAGTTGGATGAAGAA
 ATGGGTGAAATTCGTGATGATATCCAAGAAGCCCAGGCACCTTTTGTCTTTGAGTAGAAAAATTAATG
 ACGGTGTAGGAAACAGTGACGATACAGATGAAGAATACAGGCTCGAGCACCACCACCACCACTGA

Fig. 73

2 CFE 52 "homologue of SEQ. ID NO. 48"

ATGGAACCTTAATACACACAATGCTGAAATCTTGGCTCAGTGCAGCTAATAAGTCCCCTATCCGCAGGATG
 AACTGCCAGAGATTGCCCTAGCAGGGCGTTCAAATGTTGGTAAATCCAGCTTTATCAAACTATGTTGAA
 CCGTAAGAATCTCGCCCGTACATCAGGAAAACTGGTAAACCCAGCTCTGAACTTTTTAACTTGAT
 GACAAAGATGCGCTTTGTGGATGTGCTGGTTATGGCTATGCTCGTGTCTTAAAAAGGAACGTGAAAAAT
 GCGGCTGCATGATTGAGGAGTACTTAACGACTCGGAAAAATCTCCGTGCGGTTGTCTAGTCTAGTTGACCT
 TCGTCAAGACCCGTCAGCAGATGATGTGCAGATGTACGAATTTCTCAAGTATTATGAGATTCCAGTCATC
 ATTGTGGCGACCAAGCGCGACAAGATTCTCTGGTAAATGGAACAAGCATGAATCAGCAATCAAAAAG
 AATTAAACTTTGACCCCAAGTGACGATTTCTCTCTTTTCTCTGTCTGCAAGGCGAGGATGGATGAGG
 CTTGGGATGCAATCTTAGAAAAATTTGGCGGCCGCACTCGAGCACCACCACCACCACCACTGA

Fig. 74

2 CFE 53 "homologue of SEQ. ID NO. 49"

ATGAAACAAGAAAAATCCCTTTGCGCAAGTCTGTTGTGTCTAACGAAGTGATTGATAAGCGTGATTGTC
 TCCGCAATTGTCAAGAAACAAGGAAGGACAAGTCTTTATTGATCCTACGGGCAAGGCCAATGGCCCGGGCG
 CTTATATCAAACTAGACAATGCAGAAGCCCTAGAGGCGAAAAAGAAAGAGTCTTTAACCAGCAGCTTTA
 GCATGGAAGTGGAAGAAAGCTTTTATGACGAGTTGATCGCTTATGTGGATCACAAGTGAAAAAGAAAG
 AGTTGGGACTTGAACTCGAGCACCACCACCACCACCACTGA

Fig. 75

2 CFE 54 "homologue of SEQ. ID NO. 50"

ATGTTAAACCCTCTATTGATACCTTGCTGACAAAGGTTCTTCAAATATTCACCTCGTAATCTTGGAAAGC
 AAAACGTCGCCACGAATTGGAAGCAGGTGCCCCAGCAACTCAAGGTTTCAAGTCTGAAAAATCAACTCTT
 CGCCTTTAGAAGAAATCGAATCAGGAAACGTTACAATTACCCAGATCCAGAAGGAAAAACGTGAAGCA
 GTCCCTGCGCTATCGAAGAAGAAAAACGCGCAAGAAAGAAAGAAAGAAAAATCAAGAGCAAAAT
 TGCTAAAGAAAAAGAAAGATGGTGAAAAAATTCTCGAGCACCACCACCACCACCACTGA

Fig. 76

2 CFE 55 "homologue of SEQ. ID NO. 51"

ATGTCAATTAACATCAAAACAACGTGCTTCTCAACAGCCAGGCCACACACCTCAAACCTATCATCCAAA
 TCGGAAAAAATGGACTCAACGACCAAAATCAAAACAGCCTCCGTCAAGCTCTTGATCGCGGTGAATTA
 TGAAGGTTACTCTCTTACAAAACACAGATGAAAAATCCACGAAGTAGCTGAAATTTTGGAAAGAAAA
 TCGGTGTGGATACAGTCCAAAAAATAGGACGCATCTTGATTTTGTTTAAACAATCTAGCAAGAAAAAGAAA
 TCGCAAGATTTCTAAGAAAGTCAAGAAATCTCGAGCACCACCACCACCACCACTGA

Fig. 77

2 CFE 56 "homologue of SEQ. ID NO. 52"

ATGGCATTGAAAAATTATATACCAGATTTTGTGTGGAAGCAGTCTATGATCTGACAGTCCCAAGCCTGC
 AGCGCAGGGAATCAAGGCTGTTTTGTGATTTGGATAATACCTCATTTGCTTGGAAACAACCTGATGG
 AAGGCCAGAGATGAAGCAATGGCTACATGACCTTCGGGACGCGGTATTTGGCATTATCGTAGTGTCAAAT
 AAGACCAAAAAACGCTTCAACGAGCAGTTGAGAAATTTGGGATTGATTACGTTTACTGGGCTTGAAGC
 COTTCACATTTGGTATTGACCGTGCTATGAAGGAAATCCACTATGACAAAAAGGAAGTGGTCATGGTTGG
 CGACCACTCATGACAGATATACGAGCAGCCACCCTGCAAGGATTTCGGTCAATTTTAGTCAAAACCTTG
 GTCAACATGACTCAATCAAAACGCGAGATTAACCGAACTCGTGAGCGTCTGTGTTATGAGAAAAATCACTG
 AAAAGTACGGACCGATTACATATAAAAAAGGAATTTCTCGAGCACCACCACCACCACCACTGA

Fig. 78

2 CFE 57 "homologue of SEQ. ID NO. 53"

ATGTTTCBAAAAATTTAATTGCCAATCGTGGTGAATTTGCGGTTCTGATTATCCGTGCGGCACGTGAATT
 GGGGATTGGCAGCGTAGGGTTTATTCAACTGCTGATAAGGAAGCTCTCATACGCTTTTGGCAGATGAA
 GCAATTTGTATTGGTCTGGCAAGGCAAGAGTCTTATCTCAATATTAATGCAGTTCTATCACTGCACT
 CTTACTGAGGAGAAAGCTATTCACCCTGGTTTTGGATTTCTCAGTGAAATTTCCAAATTTGCGACCATGT

2CFE 57

Fig 78 (contd)

GTGAAGAGTAGGTATCAAGTTTATCGGTCCATCTGGTCATGTTATGGATATGATGGGGGATAAGATCAA
 TCCGCTTGCTCAGATGATTAAAGCAGGTGTGCTGTTATACCAGGTTGAGATGGAGAAGTGCATAACTCT
 GAAGAAAGCTTTGATTGTTGCTGAAAAAATTGGCTATCCTGTTATGCTCAAGGCTTCAGCAGGTGGAGGTG
 GTAAAGGATTTCOTAAGGTTGAAAAACCAGATGACCTCGTTTCTGCTTTGAAACTGCCTCTAGTGAGGC
 CAAGGCAATTATGGCAATGGTGCCATGTACATAGAACGGGTTATCTATCCAGCTCGGCACATTGAGGTT
 CAAATCCTAGTGATGAGCATGGACATGTGATTCACTTGGGTGAACGGGATTGTTCTCTTCAAAGGAAATA
 ACCAAAAGGTTTTGAAAGAAAGTCCCTCGATTGCAATCGGAAAAACGCTGCGTCAATGAAATAGGTGCTG
 CTCTGTTCCGAGCGGCAGAGTTTGTGGCTATGAGAATGCAGGAACCATTTGAATTTCTTCTTATGATGAAGC
 AAGTAGAAAATTTCTATTTCATGGAGATGAATACTGTTTTCAGGTAGAACATCCAGTAACAGAGTTTGT
 TCAGGTGTTGATATCGTTAAGGAACAGATTGTCATTGCGGCAGGTGAGCCTTTGTCTGTTAAGCAAGAAAG
 ATATTGTCCTACGCGGTGATGCCATCGAGTGTCTGATCAATGCAGAAAACCCAGCCTTTAACTTTGTCTCCA
 AGTCCAGGTAAGATTACTAATCTCTATCTGCCAAGTGGTGGAGTTGGCTTGGCGGTGGATTGAGCAGTTT
 ATCCAGGTTATACCATTCGCTTATTATGATAGTATGATTGCCAAAATCATAGTACACGGCGAAAAATCG
 TTTGACGCTTGATGAAAATGCAACGTGCCCTCTATGAATTAGAGATTGAAGGAGTGCAGACCAATGCA
 GATTTCAGCTTGATCTCATTTCAGATCGCAATGTCATTGCTGGGATTATGATACCTTCTTCTTGATGGA
 AACCTTTTACCTAAATATCAAGAAAAAGAACTCGAGCACCACCACCACCACCTGA

Fig 79

2CFE58: "homologue of SEQ. ID NO. 54"

ATGATTACAAAGTTTTTTATCAAGAAACAAAGAACGTAGCCACGCGGTGAAACAACACGCACGCTTT
 ACCTAGACATCGATGCCAGCTCAGAACTTGAGGGCGGTATCACTGCTCGCCAACTTGTGCAAGAAAAATCG
 CCCAGATACAAATATCGAGTATATCGAACTCTTGTCTGACAAATTGCTCGATTACGAAAAAGAACTGGC
 GCCTTCGAAATTACGGAGTTCTCTGAGCACCACCACCACCACCTGA

Fig 80

2CFE59: "homologue of SEQ. ID NO. 55"

ATGAAGGATAGATATATTTTATGACATTTGAGACATCTGTGATGAGACCAGTGTGCGCGTCTTGAAAAACG
 ACGATGAGCTCTTGTCCAAATGTCATTGCTAGTCAAATGAGAGTCAAAACGTTTTGGTGGCGTAGTGCC
 CAAAGTAGCCAGTCGTACCATGTGCGAGGTCAATACAGCCTGTATCGAGGAGGCATTGGCAQAAGCAGG
 GATTACGGAAGAGGACGTGACAGCTGTTGCGGTTACCTACGGACCAAGGCTTGGTCCGAGCCTTGCTAGTT
 GGTGTTGTCAGCTGCCAAGGCCCTTTGCTTGGGCTCACGGACTTCCACTGATTCTGTTAATCAATGGCTGG
 GCACCTCATGGCAGCTCAGAGTGTGGAGCCTTTGGAGTTTCCCTTGCTAGCCCTTTAGTCAAGTGGTGGG
 ACACAGAGTTGGTCTATGTTTCTGAGGCTGGCAATTACAAGATTGTTGGGGAGACACGAGACGATGCACT
 TGGGGAAGGCTTATGACAAGGTCGGTCTGTGATGGGCTTGACCTATCCTGCAGGTCTGTGAGATTGACGAG
 CTGGCTCATAGGGGACAGGATATTATGATTTCCTCCGTGCCATGATTAAGGAAGATAATCTGGAGTTCT
 CCTTCTCAGGTTTGAATCTGCTTTATCAATCTTCAATCAATGCGGAGCAAAAGGGAGAAAGCCTGTC
 TACAGAAAGATTGTTGTGCTTCTTCCAAGCAGCAGTTATGGACATTCTCATGGCAAAACCAAGAGGCT
 TTGAGAAATATCCTGTTAAACCCCTAGTTGTGGCAGGTGGTGTGGCAGCCAATAAAGGTCTCAGAGAAC
 GCTAGCAACTGAAATCACAGATGTCAATGTTATCATCCACCTCTGCGTCTGTGCGGAGACAATGCAAG
 TATGATTGCTTATGCCAGTGTGAGCGAGTGGAAACAAAGAAACTTTGCAAACTTGGACCTCAATGCCAAA
 CCAAGTCTTGCTTTGATACCATGGAACTCGAGCACCACCACCACCACCTGA

Fig 81

2CFE60: "homologue of SEQ. ID NO. 56"

ATGTGTGAATTTGTTGGTGTGTTGGAAAACAAAAAGCAACTGATATTTTGATTCAAGGGCTTGAAAAAGC
 TTGAATACCGTGGCTATGATTCTGCGGGAATTTTGTCTAGATGGTGTGATAACCATTTGGTGAAGGCT
 GTTGGTCTATGCGCAAAATTTGCTGCCAAGACAGCTGGTGTGAGGGAACAACTGGTATCGGACATACTC
 GTTGGGCAACTCATGGGAAACCAACGGAAGACAATGCTACCCACACCGCTCTGAGACAGAACGTTTTG
 TCTTGGTTCAAAATGGGOTGATTGAAAACTACCTTGAAATTAAGAAAGAAATACCTTGTGGGACCACTT
 CAAAGGCAAAACAGATACGGAATCGCCGTACATTTGATTGAAAAATTTGCGGAAGAAAGACCGTCTCTC
 AQTCTTGAAGCCTTTAAAAAAGCTCTTCATATTATCCGTGGTTTCATATGCCCTTTGCCTTGAATTGACTCTG
 AAAATCCAGATGTCTATGTAGCGAAAAACAAATCTCCACTTTTGATTGGTCTTGGGGAAGGCTACAA
 TATGCTCTGCTGAGATGCTATGGCTATGATTCTGTGAAACCAACCAATACATGAAATTCATGACCAAGAG
 TTGTAATCGTCAAGGCTGATAGCGTGGAAGTTCAAGACTATGATGGTAACAGTCTGTAACGCTGCTAGCT
 ATACTGCGGAACCTTGACTTGTGAGATATCGGTAAGGGAACCTTATCCTTACTACATGCTTAAGGAAATGGA
 TGAGCAACCAACTGTTATGCTAAACTCATTCAAGCCTACACGGATGATGCTGGTCAAGTAGTGATTGAT
 CCTGCTATCATTAAGGCTGTTCAAGACGACAGCCGATCTACATCCTTGCAGCTGGAACATCTTACCATG
 CAGGATTGCTTCTAAGAAAAATGTTGGAAGAATTGACAGATACACCAAGTTGAACTTGGCATCTCATCTGA
 GTGGGGCTACGTTATGCCACTTCTCAGCAAGAAACCACTTTCATCTTTATCAGCCAACTGTTGTAACA

2 CFE 60 (contd.)

Fig 81 (contd.)

GCGGATAGTCGTCAAGTTTTGGTCAAGGCTAATGAAATGGGAATTCCAAGCTTAACAGTGACAAACGGTTC
 CAGGTTCAACCCCTCTCACGTGAAGCCAATATACCATGCTCCTTEACGCAGGTCCCTGAAATTCGGCTGGC
 ATCAACTAAAGCCTATACAGCGCAAAATCGCAGCCCTTGCCCTTCCTTGCAAAAGCAGTCGGAGAAGCAAAT
 GGTAAATGCTAAAGCGCAAGCCTTTGACCTGGTTTCATGAATTGTCAATCGTAGCTCAGTCTATCGAATCAA
 CTCTTCAGAGAAAAGAAACCATTAAGCCAAGGTTCTGTGAACCTCTTGAAACAACCTCGTAACGCCCTTTTA
 CATCGGACGTGGTCAAGATTACTACGTAGCCATGGAAGCAAGTCTCAAACCTCAAAGAGATTTCTTATATC
 CAGTGTGAAGGTTTTGCGGCAGGAGAACTCAAGCACGGAACCATTTGCCCTTGATTGAAGAAGGAACACCT
 GTCTTGCTGTCTGTGATCCAGTCCCTTGCCAACCACTCGTGGAATAATCCAAGAGGTGGCAGCCC
 GTGGTCTAAGGTCTCACTATCGCAGAAAGAAATGTTGCTAAAGATAACCGACGATATCGTCCCTACGAC
 TGTACAACCTTACCTCTACCAATTTCAATGGTCTGACCGACGCAATTGGTTGCTTACTTTGCAACCCCTCC
 ACCGTGGCTCGATGTGGATAAACCACGTAACCTTGCCAAGTCAGTAACGGTAQAACCTCGAGCACCACC
 ACCACCACCACTGA

Fig 82

2 CRE61 "homologue of SEQ. ID NO. 57"

ATGATACGTATCGAAAATCTCAGTGTCTCTACAAAGACACGTTGGCACTTAAGGATATTTCACTAGTGC
 TGCATCGACCAACAATTACCGGCATCATTTGGTCCAAACGGCGCTGGGAAATCAACACTATTAAAAAGGTAT
 GGTGGGAATTAATCCACATCAAGGTCAGGCATTCTCGATGACAAGGAAGTTAAAAAATCCTTACACCGA
 ATTGGCTATGTGCAACAAAAATCAATATCGACTACAACCTTTCCCATCAAGGTCAAGGAAGTGGCAAGAGGC
 TGTGAAATCGTCGGCTAGCTGACTACGCTGAACGTCAAATTAAGTCAACTGTCTGGAGGTCAATTCAG
 CGGTTTGTGATTTGCCAGATGTTTGTGTCAGGAAGCCGACTATATCCTCTTGGATGAACCCCTTTGCTGGGAT
 TCACTGTGTCAGTGAGGAAATCATCATGAATACGTGAGAGATTTGAAAAAAGCTGGGAAGACGGTCTCT
 CATCGTTACACGACCTCAGCAAGATTCCCACTACTTCGATCAAGTCTTACTTGTCAATCGAGAAGTG
 ATTGGCTTTGTGTCGAACAAAGAAACTTTTACCGAAACCAATCTAAAAAGAGCTTACGGTAATCAACTCT
 TTTCAATGGAGGTGACCTACTCGAGCACCACCACCACCACCACTGA

Fig 83

2 CRE62 "homologue of SEQ. ID NO. 58"

ATGCCGAAAGAGTGAATTTAACAGGCGAAGAAAGTTGTGCGTTTAACCAAAGAATATTTAACCGAAAGAG
 GATGTTCAATTTGTCCATAAGGCCTTGGTCTATGCTGTTGAATGCCACAGTGGTCAATATCGCAATCAGG
 CGAGCCTTATATCATTACCCCTATCCAAGTGGCAGGTATTTTAGCTAAGCTAAAGCTGGATGCTGTAAACA
 GTAGCTTGTGGATTCTTGCAATGATGTTGGTGAAGATACAGATGCGACTTTGGACGATTGGAAAGAGAGT
 TTGCTCTGATGTGCGGATGATTGTTGACGGAGTTACCAAGCTTGGCAAGGTCGAGTACAAATCGATCGA
 GGAGCAATTAGCGGAAAAATCATCGCAAGATGCTCATGGCCATGTCTGAGGACATCCGCTTATTTGCTC
 AAAGTGTCTGACCGCTTGCACAATATGCCGACCCGTGAACATCTTCGAAAAGACAAGCAGGAGCGTATTT
 CCAAGAAACCATGGAATCTATGCCCGGCTTGCCCATCGTTTGGGGATTTCAGTGTCAAATGGGAATT
 AGAAGACTTGTCTTCCGTTATCTCAATCCAACGGAGTTTACAAGATTACCCATATGATGAAGGAAAAAG
 CGCAGGAGCGGTGAGGCCTTGGTGGATGAGGTAGTCAACAAATTAAGAGGATATACGACAGAACCTCAC
 TTGAAAAGGAAGATTATGTTGCTGCCAAGCATATTTACTCAATTTTCCGCAAAATGCAAGCAAGAGAA
 AACCGTTTGAGGAAATCTATGATCTGATTGCTATTCGTTGATTTTAGATACCCAAAGTGATGTTTATGCC
 ATGCTTGTTACGTGCATGAATTTTGAACCCGATGCCAGGTGCTTCAAAGACTATATCGCCAACCGCA
 AGGCCAATGTTATCAGTCTATCCATACGACTGTTTATGGACCAAAAGGCGGATTTGAATTCAGATTGCG
 AACCAAGGAAATGCAAGAGGTGGCTGAGTACGGGTTGCGGCTCACTGGGCTTATAAGAAAGGTATAAA
 GGGCAAGTTAACAGCAAGGAATCAGCTATTGGAATGGAAGTCAAGGAGATGAGGCTCAAGA
 CAGGCTGATGATGCTAAGGAATTTGTGACTCTGTTAAGGAAAACTATTGGGTGAGGAGATTACGTT
 TTTACCCAGATGGAGGTGTCCGTTCCCTTCCAAAGATTACAGGACCGATTGATTTTGCTACGAAATCCA
 TACCAAGGTCCGTGAAAAAGCAACTGGTGCCAAGGTCAATGGCCGCATGGTTCCACTGACAACCAAGTT
 AAAGACAGGGGATCAGGTTGAAATTAAGCAACCCGAACCTCTTGGACCTAGCCGTGACTGGCTCAAT
 ATGGTCAAGACTAGCAAGGCGCGCAATAAGATTGCGCAGTTCTTAAAAACCAAGATAAGGAATTGTCT
 GTCAACAAGGCTCGTGAGATGCTGATGGCTCAGTTCCAAAGAAAAATGGCTATGTGGCAAAATAAATTTATGG
 AQAAGGCCACATGGATCAAGTTCTGCAAAAGACCAAGTTACAAGACAGAAAGACTCCCTCTTTGCGGCCAT
 TGGTTTTGGGAAATCGGTGCGATTACCGTCTTTAACCGTCTGACTGAAAAAGGAGCGCGGTGAGGAAGAG
 CGTGCCAAGGCCAAGGCTGAGGCAAGGAGCTTGTCAAAGGTGGCGAGGTCAAGGTTGAAAAATAAAG
 AACTCTAAGGTCAAGCATGAGGGGGAGTGGTTATTGAAGGTGCTTCTGGTCTCCTAGTGGCGATTGCT
 AAGTGTGTAAACCCCGTGGTGGACGATATGTTGGCTACATTACCAAGGGTCTGTGTGGCTATTC
 ACCGTGTGACTGTATGAACCTGCGTGCCCAAGAAAACTACGAGCAACGTCTCCTTGATGTGGAATGGGA
 AGACCACTACTCTAGCTCAAATAAGGAGTATATGGCCCATATCGATATCTACCGTCTCAACCGTACAGGA

2 CFE 62 (contd)

(Contd)
Fig 83

CTGTGAAACGATGTACTGCAAGTTCTTTCAAATACAACCAAGAATATTTCAACGGTCAATGCCCAACCAA
 CCAACGATATGAAGTTTGCTAATATCCATGTGTCTTCGGTATTGCCAACCTCTCTACACTGACCAAGGTT
 GTCGATAAAATTAAGAGTGTGCCAGAGTTTACTCTGTCAAACGGACCAACGGCCTCGAGCACCACCACC
 ACCAACCCTGA

2 CFE 64 "homologue of SEQ. ID NO. 60"

ATGACAGAAAGAAATCAAAAATCTGCAGGCACAGGATTATGATGCCAGTCAAAATTCAAGTTTTAGAGGGC
 TTAGAGGCTGTTTCGTATGCGTCCAGGGATGTACATTGGATCAACCTCAAAAAGAGGTCTTCAACATCTAG
 TCTGGGAAAATGTTTGATAACTCAATTGACGAGGCCCTTGGCAGGATTGGCCAGCCATATTCAAGTTTTTATT
 GAGCCAGATGATTTCGATTACTGTTGTGGATGATGGGCGTGGTATCCAGTTCGATATTGAGGAAAAACAG
 GTCTGCTGCTGTTGAGACCGTCTTTACAGTCTTTCACGCTGGAGGAAAGTTCCGGCGTGGTGGATACAA
 GGTTCAGGTGCTCTTCACGGGGTGGGGTCTGTCAGTTGTTAATGCCCTTTCCACTCAATTAGACGTTTCATG
 TCCATAAAAACGGTAAGATTTCATTACCAAGAATACCGTCTGGTTCATGTTGTGCGCAGATCTTGAAATAGT
 TGGAGATACGGATAAAACAGGAACAACTGTTCACTTACACCGGACCCAAAAATCTTCACTGAAACAAC
 AATCTTTGATTTTGATAAATTAATAAACCGGATTCAAGAGTTGGCCTTTCTAAATCGCGGCTCTCAAATTT
 CTATCACTGATAAGCGCCAAGGTTTGGAAACAAACCAAGCATTATCATTATGAAGGTGGGATTGCTAGTTA
 CGTTGATATATCAACGAGAACAAAGGATGTAATCTTTGATACACCAATCTATACAGACGGTGAGATGGAT
 GATATACAGATTGAGGTAGCCATGCAATACACAACGGGTACCATGAAAAATGTCATGAGTTTCGCCAATA
 ATATTATACACATGAAGGTGGAAACGCATGAACAAGGTTTCCGTACAGCCTTGACACGTTTATCAACGA
 TTTAGTCTCGTAAGAATAAGTTACTGAAAGACAATGAAGACAATCTAACAGGGGAAGATGTTCCGGAAGG
 CTAAAGTGCAGTTATCTCAGTTAAACACCCAAATCCACAGTTTGAAGGACAAACGAAGACAAATTTGGGA
 AATAGCGAAGTGGTCAAGATTACCAATCGCCTCTTCAGTGAAGCCTTCTCCGATTTCCTCATGGGAAATC
 CACAGATTGCCAAACGTATCGTAGAAAAAGGAATTTTGGTGGCAAGGCTCGTGTGGCTGCCAAGCGTGC
 GCGTGAAGTCAACGTAATAAATCTGGTTTGGAAATTTCCAACCTTCCAGGGAAACTAGCAGACTGTTCT
 TCTAATAACCCCTGCTGAAACAGAACTCTTCATGCTGAAGGAGACTCAGCTGGTGGATCAGCCAAATCTG
 GTCGTAACCGTGAGTTTCAAGCTATCCTTCCAAATTCGCGGTAAAGATTTTGAACGTTGAAAAAGCAAGTAT
 CGATAAGATTCTAGCTAACGAAGAAATTCGTAGTCTTTTACAGCCATGGGAACAGGATTTCGGCGCAGAA
 TTGATTTTTCGAAAGCCCGTTACCAAAAACCTCGTTTGTATGACCGATGCCGATGTCGATGGAGCCCA
 TTCTGATCCCTTCTTTTAAACCTTGATTATCGTTATATGAAACCAATCTTAGAAGCTGGCTATGTTTATATTG
 CCCAAGCACCATCTATGGTGTCAAGGTTTGAAGCGAGATTAAGAAATATATCCAGCCGGGTGCAGATC
 AAGAAATCAAACTCCAAGAGCTTTAGCCCGTTATAGTGAAGGTCTGACCAACCGACTATTCAGCGTTA
 TAAGGCGCTAGGTGAAATGGACCATCATCAGCTGTGGGAAACAAACCATGATCCCGAACATCGCTTGAT
 CGCTAGAGTTTCTGTAGATGATGCTGCAGAAAGCAGATAAAATCTTTGATATGTTGATGGGGGATCGAGTA
 GACCCCTGTCGTGAGTTTATCGAAGAAAAATGCTGTCTATAGTACACTTGATGTCCTCGAGCACCACCACC
 ACCAACCCTGA

Fig 84

2 CFE 65 "homologue of SEQ ID NO. 61"

ATGGGATTACTGAAGAAACAGTACGTTTTAAATTTGGACGATTCCAATAAAAAAGAAATTAGCGAAACTT
 TGACAGATGTTTATGCTTCGTTGAACGATAAGGGTTACAACCCCAATTAACCAAAATCGTAGGTTACGTATT
 GAGTGGAGACCCCTGCTACGTTCTCGTTATAATAATGCACGAAATCAAATCCGTAAGTATGAGCGTGAT
 GAAATCGTTGAGGAATGGTTTCGCTACTATCTCAAAGDACAAGGAGTCGATCTACTCGAGCACCACCACC
 ACCAACCCTGA

Fig 85

2 CFE 66 "homologue of SEQ. ID NO. 62"

ATGGTCAACTATCCACATAAAGTTTCATCAGAAAAAGACAAACATCTTTTCTCAACCCAAAAATTTCTG
 CAAATCGAGGAAATGCTTTTGAAGAGATGATCAATGCTACCAACGACTACTATTGTTCTCAGGGCTTGGC
 TGTATACATAAGAAACCAACTCTTATTCAAATCGTACAAGTGGACTATCCACAACGAAGTCGTGCCAAG
 ATTGTTGAAGCCTATTTTCGACAAGCTTCAACGACGGACTATTTCTGGCGTTTATAATGATATTACATCGA
 CTGTTGAAGTCAAGGAAACAAACAAACAGTGGGATTCGATGAAAAATTTTCATCCACATCAGATTCA
 CATATGGAACAAGTCTTGCCEAAACAGGAATCTGCTTTGTCCTTCTTCACTTTTCTCTCAGCAAGAAAC
 CTACTTATGCGCGCATTGATTTGATTGCTTCTATCATCAAGATAAGGGACAAAAATCAATGCCACTTO
 AATATATTCGAATAATATGATATGAAATCAAGGCTGGTGCCTTCCCTCAAATTCCTTATCTCAATGTTATC
 AAAGAAGATTTATTAGGTGGTAAAAACAAGACTCGAGCACCACCACCACCACCCTGA

Fig 86

2 CFE 67 "homologue of SEQ. ID NO. 63"

2 CFE 67 homologue of SEQ ID NO: 63

ATGGCTTATTTAGTAAAAAGATAAGTATATTCGAATCAATCCCAATCGTTCGGTTAGGGAAAAACCTC
AAGCTAAGCCAGAGGTTCCAGATGAATTATTTCCAGTGTCAGGCTGTAAGCATACCATCTATCAGAA
GGATCTGGGAAGTGAAACGTATCTGTCCGCACTGTAGCTATACCTTTCTGATTTCTGCCCAAGAACGCTTGG
CTTTACGATTOATATGGGAACCTTCAAAGAATTGTTTACAGGGATTGAAAAGCAAGGATCCCTTGCATTT
CCCTGGTTACCAAAAAGAACTGGCATCTATGCGTGAAAAAACAGGTCTGCATGAAGCCGTTGTGACAGG
AAGTGCCTTATTAAAGGTCAGACTGTGGCTCTTGGGATTATGGATTCTAATTTATCATGGCTTCTATGG
GTACGGTTGTAGGTGAAAAAATCACTCGTTTGTGTGAGTATGCGACTGTGAAAAATTGCCAGTTGTCTCT
ATTCACAACCTCTGGTGGAGCCCGTATGCAAGGAAGGAATCATGAGTCTCATGCAAGTGGCTAAGATCTCT
CCAGCGTTAAACGCCATTCAAATGCTGGTCTCTTTACCTGACCATTTTGACAGATCCAACGACTGGTG
GTGTGACGCTTCTTTCCGCTATGGAAGGCGATATCATTTCTGGCTGAACCACAGAGCTTGGTTGGTTTGGCT
GGCGCTGTGTGATTGAAAAACGGTTCGTGAAAGCTTGCCTGAGGATTCCAAAAGGCAGAAATTCCTAT
TAGAACATGGCTTTGTGGATGCTATTGTCAAAAAGAGACTTACCAGATACGATTGCTAGCCTAGTCAG
ATTGCATGGAGGGAGTCTAGACTCGAGCACCACCACCACCCTGA

2 CFE 68 "homologue of SEQ. ID NO. 64"

ATGAGAAATTAAGGATTGGACGTCGGTTCAAAAACGGTAGGGGTGGCGATTAGCGATCCGCTTGGTTTTA
CAGCTCAGGGCTTGAATCATCCAGATAAATGAAGAACAAGGCCAATTTGGTTTTGACCCGCTTAAGG
AATGGTTGATACCTACAAGGTGGAACGATTTGTAGTGGGCTTGCCTAAAAACATGAACAATACAAGTGG
ACCGCGCTAGAAGCTAGTCAAGCCTACGGAGCAAAGCTAGAAGAGTTTTTGGTTTACCAGTAGACTAT
CAGGATGAACGCTTGACAACAGTGGCTGCTGAGCGCATGTTGATTGAACAAGCAGATATCAGTCGCAAT
AAGCGCAGAAAGTCAATTGATAAGTACGAGCTCAGCTGATTTACAAAATTATTAGATAGAAAAATTC
TCGAGCACCAACCACCACCACCCTGA

2 CFE 69 "homologue of SEQ. ID NO. 65"

ATGACAAAACCTTACTGTTAAAGACGTTGACTTGAAAGGTAAAAAAGTCCTCCTTCTGTTGACTTCAACG
TACCATTAAGATGGCGTAATCACTAACGATAACCGTATCACAGCAGCTCTTCCAACCTAATAAGTACAT
CATCGAACAAGGTGGACGTCGAATTTCTTCTCTCACCTTGGACGTTGAAAGAAGAATCTGATAAAGCT
GGTAAATCACTTGCTCTGTAGCAGCTGACTTGGCAGCAAAACTTGGTCAAGATGTTGTTTCCAGGTGT
CACTCGTGGTGCTGAATTGGAAGCGGCAATCAAACGCTCTTGAAGATGGACAAGTTCTCTTGGTTGAAAAAC
ACTCGTACGAAGATGTTGACGGCAAGAAAGAAATCTAAAAACGATCTGAACTTGGTAAATACTGGGCA
TCCTTGGAGATGGTATCTTGTAAACGATGCAATTCGGTACAGCTCACCGTGCAACGCACTAAACGTTG
GTATCTCAGCAACGTTGAAAAAGCAGTTGCTGCTTCTCTTGA AAAACGAAATTGCCATACATCCAAGA
AGCAATTAAGAACTCCAGAACGTTCCATTCCTGGCTATCCTTGGTGGTTCAAAAAGTTTCAGACAAGATCGGT
GTATCCAAAACTTCTGTTGAAAAAGCTGATAAAGTCCTTATCGGTGGTGGGATGACTTACACATTCTACA
AAGCACAAGGTATCGAAATCGGTAACTCACTTGTAAGAAGAAGACAAATTGGATGTTGCGAAAGCTCTTCT
TGAAAAAGCAAAATGGTAAATTGATCTTGCCAGTTGACTCAAAAAGAAGCTAACGCAATTTGCTGGTTACACT
GAAGTGGCTGACACTGAAGGTGAAGCAGTTTCTGAAGGCTTCTTGGTCTTGACATCGGTCCAAAATCTA
TCGCCAATTTTACGAAGCTTTGACTGGTGCCAAAACAGTTGTATGGAACGGACCTATGGGTGTATTTGA
AAACCCAGATTTCCAAGCTGGTACAATCGGTGTGATGGACGCTATCGTGAAACAACAGGAGTTAAATC
AATCATCGGTGGTGGTGACTCAGCTGCCGACGCAATTAACCTTGGCCGTGCAGACAAGTTCTCATGGATT
AGTAGGGGTGGTGGAGCATCAATGGAACTTCTTGAAGGTAAAGTTCTTCCAGGACTTGACAGCCTTGACAG
AAAAACTCGAGCACCAACCACCACCACCCTGA

2 CFE 70 "homologue of SEQ. ID NO. 66"

ATGTTAAATCAGAAAAACAATCAGTTATCAAATGTTAAATGAAGAATTGTCCTTCTTATTGGAAGGCG
AAACCAATGTTTGGCTAATCTTTCCAACGCCAAGTCTCTCATAAATCAGCTTTTCTAATACCGTATTT
GCAGGCTTTTATTTGTTGATGGAAGGAATTGGTTTATAGGCCCTTCCAAGGAGGTGTTTCTGCTATCCG
TATGCACTAGGCAAGGTTGTTGTTGGTGAGGCAGCTCACTTTCAGGAAACTGTTATTGTTGGAGATGTG
ACCACTATCTCAACTATATTTCTGTGATAGTCTAGCTAAAAGTGAATTTGTTGGTGGCGATGATGAAGA
ATGGTCAATTAATGGAGTTCTGGATCTGGATTCTTCAGAGATTGAGGATTACGATGCTATGGATCGAGA
TTATTTGAAACAATTTGCTGCTATTTGCTTGAAGAACAACATGGGACTTTACGATGTTGAGGAAAAA
TCTCTCGAGCACCAACCACCACCACCCTGA

2 CFE 71 "homologue of SEQ. ID NO. 67"

ATGAGAAATCGAACTATTGACTCCCTTTACCAAGGTAGAGTTGGAGCCAGAAATCAAGGAGAAAAAACGC
AAACAAGTTGGGATTTTAGGGGGGAATTTTAAACCTGTTCACAATGCCCATCTCATTTGTCGGATCAAG

2 CFE 71 (Contd)

Fig 91 (Contd)

TACGGCAACAGTTGGGACTGGATCAAGTCTCTCATGCTGAATACCAACCTCCTCACGTTGATAAAAA
 GQAAACCATCCCTGAACACCATCCTCTCAAGATGCTTGAGTTGGCAATTGAGGGGATTGACGGCCTAGTC
 ATTGAAACCAATTGAGTTGGAGCGCAAGGGTATTTCTACACCTACGATACCATGAAGATTTTGACAGAGA
 AGAATCCAGATACGGATTATTACTTTATCATCGGTGCCGACATGGTTGACTATCTGCCTAAGTGGTACCG
 AATTGATGAACCTGGTTGACATGGTTTCACTTTGTGGGGGTTTCAAGCTCCACGCTACAAGGTAGGGACTTCC
 TATCCAGTTATCTGGGTGGACGTACCGCTCATGGATATCTCGTCCAGCATGGTGGGGGACTTCTTGGCCA
 AGGTTCGAAACCAACTTTCTCTACCTCAGCCAAGTGCTAGACTACATCGAGAAGGAGGGGCTCTACCTC
 GAGCAACCAACCAACCACTGA

2 CFE72 "homologue of SEQ. ID NO. 68"

Fig 92

ATGAAATTGCAAAAAATAGTCAAGAGAAGCGCGTGAACAGAGTCGCTTGACAACCTTGGACTTTGGGACA
 GGCATTTTGAATTTATCCAATTACATGGTGACCGTTCTTTTCGTGATGATGGTGCACTTGTGGTGG
 TATTGGTTGGCTTGGAGACCAAGCTGTAACAGTGGTTGGTATCCAAAAAGGCAAGAGTTTGCAAGACAA
 COTCAAACGGAATTTGGCCAACCACATCCAGAAAGCTACCGAAAGGCACTGCGGTGATGAAACAGGC
 TGAGAAATTTGGCCGTCCAGTTGTGACCTTTATCAATACAGCAGGTGCTTATCCTGGTGTGGAGCGGAA
 QAACTGGTCAAGGGGAAGCTATCGCTCGCAATCTCATGAAAATGAGTGACCTGAAAGTCTTATTATCG
 CCATTATATCGGTGAAGGTGGTTCAGGCGGGGCTCTGGCTCTAGCTGTGCGGACCGTGTCTGGATGCT
 GGAATAATCTATCTATGCCATTCTCAGTCCAGAAGGCTTTGCTTCCATTTTATGAAAGGACGGTACTCGCG
 CCATGGAAGCAGCAGAACTGATGAAAACTACTTCGCATGAACTGTTAGAAATGGACGTGGTGGATAAGG
 TGATTTCTGAAGTAGGACTTTCTAGTAAAGAACTAATTAAGAGTGTCAAAAAAGAACTCCAAACCGAGCT
 GGCTAGACTTTTCAAAAAACCGCTAGAAAGAGTTGCTGGAAGAACGCTATCAACGATTTAGAAAAATACCT
 CGAGCACCAACCAACCACTGA

2 CFE75 "homologue of SEQ. ID NO. 73"

Fig 93

ATGTCAGATAAGATTGGCTTATTCACAGGCTCATTGATCCGATGACAAATGGGCATCTGGATATCATTTG
 AACGGCGAGCAGACTTTTGTATAAGCTTTATGTGGGTATTTTAAATCCCAACAAACAGGATTTCTT
 CCTATCGAAAAATCGTAAACGGGGGCTAGAAAAAGGCTTTGGACATCTGGAAAAATGTTGAAGTCGTGGCT
 TCTCATGATGAATTTGGTGGTCCGATGTTGCAAAAAAGATTGGGTGCTACTTGTCTAGTGCGTGGTTGAGGA
 ATCGGTGGGATTTGCAATATGAAGCCAGTTTGTATTACTACAATCATCAGCTGTCTTCTGATATAGAGACT
 ATTATTTACATAGTGACCTGAACATCTCTATATCAGTTTATCAGGCGTTAGAGAGCTTTTGAAGTTTGG
 TCAGGATATTGCGCTGCTATGTTCCCGAGAGTATTGAGGAAAGCGGCGCACTCGAGCACCACCACCAC
 CACCCTGA

2 CFE76 "homologue of SEQ. ID NO. 72"

Fig 94

ATGACGATTTTGTGTTGTTATCAGTGCTTCTCTTCTGTATATGGTTTCTCTTAGCATGAAACCCCTATCAA
 ACAGCTAAAAAGTGAAGGAGAAAAATTAGCTCAGCAGTATGCAGGATTAGAGCAGGCTGATCAGGTTGAT
 TTATACAAATGGCTTGGAACTTTATTACAGCGTCTTGGTCTGTAATAACAGCAAOAAGCGCTTGTCTCT
 GATTGGTAAAGATGACCATAAGATTTACGTTTATCAGCTAAATCAGGGTATTTCACAAGAAAAAGCAGA
 AACGGTTTCTAAGGAAAAAGGAGCTGGCQAGATTGACAAGATAACCTTTGGTCTGTTATCAAGACAAGCC
 AATCTGGGTAGTTAAGTCAGGATCTGATTTTATCTAGTAGATTTTGAACAGGAGCATTTGGTCAACAAG
 GAGGGCTACTCGAGCACCACCACCACCCTGA

2 CFE78 "homologue of SEQ. ID NO. 74"

Fig 95

ATGTTTCAATCGATAAAGAAAAATTTCACTTTGTAACCAAGTACGATTTTGCCCTCTGAAACTATTGATG
 CGCAGGATATTCTTACTGGAATCAGTGTTTAAACAATTTATGAAGAAAAATCAACTGTAGTCATGTT
 GGOAATCTTTGGTAGCCATCATTTTGATAAGTTTCTATCCCAATGTTTTCTAAGTTTGATTTCAATGATG
 TCAGCAAGGTAAACGACTTTAGTGTTCGTTATATCAAGCCAAATGCGGAGCATTGGTTTGGTACTGACAG
 TAACGGTAAATCGCTCTTTGACGGTGTCTGGTTCGGAGCTGTAACCTCCATCCTCATTTCTGTGATTGCGA
 CAGTGATTAACCTGGTTATCGGTGTTTTTGTGGGTGGTATTGTTGGGTATTTCAAAAATCAGTTGACCGTGT
 ATGATGAAAGTTTACAACGTCTCTCAACATCCACCTCTTTGATTGTTATTGTTCTGACTTACTCAAT
 CGGAGCTGGATTCTGGAATCTGATTTTGGCATGAGCGTAACAACATGGATTGGTATTGCTTCAATGATCC
 GTGTGCAAACTTTGGCTATCGTGACTTGGAAATACAACCTTGGCGTACGTACTTTGGGAAGCAACCTT
 GAAGATTGTTGCCAAAAATATCATGCTCAATGGTATCTGTTATTGTGACAACCATGACTCAAAATGCTTC
 CAAGCTTTATCTCATACGAAGCCTTCTGTCTTCTTCTGGTCTTGGATTACCGATTACAGTGCCAAAGTTG
 GGTGTTTGAATTCGGATTATTCACAAAAACGTAACAACCAATGCTTACTTGTCTGATTCCATTGACAAC

(Contd.)
Fig 95

2 CFE 78 (Contd.)

CCCTGTCTTGGTATCCTTGTCCCTTTTCGTAGTTGGTCAAAACTTAGCGGATGCTAGTGATCCACGTACAC
ATAGACTCGAGCACCACCACCACCACCCTGA

2 CFE 79 "homologue of SEQ. ID NO. 75"

ATGTATAACCTATTATTAACCATTTTATTAGTATTATCTGTTGTGATTGTGATTGCAATTTTCATGCAACCA
ACCAAAAACCAATCCAGCAATGTATTTGATGCCAGTTTCAGGTGATTGTTTGAACGCAGTAAAGCTCGCG
OTTTTGAAGCTGTAATGCAGCGTTTGACAGGGATTTTAGTCTTTTCTGGCTAGCCATTGCCTTAGCATTG
ACGGTATTATCAAGTAGACTCGAGCACCACCACCACCACCCTGA

2 CFE 80 "homologue of SEQ. ID NO. 76"

ATGTTTGTAGAAATAAATTATTTTGGACCACAGAAATTTACTCTTAACCATCATCTTTTACCTATGG
AGACAGATGGGATCTTTGATTAAACCTTTTGTAGCGTGCTTAATACAATTATGATTCCATTTTATTAGG
GGCTCTTCTTTATTATTGACAAACCTATTGTTACTTTCTTAAATAAAGTCTGTAAACTCAATCGTTTGT
TGGTATTTAAATTACCTTGTGACTTTGGTCTGGGGAATGGTCATAGGTGTTGCTATCTCTTACCTATTT
GATTAAACAGTTATCTAGTTTGATTATCTAGTCAAACCTATTTATAGTCGAGTACAAGACTTAAATCATAG
ACTATGTAATTATCTCGCTCCAGAAATTTGGATGTAGAAGCTACAATTCAGCAGTTAAACTTATCTTAT
GTTGATTTCTTCAAATATCCTAAATAGCGTATCAAATAGTGTGGGGAGCGTCTTGTGAGCTCTTATCAG
TACTGTTTGAATTTTGATTATGACTCCAGTTTCTTGGTTTATTTCTTATTAGATGGACATAAATCTTGGCC
ATGCTTCAAAGAAACGATTCTAAAGAGGGATCGCTTGCATATTGCAGGCTTATTAAGAATTTAAATGCGA
CGATTGCTCGGTATATTAGTGGAGTTTCGATTGACGCAATCATTATAGTTGTTGGCTTATTTGGCTAT
AGTATTATTGGTTTAAATATGCTTTAGTTTGGCAATTTTCTGGTGTAGCCAATTTAAATCTTATGTG
GGCCCAAGTATTGGTTGATTCTATGATCATCGCAATATATTCACTGATCCCATAGACTGCTGATTGC
AGTGATTATATGCTTGTGTTGACGAGGTAGATGGCAATATCTTATATCCTCGAATTTGAGGAAGTGTTA
TGAAGTTTCATCCCAATCAGATTTTAGTTTACTTTTGGTTCAGCAATATCTATGGTGTAGTTGGAATG
ATTGTCCAGTGCCAAACCAATTTCTATCTTGAAGAAATTTCTAAGTTCTTATCCCTTTGTATGAAATCA
TAAATAATGAAAGAACGAGAAAGAGAATTAGCTAAGCTCGAGCACCACCACCACCACCCTGA

2 CFE 81 "homologue of SEQ. ID NO. 77"

ATGTATTAAGCACTTTATCGAAATATAGAAGTCAAAACTTCTCCAGTTAGTTGGTCAAGAAGTTGTGG
CTAAGACTCTTAAACAAGCGGTGGAGCAAGAGAAATAAGTCACGCTTATCTTTTCTGGTCTCGTGG
AAGGGGAAAAACAGTGTGTCTAAAATCTTTGCCAAGGCTATGAACTGTCCCAATCAAGTGGGTGGCGA
ACCTTGAATAACTGCTATATTGTCAAGCAGTGACGGACGGTAGTTTGAAGATGTCATTGAAATGGAAT
GCAGCTCTAATAATGGGGTAGATGAAATTCGCGAAATTCGTGATAAATCTACCTATGCGCTAGCCTTG
CTCGTTATAAGGTTTATATCATAGATGAGGTTTACATGCTGTCTACAGGGGCTTTTAAATGCCCTCTTAAAG
ACCTGGAAGAAACCAACACAGAATGTAGTCTTTTATTTGGCCACTACTGAATTGCAACAAGATTCTCTCTA
CTATCTATCCCTGTGCAACGTTTGTAGTTTAAATCAATTAAGACACAGGATATTAAGGAACATATTCAC
TATATCTTAGAATAAGAAATATCAGTTCTGAACCAGAGGCTGTGGAAATCATTGCCAGACGGGCGGAA
GTTGGAATGGCGGACCGCTTGTCTATTTGGATCAAGCCCTGAGTTTGACACAGGGAAATGAGCTGACGA
CTGCTATCTCTGAAGAAATTAAGTGCACCATAGCCTACAGCCTTGGAATGATTATGTGGCGGCTTGTCT
CAACAGGATGTTCCCAAAGCTTTGTCTTGTGAATCTTCTTTTGAACAATGGTAAGAGCATGACTCGTTT
TGTACCGATCTTTTGAATTTTAAAGAGACTTGTAAATTGTTCAAAACAGGGGGAGAAAATATCTCATCAT
AGTTCACTCTTTGTAGAAAATTTGGCACTTCTCAAAAAAATCTGTTTGAATGATTTCGCTTAGCAACAGT
GACTTTAGCAGATATTAAGTCTAGTTTGCAGCCCAAGATTTATGCTGAAATGATGACCGTCCGTTTGGCG
GAAATCAAGTCCGAACAGCTCTATCAGGAGCGGTTGAAATGAAATGCTACGCTGAGACAGGAAATG
GCGGCTGCAAAACAGAGCTTTCTAATGTAGGTGCGGTTCTTAAACAAAGTTGCACCAGCTCCTAGTCCAC
CAGCTACGGGCAAAACAGTCTATCGTGTGATCGCAATAAAGTGCAATCTATCTTACAAGAGGCGCTCGA
AAATCTGATTTAGCAGCTCAAAATTTAATTCGTTTGCAGAATGCCTGGGGAGAGGTAATTGAAAGTCTA
GGTGGGCGGACAAAGCTCTGCTCGAGCACCACCACCACCACCCTGA

2 CFE 82 "homologue of SEQ. ID NO. 78"

ATGTTTCAATTAACCAATAAGTTAGCGGTATCGAACTTGATTAATAAACCAGCAAACTGTACTATCCTTTTGC
GCTGGCTGTTCTTGTGCACTGCTACCTATCTTTTACTCTCTAACCTTCAATCCTAAGATTGCGGA
AATCCGTGGAGGAACAACCATTCAGGCTACACTTGGATTGGTATGTTTGTGCTACCCCTTGGCTGCGT
ATTATCCTTCTCTATGCCAATAGTTTGTGATGAAGAACCCTTCAAGGAAGTAGGAATTTATGGCAATG
GGCTTGGAGAAAGCGTCTATCTATCAGTATGACCTTAAAGGAGTTAGTGGTATTTGGGATTCTAAGTGT
GAGCGGCTATCGGATTGGAGCCTTGTGTTGACAAGTTAATTTTCGCTTTCTGCTCAAACTAATGAAATTG

2 CFE 82 (contd.)

AAGGTTGAGCTGGTTGCTACCTTCCAGACGAAAGTTGTCATTACAGTGCTTGTGTCTTCGGTTTGATTTT
 CCTAGGCCTCATGTTCTGAATGCCCTTCGAATCGCCCGTATGAATGCCCTCCAGCTCTCTCGTGAGAAAA
 CTAGTGGAGAGAAAAAGGTGCTTCCCTTCTCCAAACCATTCCTTGGTTCCATAAGTTTATAGGAATTGG
 CTATTATCTTGGCCCTTACGGTAAAGATCCTCTTACAGCCTTAAACAACCTTCTTCATAGCTGTTTTACTGG
 TATCTTGGGACTTATCTCTTGTAAATGCAAGGATTACCGTTTCTCCAAATCTTAAAGAAAAATAAGA
 AATACTATTACCAACCAATAACCTCATATCTGTTCTAACTTGATTTTCCGTATGAAGAAAAATOCAGTI
 GGACTAGCCACCATCGCTATCTTGTCAACAATGGTTTTGGTAACCATGTTCAGCAGCGACAAGCATTTTCA
 ATTCTCAGAAAAGCTTTAAAAAAGTTCTAAATCCTCATGATTTTGGGGTTTCAGGGGAAAAATGTTGAAAA
 AGAAGACTTGGACAACTCTTGAGCCAGTTTGCAAGTGACAAAGGTTATAAGATTAAAGAAAAAGAAAGT
 ATTCTGTACACTTACTTTGCTGTTGCGAATCAAGAAGGAACCAAGTTAACTATTTTGAAAAAGGACAA
 AACCGTTCCAAACCAAAAAACAGTTTTCATGTTTACCAAAAAAGATTATGAAAAATATGACTGGTCAAA
 AACTGTCTCTATCAGGAAATGAGGTCCGACTCTTTGCAAGAATGAGGGAGTTAAAGAACAGAAAGCTC
 TAACTGTAATGATCATCAATTTCTGTAAAAGAAGAATTTACTAAAGATTTTATGTCAACCATGTTCCA
 AATCAGTTAAATATTTGACTGCTGATTACAATTACCTTGTGTACCTGATTACCAAGCCTTTTGGATCAA
 TTCCACATTCGGCTATCTATAATCAGTTTACCGTGGTATGAATGTAAATGCCAGTGAAGCAGAACAAAC
 TCAAGTTCGGTGAAGGAGTATGAAAAATACCTACAAAAGTTAATGCTCAATTAACACTGAAGGTAACCTA
 TGTGTATGGTAGCACTCTAGCAGATGCTAGTCTCAGATGAGTGCCCTCTTTGGTGGTGTCTTCTTTATCG
 GTATTTCTTATCCATTATCTTTATGGTCCGAACCGTTCTGGTCTACTACAAAACAAATTTCTGAAGGA
 TATGAAGACCGTGAAGCGCTTTATTATCTTGCAGAAAGTCGGTTTAGATCAAAAGCAATCAAGCAAAACCA
 TCAACAACAGGTTTAACTGTATTCTTCTCTCTTGTCTTCTTGCCTTCTTACATCTAGCCTTTGCTTACC
 ATATGCTTAGTCTGATTTTAAAGTGATTGGTGTACTGGATACGACTATGATGTTGATTGTGACCTTGTCT
 ATGTGCTCTATCTTCTCATCGCTATGTGCTGATTTTCATGATTACTTCAAGAAATTATCGCAAGATTGT
 GCAAAATCTCGAGCACCACCACCACCACCTGA

Fig 99 (contd.)

2 CFE83 "homologue of SEQ. ID NO. 79"

ATCAAAACAAGATCAACTAAAGGCTTGGCAACCAGCTCAGTTTGACCGTTTGTCCGTATCTTAGAACAAAG
 ACCAGCTCAATCACGCCTATCTCTTTTCAGGTTTCTTTGGAAGCTTGGAAATGGCGCAATTTTAGCTAAG
 AGCCTTTTGTACGGATAAAGTTGGCGTCTTACCATTGTGAGAAATGCCGAAGTTGCAAGCTGATTGAAC
 AGGAAGAGTTTCCAGATGTCACTTGATTAAGCCAGTCAATCAGGTCTATCAAGACAGAACCGATTCCGG
 AATTGGTGGGACAGTTTCTCAAGCAGGGATTGAAAAGCCAGCAACAGGTTCTTATCATCGAGCAAGCGG
 ATAAAAATGCATCCCAACGCAGCAATTTCTCTCTCAAGGTCTCGAAGAACCCAGAGTGAAAGTTTATAT
 TTCTCTGTAAGTGAAGAAAACTTATCTTACTCTTAGAACAATGGGACTTGTAAAGAAAAAGCGACTCTT
 TTAGCTAAGTTTAGTCAATCGCGAGCTGAAGCAGAAAAAGTTGGCACATCAGGCAAGTTTGGACCTTGG
 TCGATGAAGTGAACGCTGCTGACTTGGTTAGTAGCTAAGAAAAAGAAAGTTATCTACAGGTTGCGCA
 AATTAGGCAACTTGGCAGATGATAAGGAAAAACAGGATCAGGTTTACCGATTCTTGAAGTTCTCTGTGG
 GCAAGGACTCTTGCAGGTAAGAGTAAGAGTGATTCTACAAGATTACTAGAAAGCTAGAAAAATGTGGCA
 AGCTAATGTCAGCTTCAAAATGCCATGGAATATCTGGTCTTGAAGAAATACTCGAGCACCACCACCAC
 CACCACCTGA

Fig 100

2 CFE84 "homologue of SEQ. ID NO. 80"

ATGAATTCATTAAAAATTTCTTAAAGAGTGGGATTATTCCTCCTGATTCTGTCTACTAGCTTTGAG
 CCGTATTTTTTTTGGAGAAATGTTCCGCTAGAAAGGACATTCCATGGAATCCGACCTAGCGGATGGTGAA
 ATCTTTTGTGTTAAGCACCTCCCTATGACCGTTTGTATATCGTGGTGGCCCATGAGGAAAGATGGCAA
 TAAGGAGATCGTCAAGCGCGTGAATTGGAATGCCGTGGCGACACCATTCTGTACGAAAAATGATAAACTCTAC
 ATCAATGACAAAGAAACGGACGAGCCTTATCTAGCAGACTATATCAAACGCTTCAAGGATGACAAAGTCTC
 CAAAGCACTTACTCAGGCAAGGGCTTGAAGGAAATAAAGGAACTTTCTTTAGAAGTATCGCTCAAAAA
 GCCAAGCCTTACAGTTGATGTCAACTACAACCACTTACGTTTACTGTTCCAGAAAGGAGAAATACC
 TTCTCTGGGAGATGACCGCTTGGTTCCAGCGACAGCCCGCAGTAGGTACCTTCAAAGCAAAAGATAT
 CACAGGGGAAGCTAAATTCGGCTTCTGGCCAATCACCCTGATCGGAACATTCTCGAGCACCACCACCAC
 CACCACCTGA

Fig 101

2 CFE85 "homologue of SEQ. ID NO. 81"

ATGGTAGTATTTACAGGTTCAATGTTGAAGAAAGCAATCCAGAAAGGATTGAAAGAAATTAGATATTCCAA
 GAATGAAGGCTCATATCAAAGTCATTCTAGGGAGAAAAAAGGCTTTCTTGGTCTATTTGGTAAAAAAC

Fig 102

2 CFE 85 (contd.)

Fig 102 (Contd.)

AGCCCAAGTGGATATTGAAGCGATTAGTGAAACGACTGTTGTCAAAGCAAATCAACAGGTAGTAAAGG
CGTTCCGAAAAAATCAATGATTGAAACGAGCGCTGTGAAGACGGTTAGTGAAGAAACCGTTGACCTTGGT
CATGTGGTTGATGCTATTAATAAATAAGAGGAAGAAGGTCAAGGTATTTCTGATGAAGTCAAGGCTGAA
ATCTTAAACATGAAAGACATGCCAGCACTATCTTAGAAGAACTGGTCACATTGAGATTTTAAATGAAC
TTCAAATCGAGGAAGCGATGAGGGAAGAAGCAGGCGCTGATGACCTTGAAACTGAGCAAGACCAAGCTG
AAAGTCAAGAACTAGAAGACTTTGGGCTTGAAAGTTGAAACGAACTTTGATATTGAACAAGTAGCTACGG
AAAGTAAATGGCTTATGTTCAAACGATTATTGATGACATGGATGTTGAGGCTACACTTTCAAATGATTATAA
CCGTCTGAGCATCAATCTACAAATTGACACCAACGAACCAAGGTCGATTATCGGCTACCATGGTAAAGTC
TTGAAGGCTCTTGCAACTGTTGGCTCAAATAATTATCTTTACAACCGCTATTCAGAACCTTCTACGTTACAAT
CAATGTCAATGATTATGTCGAACACCGTGCAGAAGTCTTGCAGACCTATGCGCAAAAAATTGGCGACTCGT
CTTTTGAAGAAGGGCGCAGTCATAAACAGATCCAATGTCAAATAGCGAACGCAAGATTATCCATCGT
ATTATTTCACGTATGGATGGCGTGAAGTACTCTGAAGGTGATGAGCCAAATCGCTATGTTGTTGTAG
ATACAQAACCTGAGCACCACCACCACCACCACTGA

Fig 103

2 CFE 86 "homologue of SEQ. ID NO. 82"

ATGTCAATTTTCCATTATTTAGCAGCGGGTAAAGGGGACTCGCATGAAATCTGATTGTGCCAAAAAGTTT
GCACAAGGTTGCGGGTATTTCTATGTTGGAACATGTTTCCGTAGTGTGGGAGCTATCCAACCTGAAAAAG
ACAGTACAGTTGTAGGACACAAGGCAGAATTGGTTGAGGAGGTCTTGGCTGAACAGACAGAATTGTG
ACTCAATCTGAACAGTTGGGAAGTGGTCAATGACAGTTATGATGACAGAGCCTATCTTAGAAGGTTTGTGCA
GACACACCTTGGTCAATGTCAGGAGATCTCTTGAATCACTGGTGAAGGCTTGAAAACTTGATTGATT
CCATATCAATGATAAAAAATGTGGCCACTATCTTGACTGCTGAAACGGATAATCCTTTGGCTATGGACGA
ATTGTTGTAATGACAATGCTGAGGTTCTTCGTATTGTTGAGCAGAAGGATGCTACAGATTTTGAAAAAGC
AAATCAAGGAATCAACACTGGAACATACGTCTTTGACAACGAGCGTTTGTGAGGCTTTGAAAAATAT
CAATACCAATAACGCTCAAGGCGAATACTATATTACAGACGTCATTGGTATTTCCGTGAAACTGGTGAA
AAAGTTGGCGTTATACITTTGAAAGATTGTTGATGAAAGTCTTGGGGTAAATGACCGTGTGGCGCTTGCGA
CAGCTGAGTCAGTTATGCGTCGTCCGATCAATCATAAACACATGGTCAACGGTGTAGCTTTGTCAATCC
AGAAGCACTTATATCGATATTGATGTTGAGATTGCTCCGGAAGTCAAAATCGAAGCCAATGTTATCTTG
AAAGGGCAAAACGAAAAATGGTGCTGAGACTGTTTGACAAACGGTACTTATGTAGTGGACAGCACTATC
GGAGCAGGAGCGGTCATTACCAATTCTATGATTGAGGAAAGTAGTGTGACAGACGGTGTGACAGTCCGT
CCTTATGCTCACATTGCTCCAAATTCAGTGTGGGTGCCAAAGTTCATATTGGTAACTTTGTTGAGGTGAA
AGGATCTTCAATCCGTGAGAAATACCAAGGCTGGTCAATTTGACTTATATCGGAAACTGTGAAGTGGGAAGC
AAGCTTAATTTGGGTGCTGGAACATATTACAGTCAACTATGACCGCAAAAAACAAATACAAGACAGTCAATG
GAGACAATGTCTTTGTTGGTTCAAATTCACCAATTATTGACCAAGTAGAACTTGGTGACAATCCCTCGTT
GTTGCTGTTGTAACATTAATAAGACGTGCCAGCAGATGCTATTGCTATTGGTCCGGGTCOTCAAGATCA
ATAAAGACGAATATGCAACACGCTCTCTCATCATCTAAGAACCAGCTCGAGCACCACCACCACCACCA
CTGA

Fig 104

2 CFE 87 "homologue of SEQ. ID NO. 83"

ATGTCCAAGATTCTAGTATTTGGTCAACAAAAATCCAGACTCAGATGCCATCGGGTCACTGTAGCTTTTGC
CTACCTTGCAAAAGAAAGCTTACGGTTTGGATACGGAAGCTGTTGCCCTTGGAACCTCCAAATGAAGAAACA
GCCTTTTGTCTTGAATATTTTGGTGTGGAAGCACCACGTTTATCACTTCTGCCAAAGCAGAGGGGGCAG
AGCAAGTATCTTGACTGACCACAATGAATTCACCAATCTGTATCAGATATCGCTGAAAGTAGAAGTTTA
CGCTGTTGTAGACCAACCACCGTGTGGCTAACTTTGAAACTGCAAGCCCACTTTACATGCGTTTGGAGCCA
GTTGGATCAGCGTCTTCAATCGTTTACCGTATGTTCAAAGAACATGGTGTAGCTGTGCCTAAAGAGATTG
CAGGTTTATGCTTTTCAAGGTTTGAATTCAGATACCTTCTTTTGAATCACCACCAACACACCCCAACAGAT
AAAATCATTTGCTCCTGAAATTGGCTGAATTGGCTGGTGTAAACTTGGAAAGATATGGTTTGGCAATGTTGA
AAGCTGTACCAACTTGGCTAGCAAAATCTGCTGAAAGAAATTGATTGACATCGATGCTAAGACTTTGAACT
CAACGGAAATAATGTCCGTGTTGCCCAAGTGAACACAGTTGACATCGCTGAAGTTTGGAAACGCCAAGCA
GAAATTGAAGCTGCAATGCAAGCTGCCAAGCAATCAAACGGCTACTCTGACTTTGTCTTGATGATTACAG
ATAATCOTCAACTCAAACCTCAGAAATATTGGCTCTTGGTGCCAAATATGGACAAGGTGCAAGCGGCTTTCAA
TTTCAAACCTTGAAAAAATCATGCTTCTTGGTGGTGGCTTTCACGTAAAGAAACAAGTGTACCTCAAT
TAATGAAAGCTTAAATACGCTCGAGCACCACCACCACCACCACTGA

Fig 105

2 CFE 88 "homologue of SEQ. ID NO. 84"

ATGATTTCAAAGAGATTAGAATTGGTAGCTTCTTTGTGTACAGGGGGCTATTTTACTAGATGTGGGAA
GTGACCAATGCTTATCTGCCTATCGAGTTGGTTGAGAGAGGCCAAATCAAAGCGCTATTGCAGGTGAGGT

2CFE 88 (contd)

GOTGGAAGGTCCCTATCAGTCTCCGGTTAAAAATGTTGAGGCTCACGGCCTAAAGGAGAAAAATCCAAGT
 CCGTTTAGCCAATGGCTTGGCAGCTTTTGAAGAGACTGACCAAGTGTCTGTCATTACCATTGCTGGCATG
 GTGGTGGTTTGATTGCTAGGATTTTAGAAGAAGGTTTGGGGAAGTTAGCTAATGTAGAGCGTTTGATCC
 TCGAGCCCAATAATCGTGAAGACGACTTGGCTATCTGGCTACAGGATCATGGATTCCAGATTGTAGCAGA
 AAGAATCTTAGAAGAAGCTGGAAAGTTTATGAGATTTTGGTGGTGOAAGCAGGACAAATGAAAGCTATC
 AGCCAGTGATGTTCCGCTTTGGTCCCTTCTGTCCAAAGAAAGTCAGTCCAGTATTTGTCCAAAAATGGCAA
 AAAGAAGCTGAGAAGCTAGAATTCCGCCCTCGACAAATCCCAGAAAAAATCTGGAAGAACGTCAAGTT
 CTAGTAGATAAGATTCAAGCTATCAAGGAGGTGCTCCATGTTAGCAAGCTCGAGCACCACCACCACCACC
 ACTGA

2 CFE89 "homologue of SEQ. ID NO. 85"

ATGAATTAAACGATATTAAGACTTGATGACTCAATTTGACCAGTCAAGTTTGAGAGAATTTTCTTATA
 AAAATGGGACGGATGAGTTGCCAGTTTAGCAAGAAATGAAGCAAGACCTGTGCTGAAGTTGCAACTCAAG
 TCGCTCCAGCAACCGTTCTAGCAACACCGAGTCCAGTAGCTCTACATCTGCTCCAGCAGAGACTGTAGC
 AGAAGAAGTTCCAGCTCCAGCTGAAGCAAGTGTGGCTACTGAGGGAAATCTTGTAGAGAGTCCACTTGT
 GGAGTGGTTTACTTGGCTGGACAGATAAAACCTGCCTTCGTTACAGTTGGTGATAGTGTCAAAAAAG
 GTCAAAATTTGTAATTATCGAAGCCATGAAAGTCATGAATGAAATCCAGCTCCTAAGGATGGTGTGGT
 AACGGAATTTCTGCTCTAACGAAGAAATGGTTGAGTTTGGTAAAGGATTGGTACGTATCAAACTCGAG
 AACCAACCAACCACTGA

2 CFE90 "homologue of SEQ. ID NO. 86"

ATCAAACTAAATCGAGTAGTGTAACAGGTTATGGAGTAACATCTCCAATCGGAAATACACCAGAAGAA
 TTTTGGAAATAGTTTAGCAACTGGGAAAAATCGGCATTGGTGGCATTACAAAAATTTGATCATAGTGACTTTG
 ATCTGCATAATGCGGCAGAAATCCAAGATTTTCCGTTTCGATAAATACTTTGTAAAAAAGATACCAACCG
 TTTTGATAACTATTCTTTATATGCTTGTATGCAGCCCAAGAGGCTGTAAACCATGCCAATCTTGATGTAG
 AGCTCTTAATAGGGATCGTTTGGTGTTATCGTTGCATCTGGTATTGGTGGAAATCAAGGAAATTTGAAGA
 TCAGGTACTTCCGCTTCATGAAAAAGGACCCAAACGTGTCAAACCAATGACTCTTCCAAAGCTTTACCA
 AATAAGCTTCTGGGAATGTAGCCATGCGTTTGGTGCAAACGGTGTGTTGTAATCTATCAATACTGCCTG
 CTCTTCATCAAAATGATGCGATTGGGGATGCTTCCGCTCCATTAAAGTTTGGTTTCCAAAGATGTGATGTTGG
 TGGGAGGAACAGAAGCTTCTATCACACCTTTTCCATCGCTGGTTTCCAAAGCTTAACAGCTCTCTCTACT
 ACAGAGGATCCAACTCGTGCTTCGATCCCATTTTGATGAAGGATCGCAATGGGTTTGTATGGGTGAAGGTT
 CACGGAATGTTGTTGTAGAAAAGTCTTGAACACGCTGAAAAACGTGGAGCTACTATCCTGGCTGAAGTGGT
 TGGTTACGGAAATACTTGTGATGCTTACCACATGACTTCTCCACATCCAGAAGGTCAGGGAGCTATCAAG
 GCCATCAAACTAGCCTTGGAAAGAACTGAGATTCTCCAGAGCAAGTAGCCTATGTTAATGCTCACGGAA
 CGTCAACTCCTGCCAATGAAAAAGGAGAAAGTGGTGCTATCGTAGCTGTCTTGGTAAGGAAGTACCTGT
 ATCATCAACCAAGTCTTTTACAGGACATTTGCTGGGGCTGCGGGTGCAGTAGAAGCTATCGTCACCATC
 GAAGCTATGCGTCATAACTTTGTACCAATGACAGCTGGGACAAGTGAAGTATCAGATTATCGAAGCTA
 ATGTCGTTTATGGACAAGGTTTGGAGAAAGAAATTCATACGCTATTTCAAATACTTTGGTTTTGGAGGC
 CAAATGCAAGTTCTTGTCTTCAACGTTGGGAGAATAGACTCGAGCACCACCAACCACTGA

2 CFE91 "homologue of SEQ. ID NO. 87"

ATGAACATCTATGATCAACTACAAGCTGTAGAAGACCGTTATGAAGAAGTAGGAGAATTGCTGAGTGAC
 CCTGATGTCGTTTCAGACACCAAGCGTTTATGAGGCTTTCAAAAGAAGAGCTTCCAATCGTGACACCG
 TAATAGCTACCGTGAGTATAAACAAGTCTTCAAAATATCGTCCGATGCCGAAGAGATGATTAAGGAATC
 AGCCGGAGATGCGGACTTGAAGAAATGGCCAAGCAAGAACTCAAAGATGCCAAGGCTGAAAAAGAAG
 AATATGAAGAAAACTGAAAAATTTGCTCCTTCCAAAGGATCCAAACGATGACAAGAAATATCATCTTGA
 AATCCGTGGAGCAGCTGGTGGAGACGAAGCGGCACTTTTCGCTGGAGATTGCTAACTATGTACCAAAAG
 TATCCGGAAGGCCAAGGTTGGCGCTTTGAAGTCATGGAAGCCTCTATGAATGGTGTGCGTGGTTTTAAAG
 AAGTGGTTGCTATGGTTTCAAGTCACTGTGTATCTTAAAGCTTAAGTATGAATCAGGTGCCACCGTGTG
 CAACGTGTTCTGTGACAGAAAGCCAAGGCCGTGTTCACTTCCAGACGACAGTTCTTGTATGCCAG
 AAGTTGAAGAGGTTGAATACGACATTGATCCAAAGACCTTCGTGTGACATCTATCACGCCTCTGGTGC
 TGGTGGACAGAAAGTCAATAAGGTTGCGACTGCCGTTGCTATCGTTCACTTGCCAACCATAATCAAGGTT
 GAGATGCAGGAAGCAAGTACCEAGCAGAAGAACCCGAGAGGCTATGAAGATTATCCGTGCACGCGTC
 GCTGACCACTTTGCTCAGATTGCTCAGGATGAACAAGACGCTGAGCGTAAGTCGACAATCGGTACTGGTG
 ACCGTTCAAGACGGATCCGAACCTTATAACTCCCAAAAACCGTGTACAGACCACCGTATCGGCTTGAC

(contd.)

Fig 108

2CFE91 (contd.)

CGTCCAAAACTAGATACGATTTTGTCTGGTAAATTGGACGAAGTTGTGGATGCCTTGGTGCTTTATGACC
AAACACAAAACTAGAAGAATTAAACAAACTCGAGCACCACCACCACCACCTGA

2CFE92, "homologue of SEq. ID NO. 88"

ATGGCCTACACTCTTAAACCTGAAGAAAGTCGGCGTTTTTGCCATCGGTGGTCTAGGAGAAATCGGGAAAA
AAGCTTACGGAATTGAATACCAAGACGAGATTATCATCGTCGATGCTGGGATTAAATTCACAGAAAGATGA
CTTGGCTGGTATCGACTATGTCATTCTGACTACTCTTACATCGTAGACAATATCGACCGGTCAAGGCTG
TTTAAATCACACACGGACACGAGGACCACATTGGTGGGATTCCGTTCTACTCAAGCAAGCAAATGTCCC
TATTTATGCTGGACCGCTTGCCTTGGCTTTGATCCGTGGGAAACTCGAAGAACACGGCCTCTTGGCACAAC
QCCAACTTTACGAAATCAACCACAACACCGAGTTGACCTTTAAAAATCTCAAGGCAACTTTCTTTAGAA
CGACTACTCTATTCCAGAGCCTTTGGGGATTGTCATTCTACTCTCAAGGAAAAATCGTCTGTACGGGT
GACTTTAAGTTCGACTTTACTCCAGTTGGAGAACCTGCGGACTTGCATCGTATGGCTGCGCTTGGTGAAG
AAGGCGTGTCTGTCTCTGTCTGACTCGACAAATGCGGAAGTACCAACCTTTACCAACTCTGAAAAAGT
CGTTGGTCAGTCCATTATGAAGATTATCCAAGGTATTGAAGACGATATCATCTTTGCATCCTTTGGCTCAA
ATATCTTCCGTCTCCAGCAGGCAACAGAAGCTGCTGTTAAGACTGGACGCAAGATTGGGTCTTTGGTCC
TTCTATCGAAAAGGCCATTGTCAACGGAATCGATCTTGGCTACATCAAAGCTCCTAAGGGAACTTTATC
QAQCCAAATGAAATCAAAGATTATCCTGCAGGAGAAGTTCTTATCCTCTGTACAGGTAGTCAGGGTGAGC
CTATGCGAGCCTCTCTCGTATCGCCAACGGAACCCACCGTCAAGTACAATTACAACAGGTGATACCGT
TATCTTCTCTTCTAGTCCCATCCCTGGAAACACTACTAGCCTCAACAAGCTGATTAAACATCATTTCTGAAG
CTGCTGTCGAAAGTTATCCACGGTAAAGTGAACAATATCCATACATCTGGACACGGTGCCAGCAAGAGC
AAAAATCATGCTCCGCTTGATTAAAGCCAAATACTTCAATGCTGTCCACGGTGAATACCGCATGCAAAA
AGTCCACGCTGGACTAGCAGTGGATCTGGTGTGTGGAAGGACAATATCTTTATCATGAGCAATGGCGAT
GTCTTCCCTTACTGCTGACTCAGCTCGTATCGCAGGTCAATTCACGCCCAAGATATCTATGTCGATGG
AAATCGTATCGGTGAAATGGCGCAGCTGCTCTCAAAGATCGTCCGATCTATCTGAAGACGGTGTCTCT
CTAGCAGTCGCAACTGTTGACTTCAAATCGCAGATGATTCTGTCTGGGCCAGATATCCTCAGCCGAGGCT
TTGCTCATGAGAGAGTCTGGAGACTTGATTGCGCAAAGCCAGCGTATCCTCTCAATGCCATTCTGTATC
GCACTGAAAAATAAGGATGCTAGCGTGCAATCTGTCAA
TCTATGAAAAATACCGAACGTGAACCGATCATCATCCCG/
CCACCAACCACCACCTGA

Fig 109

2CFE94

ATGGCTACGGCAACAAAAAGAAAAATCAACAGTTA/
AAGGCCAAGACGATTGAAAAATATCTAGGCGAAACTACAAGGTTTTAGCCAGTGTGGGCGATATCCGT
GATTTGAAGAAATCCAGTATGTCCGTGATATTGAAAAATTAATGAACCGCAATATATTAATATCCGAG
GAAAAAGCCCTCTTATCAATGACTTGAAAAAGAAAGCTAAAAAAGCTAATAAAGTTTTCTCCGCGAGT
ACCCGACCGTGAAGGAGAAGCGATTTCTTGGCATTGGGCCATATTTCTCAACTTGGATGAAATGATGC
CAACCGTGTGCTTCAATGAAATCACCAAGGATGCAQTCAAAATGCTTTAAAGAACCTCGTAAGATC
GATATGCACTTGGTGGATGCCCAACAAGCTCGTCGGATCTTGGATCGCTTGGTAGGGTATTGATTTCCG
CTATTTTGTGGAGAAGGTCAAGAAGGGCTTGTACGAGGTGCGGTTCAGTCCATTGCCCTTAAACTCAT
CATTTGACCGTGAAAAATGAAATCAATGCCCTTCCAGCCAGAAGAACTGACAGTGTGATGCTGTCTTTAA
AAGGGAACCAACAATTTCATGCTTCTCTATGAGTAAATGGTAAAAAGATGAAACTGACCAAGCAAT
AAGGAAGTCAAGGAAGTCTTGTCTCGTCTGACGATGAAAGACTTTTCAATAGATCAGGTGGATAAGAAA
GAGCGTAAGCGCAATGCTCTTTACCTATACCACTTCATCTATGCAGATGGATGCTGCCAATAAAATCA
ATTCCGTACTCGAAAAACCATGATGGTTGCCCAACAGCTCTATGAAGGAATTAATATCGGTCTGGTGT
TCAAGGTTTGATTACCTATATGCGTACCGATTGCTGATCATGCTCTGTAGCGCAAAATGAGGCGGCA
AGCTTCATTACGATCGTTTTGGTAGCAAGTATTCTAAGCACGGTAGCAAGGTCAAAAACGCATCAGGTG
CTCAGGATGCCATGAGGCTATTGCTCCGTCAAGTGTCTTTAATACACCAGAAAGCATCGTAAATATCT
GGACAAGGATCAGCTCAAGCTATATACCTTATCTGGAATCGTTTTGTGGCTAGCCAGATGACAGCGGCC
GTTTTGATACCATGGCTOTTAATTTGTCTCAAAAAGGGTTCAATTTGCTGCCAATGGTAGTCAGGTTAA
GTTGATGGTTATCTTGGCATTATTAATGATCTGACAAGAATAAGATGTTACCGGACATGGTTGTGGAG
ATGTGGTCAAAACAGGTCAAATAGCAAAACAGCAACTTCCACCAACCGCCTGCCCGTTATTCTGAAGC
AACACTGATTAACCTTAGAGGAAAAATGGGGTTGGACGTCCATCAAGCTACGCGCCCAACCATGAAAC
CATTCAGAAAGCTTATTATGTTCCGCTGGCAGCCAAACGTTTTGAACCGACAGAGTTGGGAGAAATTTG
AATAAGCTCATGTTGAATATTTCCAGATATCGTAAACGTGACCTTCACAGCTGAAATGGAAGTAAAC
TGGATGATGTCGAAGTCGGAAAAAGAGCAGTGGCGACGGGTCAATTGATGCTTTTACAAACCATTTCTAA

Fig 110

JCFE 94 (contd)

Fig 110 (contd)

AGAAAGTTGCCAAGGCTGAAGAAGAAATGGAAAAAATCCAGATTAAGGATGAACCAGCTGGATTGACTG
TGAAGTGTGTGTAGTCCAAATGGTCATTAACCTTGGTCGTTTGGTAAATCTACGCTTGTAGCAATTTC
CAGATTGCCATCATACCAAGCAATCGTGAAGAGAGATTGGTGTGAGTGTCCAAAGCTGTATCAGGGACA
AATTATTGAGCGAAAAACCAAGCGTAATCGCCTATTCTATGGTTGCAATCGCTATCCAGAATGTGAATTT
ACCTCTTGGGACAAAGCCTGTTGGTCTGACTGTCCAAAATGTGGCAACTTCCACATGGAGAAAAAGTCC
GTGCTGTGGCAAGCAGGTTGTTGTAGCAAAAGGCGACTACGAGGAAGAAAAAGATGGCTCTTTGTCAACT
GCTCGAGCACACCACCACCACCACTGA

2 CFE95 "homologue of SEQ. ID NO. 91"

Fig 111

ATCTTTATTTTCATCACTGCTGGAATTGTGACATTTTACTAAGTTAGTAGGAATTCGGCCTTTATCCA
ATTTTATAGAAAGCGCAAAATTACAGGCCAGCAGATGCATGAGGATGTCAAACAGCATCAGGCAAAAGC
TGGGACTCCTACAATGGGAGCTTTGGTTTCTTGATTACTTCTGTTTGGTTGCTTTCTTTTCGCCCTATT
AGTAGCAATTCAGCAATAATGTGGGAATGATTTTGTTCATCTTGGTCTTGTATGGCTTGGTCTGGATTTT
AGATGACTTTCTCAAGGTCTTTCTGTAATAATCAATGAGGGGCTTAATCCTAAGCAAAAAATTAGCTCTTCA
CTTCTAGGTGGAGTTATCTTCTATCTTTCTATGAGCGCGGTGGCGATATCTGTCTGTCTTTGTTATCCA
GTTCTATTGGGATTTTCTATATTTTCTTCGCTCTTTTCTGGCTAGTCGTTTTCAAAACGCAAGTAACTTG
ACAGACGGGTGTGACGGTTTAGCTAGTATTTCCGTTGTGATTAGTTTGTGCTATGGAGTTATTGCCTA
TGTGCAAGGTGAGATGATATCTTCTAGTGATTCTTGCCATGATTGGTGGTTTGTCTGGTTTCTTCATCTT
TAACCATTAAGCTGCAAGGTCTTTATGGGTGATGTGGGAAAGTTTGGCCCTAGGTGGGATGCTGGCAGCT
ATCTCTATGGCTCTCCACCAGGAATGGACTCTCTTGATTATCGGAATTGTGTATGTTTTGAAACAACCTTC
TGTTATGATCAAGTCAGTTATTTCAAAGTCAGAGGTGTAAACGATTTTCCGTATGACGCTGTACATC
ACCAATTGAGCTTGGGGGATTGTCTGGTAAAGGAAATCCTTGAGCGAGTGGAAAGGTGACTTCTTCTT
TTGGGGAGTTGGTCTTCTAGCAAGTCTCTGACCCTAGCAATTTTATATTGATGCTCGAGCACCACCACC
ACCACCCTGA

2 CFE96 "homologue of SEQ. ID NO. 92"

Fig 112

ATGGCAAGCGAATTTTCACTTGAAAAAACTCGTAATATCGGTATCATGGCTCACGTCGATGCCGGTAAAA
CAACAATACTAGAGCGTATTCTTTACTACACTGGTAAAAATCCACAAAATCGGTGAAACTCACGAAGGTGC
GTCACAATGGACTGGATGGAGCAAGAGCAAGAACGTGGTATCACGATCACATCTGCTGCCACAACAGC
TCAATGGAACAACACCGCGTAAACATCATCGACACACCAGGACACGTTGGACTTCACAATCGAAGTACA
ACGTTCTTCTGTTGATTGGATGGTGGCGTTACCGTTCTTGACTCACAATCAGGTGTTGAGCCTCAAACTG
AAACAGTTTGGCGTCAAGCAACTGAGTACGGAGTTCCACGATCGTATTGCCAAACAAAATGGACAAAAT
CGGTGCTGACTTCTTTACTCTGTAAAGCACACTTCACGATCGTCTTCAAGCAAAATGCACACCCAATCCAAT
TCCCAATCGGTTCTGAAGATGACTTCCGTGGTATCATTGACTTGATCAAGATGAAAGCTGAAATCTATAC
TAACGAACCTTGGTACGGATATCCTTGAAGAGACATCCCAGCTGAATACCTTGACCAAGCTCAAGAATAC
CGTGAAGAAATTOATTGAAGCAGTTGCTGAAACTGACGAAGAATTGATGATGAAATACCTCGAAGGTGAA
GAAATCACTAAACAAAGAAATTGAAAGCTGGTATCCGTAAAGCGACTATCAACGTTGAATTTCTCCAGTAT
TGTGTGTTTACGCTTCAAAAAACAAAGGTGTTCAATTGATGCTTGAATGCGGTTATCGACTACCTTCAAAGT
CCAATTGACATCCCAACCAATCAAAAGGTATTAACCCAGATACAGACGCTGAAGAAAATTCGTCCAGCATCTG
ACGAAGAGCCATTGTCAGCTCTTGCCCTTCAAGATCATGACTGACCCATTCTGATGGTCTGTTGACATTCTTC
CGTGTTTACTCAGGTGTTTCTCAATCAGGTTTACATGATTTGAATACTTCTAAAGGTAAACGTGAACGAT
CCGACGTATCCTTCAAAATGCAAGCTAACAGCCGTCAAGAAATCGACACTGTTTACTCAGGTGATATCGCT
GCTGGCGTTGGTTTGAAGATATACTACAACCTGGTGACTATTGACAGATGAAAAAGCTAAAAATCATCCTTG
AGTCAATCAAGGTTCCAGAACCAGTTATCCAATTGATGGTTGAGCCAAAATCTAAAGCTGACCAAGACAA
GATGGGTATCGCCCTTCAAAAAATTGGCTGAAGAAGATCCAACATTCGCGGTTGAAACAAACGTTGAAAGT
GCTGAAACAGTTATCTCAGGTATGGGTGAACCTTCACTTGAACGCTCTTGTGATCGTATGCGTCTGAGTT
CAAGGTTGAAGCGAAGCTAGGTGCTCCTCAAGTATCTTACCGTGAAACATTCCGCGCTTCTACTCAAGCA
CGGGAATCTTCAACGTCAGTCTGGTGGTAAAGGTCAAATTCGGTGAATGATGGATTGAATTTACTCCAA
ACGAAGAAGGTAAGGATTGCAATTCGAAAAACGCAATCGTCCGTGGTGTGGTTCTCGTGAATTTATCCC
ACCGGTTGAAAGGTTTGGTGAATCTATGGCTAACGGTGTCTTGCAGGTTACCCAATGGTTGACGTT
AAAGCTAAGCTTTATGATGGTTTATATACGATGTGACTCATCTGAAACTGCCCTCAAGATTCCGGCTTC
ACTTCCCTTAAAGAGCTGCTAAATCAGCACAAACCAGCTATCCTTGAACCAATGATGCTTGTAAACAATC
ACTGTTCCAGAAAGAAAACCTTGGTGAATGTTATGGGTACGTAACCTGCTCGTGGACGTTGATGATGGA
TGGAAAGACAGGTAACAGCAAACTCGTTCGTTCATCCTTCCACTTGTGAAATGTTCCGTTACGCAAC
AGTCTTCTGTTCTGCAATCTCAAGGACGTTGGTACATTGATGGTATTGACCACTACGAAGATGTACCTA

(Contd.)

Fig 112

2CFE 96 (contd.)

AGTCAGTACAAGAGAAATTATTAAAGAAAAATAAAGGTGAAGACCTCGAGCACCACCACCACCACCTG

2CFE97 "homologue of SEQ. ID NO. 93"

ATGCCAAATTAACATATTCATTTCACCGCTGATATCACAGAAGCAGAAATTGCTGAAGTAGCGGATA
CCCTGCGTTCTGGTTGGATCACAACAGGTCCTAAAACAAAAGAACTGGAGCGCCGCTTGCTCTTTACAC
ACAGACACCTAAGACTGTTGTCTCAACTCTGCGACAGCCGCTCTGGAGTTGATTTACGCGTTTGGAAO
TGGGAOCTGGTGATGAAGTCATCGTTCCAGCCATGACCTATACGGCTTCATGTAGTGTCTATTACGCACGT
GGGAGCAACCCCTGTCATGGTGGATATCCAAGCAGATACGTTTGAGATGGACTATGACCTGCTTGAGCAA
GCTATCACTGAQAAAACTAAGGTGATTATCCAGTAGAGCTCGCAGGGATTGTTTGGCATTATGACCGTT
TGTTCCAGTGGTGGAGAAAAACGTGACTTCTTTACCGCTTCAAGCAAGTGCCAAAAAGCCCTTTAACCG
TATTGCTATTGTCTCTGATAGTGGCCACGCTTTGGGATCTACTTATAAAGGAGAACCTTCTGGTTCTATCG
CTCAATTTACTTCTCTCTCATTCATGCTGTTAAGAACTTTACAACGGCAGAAAGGTGGAAOTGCGACTTGG
AAAGCCAATCCAGTGAATTGATGACGAAGAGATGTACAAGGAATTCCAAATCCTTTCCCTTCACGGGCAAA
CTAAGGATGCTCTTGGCAAGATGCAACTGGGGTCTAGGGAATACGATATCGTTACACCCAGCCTATAAGTG
CAACATGACCGATATCATGGCTTCACTTGGTTTGGTACAATTGGACCGCTATCCAAGTTTGTGCAACGCC
GTAAAGACATTTGGGACCGCTATGATAGTGGTTTTCAGGTTCTCGCATCCATCCTTTGGCAGACAAAGAC
TGAAACTGTGCAATCTTCACGCCACCTCTACATCACCCTGTGTAAGGAAGTAAGECTAGAAAGAACGCAAC
CTCATCTCCAAGAATTGGCTAAAGCAGGAATTGCAAGTAATGTTCACTACAAAACCGCTTCTCTCTTGA
CAGCCTATAAGAATCTTGGATTGATATGACGAACCTATCCTAAGGCCTATGCTTCTTGAAGAAATGAAT
ADCTCCTCTTTCATACTAAATTAAGCGATGAAGAAAGTAAGCTATATCATTGAGACTTTCAAAACAGTTT
CTGAAAAAGTCTAATCTTTATCAAAAAACTCGAGCACCACCACCACCACCTG

Fig 113

2CFE99 "homologue of SEQ. ID NO. 95"

ATGTTTATACITATTGCGTGGATTAGTTGATTTGCTCTTATGGTCCATCAATGGCAATGCTCACTATCAT
AATACTGATAAAATTCCTAATCAAGATGAAAATTATATTTAGTTGCGCTCACCGTACCTGGTGGGATC
CTGTTTATATGGCCTTTGGACCAAGCCAAAACAGTTTCATCTTATGGCAAAAAAAGAACTCTTACCAA
CCGTATCTTTGGTTGGTGGATTCGTATGTGTGGCGCTTTCCCATCGACCGTGAAAATCCACGCGCTCAG
CCATCAAAATATCTATCAACGTTCTCAAAAAAAGTGACCGCTCTCTCATCATGTTTCCAAGTGGTAGCCGC
CACTCAACAGATGTCAAGGGGGGGCGCAGCACTGATTGGCAAAATGGCCAAAGGTCTATCATGCGGTT
ACCTACACCGGTCCCATGACTTTGAAGGGCTTGATTAGCCGTGAACGTGTGATATGAACTTTGGAAATC
CAATCGATATCTCAGATATCAAGAAAATGAATGATGAAGGCATTGAAACAGTCGCCAATCGTATTCAAA
CAGAAATCCAACGTCTGGACGAAGAAACGAAACAAATGGCACAATGATAAAAAACCAATCTCACTCTGGT
GTTTATCCGATCCCTGCCCTCATCTTGTCTATTATCTCGCTATCCTAACCATCATCTTTAGCTTTATCG
CAAGCTTCATCTGGAACCCAGATAAGAAAAGAAAGAACTTGCCTCGAGCACCACCACCACCACCT
GA

Fig 114

2CFE101 "homologue of SEQ. ID NO. 97"

ATCACCACGAATTTTACATTTTGAAAAATCAGCCGCCAGACTTGGCAATCTTTACATCGAAAGACAA
CACCTCCTTTGACAGAAGAAATTTGGAATCTATCAAGATTTTAATGACCAAAATCAGTCTCCAAGACGT
TACAGATATCTATCTCCCTTTGGCTCATCTGATTGAGATTACAAGCGAACTAAGGAAGATTAGCCTTTT
CAAAAGGAATTTTCTCCAACGTGAAAGTAAATCTCAACCTTTTATTATTGGGGTTTCTGGGAGTGTGGC
GTTGGAAATTCACAACCAAGTGGCTACTTCAAAATCTTACTGTCCCGTACGTTTACAGATGCTACGGTTG
AGTTGGTTACAACCTGATGGTTTCTCTATCCCAATCAAACCTTGATTGAGCAGGGGATTTAAATCGTAAA
GGATTTCCTGAAAGCTATGATATGGAAGCTCTTCTCAACTTCTTGGACCGCATCAAAAATGGACAAGATG
TAGATATTCCTGTCTATCTCATGAAGTTTACGACATCGTACCCGAAGAGAAAACAAAGTGTCAAAGCTGC
TGATTTTGAATTTGTTGAGGGAATCAATGCTTTTCAAAATCCACAAAACGATCGTCTCTATATCACTGACT
TCTTTGACTTTTCCATCTATGTAGATGCTGGAGTGGATGATATTGAAAGTTGGTATCTGGACCGTTTCTTG
AAAATGGTGAAGTCTAGCCCAAAACGACCTGATAGCTACTATTATCGTTTACTCAGATGCCGATTGGGG
AAGTGGAAAGCCTTTGCCCATCAGGTCTGGACCAATCAATCTCACAATCTACAAAATTTATTTGAACC
AACCAAGAAATCTGACGAAGTGATTCTTCATAAAAGCAAGAACCATGAATCGATGAAATTTACTTAAA
AAAGCTGAGGACCAACCAACCAACCACTGA

Fig 115

2CFE102 "homologue of SEQ. ID NO. 98"

ATGGAATTTTCAATTATTAACAGATGTTGGTCAGAAACGAACAAATAACCAAGACTATGTCAACCACTATG
TCAATAGAGCTGGACGTACCATGATTATTTAGCTGATGGGATGGGAGGTATCGCGCAGGGAATATCGC

Fig 116

2 CFE 102 (contd)

Fig 116 (contd)

TAGTGAATGGCGGTACAGACCTGGGTGTAGCTTGGGTTGATACCCAGATCGATACAGTCAATGAAGTG
 OGTGAATGGTTGCGCCATTACCTAGAAATTGAAATCAAAAGATTACCCAGCTTGGTCAGGATGAAGCTT
 ACAGAGGCATGGGAACCTACTTTGGAAGTCCTTGTATTATGATAATCAGGCTATCTATGCTCATATTGGT
 GATTCCCGTATCGGCTTGATTCTGGGAGAAGAATACCATCAGTTGACGAGCGATCAATTCCTTGGTTAAATG
 AATTGCTCAAGGCTGGTCAATTGACACCAGAAGAGGCAGAAGCTCATCCGCAAAAAAATATTATCACCC
 AGTCTATTGGGCAAAAAGATGAAATTCAGCCTGATTTTGGGACAGTTATCCTTGAGTCAGGTGACTATCT
 CTTCCTCAATAGTGACGGCTTGACCAACATGATTTCAGGCAGTGAGATTCTGTATATTGTAACCAAGTGAT
 ATTCTTTAGCAGATAAAACGGAGACACTTGTTCGTTTGTCTAACAAATGCAGGAGGTTTAGACAACATTA
 CGTTGCCCTTGTTCCTATGAACGAGGAGGATGAAGAACTCGAGCACCACCACCACCACCTGA

Fig 117

2 CFE103 "homologue of SEQ. ID NO. 99"

ATGACGATACAGATGAAGAATACAGGTAAACGAATTGATCTGATAGCCAATAGAAAACCGCAGAGTCAA
 AGGGTTTGTATGAATTGCGAGATCGTTTGAAGAGAAATCAGTTTATACTCAATGATACCAATCCGGATA
 TTCTCATTTCCATTGGCGGGGATGGTATGCTCTTGTCCGCCCTTCATAAGTACGAAAATCAGCTTGACAAG
 GTCCGCTTATCGGCTTCATACTGGACATTGGGCTTCTATACAGATTATCGTGATTTTGAGTTGGACAA
 GCTAGTACTAATTTGCAACTAGATACTGGGGCAAGGGTTTCTTACCCTGTTCTGAATGTGAAGGTCTTTC
 TTGAAAATGGTGAAGTTAAGATTTTCAGAGCACTCAACGAAGCCAGCATCCGAGGTCTGATCGAACCAT
 GBTGGCAATATTGTAATAAATGGTGTTCCTTTGAACGTTTTCGTGGAGACGGGCTAACAGTTTTCOACA
 CCGACTGGTAGTACTGCCTATAACAAAGTCTCTTGGCGGTGCTGTTTACACCCTACCATTGAAGCTTTGCA
 ATTAACGGAGATTGCCAGCCTTAATAATCGTGTCTATCGAACATTGGGCTCTTCCATTATTGTGCTTAAGA
 AGATAAGATTGAACCTTATCCAAACAAGAAACGATTATCATACTATTTCGGTTGACAAATAGCCTTATTCT
 TTCCGTAATATTGAGCGTATTGAGTATCAAATCGAATCATAGATTCACTTTGTGCGGACTCTAGCCA
 TACCAGTTCTGGAACCGTGTAAAGGATGCCTTTATCGGTGAGGTGGATGAACTCGAGCACCACCACCAC
 CACCACTGA

Fig 118

2 CFE104 "homologue of SEQ. ID NO. 100"

ATGTCAAAAGAAATTAATTTTCATCAGATGCCCGTTCAGCCATGGTTCTGGTGTTCGATATCCTTGCAG
 ACACCTGTAAAGTAACCTTGGGACCAAAAGGTGCAATGTCTTCTTGAAGATCATTCGGTTCAACCTT
 GATTACCAATGACGGTGTGACCATTTGCCAAAGAAATCGAATTGGAAGACCATTTTGAAGAAATATGGGTCT
 AAGTTAGTATCAGAAAGTAGCTTCTAAAACCAATGATATCGCAGGTGACGGGACTACGACTGCAACAGTCT
 TGACCGAAGCTATCGTCCGTGAAGGAATCAAAAACGTCACAGCAGGTGCAAAATCCAATCCGTATTCTGTCG
 TGGGATTGAAACAGCAGTTGCCCGCAGCAGTCAAGCTTTGAAAAACAACGCCATCCCTGTTGCCAATAA
 AGAAGCTATCGTCAAGTTGCAGCCGTATCTTCTGTTCTGAAAAAGTTGGTGAGTACATCTCTGGAAGCA
 ATGGAAGAAAGTTGGCAAGACGGTGTATCACCATCGAAGAGTCAAGTGGTATGGAACAGAGCTTGAA
 GTGTAAGAAAGAAATGCAGTTTGACCGTGGTTACCTTTACAGTACATGGTGACTGATAGCGAAAAATGG
 TGGCTGACCTTGAAAAATCCGTACATTTTGATTACAGACAAGAAAAATTCCAATATCCAAGAAATCTTGGC
 ACTTTGGAAGCAATCTCCAAAGCAATCGTCCACTCTTGAATTTGCGGATGATGTGGATGGCGAGGCT
 CTTCCAAATCTTGTTTTGAACAAGATTCTGTGAACCTTCAACCTAGTAGCAGTCAAGGCACCTGCTTTTGG
 TGACCGTTCGCAAGCCATGCTTGAAGATATCGCCATCTTAACAGGCGGAACAGTTATCACAGAAAGCCTT
 GGTCTTCAAGTTGAAAGATGCGACAATTGAAGCTCTTGGTCAAGCAGCGAGAGTGACCGTGGACAAAGAT
 AGCAGCTTATTGTAGAAGGTGCAGGAAATCCTGAAGCGATTCTCACCGTGTGCGGTTATCAAGTCTC
 AAAATGGAAGCTACAACCTTCTGAATTTGACCGTGAAAAATTGCAAGAACGCTTGGCCAAATTGTCAAGTGG
 TGTAGCGGTTATTAAAGGTTGGAGCCGCAACTGAAACTGAGTTGAAAGAAATGAAACTCCGCAATTGAAGA
 TGCCCTCAACGCTACTCGTGCAGCTGTTGAAGAAGGATTGTTGCAGGTGGTGAACAGCTCTTGCCAAT
 GTGATTTCAGCTGTTGCTACCTTGAATTGACAGGAGATGAAGCAACAGGACGTAATATTGTTCTCCGTG
 CTTTGGAGAAGACCGTTCTCAAAATTGCTCACAATGCAGGATTTGAAGGATCTATCGTTATCGATCGTTT
 AAAAATGCTGAGCTTGGTATAGGATTTAACGCAGCAACTGGCGAGTGGGTAAACATGATTAATCAAGGT
 ATCATGATCCAGTTAAAGTGAATCGTTTACGCCCTACAAAATGCAGCATCTGTAGCCAGCTTGATTTTGA
 CAACAGAAAGCAATCGTAGCCAATAAACAGAACCAAGTAACCCAGCTCCAGCAATGGATCCAAGTATGA
 TGGGCGGATGATGCTCGAGCACCACCACCACCACCTGA

Fig 119

2 CFE105 "homologue of SEQ. ID NO. 101"

ATGATTAGATTGAACCGTATTAGATATTTAAAGAAAGATGGCCTTTTTCGCGAAATTTGACCAAO
 GTCATTACCACTACAACCTACAGCAAAGTTATTTTGTAGCATCAGCTACGACAGCCGAAAGTAACAGA
 AGACACTCTTTTGTGCAAAAGGCGCTGCCTTTAAAAAGAAATACCTTCTTCTGCTATAACACAAGOTT
 TAGCTTGTATGTAGCTGAAAAGGACTACGAAGTCATATCCCTGTCTCATTTGTGAACGATATAAGAA

2 CFE 105 homologue of SEQ ID NO: 101 (Contd.)

Fig. 119 (Contd.)

AGCCATGAGTTTGATTGCCATGGAGTTCTATGGTAAATCCACAAGAGAACTCAAACCTCCTTGCTTTACT
 GGTACTAAGGGTAAGACAACAGCAACCTATTTGCGCTATAACATCTTATCTCAAGGGCATAGACCTGCTA
 TGTGTGACGATGAACACAACCTCTTGATGGCGAGACTTTCTTTAAGTCAGCGTTGACAACCCCTGAGAG
 TATGAACTCTTTGACATGATGAATCAGGCTGTGCAAAATGACCGTACCCACCTCATCATGGAAGTCTCC
 AGTCAAGCCTATCTAGTCCATCGAGTCTATGGACTGACCTTTGATGTAGGAGTCTTTCTTAACATCACTCC
 TGACCATATCGGCCCCGATTGAACACCCTAGCTTTGAAGACTATTTCTACCACAAGCGTCTCTTGATGGAA
 AATAGCCGAGGAGTCATCATTAAACAGTGACATGGACCCTTCTCAGTCTTGAAGAAGCAGGTTGAAGATC
 AAGACCATGATTTCTATGGTAGCCAATTTGATAACCAAATCGAGAATTCCAAAGCCTTTAGCTTTTCAGCT
 ACGGGTAAACTCGTGGAGATTATGATATCCAATCATTTGCAACTTCAACCAAGAAAATGCAGTTGCTG
 CTGACCTGCTTGTCTCGGTCTCGGAGCAAGCTTGAAGGACATCAAAAAAGGCATCGCTGCAACCCGCT
 TCGTGTGCTATGGAAGTCTCACTCAGAAAAATGGAGCCAAGGTCTTCATCGACTATGCCCAATGGG
 GATAGTCTGAAAAAACTCATCAATGTGGTTGAAACTCATCAAAACGGAAAGATTGCTCTGGTCTGGGAT
 CAACAGAAAAAAGGGAGAAAGTCGTGTAAGGACTTTGGCCTCTCTCAATCAACACCTGAGATTTC
 AAGTCTTCTGACTGCTGATGACCCTAACTATGAAGACCCAAATGGCCATTGCAGATGAAATTAGTAGCTA
 CATCAATCATCTGTTGAAAAGATTGCGGATCGCCAAGAAGCCATCAAGGCGGCAATGGCTATCAGAAA
 TCACGAATTAGATGCAGTTATTATTGCGGGTAAGGGGACCGATTGTTACCAAAATCATCCAGGGCAAGAAA
 GAATCTACCCAGGAGATACAGCCGTCGAGAAAAATTATTCTGAGCACCACCACCACCACCTGA

2 CFE 106 "homologue of SEQ. ID NO. 102"

Fig. 120

ATGATCCAAATCGGCAAGATTTTGGCGGACGCTATCGGATTGTCAAACAGATTGGTGGAGGAGGCATGG
 CGGATGTCTACCTAGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCA
 ACTACCAAGCGGACCCGATAGCTGTAGCTCGTTTCAGCGTGAAGCGAGAGCTATGGCAGATGTAGACCA
 TCCTGATATCGTTCCGATAACAGATATTGGTGAGGAAGACGGTCAACAGTATCTTGCAATGGAGTATGTT
 GCTGGACTAGACCTCAAACGCTATATCAAGGAACATTATCTCTTTCTAATGAAGAAGCAGTCCGTATCA
 TGGACAAATTTCTCTTGGCTATGCGCTTGGCCATACTCGAGGAATTGTTCACAGGGACTTGAAACCTCA
 AATATGCTTTTGAACCCAGATGGGACTGCCAAGGTCAAGACTTTGGGATTGCTGTAGCTTTGTCAGAG
 ACAAGTCTGACCCAGACTAACTCGATGTGTGGGCTCAGTTCACTTGTTCACAGAGCAGGCGCGTGGTT
 CGAAGGCGACTGTGCAGAGTGATATCTATGCCATGGGGATTATTTCTATGAGATGTTGACAGGCCATAT
 CCGTTATGACGGGGATAGCGCGGTGACCATTTGCCCTCCAGCATTTCCAGAACCCCTGCGGTGCGTTATTO
 CAGAAAAATTCATCTGTACCTCAGGCTTTAGAAAAATGTTATATCAAGGCAACTGCTAAAAAOKTOACCA
 TCGCTATCGCTCGGTTTCAGAGATGTATGTAGACTGTCTAGTAGCTTGTCTCAAAATCGTAGAAAAAGAA
 GTAAGTTAATGTTGATGAAACGAGCAAGGCAAGTACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTT
 GACATCTATTCCTAAGGTTCAAGCGCAGACAGAACCAAAATCAATCAAAAAACCCAGGCGGTGAC
 AAGGAAGTACCAACCCAGAACCGCAAAAAACATAGATTTAAGATGCGTTACCTGATTTGTTGGCC
 AGCCTTGTATTGGTGGCAGCTTCTCTATTGTTGGATACTATCCAGAACTCTGCAACCATTTGCCATTCCAGA
 TGTGGCAGGTCAGACAGTTGCAAGGGCCAAAGGCAAGCTCAAAAAAGCCAATTTGAGATTGTTGAGGA
 GAAGACAGAGGCTAGTGAAGAGGTGGAAAGAAAGGCGGATTATCCGTACAGATCCTGGGCGTGGAACTGG
 TCGAAAAGAAAGGAACGAAAATTAATCTGTTGTCTCATCAGGCAAAACAATCCTTCCAAATTAGTAATTAT
 GTGGGCGGAAAATCTTCTGATGTTATCGCGGAATTAAGAGAAAAAGTTCCAGATAAATTGATTAAAA
 TTGAGGAAGAAAGTGAATGAAAGTGAGGCTGGAACGGTCTGAAGCAAAGTCTACCAGAAGGTACG
 ACCATGACTTGAAGCAAGGCAACTCAAATGTTTGGACAGTAGCTAAAAAGCTACGACGATTCAATTAG
 GGAATATATTGGACGGAACCTTACAGAAAGTAATCTCAGAACTCAAGCAGAAGAAGGTTCTGAGAATT
 TGATTAGATAGAGGAAGAAGAGTCCAGCGAAAGCGAAACGAGGAAACGATTATGAAACAAAGTCCAGGT
 GCGGGAACCACTTATGATGTGAGTAAACCTACTCAAATTTGCTTGCAGTAGCTAAAAAAGTTACAAGTG
 TTGCCATCCGAGTTACATTGTTCCAGCTTGGAGTTTACTAAGAACAATTTGATTCAAATTTGTTGGGATT
 AAGGAAGCTAATATAGAAGTTGTAAGAGTGACGACAGCGCTGCAGGTAGTGTAGAAGGCATGGTTGTT
 GAAACAAAGTCTAGAGCAGGTGAAAAGGTAGACCTAAATAAGACTAGAGTCAAGATTTCATCTACAAA
 CCTAAACAAGTTCACTACTCTGCGGCGCACTGAGCACCACCACCACCACCTGA

2 CFE 107 "homologue of SEQ. ID NO. 103"

Fig. 121

ATGAACATTTGATACTATTTGTCATCGGTGGGGACCTGCTGGTATGATGGCTACGATTTCCAGTAGCTT
 TTATGGACAGAAACCCCTCTCATCGAAAAAATCGGAAACTTGGAAAAAATAGCTGGGACTGOTGG
 GGGACGTTGCAATGTGACCAACAATGGTAGCTTAGACAACCTGCTAGCTGGAATTCCTGGAACGGACG
 CTTCTTTACAGTGTTTTCTCCAGTTTCGATAATCATGACATCAACTTTTTACAGAAAAATGTTGTTAA
 ACTTAAGGTGGAAGACCAGGACGGCTTTTCCAGCAGTGACAAGTCTCGGACTATTATCGAAGCTTTG
 GAAAAAGAAATCACTGAACAGGTGGTCAAGTTGCTACTCAAATAGAAATCGTTTCTGTTAAAAAAGTA

2CFE 107 (Contd.)

Fig 121 (Contd.)
 GATGACAGTTTGTCTTAAGTCAACGGATCAAACTTCACTTGTAAAGAACTCATTGTGACAAACAGGTG
 GTAAGTCTTATCCTTCGACTGGTTTCGACTGGCTTTGGTCACGAGATTGCTCGCCATTTTAAGCATACCATC
 ACCGATCTTGAGGCTGCTGAAAGTCTTTATTAACAGATTTTCCACATAAAGCCTTACAAGGGATTTCCT
 GGACGATGTGACCTTAAGTTATGGTAAGCATGTCACTCATGATTACTCTTTACCCACTTTGGTTTGT
 CAGGTCTGTGCTGCCCTACGCATGTCTAGCTTTGTCAAAGGTGGGGAGGTCTCTCACTCGATGTTTGCCT
 CACTTTCTGAGAAGGACTTGGTTACATTTCTAGAAGAAAAATCGGGAAAAATCCTTGAAAAACCGCTTAA
 AAACCTTGTATCCAGAACGCTTGGCCGAATTTTTGTACAAGGATATCCTGAAAAAGTCAAAACAGCTGAC
 TGAAGGAAAGGAAACGAGAACAACTTGTCCAGTCCATTAAAGAACTTAAATTCCTGTAACCTGAAAAATGTC
 CCTTGCAAAAGTCTTTGTACCAAGGGTGGAGTCAGTCTCAAGGAAATCAATCCTAAACCCCTTGAAAGT
 AAGCTGTACCTGGCCTCCACTTTGCAGGGAAGTTATGGATATCAATGCCACACGGGTGGCTTTAACA
 TCACTTGTGCCCTCTGTACCGGCTGGGTGGCGGGAAGTCTGCATTATGATCTCGAGCACCACCAACCA
 CCACTGA

2 CFE108 "homologue of SEQ. ID NO. 104"

Fig 122
 ATGCTGAATGGAAGACTTGCCTGTGGAAATGAAATCAAGCGAGGTTGAGTCTTACTACCAGCTTGTCT
 CTAAAAGGAGGGTTTCGCTGATTTTCAAGCGTTTGGCTTGGACTGGGTTTGGCCTTGGTCTTACTGGTCTA
 ACTTCTCCATCTTTCTCATCTTGAGCATTGGATCAAGTTGGATAGCAAGGGGCCAGTGATTACAAGCA
 AGAGCGTGTGACCCAGTACAACCGTCCGTTCAAGATTGGAAGTTCGTACCATGGTGACGGATGCGGAT
 AAAAAAGGAAGTCTGGTGACTTCTGCTAACGATAGCCGATTACCAAGGTTGGAATTTCACTCCACCGTG
 TCGGTTTGGACGAAGTCCCTCAATTGGTCAATGTCCTTAAAGGTGAGATGTCCTTTGTGCGGTACACGACCT
 GAAGTGCCACGTTATACAGAGCAGTATAGCCGTGAAATGATGGCAACCTTGGCTCTTGCAAGCAGGAATTA
 CCTCTCCAGCCAGCATCAACTACAAGGATGAGGACACCATCATCAGTCAAATGACGGAGAAAGGTCTGT
 CAATTGATCAGGCCTATGTGGAGCATGTTCTTCTGAAAAAGATGCGCTATAACCTCGCTATCTCCGAGA
 GTTAGTTCTTTGGGGACATCAAAATCATGTTTCAAAACCGTGTGTTGAGGTACTAAAACCTCGAGCACCACC
 ACCAACCACCTGA

2 CFE109 "homologue of SEQ. ID NO. 105"

Fig 123
 ATGACTAGTCCACTATTAGAATCTAGACGCCAACCTCGTAAATGCGCTTTTCAAGCTCTCATGAGCCTTGA
 GTTCGGTACGGATGTGCAAACTGCTTGTGCTTTCGCTTACTCATGATCGTGAAGATACGGATGTACAA
 CTTCACGCTTTTGTATAGACCTCGTTCTGTGTTCAGCTAAAAAGGAAGAACTAGATAAGCAAAATCA
 CTCAGCATTTAAAGCAGGTTGGACCATTTGAACGCTTAAACGCTCGTGGAGAGAAACCTCCTCGCTTGGG
 AGTCTTTGAAATCACTTCATTGACACTCCTCAGCTGCTGTTGCTGTTAATGAAGCTATCGAGCTTGCAAAAG
 ACTTCTCCGATCAAAATCTGCCCGTTTTATCAATGGACTGCTCAGCCAGTTTGTAAACAGAAGAACAAT
 CGAGCAACCACCACCACCACCTGA

2 CFE111 "homologue of SEQ. ID NO. 107"

Fig 124
 ATGACAAAACGTGTAACGATTATGATGTAAGAACTATGTTGGTCAGGAAGTGACGATTGGCGCTTGGG
 TTGCCAACAAATCAGGAAAAGGGAATCGCTTTCTTACAATTGCGTGATGGAACAGCCTTCTTCAAGG
 TGTACTTTTAAACCAAACTTTGTGCAAAAAATTTGGTGAAGAAAGTGGGACTTGAGAAGTTTGATGTTATC
 AAACGCTTGAGCCAAGAAACGCTCTGTTTATGTGACAGGTATTGTCAAAGAGGACGAACGTTCTAAATTTG
 GCTATGAGTTGGACATCACAGACATGGAAGTATCGGTGAATCTCAAGACTACCCAATCACACCAAAAG
 AACACGGAACAGACTTTTGTATGGATAACCGTCACTTGTGGCTACGCTCTCGTAAGCAAGTAGCTGTGTT
 GCAAAATCGTAACGCTATTATCTATGTAACCTATGAGTTCTTTGACAAGAAATGGTTTATGAAGTTTGACA
 GOCCTAATCTTTAGGAAATGCGGCAGAAAGATTCTACAGAACTCTTTGAAACTGACTACTTCGGAACGCC
 AGCCTACTTGAGCCAATCAGGTCACTTTACCTAGAAGCAGGGGCTATGGCTCTTGGTCTGTTCTTGACT
 TTGTTCCAGTTTTCGCTGTGAAAAATCAAAAAACGCGCTCACTTGAAGTCTGGAATGATGGAATGC
 TGAGTACTCATACTTGACACATGATGATGCTGCTTGAAGTGAAGGCTTATGTGAAAGCTCTTCTACAA
 GGTGTTCTTGACCGCGCGCTCAAGCCTTGGAAACCTTGGAACTGATACAGAACTCTTGAAACGCTACA
 TTGCAGAGCCATTCAAACGTATCACTTACGATCAAGCCATTGACCTCTTGCAAGAGCATGAAATGATGA
 AGATGCTGACTACGAGCATCTTGAGCATGGTGAAGTCTTGGGTCAACCACCGAACTTGAATTTCAAAC
 CACTTGTGTGCCAACATTTGTATGAAGTATCCAGCAGCCATCAAGGCCTTCTACATGAACCACTTCC
 TGGAAATCCAGAGCGGTGCTTTGTGACAGCTTGTCTGCTCCAGAGGCTATGGAGAAATTAAGGTGGG
 TCTATGCTGAGGAAGATTACGATGCCCTTGTGCTAAGATGGATGAAGTGGCATGGATCGTACAGAAT
 ATGAATTTACCTTGACCTTCGFAAATACGTTACAGTTCACACGGAGGATTTGGTATCGGTATCGAAG
 TATGGTAACCTTCGAGCAGGAACAAAAATATCCGTGAAGCTATTTCAATCCACGATGTTGACCGT
 ATCAAACACTTGAGCACCACCACCACCACCTGA

2 CFE112 "homologue of SEQ. ID NO. 108"

ATGTCCTAAAAAATTAGTAGAAATCAAAGATTTAGAAATTTCTTCCGCTGAAGGAAGTAAGAAGTTTGTGCG
CGCTTAAAAATGCTAACTTCTTTATCAACAAGGGAGAAACTTTCTCGCTTGTAGGTGAGTCCGGTAGTGG
GAAAACAACTATTGGTCGTGCTATCATCGGTCTAAATGATACAAAGTAATGGAGATATCATTTTGTATGGT
CAAAAGATTAAATGGTAAGAAATCCGCGTGAACAAGCTGCGGAATTGATTGCTCGAATCCAGATGATTTTCC
AAGACCTGCGCGCAAGTTTGAATGAACGTGCGACTGTTGATTATATTATTTCTGAAGGTCTTTACAATCAC
CGTTATTTAAGGATGAAGAAGAACGTAAAGAGAAAGTTCAAAGTATTATCCGTGAAGTAGGTCTTCTTG
CTGAGCACTTGACTCGTTACCTCATGAATTCTCAGGCGGTCAAACGTCAACGTATCGGTATTGCCCGTGCC
TTGGTCATGCAACCAGACTTTGTTATTGCAGATGAGCCAATTCAGCCTTGGACGTTTCTGTACGTGCCCA
AGTCTTGAACCTTGCTCAAAAAATTCAAAAAGAGCTCGGCTTGACCTATCTCTTCATCGCCCATGACTTGT
CGCTTCTCGCTTTATTTTTCAGATCGTATCGCAGTTATTACAAAGGTGTTATTGTAGAGGTTCAGAAACA
GAAGAATTGTTTAAACAATCCAATTCACCCATATACTCAAGCCTTGCTTTTACGCGGTACCAATCCAGATCC
AATCTTGAAGGTGAAGAAGGTCTTGAAGGTTTACGACCCAAGTCAACACGACTATGAGACTGATAAGCC
ATGATATGTAAGAAATCCGTCCAGGTCACTATGTTTGGGCGAACCAGCTGAATTAGCACGTTATCAAAAA
GGACTAAACCTCGAGCACCACCACCACCACCCTGA

2 CFE113 "homologue of SEQ. ID NO. 109"

ATGAAGATAAGTTGGAATGGATTCTTAAAAAATCATACCAAGAGCGCCTCGAGCTGCTAAAAAGCTCAG
GCGCTCCTTAGTCTGAGAGACAAGCTAGTCTGGAGAAGGATGAACAGATGAGTGTGACTGTGGCAGAC
CAGCTGAGTGAGAATGTGGTGGAACTTTTCTCTGCTTATTCGCTGGTTCGCGAAGGTACTTGTCAACGG
TCAGGAATACACCGTTCCCTATGTGACAGAAGAACCCTGTGTTGCGGCGGCCAGCTATGCCAGCAAA
ATGATCTAAGCGTGCAGGTGGTTTACTGCAACAAGTCCATCAGCGCCAGATGATTGGGCAGGTAGCCCTTT
ATGAAGTTGCTAATCTTAACTAGCGCAAGAGAAGATTGCCAGCAAGAAAGCGGAGCTCTTGAGCTTG
CCAATCAAGCCTATCCTTCTATCGTTAAACGTGGGGGTGGGGCGCGTGATCTGCATGTGAGCAGATAAA
AGCGCAACCAACTTTCTCGTTGTTTATATTCTATGTCGATACCCAGGAAGCCATGGGTGCCAATATGCTC
AAGACCAATGCTGGAAGCCTTGAACCAGTCTTAGAAGAACTCAGTCAGGGACAGAGTCTCATGGGAATC
CTGTCCAACCTACGCGACTGATCTCTGTTGACTGCAAGCTGTGCGCATCGCCTTTCGCTACTTGAGCCGCCA
AAAGGATCAAGGACGAGAGATTGCGGAGAAAATTGCGTTGGCTAGTCAGTTTGGCGAGGCTGATCCTTA
CCGAGCTGCTACTATAATAAAGGAATTTTAAATGGTATTGATGCGATTTTGATTGCCACTGGTAATGACT
GGGGTGGCATCGAAGCTGGGGGCCATGCCCTTGGCAGTCGAGATGGACGCTATCAAGGTCTTACGTGCTG
GAGGCTGACCTTGAAGAGAAGAATTGGTGGTGAGATGACCTGCCCATGCCCTGTAGCGACTAAGGG
TGGCTCTATCGGCTCAACCCACGTGTAGCTCTCAGTCATGATCTACTAGGAAATCCTTCTGCCAGAGAAT
TAGCCCAATTATCGTGTCCATCGGTCTTGGCTCAAAATTTTGCAGCCCTCAAAGCCTTGGTAAGTACGGGC
ATCCAGCAAGGCCACATGAAACTACAGGCCAAATCCCTAGCTCTCCTAGCTGGGGCTAGTGAATCTGAAG
TTGCTCCCTAGTAGAGCGCCTCATCTCAGATAAAACCTTTAACTAGAGACAGCCAGCCTATCTCGA
AAATTTAAGATCAGCGGCCGCACTCGAGCACCACCACCACCACCCTGA

2 CFE114 "homologue of SEQ. ID NO. 110"

ATGCCAATTACATCATTAGAAATAAAGGACAAGACTTTTGAAATCGATTGAGAGGTTTGTATCCAGAAAG
AAGTCGATGAATTTTATGATATTGTGGTTCTGATTACGAAGATCTTGTGCGTGCGAATCATGATAAAAA
TTTCCGTATTAAAGAGTTTGAAGAGCGTTTGTCTTACTTTGATGAAATAAAAGATTCAATTGAGCCAGTCTG
TATTGATTGCTGAGGATACAGCTGAGAGAGTGAACAGGCGCGCATGAACGTTCAAACAATATCATTC
ATCAAGGAGAGCAAGATGCGCAACGCTTGTGGAAGAAGCTAAATATAAGGCAAAACGAGATTCTTCTGTC
AAGCAAGTGATAATGCTAAGAAAGTCCGCTGTTGAACAGAAAGATTGAAGAACAAGAGCCGTGTCTTCC
ACCAACCTCTCAAATCTACAATTGAGAGTCAAGTTGGCTATTGTTGAATCTTCAGATTGGGAAGATATTCTC
CGTCCAACAGCTACTTATCTTCAAACAGTGATGAAGCCTTTAAAGAAGTGGTTAGCGAAGTACTTGGAG
AAGCAATCCAGCTCCAATTGAAGAAGAACCAATTGATATGACACGTCAGTTCTCTCAAGCAGAAATGGA
AGATTACAAGCTCGTATTGAGGTAGCCGATAAAGAATTGCTGAATTGAAGCTCAGATTAAACAGGA
AGTGAAGCTCAACTCTGTAGTGAAGTCCCAAGTTGAAGAAGAGCCTCTGCTCATCCAGTTGGGCCAA
TGATTAAGAACCAGAAAGCTCGAGCACCACCACCACCACCCTGA

2 CFE115 "homologue of SEQ. ID NO. 111"

ATGCTAATGGACAACATAATTATTTAATGGTTGCAATTGCAGTCATTTAGTTCTGGCTTATGTAGTGGC
AATCTTTCTACCTAAGCGAAACGAGGGGAGATTAGAGGCGCTAGAAGAAAGAAAAAGAACTATAACA
ATCTTCCAGTAAATGATGAAGTGAAGCTGTAAAAAATATGCACCTTGATTGGACAAAGTCAAGTGGCTTT

2CFE 115 (Contd)

Fig 128 (Contd)

CCGTGAATGGAATCAAAAATGGGTGCGATTATCTCTCAACTCTTTGCCGATATTGAAAAATAATCTCTTGG
 AAGCAGAAAGGCTATAACCAATTCATTTTCGTTTTCTCAAGGCCAGTCATCAAATTGACCAAATTGAGAGTCA
 AATTACTTTGATTGAAGAAGATATTGCGGCAATTCGCAATGCTTTGGCAGACTTAGAGAAGCAAGAATCT
 AAAAAATAGTGGTTCGTGTTCTTCATGCTTTGGATTATTTGAGGAACTTCAGCATAGAGTTGCTGAAAAATTC
 AGAACAGTATGGTCAAGCCTTGGATGAAAATTGAAAAACAATTAGAAAATATCCAATCTGAATTTTCACAA
 TTTGTAACTTGAATTCATCGGGTGACCTGTGGAAGCCGCGAGTGATTTGGATAATACAGAAAAATCACA
 TTTTGGCCTTAAAGTCATATTGTGGATCGTGTTCAGCCTTGGTTACGACGCTTTCTACAGAATTGCCAGAT
 CAATTAAGGATTTGGAAGCCGGTTATCGTAACTAATTGATGCTAATTATCATTTTGTGAAAACGGATAT
 TGAAGGCGCTTTCCACTTGCTTTATGAAGCATTCAAGAAAAACCAAGAGAATATTGTCAGTTGGAATTG
 GATAATGCGCAATATGAGAATGGACAGGCACAAGAGGAAATCAATGCCCTGTATGATATTTTACTCGAG
 AAATTGCTGCTCAGAAAAGTAGTGGAAAAATCTACTTGGCAACTCTTCCAACCTACCTTCAACATATGAAAAG
 GAATAATACTTTATTGGGAGAAGATATTGCACGTTTGAACAAGACCTATTTACTTCTGAGACAGCTGCA
 AGCCATGTTGCTCGTATTTCAGACAGAATTAGAGAGTTTTGAGGCAGCTATTGTTGAGGTAACCTTCAAATC
 AAGAAAGAACCAACCAAGCTTATTCAGTTCTTGAAGAAAATCTTGAGGATTTACAACTCAACTAAAAAG
 ATATTGAAGATGAGCAAAATTCAGTTAGTGAGCGCTGACACAAATTGAGAAAGATGATATTAATGCAC
 GTCAAAAAGCCAATGTTTATGTCAATCGTCTCCATACTATCAAGCGATACATGGAAAAACGCAATCTGCC
 AGGTATCCACAACTTTCTGAAGTTATCTTTACGGCAAGCAATAATACCGAGGATTTAATGGTTGAGT
 TAGAACAACAAAATGATTAACATTTGAATCTGTTACCCGAGTTCTTGAAATTGCAACGAATGATATGGAAGC
 TTTAGAACGGAACTTATAATATTGTACAATATGCAACTTTGACAGAGCAACTCTTGCAATATTCTTAAC
 CGCTATGCTGCTATTGATGAACGCATTCAAGAAGCATTTAACGAAGCTTTAGATATTTTGAAGAAAGAT
 TTGATTATCACGCTTCATTTGACAAGATTCTCAAGCATTTGGAAGTGGCAGAGCCTGGTGTAAACCAATCG
 CTTTGTACCTCATATGAGAAAACACGTGAAACGATTCTGTTTGGCGCCGCACTCGAGCACCACCAACAC
 CACCACTGA ||

Fig 129

2 CFE116 "homologue-of-SEQ. ID NO.112"

ATGCTTATATCTTATAAATGGTTAAAGAATTGGTGGACATTGATGTGCCATCACAAGAGTTGGCTGAAA
 AAATGTCAACTACAGGAATCGAGGTAGAGGGTGTGCAATCACCAGCTGCTGGTCTCTCAAAAATTGTCGT
 CGGTGAGGTCTTGTCTTGGCAAGATGTGCCAGAGACTCACCTCCATGTTTGTGAGGTTAACGTTGGCGAA
 GAAGAGCGTCAAGTCGTTTGTGGTGCCCCAAATGTGCGTGTGGGATCAAGGTTCATGTTGGCTCTTCCAG
 GAGCTCTATGCTGATAACTACAAAATCAAAAAGGAAAAATCCGTGGTTTGGAGTCACTTGGAAATGA
 TCTGTTCACTTGGTGAATTGGGAATTTCTGACTCAGTTGTGCTAAGGAATTGCGAGATGGCATCCAAATC
 TTGCTGAAGATGCCGTGCCAGGTGAGGAAGTCTTTTCTTACCTAGACTTGGATGATGAAATCATCQAAC
 TTCCATCACACCAACCGTGCAGATGCCCTTTCTATGTGTGGAGTGGCTCACGAAGTGGCAGCCATCTA
 TGACAAAGCAGTCAACTTTAAAGAAATTAACCTAACAAGAACTAATGAAGCTGCGGCAGATGCCCTTTCT
 GTGAGCATTTGACACACAAGGCGCCTTACTATGCAGCTCGTATCTTGGACAAATGTGACCATCGCACCAA
 GTCCACTATGCTTGCAAAACCTTCTCATGAACGAAGGAATCCGTCCCATCAATAACGTAAGTGGACGTGAC
 CAATCAATCTGCTCTATTTTGGTCAACCAATGCATGCCCTTTGACTTGGATAACTTTGAAGGGACTGACA
 TCGGTGTGCGTGAAGCGCGTGTGGTGAAGAAATTTGGTGACCTTGGACGGTGAAGAACGTAAGTGGAGT
 GAATGACCTAGTCACTGTCTGCAGACAAGCCAGTAGCCCTTGCAGGTGTGATGGGTGGTCAAGCAACA
 GAAATCTCTGAAAAATCTATGCTGTGTCTTGAAGCTGCTGTTTCAATGGCAAAATCTATCCGTAAGAC
 AAGTGGTCCGCTGAACCTTCGTTCTGAGTCACTTCTCGCTTTGAAAAAGGAATTAATGTGGCAACAGTT
 AATGAAGCCCTTGATGCGGCAGCTAGCCTGATTGCGGAACCTTGCAAGTGGCAGCGGTGCGTAAGGGCATC
 GTTTCAGCGGGTGAGCTTGATACTTCAGATGTAGAAGTTTCTTCAACCTTGTGATGTTAACCCTGTCTCT
 CGCAACTGAGCTGTCTTATGCTGATGTAGAAGACGCTTCCGTCGCTTGGCTTTGGCTTTCTGAAAATG
 CACACACCTTTACAGTCAGAGTCCCACGTCGCTGTTGGGATATCACAATCGAAGCTGACCTCTTTGAAGA
 AATTGCTGATCTATGTTATGACCGCTTGCCAACTAGTCTACCAAAAGACGATGGTACAGCAGGTGAA
 TTGACAGCCACACAAAACCTCCGCCGTCAAGTTCTGTAATTTGCTGAAGGAGCAGGTTTGACAGAAATCA
 TCACTATCTCTAACAACCTCTGAAAAAGCAGTTGAGTTTACGGCTCAACCAAGTAACCTTACGGAACCT
 CATGTGCGCAATGACTGTGGATCGTTCACTCTCCGTCAAAAATATGATTTCAAGGTATCTTGTATACCGTTG
 CCTACAAACGTGGCTGTAAGAAATAAAAATTTGCGCTTTACGAGATTGGAAGAGTCTTTGAACAAACAGG
 TAATCCAAAGAAAGAACTTCCAAATGAAGTCAACAGTTTTCCTTTGCTTGAAGGCTTGGTTGCTGAA
 AAAGATTCCAAACAGCAGCAGTTCCAGTTGATTCTTCTATGTAAAGGGAATCCCTGAAGCCCTATTAC
 TCGTTTGGGACTCCAAGTAACCTATACAGCAACATCTGAAATCGCTAGCCTTCATCCAGCTCGTACAGCC
 GTGATTCTACTGGGTGACCAAGTTCTTGGTTTCCCTTGGCCAAGTGCATCCAGTCACTGCCAAGGCTTACGA
 TATCCAGAAAAGTATGTGGCTGAGCTTAACCTTTCAGCTATCGAAGCTGCGCTTACGCCAGCGACTCCA
 TTTGTAGAAATACCAAAATCCCGGCAGTCAGCCGTGACGTTGCCCTTCTCTCAAGGCAGAAAGTGACTC

2CFE 116 (contd)

Fig 129
(contd)

ATCAAGAAAGTTGTAGATGCTATCCAAGCTGCCGGCGTGAAACGTTTGACAGATATCAAACCTCTTTGACGT
 CTCTCAGGTGAGAAATTGGGACTTGGTATGAAGTCAATGGCTTATAGCTTGACCTTCCAAAATCCAGAA
 GATAGCTTAACGGACGAAGAAGTCGCACGCTATATGGAAAAAATCCAAGCATCGCTCGAAGAAAAAGTC
 AATGCAGAAAGTGCGTCTCGAGCACCACCACCACCACCTGA

Fig 130

2 CFE117 "homologue of SEQ. ID NO. 113"
 ATGTTAGAAAACGATATTAAAAAGTCCTCGTTTCACACGATGAAATTACAGAAGCAGCTAAAAAACTA
 GGTGCTCAATTAACTAAAGACTATGCAGGAAAAAATCCAATCTTAGTTGGGATTTAAAAAGGATCTATT
 CTTTATGGCTGAATTGGTCAAAACATATTGATACACATATTGAAATGGACTTCATGATGTTCTAGCTAC
 CATGOTEGAAACAGCAAGTAGTGGTGTATCAATATTAAACAAGATGTGACTCAAGATATCAAAGGAAGA
 CAAGTTCTATTGTAGAAGATATCATTGATACAGGTCAAACCTTGAAGAATTGCGAGATATGTTTAAAG
 AAAGACAAGCAGCTTCTGTTAAAAATGCAACCTTGTGGATAAACCAGAAGGACGTGTTGTAGAAATTG
 AGGCAGACTATACCTGCTTTACTATCCCAAATGAGTTTGTAGTAGGTTATGGTTTAGACTACAAAGAAAA
 TTATCGTAATCTTCCTTATATTGGAGTATTGAAAGAGGAAGTGATTCAAATCTCAGCAACCACCAC
 CACCACTGA








FIGURE 131

SEQUENCE LISTING

- <110> Dougherty, Thomas J.
Pucci, Michael J.
5 Dougherty, Brian A.
Davison, Daniel B.
Bruccoleri, Robert E.
Thanassi, Jane A.
- 10 <120> NOVEL BACTERIAL GENES AND PROTEINS THAT ARE ESSENTIAL
FOR CELL VIABILITY AND THEIR USES
- <130> 30436.44USU1
- 15 <140> Not yet known
<141> 2000-12-30
- <160> 226
- 20 <170> PatentIn Ver. 2.0
- <210> 1
<211> 708
<212> DNA
25 <213> Streptococcus pneumoniae
- <400> 1
atgatttatg caggaattct tgccggtgga actggcacac gcatgggaat cagtaacttg 60
ccaaaacaat ttttagagct aggtgatcga cctattttga ttcatacaat tgaaaaattt 120
30 gtcttggaac caagtattga aaaaattgta gttgggggtc atggagactg ggttttacat 180
gcagaagatc ttgtagataa atatcttcct cttcataagg aacgtattat cattacaaag 240
gggtggtgctg accgcaatac aagtattgag aacatcattg aagccattga tgcttatcgc 300
ccgcttactc cagaggatat cgttggtacc cagcattctg ttcgtccatt tattacgctt 360
cgcatgattc aagacagtat caaacttgct caaaatcatg acgcagtgga tacagtagta 420
35 gaagcagtggt atactatcgt tgaaagtacc aatggtcaat tcattacagg tattccaaat 480
cgtgctcacc tctatcaggg acaaacacct caaacattcc gttgcaagga cttcatggac 540
ctttatggat ctctttctga tgaagagaag gaaatcttga cagatgcatg taaaatcttt 600
gtgatcaaag gaaaagatgt agccttggcc aaaggcgaat actcaaactc gaagattaca 660
accgtaacag atttgaagat tgcaaaaagt atgattgaga aagactag 708
- 40 <210> 2
<211> 558
<212> DNA
<213> Streptococcus pneumoniae
- 45 <400> 2
atggctaacg taattattga aaaagctaaa gagagaatga cccagtctca ccaatcactt 60
gctcgtgaat ttggtggtat ccgtgctggt cgtgccaatg caagcttgct tgaccgtgta 120
catgtagaat actatggagt cgaaactcct cttaacccaa tcgcttcaat tacgattoca 180
50 gaagcgcgtg tttgttgggt aacaccattt gacaagtcct cattgaaaga catcgaacgt 240
gccttgaacg cttctgatct tgggtatcaca ccggctaagt acggttctgt gattcgttg 300
gttatccag ctcttacaga agaaactcgt cgtgaccttg ctaaagaagt gaagaaggtc 360
ggcgaaaatg ctaaagtggc tgtccgcaat atccgtcgcg atgctatgga cgaagctaa 420
aaacaagaaa aagcacaaga aatcactgaa gacgaattga agactcttga aaaagatatt 480
55 caaaaagtaa cagacgatgc tgtaaacac atcgacgaca tgactgctaa caaagagaaa 540
gaacttttgg aagtctaa 558

<210> 3
<211> 1353
<212> DNA
<213> Streptococcus pneumoniae

5
<400> 3
atgggtaaat attttgggac tgatggagtc cgtggagaag ctaacctaga actaacacca 60
gaattagcct ttaaaactagg acgttttggg ggctatgttc ttagtcaaca tgaaacggaa 120
gcgccgaaag tctttgtagg acgtgacaca cgtatttcag gggaaatgct ggaatcggcc 180
10 ttggtggcag gtctcctttc agtagggatt cacgtataca aacttggtgt ccttgcaaca 240
ccagcagtag cttacttggg tgaactgaa ggagcaagtg ccggtgtcat gatttctgct 300
agccacaacc cagcccttga taacggaatc aagttctttg gcggtgatgg cttcaacta 360
gatgatgaaa aagaagcaga aattgaagcc ttgctagatg ctgaggaaga cactcttctc 420
cgtccaagtg cagaaggcct aggaattttg gtagattatc cagaaggcct gcgtaagtat 480
15 gaaggatacc gtgtgtcaac tggaaactcct cttgatggaa tgaaggttgc cttggataca 540
gctaattggag cagcttctac cagtgcccggt caaatctttg cagaccttgg tgcccaattg 600
acggttatcg gggaaacacc agacggtcct aacatcaacc ttaatgttgg ttcaacacat 660
ccagaagccc ttcaagaagt ggtcaaagaa agtgggtcag ctattgggtt ggcccttgat 720
ggagacagtg accgcttgat tgctgttgat gagaatgggt acatcgctga tggtgacaag 780
20 attatgtaca tcatcggaat ataccttctt gaaaaaggac aattggctca aaatacaatt 840
gtgacaactg ttatgtctaa ccttgggttc cacaaggcct tgaatcgaga aggtattaac 900
aaggcagtta ctgcagttgg tgaccgctac gttgttgaag aatgagaaa atcaggctac 960
aaccttgggt gtgaacagtc tggtcacgtt atcttgatgg attacaatac cacagggtat 1020
ggtcaattat cagcagttca attgactaaa atcatgaagg aaactggtaa gagcttatca 1080
25 gagttggcgg cagaagtaac gatttatcca caaaaattag ttaatatccg agtggaaaac 1140
gtcatgaagg aaaaggccat ggaagtgccg gctatcaagg ccatcatcga gaagatggaa 1200
gaagaaatgg cggggaacgg ccgtatcctt gttcgtccaa gtggaacaga gcccctcttg 1260
cgtgttatgg cagaagcgcc tacaacagaa gaagtggact actatgttga taccatcaca 1320
gatgtagttc gtgctgaaat tgggattgac taa 1353

<210> 4
<211> 705
<212> DNA
<213> Streptococcus pneumoniae

35
<400> 4
atgaaaaaaa tactaattgt agatgatgag aaaccaatct cggatattat caagtttaat 60
atgaccaagg aaggttatga agttgtaact gcttttaatg gtcgtgaagc gctagagcaa 120
tttgaagcag agcaaccaga tattattatt ctggatttga tgcttccaga aattgatggg 180
40 ttagaagttg ctaagaccat tcgtaagaca agcagtgtgc ccattcttat gctttcagcc 240
aaagatagtg aatttgataa ggttatcggt ttggaacttg gggcagatga ctatgtaacg 300
aaacccttct ccaatcgtga gttgcaggcg cgtgttaaag ctcttctgcg tcgttctcaa 360
cctatgccag tagatgggtca ggaagcagat agtaaaccctc aacctatcca aattggggat 420
ttagaaattg ttccagacgc ctacgtggct aaaaaatatg gcgaagaact agacttaacc 480
45 catcgtgaat ttgagctttt gtatcattta gcatcgcata cagggtcaagt catcacgcgc 540
gaacacttgc ttgagactgt ctggggttat gactattttg gtgatgtccg cacagttgat 600
gtgactgtac gacgtctgcg tgagaagatt gaagatacgc ccagccgacc agagtatatc 660
ttgacgcgcc gtggtgtagg gtattacatg agaaataatg cttga 705

50
<210> 5
<211> 1107
<212> DNA
<213> Streptococcus pneumoniae

55
<400> 5
atggaagaaa ttctctgtat tggttgtgga gcaaccattc agacgacaga taaagctggg 60
cttggtttta cccccagtc ggcacttgaa aaagggttgg agactggcga agtctattgc 120

caacgctgtt tccgtctccg ccactacaat gaaatcacag atgtccagtt gacgaacgat 180
 gatttcctca agctcttgca cgagggtgga gacagtgatg ctttagtggt caatgtcatt 240
 gatatactttg attttaatgg atctgtcatc ccagggtttac caggtttcgt ctcgggcaat 300
 gatgtcctct tggtaggaaa taaaaaagat atccttccta agtcagttaa gtctggttaag 360
 5 attagccagt ggctcatgaa acgtgccccat gaagaagggtc ttcgtccagt cgatgtggtc 420
 ctaacttcag cacaaaataa acatgccatt aaggaagtca ttgacaagat tgaacactac 480
 cgtaagggcc gcgatgtcta tgtgggtcggg gtgaccaacg ttggaaaatc aactctaatac 540
 aatgctatta tccaagaaat cacgggtgat cagaatgtca tcactacttc acgcttccca 600
 gggacaacct ttgacaaaat agagattccg cttgacgacg gatcttataa ttacgatacg 660
 10 ccgggaatta tccaccgcca ccagatggct caactactga cggccaaaaa cctcaagta 720
 gtcagtccta aaaaggaaat caagcctaag acctatcagc ttaatcctga gcaaacccta 780
 tttttagggtg gtttgggacg ctttgacttt atagcaggag aaaagcaagg atttactgct 840
 ttctttgata atgaactcaa actccatcgt agcaagcttg aaggagctag tgctttctac 900
 gataagcacc tgggaactct tctgacacca ccaaatagca aggaaaaaga agatttccca 960
 15 aggttagtcc agcatgtctt taccattaaa gataagacag acctagtcatt ctcaggccta 1020
 ggtggtgatt gtgtaacagg cacagcaaaa gtcgccgtct gggcaccaga aggcgtcgcc 1080
 gtcgtcacac gaaaagcaat tatttaa 1107

<210> 6
 20 <211> 1461
 <212> DNA
 <213> Streptococcus pneumoniae

<400> 6
 25 atgtatccag atgatagttt gacattgcac acggacttgt accagatcaa catgatgcag 60
 gtttactttg accaagggat tcacaataag aaggcgggtc ttgaggtgta tttccgcca 120
 cagcctttta agaacggcta tgcggttttt gcagggtttg aaagaattgt gaactatctt 180
 gaagacttgc gtttttcaga tagtgatata gcctatttgg agtcgcttgg ttatcatggg 240
 gcgttcttgg attaccttcg caatttcaag ttggagttga ccgttcgttc tgcccaagaa 300
 30 ggggatttgg tttttgctaa tgaaccgatt gtgcagggtg aaggacctct agcccaatgt 360
 cagtttggtc aaacggctct tttgaacatc gtcactacc agaccttggg ggcgacgaag 420
 gcagctcgta ttcgttcggg tatcgaagat gaaccttga tggagtttgg gacacgtcgg 480
 gctcaagaaa cggatgcggc catctgggga acacgcgcag cggtgatttg tggcgccaat 540
 ggaaccagca acgtgcgtgc gggtaagctc tttgacattc ctgttttggg aacctatgcc 600
 35 catgccttgg tacaggttta tggcaatgac tatgaggctt tcaaggctta cgctgcgacc 660
 cacaaaaatt gtgtctttct tgtggatacc tatgataccc ttgcgacggt tgtaccagct 720
 gccattcagg tggcgcggtg gctgggtgat cagattaact ttatgggtgt gcgattgac 780
 tctggggata ttgcctacat ttctaagaaa gtccgtcagc aactggacga ggctggattt 840
 acagaggcta agatttatgc ttctaattgat ttggacgaaa atactatcct caatctcaag 900
 40 atgcaaaagg ccaagattga tgtctggggt gtgggtacca agctgattac agcctatgac 960
 cagccggctc ttggggcggg ttacaagatt gttgcaatcg aagatgaaac tggtcagatg 1020
 cgcaatacga ttaagctgtc taataatgcg gaaaaagtgt cgacgccagg taagaagcag 1080
 gtgtggcgca ttaccagtcg tgaaaaagggt aagtcagaag gtgattacat cacttatgat 1140
 ggtgtggata ttagcgacat gacagaaatc aagatgttcc atccgaccta tacatacatc 1200
 45 aagaagacgg ttcgtaattt tgatgccgtt cctctcttgg tggatatctt caaagaagga 1260
 atattagttt acaacttgcc tagtttgact gacattcagg attatgcccg taaagaattt 1320
 gacaagttgt gggatgagta taagcgtgtg ctcaatccgc agcactatcc agtggatttg 1380
 gcgcgtgatg tatggcaaga taagatggac ttgattgata agatgcgcaa ggaagccctt 1440
 50 ggtgaaggag aagaagaatg a 1461

<210> 7
 <211> 852
 <212> DNA
 <213> Streptococcus pneumoniae

55 <400> 7
 atggctacta ttcaatgggt tccgtgtcac atgtctaaag ctcgtcgaca ggtgcaggag 60

aattttaaatt ttgttgattt tgtgacgatt ttagtagatg cacgcttgcc tctatctagt 120
 caaaatccta tgttgacca gattgttggt gataaaccaa aactcttgat tttaaacaag 180
 gccgacttgg ctgatccagc aatgaccaag gaatggcgtc agtattttga atcacaagga 240
 atccagacgc tagctatcaa ctccaaagag caagtgactg taaaagttgt aacagatgcg 300
 5 gccaagaagc tcatggctga taagattgct cgccagaaag aacgtgggat tcagattgaa 360
 accttgcgta ctatgattat cgggattcca aacgctggta aatcaactct gatgaaccgt 420
 ttggctggta aaaagattgc tgttgttggg aacaagccag gggtcacaaa aggtcaacaa 480
 tggcttaaaa ccaataaaga cctggaaatc ttggatacac cggggattct ctggcctaag 540
 10 tttgaggatg aaactgttgc acttaagttg gcattgactg gagctatcaa ggatcagttg 600
 cttcctatgg atgaggttac catTTTTTgt atcaattatt tcaaagaaca ttatccagaa 660
 aagctggctg aacgcttcaa acaaatgaaa attgaagaag aaccgtctgt gattattatg 720
 gatatgaccc gcgccctcgg tttccgtgat gactatgacc gtttttacag tctctctgtg 780
 aaggaaagttc gtgatggcaa actcggtaac tataccttag atacattgga agacctcgat 840
 ggcaacgatt aa 852
 15 <210> 8
 <211> 471
 <212> DNA
 <213> Streptococcus pneumoniae
 20 <400> 8
 atgattaaca atgttgtact tgtaggcggt atgacacgtg acgctgagtt gcgttatacc 60
 ccatcaaatg tagcagttgc gacttttact cttgcagtaa accgtacatt taagagtcaa 120
 25 aatgggtgaac gtgaggctga ttttatcaat gtcgttatgt ggcgccaaca ggctgaaaat 180
 cttgctaact gggctaaaaa aggctcactt atcgggggtg caggctcgtat ccagactcgt 240
 agttacgata accagcaagg acaacgtgtc tacgtgacag aggtcgtggc tgagaatttc 300
 caaatgttgg aaagccgtag tgtgcgtgag ggccacacag gtggagctta ctctgcacca 360
 actgcaaaact attcagcacc tacaatttca gtaccagact tttcacgtaa tgaaaatcca 420
 30 tttggagcaa caaacccatt ggatatttca gatgatgatt taccattcta a 471
 <210> 9
 <211> 975
 <212> DNA
 <213> Streptococcus pneumoniae
 35 <400> 9
 atgaaaacgc gtattacaga attattgaag attgattatc ctattttcca aggagggatg 60
 gcctggggtg ctgatgggtga tttggcaggg gctgtttcca aggctggagg attaggaatt 120
 40 atcgggtggg gaaatgcccc gaaagaagtt gtcaaggcca atattgataa aatcaaatca 180
 ttgactgata aacccttttg ggtcaacatc atgctcttat ctccctttgt ggaagatata 240
 gtggatctcg ttattgaaga aggtgtttaa gttgtcaca caggagcagg aaatccaagc 300
 aagtatatgg aacgtttcca tgaagctggg ataactgtta ttctgttgt tctagtgtc 360
 gctttagcta aacgcattga aaaaatcggt gcagacgctg ttattgcaga aggaatggaa 420
 45 gctggggggc atatcggtta attacaacc atgacctgg tgcgacaggt agccacagct 480
 atatctattc ctgttattgc tgcaggagga attgcggatg gtgaagggtc tgcggctggc 540
 tttatgctag gtgcagaggc tgtacagggt gggacacggt ttgtagttgc aaaagagtcg 600
 aatgccatc caaactacaa ggagaaaatt ttaaaagcaa gggatattga cactacgatt 660
 tcagctcagc acttttgtca tgcgtgtcgt gctattaaaa atcagttgac tagagatttt 720
 50 gaactggctg aaaaagatgc ctttaagcag gaagatcctg atttagaaat ctttgaacaa 780
 atgggagcag gtgccctagc caaagcagtt gttcacgggt atgtggaggg tggctctgtc 840
 atggcaggtc aaatcgaggc gcttgtttct aaagaagaaa cagctgaaga aatcctaaaa 900
 gatttgtatt acggagccgc taagaaaatt caagaagaag cctctcgctg gacaggagtt 960
 gtaagaaatg actaa 975
 55 <210> 10
 <211> 423
 <212> DNA

<213> Streptococcus pneumoniae

<400> 10

5 atgatcgata ttcaaggaat caaagaagcc cttccccacc gttatcctat gcttcttagtg 60
 gaccgtgtct tggaggtgag cgaggatacc attgttgcta tcaaaaatgt gaccatcaac 120
 gagcctttct ttaacggcca ctttcctcaa taccaggtta tgccaggtgt tctgattatg 180
 gaagccttgg cgcaaactgc cgggtgtgtg gagttatcaa aacctgaaaa taaaggaaaa 240
 ctggctcttt acgctggtat ggataagggtt aagtccaaga agcaagttgt accaggcgac 300
 caattgggta tgacagcgac ttttgtaaaa cgtcgtggca ccatagctgt ggttgaagca 360
 10 aaggctgaag tggatggcaa gcttgacgcc agtgggtacc ttacttttgc aattgggaac 420
 taa 423

<210> 11

<211> 1023

<212> DNA

<213> Streptococcus pneumoniae

<400> 11

20 atgattaatc aaatztatca actaactaaa cctaagttaa tcaatgtcaa atatcaggaa 60
 gaggtctattg accaagagaa tcatatcctt atccgtccca actacatggc tgtctgtcat 120
 gcggatcagc gttactacca gggaaaacgt gatcccaaga ttttgaataa aaagcttcca 180
 atggcaatga ttacagagtc atgtggaatc gtcatttctg acccgagcgg aacctacgag 240
 gttgggtcaaa aagtgtgcat gattcccaat cagtctccta tgcagagtga tgaagaattc 300
 tatgaaaact acatgacagg gacccatttc ttgtctagt gatttgatgg ctttatgaga 360
 25 gagtttgttt ctctccctaa agatcgtgtg gtggcttatg atgctattga agatacgggt 420
 gcagccatta cagagtttgt cagtgtgggc atgcacgcta tgaatcgtct attgactctt 480
 gctcatagca agcgggagcg gatccccgtt attggagatg gaagtttagc ttttgtggtt 540
 gccaatatta tcaactatac tttgccagaa gcagagattg tggttattgg tcgtcattgg 600
 gaaaagttgg aactcttctc atttgccaaa gaatgctata ttacggataa tattcctgaa 660
 30 gagttggcct ttgaccatgc ttttgaatgt tgtggtggtg atgggtactg accagctatt 720
 aatgacttga ttctgctacat tcgtcctcag ggaacaattc tcatgatggg agtttagcgaa 780
 tataaagtca atctcaatac tcgcgatgcc tttagaaaagg gcttgcctct gggtgggtca 840
 tctcgttctg gtcgcattga ttttgaaaat gctatccaaa tgatgaaagt caagaaattt 900
 gccaatcgtc ttaaaaaatat cctttatcta gaagaacctg taagagaaat taaagatatt 960
 35 caccgtgtct ttgcaaccga tttaaacaca gcctttaaaa cagtgtttaa gtgggaagta 1020
 taa 1023

<210> 12

<211> 1344

<212> DNA

<213> Streptococcus pneumoniae

<400> 12

45 atgaacttaa aaactacttt gggccttctt gctggacgtt cttcccactt cgttttaagc 60
 cgtcttggac gtggaagtac gctcccaggg aaagtcgccc ttcaatttga taaagatatt 120
 ttacaaaacc tagctaagaa ctacgagatt gtcgttgta ctggaacaaa tggaaaaacc 180
 ctgacaactg ccctcactgt cggcatttta aaagaggtct atggtaagt tctaaccaat 240
 ccaagcgggtg ccaacatgat tacagggatt gcaacaacct tcctaacagc caaatcttct 300
 aaaactggga aaaatattgc cgtcctcgaa attgacgaag ccagtctatc tcgtatctgt 360
 50 gactatatcc agcctagtct tttgtcatt actaatatct tccgtgacca gatggaccgt 420
 ttccgtgaaa tctatactac ctataacatg atattggatg ccattcggaa agttccaact 480
 gctactgttc tccttaacgg agacagtcca cttttctaca agccaactat tccaaacctt 540
 atagagtatt ttggttttga cttggaaaaa ggaccagccc aactggctca ctacaatacc 600
 gaagggattc tctgtcctga ctgccaaagg atcctcaaat atgagcataa tacctatgca 660
 55 aacttgggtg cctatatctg tgaggggtgt ggatgtaaac gtcctgatct cgactatcgt 720
 ttgacaaaac tgggtgagtt gaccaacaat cgtctcgtct ttgtcataga cggccaagaa 780
 tacggtatcc aaatcgccgg gctctataat atctataac ccctagctgc tgtggccatc 840

gcccgtttcc tcggcgacaga ttcccaactc atcaaacagg gatttgacaa gagccgtgct 900
 gtcttttgac gccaaagaaac ctttcataac ggtgacaagg aatgtaccct tgtcttgatt 960
 aaaaatccag tcgggtgcaac ccaagctatc gaaatgatca aactagcacc ttatccattt 1020
 5 agcctatctg tctccttaa tgccaactat gcagatggaa ttgacactag ctggatctgg 1080
 gatgcagact ttgagcaaat cactgacatg gacattcctg aaatcaacgc tggcggtggt 1140
 cgctattctg aaatcgctcg tcgcctccga gtgactggct atccagctga gaaaatcact 1200
 gaaacgagta atctggagca agttctcaag accattgaga atcaagactg caagcatgcc 1260
 tatattctgg caacttatac tgccatgctg gaatttcgtg aactgctggc tagtcgtcag 1320
 attgttagaa aggagatgaa ctaa 1344
 10
 <210> 13
 <211> 783
 <212> DNA
 <213> Streptococcus pneumoniae
 15
 <400> 13
 atggtttata cttcactttc ctcaaaagat ggcaattacc cctatcagct caacattgcc 60
 .cacctctacg gaaatctcat gaatacctac ggggacaatg gaaacatcct catgctcaag 120
 20 tatgtggctg aaaaactggg agcccatgtg accgttgaca tcgtttctct ccatgatgac 180
 tttgatgaaa atcactacga catcgccctt ttcgggtgtg gtcaagactt tgaacaaagt 240
 atcattgcag acgacctacc tgctaaaaaa gagagcattg acaactacat ccaaaacgac 300
 ggtgtagttc tggctatctg cgggtggttc caactattgg gtcaatatta tgttgaagct 360
 tcaggaaaaac gtatcgaagg gctaggggtc atgggacact acacgctcaa ccagaccaat 420
 aaccgtttta tcggtgacat caagattcac aatgaagatt tcgatgaaac ctactatgga 480
 25 tttgaaaatc accaaggctg taccttctc tctgatgacc aaaaaccgct gggacaggtt 540
 gtctatggaa atggaaacaa cgaagaaaag gtcggtgaag gggttcatta taagaatgtc 600
 tttggttctt acttccacgg gcctatcctc tctcgtaatg ccaatctggc ttatcgcccta 660
 gttactactg cctcaagaa gaaatatggt caggacatcc aactccctgc ctatgaggac 720
 attctcagcc aagaaatcgc tgaagagtac agtgacgtca aaagcaaggc tgacttttct 780
 30 taa 783
 <210> 14
 <211> 276
 <212> DNA
 35 <213> Streptococcus pneumoniae
 <400> 14
 atggcaaaca aacaagattt gatcgctaaa gtagcagaag ctacagaatt aactaagaaa 60
 gactcagcag cagcagttga agctgtatct gcagcagtag ctgactatct tgcagctggg 120
 40 gaaaaagttc agttgatcgg ttttagtaac tttgaagttc gtgagcgcgc agaacgtaaa 180
 ggtcgcaacc caaaaactgg taaagaaatg acaattgcag cttctaaagt accagcattc 240
 aaagctggta aagctcttaa agacgctggt aaataa 276
 <210> 15
 45 <211> 840
 <212> DNA
 <213> Streptococcus pneumoniae
 <400> 15
 50 atgggaattg ctctagaaaa tgtgaatttt acatatcaag aaggtactcc cttagcttca 60
 gcagctttgt cggatgtttc tttagcagatt gaagatggct cttatacagc ttttaattggg 120
 cacacaggtg gtggtaaatc aactatttta caactcttaa atggtttatt ggtgccaaagt 180
 caagggagtg tgaggggttt tgatacctta atcacctcga cttctaaaaa taaagatatt 240
 cgtcaaatta gaaaacaggt tggcttggtg tttcagtttg ctgaaaatca gatttttgaa 300
 55 gaaacggttt tgaaggacgt tgcttttgga ccgcaaaatt ttggagtttc tgaagaagat 360
 gctgtgaaga ctgcgcgtga gaaactggct ctggttgga ttgatgaatc actttttgat 420
 cgtagtccgt ttgagctgtc agggggacaa atgagacgtg ttgccattgc aggcatactt 480

gccatggagc cagctatatt agtcttagat gagccaacag ctggctctaga tcctctaggg 540
 agaaaagagt tgatgaccct gttcaaaaaa ctccaccagt cagggatgac catcgtcttg 600
 gtaacgcatt tgatggatga tgttgctgaa tatgcgaatc aagtctatgt aatggaaaaa 660
 ggacgttttag taaagggggg caaaccaagt gatgtctttc aagacgttgt ttttatggaa 720
 5 gaagttcagt tgggagtacc taaaattacg gccttttgta aacgattggc tgatagaggc 780
 gtgtcattta aacgattacc ggttaagata gaggagttca aggagtcgct aaatggatag 840

<210> 16

<211> 930

10 <212> DNA

<213> Streptococcus pneumoniae

<400> 16

atggatattc aatttttagg aacgggggct ggtcagccct cttaaagccc caacgtttca 60
 15 agtctcgccc tgaactttt ggatgagatt aacgaagttt ggctctttga ctgtggagaa 120
 ggtacgcaaa atcgatttct ggaaaccaca attcgaccac gtaaggctcag caaaatcttt 180
 attaccatc tgcattggaga ccacattttt ggtttgccag gtttcctttc tagccgtgcc 240
 tttcaggcca atgaagagca gacagatttg gaaatctacg gacctcaagg aatcaagtca 300
 20 tttgtcttaa ccagccttcg tgtgtcaggt tctcgtctgc cctaccgcat tcatttccat 360
 gaggatgacc aagattctct aggtaaaatt cttgaaatcg ataaattcac tgtgtatgca 420
 gaggagctgg accacactat tttctgtgtt ggctatcgtg tcatgcaaaa ggatctagaa 480
 gggacgctgg atgtgaaaa actcaaggct gctggtgttc cgttcggccc gctttttggt 540
 aaaatcaaaa atggccagga tcttgttttg gaagacggaa ctgaaatcaa ggcagcagac 600
 tatactcag cgccacgtcc aggttaagatt atcactattt taggagacac tcgaaaaacg 660
 25 gatgccagtg tgcgtctggc tgtcaatgca gatgtcctag ttcattgagc cacttatggc 720
 aagggtgatg aaaaaattgc tcgttaacct ggtcactcaa ctaatatgca agctgcacaa 780
 gtagcggtag aagcaggtgc caaacgcctc ctactcaacc atatcagtgc ccgtttcctc 840
 tcaaaagata ttagcaaaact caagaaagac gctgccacaa tttttgaaaa tgtccatgtg 900
 30 gtcaaagact tggaagaagt ggaatctag 930

<210> 17

<211> 1662

<212> DNA

<213> Streptococcus pneumoniae

35

<400> 17

atgagtaata tcagtttaac aacacttggt ggtgtgctg agaatggaaa aaatatgtac 60
 attgtgaaa ttggagagtc catttttgtt ttgaatgtag ggttaaaata tcctgaaaat 120
 40 gaacaattag ggtcgatgt ggtgattcca aacatggatt acctttttga aaatagcgac 180
 cgtattgctg ggtttttctt gacccacggg catgcggatg cgattggtgc tctaccttat 240
 ctcttggcag aggtctaaagt tctgtattt gggctctgagtgacattga gttggcaaaag 300
 ctctttgtca aaggaaatga tgccgttaag aaatttaattg atttccatgt cattgatgag 360
 aatacggaga ttgatttttg tgggacagtg gtttccttct tccctacgac ttactccgtt 420
 ccagagagtc tgggaattgt cttgaagaca tcggaaggaa gcacgtttta tacaggtagac 480
 45 ttcaaatttg accaaacggc tagtgaatct tatgcaactg attttgctcg tttggcagag 540
 attggctcgtg acggcgtcct ggctctcctc agtgattcgg ccaatgcaga cagcaatatt 600
 cagggtggcta gtgaaagtga agttagggat gaaattaccc aaactattgc tgactgggaa 660
 ggtcgtatca tcgttgacgc tgtttccagt aatctttctc gtattcagca gatttttgac 720
 gctgcggata aaacaggtcg acgtatcgtc ttgacaggat ttgatattga aaatatcgtc 780
 50 cgcacagcga ttcgtcttaa gaagttgtct ttagccaacg aaattctctt gattaagcct 840
 aaagatatgt ctgcgtttga agaccatgag ttgattatc ttgagacagg tcgtatgggt 900
 gaacctatca atggacttcg taagatgtcg attggctgcc atcgttatgt agaaatcaag 960
 gatggggacc tggctctatat tgctacggct ccgtctattg cttaaagaagc ctttgttgcg 1020
 cgtgtagaaa atatgattta tcaggcaggt ggggttgtca aattgattac ccaaagtta 1080
 55 catgtatcag ggcacggaaa tgtgcgtgat ttgcagctga tgatcaatct tttgcaacct 1140
 aagtacctct tccctgtcca aggggagat cgtgagttgg atgctcacgc taaggctgcc 1200
 atggcagttg ggatgttgcc agaacgcac ttcattccta aaaaggggac gaccatggct 1260

tacgagaatg gagactttgt tccagctgga tccggtttcag caggagatat cttaattgat 1320
 gggaaatgcc tgggtgatgt tggaaatgtt gttcttcgtg accgtaagggt cttgtcagag 1380
 gatggaaattt tcatcgtggc tattacagtc aaccgctcgtg agaagaaaaat tgtggctaga 1440
 gctcgtgttc acacgcgtgg atttggtttat ctcaagaaga gtcgcgatat tctccgtgaa 1500
 5 agttcagaat tgattaacca aacggtagaa gattatcttc aaggagatga ctttgactgg 1560
 gcagatctta aagggaagggt tgcagataat ttgaccaagt atctctttga ccaaaccaag 1620
 cgctcgtccag ctattttacc agtagtcatg gaagcaaaat aa 1662

<210> 18
 10 <211> 951
 <212> DNA
 <213> Streptococcus pneumoniae

<400> 18
 15 atgacaaaag aatttcatca tgtaacggtc ttactccacg aaacgattga tatgcttgac 60
 gtaaaacctg acggtatcta cgttgatgag actttgggtg gagcaggcca tagcgagtat 120
 ttattaagta aattaagtga aaaaggccat ctctatgcct ttgaccagga tcagaatgcc 180
 attgacaatg cgcaaaaacg cttggcacct tacattgaga agggagtggt gacctttatc 240
 aaggataact tccgtcattt acaggcacgt ttgcgcgaag ctggtgttca ggaaattgat 300
 20 ggaatttggt atgacttggg agtgtctagt cctcaattgg accagcgtga gcgtggtttt 360
 tcttataaaa aggatgcgcc actggacatg cggatgaatc aggatgctag tctgacagcc 420
 tatgaagtgg ttaatcatta tgactatcat gatttggttc gtattttctt caaatacggg 480
 gaggataaat tctctaaaca gattgcgcgt aagattgagc aagcgcgtga agtgaagccg 540
 attgagacaa cgactgagtt agcagagatt atcaagttgg tcaaacctgc caaggaactc 600
 25 aagaagaagg gtcacctctg taagcagatt ttccaggcta ttcaaatga agtcaatgat 660
 gaactggggg ggcagatga gtccatccag caggctatgg atatgttggc tctggatggg 720
 agaatttcag tgattacctt tcattcctta gaagacgct tgaccaagca attgttcaag 780
 gaagcttcaa cagttgaagt tccaaaaggc ttgcctttca tcccagatga tctcaagccc 840
 aagatggaat tgggtgtccg taagccaatc ttgccaagtg cggaagagtt agaagccaat 900
 30 aaccgctcgc actcagccaa gttgcgcgtg gtcagaaaaa ttcacaagta a 951

<210> 19
 <211> 999
 <212> DNA
 35 <213> Streptococcus pneumoniae

<400> 19
 atgagtagaa ttttagataa tgagataatg ggggatgagg agttagtaga acgcacgctc 60
 cgtcctcagt atttacgtga atatatcgga caggataagg tcaaggacca gctacaaatc 120
 40 tttattgaag ctgccaaaat gcgggatgaa gcgctggatc atgtgctctt atttgggcct 180
 ccaggctctg ggaaaacgac catggccttt gttattgcca acgaactggg agtcaatctt 240
 aagcagacgt cgggtccagt cattgaaaaa gccggagatc tggtagctat tttgaatgag 300
 tttagacctg gggatgtact ttttattgat gagatccatc gtttgccaat gtcagtggaa 360
 gaggtgcttt atagtgtctat ggaggacttc tacatcgata ttatgattgg ggctggtagg 420
 45 ggtagtctga gtgttcattt ggagttacca ccttttacct tgattgggtg gacgactcgg 480
 gctgggtatgc tctccaatcc gctacgggca cgttttggga ttacaggcca tatggagtat 540
 tatgcccatg ctgacttgac agaaattgtc gagcggacgg cagatatttt tgagatggaa 600
 atcactcatg aggcagcatc tgagttggcc ctacgtagtc gtgggacccc tcgtattgcc 660
 aatcgtctcc tcaagcgcgt gcgcgatttt gccagataa tggggaatgg ggtaatgat 720
 50 gatattatta ccgataaggc tttgactatg ctggatgttg acctgaagg tttggactat 780
 gtggatcaaa aaatccttcg taccatgatt gagatgtaca gtggaggacc tgttggctta 840
 ggaactcttt ctgtgaatat cgccgaagag cgtgagacag ttgaagacat gtatgagcct 900
 tacttgattc aaaaagggtt tatcatgcgg acacggtctg gacgggtggc gactgctaag 960
 gcatatgagc acttaggtta tgaatacagt gaaaataa 999

<210> 20
 <211> 1311

<212> DNA

<213> Streptococcus pneumoniae

<400> 20

5 atgagtatgt ttttagatac agctaagatt aaggtcaagg ctggtaatgg tggcgaatgg 60
 atgggtgcct ttcgtcgtga aaaatatgtc cctaattggag gcccttgggg tggatgatgg 120
 ggtcgtggag gcaatgtggg cttcgttgta gacgaaggac tacgtacctt gatggatttc 180
 cgctacaatc gccatttcaa ggctgattct ggtgaaaaag ggatgaccaa agggatgcat 240
 10 ggtcgtggg ctgaggacct tagagtgcga gtatcacaag gtacgactgt tctgatgacg 300
 gagactggca aggttttaac agatttgatt aaacatgggc aagaatttat cgttgccac 360
 ggtggtcgtg ttggacgtgg aaatattcgt ttgacgacac caaaaaatcc tgcaccggaa 420
 atctctgaaa atggagaacc aggtcaggaa cgtgagttac aattggaact aaaaatcttg 480
 gcagatgtcg gtttagtagg attcccatct gttaggaagt caacactttt aagtgttatt 540
 15 acctcagcta agcctaaaat tggcgcctac cactttacca ctattgtacc aaatttaggt 600
 atggttcgca cccaatcagg tgaatccttt gcagtagccg acttgccagg ttgtattgaa 660
 ggggctagtc aaggtgttgg ttgggaact cagttcctcc gtcacatcga gcgtacacgt 720
 gttatccttc acatcattga tatgtcagct agcgaaggcc gtgatccata tgaggattac 780
 ctagtcatca ataaagagct ggagtcttac aatcttcgcc tcatggagcg tccacagatt 840
 attgtagcta ataagatgga catgccttag agtcaggaaa atcttgaaga atttaagaaa 900
 20 aaattggctg aaaattatga tgaatttgaa gagttaccag ctatcttccc aatttctgga 960
 ttgaccaagc aaggtctggc aacactttta gatgctacag ctgaattggt agacaagaca 1020
 ccagaatttt tgctctacga cgagtccgat atggaagaag aagcttacta tggatttgac 1080
 gaagaagaaa aagcctttga aattagtcgt gatgacgatg cgacatgggt actttctggt 1140
 gaaaaactca tgaaactctt taatatgacc aactttgatc gtgatgaatc tgtcatgaaa 1200
 25 tttgcccgtc agcttcgtgg tatgggggtt gatgaagccc ttcgtgcgcg tggagctaaa 1260
 gatggggatt tggcccgcat tggtaaatat gagtttgaat ttgtagacta g 1311

<210> 21

<211> 519

30 <212> DNA

<213> Streptococcus pneumoniae

<400> 21

atgaactact ttaatgttgg gaaaatcggt aatacgcagg gattacaggg tgagatgcga 60
 35 gtcttgtctg tgacggattt tgcagaagaa cggtttaaaa aaggagctga gctggctttg 120
 tttgatgaaa aagatcagtt tgtccaaaca gtgaccatcg ctagccaccg taaacagaag 180
 aactttgaca ttattaaatt caaagatatg taccatatca atactatcga aaagtacaag 240
 ggatacagtc tcaaggctgc tgaggaagat ttgaatgacc tagacgatgg tgaattttac 300
 40 tatcacgaga ttatcggttt ggaagtctat gagggtgata gcttgggttg aaccatcaag 360
 gaaatcctgc aaccaggtgc taatgatgtc tgggtggtca aacgaaaagg caaacgtgat 420
 ttgcttttac cttatatccc accagtgggt ctcaatgttg atattccaaa taaacgggtc 480
 gatgtggaaa tcttagaagg gtttagacgat gaagattga 519

<210> 22

45 <211> 720

<212> DNA

<213> Streptococcus pneumoniae

<400> 22

atgaagattg atattttaac cctctttcca gagatgtttt ctccactgga gcaactcaatc 60
 gttggaaagg ctgcagaaaa agggctcttg gatatccagt atcataattt tcgagaaaaat 120
 gctgaaaagg cccgtcatgt agatgatgag ccctacggag gcggtcaggg catgttgctc 180
 agagcacaac ctattttcga ttcttttgat gctattgaaa agaaaaatcc gcgcgttatt 240
 ctctcgatc ctgctggaaa gcagtttgat caggcttatg ctgaagattt ggctcaagag 300
 55 gaagagctaa tctttatctg tgggcactat gaggttatg atgagcgcat taagaccttg 360
 gtaacagatg agatttcctt aggcgactat gtccctactg gtggagaatt ggcagctatg 420
 accatgattg atgctacagt tgcctgatt ccagaagtga ttggcaagga gtctagccac 480

caagatgata gtttttcttc aggtctttta gaatatcatc agtacacacg tccctatgat 540
 tatcgaggca tggctcgtgcc agatgtattg atgagtggcc atcatgaaaa gattcgtcag 600
 tggcgattgt acgagagttt aaagaaaaacc tacgagcgca gaccggattt acttgaacat 660
 tatcaactga cagtagaaga agaaaaaatg ctggcagaaa tcaaagaaaa caaagaataa 720
 5 <210> 23
 <211> 561
 <212> DNA
 <213> Streptococcus pneumoniae
 10 <400> 23
 atgattgaag caagtaaatt aaaagctggt atgacctttg aaacagctga cggcaaattg 60
 attcgcgttt tggagctag tcaccacaaa ccaggtaaaag gaaacacgat catgcgtatg 120
 aaattgcgtg atgtccgtac tggttctaca tttagacaaa gctaccgtcc agaggaaaaa 180
 15 tttgaacaag ctattatcga gactgtccca gctcaatact tgtacaaaaat ggatgacaca 240
 gcatacttca tgaatacaga aacttacgac cagtacgaaa tccctgtagt caatgttgaa 300
 aacgaattgc tttacatcct tgaaaactct gatgtgaaaa tccaattcta cggaactgaa 360
 gtgatcgggtg tcaccgttcc tactactgtt gagttgacag ttgctgaaac tcaaccatct 420
 atcaaagggtg ctactgttac aggttctggt aaaccagcaa cgatggaaac tggacttgct 480
 20 gtaaacgttc cagacttcat cgaagcagga caaaaactcg ttatcaacac tgcagaagga 540
 acttacgttt ctctgccta a 561
 <210> 24
 <211> 1572
 25 <212> DNA
 <213> Streptococcus pneumoniae
 <400> 24
 atggcatttg aaagtttaac agaacgtttg cagaacgtct ttaaaaaatct acgtaaaaaa 60
 30 ggaaaaatct ctgaatctga tgtccaagag gcaaccaaag aaattcgtct ggcttgcctc 120
 gaggccgacg ttgccttgcc tgttgtaaag gactttatca agaaagttcg tgagcgtgca 180
 gtccggcatg aggtcattga tacacttaac cctgcgcaac agattattaa aatcgttgat 240
 gaggaactga cagccgtttt aggttctgat acggcagaaa ttatcaagtc acctaaagatt 300
 ccaaccatca tcatgatggt tggtttaciaa ggggctggtg aaacaacott tgcgtgtaaa 360
 35 ttggccaaca aactcaagaa agaagaaaat gctcgtcctt tgatgattgc ggccgatatt 420
 tatcgtccag ctgccattga ccagcttaag accttgggac aacagattga tgtgcctgtc 480
 tttgcacttg gaacagaagt accagctggt gagattgtac gtcaagggtt ggagcaagcc 540
 caaactaatc ataacgacta tgtcttgatt gatactgcgg gtcgtttgca gattgatgag 600
 ctctcatga atgagcttcg tgatgtgaaa acattggctc aaccaaatga aatcttgctt 660
 40 gtcgttgatg ctatgattgg tcaggaagca gccaatggtg cgcgtgagtt taatgctcag 720
 ttggaagtga ctgggggtcat ccttaccaag attgatggcg atactcgtgg tgggtgctgct 780
 ctgtctgttc gtcacattac tggaaaaacca atcaagttca ctggtacagg tgaaaagatt 840
 acggacattg aaaccttcca ccagaccgc atgtctagcc gtatccttgg tatgggggat 900
 atgctcactt tgattgagaa agcttctcag gaatacgtg aacaaaaagc ccttgaaatg 960
 45 gctgagaaga tgcgcgaaaa cacctttgat ttaatgatt tcatcgatca attagatcag 1020
 gtgcaaaata tggggccgat ggaagacttg ctcaagatga ttccaggtat ggcaacaat 1080
 ccagcccttc aaaacatgaa ggtggatgaa cgcagattg ctcgtaaagc tgcattgtg 1140
 tcttcgatga cacctgaaga gcgtgaaaac ccagatttgt taaatccaag ccgtcgccgt 1200
 cgtattgctg ctggttcttg aaatacatte gtccaagtca ataaattcat caaggacttt 1260
 50 aaccaggcta aacagctcat gcagggtggt atgtctgggg atatgaataa aatgatgaag 1320
 caaatgggga ttaatccaaa taaccttctt aaaaatatgc caaatatggg aggaatggat 1380
 atgtctgccc ttgaaggaaat gatgggacaa ggcgggatgc ctgacttacc agctctcgga 1440
 ggagcaggaa tgccagatat gagccagatg tttggtggcg gtttgaaagg taaaattggt 1500
 55 gaatttgcta tgaaacagtc catgaaacgt atggctaaca aatgaagaa agcgaagaag 1560
 aaacgcaagt aa 1572
 <210> 25

<211> 846

<212> DNA

<213> Streptococcus pneumoniae

5 <400> 25

atgtatctta ttgaaatctt aaaatctatc ttcttcggga ttgttgaagg aattacggaa 60
 tgggtgccga tttccagtac aggtcatttg attttagcag aggagtttat ccaataccaa 120
 aatcaaaatg aagcctttat gtccatgttt aatgtcgtga ttcagcttgg tgctatttta 180
 gcagttatgg tgattttatt taacaagctc aatcctttta aaccgactaa ggacaaacag 240
 10 gaagttcgtg agacttgag actatgggtg aaggtcctga ttgctacttt acctttactt 300
 ggtgtcttta aatttgatga ttggtttgat acccacttcc ataacatggt ttcagttgct 360
 ctcatgttga ttatctacgg ggttgccttc atctatttgg aaaagcgcaa taaagcgcg 420
 gctatcgagc caagtgtaac agagttggac aagcttcctt atacgaccgc tttctatatc 480
 ggactcttcc aagttcttgc tcttttaccg gggactagcc gtccaggtgc aacgattgtc 540
 15 ggtggtttgt taaatggaac cagtcgttca gttgtgacag aattttacct ctatcttggg 600
 attcccgtta tgtttggagc tagtgccotta aagattttca aattttgtga agccggagaa 660
 ctcttgagct ttgggcaatt gtttttgctc ttggtcgcga tgggagtagc ttttgcggtc 720
 agcatggtgg ctattcgtct cttgaccagc tatgtgaaaa aacacgactt cacccttttt 780
 ggtaaatacc gtatcgtgct tggtagtggt ttgctacttt acagttttgt ccgtttattt 840
 20 gtataa 846

<210> 26

<211> 1290

<212> DNA

25 <213> Streptococcus pneumoniae

<400> 26

atgggattat ttgaccgtct attcggaaaa aaagaagaac ctaaaatcga agaagttgta 60
 aaagaagctc tggaaaatct tgatttgtct gaagatattg agcctgcctt cacagaagct 120
 30 gaggaagttt ctcaagaaga agcagagggt gaaagttctg aagaatctgt gttccaagaa 180
 gaggatagtc aagacacagt cgaagaaaat ctggatttag agccagttgt agaggtttct 240
 caagaagaag tagaagaatt tccaaactca caagaagtca cagaggaaga gaagcttgag 300
 cacgaaggaa ctgtagaaga aaataatctt gaagtgcctg aaccagaagc tcctcaaaca 360
 gaagaaactg ttcaggaaaa atatgaccgc agtcttaaga aaactcgcac aggtttcggg 420
 35 gcccgcttga atgccttctt tgctaacttc cgctctgttg acgaagaatt tttcgaggaa 480
 ctggaagaac tgttgattat gagtgatggt ggtgtccaag tcgcttctaa cttaacggag 540
 gaactacggt acgaagccaa gcttgaaaat gccagaagac ctgatgcact tcgtcgtgct 600
 atcattgaga aattgggtga gctttatgaa aaggatggta gctacgatga aagcatccac 660
 ttcaaagata acttgacagt tatgctcttt gttgggtgta atggtgttgg gaaaacaact 720
 40 tctatcggaa aactagccca ccgctacaaa cgagctggtg agaaggtcat gctggttgca 780
 gcagatacct tccgtgcggg tgcagtagct cagctagctg aatggggccg acgagtagat 840
 gttccagtag taactggacc tgaaaaagct gatccagcca gcgtgggtct tgatggtagt 900
 gaacgtgccg tggctgaagg tatcgatatt ctcatgattg atactgctgg tcgtctgcaa 960
 aataaggata acctatggc tgagttggaa aagattgggt gtattatcaa acgtgttgtg 1020
 45 ccagaagcac cacatgaaac cttcttggca cttgatgcac caacaggtca aaatgcccta 1080
 gtacaggcca aagaattttc gaaaaacaca cctttaacgg gaattgtttt gactaagatt 1140
 gatggaactg ctcgaggagg tgtggttcta gccattcgtg aagaactcaa tattcctgta 1200
 aaattgattg gttttggtga aaaaatcgat gatattggag agtttaactc agaaaacttc 1260
 50 atgaaaggct tcttgggaagg tttaatctaa 1290

<210> 27

<211> 498

<212> DNA

<213> Streptococcus pneumoniae

55

<400> 27

atgtatattg aaatggtaga tgaaactggg caagtttcaa aagaatggtt gcaacaaacc 60

12.

gctctccttg agccagctag ccagaaacta gctgaaactc tagctcaggt aagtttttca 660
 gattttactt gtcccctagt cggcaatata gaagctgctg tgatgcaaaa agaggacatt 720
 gctcagctct tgacgcgtca ggtcaaggaa cccgttcggt tctatgaaag tattgggggtc 780
 atgcaagaag caggcataag caactttatc gagattggac cggggaaagt cttgtcaggt 840
 5 tttgttaaaa aaattgatca aactgctcac ttagctcatg tggaagatca agcgagtta 900
 gtagcacttt tagaaaaata g 921

<210> 31

<211> 732

10 <212> DNA

<213> Streptococcus pneumoniae

<400> 31

15 atgaaactag aacataaaaa tatctttatt acaggttcga gtcgtggaat tgggtcttgcc 60
 atcggccaca agtttgctca agcaggagcc aacattgtct taaacagtcg tggggcaatc 120
 tcagaagaat tgctcgctga gttttcaaac tatgggtatca aggtggttcc catttcagga 180
 gatgtatcag attttgcaga cgctaagcgt atgattgatc aagctattgc agaactgggt 240
 tcagtagatg ttttgggtcaa caatgcaggg attacccaag atactcttat gctcaagatg 300
 acagaagcag attttgaaaa agtgctcaag gtcaatctga ctggtgcctt taatatgaca 360
 20 caatcagctc tgaaccgat gatgaaagcc agagaagggt ctatcattaa tatgtctagt 420
 gttgttggtt tgatggggaa tattgggtcaa gctaactatg ctgcttctaa ggctggcttg 480
 attggcttta ccaagtctgt ggcacgcgag gtcgctagtc ggaatatacg agtcaatgtg 540
 attgtccag gaatgattga gtctgatatg accgctatct tatcagataa gattaaggaa 600
 gctacactag ctcagattcc gatgaaagaa tttgggcagg cagagcaggt tgcagatttg 660
 25 acagtatttt tagcaggcca agattatcta actggtcaag tggttgccat tgatggtggc 720
 ttaagtatgt ag 732

<210> 32

<211> 831

30 <212> DNA

<213> Streptococcus pneumoniae

<400> 32

35 atgggagtg aaaaagaaact aaagttgact agtttgctag gactgtctct gttaatcatg 60
 acagcctgtg cgactaatgg ggtaactagc gatattacag ccgaatcggc tgatttttgg 120
 agtaaattgg tttacttctt tgcggaaatc attcgctttt tatcgtttga tattagtatc 180
 ggagtgggga ttattctctt tacggtcttg attcgtagc tctctttgcc agtctttcag 240
 gtgcaaatgg tggtctctag gaaaatgcag gaagctcagc cacgcattaa ggcgcttcga 300
 gaacaatata caggtcgaga tatggaaagc agaaccaaac tagagcagga aatgcgtaaa 360
 40 gtattttaag aaatgggtgt cagacagtca gactctcttt ggccgatttt gattcagatg 420
 ccggttattt tggccctgtt ccaagcccta tcaagagttg actttttaa gacaggtcat 480
 ttcttatgga ttaaccttgg tagtgtggat acaacccttg ttcttcgat tttagcagca 540
 gtattcacct ttttaagtac ttggttgctc aacaaagctt tgtctgagcg aaatggcgct 600
 acgactgcga tgatgtatgg gattccagtc ttgattttta tctttgcagt ttatgcgcca 660
 45 ggtggagtcg ccttatactg gacagtgtct aatgcttata aagtcttgca aacctatttc 720
 ttgaataatc cattcaagat tatcgagag cgcgaggccg tagtacaggc acaaaaagat 780
 ttggaaaata gaaaaagaaa agccaagaaa aaggctcaga aaacgaaata a 831

<210> 33

50 <211> 1230

<212> DNA

<213> Streptococcus pneumoniae

<400> 33

55 atgaagatta gtaagaggca cttattaaat tattccatct tgattcccta cttactttta 60
 tctatttttg gcttgattgt ggtctattcg accaccagtg ctattttta tgaagaaggc 120
 aagagcgct tgcagttggt tcgaaaccaa ggaatctttt ggattgttag tttgatactg 180

attgccttaa tttataaatt gagactagat tttttgagaa atgagcgact aatcatttta 240
 gttatattaa tagaaatgct tttattgttc ttggctcggt ttattgggtat ttcagtaaac 300
 ggggcatacg gttggatttc ggttgcagga gtaactattc agccagctga gtacttaaaa 360
 atcattatta tttggtattt agctcaccga ttctccaaac agcaagaaga aatagctact 420
 5 tatgattttc aagttttgac tcaaaatcaa tggtttcccc gtgcttttaa tgattggcga 480
 ttctgtctcc tagttctgat tggaggtttg ggaattttcc ctgatttagg aaatgcgact 540
 attttagtct tggtttccct gattatgtat acagtttagt gaatcgctta tcgctgggtt 600
 tcaaccattc tggcgtcgt atctgccact tctgtctttg tcttgaccac tatcagccta 660
 atcgggtgtg agaccttttc aaaaattcca gtatttggct atgtagccaa gcgctttagt 720
 10 gcctttttta atccttttgc cgatcggtgt gatgcaggtc accagtttag taattcttat 780
 ttggccatgg tcaatgggtg ttggtttggt ctaggtcttg gaaactcgat tgaanaacga 840
 ggttatttgc cagaagctca tacagacttt gtcttttcta tctgtattga agaatttggc 900
 tttgttgggt ccagttctat tttagctctc ttgtttttca tgattttgag gattatcttg 960
 gtcggtatcc gagcggagaa tcttttcaat gccatggtt cactcggtgt cggagggtg 1020
 15 atgttgggtc aggtatttgt caatatcgga gggatttcgg gcttgattcc atctacagga 1080
 gtgactttcc ctttcttctc ccagggtgga aatagctctc tagtcttctc agtggcagta 1140
 gcctttgtct taaatattga tgccagtga aaacgcgcta agttgtaccg agaattggaa 1200
 aatcaaccaa tgaaccttct gttgaagtag 1230

20 <210> 34
 <211> 1260
 <212> DNA
 <213> Streptococcus pneumoniae

25 <400> 34
 atgctcgga ttttaacctt tattctgggt tttgggatta ttgtagtggt gcacgagttc 60
 gggcacttct actttgcca gaaatcaggg atttttagtac gtgaatttgc catcggtatg 120
 ggacctaata tctttgctca cattggcaag gatggaacgg cctataccat tgaattcttg 180
 30 cctctgggtg gctatgtccg catggccggt tgggtgatg atacaactga aatcaagaca 240
 ggaacgcctg ttagtttgac acttgctgat gatggttaagg ttaaaccgat caatctctca 300
 ggtaaaaaat tggatcaaac agccctccct atgcaggtga cccagtttga ttttgaagac 360
 aagctcttta tcaaaggatt ggttctggaa gaagaaaaaa catttgacgt ggatcacgat 420
 gcaacgggtg tggagcaga tggactgag gttcggattg cacctttaga tgttcaatat 480
 caaatgctga ctatctgggg caaactgatt accaattttg caggctctat gaacaatttt 540
 35 atcttaggtg tctgtgtttt ttgggtttta atctttatgc aggggtggtg cagagatgtt 600
 gataccaatc agttccatat catgccccaa ggtgccttgg ccaaggtagg agtaccagaa 660
 acggcacaaa ttaccaagat cggctcacat gaggttagca actgggaaag cttgatccaa 720
 gctgtggaaa cagaaaccaa agataagacg gcaccgactt tggatgtgac tatttctgaa 780
 aaggggagtg acaacaagt cactgttaca cccgaagata gtcaaggctg ttaccttcta 840
 40 ggtgttcaac cgggggttaa gtcagatttt ctatccatgt ttgtaggttg ttttacaact 900
 gctgctgact cagctctccg aattctctca gctctgaaaa atctgatttt ccaaccgat 960
 ttgaacaagt tgggtggacc tgttgctatc ttttaaggcaa gtatgtatgc tgctaaaaat 1020
 ggaattgaga atatcttgta cttcttggca atgatttcca tcaatattgg gatttttaat 1080
 cttattccga ttccagcctt ggatgggtgt aagattgtgc tcaatatcct agaagccatc 1140
 45 cgccgcaaac cattgaaaca agaaattgaa acctatgtca ccttggccgg agtggctatc 1200
 atggttgtct tgatgattgc tgtgacttgg aatgacatta tgcgactctt ttttagaata 1260

<210> 35
 <211> 594
 50 <212> DNA
 <213> Streptococcus pneumoniae

<400> 35
 atgtacgcat atttaaaagg aatcattacc aaaattactg ccaaatacat tgttcttgaa 60
 55 accaatggtt ttggttatat cctgcatgtg gccaatcctt atgcctatc aggtcaggtt 120
 aatcaggagg ctcagattta tgtgcatcag gttgtcgtg aggaagccca tttgctttat 180
 ggatttcgct cagaggatga gaaaaagctc tttcttagtc taatttcggt ctctgggatt 240

5 ggtcctgtat,cagctcttgc tattatcgct gctgatgaca atgctggctt ggttcaagcc 300
 attgaaacca agaacatcac ctacttgacc aagttcccta aaattggcaa gaaaacagcc 360
 cagcagatgg tgctggactt ggaaggcaag gtagtagttg caggagatga ccttcctgcc 420
 aaggtcgcag tgcaagcaag tgctgaaaac caagaattgg aagaagctat ggaagccatg 480
 ttggctctgg gctacaaggc aacagagctc aagaaaatca agaaattctt tgaaggaaacg 540
 acagatacag ctgagaacta tatcaagtcg gcccttaaaa tgttggtcaa atag 594

<210> 36

<211> 774

10 <212> DNA

<213> Streptococcus pneumoniae

<400> 36

15 atgaagaata atcgatattt agcaatttct ggaaatgata ttttttagtgg tggtaggactg 60
 tcagctgatt tggctaccta taccttgaac ggcttgcag ggtttgtagc agtgacttgt 120
 ttgacagcct tgacagaaaa aggatttgaa gtctttccaa ctgatgatac catTTTTTcaa 180
 catgaattag atagcttgcg tgatgtggaa tttgggggaa ttaagattgg tcttctccct 240
 actgtcagtg tggctgagaa ggccttggac tttatcaaac aacgcccagg agtacctgtg 300
 gtgttggatc ctgtcttggg ctgcaaggaa acgcatgatg tagctgtcag tgagctctgc 360
 20 caagagttga ttcgcttctt cctttatgtc agtgtgatta cgcctaactc cccagaagca 420
 gaattattat ccggtcagga aattaaaacc ttggaagaca tgaaaactgc agcgagaaa 480
 ttgcatgatt taggagcgcc agcagtcatt atcaaggag gcaatcgtct tagtcaggac 540
 aaggctgtgg atgtcttcta tgatggacag acctttacta tcctagaaaa tccagttatc 600
 caaggccaaa atgctggtgc aggttgtacc ttgcctcta gcattgccag tcacctggtt 660
 25 aaagtgata aatttttgcc agcagtagaa agctctaagg ctttcgttta tcgtgctatt 720
 gcacaagcag atcagtatgg agtaagacaa tatgaagcaa acaaaaacaa ctaa 774

<210> 37

<211> 1239

30 <212> DNA

<213> Streptococcus pneumoniae

<400> 37

35 atgattgaaa cggagaaaaa agaggagcga gtcctgctga ttggtgtgga attgcagggt 60
 atggacagtt ttgacctctc catggaagaa ttggctagtt tagcgaatac ggcaggggca 120
 gtcgtttag atagctacag acaaaaacgt gaaaaatatg attccaagac cttcgtcggc 180
 tctggtaagt tggaagagat tgcgcttatg gtggatgcag aagaaatcac tactgtcatc 240
 gtcaacaatc gtctgacccc aaggcagaat gtcaatctag aggaagttct cgggtgtaag 300
 gtcattgacc gtagtcagtt gattttggat atctttgcca tgcgggctcg aagccatgaa 360
 40 gggaagctcc aagtcacact agcccaattc aaatacctct tgcctcgctt ggttggtcag 420
 gggattatgc tcagccgtca ggcaggggga attggttccc gtggtcctgg tgaaagccaa 480
 ctggagctga accgtcgtag cgttcgcaat caaatcacgg atatcgagcg ccagcttaag 540
 gtggttgaga aaaatcgtgc gactgtcaga gaaaaacgtt tggagtctag cacttttaag 600
 attggtttga ttggttatc taatgctggg aaatcaacta tcatgaacat cttgaccagt 660
 45 aagaccagt atgaagcaga tgagctcttt gcgactctgg atgcgacaac caagagtatt 720
 catctgggag gcaatctcca agtaactttg acagataccg ttggctttat ccaagatttg 780
 ccgacagagt ttggtgtccag tttcaagtca accttggaag aaagcaagca tgtggacctt 840
 ctggttcag ttatcgatgc tagcaatcct taccacgagg agcatgaaaa aacggttctc 900
 tccatcatga aagacctgga catggaagat attcctcact tgacgcttta taataaagcg 960
 50 gatttgggtg aggatttcac gcctacccaa acgcatata ccttcatttc tgccaagtct 1020
 gaggacagtc gtgaaaactt gcaagcatta ttgctagata agattaagga aatttttgaa 1080
 gcatttacc tgcgagtgc tttttcaaag tcctacaaga ttcattgatt agagagtgtt 1140
 gcaattctgg aagaacgtga ttatcaggaa gacggcgaag tgattacagg ctacatttcc 1200
 55 gagaaaaata aatggagggtt agaagaattt tatgactga 1239

<210> 38

<211> 483

<212> DNA

<213> Streptococcus pneumoniae

<400> 38

5 atggcagaaa aaacatatcc tatgaccctt gaggaaaaagg aaaaacttga aaaagaatta 60
 gaagaattga aattggttcg tcgaccagaa gtggtagaac gcattaagat tgcccggttca 120
 tacggtgacc ttccagaaaa cagtgtgtac gaagcagcta aggatgaaca agcctttgtc 180
 gaaggacaaa tctctagctt agaaacaaaa atccgctatg ctgaaatcgt caatagcgac 240
 gcagttgccc aggacgaagt agcgattggt aaaacagtca ccatccaaga aattggtgag 300
 10 gacgaagaag aagtttatat tategttagt tcagctggtg cggatgcctt tgcaggtaag 360
 gtttcaaatg aaagcccaat tgggcaggcc ttgattggca agaaaacagg tgatacagca 420
 accattgaaa cgctgttg tagctatgat gtaaaaatct tgaaggttga aaaaacagcc 480
 taa 483

15 <210> 39

<211> 570

<212> DNA

<213> Streptococcus pneumoniae

20 <400> 39

atgaccaa at tacttgtagg cttgggaaat ccaggggata aatattttga aacaaaacac 60
 aatgttgggtt ttatgttgat tgatcaacta gcgaagaaac agaattgtcac ttttacacac 120
 gataagatat ttcaagctga cctagcatcc tttttcctaa atggagaaaa aatttatctg 180
 gttaaaccaa cgacctttat gaatgaaagt ggaaaagcag ttcatgcttt attaaacttac 240
 25 tatgggttgg atattgacga tttactttatc atttacgatg atcttgacat ggaagttggg 300
 aaaattcggt taagagcaaa aggctcagca ggtggtcata atggtatcaa gtctattatt 360
 caacatatag gaactcaggt ctttaaccgt gttaagattg gaattggaag acctaaaaat 420
 ggtatgtcag ttgttcatca tgttttgagt aagtttgaca gggatgagta tatcggtatt 480
 ttacagtctg ttgacaaaagt tgacgattct gtaaaactact atttacaaga gaaaaatttt 540
 30 gagaaaacaa tgcagaggta taacggataa 570

<210> 40

<211> 852

<212> DNA

35 <213> Streptococcus pneumoniae

<400> 40

atgatttttaa ttacaggggc aaatggccaa ttaggaaacgg aacttcgcta tttattggat 60
 gaacgtaaatg aagaatacgt ggcagtagat gtggctaaga tggacattac caatgaagaa 120
 40 atggttgaga aagtttttga agaggtgaaa ccgacttttag tctaccattg tgcagcctac 180
 accgctgttg atgcagcaga ggatgaagga aaagagttgg acttcgccat caatgtgacg 240
 gggacaaaaa atgtcgcaa agcatctgaa aagcatggtg caactctagt ttatatttct 300
 acggactatg tctttgacgg taagaaacca gttggacaag agtgggaagt tgatgaccga 360
 ccagatccac agacagaata tggacgcaact aagcgtatgg gggaaagatt agttgagaag 420
 45 catgtgtcta atttctatat tatccgtact gcctgggtat ttggaaatta tggcaaaaaac 480
 ttcgttttta ccatgcaaaa tcttgcgaaa actcataaga ctttaacagt tgtaaatgat 540
 cagtacggtc gtcgacttg gactcgtaac ttggctgagt tcatgaccta cctagctgaa 600
 aatcgtaagg aatttgggta ttatcatttg tcaaatgatg cgacagaaga cacaacatgg 660
 tatgattttg cagttgaaat ttgaaagat acagatgtcg aagtcaagcc agtagattcc 720
 50 agtcaatttc cagccaaagc taaacgtccg ctaaactcaa cgatgagcct ggccaaagcc 780
 aaagctactg gatttggtat tccaacttgg caagatgcat tgcaagaatt ttacaaacaa 840
 gaagtgagat aa 852

<210> 41

55 <211> 1224

<212> DNA

<213> Streptococcus pneumoniae

<400> 41
 atgaaacggt ctctcgactc aagagtcgat tacagtttgc tcttgccagt attttttcta 60
 ctgggtcatcg gtgtgggtggc tatctatata gccgttagtc atgattaccc caataatatt 120
 5 ctgcccattt tagggcagca ggctgcctgg attgccttgg ggcttgatg tggttttgg 180
 gtcattgctct ttaatacaga atttcttgg aaggtagccc cctttctata ttttttaggc 240
 ttgggactta tgatcttgcc gattgtattt tataatccaa gcttagttgc atcaacgggt 300
 gccaaaaact gggatcaat aaatggaatt accctattcc aaccgtcaga atttatgaag 360
 atatctata tctcatgtt ggctcgtgtc attgtccaat ttacaaagaa acataaggaa 420
 10 tggagacgca cggttccgct ggacttttgg ttaattttct ggatgattct ctttaccatt 480
 ccagtcctag ttcttttagc acttcaaagt gacttgggga cggettgggt tttttagacc 540
 attttctcag gaatcgttt attatcaggg gtttcttgg aaattattat cccagtattt 600
 gtgactgctg taacaggagt tgctggtttc ttagctatct ttattagcaa ggacggacga 660
 gcttttcttc accagattgg aatgccgacc taccaaatca atcggatttt ggcttggtc 720
 15 aatcccttgg agtttgccca aacaacgact taccagcagg ctcaagggca gattgccatt 780
 gggagtgggt gcttatttgg tcagggattt aatgcttcca atctgcttat cccagttcga 840
 ggtcagata tgatttttac ggttatttga gaagatttgg gctttattgg ctctgtcctg 900
 gttattgccc tctatctcat gttgatttac cgtatgttga agattactct taaatcaaat 960
 aaccagtctt acaattatat ttccacaggt ttgattatga tgttgctctt ccacatcttt 1020
 20 gagaatatcg gtgctgtgac tggactactt cctttgacgg ggattccctt gcctttcatt 1080
 tcgcaagggg gatcagctat tatcagtaat ctgattggtg ttggtttgct tttatcgatg 1140
 agttaccaga ctaatctagc tgaagaaaag agcgaaaag ttccattcaa acggaaaaag 1200
 gttgtattaa aacaaattaa ataa 1224

25 <210> 42
 <211> 609
 <212> DNA
 <213> Streptococcus pneumoniae

30 <400> 42
 atgggaaaaa tcatcggaat cactggggga attgcctcag gtaagtcaac tgtgacaaat 60
 tttctaaaaa accaagggtt ttcaagcagt ggattgccga cgcagtgttc caccaactac 120
 agaaaacctg gtggtcgtct gtttgaggct ttagtacagc actttgggca agaaatcatt 180
 35 cttgaaaaac gagaaactcaa tcgccctctc atagctagtc tcatcttttc aaatcctgaa 240
 gagcaaaaat ggtctaataa aattcaaggg gagattatcc gtgaggaact ggctactttg 300
 agagaacagt tggctcagac agaagagatt ttcttcatgg atattccctt actttttgaa 360
 caggactaca gcgattgggt tgctgagact tggttgggtc atgtggaccg agatgcccaa 420
 gtagaacgct taatgaaaag ggaccagttg tccaaagatg aagctgagtc tcgtatggca 480
 40 gccagtggtc ctttagaaaa aaagaaagat ttggccagcc aggttcttga taataatggc 540
 aatcagaacc agcttcttaa tcaagtgcatt atccttcttg agggaggtag gcaagatgac 600
 agagattaa 609

<210> 43
 <211> 1260
 45 <212> DNA
 <213> Streptococcus pneumoniae

<400> 43
 atgagaaaaa ttgttatcaa tgggtggatta ccactgcaag gtgaaattac tattagtgg 60
 50 gctaaaaata gtgttggtgc cttaattcca gctattatat tggctgatga tgtgggtgact 120
 ttggattgtg ttccagatat ttccgatgta gccagtcttg tcgaaatcat ggaattgatg 180
 ggagctactg ttaagcgtaa tgacgatgtc ttggagattg atccaagagg tgttcaaaa 240
 attccaatgc cttatggtta aattaacagt cttcgtgcat cttactattt ttatgggagc 300
 ctcttaggcc gttttgttga agcgacagtt ggtctaccgg gaggatgtga tcttgggtcct 360
 55 cgtccgattg acttacacct taaggcgttt gaagctatgg gtgccactgc tagctacgag 420
 ggagataaca tgaagttatc tgctaaagat acaggacttc atggtgcaag tttttacatg 480
 gatacgggta gtgtgggagc aacgattaat acgatgattg ctgcagttaa agcaaatggt 540

cgtactatta ttgaaaatgc agcccggtgaa cctgagatta ttgatgtagc tactctcttg 600
 aataatatgg gtgcccataat ccgtggggca ggaactaata tcatcattat tgatgggtgtt 660
 gaaagattac atgggacacg tcatcaggtg attccagacc gcattgaagc tggaacatat 720
 5 atatcttttag ctgctgcagt tggtaaaggga attcgtataa ataagtgtct ttacgaacac 780
 ctggaagggt ttattgctaa gttggaagaa atgggagtga gaatgactgt atctgaagac 840
 agcatttttg tgcaggaaca gtctaatttg aaagcaatca atattaagac agctccttac 900
 ccaggctttg caactgattt gcaacaaccg cttacccctc ttttactaag agcgaatggt 960
 cgtggtacaa ttgtcgatac gatttacgaa aaacgtgtaa atcatgtttt tgaactagca 1020
 aagatggatg cggatatttc gacaacaaat ggtcatattt tgtacacggg tggacgtgat 1080
 10 ttacgtgggg ccagtgttaa agcgaccgac ttaagagctg gggctgcact agtcattgct 1140
 gggcttatgg ctgaaggtaa aactgaaatt accaatattg agtttatctt acgtggttat 1200
 tctgatatta tcgaaaaatt acgtaattta ggagcggata ttagacttgt tgaggattaa 1260

<210> 44

15 <211> 696

<212> DNA

<213> Streptococcus pneumoniae

<400> 44

20 atgtcaagaa ttgaattttc accatctttg atgaccatgg atttgacaa attcaaagag 60
 cagattactt ttttgaatga taaagtagca tcttatcata tcatattat ggatggccat 120
 tttgttccca atattacctt gtctccttgg ttcattcaag aagttcaaaa aattagtgc 180
 acacctttat cagttcatct gatggtcaca gacccaacct tttgggtaga tcaagttctc 240
 gatttacaat gtgagtatat ttgtattcat gctgaagttc tgaatggtct tgcttttcgt 300
 25 ttgattgata aaattcatga tgcaggtcta aaggctgggt ttgtccttaa tctgaaaca 360
 cctgtttcta caatctttcc ctacattgat ttacttgaca aagtaactat tatgactgta 420
 gatccagggt ttgcaggaca acgctttttg gactctacct tgtataaaat ccaagaactc 480
 cgtcagctta gagttcagaa tggttatcac tacatcattg agatggatgg ttcttcgagt 540
 cgtaagactt tcaaacaaat tgatgtggca ggaccagata tttatgttat aggtcgcagt 600
 30 ggattatttg gtttgatga cgatattgcc aaagcctggg atatctgttc tagagattac 660
 gaagaaatga ccggaaaaac aatgccaatc aaataa 696

<210> 45

<211> 1125

35 <212> DNA

<213> Streptococcus pneumoniae

<400> 45

atgagaaata tggctttgac agcagggtatc gttgggtttgc caaacgttgg taaatcaaca 60
 40 ctatttaatg caattacaaa agcaggagca gaggcagcaa actaccatt tgcgactatt 120
 gatccaaatg ttggaatggt ggaagatcca gatgaacgcc tacaaaaact aactgaaatg 180
 ataactccta aaaagacagt tcccacaaca ttggaattta cggatattgc agggattgta 240
 aaaggagctt caaaaggaga agggctaggg aataaattct tggccaatat tctgaaagta 300
 gatgcgattg ttcacgtagt tctgtctttt gatgatgaaa atgtgatgag cgagcaagga 360
 45 cgtgaagacg cctttgtaga tccacttgca gatattgata caattaatct ggaattaatt 420
 cttgctgact tagaatcagt gaacaaacga tatgcgcgtg tagaaaagat ggcacgtacg 480
 caaaaagata aagaatcagt agcagaattc aatgttcttc aaaagattaa accagtctta 540
 gaagacggga aatcagctcg taccattgaa tttacagatg aggaacaaaa ggttgtcaaa 600
 ggtcttttcc ttttgacgac taaaccagtt ctttatgtag ctaatgtgga cgaggatgtg 660
 50 gtttcagaac ctgactctat cgactatgtc aaacaaattc gtgaatttgc agcgacagaa 720
 aatgctgaag tagtcgttat ttctgcgcgt gctgaggaag aaatttctga attggatgat 780
 gaagataaaa aagagtttct tgaagccatt ggtttgacag aatcagggtg agataagttg 840
 acgcgtgcag cttaccactt gcttggattg ggaacttact tcacagctgg tgaaaaagaa 900
 gttcgcgctt ggaactttcaa acgtggtatg aagctcctc aagcagctgg tattatccac 960
 55 tcagactttg aaaaaggctt tattegtgca gtaaccatgt catatgaaga tctagtgaaa 1020
 tacggatctg aaaaggccgt aaaagaagct ggacgcttgc gtgaagaagg aaaagaatat 1080
 atcgttcaag atggcgatat catggaattc cgctttaatg tctaa 1125

- <210> 46
 <211> 333
 <212> DNA
 5 <213> *Streptococcus pneumoniae*

 <400> 46
 atggaaatcg aaaaaaccaa tcgtatgaat gcgctctttg aattttatgc ggcgcttttg 60
 acagataagc aatgaatta tatagagctt tactacgctg atgattacag tcttgctgag 120
 10 atagctgagg agtttggtgt tagtcgtcag gctgtctatg acaatatcaa gcgaacagaa 180
 aagattctgg aagattatga gatgaaattg cacatgtact cggactacat tgtccgtagt 240
 cagatttttg accaaatctt ggagcgctat cccaaggatg attttctgca ggagcagata 300
 gaaattttta caagcattga taatagagaa taa 333

 15 <210> 47
 <211> 672
 <212> DNA
 <213> *Streptococcus pneumoniae*

 20 <400> 47
 atgaccttag aatgggaaga atttctagat ccttacattc aagctgttgg tgagttaaag 60
 attaaacttc gtggtattcg taagcaatat cgtaagcaaa ataagcattc tccaattgag 120
 tttgtgaccg gtcgagtcaa gccaattgag agcatcaaa aaaaaatggc tcgtcgtggc 180
 25 attacttatg cgaccttga acacgatttg caggatattg ctggcttacg tgtgatggtt 240
 cagttttag atgacgtcaa ggaagtagtg gatattttgc acaagcgtca ggatatgcga 300
 atcatacagg agcgagatta cattactcat agaaaagcat caggctatcg ttcctatcat 360
 gtggtagtag aatatacggg tgataccatc aatggagcta agactatttt ggcagaaatt 420
 caaattcgta ctttgcccat gaatttctgg gcaacgatag aacattctct caactacaag 480
 30 taccaagggg atttcccaga tgagattaag aagcgactgg aaattacagc tagaatcgcc 540
 catcagttgg atgaagaaat gggtgaaatt cgtgatgata tccaagaagc ccaggcactt 600
 tttgatcctt tgagtagaaa attaatgac ggtgtaggaa acagtgcga tacagatgaa 660
 gaatacaggt aa 672

 35 <210> 48
 <211> 588
 <212> DNA
 <213> *Streptococcus pneumoniae*

 40 <400> 48
 atggaactta atacacaaa tgctgaaatc ttgctcagtg cagctaataa gtcccactat 60
 ccgcaggatg aactgccaga gattgcccta gcaggcggtt caaatgttgg taaatccagc 120
 tttatcaaca ctatgttgaa ccgtaagaat ctgcgtcgta catcaggaaa acctggtaaa 180
 acccagctcc tgaacttttt taacattgat gacaagatgc gctttgtgga tgtgcctggg 240
 45 tatggctatg ctcggttttc taaaaaggaa cgtgaaaagt ggggggtgcat gattgaggag 300
 tacttaacga ctcgggaaaa tctccgtgcg gttgtcagtc tagttgacct tcgtcatgac 360
 ccgtcagcag atgatgtgca gatgtacgaa tttctcaagt attatgagat tccagtcac 420
 attgtggcga ccaaggcgga caagattcct cgtggtaaat ggaacaagca tgaatcagca 480
 atcaaaaaga aattaaactt tgaccgaagt gacgatttca tcctcttttc atctgtcagc 540
 50 aaggcaggga tggatgaggc ttgggatgca atcttagaaa aattgtga 588

 <210> 49
 <211> 294
 <212> DNA
 <213> *Streptococcus pneumoniae*

 55 <400> 49
 atgaaaacaa gaaaaatccc tttgcgcaag tctgttgtgt ctaacgaagt gattgataag 60

cgtgatttgc tccgcattgt taagaacaag gaaggacaag tctttattga tcttacgggc 120
 aaggccaatg gccgcggcgc ttatatcaaa ctagacaatg cagaagccct agaggcgaaa 180
 aagaagaagg tctttaaccg cagcttttagc atggaagtgg aagaagcctt ttatgacgag 240
 ttgatcgctt atgtggatca caaagtgaag agaagagagt tgggacttga ataa 294
 5
 <210> 50
 <211> 312
 <212> DNA
 <213> Streptococcus pneumoniae
 10
 <400> 50
 atgttaaaac cctctattga taccttgctc gacaagggtc cttcaaaata ttcactcgta 60
 atcttgaag caaaacgtgc ccacgaattg gaagcaggtg cccagcaac tcaagggttc 120
 aagtctgaaa aatcaactct tcgcgtttta gaagaaatcg aatcaggaaa cggtacaatt 180
 15 caccagatc cagaaggaaa acgtgaagca gtgcgtcgcc gtatcgaaga agaaaaacgc 240
 cgcaaagaag aagaagaaaa gaaatcaaa gagcaaatg ctaaagaaaa agaagatggt 300
 gaaaaaattt aa 312
 <210> 51
 20 <211> 312
 <212> DNA
 <213> Streptococcus pneumoniae
 <400> 51
 25 atgtcattaa catcaaaaca acgtgccttc ctcaacagcc aggcacacac cctcaaacct 60
 atcatccaaa tcgggaaaaa tggactcaac gaccaaatac aaaccagcgt ccgtcaagct 120
 ctctgatcgc gtgaattaat caaggttact ctcttacaaa acacagatga aaacatccac 180
 gaagtagctg aaattttga agaagaaatc ggtgtggata cagtccaaaa aataggacgc 240
 atcttgattt tgttttaaca atctagcaag aaagaaaatc gcaagatttc taagaaagtc 300
 30 aaagaaatct aa 312
 <210> 52
 <211> 528
 <212> DNA
 35 <213> Streptococcus pneumoniae
 <400> 52
 atggcgattg aaaattatat accagatttt gctgtggaag cagtctatga tctgacagtc 60
 ccaagcctgc aggcgcaggg aatcaaggct gttttggctg atttgataa taccctcatt 120
 40 gcttgaaca accctgatgg aacgccagag atgaagcaat ggctacatga ccttcgggac 180
 gcgggtattg gcattatcgt agtgtaaat aacacaaaa aacgcgttca acgagcagtt 240
 gagaaatttg ggattgatta cgtttactgg gccttgaagc ccttcacatt tggattgac 300
 cgtgctatga aggaattcca ctatgacaaa aaggaagtgg tcatgggttg tgaccagctc 360
 atgacagata tacgagcagc ccaccgtgca gggattcggg caattttagt caaaccttg 420
 45 gtccaacatg actcaatcaa aacgcagatt aaccgaactc gtgagcgtcg tggtatgaga 480
 aaaatcactg aaaagtacgg accgattaca tataaaaaag gaatttaa 528
 <210> 53
 <211> 1368
 50 <212> DNA
 <213> Streptococcus pneumoniae
 <400> 53
 atgtttcgaa aaattttaat tgccaatcgt ggtgaaattg cggttcgtat tatccgtgcg 60
 55 gcacgtgaat tggggattgc gacggtagcg gtttattcaa ctgctgataa ggaagctctt 120
 catacgctgt tggcagatga agcagtttct attggtcctg gcaaggcaac agagtcttat 180
 ctcaatatta atgcagttct atcagctgca gtcttgactg aggcagaagc tattcaccct 240

```

ggttttgat ttctcagtga aaattccaaa ttgcgacca tgtgtgaaga aataggtatc 300
aagtttatcg gtccatctgg tcatgttatg gatatgatgg gggataaaat caatgcgcgt 360
gctcagatga ttaaagcagg tgtgcctggt ataccaggtt cagatggaga agtgcataac 420
tctgaagaag ctttgattgt tgctgaaaaa attggctatc ctgttatgct caaggcttca 480
5 gcaggtggag gtggtaaagg gattcgtaag gttgaaaaac cagatgacct cgtttctgcc 540
tttgaactg cctctagtga ggccaaggcc aattatggca atgggtgcat gtacatagaa 600
cgggttatct atccagctcg gcacattgag gttcaaatcc taggtgatga gcatggacat 660
gtgattcaact tgggtgaacg ggattgttct cttcaaagga ataaccaaaa ggttttgaa 720
gaaagtccct cgattgcaat cggaaaaacg ctgcgtcatg aaatagggtc tgctgctgtt 780
10 cgagcggcag agtttgttgg ctatgagaat gcaggaacca ttgaatttct tcttgatgaa 840
gcaagtagca atttctatct catggagatg aatactcgtg ttcaggtaga acatccagta 900
acagagtttg tttcaggtgt tgatatcgtt aaggaacaga tttgcattgc ggcaggtcag 960
cctttgtctg ttaagcaaga agatattgtc ctacgcggtc atgccatcga gtgtcgtatc 1020
aatgcagaaa acccagcctt taactttgct ccaagtccag gtaagattac taatctctat 1080
15 ctgccaagtg gtggagttgg cttgcgcgtg gattcagcag tttatccagg ttataccatt 1140
ccgccttatt atgatagtat gattgccaaa atcatagtac acggcgaaaa tcgttttgac 1200
gccttgatga aaatgcaacg tgccctctat gaattagaaa ttgaaggagt gcagaccaat 1260
gcagatttcc agcttgacct catttcagat cgcaatgtca ttgctgggga ttatgatact 1320
tgcttcttga tggaaacctt cttacctaaa tatcaagaaa aagaataa 1368
20
<210> 54
<211> 234
<212> DNA
<213> Streptococcus pneumoniae
25
<400> 54
atgatttaca aagtttttta tcaagaaaca aaagaacgta gcccacgccg tgaaacaaca 60
cgcgcgcttt acctagacat cgataccagc tcagaacttg agggccgtat cactgctcgc 120
caacttgtcg aagaaaatcg cccagagtac aatatcgaat atatcgaact cttgtctgac 180
30 aaattgctcg attacgaaaa agaaactggc gccttcgaaa ttacggagtt ctaa 234
<210> 55
<211> 1011
<212> DNA
35 <213> Streptococcus pneumoniae
<400> 55
atgaaggata gatatatattt agcatttgag acatcctgtg atgagaccag tgtcgcgctc 60
ttgaaaaaac acgatgagct cttgtccaat gtcattgcta gtcaaattga gagtacaaa 120
40 cgttttggtg gcgtagtgc cgaagtagcc agtcgtcacc atgtcgaggt cattacagcc 180
tgtatcgagg aggcattggc agaagcaggg attaccgaag aggacgtgac agctgttgcg 240
gttacctacg gaccaggctt ggtcggagcc ttgctagtgt gtttgtcagc tgccaaggcc 300
tttgcttggg ctacaggact tccactgatt cctgttaatc acatggctgg gcacctcatg 360
gcagctcaga gtgtggagcc tttggagttt cccttgctag ccctcttggg cagcggcgga 420
45 cacacagagt tgggtctatgt ttctgaggct ggcgattaca agattgttgg ggagacacga 480
gatgacgcgg ttggcgaggg ctatgataag gtcggccgtg tcatgggctt gacctatcct 540
gcaggtcgtg agattgacga gctggctcat caggggcagg atatttatga tttccccctg 600
gccatgatta aggaagataa tctggagttt tcatttctctg gtttgaagtc agcctttatc 660
aatcttcatc acaatgccga gcaaaaggga gaaagcctgt ctacagaaga tttgtgtgct 720
50 tcttccaag cagcagttat ggacattctc atggcaaaaa ccaagaaggc tttggaggaa 780
tatcctgtta aaacctatt tgtggcaggt ggtgtggcag ccaataaagg tctcagagaa 840
cgcttagcag ccgaaatcac agatgtcaag gttatcatcc cccctctgcg actctgcgga 900
gacaatgcag gtatgattgc ctatgccagc gtcagcgagt ggaacaaaga aaacttcgca 960
ggctgggacc tcaatgccaa accaagtctt gcctttgata ccatggaata a 1011
55
<210> 56
<211> 1809

```

<212> DNA

213> Streptococcus pneumoniae

<400> 56

```

5 atgtgtggaa ttgttgggtg ttgttggaaac acaaatgcaa ctgatatttt gattcaaggg 60
  cttgaaaagc ttgaataaccg tggctatgat tctgcgggaa tttttgtcct agatgggtgct 120
    gataaccatt tggatgaaggc ggttggctgt attgcagaat tgtctgccaa gacagctgggt 180
      gttgagggaa caactgggtat cggacatact cgttgggcta ctacaggaaa accaactgag 240
        gacaatgctc acccacaccg ctctgagaca gaacgttttg tcttgggtgca taatgggggtg 300
          attgagaact atcttgaaat caaggaagaa taccttgagc gtcaccactt caagggggcag 360
            acagatactg aaatagccgt tcatttgatt ggaaaatttg cggaagaaga agggctctca 420
              gttcttgaag cctttaaaaa agctcttcat attatccgtg gttcatatgc ctttgccttg 480
                attgactctg aaaatccaga tgtcatctat gtacgaaaaa acaaatctcc acttttgatt 540
                  ggtcttgggg aaggctacaa tatggtctgc tcagatgcta tggctatgat tcgtgaaacc 600
                    aaccaatata tggaaattca tgaccaagag ttggtaatcg tcaaggctga tagcgtggaa 660
                      gttcaagact atgatggtaa cagtcgtgaa cgtgctagct atactgcgga acttgacttg 720
                        tcagatatcg gtaagggaac ttatccttac tacatgctta aggaaattga tgagcaacca 780
                          actgttatgc gtaaaactcat tcaagcctac acggatgatg ctgggtcaagt agtgggtgct 840
                            cctgctatca ttaaggctgt tcaagacgca gaccgcatct acatccttgc agctggaaca 900
                              20 tcttaccatg caggatttgc ttctaagaaa atgttggaa aattgacaga tacaccagt 960
                                gaacttgaa tctcatctga gtggggctac ggtatgccac ttctcagcaa gaaaccactc 1020
                                  ttcatttcta tcagccaatc tggatgaaca gcggatagtc gtcaagtttt ggtcaaggct 1080
                                    aatgaaatgg gaattccaag cttaacagtg acaaatgttc caggttcaac cctctcacgt 1140
                                      gaagccaact ataccatgct ctttcacgca ggacctgaaa ttgccgtggc atcaactaaa 1200
                                        25 gcctatacag cgcaaatcg agcccttgcc ttcttgcaa aagcagtcgg agaagcaaat 1260
                                          ggtaatgcta aagcgcaagc ctttgacctg gttcatgaat tgtcaatcgt agctcagct 1320
                                            attgaatcaa ctctttcaga gaaagaaacc attgaagcca aggttcgtga acttcttgaa 1380
                                              acaactcgta acgcctttta catcggaagt ggtcaagatt actacgtagc catggaagca 1440
                                                agtctcaaac tcaagagat ttcttatatc cagtgtgaag gttttgcggc aggagaactc 1500
                                                  30 aagcacggaa ccattgcctt gattgaagaa ggaacgcctg ttttggtctt cttgtcagat 1560
                                                    ccagttcttg ccaaccatac tcgtggaaat atccaagagg tcgcagcccg tggtgccaaa 1620
                                                      gtctcacta tcgcagaaga gaatgtagcc aaagataccg acgatatcgt ccttacgacc 1680
                                                        gtacatccat acctctcacc aatttcaatg gtctgaccaa cgcaattagt cgcttacttt 1740
                                                          35 gcaaccctcc accgtggcct cgatgtggac aaaccaagta accttgccaa gtcagtaacg 1800
                                                            gtagaataa 1809

```

<210> 57

<211> 723

<212> DNA

40 <213> Streptococcus pneumoniae

<400> 57

```

atgatacgta tcgaaaatct cagtgtctcc taaaagaaa cgttggcact taaggatatt 60
45 tcactagtgc tccatggacc aacaattacc ggcattcttg gtccaaacgg cgctgggaaa 120
  tcaacactat taaaaggatg gctgggaatt atcccacatc aaggtcaggc atttctcgat 180
    gacaaggaag ttaaaaaatc cttacaccga attgcctatg tcgaacaaaa aatcaatatc 240
      gactacaact ttcccatcaa ggtcaaggaa tgcgtctcgt taggactatt tccctctatt 300
        cctctctttc gaagttttaa ggctaaacat tggaagaaag tgcaagaggc cttgaaatc 360
          gtcggcctag ctgactacgc tgaacgtcaa attagtcaac tgtctggagg tcaattccag 420
            cgggtcttga ttgceagatg tttgggtgag gaagccgact atatcctctt ggatgaacct 480
              tttgctggga ttgactctgt cagtggaggaa atcatcatga atacgtgag agatttgaaa 540
                aaagctggga agacggttct catcgttcac cagcactca gcaagattcc ccactacttc 600
                  gatcaagtct tacttgtaa tcgagaagtg attgcctttg gtccaacaaa agaaaactttt 660
                    accgaaacca atctaaaaga agcttacggt aatcaactct ttttcaatgg aggtgacct 720
                      55 tga 723

```

<210> 58

<211> 2223
 <212> DNA
 <213> Streptococcus pneumoniae

5 <400> 58
 atgccgaaag aagtgaattt aacaggcgaa gaagttgtcg ctttaaccaa agaataattta 60
 acggaagagg atgttcattt tgtccataag gccttggctt atgctgttga atgccacagt 120
 ggtcaatata gcaaatcagg cgagccttat atcattcacc ctatccaagt ggcaggtatt 180
 ttagctaagc taaagctgga tgctgtaaca gtagcttgtg gattcttgca tgatgtggtg 240
 10 gaagatacag atgcgacctt ggacgatttg gaaagagagt ttggctcctga tgtgcgggtg 300
 attgttgacg gagttaccaa gcttggcaag gtcgagtaca aatcgatcga ggagcaatta 360
 gcggaaaatc atcgcaagat gctcatggcc atgtctgagg acatccgctg tattttgggtc 420
 aaactgtctg accgcttgca caatatgcgg accctgaaac atcttcgaaa agacaagcag 480
 gagcgtattt ccaaagaaac catggaaatc tatgccccac ttgcccacgt tttggggatt 540
 15 tccagtgtca aatgggaatt agaagacttg tctttcgtt atctcaatcc aacggagttt 600
 tacaagatta cccatatgat gaaggaaaag cgcagggagc gtgaggcctt ggtggatgag 660
 gtagtcacaa aattagagga gtatacgaca gaacgtcact tgaaagggaa gatttatggt 720
 cgtcccaagc atatttactc aattttccgc aaaatgcagg acaagagaaa acggtttgag 780
 gaaatctatg atctgattgc tattcgttgt attttagata cccaaagtga tgtttatgcc 840
 20 atgcttgggt acgtgcatga attttgaaa ccgatgccag gtcgcttcaa agactatatt 900
 gccaacgcga aggccaatgg ttatcagtct atccatacga ctgtttatgg accaaaagg 960
 ccgattgaat tccagattcg aaccaaggaa atgcacgagg ttgctgagta cgggggttgcg 1020
 gctcactggg cttataagaa aggtataaag gggcaagtta acagcaagga atcagctatt 1080
 ggaatgaact ggatcaagga gatgatggag ctccaagacc aggcgtgatga tgctaaggaa 1140
 25 tttgtggact ctgttaagga aaactatctg gctgaggaga ttacggtttt taccacagat 1200
 ggagctgtcc gttcccttcc caaagattca ggaccgattg attttgctta cgaaatccat 1260
 accaaggtcg gtgaaaaagc aactggtgcc aaggtcaatg gccgcatggt tccactgaca 1320
 accaagttaa agacagggga tcaggttgaa attatcgcca acccgaactc ctttgacct 1380
 agccgtgact ggctcaatat ggtcaagact agcaaggcgc gcaataagat tcgccagttc 1440
 30 tttaaaaacc aagataagga attgtctgtc aacaagggtc gtgagatgct gatggctcag 1500
 ttccaagaaa atggctatgt ggcaataaaa tttatggaca agcgccacat ggatcaagtt 1560
 ctgcaaaaaga ccagttacaa gacagaagac tcctcttttg cggccatttg ttttggggaa 1620
 atcgtgtcga ttaccgtctt taaccgtctg actgaaaagg aacgccgtga ggaagagcgt 1680
 gccaaaggcca aggcgtgaggc agaggagctt tccaaagggt gcgagggtcaa ggttgaaaat 1740
 35 aaagaaactc tcaagggtcaa gcatgagggg ggagtgggta ttgaagggtc ttctggtctc 1800
 ctagtgcgga ttgctaagtg ttgtaacccc gtgcctgggt acgatattgt tggctacatt 1860
 accaagggtc gtggtgtggc tattcaacct gtggactgta tgaacctgcg tgcccaagaa 1920
 aactacgagc aacgtctcct tgatgtggaa tgggaagacc agtactctag ctcaaataag 1980
 gagtatctgg cccatatcga tatctacggt ctcaaccgta caggactgtt gaacgatgta 2040
 40 ctgcaagttc tttcaaatac aaccaagaat atttcaacgg tcaatgccca accaaccaag 2100
 gatatgaagt ttgctaatat ccatgtgtcc ttcggtattg ccaacctctc tacactgacc 2160
 acggttgtcg ataaaattaa gagtgtgccg gaagtttact ctgtcaaacg gaccaacggc 2220
 tag 2223

45 <210> 59
 <211> 1479
 <212> DNA
 <213> Streptococcus pneumoniae

50 <400> 59
 atgtctaatt gggacactaa atttttgaaa aaaggtttta cttttgatga tgtattgctt 60
 attccagctg aaagtcattg gttgcctaac gatgcagatt taacaactaa attggcagat 120
 aatttgactt taaatatccc aattattacc gctgccatgg acacagttac agagagtcaa 180
 atggccattg ctattgctcg tgcaggcggg ctccgagttt tccataaaaa catgtcaatt 240
 55 gctcaacaag cagacgaggt tcgtaaggta aaacgttctg aaaatggagt tattattgat 300
 ccgttcttct tgacgcctga acatacaatt gctgaagcag atgagcttat gggtcggtac 360
 cgcacagctg gtgttccagt tgttgaaaca cttgaaaatc gtaaatgggt tgggtttttg 420

acaaaccgag atcttcggtt tatttcagat tataatcaac caatttcaaa ccatatgact 480
 agtgaataatc ttgttactgc tcctgtgggt acggatcttg caacggctga gagtattctt 540
 caagagcatc gtattgaaaa acttccggtt gtcgatgaag aaggcagttt ttctggtttg 600
 atcactatca aagatattga aaaagttatt gagtttccaa atgcggctaa agatgagttt 660
 5 ggtcgtcttc tagttgcagg tgcagtaggt gttacttcag atacatttga acgtgcagag 720
 gctctttttg aggcaggagc ggatgcgatt gttattgata ctgcacatgg tcattctgca 780
 ggtgtcttgc gtaaaattgc cgagattcgt gctcatttcc cagatcggac tttgattgct 840
 ggaaatattg ctactgctga aggtgcacgt gccctttatg aagcgggtgt agacgttggt 900
 aaggttggtg ttggaccagg ttctatctgt actactcgtg tgattgctgg tgttggtggt 960
 10 ccgcaagtaa cagctatcta cgtgctgca gctgttgcgc gcgaatatgg taaaacgatt 1020
 attgctgacg gtgggatcaa gtattctgga gatattgtaa aagcacttgc tgcaggtgga 1080
 aatgctgtta tcttggatc tatgtttgct ggaactgatg aagctccagg cgaaactgaa 1140
 atcttccaag gacgtaaatt caagacttac cgtggtatgg gatcaattgc tgctatgaag 1200
 aaaggttcaa gcgaccgtta tttccaaggt tctgtcaatg aagcaaaaaa gcttgttcca 1260
 15 gaaggaattg aaggtcgtgt tgcttataaa ggagcggcag ctgatattgt tttccaaatg 1320
 attggtggtg ttcgctctgg tatgggttac tgtgtgcag ctaaccttaa agaactacac 1380
 gataatgctc aatttattga aatgtctggt gctggtttga aagaaagcca tctcatgat 1440
 gtgcaaatga ctaatgaggc accaaattat tctatgtaa 1479

20 <210> 60
 <211> 1947
 <212> DNA
 <213> Streptococcus pneumoniae

25 <400> 60
 atgacagaag aaatcaaaaa tctgcaggca caggattatg atgccagtca aattcaagtt 60
 ttagagggtc tagaggctgt tcgtatgcgt ccagggatgt acattggatc aacctcaaaa 120
 gaaggtcttc accatctagt ctgggaaatt gttgataact caattgacga ggccttggca 180
 30 ggatttgcca gccatattca agtttttatt gagccagatg attcgattac tgttgtggat 240
 gatgggcgtg gtatcccagt cgatattcag gaaaaaacag gccgtcctgc tgttgagacc 300
 gtctttacag tccttcacgc tggaggaaag ttccggcgggtg gtggatacaa ggtttcaggt 360
 ggtcttcacg ggggtgggtc gtcagtagtt aatgcccttt ccaactcaatt agacgttcat 420
 gttcacaaaa atggtgaagt tcattaccaa gaataccgtc gtggtcatgt tgtcgcagat 480
 cttgaaatag ttggagatac ggataaaaaca ggaacaactg ttcacttcac accggacca 540
 35 aaaatcttca ctgaacaac aatctttgat tttgataaat taaataaacg gattcaagag 600
 ttggcctttc taaatcgcg tcttcaaatt tcaattacag ataagcgcca aggtttggaa 660
 caaaccaagc attatcatta tgaagggtgg attgctagt acgttgaata tatcaacgag 720
 aacaaggatg taatctttga tacaccaatc tatacagacg gtgagatgga tgatatcaca 780
 gttgaggtag ccatgcagta cacaactggt taccatgaaa atgtcatgag tttcgccaat 840
 40 aatattcata cacatgaagg tgaacgcag gaacaagggt tccgtacagc cttgacacgt 900
 gttatcaatg attatgctcg taaaaataag ttactgaaag acaatgaaga caacctaa 960
 ggggaagatg ttccggaagg cttaactgca gttatctcag ttaaaccacc aaatccacag 1020
 ttgaaggac aaaccaagac caaattggga aatagcgaag tggtaagat taccaatcgc 1080
 ctcttcagtg aagccttctc cgatttcctc atggaaaatc cacagattgc caaacgtatc 1140
 45 gtggaaaaag ggattttagc tgccaaggct cgtgtggctg ccaagcgtgc gcgtgaagtc 1200
 acacgtaaaa aatctggttt ggaaatttcc aaccttcag ggaaactagc agactgttct 1260
 tctaataacc ctgctgaaac agaactcttc atcgtcgaag gagactcagc tgggtgatca 1320
 gccaaatctg gtcgtaaccg tgagtttcag gctatccttc caattcgcgg taagattttg 1380
 aacgttgaaa aagcaagtat ggataagatt ctagctaacc aagaaattcg tagtcttttc 1440
 50 acagccatgg gaacaggatt tggcgcagaa tttgatgttt cgaaagcccg ttaccaaaaa 1500
 ctggttttga tgaccgatgc cgatgtcgat ggagcccaca ttcgtacctt tcttttaacc 1560
 ttgatttatc gttatatgaa accaatccta gaagctggtt atgtttatat tgcccaacca 1620
 ccaatctatg gtgtcaaggt tggagcgag attaaagaat atatccagcc gggtgcagat 1680
 caagaaatca aactccaaga agctttagcc cgttatagtg aaggtcgtac caaacccact 1740
 55 attcagcgtt ataaggggct aggtgaaatg gacgatcatc agctgtggga aacaacctat 1800
 gatcccgaac atcgtttgat ggctagagtt tctgtagatg atgctgcaga agcagataaa 1860
 atctttgata tgttgatggg ggatcgagta gagcctcgtc gtgagtttat cgaagaaaat 1920

gctgtctata gtacacttga tgtctaa

1947

<210> 61

<211> 267

5 <212> DNA

<213> Streptococcus pneumoniae

<400> 61

10 atgggattta ctgaagaaac agtacgtttt aaattggacg attccaataa aaaagaaatt 60
 agcgaaactt tgacagatgt ttatgcttcg ttgaacgata agggttacaa cccaattaac 120
 caaatcgtag gttacgtatt gagtggagac cctgcctacg ttcctcgta taataatgca 180
 cgaaatcaaa cccgtaagta tgagcgtgat gaaatcggtg aggaattggt tcgctactac 240
 ctcaaaggac aaggagtcga tctataa 267

15 <210> 62

<211> 597

<212> DNA

<213> Streptococcus pneumoniae

20 <400> 62.

atgggtcaact atccacataa agtttcatca caaaaaagac aaacatctct ttctcaaccc 60
 aaaaatttcg caaatcgagg aatgtctttt gaaaagatga tcaatgctac caacgactac 120
 tatttgtctc agggcttggc tgttatacat aagaaaccaa ctctatttca aatcgtaaca 180
 gtggactatc cacaacgaag tcgtgccaag attgttgaag cctattttcg acaagcttca 240
 25 acgacggact attctggcgt ttataatgga tattacatcg actttgaagt caaggaaaca 300
 aaacaaaaac gtgcgattcc gatgaaaaat ttcatccac atcagattca gcatatggaa 360
 caagtccttg cccaacaagg aatctgcttt gtccttcttc acttttcttc tcagcaagaa 420
 acctacttat tgccggcatt cgatttgatt gccttctatc atcaagataa gggacaaaaa 480
 tcaatgccac ttgaatatat tcgagaatat ggatatgaaa tcaaggctgg tgccttcctt 540
 30 caaatctcctt atctcaatgt tatcaaagaa catttattag gtggtaaaac aagatga 597

<210> 63

<211> 867

<212> DNA

35 <213> Streptococcus pneumoniae

<400> 63

atggctctat ttagtaaaaa agataagtat attcgaatca atcccaatcg ttcgggttagg 60
 gaaaaacctc aagctaagcc agaggttcca gatgaattat ttcccagtg tccaggctgt 120
 40 aagcatacca tctatcagaa ggatctggga agtgaacgta tctgtccgca ctgtagctat 180
 acctttcgta tttctgcca agaacgcttg gctttgacga ttgatattgg aaccttcaaa 240
 gaattgttta cagggattga aagcaaggat cccttgcat tccctgggta ccaaaagaaa 300
 ctggcatcta tgcgtgaaaa aacaggctcg catgaagccg ttgtgacagg aactgctctt 360
 attaaaggtc agactgtggc tcttgggatt atggattcta actttatcat ggcttctatg 420
 45 ggtacggttg taggtgaaaa aatcactcgt ttgtttgagt atgcgactgt cgaaaaattg 480
 ccagttgtcc tattcacagc ctctgggtga gcccgatgc aggaaggaat catgagtctc 540
 atgcagatgg ctaagatctc tgcggcggtt aaacgccatt caaatgctgg tctcttttac 600
 ctgaccattt tgacagatcc aacgactggt ggtgtgacag cttctttcgc tatggaaggc 660
 gatatcattc tggtgaacc acagagcttg gttggttttg ctggacgtcg tgtgattgaa 720
 50 aatacggttc gtgaaagctt gcctgaggat ttccaaaagg cagaattcct attagaacat 780
 ggctttgtgg atgctattgt caaaagaaga gacttaccag atacgattgc tagcctagtc 840
 agattgcatg gagggagtcc tagatga 867

<210> 64

55 <211> 420

<212> DNA

<213> Streptococcus pneumoniae

<400> 64
 atgagaatta tgggattgga cgtcggttca aaaacggtag ggggtggcgat tagcgatccg 60
 5 cttgggtttta cagctcaagg gcttgaaatc atccagataa atgaagaaca aggccaattt 120
 ggttctgacc gcgttaagga attggttgat acttacaagg tggaacgatt tgtagtgggc 180
 ttgcctaaaa acatgaacaa tacaagtga cgcgcgtag aagctagtca agcatacga 240
 gcaaagctag aagagttttt tggtttacca gtagactatc aggatgaacg cttgacaaca 300
 gtggctgctg agcgcgatgtt gattgaacaa gcagatatca gtcgcaataa gcgcaagaaa 360
 10 gtcattgata agttagcagc tcagctgatt ttacaaaatt atttagatag aaaattttta 420

 <210> 65
 <211> 1197
 <212> DNA
 <213> Streptococcus pneumoniae
 15
 <400> 65
 atggcaaaac ttactgttaa agacgttgac ttgaaaggta aaaaagtcct cgttcgtgtt 60
 gacttcaaoc taccattgaa agatggcgta atcactaacg ataaccgtat cacagcagct 120
 20 cttccaacta ttaagtacat catcgaacaa ggtggacgtg caattctttt ctctcacctt 180
 ggacgtgtga aagaagaagc tgataaagct ggtaaatcac ttgctcctgt agcagcagac 240
 ttggcagcaa aacttgggtc agatgttgtt ttcccagggt tccactcgtg tgctgaattg 300
 gaagcggcaa tcaacgctct tgaagatgga caagttctct tggttgaaaa cactcgttac 360
 gaagatgttg acggcaagaa agaactctaa aacgatcctg aacttggtta atactgggca 420
 tcacttggag atggtatctt cgtaaacgat gcattcggta cagctcaccg tgcacacgca 480
 25 tctaacgttg gtatctcagc aaacgttgaa aaagcagttg ctggtttcct tcttgaaaac 540
 gaaattgcct acatccaaga agcagttgaa attccagaac gtccattcgt ggctatcctt 600
 ggtggttcaa aagtttcaga caagatcggg gttatcgaaa acttgcttga aaaagctgat 660
 aaagtcctta tcgggtggtg gatgacttac acattctaca aagcacaagg tatcgaaatc 720
 ggtaactcac ttgtagaaga agacaaattg gatgttgcca aagctcttct tgaaaaagca 780
 30 aatggtaaat tgatcttgcc agttgactca aaagaagcta acgcatttgc tggttacact 840
 gaagtgcgtg acactgaagg tgaagcagtt tctgaaggct tccttgggtc tgacatcggg 900
 ccaaaatcta tcgccaaatt tgacgaagct ttgactggtg ccaaaacagt tgtatggaac 960
 ggacctatgg gtgtatttga aaaccagat ttccaagctg gtacaatcgg tgtgatggac 1020
 gctatcgtga aacaaccagg agttaaatca atcatcggtg gtggtgactc agctgccgca 1080
 35 gcgattaacc ttggccgtgc agacaagttc tcatggatta gtacgggtgg tggagcatca 1140
 atggaacttc ttgaaggtaa ggttcttcca caacttgcag ccttgacaga aaaataa 1197

 <210> 66
 <211> 498
 <212> DNA
 <213> Streptococcus pneumoniae
 40
 <400> 66
 atgttaaaat cagaaaaaca atcacgttat caaatgttaa atgaagaatt gtccttccta 60
 45 ttggaaggcg aaaccaatgt tttggcta atcttccaac ccagtgtctc cataaaatca 120
 cgttttccta ataccgtatt tgcaggcttt tatttggtcg atggaaagga attggtttta 180
 ggcccttcc aaggaggtgt ttctgcac cgtattgcac taggcaaggg tgtttgtgg 240
 gaggcagtc actttcagga aactgttatt gttggagatg tgacgaccta tctcaactat 300
 atttcttg atagtctagc taaaagtga attgtggtgc cgatgatgaa gaatggtcag 360
 50 ttacttggag ttctggatct ggattcttca gagattgagg attacgatgc tatggatcga 420
 gattatttgg aacaatttgt cgctattttg cttgaaaaga cagcatggga ctttacgatg 480
 ttgaggaaa aatcttaa 498

 <210> 67
 <211> 630
 <212> DNA
 <213> Streptococcus pneumoniae
 55

<400> 67
 atgacaatcg aactattgac tccctttacc aaggtagagt tggagccaga aatcaaggag 60
 5 aaaaaacgca aacaagttgg gatttttaggg gggaatttta accctgttca caatgcccat 120
 ctcatgttg cggatcaagt acggcaacag ttgggactgg atcaagttct gctcatgcct 180
 gaataccaac ctctcacgt tgataaaaag gaaaccatcc ctgaacacca tgcgtctcaag 240
 atgcttgagt tggcaattga gggaattgac ggcctagtca ttgaaacccat tgagttggag 300
 cgcaagggtta tttcctacac ctacgacacc atgaagattt tgacagagaa gaatccagat 360
 10 acggattatt actttatcat cgggtccgac atggttgact atctgcctaa gtggtaccga 420
 attgatgaac tggttgacat ggttcagttt gtgggggttc agcgtccacg ctacaaggta 480
 gggacttcct atccagttat ctgggtggac gtaccgctca tggatatctc gtccagcatg 540
 gtgctgcct tccttgccca aggtcggaac cccaactttc tctacctca gccagtgcta 600
 gactacatcg agaaggagg gctctactga 630

15 <210> 68
 <211> 768
 <212> DNA
 <213> Streptococcus pneumoniae

20 <400> 68
 atgaatattg caaaaatagt cagagaagcg cgtgagcaga gtcgcttgac aaccttggac 60
 tttgcgacag gcatttttga tgaatttatc caattacatg gtgaccgttc tttcgtgat 120
 gatggtgcag ttgttggtgg tattggttgg cttggagacc aagctgtaac agtgggttgg 180
 25 atccaaaaag gcaagagttt gcaagacaac ctcaaacgga attttggcca accacatcca 240
 gaaggctacc gaaaggcact gcggttgatg aaacaggctg agaaatttgg ccgtccagtt 300
 gtgaccttta tcaatacagc aggtgcttat cctggtgtcg gagcggaaga acgtgggtcaa 360
 ggggaagcta ttgctcgcaa tctcatggaa atgagtgaac tgaaagttcc tattatcgcc 420
 attattatcg gtgaagggtg ttcaggcggtg gctctggctc tagctgtcgc ggaccgtgtc 480
 tggatgctgg aaaattctat ctatgccatt ctacgtccag aaggctttgc ttccatttta 540
 30 tgggaaggacg gtactcgcgc catggaagca gcagaactga tgaaaatcac ttgcgatgaa 600
 ctggttagaaa tggacgtggt ggataagggtg atttctgaag taggactttc tagtaaagaa 660
 ctgattaaga gtgtcaaaaa agaactccaa acggagctgg ctagactttc acaaaaaccg 720
 ctagaagagt tgctggaaga acgctatcaa cgatttagaa aataactaa 768

35 <210> 69
 <211> 510
 <212> DNA
 <213> Streptococcus pneumoniae

40 <400> 69
 atgattataa aagtagaaat ggcagatggt gaggtgttgg ctaaaattgc caaacaacc 60
 tttcgtgaaa cttttgcgta tgataatacg gaagagcagt tacaggaata ctttgaagag 120
 gcttatagtc tgaaaacttt gtcaactgag ttgggaaatc ctgactctga aacctatttc 180
 45 attatgcatg aggaggagat agctgggttt ctcaaagtca actggggaag tgctcaaaact 240
 gagagagaat tagaggacgc ttttgaaatt caacgcctct atgtgctaca aaaattccaa 300
 ggatttggac taggtaagca actgtttgaa ttgcgacttg aacttgctac aaaaaatagt 360
 ttttcttggg ctgggctagg tgtttgggag cataatacaa aagctcaagc cttttataat 420
 cgatatggtt ttgaaaaatt tagccaacat cattttatgg ttggtcaaaa agtagatacg 480
 50 gattggttac tgagaaagaa attaaggtaa 510

<210> 70
 <211> 1590
 <212> DNA
 <213> Streptococcus pneumoniae

55 <400> 70
 atgttacggg ggactgcttt gctaaccggt agtaacttta tcagtcgcct actcggggct 60

5 gtttacatta tcccttggtg catctggatg ggggcttatg cagctaaggc aaatggtctc 120
 tttaccatgg gttacactat ctatgcttgg ttcttggttg tttcaacagc ggggattcca 180
 gttgcggtgg ccaagcaagt tgccaagtat aataccatgc gagaagaaga gcatagcttt 240
 gcccgtgatc ggagcttctt aggcctttatg acaggactag gcctggtttt tgctttagtc 300
 ttgtatgtct ttgctccttg gctagcagac ttgtctggcg tgggcaaaga cttgatccca 360
 atcatgcaaa gcttggcttg gggagtcttg attttcccg ctatgagtgt tatccgagga 420
 tttttccaag ggaatgaataa cctcaaacc tatgccatga gccaaattgc tgagcaggtc 480
 attcgtgtta tctggatgct cctagcaacc tttatcatta tgaagctcgg ttcaggagat 540
 10 tatctagcag ccgttaccca atcaaccttt gctgcctttg tcggtatggt agccagtttt 600
 gcagtcttga tttatttcct tgccaagaa agttcactca aaagagtctt tgaacagga 660
 gataagatta acagtaagcg tctcttggtt gataccatta aggaagccat tccttttacc 720
 ctgacagggt ctgccatcca gatcttcagc attttgatc agctgacctt tatcaatagt 780
 atgagctggt ttaccaacta cagcaatgag gacttggttg tcatgttttc ttatttctca 840
 gccaatccca ataaaaacac gatgattttg atttctgtag gggtttcgat tgggagtgtt 900
 15 ggtttgccac ttttgacgga aaactatgtc aagggggact tgaagcggc ttctcgtctc 960
 gttcaggaca gtctcaccct actctttatg ttcttgctac cagcaacggt tggagtgggt 1020
 atggtaggag aacctcttta tacggctctc tatggttaagc cagatagttt ggctctgggc 1080
 ttatttgtct ttgcagtttt gcagctctatt attttaggct tgtacatggt cttgtctcca 1140
 atgcttcagg ccatgttccg caaccgcaag gccgttctct attttatcta tggttctatt 1200
 20 gccaaagctag tcttgcaact acctaccatc gccctcttcc acagttatgg tcctttgatt 1260
 tcaacaacca ttgctctcat cattcctaac gcttgatgt atcgggatat ttgtaaagta 1320
 actggtgtca agcgcaaggt gattttgaag cgaaccattt taatcagttt gctgacccta 1380
 gtcattgttc tgttaatagg aaccatccag tggctgttag gatttttctt ccaaccaagt 1440
 ggacgtttgt ggagcttctt ttatgtagct cttgtcgggt ccatgggggg tggactttat 1500
 25 atggttatga gtctgcgtac ctatttatta gataaggtaa taggaaaagc ccaagcagat 1560
 cgctgcgag caaaatttaa gctttcgtaa 1590

<210> 71

<211> 468

30 <212> DNA

<213> Streptococcus pneumoniae

<400> 71

35 atgtcagata agattggctt attcacaggc tcatttgatc cgatgacaaa tgggcattctg 60
 gatatcattg aacgggagag cagactcttt gataagctct atgtcgggtat tttttttaat 120
 ccccaacaac aaggatttct tcctatcgaa aatcgtaaac gggggctaga aaaggctttg 180
 ggacatctgg aaaatgttga agtcgtggct tctcatgatg aattggtggt cgatgttgca 240
 aaaagattgg gtgctacttg tctagtgcgt ggtttgagga atgcgtcgga tttgcaatat 300
 40 gaagccagtt ttgattacta caatcatcag ctgtcttctg atatagagac tatttattta 360
 catagtgcag ctgaacatct ctatatcagt tcatcaggcg ttagagagct tttgaagttt 420
 ggtcaggata ttgcctgcta tgttcccag agtatttga ggaaataa 468

<210> 72

<211> 432

45 <212> DNA

<213> Streptococcus pneumoniae

<400> 72

50 atgacgattt tgtttgtggt tatcagtget tcctttctgt atatggtttc tcttagcatg 60
 aaaccctatc aaacagctaa aagtgaagga gaaaaattag ctacagcagta tgcaggatta 120
 gagcaggccg atcaggttga tttatacaat ggcttggaa cttattacag cgttcttgggt 180
 cgtaataaac agcaagaagc acttgctggt ctgattggaa aagatgatca taagatttac 240
 gtttatcagc taaatcaggg tgtttcacia gaaaaagcag aaacggtttc taaggaaaag 300
 ggagctggcg aaattgacaa gattatcttt ggtcgttatc aagataagcc aatctgggaa 360
 55 gtcaagtcag gatctgattt ttatctagta gattttgaaa caggagcatt ggtcaacaag 420
 gagggcctat ga 432

<210> 73
 <211> 732
 <212> DNA
 <213> Streptococcus pneumoniae

5

<400> 73
 atgattgata ttcattcgca cattgtcttt gatgtagatg atgggcccaa gtcaagagag 60
 gaaagtaagg ctctcttgac agaagcctac aggcaggggg tgcgaacat tgctcttacc 120
 tctcaccgtc gcaagggcat gtttgaaact ccagaagaga agatagcaga aaactttctt 180
 10 cagggttcggg aaatagctaa ggaagtcgag agtgacttgg tcattgctta tggggctgaa 240
 atttactaca cgccagatgt tttggataag ctggaaaaca atcggtattcc gaccctcaat 300
 aatagtcggt atgccttgat agagttagt atgaacactc cttatcgca tattcatagt 360
 gccttgaata aaatattgat gttgggaatt actccgtca ttgccacat agagcgctat 420
 gatgttcttg aaaataatga aaaacgcgtt cgagagctga tcgatatggg ctgttacacg 480
 15 caaataaata gttcacatgt cctcaaatcc aaactttttg gagaacctta taaattcatg 540
 aaaaaagag cgcagtattt cttggagcgt gatttgggtc atatcattgc aagtgatatg 600
 cataatgtgg acggcagacc ccccatatg gcagaagcat atgacctgt tccccaaaaa 660
 tacggagaag cgaaggctca ggaacttttt atagacaatc ctgaaaaat tgtaatggat 720
 caactaattt ag 732

20

<210> 74
 <211> 927
 <212> DNA
 <213> Streptococcus pneumoniae

25

<400> 74
 atgtctacaa tcgataaaga aaaatttcag tttgtaaaac gtgacgattt tgcctctgaa 60
 actattgatg cgccagcata ttcttactgg aaatcagtgt ttaaacaatt tatgaagaaa 120
 aaatcaactg tagtcatgtt gggaatcttg gtagccatca ttttgataag tttcatctac 180
 30 ccaatgtttt ctaagtgtga tttcaatgat gtcagcaagg taaacgactt tagtggtcgt 240
 tatatcaagc caaatgcgga gcattgggtc ggtactgaca gtaacggtaa atcgctcttt 300
 gacggtgtct ggttcggagc tcgtaactcc atcctcattt ctgtgattgc gacagtatt 360
 aacttgggtta tcggtgtttt tgtcgggtgt atttgggtta tttcaaaatc agttgacgt 420
 gtcattgatg aagttttaca cgtcatctca aacatccac ctcttttgat tgttattgtc 480
 35 ttgacttact caatcggagc tggattctgg aatctgattt ttgccatgag cgtacaaca 540
 tggattggta ttgccttcac gatccgtgtg caaatcttg gctatcgtga cttggaatac 600
 aacttggcgt cacgtacttt gggaacacca acctgaaga ttgttgccaa aaatatcatg 660
 cctcaattg tttctgttat tttgacaacc atgactcaa tgcttccaag ctttatctca 720
 tacgaagcct tcttgtcttt cttcgggtct ggattaccga ttacagtgc aagtttgggt 780
 40 cgtttgattt cggattattc aaaaaacgta acaaccaatg cttacttgtt ctggattcca 840
 ttgacaacct ttgtcttgg atccttgtcc cttttcgtag ttggtcaaaa cttagcggat 900
 gctagtgtac cacgtacaca tagatag 927

45

<210> 75
 <211> 234
 <212> DNA
 <213> Streptococcus pneumoniae

50

<400> 75
 atgtataacc tattattaac ctttttatta gtattatctg ttgtgattgt gattgcaatt 60
 ttcattgcaac caacaaaaa ccaatccagc aatgtatttg atgccagttc aggtgatttg 120
 tttgaacgca gtaaagctcg cgtttttgaa gctgtaatgc agcgtttgac agggatttta 180
 gtctttttct ggctagccat tgccttagca ttgacggtat tatcaagtag ataa 234

55

<210> 76
 <211> 1110
 <212> DNA

<213> Streptococcus pneumoniae

<400> 76

5 atgtttcgtg gaaataaatt attttttttg accacagaaa ttttactctt aaccatcatc 60
 ttttacctat ggagacagat gggatccttg attaacctt ttgttagcgt gcttaataca 120
 attatgattc cttttttatt agggggcctt ctttattatt tgacaaaccc tattgttact 180
 ttcttaaata aagtctgtaa actcaatcgt ttgcttggtg ttttaattac cttgtgtact 240
 ttgggtctggg gaatgggcat aggtgtgtgc tatctcttac ctattttgat taatcagtta 300
 10 tctagtttga ttatatctag tcaaaactatt tatagtcgag tacaagactt aatcatagac 360
 ttatctaatt atcctgcgct ccagaatttg gatgtagaag ctacaattca gcagttaaac 420
 ttatcctatg ttgatattct tcaaaatata ctaaatagcg tatcaaatag tgtggggagc 480
 gtcttgtcag ctcttatcag tactgttttg attttgatta tgactccagt ttttttggtt 540
 tatttcttat tagatggaca taaattcttg cccatgcttg aaagaacgat tctaaagagg 600
 gatcgcttgc atattgcagg cttattaaag aattttaaag cgacgattgc tcgctatatt 660
 15 agtggagttt cgattgacgc aatcattata ggttgttttg cttatatttg ctatagtatt 720
 attggtttta aatatgcttt agtttttgcc atttttctg gtgtagccaa ttttaattcct 780
 tatgtggggc caagtattgg tttgattcct atgacatcg caaatatatt cactgtaccc 840
 catagactgc tgattgcagt gatttatatg cttgttggtc agcaggtaga tggcaatatc 900
 ttatatctc gaattgtagg aagtgttatg aagggtcctc caatcacgat ttttagtttta 960
 20 cttttgttgt caagcaatat ctatggtgta gttggaatga ttgtcgcagt gccaacctat 1020
 tctatcttga aagaaatttc taagtcttta tcccggttgc atgaaaatca taaaataatg 1080
 aaagaacgag aaagagaatt agctaagtaa 1110

<210> 77

<211> 1356

<212> DNA

<213> Streptococcus pneumoniae

<400> 77

30 atgtatcaag cactttatcg aaaatataga agtcaaaact tctcccagtt agttggtcaa 60
 gaagttgtgg ctaagactct taaacaagcg gtggagcaag agaaaataag tcacgcttat 120
 cttttttctg gtcctcgtgg aacgggaaaa accagtgttg ctaaaatctt tgccaaggct 180
 atgaactgtc ccaatcaagt ggggtggcga ccttgcaata actgctatat ttgtcaagca 240
 35 gtgacggacg gtagttttaga agatgtcatt gaaatggatg cagcttctaa taatggggta 300
 gatgaaattc gcgaaattcg tgataaatct acctatgcgc ctagccttgc tcgttataag 360
 gtttatatca tagatgaggt tcacatgctg tctacagggg cttttaatgc cctcctaaag 420
 acgctggaag aaccaacaca gaatgtagtc tttatttttg ccactactga attgcacaag 480
 attcctgcta ctattctatc ccgtgtgcaa cgttttgagt ttaaatcaat taagacacag 540
 40 gatattaagg aacatattca ctatatctta gaaaaagaaa atatcagttc tgaaccagag 600
 gctgtggaaa tcattgccag acgggcggaa ggtggaatgc gggacgcctt gtctattttg 660
 gatcaagccc tgagtttgac acagggaaat gagctgacga ctgctatctc tgaagaaatt 720
 actggcacca ttacgctatc agccttgat gattatgtgg cggccttgtc tcaacaggat 780
 gttcccaaag ctttgtcttg cttgaaatctt ctttttgaca atggtaagag catgactcgt 840
 tttgtgaccg atcttttgca ctatttaaga gacttgtaa ttgttcaaac agggggagaa 900
 45 aatactcatc atagttcagt cttttagtaa aatttggcac ttccctcaaaa aaatctgtt 960
 gaaatgattc gcttagcaac agtgaattta gcagatatta agtctagttt gcagcccaag 1020
 atttatgctg aaatgatgac cgtccgtttg gcggaaatca agcccgaacc agctctatca 1080
 ggagcggttg aaaatgaaat tgctacgctg agacaggaag ttgcccgtct caaacaagag 1140
 50 ctttctaagc caggtgcggt tctaaacaa gttgcaccag ctctagtcg accagctacg 1200
 ggcaaaacag tctatcgtgt cgatcgcaat aaagtgcaat ctatcttaca agaggccgtc 1260
 gaaaatcctg atttaacacg tcaaaatcta attcggttgc agaatgcatg gggagaggta 1320
 attgaaagtc taggtgggccc ggacaagctc tgctag 1356

<210> 78

<211> 1989

<212> DNA

<213> Streptococcus pneumoniae

<400> 78
 atgttttcgat taaccaataa gtttagcggtta tctgaacttga ttaaaaaccg caaactctac 60
 tatcctttttg cgctggctgt tctcttggca gtcactctca cctatctctt ttactctcta 120
 5 accttcaatc ctaagattgc ggaaatccgt ggaggaaaca ccattcaggc tacacttggga 180
 tttggatgtg ttgtcgtcac ccttgcgtca gccattatcg ttctctatgc caatagtgtt 240
 gtcattgaaga aacgttccaa ggaactagga atttatggca tgttgggctt ggagaagcgt 300
 catcttatca gtatgacctt taaggagtta gtggtatttg ggattctaac tgttggagcg 360
 ggtatcggtta ttggagcctt gtttgacaag ttaattttcg ctttcctgct caaactaatg 420
 10 aaattgaagg ttgagctggt tgctaccttc cagacgaaag ttgtcattac agtgcttgtt 480
 gtcttcggtt tgattttcct aggcctcatg ttcttgaatg cccttcgaat cgcccgatg 540
 aatgcctcc agctctctcg tgagaaagct agtgagagaga aaaaaggctg cttccttcc 600
 ctccaaacca ttcttgggtc cataagtta ggaattggct attatcttgc cttacggtta 660
 aaagatcctc ttacagcctt aacaaccttc ttcatagctg ttttactggt tatctttggg 720
 15 acttatctct tgtttaatgc agggattacc gttttcctcc aaatcttaaa gaaaaataag 780
 aaatactatt accaaccaaa taacctcata tctgtttcta acttgatttt ccgtatgaag 840
 aaaaatgcag ttggactagc aactatcgct attttgtcaa caatgggttt ggtaaccatg 900
 tcagcagcga caagcatttt caattccgca gaatccttta aaaaagttct aaatcctcat 960
 gattttgggg ttccaggaca aaatgttgaa aaagaagatt tggacaaact cttgagccag 1020
 20 tttgcaagtg acaatgggtta taagattaaa gaaaaagaag tgtttcggtta cacttacttt 1080
 ggtgtttcga accaagaagg aaataagtta acctttttg aaaaaggaca aaatcggtgc 1140
 caaccacaaa cagttttcat ggtatttgac caaaaagatt atgaaaaat gactgggtcaa 1200
 aaactgtctc tatcaggaaa tgaggtcggt ctctttgcca aaaatgacgg actgaaagga 1260
 cagaaaactc taattctgaa tgatcatcaa ttttctgtaa aagaagaatt taataaagat 1320
 25 tttattgtca accatgtccc aaatcagttt aatattttga ctgctgatta caattacctt 1380
 gttgtacctg atttacaagc ctttttgaac caattcccag attcggatat ctataatcag 1440
 ttttacggtg gtatgaatgt aaatgtcagt gaagaagaac aactcaaggc cgctgaggag 1500
 tatgaaaact acctcaatca atttaatgct caattagaca cagaaggtag ctatgtttat 1560
 ggtagcaatc tagcagatgc tagttctcag atgagtgcct tctttggttg tgtcttcttt 1620
 30 atcgggtattt tcctatccat tatctttatg gtcggaactg ttctggtcat ctactacaaa 1680
 caaattttctg aaggctacga agaccgtgaa cgctttatta tcttgacaaa agtcgggtttg 1740
 gacaaaaagc aaatcaagca aacctccac aaacagggtt taactgtttt cttccttcc 1800
 ttgctctttg cttcataca tctcgctttt gcctaccata tgcttagcct gattttaaaa 1860
 gtgattgggt tactggatc gactatgatg ttgattgtga ccttgtctat ctgcgctatc 1920
 35 ttcctcatcg cctatgtgct gattttcatg attacttcaa gaagttatcg caagattgtg 1980
 caaatgtaa 1989

<210> 79

<211> 891

40 <212> DNA

<213> *Streptococcus pneumoniae*

<400> 79

atgaaacaag atcaactaaa ggcttggcaa ccagctcagt ttgaccgttt tgtccgtatc 60
 45 ttagaacaag accagctcaa tcacgcctat ctcttttcag gtttcttttg aagcttggaa 120
 atggcgcaat ttttagctaa gagcctcttt tgtagcgata aagttggcgt cttaccatgt 180
 gagaaatgcc gaagtgtcaa gctgattgaa caggaagagt ttccagatgt caccttgatt 240
 aagccagtca atcaggtcat caagacagaa cgcattcggg aattgggtgg acagttttct 300
 50 caagcaggga ttgaaagcca gcaacaggtc tttattatcg agcaagcggg taaaatgcat 360
 cccaacgcag ccaattctct gctcaaggtc atcgaagaac ccagagtga agtttatatt 420
 ttcttcttga ctagcgatga ggaaaagatg ttaccgacaa tccgaagtgc gactcagatc 480
 ttccacttta aaaagcaaga agaaaaactt atcttactct tagaacaat gggacttgtt 540
 aagaaaaaag cgactctttt agctaagttt agtcaatcgc gagctgaagc agaaaagttg 600
 gctaactcagg caagtttttg gaccttggtc gatgaaagtg aacgcctgct gacttgggtta 660
 55 gttagctaaaga aaaaagaaag ttatctacag gttgcaaat tagccaactt ggcatgat 720
 aaggaaaaac aggatcagggt tttacggatt cttgaagttc tctgtgggca ggacctcttg 780
 caggtaagag taagagtgat tctacaagat ttactagaag ctagaaaaat gtggcaagct 840

aatgtcagct ttcaaaatgc catggaatat ctggtcttga aagaaatata a 891

<210> 80
<211> 615
5 <212> DNA
<213> Streptococcus pneumoniae

<400> 80
10 atgaattcat ttaaaaattt cttaaaagag tggggactgt tcttccta at tctgtcatta 60
ctagctttta gtcgtatctt tttttggagc aatgttcgcg tagaaggaca ttccatggat 120
ccgaccctag cggatggcga aattctcttc gttgtaaaac accttctctat tgaccgtttt 180
gatatcgtgg tggcccatga ggaagatggc aataaggaca tctgcaagcg cgtgattgga 240
atgcctggcg acaccattcg ttacgaaaat gataaactct acatcaatga caaagaacg 300
gacgagcctt atctagcaga ctatatcaaa cgcttcaagg atgacaaact ccaaagcact 360
15 tactcaggca agggctttga aggaaataaa ggaactttct ttagaagtat cgctcaaaaa 420
gcccaagcct tcacagttga tgtcaactac aacaccaact ttagctttac tgttccagaa 480
ggagaatacc ttctctcgg agatgaccgc ttggtttcga gcgacagccg ccacgtagggt 540
accttcaaag caaaagatat cacaggggaa gctaaattcc gcttctggcc aatcaccctg 600
atcggaacat tttaa 615

<210> 81
<211> 987
<212> DNA
<213> Streptococcus pneumoniae

<400> 81
25 atggtagtagt ttacaggttc aactgttgaa gaagcaatcc agaaaggatt gaaagaatta 60
gatattccaa gaatgaaggc tcatatcaaa gtcatttcta gggagaaaaa aggcttttctt 120
30 ggtctatttg gtaaaaaacc agcccaagt gattattgaag cgattagtga aacgactgtt 180
gtcaaagcaa atcaacaggt agtaaaaggc gttccgaaaa aaatcaatga tttgaacgag 240
cctgtgaaga cgttagtgga agaaaccgtt gaccttggtc atgtggttaa tgcattataa 300
aaaatagagg aagaagggtca aggtatttct gatgaagtca aggctgaaat cttaaaacat 360
gaaagacatg ccagcactat cttagaagaa actggtcaca ttgagatttt aaatgaactt 420
caaactcgagg aagcgatgag ggaagaagca ggcgctgatg accttgaaac tgagcaagat 480
35 caaactgaaa atcaagactt gaaagagatg ggcttgaagg tcgagcaaag ttatgatatt 540
gcccggttgg ctacggatgt gactgcctat gttcaagcga ttgtggatga catggatgtt 600
gaagctacac tttcaaatga ttataaccgt cgtagcatca atctacaaat tgacaccaac 660
gaaccaggtc gtattatcgg ctaccatggt aaagtcttga aggccttgca actggttggt 720
caaaattatc tttacaaccg ctattccaaa accttctacg ttacaatcaa tgtcaatgat 780
40 tatgtcgaac accgtgcaga agtcttgcag acctatgcgc aaaaattggc gaatcgtgtt 840
ttggaagaag gtcgcagtca taaaacagat ccaatgtcaa atagcgaacg caagattatc 900
catcgtatta tttcacgtat ggatggcgtg actagttact ctgaagggtga tgagccaaat 960
cgctatgttg ttgtagatac agaataa 987

<210> 82
<211> 1383
<212> DNA
<213> Streptococcus pneumoniae

<400> 82
50 atgtcaaat ttgccattat ttagcagcg ggtaaaggga ctgcgatgaa atctgatttg 60
ccaaaagttt tgcaaacggt tgcgggtatt tctatgttgg aacatgtttt cgtagtgtg 120
ggagctatcc aacctgaaaa gacagtaaca gttgtaggac acaaggcaga attgggtgag 180
gaggtcttgg ctggacagac agaatttggg actcaatctg aacagttggg aactgggtcat 240
55 gcagttatga tgacagaacc tatcttagaa ggtgtgtcag gacacacctt ggtcattgca 300
ggagatactc ctttaatcac tgggtgaaagc ttgaaaaact tgattgattt ccatatcaat 360
cataaaaatg tggccactat cttgactgct gaaacggata atccttttgg ctatggacga 420

attgttcgta atgacaatgc tgaggttctt cggtcattgt tgagcagaag gatgctacag 480
 attttgaaaa gcaaatcaag gaaatcaaca ctggttaacat acgtctttga caacgagcgt 540
 ttgtttgagg ctttgaaaaa tatcaatacc aataacgctc aaggcgaata ctatattaca 600
 5 gacgtcattg gtattttccg tgaaactggg gaaaaagtgg gcgcttatac tttgaaagat 660
 tttgatgaaa gtcttggggg aaatgaccgt gtggcgcttg cgacagctga gtcagttatg 720
 cgctcgtcga tcaatcataa acacatggtc aacgggtgta gctttgtcaa tccagaagca 780
 acttatatcg atattgatgt tgagattgct ccggaagttc aaatcgaagc caatgttatc 840
 ttgaaagggc aaacgaaaat tgggtgctgag actgttttga caaacgggtac ttatgtagtg 900
 10 gacagcacta tcggagcagg agcggtcatt accaattcta tgattgagga aagtagtggt 960
 gcagacgggt tgacagtcgg tccttatgct caccatcgct caaattcaag tctgggtgcc 1020
 caagttcata ttggttaactt tgttgagggt aaaggatctt caatcggtga gaataccaag 1080
 gctgggtcatt tgacttatat cggaaactgt gaagtgggaa gcaacgttaa tttcggtgct 1140
 ggaactatta cagtcaacta tgacggcaaa aacaaatata agacagtcac tggagtcaat 1200
 gtctttgttg gttcaaatc aaccattatt gcaccagtag aacttgggtga caattccctc 1260
 15 gttgggtgctg gttcaactat tactaaagac gtgccagcag atgctattgc tattggctgc 1320
 ggtcgtcaga tcaataaaga cgaatatgca acacgtcttc ctcatcatcc taagaaccag 1380
 tag 1383

<210> 83
 20 <211> 936
 <212> DNA
 <213> Streptococcus pneumoniae

<400> 83
 25 atgtccaaga ttctagtatt tggtcaccaa aatccagact cagatgccat cggatcatct 60
 gtagcttttg cctaccttgc aaaagaagct tacggtttgg atacggaagc tgttgccctt 120
 ggaactccaa atgaagaaac agcctttgtc ttgaactatt ttggtgtgga agcaccaggt 180
 gttatcactt ctgccaaagc agagggggca gagcaagtta tcttgactga ccacaatgaa 240
 30 ttccaacaat ctgtatcaga tatcgctgaa gtagaagttt acgggtgtgt agaccaccac 300
 cgtgtggcta actttgaaac tgcaagccca ctttacatgc gtttggagcc agttggatca 360
 gcgtcttcaa tcgtttaccg tatgttcaaa gaacatgggt tagctgttcc taaagagatt 420
 gcaggtttga tgctttcagg tttgatttca gatacccttc ttttgaaatc accaacaaca 480
 caccacaacag ataaaatcat tgctcctgaa ttggctgaat tggctggtgt aaacttggaa 540
 gaatatggtt tggcaatggt gaaagctggg accaacttgg ctagcaaac tgctgaagaa 600
 35 ttgattgaca tcgatgctaa gacttttgaa ctcaacggaa ataatgtocg tgttgcccaa 660
 gtgaacacag ttgacatcgc tgaagttttg gaacgccaag cagaaattga agctgcaatg 720
 caagctgccca acgaatcaaa cggctactct gactttgtct tgatgattac agatatactc 780
 aactcaaaact cagaaatatt ggctcttggg gccaatatgg acaaggtcga agcggctttc 840
 aatttcaaac ttgaaaacaa tcatgccttc cttgctgggt ccgtttcacg taagaacaaa 900
 40 gtggtacctc aattaactga aagctttaat acgtaa 936

<210> 84
 <211> 678
 <212> DNA
 45 <213> Streptococcus pneumoniae

<400> 84
 atgatttcaa agagattaga attgtagctt tcttttgtgt cacagggggc tattttacta 60
 gatgtgggaa gtgaccatgc ttatctgcct atcgagttgg ttgagagagg ccaaatcaaa 120
 50 agcgtattg cagggtgagg ggtggaaggc ccctatcagt ctgcggttaa aaatgttgag 180
 gctcacggcc taaaggagaa aatccaagtc cgtttagcca atggcttggc agcttttgaa 240
 gagactgacc aagtgtctgt cattaccatt gctggcatgg gtggctggtt gattgctagg 300
 attttagaag aaggtttggg gaagtttagct aatgtagagc gtttgatcct ccagcccaat 360
 aatcgtgaag acgacttgcg tatctggcta caggatcatg gattccagat ttagcagaaa 420
 55 agcatcttag aagaagctgg aaagttttat gagatttttg tgggtggaagc aggacaaatg 480
 aagctatcag ccagtgatgt tcgcttttgg cccttcttgt ccaaagaagt cagtccagta 540
 tttgtccaaa aatggcaaaa agaagctgag aagctagagt tcgccctcgg acaaatccca 600

gaaaaaaatc tggaagaacg tcaagttcta gtagataaga ttcaagctat caaggaggtg 660
 ctccatgtta gcaagtga 678

5 <210> 85
 <211> 486
 <212> DNA
 <213> Streptococcus pneumoniae

10 <400> 85
 atgaatttaa acgatattaa agacttgatg actcaatttg accagtcaag tttgagagaa 60
 ttttcttata aaaatgggac ggatgagttg cagtttagca agaatgaagc gagacctgtg 120
 cctgaagttg caactcaagt cgctccagca cccgttctag caacaccgag tccagtagct 180
 cctacatctg ctccagcaga gactgtagca gaagaagttc cagctccagc tgaagcaagt 240
 gtggctagtg agggaaaatct tgtagagagt ccacttgttg gagtggttta cttggctgct 300
 15 ggaccagata aaactgcctt cgttacagtt ggtgatatg tcaaaaaagg tcaaacattg 360
 gtaattatcg aagccatgaa agtcatgaat gaaatcccag ctctaagga tgggtgtgga 420
 acggaaattc tcgtctctaa cgaagaaatg gttgagttt gttaaaggatt ggtacgtatc 480
 aatga 486

20 <210> 86
 <211> 1236
 <212> DNA
 <213> Streptococcus pneumoniae

25 <400> 86
 atgaaactaa atcgagtagt ggtaacaggt tatggagtaa catctccaat cggaaataca 60
 ccagaagaat tttggaatag tttagcaact gggaaaaatcg gcattggtgg cattacaaaa 120
 tttgatcata gtgactttga tgtgcataat gcggcagaaa tccaagattt tccgttcgat 180
 30 aaatactttg taaaaaaaaga taccaaccgt tttgataact attctttata tgccttgat 240
 gcagcccaag aggtgtgaaa tcatgccaat cttgatgtag aggctcttaa tagggatcgt 300
 tttggtgtta tcgttgcac tggtatttgt ggaatcaagg aaattgaaga tcaggactct 360
 cgcttcatg aaaaaggacc caaacgtgtc aaaccaatga ctcttccaaa agctttacca 420
 aatatggctt ctgggaatgt agccatgcgt tttggtgcaa acggtgtttg taaatctatc 480
 aatactgcct gctcttcac aaatgatgcg attggggatg ccttccgctc cattaagttt 540
 35 ggtttccaag atgtgatgtt ggtgggagga acagaagctt ctatcacacc ttttgccatc 600
 gctggtttcc aagccttaac agctctctct actacagagg atccaactcg tgcttcgatc 660
 ccatttgata aggatcgcaa tgggtttgtt atgggtgaag gttcaggat gttggttcta 720
 gaaagtcttg aacacgtga aaaacgtgga gctactatcc tggctgaagt ggttggttac 780
 ggaaataact gtgatgccta ccacatgact tctccacatc cagaaggtca gggagctatc 840
 40 aaggccatca aactagcctt ggaagaagct gagatttctc cagagcaagt agcctatgtc 900
 aatgctcacg gaacgtcaac tcctgccaat gaaaaaggag aaagtgtgtc tatcgtagct 960
 gttcttggtta aggaagtacc tgtatcatca accaagtctt ttacaggaca tttgctggg 1020
 gctgcgggtg cagtagaagc tatcgtcacc atcgaagcta tgcgtcataa ctttgtacca 1080
 atgacagctg ggacaagtga agtatcagat tatatcgaag ctaatgtcgt ttatggacaa 1140
 45 ggcttgaga aagaaattcc atacgtatt tcaataactt ttggtttttg aggccacaat 1200
 gcagttcttg ctttcaaacg ttgggagaat agataa 1236

50 <210> 87
 <211> 1080
 <212> DNA
 <213> Streptococcus pneumoniae

55 <400> 87
 atgaacatct atgatcaact acaagttgta gaagaccgtt atgaagaatt aggagaattg 60
 ctgagtgacc ctgatgtcgt ttcagacacc aagcgtttta tggagctttc aaaagaagaa 120
 gttccaatc gtgacaccgt aatagcctac cgtgagtata aacaagtcct tcaaatatc 180
 gtcgatgccg aagagatgat taaggaaatc ggaggagatg cggacttga agaattggcc 240

aagcaagaac tcaaagatgc caaggctgaa aaagaagaat atgaagaaaa actgaaaatt 300
 ttgtccttc caaaggatcc aaacgatgac aagaatatca tccttgaaat ccgtggagca 360
 gctgggtggag acgaagcggc acttttcgct ggagatttgc taactatgta ccaaaagtat 420
 5 gcggaagccc aaggttggcg ctttgaagtc atggaagcct ctatgaatgg tgtcgggtgt 480
 tttaaagaag tgggtgctat ggtttcaggt cagtctgtat actctaagct taagtatgaa 540
 tcaggtgcc accgtgtgca acgtgttcc gtgacagaaa gccaaaggccg tgttcatact 600
 tcgacagcga cagttcttgt tatgccagaa gttgaagagg ttgaatacga cattgatcca 660
 aaagaccttc gtgtcgacat ctatcacgcc tctggtgctg gtggacagaa cgtcaataag 720
 10 gttgcgactg cgttctgtat cgttcaactg ccaaccaata tcaaggttga gatgcaggaa 780
 gaacgtacc agcagaagaa ccgcgagaag gctatgaaga ttatccgtgc acgcgtcgct 840
 gaccactttg ctacagattgc tcaggatgaa caagacgctg agcgttaagtc gacaatcgg 900
 actggtgacc gttcagaacg gatccgaact tataacttcc caaaaaccg tgtcacagac 960
 caccgtatcg gcttgacct ccaaaaacta gatacgattt tgtctggtaa attggacgaa 1020
 15 gttgtggatg ccttgggtgct ttatgaccaa acacaaaaac tagaagaatt aaacaaataa 1080
 <210> 88
 <211> 1680
 <212> DNA
 <213> Streptococcus pneumoniae
 20
 <400> 88
 atggcctaca ctcttaaacc tgaagaagtt ggtgtttttg ccatcggtgg tctaggagaa 60
 atcgggaaaa acacttacgg aattgaatac caagacgaga ttatcatcgt cgtgctggg 120
 attaaattcc cagaagatga cttgcttgggt atcgactatg tcatttctga ctactcttac 180
 25 atcgtagaca atatcgaccg cgtcaaggct gttttaatca cacacggaca cgaggaccac 240
 attggtggga ttccgttccct actcaagcaa gcaaatgtcc ctatttatgc tggacccgtt 300
 gccttggctt tgatccgtgg gaaactcgaa gaacacggcc tcttgcgcaa cgccaaactt 360
 tacgaaatca accacaacac cgagttgacc tttaaaaatc tcaaggcaac tttctttaga 420
 acgactcact ctattccaga gcctttgggg attgtcattc atactcctca agggaaaatc 480
 30 gtctgtacgg gtgactttaa gttcgacttt actccagttg gagaacctgc ggacttgcac 540
 cgtatggctg cgcttgggtga agaaggcgtg ctctgtctcc tgtctgactc gacaaatgca 600
 gaagtaccaa cctttaccaa ctctgaaaaa gtcgttggtc agtccattat gaagattatc 660
 caaggtattg aaggacgtat catctttgca tcotttgcct caaatatctt ccgtctccag 720
 caggcaacag aagctgctgt taagactgga cgcaagattg cggctcttgg tcttctatg 780
 35 gaaaaggcca ttgtcaacgg aatcgatctt ggctacatca aagctcctaa gggaaacctt 840
 atcgagccaa atgaaatcaa agattatcct gcaggagaag ttcttatcct ctgtacaggt 900
 agtcagggtg agcctatggc agccctctct cgtatcgcca acggaaccca ccgtcaagta 960
 caattacaac caggtgatac cgttatcttc tcttctagtc ccatccctgg aaacactact 1020
 agcgtcaaca agctgattaa catcatttct gaagctggtg tcgaagttat ccacggtaaa 1080
 40 gtgaacaata tccatacatc tggacacggg ggtcagcaag agcaaaaact catgctctgc 1140
 ttgattaagc caaaatactt catgctgttc cagggtgaat accgcatgca aaaagtccac 1200
 gctggactag cagtggatac tgggtgttag aaggacaata tctttatcat gagcaatggc 1260
 gatgtgcttg cccttactgc tgactcagct cgtatcgag gtcatttcaa cgcccaagat 1320
 atctatgtcg atggaaatcg tatcggtgaa attggcgcag ctgtcctcaa agatcgctgc 1380
 45 gatctatctg aagacgggtg cgttctggca gtcgcaactg ttgacttcaa atcgagatg 1440
 attctgtctg gccagatat cctcagccga ggcttgtct acatgagaga gtctggagac 1500
 ttgattcgcc aaagccagcg tatcctcttc aatgccattc gtatcgact gaaaaataag 1560
 gatgctagcg tgcaatctgt caatgggtgc attgtcaacg ctattcgccc ctctctctat 1620
 50 gaaaaataccg aacgtgaacc gatcatcatc ccgatgatcc tcacaccaga tgaagaataa 1680
 <210> 89
 <211> 1362
 <212> DNA
 <213> Streptococcus pneumoniae
 55
 <400> 89
 atggcagaag tagaagagtt acgagtacaa cctcaagata tcttagctga gcaatccgtt 60

	ttaggggcta	tctttattga	tgagagtaaa	cttggttttg	tgcgagaata	cattgagtct	120
	cgggactttt	ttaagtatgc	ccatcgtttg	attttccaag	ccatgggtcga	tttatccgat	180
	cgtgggtgatg	ccatagatgc	aacaacgggt	cgtactatcc	ttgataatca	aggtgattta	240
	cagaatattg	gtggccttg	ttacttgggt	gagattgtta	attctgtgcc	aacttctgct	300
5	aatgcggagt	attatgctaa	gattgttgca	gaaaaagcaa	tgctacgtcg	tttaattgcc	360
	aagttgacag	agtctgtcaa	ccaagcttac	gaagcgtcac	aaccagctga	tgaaattatt	420
	gctcaggcag	aaaaagggtt	gattgatgtc	agtgaataatg	caaatacgaag	cgggtttaag	480
	aacattcgag	atgtgttgaa	tctcaacttt	ggaaatctgg	aagctcgctc	gcaacaaacg	540
	accgatatta	cagggtattgc	gacagggttat	cgtgatttgg	atcatatgac	aacaggactt	600
10	catgaggagg	agttgattat	cttagcagct	cgtccagcag	ttggtaagac	agcatttgcc	660
	ttgaatatcg	ctcagaacat	tgggactaag	ttggacaaaa	cggttgctat	tttttcactc	720
	gaaatgggtg	cggaaagcct	ggtagatcgt	atggttagctg	cagaaggctt	ggtggagtca	780
	cattctatcc	gtacagggca	attgacagat	gaggagtggc	aaaaatatac	tattgctcag	840
	ggtaatctcg	ctaacgccag	tatctatatc	gatgatacgc	caggtattcg	gattacagag	900
15	attcgttctc	gttctcgtaa	attggctcaa	gaaactggaa	atcttggttt	gattgtgata	960
	gactatttgc	aacttatcac	gggaactgg	cgagaaaatc	gtcaacaaga	agtttctgaa	1020
	atctctcgtc	agttgaaaat	actagccaag	gaattgaagg	ttccagtaat	cgctctgagt	1080
	cagctttctc	gtggtgtaga	acaacgtcag	gacaagagac	cggcttctgc	tgatattcgt	1140
	gaatctgggt	ctattgagca	ggacgctgat	atcgtagctt	ttctctatcg	cgatgactac	1200
20	tatgaacgtg	gtggtgaaga	agaggagggt	atcccaaata	ataagggtga	agttattatc	1260
	gagaaaaacc	gtagtggagc	tcgtggaaca	gtggaattga	ttgtccaaaa	agaatacaat	1320
	aaattcttca	agtattcaag	tatctcaaa	agggaggcat	aa		1362
	<210> 90						
25	<211> 693						
	<212> DNA						
	<213> Streptococcus pneumoniae						
	<400> 90						
30	atggcgtata	aatatttagt	gattgtagaa	tcacctgcaa	aagccaagac	aattgagaaa	60
	tatcttggac	gaaactataa	agtaatggcc	agtgttggcc	atataagaga	tttaccgaaa	120
	agtaaaatgg	gtatcgattt	tgaaaacaat	tatgaacccc	attatatttc	tatacgcgga	180
	aaaggcgatg	tcatcaaaaag	cctgaaaagcc	gcagcaaaaa	aagctcaaaa	agtttacttg	240
	gcaagtgacc	cggatagaga	aggagaagcg	attgcttggc	atttagcgta	cctacttggg	300
35	ttggatctga	aagaaaaaaa	tcgggtgggtc	ttcaatgaaa	tcacaaaaaga	cgcagtcaaa	360
	gcagctttta	aggaaccaag	aacgatcgat	gtagatttag	tagatgcaca	gcaagctcgt	420
	cgtaccttag	acagaatcgt	tggttattcg	atcagtccta	ttctctggcg	taagggtcaag	480
	aaagggttaa	gtgcaggacg	tgtccaatct	gtcgcgttaa	aaattattat	tgaccgtgaa	540
	aaagagatcc	gagaatttgt	tccagaagaa	tattggagca	tcgacggtaa	ttttaaaaaa	600
40	gctcgcaaga	aattcaaaagc	aaatttctgg	ggaatcgacg	gtaagaaaaa	gaaattacca	660
	gatgcacaaa	gtgtaaaaaa	aagtcactgc	tag			693
	<210> 91						
	<211> 981						
45	<212> DNA						
	<213> Streptococcus pneumoniae						
	<400> 91						
	atgtttattt	ccatcagtg	tggaattgtg	acattttttac	taacttttagt	aggaattccg	60
50	gcctttatcc	aattttatag	aaaggcgcaa	attacaggcc	agcagatgca	tgaggatgtc	120
	aaacagcatc	aggcaaaaagc	tgggactcct	acaatgggag	gttttggtttt	cttgattact	180
	tctgttttgg	ttgctttctt	tttcgcccta	tttagtagcc	aattcagtaa	taatgtggga	240
	atgattttgt	tcatcttgg	cttgatggc	ttggctggat	ttttagatga	ctttctcaag	300
	gtctttcgta	aaatcaatga	ggggtcta	cctaagcaaa	aattagctct	tcagcttcta	360
55	ggtggagtta	tcttctatct	tttctatgag	cgcgggtggc	atatgctttc	tgtctttgg	420
	tatcaagtgc	atctagggat	tttctatatt	gttttcgctc	ttttctggct	agtcggtttt	480
	tcaaacgcag	taaacttgac	agacgggtgt	gacggtttag	ctagtatttc	cgttgtgatt	540

- agtttgtctg cctatggagt tattgcctat gtgcaaggtc agatggatat tcttctagt 600
 attctggcca tgattggtgg tttgtcagtt ttcttcatct ttaaccataa gcctgctaag 660
 atctttatgg gtgatgtggg aagtttggct ttaggtggaa tgctggcagc tatctctatg 720
 5 gctctccacc aagaatggac tctcttgatt atcggaattg tgtatgtttt tgaacaact 780
 tctgttatga tgcaagtcag ttatttcaaa ctgacagggtg gtaaactgat tttccgtatg 840
 acgcctgtac atcaccattt tgagcttggg ggattgtctg gtaaaggaaa tccttggagc 900
 gagtgggaagg ttgacttctt cttttgggga gttgggcttc tagcaagtct cctgacccta 960
 gcaattttat atttgatgta a 981
- 10 <210> 92
 <211> 2082
 <212> DNA
 <213> *Streptococcus pneumoniae*
- 15 <400> 92
 atggcacgcg aattttcact tgaaaaaact cgtaatatcg gtatcatggc tcacgtcgat 60
 gccggtaaaa caacaactac tgagcgtatt ctttactaca ctggtaaaat ccacaaaatc 120
 ggtgaaactc acgaagggtc gtcacaaatg gactggatgg agcaagagca agaactggtt 180
 20 atcacgatca catctgctgc gacgacagct caatggaaca accaccgcgt aaacatcatc 240
 gacacaccag gacacgtgga cttcacaatc gaagtacaac gttctcttcg tgtattggat 300
 ggtgcgggta ccgttcttga ctcacaatc ggtgttgagc ctcaaaactga aacagtttgg 360
 cgtcaagcaa ctgagtagcg agttccacgt atcgattttg ccaacaaaat ggacaaaatc 420
 ggtgctgact tcctttactc tgtaagcaca cttcacgacg gtcttcaagc aaatgcacac 480
 ccaatccaat tgccaatcgg ttctgaagat gacttcogtg gtatcattga cttgatcaag 540
 25 atgaaagctg aaatctatac taacgacctt ggtacggata tccttgaaga agacatccca 600
 gctgaatacc ttgaccaagc tcaagaatac cgtgaaaaat tgattgaagc agttgctgaa 660
 actgacgaag aattgatgat gaaataacct gaagggtgaag aaatcactaa cgaagaattg 720
 aaagctggta tccgtaaagc gactatcaac gttgaattct tcccagtatt gtgtggttca 780
 gccttcaaaa acaaagggtg tcaattgatg cttgatgcgg ttatcgacta ccttccaagc 840
 30 ccacttgaca tcccagcaat caaagggtatt aaccagata cagacgctga agaaattcgt 900
 ccagcatctg acgaagagcc atttgacgct cttgccttca agatcatgac tgacccattc 960
 gtaggtcggt tgacattctt ccgtgtttac tcaggtgttc ttcaatcagg ttcatacgta 1020
 ttgaatactt ctaaaggtaa acgtgaacgt atcgagcgta tccttcaaat gcacgctaac 1080
 agccgtcaag aaatcgacac tgtttactca ggtgatatcg ctgctgccgt tgggttgaaa 1140
 35 gatactacaa ctggtgactc attgacagat gaaaaagcta aaatcatcct tgagtcaatc 1200
 aacgttccag aaccagttat ccaattgatg gttgagccaa aatctaaagc tgaccaagac 1260
 aagatgggta tcgcccttca aaaattggct gaagaagatc caacattccg cgttgaaaca 1320
 aacgttgaaa ctggtgaaac agttatctca ggtatgggtg aacttcacct tgacgtcctt 1380
 gttgatcgta tgcgtcgtga gttcaaaagt gaagcgaacg taggtgctcc tcaagtatct 1440
 40 taccgtgaaa cattccgcgc ttctactcaa gcacgtggat tcttcaaacg tcagtctggt 1500
 ggtaaaggtc aattcgggtga tgtatggatt gaatttactc caaacgaaga aggtaaaagga 1560
 ttcgaattcg aaaacgcaat cgtcgggtgt gttgttcttc gtgaatttat cccagcgggt 1620
 gaaaaagggt tggtagaatc tatggctaac ggtgttcttg caggttacc aatggttgac 1680
 gttaaagcta agctttatga tggttcatat cacgatgtcg actcatctga aactgccttc 1740
 45 aagattgcgg cttcacttcc ccttaaagaa gctgctaaat cagcacaacc agctatcctt 1800
 gaaccaatga tgcttgtaac aatcactgtt ccagaagaaa accttgggtga tgttatgggt 1860
 cacgtaactg ctcgtcgtgg acgtgtagat ggtatggaag cacacggtaa cagccaaatc 1920
 gttcgtgctt acgttcactt tgctgaaatg ttcggttacg caacagttct tcgttctgca 1980
 tctcaaggac gtggtacatt catgatggta tttgaccact acgaagatgt acctaaagtca 2040
 50 gtacaagaag aaattattaa gaaaaataaa ggtgaagact aa 2082
- <210> 93
 <211> 1227
 <212> DNA
 55 <213> *Streptococcus pneumoniae*
- <400> 93

atgccaaatt acaatattcc attttcaccg cctgatatca cagaagcaga aattgctgaa 60
 gtagcggata ccttgcgttc tggttggatc acaacaggtc ctaaaacaaa agaactggag 120
 cgccgcttgt ctctttacac acagacacct aagactgttt gtctcaactc tgcgacagcc 180
 5 gctctggagt tgattttacg cgttttggaa gtgggacctg gtgatgaagt catcgttcca 240
 gccatgacct atacggcttc atgtagtgtc attacgcacg tgggagcaac ccctgtcatg 300
 gtggatatcc aagcagatac gtttgagatg gactatgacc tgcttgagca agctatcact 360
 gagaaaacta aggtgattat cccagtagag ctgcgaggga ttgtttgcga ttatgaccgt 420
 ttgttccaag tcgtggagaa aaaacgtgac ttctttaccg cttcaagcaa gtggcaaaaag 480
 10 gcctttaacc gtattgtcat tgtctctgat agtgcccacg ctttgggacg tacttataaa 540
 ggacaacctt ctggttctat cgctgatttt acttccttct cattccatgc cgtaagaac 600
 ttacaacgg cagaaggtgg aagtgcgact tggaaagcca atccagtgtat tgatgacgaa 660
 gagatgtaca aggaattcca aatcctttcc cttcacgggc aaactaagga tgctcttgcc 720
 aagatgcaac tgggggtcatg ggaatacgat atcgttacac cagcctataa gtgcaacatg 780
 accgatatac tggcttcact tggtttggta caattggacc gctatccaag ttgtttgcaa 840
 15 cgccgtaagg acattgtgga ccgctatgat agtggttttg caggttctcg catccatcct 900
 ttggcacaca agactgaaac tgcgaatct tcacgccacc tctacatcac ccgtgtagaa 960
 ggagcaagcc tagaagaacg cagcctcatc atccaagaat tggctaaagc aggaattgca 1020
 agtaatgttc actacaaacc gcttcctctc ttgacagcct ataagaatct tggatttgat 1080
 atgacgaact atcctaaggc ctatgccttc ttgagaatg aaattaccct ccctcttcct 1140
 20 actaaattaa gcgatgaaga agtagactat atcattgaga ctttcaaac agtttctgaa 1200
 aaagtgctaa ctttatcaaa aaaatga 1227

<210> 94

<211> 978

25 <212> DNA

<213> Streptococcus pneumoniae

<400> 94

atgacagaac ctgatttttg gaacgataat attgcggccc aaaaaacgtc gcaagaattg 60
 30 aatgtatttta aaaacactta caataccttc cataagatgg aagagttgca ggtagaagtc 120
 gaaattttat tggatttttt ggctgaagac gagtcagtgat atgatgaact ggtagcgcag 180
 ttagccgaac ttgataagat aatgaccagc tacgagatga ctttactctt gtcagaacct 240
 tatgaccaca acaatgccat cttggaaatc catccagggt ctggtgggtac tgaggcgcag 300
 gactgggggtg atatgttgcg tcgtatgtat actcgttatg gtaatgctaa aggccttttaa 360
 35 gtggaagtgt tggattacca agcagggtgat gaggtcggtt ttaagtgggt aacttttatca 420
 tttgaagggt ctaatgccta tggctcctc aagtcagaaa tgggtgttca ccgcttagtg 480
 cgaatctcac ctttgactc tgccaaacgt cgccatacct ctttcacatc tgtagaagtg 540
 atgccagaat tggatgatac tattgaagtg gaaatccgtg aagatgatat caagatggat 600
 accttccgtt cagggtggtg cggtggacaa aacgtcaata aagtttcaac aggtgtacgt 660
 40 ttaaccaca ttccaactgg aattgttgct caatcaacag tggatcgatc ccagtatgga 720
 aatagagatc gtgccatgaa gatgttcag gctaagctct atcaaatgga gcaagagaag 780
 aaggctgcgg aggtagattc tctcaaaggt gagaaaaagg agattacttg gggaagccaa 840
 atccgttctt atgtcttcac gccttatact atggtaaaag atcaccgaac tagctttgag 900
 gttgctcagg tagataaggt tatggatggg gacctagatg gttttatcga tgcttatctc 960
 45 aagtggcgaa ttagctaa 978

<210> 95

<211> 750

<212> DNA

50 <213> Streptococcus pneumoniae

<400> 95

atgttttata cttatttgcg tggattagtt gtattgctct tatggtccat caatggcaat 60
 55 gtcactatc ataatactga taaaattcct aatcaagatg aaaattatat tttagttgag 120
 cctcaccgta cctgggtgga tctgtttat atggcctttg cgaccaagcc aaaacagttc 180
 atcttttatg caaaaaaaga actctttacc aacgatatct ttggttggtg gattcgtatg 240
 tgtggcgctt ttccatcga ccgtgaaaat cccagcgct cagccatcaa atatcctatc 300

aacgtttctca aaaaaagtga ccgctctctc atcatgtttc caagtggtag ccgccactca 360
 aacgatgtca aggggggccc agcactgatt gccaaaatgg ccaagggtccg tatcatgccg 420
 gttacctaca ccggtcccat gactttgaag ggcttgatta gccgtgaacg tgcgatgatg 480
 aactttggaa atccaatcga tatctcagat atcaagaaaa tgaatgatga aggcattgaa 540
 5 acagtgcgca atcgtattca aacagaattc caacgtctgg acgaagaaac gaaacaatgg 600
 cacaatgata aaaaacccaa tccactctgg tggtttatcc gcatccctgc cctcatcctt 660
 gctattatcc tcgctatcct aacctatcct tttagcttta tcgcaagctt catctggaac 720
 ccagataaga aaagagaaga acttgcatag 750

10 <210> 96
 <211> 3102
 <212> DNA
 <213> Streptococcus pneumoniae

15 <400> 96
 ttgatcgac aactagatac aaaaacagtc tatagtttta tggaaagcgt catttcgac 60
 gaaaaagtatg tgagagcagc taaagaatac ggctacactc atttggtat gatggatatt 120
 gacaatcttt atggcgcttt cgactttcta gagattacaa aaaaatacgg cattcatcct 180
 20 ttgctagggc ttgaaatgac agtgtttgta gatgatcagg gagtaaatgt gcgcttttta 240
 gctctatcta gtgtgggcta tcagcagttg atgaagcttt cgacagccaa gatgcagggg 300
 gagaaaactt ggtcagtcct gtcccagtac ctggaggata tcgcggtcat tgtgccttat 360
 tttgatagag ttgagtcgtt agaactaggg tgtgattact atataggggt ttatccagaa 420
 acactagcaa gcgaatttca tcactctatc ttacctcttt atcgggtcaa cgcttttgaa 480
 agcagggata gagaagtctt tcaagtttta acagcgatta aagaaaatct accgctcaga 540
 25 gaagttccct tcggttcgag acaagatgct tttatatcag caagttcttt agagaaacta 600
 ttccaagagc gttttccgca agctttggac aatttagaaa agcttatttc aggcatttct 660
 tacgacttgg atactagtct gaaactgcct cgttttaatc cagctagacc agcagtagag 720
 gagttgagag agcgtgctga actggggcct gtccagaagg ggttgactag taaagaatat 780
 caagatagac tagaccaaga attgtctgtt attcatgata tgggctttga tgattatttc 840
 30 ttggttgttt gggatttgtt gcgttttgga cgatcgaatg gctattatat gggaatggga 900
 aggggttctg cagtaggcag tttggtttct tatgccttag acatcacggg gattgaccca 960
 gttagagaaa atctgatttt tgaacgcttt cttaatcgtg aacgctatac catgcctgat 1020
 attgatattg atatcccaga tatttatcgt ccagatttta tcagatatgt tggtaataaa 1080
 tatggtagta aacatgcggc acaaatcgtt actttttcaa cctttggagc caagcaagct 1140
 35 cttcgagatg tcttgaaacg ctttggtgtg ccagagtatg aattatctgc aattactaag 1200
 aaaatcagtt ttcgtgacaa tcttaagtcg gcctatgagg gcaatctcca gtttcgtcag 1260
 caaatcaata gtaagttaga ataccacaaa gcttttgaga ttgcttgcaa gatagagggc 1320
 tatccaaggc aaacctctgt ccatgcggct ggtgttgtaa ttagtgacca agatttaacc 1380
 aactacattc ctctaaagta tggatgaa attccactga ctcagtatga tgctcatgga 1440
 40 gttgaggcta gcggactttt gaagatggac tttctgggac tacgaaattt gacctttgtc 1500
 cagaagatgc aagagttgct tgctgaaata gaaggtattc accttaaaat tgaagaaata 1560
 gatttggaag acaagaaac gttagattta tttgcctctg gaaatacaaa aggtatcttt 1620
 caatttgagc aacctggtgc tattcgcttg ctcaaacgtg ttcaaccagt ctgttttgaa 1680
 gatgtcgtag caactacttc tctaaatcga ccgggtgcta gtgactatat caataatttt 1740
 45 gtggcaagaa agcatgggca ggaagaagtg actgttctgg atccagtagt ggaggatatt 1800
 ttggctccaa cctacggcat aatgctctat caggagcagg ttatgcaggt tgcccagcga 1860
 tttgccggat ttagtcttgg gaaagccgat attttgcgtc gggctatggg gaaaaaggat 1920
 gcctctgcca tgcattgagat gagggcttcc tttattcaag gttcattaga agctggtcat 1980
 actgtggaag aagcagagca ggtctttgat gttatggaga agtttgagg ctatggtttt 2040
 50 aacaggtcac acgcctatgc ctactcagca ttggccttcc agttggctta ttttaaaaca 2100
 cattatccag ccatatttta tcagatcatg ttgaattctg ccaacagtga ttacttaata 2160
 gatgcacttg aagcaggttt tgaagtggcg cctctgtcca tcaacacgat tccctatcac 2220
 gataaaattg ccaacaaggc catctatcta ggtttgaaat ccattaaagg agtcagtaat 2280
 gatttagctc tctggattat tgaacttctc ctgtatgaac ctttggttaa agttggtctt 2340
 55 aaattacctg agaattatct gaaacttctc ctgtatgaac ctttggttaa agttggtctt 2400
 ttcgattcat ttgaaaaaaa tcgtcaaaaa gtatttaata acttagctaa tctattgaa 2460
 tttgtgaaag agttgggaag tttgtttgga gatgctattt atagttggca ggaatcggaa 2520

gattggacgg aacaagaaaa attttatatg gaacaagagc ttttagggat aggtgtcagc 2580
 aaacatccac tacaagctat tgcaagtaag gctatttacc cgattacccc aatcggaat 2640
 ttgtcagaaa atagctatgc tattattttg gttgaagttc agaaaataaa agtgattcgt 2700
 5 accaaaaagg gtgaaaatat ggcttcttta caggcagatg atagtaagaa aaaattggat 2760
 gtcactctct tttcagactt atatcgtcag gttggacagg aaataaaaga gggagccttc 2820
 tactatgtaa aaggaaaaat acaatcacgt gatggccgtc tgcaaatgat tgcacaagaa 2880
 ataagagaag cagttgctga acgcttttgg atacagggtga aaaatcatga atcggtatcaa 2940
 gaaatttcac gtatttttaga acaattttaa ggccaatcc cagtcacatc cgggtatgaa 3000
 10 gaggaacaga aaaccatcgt ttctcccat cattttgtag ctaaatccaa tgaattagag 3060
 gagaaattga atgaaatcgt tatgaaaacg atttatcgct aa 3102

 <210> 97
 <211> 921
 <212> DNA
 15 <213> Streptococcus pneumoniae

 <400> 97
 atgaccaacg aattttttaca ttttgaaaaa atcagccgcc agacttggca atctttacat 60
 20 cgaaagacaa cacctccttt gacagaagaa gaattggaat ctatcaagag ttttaatgac 120
 caaatcagtc tccaagacgt tacagatatc tatctccctt tggctcatct gattcagatt 180
 tacaagcgaa ctaaggaaga ttttagccttt tcaaaaggaa ttttctcca acgtgaaagt 240
 aaatctcaac cttttattat tggggtttct gggagtgttg ccgttggaaa atccacaacc 300
 agtcgcctac ttcaaatcct actgtcccgt acgtttacag atgctacggg tgagttgggt 360
 25 acaactgatg gttttctcta tcccaatcaa accttgattg agcagggaaat tttaaatcgt 420
 aaaggatttc ctgaaagcta tgatatggaa gctcttctca acttcttggg ccgcatcaaa 480
 aatggacaag atgtagatat tctgtcttat tctcatgaag tttacgacat cgtacccaaa 540
 aagaaacaaa gtgtcaaagc tgctgatttt gtaatcgttg agggaattaa tgtctttcaa 600
 aatccacaaa acgatcgtct ctatcact gacttctttg acttttccat ctatgtagat 660
 30 gctggagtgg atgatattga aagttgggtat ctggaccgtt tcttgaaaat gctgagtcta 720
 gcccaaacg accctgatag ctactattat cgttttactc agatgccgat tggggaagtg 780
 gagtcctttg cccatcaggt ctggaccagt atcaatctca caaatctgca aaattatatt 840
 gaaccaacca gaaatcgtgc agaagtgatt cttcataaaa gcaagaacca tgaatcgat 900
 gaaatttact taaaaaagta a 921

 35 <210> 98
 <211> 741
 <212> DNA
 <213> Streptococcus pneumoniae

 40 <400> 98
 atggaaattt cattattaac agatgttggg cagaaacgaa caaataacca agactatgtc 60
 aaccactatg tcaatagagc tggacgtacc atgattattt tagctgatgg gatgggaggt 120
 catcgtgcag ggaatatcgc tagtgaaatg gcggtcacag acctgggtgt agcttgggtt 180
 45 gataccaga tcgatacagt caatgaagtg cgtgaatggg tgcgccatta cctagaaatt 240
 gaaaaacaaa agattcacca gcttggtcag gatgaagctt acagagggcat gggaactact 300
 ttggaagtcc ttgctattat tgataatcag gctatctatg ctcatattgg tgattcgcgt 360
 atcggcttga ttctgtgaga agaataccat cagttgacga gcgatcattc cttgggttaat 420
 gaattgtca aggtgtgtca attgacacca gaagaggcag aagctcatcc gcaaaaaaat 480
 50 attatcacc agtctattgg gcaaaaagat gaaattcagc ctgattttgg gacagttatc 540
 cttgagtcag gtgactatct cttgctcaat agtgacggct tgaccaacat gatttcaggc 600
 agtgagattc gtgatattgt aaccagtgat attcctttag cagataaaac ggagacactt 660
 gttcgttttg ctaacaatgc aggaggttta gacaacatta cggttgccct tgtttctatg 720
 aacgaggagg atgaagaatg a 741

 55 <210> 99
 <211> 831
 <212> DNA

<213> *Streptococcus pneumoniae*

<400> 99

5 gtgacgatac agatgaagaa tacaggtaaa cgaattgatac tgatagccaa tagaaaaccg 60
 cagagtcaaa gggctcttga tgaattgcga gatcggttga agagaaatca gtttatactc 120
 aatgatacca atccggatat tgtcatttcc attggcgggg atggtatgct cttgtcggcc 180
 tttcataagt acgaaaatca gcttgacaag gtccgcttta tcggtcttca tactggacat 240
 ttgggcttct atacagatta tcgtgatttt gaggttggaca agctagtgc taatttgcag 300
 10 ctagatactg gggcaagggt ttcttaccct gttctgaatg tgaaggctct tcttgaaaat 360
 ggtgaagtta agattttcag agcactcaac gaagccagca tccgcaggtc tgatcgaacc 420
 atggtggcag atattgtaat aaatgggtgtt ccctttgaac gttttcgtgg agacgggcta 480
 acagtttcca caecgactgg tagtactgcc tataacaagt ctcttgccgg tgctgtttta 540
 caccctacca ttgaagcttt gcaattaacg gaaattgcc gcttaataa tcgtgtctat 600
 cgaacactgg gctcttccat tattgtgcct aagaaggata agattgaact tattccaaca 660
 15 agaaacgatt atcatactat ttcggttgac aatagcgttt attctttccg taatattgag 720
 cgtattgagt atcaaatcga ccatcataag attcactttg tcgcgactcc tagccatacc 780
 agtttctgga accgtgttaa ggatgccttt atcggtgagg tggatgaatg a 831

<210> 100

20 <211> 1623

<212> DNA

<213> *Streptococcus pneumoniae*

<400> 100

25 atgtcaaaag aaattaaatt ttcatcagat gcccgttcag ccatgggtcg tgggtgcgat 60
 attcttgcag acactgttaa agtaaccttg ggaccaaag gtcgcaatgt cgttcttgaa 120
 aagtcattcg gttcaccctt gattaccaat gacggtgtga ccattgccaa agaaatcgaa 180
 ttggaagacc attttgaaaa tatgggtgct aagtagtat cagaagtagc ttctaaaacc 240
 aatgatatcg cagggtgacgg aactacgact gcaacagtct tgaccaagc tatcgctcgt 300
 30 gaaggaaatca aaaacgtcac agcaggtgca aatccaatcg gtattcgtcg tgggattgaa 360
 acagcagttg ccgcagcagt tgaagctttg aaaaacaacg ccatccctgt tgccaataaa 420
 gaagctatcg ctcaagttgc agcagtatct tctcgttctg aaaaagttgg tgagtacatc 480
 tctgaagcaa tggaaaaagt tggcaagac ggtgtcatca ccatcgaaga gtcacgtggt 540
 atggaaacag agcttgaagt cgtagaagga atgcagtttg accgtgggtta cctttcacag 600
 35 tacatggtga cagatagcga aaaaaagggtg gctgaccttg aaaatccgta cattttgatt 660
 acagacaaga aaatttccaa catccaagaa atcttgccac ttttgaaaag cattctccaa 720
 agcaatcgtc cactettgat tattgctgat gatgtggatg gtgaggetct tccaactctt 780
 gttttgaaca agattcgtgg aaccttcaac gtagtagcag tcaaggcacc tgggtttggt 840
 gaccgtcgca aagccatgct tgaagatcgc gccatcttaa caggcggaac agttatcaca 900
 40 gaagaccttg gtcttgagtt gaaagatgcg acaattgaag ctcttggtca agcagcgaga 960
 gtgaccgtgg acaaagatag cacggttatt gtagaagggt caggaaatcc tgaagcgatt 1020
 tctcaccgtg ttgcggttat caagtctcaa atcgaaacta caacttctga atttgaccgt 1080
 gaaaaattgc aagaacgctt ggccaaattg tcagggtggtg tagcggttat taaggctcga 1140
 gccgcaactg aaactgagtt gaaagaaatg aaactccgca ttgaagatgc cctcaacgct 1200
 45 actcgtgcag ctgttgaaga aggtattggt gcagggtggtg gaacagctct tgccaatgtg 1260
 attccagctg ttgctacctt ggaattgaca ggagatgaag caacaggacg taatattggt 1320
 ctccgtgctt tggagaacc cgttcgtcaa attgctcaca atgcaggatt tgaaggatct 1380
 atcggttatcg atcgtttgaa aaatgctgag cttggtatag gattcaacgc agcaactggc 1440
 50 gagtgggtta acatgattga tcaaggatc attgatccag ttaaagtgag tcgttcagcc 1500
 ctacaaaatg cagcatctgt agccagcttg attttgacaa cagaagcagt cgtagccaat 1560
 aaaccagaac cagtagccc agctccagca atggatccaa gtatgatggg cgggatgatg 1620
 taa 1623

<210> 101

55 <211> 1446

<212> DNA

<213> *Streptococcus pneumoniae*

<400> 101
 atgattaaga ttgaaaccgt attagatatt ttaaagaaag atggcctttt tcgcgaaatt 60
 attgaccaag gtcattacca ctacaactac agcaaagtta tttttgatag catcagctac 120
 5 gacagccgaa aagtaacaga agacactctt ttttttgcaa aaggcgctgc ctttaaaaaa 180
 gaataccttc tttctgctat aacacaaggt ttagcttggg atgtagctga aaaggactac 240
 gaagtcgata tccctgtcat cattgtgaac gatataaaga aagccatgag tttgattgcc 300
 atggagttct atggtaatcc acaagagaaa ctcaaactcc ttgcctttac tggactaag 360
 ggtaagacaa cagcaaccta tttcgctat aacatcttat ctcaagggca tagacctgct 420
 10 atgttgctga ccatgaacac aactcttgat ggcgagactt tctttaagtc agcgttgaca 480
 acccctgaga gtattgacct ctttgacatg atgaatcagg ctgtgctaaa tgaccgtacc 540
 cacctcatca tggaagtctc cagtcaagcc tatctagtcc atcgagtcta tggactgacc 600
 tttgatgtag gagtctttct taacatcact cctgaccata tcggcccgat tgaacaccct 660
 agctttgaag actatttcta ccacaagcgt ctcttgatgg aaaatagccg agcagtcac 720
 15 attaacagt acatggacca cttctcagtc ttgaaagaac aggttgaaga tcaagaccat 780
 gatttctatg gtagccaatt tgataaccaa atcgagaatt ccaaagcctt tagcttttca 840
 gctacgggta aactcgtctg agattatgat atccaactca ttggcaactt caaccaagaa 900
 aatgcagtgt ctgctggact tgctgtctc cgtctcggag caagtcttga ggacatcaaa 960
 20 aaaggcatcg ctgcaaccgg cgttcctggg cgtatggaag tctcactca gaaaaatgga 1020
 gccaaagtct tcatcgacta tgcccacaat ggggatagtc tgaaaaaact catcaatgtg 1080
 gttgaaactc atcaaacggg aaagattgct ctggttctgg gatcaacagg aaacaaggga 1140
 gaaagtcgtc gtaaggactt tggcctcctc ctcaatcaac accctgagat tcaagtcttt 1200
 ctgactgctg atgaccctaa ctatgaagac ccaatggcca ttgcagatga aattagtagc 1260
 25 tacatcaatc atcctgttga aaagattgct gatcgccaag aagccatcaa ggcggcaatg 1320
 gctatcacia atcacgaatt agatgcagtt attattgcgg gtaagggagc cgattgttac 1380
 caaatcatcc agggcaagaa agaactctac ccaggagata cagccgtcgc agaaaattat 1440
 ttataa 1446

<210> 102
 30 <211> 1980
 <212> DNA
 <213> Streptococcus pneumoniae

<400> 102
 35 atgatccaaa tcggcaagat ttttgccgga cgctatcgga ttgtcaaaca gattggctga 60
 ggaggtatgg cggatgtcta cctagccaaa gacttaatct tagatgggga agaagtggca 120
 gtgaagggtc tgaggaccaa ctaccagacg gaccgtagat ctgtagctcg ttttcagcgt 180
 gaagcgagag ctatggcaga tctagaccat cctcatatcg ttcggataac agatattggc 240
 40 gaggaagacg gtcaacagta cctagctatg gagtatgtgg ctggactgga cctcaaacgc 300
 tatatcaagg aacattatcc tctttctaata gaagaagcag tccgtatcat gggacaaatt 360
 ctcttggeta tgcgcttgge ccatactega ggaattgttc acagggactt gaaacctcaa 420
 aatatcctct tgacaccaga tgggactgcc aaggtcacag actttgggat tgctgtagcc 480
 tttgcagaga caagtctgac ccagactaac tccatgttgg gctcagttca ttacttgtca 540
 ccagagcagg cgcgtgggtc gaaggcgact gtgcagagtg atatctatgc catggggatt 600
 45 attttctatg agatgctgac aggcataatc ccttatgacg gggatagcgc ggtgaccatt 660
 gccctccagc atttccagaa acccctgccg tccgttattg cagaaaatcc atctgtacct 720
 caggctttag aaaatgttat tatcaaggca actgctaaaa agttgaccaa tcgctaccgc 780
 tcggtttcag agatgtatgt ggacttgtct agtagcttgt cctacaatcg tagaaatgaa 840
 agtaagttaa tctttgatga aacgagcaag gcagatacca agaccttgcg gaaggtttct 900
 50 cagagtaact tgacatctat tcctaagggt caagcgcaaa cagaacacaa atcaatcaaa 960
 aacccaagcc aggtgtgac agaggaaact taccaaccac aagcaccgaa aaaacataga 1020
 ttttaagatgc gttacctgat tttgttgcc agccttgat tgggtggcagc ttctcttatt 1080
 tggatactat ccagaactcc tgcaaccatt gccattccag atgtggcagg tcagacagtt 1140
 gcagaggcca aggcaacgct caaaaaagcc aattttgaga ttggtgagga gaagacagag 1200
 55 ctagtgaaa aggtggaaga agggcggatt atccgtacag atcctggcgc tggaactggg 1260
 cgaagaagag gaacgaaaat caatttggtt gtctcatcag gcaagcaatc tttccaaatt 1320
 agtaattatg tcggtcggaa atcctctgat gtcattgcgg aattaaaaga gaaaaagtt 1380

ccagataatt tgattaaaat tgaggaagaa gagtcgaatg agagttaggc tggaaacggtc 1440
 ctgaagcaaa gtctaccaga aggtacgacc tatgacttga gcaaggcaac tcaaattgtt 1500
 ttgacagtag ctaaaaaagc tacgacgatt caattaggga actatattgg acggaactct 1560
 5 acagaagtaa tctcagaact caagcagaag aaggttcctg agaatttgat taagatagag 1620
 gaagaagagt ccagcgaaag cgaaccagga acgattatga aacaaagtcc aggtgccgga 1680
 acgacttatg atgtgagtaa acctactcaa attgtcttga cagtagctaa aaaagttaca 1740
 agtgttgcca tgccgagtta cattggttct agcttgaggt ttactaagaa caatttgatt 1800
 caaattgttg ggattaagga agctaataa gaagtgttag aagtgcgac agcgccctgca 1860
 ggtagtgacg aaggcatggt tgttgaacaa agtcctagag caggtgaaaa ggtagacctc 1920
 10 aataagacta gagtcaagat ttcaatctac aaacctaaaa caacttcagc tactccttaa 1980

<210> 103

<211> 1176

<212> DNA

15 <213> Streptococcus pneumoniae

<400> 103

atgaaacatt ttgatactat tgtcatcggt gggggacctg ctggtatgat ggctacgatt 60
 20 tccagtaact tttatggaca gaaaaccctc ctcatcgaaa aaaatcggaa acttgaaaaa 120
 aaattagctg ggactgggtg gggacgttgc aatgtgacca acaatggtag cttagacaac 180
 ctgctagctg gaattcctgg aaacggacgc tttctttaca gtgttttctc ccagttcgat 240
 aatcatgaca tcatcaactt ttttacagaa aatgggtgta aacttaaggt cgaagaccac 300
 ggacgcgtct ttccagccag tgacaagtct cggactatta tcgaagcttt ggaaaaagaa 360
 25 atcactgaac taggtggtca agttgctact caaatagaaa tcgtttctgt taaaaaagta 420
 gatgaccagt ttgtccttaa gtcagcggat caaaccttca cttgtgagaa actcattgtc 480
 acaacagggt gtaagtctta tccttcgact gggttcgactg gttttggtca cgagattgct 540
 cgccatttta agcataccat caccgatctt gaggtctgtg aaagtccttt attaacagat 600
 tttccacata aagccttaca agggatttct ctggacgatg tgaccctaag ttatggtaag 660
 30 catgtcatca ctcatgattt actctttacc cactttgggt tgtcaggtcc tgctgcccta 720
 cgcatgtcta gctttgtcaa aggtggggag gttctctcac tcgatgtttt gcctcaactt 780
 tctgagaagg acttggttac atttctagaa gaaaatcggg aaaaatcctt gaaaaacgct 840
 ttaaaaacct tgttaccaga acgcttgccc gaattttttg tacaaggata tctgaaaaa 900
 gtcaaacagc tgactgaaaa ggaacgagaa caacttgccc agtccattaa agaacttaaa 960
 attcctgtaa ctggaaaaat gtcccttgca aagtcctttg ttaccaaggg tggagtcagt 1020
 35 ctcaaggaaa tcaatcctaa aacccttgaa agtaagctgg tacctggcct ccactttgca 1080
 ggcaagttta tggatatcaa tgcccacagc ggtggcttta acatcacttc tgccctctgt 1140
 accggctggg tggcgggaag tctgcattat gattaa 1176

<210> 104

40 <211> 696

<212> DNA

<213> Streptococcus pneumoniae

<400> 104

atgctgaaat gggaagactt gcctgtggaa atgaaatcaa gcgaggttga gtcttactac 60
 45 cagcttgtct ctaaaaggaa gggttcgctg attttcaagc gttgcttga ctgggttttg 120
 gccttggtgc ttacatgggt tctaacttct ccatcttctc tcatcttgag catttggatc 180
 aagttggata gcaaggggccc agtgatttac aagcaagagc gtgtgaccca gtacaaccgt 240
 50 cggttcaaga tttggaagtt ccgtaccatg gtgacggatg cggataaaaa aggaagtctg 300
 gtgacttctg ctaacgatag ccgtattacc aaggttgga atttcatccg acgtgtccgt 360
 ttggacgaac tgccctcagtt ggtcaatgtc cttaaagggt agatgtcctt tgcggtaca 420
 cgacctgaag tgccacgtta tacagagcag tatagccctg aaatgatggc aaccttgctc 480
 ttgcaagcag gaattacctc tccagccagc atcaactaca aggatgagga caccatcatc 540
 agtcaaatga cggagaaaag tctgtcagtt gatcaggcct atgtggagca tgttcttctc 600
 55 gaaaagatgc gctataacct cgcctatctc cgagagttaa gtttcttttg ggacatcaaa 660
 atcatgtttc aaaccgtgtt tgaggtacta aaataa 696

<210> 105
 <211> 423
 <212> DNA
 <213> Streptococcus pneumoniae

5

<400> 105
 atgactagtc cactattaga atctagacgc caactccgta aatgcgcttt tcaagctctc 60
 atgagccttg agttcggtag ggatgtcgaa actgcttgct gtttcgccta tactcatgat 120
 10 cgtgaatata cggatgtaca acttccagcc tttttgatag acctcgtttc tgggtgttcaa 180
 gctaaaaaagg aagaactaga taagcaaact actcagcatt taaaagcagg ttggaccatt 240
 gaacgcttaa cgctcgtgga gagaaacctc ctctcgcttg gagtctttga aatcacttca 300
 tttgacactc ctacagctggt tgctgttaat gaagctatcg agcttgcaaa ggacttctcc 360
 gatcaaaaat ctgcccgttt tatcaatgga ctgctcagcc agtttgtaac agaagaacaa 420
 taa 423

15

<210> 106
 <211> 3540
 <212> DNA
 <213> Streptococcus pneumoniae

20

<400> 106
 atgtatttaa aggaaatcga aattcagggg ttcaagtctt ttgctgataa gaccaaggctc 60
 gtttttgacc aaggtgtgac ggcagttggt ggacccaatg gatctggaaa gtccaatatt 120
 acagaaagtc tgcgttgggc tttgggggag tctagtgtca agagtctccg tgggggcaag 180
 25 atgccggatg tcatctttgc tggaaacagaa agtcgcaaac cgctcaatta tgcttctgta 240
 gttgtgactc tggataatca tgacggatct atcaaggatg caggtaaga aatcagggtg 300
 gaacgccata tctatcgtag tggagatagc gaatacaaga ttgacggcaa gaaagtccgt 360
 ctgcgtgata ttcatgacct ctcttggat actggattgg gacgagattc ctctcttatt 420
 atttcccaag ggaagggtga ggagattttt aattccaagc ctgaggaacg acgagctatt 480
 30 tttgaagaag ctgctggagt tttaaaatac aagactcgca gaaaagaaac cgagagttaa 540
 ctgcagcaaa ctcaggataa tctggaccgc ttagaggaca ttatctacga gttggataat 600
 caaatcaagc ctcttgagaa gcaagctgag aatgcccgta agttttttaga cttggaagga 660
 caacgtaagg ctattttatt agacgttctg gttgtctaaa tcaaggaaaa taaggcagaa 720
 ctagagtcga cagaagaaga gttggctcag gttcaagaac tcttgatgag ttattacca 780
 35 aagcgtgaaa aattagaaga agaaaatcaa actcttaaaa agcaacgcca agatttacag 840
 gctgaatg ccaaagacca aggcagtttg atggacttga ctagtctgat tagtgattta 900
 gaaagaaaat tagccctatc gaaactggag tccgagcaag tggccctgaa tcaacaggag 960
 gcacaagctc gtttggctgc tttggaggat aagagaaatt cactcagcaa agaaaagtat 1020
 gataaagaaa gctcttttag tctgttagag ggaatctag tccaaaataa tcaaaaactc 1080
 40 aatcgtttag aagctgaatt gctggctttc tcagacgac ctgatcagat gattgagctc 1140
 ttacgtgaac gctttgtagc tcttttaaaa gaagaagcgg atgtctcaa ccagttgacc 1200
 cgtattgaga atgagttgga aaatagctcg cagctttctc aaaaacaagc agatcaacta 1260
 gaaaagctga aagagcaatt agctacagct aaagagaagg ctagtcaaga aaaagacgag 1320
 ctfgaaactg ccaaggtgca ggttcagaaa ttattggctg actatcaagc tattgccaag 1380
 45 gagcaagagg agcagaaaac ttcctatcaa gctcaacaaa gtcaactctt tgaccgtctg 1440
 gatagctca aaaaacagca ggcagagctc caaagtttgg aaaatatcct gagaaatcat 1500
 agtaactttt atgcaggtgt taagagtgtt ctccaagaaa aagatcgccct aggtgggatt 1560
 attggtgcag tcagtgcga tctgaccttt gatgtttatt atcaaaactgc cctagagatt 1620
 gccttagggg caagtagcca gcatatcatc gtagaagatg aagagtcggc aaccaagct 1680
 50 attgatttcc tcaaacgaaa cagagtcggt cgtgcaacct ttcttcttt gaccactatt 1740
 aaggcgcgta cgatttctag tcagaaccaa gatgctatcg ctgtaagccc aggtttcctt 1800
 gggatggcag atgagttggt gacttttgat actagactgg aagccatttt caagaacttg 1860
 ctagctacga cggctatctt tgataccgta gaacatgcgc gtgaagctgc tcgacaagtt 1920
 cgttatcagg ttctgtatgt gacattggat gggacagaat tacgcacggg tggttcctat 1980
 55 gcgggtggtg ccaatcgcca aaataacagt attttcatca agccagaact ggagcaatta 2040
 caaaaagaaa ttgctgcaga tgaagcaagc ttgggttcag aagaagcggc tttgaagacc 2100
 ttcaagacc agatggctgc attgacagaa agattagaag ccatcaaatc tcaaggagag 2160

	caggcacgta	ttcaggagca	aggcttgtcc	ctcgcttatc	agcaaactag	tcagcaagtt	2220
	gaagaactgg	aaactctttg	gaaactccaa	gaagaggaaa	tagatcgtct	ttctgaggga	2280
	gattggcaag	cggataagga	aaaatgtcaa	gagagccttg	ctactatcgc	cagtgacaag	2340
	caaaatctgg	aagctgagat	tgaagaaatt	aagtctaata	aaaacgccat	ccaagaacgc	2400
5	tatcaaaatt	tgcaaggaaga	ggtggcgcaa	gctcgcttgc	ttaagacaaa	actgcaaggg	2460
	caaaaacggt	atgaagtagc	tgatattgag	cgtttaggca	aggaattgga	caatcttaat	2520
	atcgaacaag	aagaaattca	gcgcattgctc	caagaaaaag	ttgacaatct	tgagaagggt	2580
	gatacagaat	tgctcagtca	acaggcgga	gaatccaaaa	ctcagaaaaac	aaatctccaa	2640
	caaggtttga	ttcgcaagca	gtttgagttg	gatgatatag	aaggtcaact	ggatgatatt	2700
10	gccagtcact	tggtatcaagc	tcgccagcag	aatgaggagt	ggattcgcaa	gcaaacacgt	2760
	gctgaagcca	agaaagaaaa	ggtcagcgag	cgcttgcgcc	atctacaaaa	tcaattaaca	2820
	gaccagtacc	agattagcta	tactgaagca	ctagaaaagg	cacatgaatt	ggaaaacctc	2880
	aatctggcag	agcaagaggt	gcaggattta	gagaaggcta	ttcgctcatt	gggacctgtc	2940
	aacttggaag	ctattgacca	gtacgaagaa	gttcacaacc	gtctggactt	tctaaatagt	3000
15	cagcgagatg	atattttgtc	agcgaaaaat	ctgctccttg	aaaccattac	agagatgaat	3060
	gatgaggtca	aggaacgctt	taaatcaacc	tttgaagcta	ttcgtgagtc	ctttaaagt	3120
	accttcaagc	agatgtttgg	cggaggtcag	cgagacttga	tattgactga	gggcgacctt	3180
	ttacacagctg	gtgtggagat	ttctgttcaa	cctccaggta	agaaaatcca	gtcgcttaac	3240
	ctcatgagtg	gtggtgaaaa	agctctatcg	gctcttgcc	tgcttttctc	cattattcgt	3300
20	gtcaagacca	ttccttttgt	catcttggat	gagggtggaag	ctgcgctgga	tgaagccaat	3360
	gttaaacggt	ttggggatta	cctcaaccgc	tttgacaagg	acagccagtt	tatcgctgta	3420
	acccaccgta	aggaaccat	ggcagcggt	gattccatct	atggagtgaac	catgcaagaa	3480
	tcaggtgtct	caaaaattgt	ttcggttaag	ttaaaagatt	tagaaagtat	tgaaggatga	3540
25	<210> 107						
	<211> 1344						
	<212> DNA						
	<213> Streptococcus pneumoniae						
30	<400> 107						
	atgacaaaaac	gtgtaacgat	tattgacgta	aaagactatg	ttgggtcagga	agtgaacgatt	60
	ggcgcttggg	ttgccaacaa	atcaggaaaa	ggaaaaatcg	ctttcttaca	attgcgtgat	120
	ggaacagcct	tctttcaagg	tgtggctttt	aaaccaaact	ttgtcgaaaa	atttgggtgaa	180
	gaagtgggac	ttgagaagtt	tgatgttatc	aaacgcttga	gccaaagaaac	gtctgtttat	240
35	gtgacaggta	ttgtcaaaga	ggacgaacgt	tctaaatttg	gctatgagtt	ggacatcaca	300
	gacatcgaag	tgatcggtga	atctcaagac	tacccaatca	cacaaaaaga	acacggaaca	360
	gactttttga	tgataaccg	tcacttgtgg	ctacgctctc	gtaagcaagt	agctgtgttg	420
	caaattccgta	acgctattat	ctatgcaact	tatgagttct	ttgacaagaa	cggtttttatg	480
	aagtttgaca	gcccattctt	ttcaggaaat	gcggcagaag	attctacaga	actctttgaa	540
40	actgactact	tcggaacgcc	agcctacttg	agccaatcag	gtcagcttta	cctagaagca	600
	ggggctatgg	ctcttggtcg	tgtctttgac	tttgggtccag	ttttccgtgc	tgaaaaatca	660
	aaaacacgcc	gtcacttgac	tgagttctgg	atgatggatg	ctgagtaactc	atacttgaca	720
	catgatgagt	cgcttgactt	gcaagaagct	tatgtgaaag	ctcttctaca	aggtgttctt	780
	gaccgcgcgc	ctcaagcctt	ggaacotttg	gaacgtgata	cagaactctt	gaaacgtac	840
45	attgcagagc	cattcaaacg	tatcacttac	gatcaagcca	ttgacctctt	gcaagagcat	900
	gaaaatgatg	aagatgctga	ctacgagcat	cttgagcatg	gtgatgactt	tggttcacca	960
	cacgaaactt	ggatttcaaa	ccactttggt	gtgccaacat	ttgtcatgaa	ctatccagca	1020
	gccatcaagg	ccttctacat	gaaaccagtt	cctggaaatc	cagagcgctg	gctttgtgca	1080
	gacttgcttg	ctccagaagg	ctatggagaa	attatcggtg	ggctatgcg	tgaggaagat	1140
50	tacgatgccc	ttgtcgctaa	gatggatgaa	cttggcatgg	atcgtaacaga	atatgaattc	1200
	taccttgacc	ttcgtaaata	cggtacagtt	ccacacggag	gatttggat	cggtatcgaa	1260
	cgtatggtaa	ccttcgcagc	aggaacaaaa	catatccgtg	aagctattcc	attcccacgt	1320
	atgttgacc	gtatcaaacc	ataa				1344
55	<210> 108						
	<211> 927						
	<212> DNA						

<213> Streptococcus pneumoniae

<400> 108

5 atgtctgaaa aattagtaga aatcaaagat ttagaaatth ccttcggtga aggaagtaag 60
 aagtttgtcg cgggttaaaaa tgctaacttc tttatcaaca agggagaaac tttctcgctt 120
 gtaggtgagt cggtagtggt gaaaacaact attggtcggt ctatcatcgg tctaaatgat 180
 acaagtaatg gagatatcat ttttgatggt caaaagatta atggtaagaa atcgcgtgaa 240
 caagctgcgg aattgattcg tcgaatccag atgattttcc aagaccctgc cgcaagtttg 300
 10 aatgaacgtg cgactgttga ttatattatt tctgaaggte tttacaatca ccgtttattt 360
 aaggatgaag aagaacgtaa agagaaagtt caaaatatta tccgtgaagt aggtcttctt 420
 gctgagcact tgactcgtta ccctcatgaa ttctcaggcg gtcaacgtca acgtatcgtt 480
 attgccgtg ccttggtcat gcaaccagac tttgttattg cagatgagcc aatttcagcc 540
 ttggacgttt ctgtacgtgc ccaagtcttg aacttgctca aaaaattcca aaaagagctc 600
 ggcctgacct atctcttcat cgcccatgac ttgctggttg ttcgctttat ttcagatcgt 660
 15 atcgcagta tttacaaggg tggtattgta gaggttgagc aaacagaaga attgtttaac 720
 aatccaattc acccatatac tcaagccttg ctttcagcgg taccaatccc agatccaatc 780
 ttggaacgta agaaggtctt gaaggtttac gacccaagtc aacacgacta tgagactgat 840
 aagccgtcta tggtagaat ccgtccaggt cactatgttt gggcgaaaca aaccgaattg 900
 gcacgttatc aaaaaggact aaactag 927

<210> 109

<211> 1275

<212> DNA

<213> Streptococcus pneumoniae

25

<400> 109

atgaagataa gttggaatgg attttctaaa aaatcatacc aagagcgctt cgagctgcta 60
 aaagctcagg cgctccttag tcctgagaga caagctagtc tggagaagga tgaacagatg 120
 agtgtgactg tggcagacca gctgagttag aatgtggtgg gaactttttc tctgccttat 180
 30 tcgctgggttc cggaggtagt tgtcaacggt caggaatata ccgttcccta tgtgacagaa 240
 gaacctcttg tggttgcggc ggccagctat gccagcaaaa tcatcaagcg tgcagggtgt 300
 tttactgcac aagtccatca gcgccagatg attgggcagg tagcccttta tcaaattgct 360
 aatcctaaac tagcgcaaga gaagattgcc agcaagaaag cggagctctt ggagcttgcc 420
 aatcaagcct atccttctat cggttaaactg ggggtggggg cgcgtgatct gcatgtcgag 480
 35 cagataaaag gcgaaccaga ctttctcgtt gtttatattc atgtcgatac ccaggaagcc 540
 atgggtgcca atatgtcaa caccatgctg gaagccttga aaccagtctt agaagaactc 600
 agtcagggac agagtctcat gggaatcctg tccaactacg cgactgattc tctggtagct 660
 gcaagctgtc gcatcgctt tcgctacttg agccgcaaaa aggatcaagg acgagagatt 720
 gcggagaaaa ttgcgttggc tagtcagttt gcgcaggctg atccttaccg agctgctact 780
 40 cataataaag gaatttttaa tggatttgat gcgattttga ttgccactgg taatgactgg 840
 cgtgccatcg aagctggggc ccattgcctt gccagtcgag atggacgcta tcaaggtctt 900
 agctgctgga cgctggacct tgaaagagaa gaattggtcg gtgagatgac cctgccccatg 960
 cctgtagcga ctaagggttg ctctatcggc ctcaaccac gtgtagctct cagtcatgat 1020
 ctactaggaa atccttctgc cagagaatta gccagatta tctgttccat cggctcttgc 1080
 45 caaaattttg cagccctcaa agccttggtg agtacgggca tccagcaagg ccacatgaaa 1140
 ctacaggcca aatccctagc tctcctagct ggggctagtg aatctgaagt tgctccccta 1200
 gtagagcgcc tcatctcaga taaaacctt aacctagaga cagcccagcg ctatctcgaa 1260
 aatttaagat cataa 1275

50 <210> 110

<211> 789

<212> DNA

<213> Streptococcus pneumoniae

55 <400> 110

atgccaatga catcattaga aataaaggac aagacttttg gaactcgatt cagaggtttt 60
 gatccagaag aagtcgatga attttttagat attgtggttc gtgattacga agatcttgg 120

- cgtgcgaatc atgataaaaa tttgcgtatt aagagtttag aagagcggtt gtcttacttt 180
 gatgaaataa aagattcatt gagccagtct gtaattgattg ctcaggatac agctgagaga 240
 gtgaaacagg cggcgcatga acgttcaaac aatatcattc atcaagcaga gcaagatgag 300
 5 caacgcttgt tggagaagc taaatataag gcaaacgaga ttcttcgtca agcaactgat 360
 aatgctaaga aagtcgctgt tgaacagaa gaattgaaga acaagagccg tgtcttcac 420
 caacgtctca aatctacaat tgagagtcag ttggctattg ttgaatcttc agattgggaa 480
 gatattctcc gtccaacagc tacttatctt caaaccagtg atgaagcctt taaagaagt 540
 gttagcgaag tacttgga accgattcca gctccaattg aagaagaacc aattgatatg 600
 10 acacgtcagt tctctcaagc agaaatggca gaattacaag ctgctattga ggtagccgat 660
 aaagaattgt ctgaatttga agctcagatt aaacaggaag tggaagctcc aactcctgta 720
 gtgagtcctc aagttgaaga agagcctctg ctcatccagt tggcccaatg tatgaagaac 780
 cagaagtag 789
- <210> 111
 15 <211> 1728
 <212> DNA
 <213> Streptococcus pneumoniae
- <400> 111
 20 atgtctaag gacaactaat ttatttaatg gttgcaattg cagtcatttt agttctggct 60
 tatgtagtgg caatctttct acgtaagcga aacgagggga gattagaggc gctagaagaa 120
 agaaaagaag aactatacaa tcttcagta aatgatgaag tagaagctgt aaaaaatatg 180
 cacttgattg gacaaagtca agtggcttcc cgtgaatgga atcaaaaatg ggtcgattta 240
 25 tctctcaact cttttgccga tattgaaaat aatctctttg aagcagaagg ttataacct 300
 tcatttcggt ttctcaaggc cagtcacaa attgaccaa ttgagagtca aattactttg 360
 attgaagaag atattgcggc aattcgcaat gctttggcag acttagagaa gcaagaatct 420
 aaaaatagtg gtcgtgttct tcatgctttg gatttatttg aggaacttca gcatagagtt 480
 gctgaaaatt cagaacagta tggtaagcc ttggatgaaa ttgaaaaaca attagaaaat 540
 30 atccaatctg aattttcaca atttgaacc ttgaattcat cgggtgaccc tgtggaagcc 600
 gcagtgattt tggataatac agaaaatcac attttggcct taagtcatat tgtggatcgt 660
 gttccagcct tggttacgac gctttctaca gaattgccag atcaattaca ggatttgaa 720
 gccggttatc gtaaaactaat tgatgctaatt tatcattttg ttgaaacgga tattgaagcg 780
 cgtttccact tgctttatga agcattcaag aaaaaccaag agaattatcg tcagttggaa 840
 35 ttggataatg ccgaatatga gaattggacag gcacaagagg aaatcaatgc ctgtgatgat 900
 atttttactc gagaaattgc tgcacagaa gtagtggaat atctacttgc aactcttcca 960
 acttaccttc aacatatgaa agagaataat actttatttg gagaagatat tgcacgtttg 1020
 aacaagacct atttacttcc tgagacagct gcaagccatg ttctgctgat tcagacagaa 1080
 ttagagagtt ttgaggcagc tattgttgag gtaacttcaa atcaagaaga accaacccaa 1140
 gcttattcag ttcttgaaga aaatcttgag gatttacaata ctcaactaaa agatattgaa 1200
 40 gatgagcaaa tttcagttag tgagcgctg acacaaattg agaaagatga tattaatgca 1260
 cgtcaaaaagg ccaatgttta tgcattcgt ctccatacta tcaagcgata catggaaaaa 1320
 cgcaatctgc caggatttcc acaaaacttcc ttgaagttat tctttacggc aagcaataat 1380
 accgaggatt taatgggttg gttagaacaa aaaatgatta acattgaatc tgttaccgga 1440
 gttcttgaaa ttgcaacgaa tgatattgaa gctttagaaa cggaactta taatattgta 1500
 45 caatatgcaa ctttgacaga gcaactcttg caatattcta accgctatcg ctcatattgat 1560
 gaacgcattc aagaagcatt taacgaagct ttagatattt ttgaaaaaga atttgattat 1620
 cacgcttcatt ttgataagat ttctcaagca ttggaagtgg cagagcctgg tgtaaccaat 1680
 cgctttgtta cctcatatga gaaaacacgt gaaacgattc gtttttaa 1728
- 50 <210> 112
 <211> 2403
 <212> DNA
 <213> Streptococcus pneumoniae
- 55 <400> 112
 atgcttatat cttataaatg gttaaaagaa ttgggtggaca ttgatgtgcc atcacaagag 60
 ttggctgaaa aaatgtcaac tacaggaatc gaggtagagg gtgtcgaatc accagctgct 120

5 ggctctctcaa aaattgtcgt cggtagaggtc ttgtcttgcg aagatgtgcc agagactcac 180
 ctccatgttt gtcaggttaa cgttggcgaa gaagagcgtc agatcgtttg tggtgcccca 240
 aatgtgcgtg ctgggatcaa ggtcatgggt gctcttcag gagctcgat cgctgataac 300
 taaaaaatca aaaaaggaaa aatccgtggg ttggagtcac ttggaatgat ctgttcactt 360
 ggtgaattgg gaatttctga ctacgttgtg cctaaggaat tcgcagatgg catccaaatc 420
 ttgcctgaag atgccgtgcc aggtgaggaa gtcttttctt acctagactt ggatgatgaa 480
 atcatcgaac ttccatcac accaaaccgt gcagatgcc tttctatgtg tggagtgggt 540
 cacgaagtgg cagccatcta tgacaaggca gtcaacttta aagaatttac tctaacagaa 600
 10 actaatgaag ctgcggcaga tgccctttct gtcagcattg agacagacaa ggcgccttac 660
 tatgcagctc gtatcttga caatgtgacc atcgacacaa gtccacaatg gttgcaaaac 720
 cttctcatga acgaaggaat ccgtcccac aataacgtag tggacgtgac caactacatc 780
 ctgctctatt ttggtcaacc aatgcattgc tttgacttgg ataactttga agggactgac 840
 atccgtgtgc gtgaagcgcg tgctgggtgaa aaattgggtga ccttggacgg tgaagaacgt 900
 gacttggacg tgaatgacct agtcatcact gtcgcagaca agccagtagc cettgcaggt 960
 15 gtcattgggtg gtcaagcaac agaaatctct gaaaaactta gtcgtgttgt cettgaagct 1020
 gctgttttca atggcaaatc tatccgtaag acaagtgggt gcctgaacct tcgttctgag 1080
 tcatcttctc gctttgaaaa aggaattaat gtggcaacag ttaatgaagc cettgatgag 1140
 gcagctagcc tgattgcgga acttgcaggt gcgacggtgc gtaagggtcat cgtttcagcg 1200
 20 ggtgagcttg atacttcaga ttagaaggtt tcttcaaccc ttgctgatgt taaccgtgtc 1260
 ctcggaactg agctgtctta tgctgatgta gaagacgtct tccgtcgtct tggctttggg 1320
 ctttctggaa atgcagacag ctttacagtc agagtcccac gtcgtcgttg ggatatcaca 1380
 atcgaagctg acctcttga agaaattgct cgtatctatg gttatgaccg cttgccaact 1440
 agtctaccaa aagacgatgg tacagcaggt gaattgacag ccacacaaaa actccgcccgt 1500
 25 caagttcgta ctattgctga aggagcaggt ttgacagaaa tcatcaccta tactctaaca 1560
 actcctgaaa aagcagttga gtttacggct caaccaagta accttacgga actcatgttg 1620
 ccaatgactg tggatcggtc agtccctccg caaaatatga tttcaggtat cettgatacc 1680
 gttgcctaca acgtggctcg taagaataaa aacttggccc ttacagagat tggaaaagtc 1740
 tttgaacaaa caggtaatcc aaaaagaaga ttccaaacag aaatcaacag ttttgccttt 1800
 30 gccttgacag gcttggttgc tgaaaaagat tccaaacag cagcagttcc agttgatctt 1860
 ttctatgcta aggaatcct tgaagcccta tttactcgtt tgggactcca agtaacctat 1920
 acagcaacat ctgaaatgc tagccttcat ccaggtcgta cagccgtgat ttactcggg 1980
 gaccaagttc ttggtttcct tggccaagtg catccagtca ctgccaaggc ttacgatatt 2040
 ccagaaacgt atgtggctga gcttaacctt tcagctatcg aagctgcgct tcagccagcg 2100
 actccatttg tagaaatcac caaattcccg gcagtcagcc gtgacgttgc ccttctctc 2160
 35 aaggcagaag tgactcatca agaagtgtga gatgctatcc aagctgccgg cgtgaaacgt 2220
 ttgacagata tcaaactctt tgacgtcttc tcaggtgaga aattgggact tggatgaag 2280
 tcaatggctt atagcttgac cttccaaaat ccagaagata gcttaacgga cgaagaagtc 2340
 gcacgctata tggaaaaaat ccaagcatcg ctcgaagaaa aagtcaatgc agaagtgcgt 2400
 40 taa 2403
 <210> 113
 <211> 543
 <212> DNA
 <213> Streptococcus pneumoniae
 45
 <400> 113
 atgttagaaa acgatattaa aaaagtcctc gtttcacacg atgaaattac agaagcagct 60
 aaaaaactag gtgctcaatt aactaaagat tatgcaggaa aaaatccaat cttagttggg 120
 attttaaaag gatctattcc ttttatggct gaattgggtc aacatattga tacacatatt 180
 50 gaaatggact tcatgatggg ttctagctac catgggtgaa cagcaagtag tgggtgttatc 240
 aatattaaac aagatgtgac tcaagatata aaaggaagac atgttctatt ttagaagat 300
 atcattgata caggtcaaac tttgaagaat ttgcgagata tgtttaaagc aagagaagca 360
 gcttctgtta aaattgcaac cttgttggat aaaccagaag gacgtgttgt agaaattgag 420
 gcagactata cctgctttac tatcccaaat gagttttag taggttatgg ttagactac 480
 55 aaagaaaatt atcgtaattc tccttatatt ggagtattga aagaggaagt gtattcaaat 540
 tag 543

<210> 114
 <211> 235
 <212> PRT
 <213> Streptococcus pneumoniae
 5
 <400> 114
 Met Ile Tyr Ala Gly Ile Leu Ala Gly Gly Thr Gly Thr Arg Met Gly
 1 5 10 15
 10 Ile Ser Asn Leu Pro Lys Gln Phe Leu Glu Leu Gly Asp Arg Pro Ile
 20 25 30
 Leu Ile His Thr Ile Glu Lys Phe Val Leu Glu Pro Ser Ile Glu Lys
 35 40 45
 15 Ile Val Val Gly Val His Gly Asp Trp Val Leu His Ala Glu Asp Leu
 50 55 60
 Val Asp Lys Tyr Leu Pro Leu His Lys Glu Arg Ile Ile Ile Thr Lys
 65 70 75 80
 Gly Gly Ala Asp Arg Asn Thr Ser Ile Glu Asn Ile Ile Glu Ala Ile
 85 90 95
 25 Asp Ala Tyr Arg Pro Leu Thr Pro Glu Asp Ile Val Val Thr His Asp
 100 105 110
 Ser Val Arg Pro Phe Ile Thr Leu Arg Met Ile Gln Asp Ser Ile Lys
 115 120 125
 30 Leu Ala Gln Asn His Asp Ala Val Asp Thr Val Val Glu Ala Val Asp
 130 135 140
 Thr Ile Val Glu Ser Thr Asn Gly Gln Phe Ile Thr Gly Ile Pro Asn
 145 150 155 160
 Arg Ala His Leu Tyr Gln Gly Gln Thr Pro Gln Thr Phe Arg Cys Lys
 165 170 175
 40 Asp Phe Met Asp Leu Tyr Gly Ser Leu Ser Asp Glu Glu Lys Glu Ile
 180 185 190
 Leu Thr Asp Ala Cys Lys Ile Phe Val Ile Lys Gly Lys Asp Val Ala
 195 200 205
 45 Leu Ala Lys Gly Glu Tyr Ser Asn Leu Lys Ile Thr Thr Val Thr Asp
 210 215 220
 Leu Lys Ile Ala Lys Ser Met Ile Glu Lys Asp
 50 225 230 235
 55
 <210> 115
 <211> 185
 <212> PRT
 <213> Streptococcus pneumoniae

<400> 115
 Met Ala Asn Val Ile Ile Glu Lys Ala Lys Glu Arg Met Thr Gln Ser
 1 5 10 15
 5 His Gln Ser Leu Ala Arg Glu Phe Gly Gly Ile Arg Ala Gly Arg Ala
 20 25 30
 Asn Ala Ser Leu Leu Asp Arg Val His Val Glu Tyr Tyr Gly Val Glu
 35 40 45
 10 Thr Pro Leu Asn Gln Ile Ala Ser Ile Thr Ile Pro Glu Ala Arg Val
 50 55 60
 15 Leu Leu Val Thr Pro Phe Asp Lys Ser Ser Leu Lys Asp Ile Glu Arg
 65 70 75 80
 Ala Leu Asn Ala Ser Asp Leu Gly Ile Thr Pro Ala Asn Asp Gly Ser
 85 90 95
 20 Val Ile Arg Leu Val Ile Pro Ala Leu Thr Glu Glu Thr Arg Arg Asp
 100 105 110
 Leu Ala Lys Glu Val Lys Lys Val Gly Glu Asn Ala Lys Val Ala Val
 115 120 125
 25 Arg Asn Ile Arg Arg Asp Ala Met Asp Glu Ala Lys Lys Gln Glu Lys
 130 135 140
 30 Ala Gln Glu Ile Thr Glu Asp Glu Leu Lys Thr Leu Glu Lys Asp Ile
 145 150 155 160
 Gln Lys Val Thr Asp Asp Ala Val Lys His Ile Asp Asp Met Thr Ala
 165 170 175
 35 Asn Lys Glu Lys Glu Leu Leu Glu Val
 180 185
 40 <210> 116
 <211> 450
 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 116
 45 Met Gly Lys Tyr Phe Gly Thr Asp Gly Val Arg Gly Glu Ala Asn Leu
 1 5 10 15
 Glu Leu Thr Pro Glu Leu Ala Phe Lys Leu Gly Arg Phe Gly Gly Tyr
 20 25 30
 50 Val Leu Ser Gln His Glu Thr Glu Ala Pro Lys Val Phe Val Gly Arg
 35 40 45
 55 Asp Thr Arg Ile Ser Gly Glu Met Leu Glu Ser Ala Leu Val Ala Gly
 50 55 60
 Leu Leu Ser Val Gly Ile His Val Tyr Lys Leu Gly Val Leu Ala Thr

	65	70	75	80
	Pro Ala Val	Ala Tyr Leu Val	Glu Thr Glu Gly Ala Ser	Ala Gly Val
		85	90	95
5	Met Ile Ser	Ala Ser His Asn Pro	Ala Leu Asp Asn Gly	Ile Lys Phe
	100		105	110
10	Phe Gly Gly	Asp Gly Phe Lys Leu Asp	Asp Glu Lys Glu Ala	Glu Ile
	115		120	125
	Glu Ala Leu	Leu Asp Ala Glu Glu Asp	Thr Leu Pro Arg Pro	Ser Ala
	130		135	140
15	Glu Gly Leu	Gly Ile Leu Val Asp Tyr Pro	Glu Gly Leu Arg Lys	Tyr
	145		150	155
	Glu Gly Tyr	Arg Val Ser Thr Gly Thr	Pro Leu Asp Gly Met	Lys Val
		165	170	175
20	Ala Leu Asp	Thr Ala Asn Gly Ala Ala Ser	Thr Ser Ala Arg Gln	Ile
		180	185	190
25	Phe Ala Asp	Leu Gly Ala Gln Leu Thr Val	Ile Gly Glu Thr Pro	Asp
	195		200	205
	Gly Leu Asn	Ile Asn Leu Asn Val Gly Ser	Thr His Pro Glu Ala	Leu
	210		215	220
30	Gln Glu Val	Val Lys Glu Ser Gly Ser Ala	Ile Gly Leu Ala Phe	Asp
	225		230	235
	Gly Asp Ser	Asp Arg Leu Ile Ala Val Asp	Glu Asn Gly Asp Ile	Val
		245	250	255
35	Asp Gly Asp	Lys Ile Met Tyr Ile Ile Gly	Lys Tyr Leu Ser Glu	Lys
		260	265	270
40	Gly Gln Leu	Ala Gln Asn Thr Ile Val Thr	Thr Val Met Ser Asn	Leu
	275		280	285
	Gly Phe His	Lys Ala Leu Asn Arg Glu Gly	Ile Asn Lys Ala Val	Thr
	290		295	300
45	Ala Val Gly	Asp Arg Tyr Val Val Glu Glu	Met Arg Lys Ser Gly	Tyr
	305		310	315
	Asn Leu Gly	Gly Glu Gln Ser Gly His Val	Ile Leu Met Asp Tyr	Asn
		325	330	335
50	Thr Thr Gly	Asp Gly Gln Leu Ser Ala Val	Gln Leu Thr Lys Ile	Met
		340	345	350
55	Lys Glu Thr	Gly Lys Ser Leu Ser Glu Leu	Ala Ala Glu Val Thr	Ile
	355		360	365
	Tyr Pro Gln	Lys Leu Val Asn Ile Arg Val	Glu Asn Val Met Lys	Glu

370 375 380
 Lys Ala Met Glu Val Pro Ala Ile Lys Ala Ile Ile Glu Lys Met Glu
 385 390 395 400
 5 Glu Glu Met Ala Gly Asn Gly Arg Ile Leu Val Arg Pro Ser Gly Thr
 405 410 415
 10 Glu Pro Leu Leu Arg Val Met Ala Glu Ala Pro Thr Thr Glu Glu Val
 420 425 430
 Asp Tyr Tyr Val Asp Thr Ile Thr Asp Val Val Arg Ala Glu Ile Gly
 435 440 445
 15 Ile Asp
 450
 20 <210> 117
 <211> 234
 <212> PRT
 <213> Streptococcus pneumoniae
 25 <400> 117
 Met Lys Lys Ile Leu Ile Val Asp Asp Glu Lys Pro Ile Ser Asp Ile
 1 5 10 15
 Ile Lys Phe Asn Met Thr Lys Glu Gly Tyr Glu Val Val Thr Ala Phe
 20 25 30
 30 Asn Gly Arg Glu Ala Leu Glu Gln Phe Glu Ala Glu Gln Pro Asp Ile
 35 40 45
 35 Ile Ile Leu Asp Leu Met Leu Pro Glu Ile Asp Gly Leu Glu Val Ala
 50 55 60
 Lys Thr Ile Arg Lys Thr Ser Ser Val Pro Ile Leu Met Leu Ser Ala
 65 70 75 80
 40 Lys Asp Ser Glu Phe Asp Lys Val Ile Gly Leu Glu Leu Gly Ala Asp
 85 90 95
 Asp Tyr Val Thr Lys Pro Phe Ser Asn Arg Glu Leu Gln Ala Arg Val
 100 105 110
 45 Lys Ala Leu Leu Arg Arg Ser Gln Pro Met Pro Val Asp Gly Gln Glu
 115 120 125
 50 Ala Asp Ser Lys Pro Gln Pro Ile Gln Ile Gly Asp Leu Glu Ile Val
 130 135 140
 Pro Asp Ala Tyr Val Ala Lys Lys Tyr Gly Glu Glu Leu Asp Leu Thr
 145 150 155 160
 55 His Arg Glu Phe Glu Leu Leu Tyr His Leu Ala Ser His Thr Gly Gln
 165 170 175

Val Ile Thr Arg Glu His Leu Leu Glu Thr Val Trp Gly Tyr Asp Tyr
 180 185 190
 5 Phe Gly Asp Val Arg Thr Val Asp Val Thr Val Arg Arg Leu Arg Glu
 195 200 205
 Lys Ile Glu Asp Thr Pro Ser Arg Pro Glu Tyr Ile Leu Thr Arg Arg
 210 215 220
 10 Gly Val Gly Tyr Tyr Met Arg Asn Asn Ala
 225 230
 <210> 118
 15 <211> 368
 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 118
 20 Met Glu Glu Ile Leu Cys Ile Gly Cys Gly Ala Thr Ile Gln Thr Thr
 1 5 10 15
 Asp Lys Ala Gly Leu Gly Phe Thr Pro Gln Ser Ala Leu Glu Lys Gly
 20 25 30
 25 Leu Glu Thr Gly Glu Val Tyr Cys Gln Arg Cys Phe Arg Leu Arg His
 35 40 45
 Tyr Asn Glu Ile Thr Asp Val Gln Leu Thr Asn Asp Asp Phe Leu Lys
 30 50 55 60
 Leu Leu His Glu Val Gly Asp Ser Asp Ala Leu Val Val Asn Val Ile
 65 70 75 80
 35 Asp Ile Phe Asp Phe Asn Gly Ser Val Ile Pro Gly Leu Pro Arg Phe
 85 90 95
 Val Ser Gly Asn Asp Val Leu Leu Val Gly Asn Lys Lys Asp Ile Leu
 100 105 110
 40 Pro Lys Ser Val Lys Ser Gly Lys Ile Ser Gln Trp Leu Met Lys Arg
 115 120 125
 Ala His Glu Glu Gly Leu Arg Pro Val Asp Val Val Leu Thr Ser Ala
 45 130 135 140
 Gln Asn Lys His Ala Ile Lys Glu Val Ile Asp Lys Ile Glu His Tyr
 145 150 155 160
 50 Arg Lys Gly Arg Asp Val Tyr Val Val Gly Val Thr Asn Val Gly Lys
 165 170 175
 Ser Thr Leu Ile Asn Ala Ile Ile Gln Glu Ile Thr Gly Asp Gln Asn
 180 185 190
 55 Val Ile Thr Thr Ser Arg Phe Pro Gly Thr Thr Leu Asp Lys Ile Glu
 195 200 205

Ile Pro Leu Asp Asp Gly Ser Tyr Ile Tyr Asp Thr Pro Gly Ile Ile
 210 215 220
 5 His Arg His Gln Met Ala His Tyr Leu Thr Ala Lys Asn Leu Lys Tyr
 225 230 235 240
 Val Ser Pro Lys Lys Glu Ile Lys Pro Lys Thr Tyr Gln Leu Asn Pro
 245 250 255
 10 Glu Gln Thr Leu Phe Leu Gly Gly Leu Gly Arg Phe Asp Phe Ile Ala
 260 265 270
 Gly Glu Lys Gln Gly Phe Thr Ala Phe Phe Asp Asn Glu Leu Lys Leu
 15 275 280 285
 His Arg Ser Lys Leu Glu Gly Ala Ser Ala Phe Tyr Asp Lys His Leu
 290 295 300
 20 Gly Thr Leu Leu Thr Pro Pro Asn Ser Lys Glu Lys Glu Asp Phe Pro
 305 310 315 320
 Arg Leu Val Gln His Val Phe Thr Ile Lys Asp Lys Thr Asp Leu Val
 325 330 335
 25 Ile Ser Gly Leu Gly Trp Ile Arg Val Thr Gly Thr Ala Lys Val Ala
 340 345 350
 Val Trp Ala Pro Glu Gly Val Ala Val Val Thr Arg Lys Ala Ile Ile
 30 355 360 365
 35
 <210> 119
 <211> 486
 <212> PRT
 <213> Streptococcus pneumoniae
 40
 <400> 119
 Met Tyr Pro Asp Asp Ser Leu Thr Leu His Thr Asp Leu Tyr Gln Ile
 1 5 10 15
 45 Asn Met Met Gln Val Tyr Phe Asp Gln Gly Ile His Asn Lys Lys Ala
 20 25 30
 Val Phe Glu Val Tyr Phe Arg Gln Gln Pro Phe Lys Asn Gly Tyr Ala
 35 40 45
 50 Val Phe Ala Gly Leu Glu Arg Ile Val Asn Tyr Leu Glu Asp Leu Arg
 50 55 60
 55 Phe Ser Asp Ser Asp Ile Ala Tyr Leu Glu Ser Leu Gly Tyr His Gly
 65 70 75 80
 Ala Phe Leu Asp Tyr Leu Arg Asn Phe Lys Leu Glu Leu Thr Val Arg

	85	90	95
	Ser Ala Gln Glu Gly Asp Leu Val Phe Ala Asn Glu Pro Ile Val Gln		
	100	105	110
5	Val Glu Gly Pro Leu Ala Gln Cys Gln Leu Val Glu Thr Ala Leu Leu		
	115	120	125
10	Asn Ile Val Asn Tyr Gln Thr Leu Val Ala Thr Lys Ala Ala Arg Ile		
	130	135	140
	Arg Ser Val Ile Glu Asp Glu Pro Leu Met Glu Phe Gly Thr Arg Arg		
	145	150	155 160
15	Ala Gln Glu Thr Asp Ala Ala Ile Trp Gly Thr Arg Ala Ala Val Ile		
	165	170	175
	Gly Gly Ala Asn Gly Thr Ser Asn Val Arg Ala Gly Lys Leu Phe Asp		
	180	185	190
20	Ile Pro Val Leu Gly Thr His Ala His Ala Leu Val Gln Val Tyr Gly		
	195	200	205
	Asn Asp Tyr Glu Ala Phe Lys Ala Tyr Ala Ala Thr His Lys Asn Cys		
25	210	215	220
	Val Phe Leu Val Asp Thr Tyr Asp Thr Leu Arg Ile Gly Val Pro Ala		
	225	230	235 240
30	Ala Ile Gln Val Ala Arg Glu Leu Gly Asp Gln Ile Asn Phe Met Gly		
	245	250	255
	Val Arg Ile Asp Ser Gly Asp Ile Ala Tyr Ile Ser Lys Lys Val Arg		
	260	265	270
35	Gln Gln Leu Asp Glu Ala Gly Phe Thr Glu Ala Lys Ile Tyr Ala Ser		
	275	280	285
	Asn Asp Leu Asp Glu Asn Thr Ile Leu Asn Leu Lys Met Gln Lys Ala		
40	290	295	300
	Lys Ile Asp Val Trp Gly Val Gly Thr Gln Leu Ile Thr Ala Tyr Asp		
	305	310	315 320
45	Gln Pro Ala Leu Gly Ala Val Tyr Lys Ile Val Ala Ile Glu Asp Glu		
	325	330	335
	Thr Gly Gln Met Arg Asn Thr Ile Lys Leu Ser Asn Asn Ala Glu Lys		
	340	345	350
50	Val Ser Thr Pro Gly Lys Lys Gln Val Trp Arg Ile Thr Ser Arg Glu		
	355	360	365
	Lys Gly Lys Ser Glu Gly Asp Tyr Ile Thr Tyr Asp Gly Val Asp Ile		
55	370	375	380
	Ser Asp Met Thr Glu Ile Lys Met Phe His Pro Thr Tyr Thr Tyr Ile		

385 390 395 400
 Lys Lys Thr Val Arg Asn Phe Asp Ala Val Pro Leu Leu Val Asp Ile
 405 410 415
 5 Phe Lys Glu Gly Ile Leu Val Tyr Asn Leu Pro Ser Leu Thr Asp Ile
 420 425 430
 10 Gln Asp Tyr Ala Arg Lys Glu Phe Asp Lys Leu Trp Asp Glu Tyr Lys
 435 440 445
 Arg Val Leu Asn Pro Gln His Tyr Pro Val Asp Leu Ala Arg Asp Val
 450 455 460
 15 Trp Gln Asp Lys Met Asp Leu Ile Asp Lys Met Arg Lys Glu Ala Leu
 465 470 475 480
 Gly Glu Gly Glu Glu Glu
 485
 20
 <210> 120
 <211> 283
 <212> PRT
 25 <213> Streptococcus pneumoniae
 <400> 120
 Met Ala Thr Ile Gln Trp Phe Pro Gly His Met Ser Lys Ala Arg Arg
 1 5 10 15
 30 Gln Val Gln Glu Asn Leu Lys Phe Val Asp Phe Val Thr Ile Leu Val
 20 25 30
 35 Asp Ala Arg Leu Pro Leu Ser Ser Gln Asn Pro Met Leu Thr Lys Ile
 35 40 45
 Val Gly Asp Lys Pro Lys Leu Leu Ile Leu Asn Lys Ala Asp Leu Ala
 50 55 60
 40 Asp Pro Ala Met Thr Lys Glu Trp Arg Gln Tyr Phe Glu Ser Gln Gly
 65 70 75 80
 Ile Gln Thr Leu Ala Ile Asn Ser Lys Glu Gln Val Thr Val Lys Val
 85 90 95
 45 Val Thr Asp Ala Ala Lys Lys Leu Met Ala Asp Lys Ile Ala Arg Gln
 100 105 110
 50 Lys Glu Arg Gly Ile Gln Ile Glu Thr Leu Arg Thr Met Ile Ile Gly
 115 120 125
 Ile Pro Asn Ala Gly Lys Ser Thr Leu Met Asn Arg Leu Ala Gly Lys
 130 135 140
 55 Lys Ile Ala Val Val Gly Asn Lys Pro Gly Val Thr Lys Gly Gln Gln
 145 150 155 160

Trp Leu Lys Thr Asn Lys Asp Leu Glu Ile Leu Asp Thr Pro Gly Ile
 165 170 175
 5 Leu Trp Pro Lys Phe Glu Asp Glu Thr Val Ala Leu Lys Leu Ala Leu
 180 185 190
 Thr Gly Ala Ile Lys Asp Gln Leu Leu Pro Met Asp Glu Val Thr Ile
 195 200 205
 10 Phe Gly Ile Asn Tyr Phe Lys Glu His Tyr Pro Glu Lys Leu Ala Glu
 210 215 220
 Arg Phe Lys Gln Met Lys Ile Glu Glu Glu Pro Ser Val Ile Ile Met
 225 230 235 240
 15 Asp Met Thr Arg Ala Leu Gly Phe Arg Asp Asp Tyr Asp Arg Phe Tyr
 245 250 255
 20 Ser Leu Phe Val Lys Glu Val Arg Asp Gly Lys Leu Gly Asn Tyr Thr
 260 265 270
 Leu Asp Thr Leu Glu Asp Leu Asp Gly Asn Asp
 275 280
 25
 <210> 121
 <211> 156
 <212> PRT
 <213> Streptococcus pneumoniae
 30
 <400> 121
 Met Ile Asn Asn Val Val Leu Val Gly Arg Met Thr Arg Asp Ala Glu
 1 5 10 15
 35 Leu Arg Tyr Thr Pro Ser Asn Val Ala Val Ala Thr Phe Thr Leu Ala
 20 25 30
 Val Asn Arg Thr Phe Lys Ser Gln Asn Gly Glu Arg Glu Ala Asp Phe
 35 40 45
 40 Ile Asn Val Val Met Trp Arg Gln Gln Ala Glu Asn Leu Ala Asn Trp
 50 55 60
 Ala Lys Lys Gly Ser Leu Ile Gly Val Thr Gly Arg Ile Gln Thr Arg
 45 65 70 75 80
 Ser Tyr Asp Asn Gln Gln Gly Gln Arg Val Tyr Val Thr Glu Val Val
 85 90 95
 50 Ala Glu Asn Phe Gln Met Leu Glu Ser Arg Ser Val Arg Glu Gly His
 100 105 110
 Thr Gly Gly Ala Tyr Ser Ala Pro Thr Ala Asn Tyr Ser Ala Pro Thr
 115 120 125
 55 Asn Ser Val Pro Asp Phe Ser Arg Asn Glu Asn Pro Phe Gly Ala Thr
 130 135 140

Asn Pro Leu Asp Ile Ser Asp Asp Asp Leu Pro Phe
 145 150 155

5
 <210> 122
 <211> 324
 <212> PRT
 <213> Streptococcus pneumoniae

10
 <400> 122
 Met Lys Thr Arg Ile Thr Glu Leu Leu Lys Ile Asp Tyr Pro Ile Phe
 1 5 10 15

15
 Gln Gly Gly Met Ala Trp Val Ala Asp Gly Asp Leu Ala Gly Ala Val
 20 25 30

20
 Ser Lys Ala Gly Gly Leu Gly Ile Ile Gly Gly Gly Asn Ala Pro Lys
 35 40 45

25
 Glu Val Val Lys Ala Asn Ile Asp Lys Ile Lys Ser Leu Thr Asp Lys
 50 55 60

30
 Pro Phe Gly Val Asn Ile Met Leu Leu Ser Pro Phe Val Glu Asp Ile
 65 70 75 80

35
 Val Asp Leu Val Ile Glu Glu Gly Val Lys Val Val Thr Thr Gly Ala
 85 90 95

40
 Gly Asn Pro Ser Lys Tyr Met Glu Arg Phe His Glu Ala Gly Ile Ile
 100 105 110

45
 Val Ile Pro Val Val Pro Ser Val Ala Leu Ala Lys Arg Met Glu Lys
 115 120 125

50
 Ile Gly Ala Asp Ala Val Ile Ala Glu Gly Met Glu Ala Gly Gly His
 130 135 140

55
 Ile Gly Lys Leu Thr Thr Met Thr Leu Val Arg Gln Val Ala Thr Ala
 145 150 155 160

60
 Ile Ser Ile Pro Val Ile Ala Ala Gly Gly Ile Ala Asp Gly Glu Gly
 165 170 175

65
 Ala Ala Ala Gly Phe Met Leu Gly Ala Glu Ala Val Gln Val Gly Thr
 180 185 190

70
 Arg Phe Val Val Ala Lys Glu Ser Asn Ala His Pro Asn Tyr Lys Glu
 195 200 205

75
 Lys Ile Leu Lys Ala Arg Asp Ile Asp Thr Thr Ile Ser Ala Gln His
 210 215 220

80
 Phe Gly His Ala Val Arg Ala Ile Lys Asn Gln Leu Thr Arg Asp Phe
 225 230 235 240

85
 Glu Leu Ala Glu Lys Asp Ala Phe Lys Gln Glu Asp Pro Asp Leu Glu

245 250 255

Ile Phe Glu Gln Met Gly Ala Gly Ala Leu Ala Lys Ala Val Val His
260 265 270

5 Gly Asp Val Glu Gly Gly Ser Val Met Ala Gly Gln Ile Ala Gly Leu
275 280 285

10 Val Ser Lys Glu Glu Thr Ala Glu Glu Ile Leu Lys Asp Leu Tyr Tyr
290 295 300

Gly Ala Ala Lys Lys Ile Gln Glu Glu Ala Ser Arg Trp Thr Gly Val
305 310 315 320

15 Val Arg Asn Asp

<210> 123
<211> 140
<212> PRT
<213> Streptococcus pneumoniae

<400> 123

25 Met Ile Asp Ile Gln Gly Ile Lys Glu Ala Leu Pro His Arg Tyr Pro
1 5 10 15

Met Leu Leu Val Asp Arg Val Leu Glu Val Ser Glu Asp Thr Ile Val
20 25 30

30 Ala Ile Lys Asn Val Thr Ile Asn Glu Pro Phe Phe Asn Gly His Phe
35 40 45

35 Pro Gln Tyr Pro Val Met Pro Gly Val Leu Ile Met Glu Ala Leu Ala
50 55 60

Gln Thr Ala Gly Val Leu Glu Leu Ser Lys Pro Glu Asn Lys Gly Lys
65 70 75 80

40 Leu Val Phe Tyr Ala Gly Met Asp Lys Val Lys Phe Lys Lys Gln Val
85 90 95

Val Pro Gly Asp Gln Leu Val Met Thr Ala Thr Phe Val Lys Arg Arg
100 105 110

45 Gly Thr Ile Ala Val Val Glu Ala Lys Ala Glu Val Asp Gly Lys Leu
115 120 125

Ala Ala Ser Gly Thr Leu Thr Phe Ala Ile Gly Asn
130 135 140

<210> 124
<211> 340
<212> PRT
<213> Streptococcus pneumoniae

55

<400> 124
 Met Ile Asn Gln Ile Tyr Gln Leu Thr Lys Pro Lys Phe Ile Asn Val
 1 5 10 15
 5 Lys Tyr Gln Glu Glu Ala Ile Asp Gln Glu Asn His Ile Leu Ile Arg
 20 25 30
 Pro Asn Tyr Met Ala Val Cys His Ala Asp Gln Arg Tyr Tyr Gln Gly
 35 40 45
 10 Lys Arg Asp Pro Lys Ile Leu Asn Lys Lys Leu Pro Met Ala Met Ile
 50 55 60
 15 His Glu Ser Cys Gly Ile Val Ile Ser Asp Pro Ser Gly Thr Tyr Glu
 65 70 75 80
 Val Gly Gln Lys Val Val Met Ile Pro Asn Gln Ser Pro Met Gln Ser
 85 90 95
 20 Asp Glu Glu Phe Tyr Glu Asn Tyr Met Thr Gly Thr His Phe Leu Ser
 100 105 110
 Ser Gly Phe Asp Gly Phe Met Arg Glu Phe Val Ser Leu Pro Lys Asp
 115 120 125
 25 Arg Val Val Ala Tyr Asp Ala Ile Glu Asp Thr Val Ala Ala Ile Thr
 130 135 140
 30 Glu Phe Val Ser Val Gly Met His Ala Met Asn Arg Leu Leu Thr Leu
 145 150 155 160
 Ala His Ser Lys Arg Glu Arg Ile Pro Val Ile Gly Asp Gly Ser Leu
 165 170 175
 35 Ala Phe Val Val Ala Asn Ile Ile Asn Tyr Thr Leu Pro Glu Ala Glu
 180 185 190
 Ile Val Val Ile Gly Arg His Trp Glu Lys Leu Glu Leu Phe Ser Phe
 195 200 205
 40 Ala Lys Glu Cys Tyr Ile Thr Asp Asn Ile Pro Glu Glu Leu Ala Phe
 210 215 220
 45 Asp His Ala Phe Glu Cys Cys Gly Gly Asp Gly Thr Gly Pro Ala Ile
 225 230 235 240
 Asn Asp Leu Ile Arg Tyr Ile Arg Pro Gln Gly Thr Ile Leu Met Met
 245 250 255
 50 Gly Val Ser Glu Tyr Lys Val Asn Leu Asn Thr Arg Asp Ala Leu Glu
 260 265 270
 Lys Gly Leu Leu Leu Val Gly Ser Ser Arg Ser Gly Arg Ile Asp Phe
 275 280 285
 55 Glu Asn Ala Ile Gln Met Met Lys Val Lys Lys Phe Ala Asn Arg Leu
 290 295 300

Lys Asn Ile Leu Tyr Leu Glu Glu Pro Val Arg Glu Ile Lys Asp Ile
 305 310 315 320
 5 His Arg Val Phe Ala Thr Asp Leu Asn Thr Ala Phe Lys Thr Val Phe
 325 330 335
 Lys Trp Glu Val
 340
 10
 <210> 125
 <211> 447
 <212> PRT
 15 <213> Streptococcus pneumoniae
 <400> 125
 Met Asn Leu Lys Thr Thr Leu Gly Leu Leu Ala Gly Arg Ser Ser His
 1 5 10 15
 20 Phe Val Leu Ser Arg Leu Gly Arg Gly Ser Thr Leu Pro Gly Lys Val
 20 25 30
 25 Ala Leu Gln Phe Asp Lys Asp Ile Leu Gln Asn Leu Ala Lys Asn Tyr
 35 40 45
 Glu Ile Val Val Val Thr Gly Thr Asn Gly Lys Thr Leu Thr Thr Ala
 50 55 60
 30 Leu Thr Val Gly Ile Leu Lys Glu Val Tyr Gly Gln Val Leu Thr Asn
 65 70 75 80
 Pro Ser Gly Ala Asn Met Ile Thr Gly Ile Ala Thr Thr Phe Leu Thr
 85 90 95
 35 Ala Lys Ser Ser Lys Thr Gly Lys Asn Ile Ala Val Leu Glu Ile Asp
 100 105 110
 40 Glu Ala Ser Leu Ser Arg Ile Cys Asp Tyr Ile Gln Pro Ser Leu Phe
 115 120 125
 Val Ile Thr Asn Ile Phe Arg Asp Gln Met Asp Arg Phe Gly Glu Ile
 130 135 140
 45 Tyr Thr Thr Tyr Asn Met Ile Leu Asp Ala Ile Arg Lys Val Pro Thr
 145 150 155 160
 Ala Thr Val Leu Leu Asn Gly Asp Ser Pro Leu Phe Tyr Lys Pro Thr
 165 170 175
 50 Ile Pro Asn Pro Ile Glu Tyr Phe Gly Phe Asp Leu Glu Lys Gly Pro
 180 185 190
 55 Ala Gln Leu Ala His Tyr Asn Thr Glu Gly Ile Leu Cys Pro Asp Cys
 195 200 205
 Gln Gly Ile Leu Lys Tyr Glu His Asn Thr Tyr Ala Asn Leu Gly Ala

	210	215	220
	Tyr Ile Cys Glu Gly Cys Gly Cys Lys Arg Pro Asp Leu Asp Tyr Arg		
	225	230	235 240
5	Leu Thr Lys Leu Val Glu Leu Thr Asn Asn Arg Ser Arg Phe Val Ile		
	245	250	255
10	Asp Gly Gln Glu Tyr Gly Ile Gln Ile Gly Gly Leu Tyr Asn Ile Tyr		
	260	265	270
	Asn Ala Leu Ala Ala Val Ala Ile Ala Arg Phe Leu Gly Ala Asp Ser		
	275	280	285
15	Gln Leu Ile Lys Gln Gly Phe Asp Lys Ser Arg Ala Val Phe Gly Arg		
	290	295	300
	Gln Glu Thr Phe His Ile Gly Asp Lys Glu Cys Thr Leu Val Leu Ile		
	305	310	315 320
20	Lys Asn Pro Val Gly Ala Thr Gln Ala Ile Glu Met Ile Lys Leu Ala		
	325	330	335
25	Pro Tyr Pro Phe Ser Leu Ser Val Leu Leu Asn Ala Asn Tyr Ala Asp		
	340	345	350
	Gly Ile Asp Thr Ser Trp Ile Trp Asp Ala Asp Phe Glu Gln Ile Thr		
	355	360	365
30	Asp Met Asp Ile Pro Glu Ile Asn Ala Gly Gly Val Arg His Ser Glu		
	370	375	380
	Ile Ala Arg Arg Leu Arg Val Thr Gly Tyr Pro Ala Glu Lys Ile Thr		
	385	390	395 400
35	Glu Thr Ser Asn Leu Glu Gln Val Leu Lys Thr Ile Glu Asn Gln Asp		
	405	410	415
40	Cys Lys His Ala Tyr Ile Leu Ala Thr Tyr Thr Ala Met Leu Glu Phe		
	420	425	430
	Arg Glu Leu Leu Ala Ser Arg Gln Ile Val Arg Lys Glu Met Asn		
	435	440	445
45			
	<210> 126		
	<211> 260		
	<212> PRT		
	<213> Streptococcus pneumoniae		
50			
	<400> 126		
	Met Val Tyr Thr Ser Leu Ser Ser Lys Asp Gly Asn Tyr Pro Tyr Gln		
	1	5	10 15
55	Leu Asn Ile Ala His Leu Tyr Gly Asn Leu Met Asn Thr Tyr Gly Asp		
	20	25	30

Asn Gly Asn Ile Leu Met Leu Lys Tyr Val Ala Glu Lys Leu Gly Ala
 35 40 45
 5 His Val Thr Val Asp Ile Val Ser Leu His Asp Asp Phe Asp Glu Asn
 50 55 60
 His Tyr Asp Ile Ala Phe Phe Gly Gly Gly Gln Asp Phe Glu Gln Ser
 65 70 75 80
 10 Ile Ile Ala Asp Asp Leu Pro Ala Lys Lys Glu Ser Ile Asp Asn Tyr
 85 90 95
 Ile Gln Asn Asp Gly Val Val Leu Ala Ile Cys Gly Gly Phe Gln Leu
 100 105 110
 15 Leu Gly Gln Tyr Tyr Val Glu Ala Ser Gly Lys Arg Ile Glu Gly Leu
 115 120 125
 Gly Val Met Gly His Tyr Thr Leu Asn Gln Thr Asn Asn Arg Phe Ile
 130 135 140
 Gly Asp Ile Lys Ile His Asn Glu Asp Phe Asp Glu Thr Tyr Tyr Gly
 145 150 155 160
 25 Phe Glu Asn His Gln Gly Arg Thr Phe Leu Ser Asp Asp Gln Lys Pro
 165 170 175
 Leu Gly Gln Val Val Tyr Gly Asn Gly Asn Asn Glu Glu Lys Val Gly
 180 185 190
 30 Glu Gly Val His Tyr Lys Asn Val Phe Gly Ser Tyr Phe His Gly Pro
 195 200 205
 Ile Leu Ser Arg Asn Ala Asn Leu Ala Tyr Arg Leu Val Thr Thr Ala
 210 215 220
 Leu Lys Lys Lys Tyr Gly Gln Asp Ile Gln Leu Pro Ala Tyr Glu Asp
 225 230 235 240
 40 Ile Leu Ser Gln Glu Ile Ala Glu Glu Tyr Ser Asp Val Lys Ser Lys
 245 250 255
 Ala Asp Phe Ser
 260
 45
 <210> 127
 <211> 223
 <212> PRT
 50 <213> Streptococcus pneumoniae
 <400> 127
 Met Asn Val Lys Glu Asn Thr Glu Leu Val Phe Arg Glu Val Ala Glu
 1 5 10 15
 55 Ala Ser Leu Ser Ala Asn Arg Glu Ser Gly Ser Val Ser Val Ile Ala
 20 25 30

Val Thr Lys Tyr Val Asp Val Pro Thr Ala Glu Ala Leu Leu Pro Leu
 35 40 45

5 Gly Val His His Ile Gly Glu Asn Arg Val Asp Lys Phe Leu Glu Lys
 50 55 60

Tyr Glu Ala Leu Lys Asp Arg Asp Val Thr Trp His Leu Ile Gly Thr
 65 70 75 80

10 Leu Gln Arg Arg Lys Val Lys Asp Val Ile Gln Tyr Val Asp Tyr Phe
 85 90 95

15 His Ala Leu Asp Ser Val Lys Leu Ala Gly Glu Ile Gln Lys Arg Ser
 100 105 110

Asp Arg Val Ile Lys Cys Phe Leu Gln Val Asn Ile Ser Lys Glu Glu
 115 120 125

20 Ser Lys His Gly Phe Ser Arg Glu Glu Leu Leu Glu Ile Leu Pro Glu
 130 135 140

Leu Ala Gly Leu Asp Lys Ile Glu Tyr Val Gly Leu Met Thr Met Ala
 145 150 155 160

25 Pro Phe Glu Ala Ser Ser Glu Gln Leu Lys Glu Ile Phe Lys Ala Ala
 165 170 175

30 Gln Asp Leu Gln Arg Glu Ile Gln Glu Lys Gln Ile Pro Asn Ile Pro
 180 185 190

Met Thr Glu Leu Ser Met Gly Met Ser Arg Asp Tyr Lys Glu Ala Ile
 195 200 205

35 Gln Phe Gly Ser Thr Phe Val Arg Ile Gly Thr Ser Phe Phe Lys
 210 215 220

<210> 128
 40 <211> 279
 <212> PRT
 <213> Streptococcus pneumoniae

<400> 128

45 Met Gly Ile Ala Leu Glu Asn Val Asn Phe Thr Tyr Gln Glu Gly Thr
 1 5 10 15

Pro Leu Ala Ser Ala Ala Leu Ser Asp Val Ser Leu Thr Ile Glu Asp
 20 25 30

50 Gly Ser Tyr Thr Ala Leu Ile Gly His Thr Gly Ser Gly Lys Ser Thr
 35 40 45

Ile Leu Gln Leu Leu Asn Gly Leu Leu Val Pro Ser Gln Gly Ser Val
 50 55 60

55 Arg Val Phe Asp Thr Leu Ile Thr Ser Thr Ser Lys Asn Lys Asp Ile

	65		70		75		80									
	Arg	Gln	Ile	Arg	Lys	Gln	Val	Gly	Leu	Val	Phe	Gln	Phe	Ala	Glu	Asn
					85					90					95	
5	Gln	Ile	Phe	Glu	Glu	Thr	Val	Leu	Lys	Asp	Val	Ala	Phe	Gly	Pro	Gln
				100					105					110		
10	Asn	Phe	Gly	Val	Ser	Glu	Glu	Asp	Ala	Val	Lys	Thr	Ala	Arg	Glu	Lys
			115					120					125			
	Leu	Ala	Leu	Val	Gly	Ile	Asp	Glu	Ser	Leu	Phe	Asp	Arg	Ser	Pro	Phe
		130					135						140			
15	Glu	Leu	Ser	Gly	Gly	Gln	Met	Arg	Arg	Val	Ala	Ile	Ala	Gly	Ile	Leu
	145					150					155					160
	Ala	Met	Glu	Pro	Ala	Ile	Leu	Val	Leu	Asp	Glu	Pro	Thr	Ala	Gly	Leu
					165					170					175	
20	Asp	Pro	Leu	Gly	Arg	Lys	Glu	Leu	Met	Thr	Leu	Phe	Lys	Lys	Leu	His
				180					185						190	
25	Gln	Ser	Gly	Met	Thr	Ile	Val	Leu	Val	Thr	His	Leu	Met	Asp	Asp	Val
		195						200						205		
	Ala	Glu	Tyr	Ala	Asn	Gln	Val	Tyr	Val	Met	Glu	Lys	Gly	Arg	Leu	Val
		210					215					220				
30	Lys	Gly	Gly	Lys	Pro	Ser	Asp	Val	Phe	Gln	Asp	Val	Val	Phe	Met	Glu
	225					230					235					240
	Glu	Val	Gln	Leu	Gly	Val	Pro	Lys	Ile	Thr	Ala	Phe	Cys	Lys	Arg	Leu
				245						250					255	
35	Ala	Asp	Arg	Gly	Val	Ser	Phe	Lys	Arg	Leu	Pro	Val	Lys	Ile	Glu	Glu
			260						265						270	
40	Phe	Lys	Glu	Ser	Leu	Asn	Gly									
			275													
	<210>	129														
	<211>	309														
45	<212>	PRT														
	<213>	Streptococcus pneumoniae														
	<400>	129														
50	Met	Asp	Ile	Gln	Phe	Leu	Gly	Thr	Gly	Ala	Gly	Gln	Pro	Ser	Lys	Ala
	1					5					10				15	
	Arg	Asn	Val	Ser	Ser	Leu	Ala	Leu	Lys	Leu	Leu	Asp	Glu	Ile	Asn	Glu
					20					25					30	
55	Val	Trp	Leu	Phe	Asp	Cys	Gly	Glu	Gly	Thr	Gln	Asn	Arg	Ile	Leu	Glu
			35						40					45		

Thr Thr Ile Arg Pro Arg Lys Val Ser Lys Ile Phe Ile Thr His Leu
 50 55 60
 5 His Gly Asp His Ile Phe Gly Leu Pro Gly Phe Leu Ser Ser Arg Ala
 65 70 75 80
 Phe Gln Ala Asn Glu Glu Gln Thr Asp Leu Glu Ile Tyr Gly Pro Gln
 85 90 95
 10 Gly Ile Lys Ser Phe Val Leu Thr Ser Leu Arg Val Ser Gly Ser Arg
 100 105 110
 Leu Pro Tyr Arg Ile His Phe His Glu Phe Asp Gln Asp Ser Leu Gly
 115 120 125
 15 Lys Ile Leu Glu Ile Asp Lys Phe Thr Val Tyr Ala Glu Glu Leu Asp
 130 135 140
 20 His Thr Ile Phe Cys Val Gly Tyr Arg Val Met Gln Lys Asp Leu Glu
 145 150 155 160
 Gly Thr Leu Asp Ala Glu Lys Leu Lys Ala Ala Gly Val Pro Phe Gly
 165 170 175
 25 Pro Leu Phe Gly Lys Ile Lys Asn Gly Gln Asp Leu Val Leu Glu Asp
 180 185 190
 Gly Thr Glu Ile Lys Ala Ala Asp Tyr Ile Ser Ala Pro Arg Pro Gly
 195 200 205
 30 Lys Ile Ile Thr Ile Leu Gly Asp Thr Arg Lys Thr Asp Ala Ser Val
 210 215 220
 35 Arg Leu Ala Val Asn Ala Asp Val Leu Val His Glu Ser Thr Tyr Gly
 225 230 235 240
 Lys Gly Asp Glu Lys Ile Ala Arg Asn His Gly His Ser Thr Asn Met
 245 250 255
 40 Gln Ala Ala Gln Val Ala Val Glu Ala Gly Ala Lys Arg Leu Leu Leu
 260 265 270
 Asn His Ile Ser Ala Arg Phe Leu Ser Lys Asp Ile Ser Lys Leu Lys
 275 280 285
 45 Lys Asp Ala Ala Thr Ile Phe Glu Asn Val His Val Val Lys Asp Leu
 290 295 300
 50 Glu Glu Val Glu Ile
 305
 <210> 130
 <211> 553
 55 <212> PRT
 <213> Streptococcus pneumoniae

<400> 130
 Met Ser Asn Ile Ser Leu Thr Thr Leu Gly Gly Val Arg Glu Asn Gly
 1 5 10 15
 5 Lys Asn Met Tyr Ile Ala Glu Ile Gly Glu Ser Ile Phe Val Leu Asn
 20 25 30
 Val Gly Leu Lys Tyr Pro Glu Asn Glu Gln Leu Gly Val Asp Val Val
 35 40 45
 10 Ile Pro Asn Met Asp Tyr Leu Phe Glu Asn Ser Asp Arg Ile Ala Gly
 50 55 60
 15 Val Phe Leu Thr His Gly His Ala Asp Ala Ile Gly Ala Leu Pro Tyr
 65 70 75 80
 Leu Leu Ala Glu Ala Lys Val Pro Val Phe Gly Ser Glu Leu Thr Ile
 85 90 95
 20 Glu Leu Ala Lys Leu Phe Val Lys Gly Asn Asp Ala Val Lys Lys Phe
 100 105 110
 Asn Asp Phe His Val Ile Asp Glu Asn Thr Glu Ile Asp Phe Gly Gly
 115 120 125
 25 Thr Val Val Ser Phe Phe Pro Thr Thr Tyr Ser Val Pro Glu Ser Leu
 130 135 140
 Gly Ile Val Leu Lys Thr Ser Glu Gly Ser Ile Val Tyr Thr Gly Asp
 145 150 155 160
 Phe Lys Phe Asp Gln Thr Ala Ser Glu Ser Tyr Ala Thr Asp Phe Ala
 165 170 175
 35 Arg Leu Ala Glu Ile Gly Arg Asp Gly Val Leu Ala Leu Leu Ser Asp
 180 185 190
 Ser Ala Asn Ala Asp Ser Asn Ile Gln Val Ala Ser Glu Ser Glu Val
 195 200 205
 40 Arg Asp Glu Ile Thr Gln Thr Ile Ala Asp Trp Glu Gly Arg Ile Ile
 210 215 220
 Val Ala Ala Val Ser Ser Asn Leu Ser Arg Ile Gln Gln Ile Phe Asp
 225 230 235 240
 Ala Ala Asp Lys Thr Gly Arg Arg Ile Val Leu Thr Gly Phe Asp Ile
 245 250 255
 50 Glu Asn Ile Val Arg Thr Ala Ile Arg Leu Lys Lys Leu Ser Leu Ala
 260 265 270
 Asn Glu Ile Leu Leu Ile Lys Pro Lys Asp Met Ser Arg Phe Glu Asp
 275 280 285
 55 His Glu Leu Ile Ile Leu Glu Thr Gly Arg Met Gly Glu Pro Ile Asn
 290 295 300

Gly Leu Arg Lys Met Ser Ile Gly Arg His Arg Tyr Val Glu Ile Lys
 305 310 315 320
 5 Asp Gly Asp Leu Val Tyr Ile Ala Thr Ala Pro Ser Ile Ala Lys Glu
 325 330 335
 Ala Phe Val Ala Arg Val Glu Asn Met Ile Tyr Gln Ala Gly Gly Val
 340 345 350
 10 Val Lys Leu Ile Thr Gln Ser Leu His Val Ser Gly His Gly Asn Val
 355 360 365
 Arg Asp Leu Gln Leu Met Ile Asn Leu Leu Gln Pro Lys Tyr Leu Phe
 370 375 380
 15 Pro Val Gln Gly Glu Tyr Arg Glu Leu Asp Ala His Ala Lys Ala Ala
 385 390 395 400
 20 Met Ala Val Gly Met Leu Pro Glu Arg Ile Phe Ile Pro Lys Lys Gly
 405 410 415
 Thr Thr Met Ala Tyr Glu Asn Gly Asp Phe Val Pro Ala Gly Ser Val
 420 425 430
 25 Ser Ala Gly Asp Ile Leu Ile Asp Gly Asn Ala Ile Gly Asp Val Gly
 435 440 445
 Asn Val Val Leu Arg Asp Arg Lys Val Leu Ser Glu Asp Gly Ile Phe
 450 455 460
 30 Ile Val Ala Ile Thr Val Asn Arg Arg Glu Lys Lys Ile Val Ala Arg
 465 470 475 480
 35 Ala Arg Val His Thr Arg Gly Phe Val Tyr Leu Lys Lys Ser Arg Asp
 485 490 495
 Ile Leu Arg Glu Ser Ser Glu Leu Ile Asn Gln Thr Val Glu Asp Tyr
 500 505 510
 40 Leu Gln Gly Asp Asp Phe Asp Trp Ala Asp Leu Lys Gly Lys Val Arg
 515 520 525
 Asp Asn Leu Thr Lys Tyr Leu Phe Asp Gln Thr Lys Arg Arg Pro Ala
 530 535 540
 45 Ile Leu Pro Val Val Met Glu Ala Lys
 545 550
 50
 <210> 131
 <211> 316
 <212> PRT
 <213> Streptococcus pneumoniae
 55
 <400> 131
 Met Thr Lys Glu Phe His His Val Thr Val Leu Leu His Glu Thr Ile

69

70

Gly Leu Asp Tyr Val Asp Gln Lys Ile Leu Arg Thr Met Ile Glu Met
 260 265 270
 5 Tyr Ser Gly Gly Pro Val Gly Leu Gly Thr Leu Ser Val Asn Ile Ala
 275 280 285
 Glu Glu Arg Glu Thr Val Glu Asp Met Tyr Glu Pro Tyr Leu Ile Gln
 290 295 300
 10 Lys Gly Phe Ile Met Arg Thr Arg Ser Gly Arg Val Ala Thr Ala Lys
 305 310 315 320
 Ala Tyr Glu His Leu Gly Tyr Glu Tyr Ser Glu Lys
 325 330
 15
 <210> 133
 <211> 436
 <212> PRT
 20 <213> Streptococcus pneumoniae
 <400> 133
 Met Ser Met Phe Leu Asp Thr Ala Lys Ile Lys Val Lys Ala Gly Asn
 1 5 10 15
 25 Gly Gly Asp Gly Met Val Ala Phe Arg Arg Glu Lys Tyr Val Pro Asn
 20 25 30
 Gly Gly Pro Trp Gly Gly Asp Gly Gly Arg Gly Gly Asn Val Val Phe
 30 35 40 45
 Val Val Asp Glu Gly Leu Arg Thr Leu Met Asp Phe Arg Tyr Asn Arg
 50 55 60
 35 His Phe Lys Ala Asp Ser Gly Glu Lys Gly Met Thr Lys Gly Met His
 65 70 75 80
 Gly Arg Gly Ala Glu Asp Leu Arg Val Arg Val Ser Gln Gly Thr Thr
 85 90 95
 40 Val Arg Asp Ala Glu Thr Gly Lys Val Leu Thr Asp Leu Ile Lys His
 100 105 110
 Gly Gln Glu Phe Ile Val Ala His Gly Gly Arg Gly Gly Arg Gly Asn
 115 120 125
 45 Ile Arg Phe Ala Thr Pro Lys Asn Pro Ala Pro Glu Ile Ser Glu Asn
 130 135 140
 50 Gly Glu Pro Gly Gln Glu Arg Glu Leu Gln Leu Glu Leu Lys Ile Leu
 145 150 155 160
 Ala Asp Val Gly Leu Val Gly Phe Pro Ser Val Gly Lys Ser Thr Leu
 165 170 175
 55 Leu Ser Val Ile Thr Ser Ala Lys Pro Lys Ile Gly Ala Tyr His Phe
 180 185 190

Thr Thr Ile Val Pro Asn Leu Gly Met Val Arg Thr Gln Ser Gly Glu
 195 200 205
 5 Ser Phe Ala Val Ala Asp Leu Pro Gly Leu Ile Glu Gly Ala Ser Gln
 210 215 220
 Gly Val Gly Leu Gly Thr Gln Phe Leu Arg His Ile Glu Arg Thr Arg
 225 230 235 240
 10 Val Ile Leu His Ile Ile Asp Met Ser Ala Ser Glu Gly Arg Asp Pro
 245 250 255
 Tyr Glu Asp Tyr Leu Ala Ile Asn Lys Glu Leu Glu Ser Tyr Asn Leu
 15 260 265 270
 Arg Leu Met Glu Arg Pro Gln Ile Ile Val Ala Asn Lys Met Asp Met
 275 280 285
 20 Pro Glu Ser Gln Glu Asn Leu Glu Glu Phe Lys Lys Lys Leu Ala Glu
 290 295 300
 Asn Tyr Asp Glu Phe Glu Glu Leu Pro Ala Ile Phe Pro Ile Ser Gly
 305 310 315 320
 25 Leu Thr Lys Gln Gly Leu Ala Thr Leu Leu Asp Ala Thr Ala Glu Leu
 325 330 335
 Leu Asp Lys Thr Pro Glu Phe Leu Leu Tyr Asp Glu Ser Asp Met Glu
 30 340 345 350
 Glu Glu Ala Tyr Tyr Gly Phe Asp Glu Glu Glu Lys Ala Phe Glu Ile
 355 360 365
 35 Ser Arg Asp Asp Asp Ala Thr Trp Val Leu Ser Gly Glu Lys Leu Met
 370 375 380
 Lys Leu Phe Asn Met Thr Asn Phe Asp Arg Asp Glu Ser Val Met Lys
 385 390 395 400
 40 Phe Ala Arg Gln Leu Arg Gly Met Gly Val Asp Glu Ala Leu Arg Ala
 405 410 415
 Arg Gly Ala Lys Asp Gly Asp Leu Val Arg Ile Gly Lys Phe Glu Phe
 45 420 425 430
 Glu Phe Val Asp
 435
 50
 <210> 134
 <211> 172
 <212> PRT
 <213> Streptococcus pneumoniae
 55
 <400> 134
 Met Asn Tyr Phe Asn Val Gly Lys Ile Val Asn Thr Gln Gly Leu Gln

73

Leu Ala Gln Glu Glu Glu Leu Ile Phe Ile Cys Gly His Tyr Glu Gly
 100 105 110
 5 Tyr Asp Glu Arg Ile Lys Thr Leu Val Thr Asp Glu Ile Ser Leu Gly
 115 120 125
 Asp Tyr Val Leu Thr Gly Gly Glu Leu Ala Ala Met Thr Met Ile Asp
 130 135 140
 10 Ala Thr Val Arg Leu Ile Pro Glu Val Ile Gly Lys Glu Ser Ser His
 145 150 155 160
 Gln Asp Asp Ser Phe Ser Ser Gly Leu Leu Glu Tyr His Gln Tyr Thr
 165 170 175
 15 Arg Pro Tyr Asp Tyr Arg Gly Met Val Val Pro Asp Val Leu Met Ser
 180 185 190
 20 Gly His His Glu Lys Ile Arg Gln Trp Arg Leu Tyr Glu Ser Leu Lys
 195 200 205
 Lys Thr Tyr Glu Arg Arg Pro Asp Leu Leu Glu His Tyr Gln Leu Thr
 210 215 220
 25 Val Glu Glu Glu Lys Met Leu Ala Glu Ile Lys Glu Asn Lys Glu
 225 230 235
 30
 <210> 136
 <211> 186
 <212> PRT
 35 <213> Streptococcus pneumoniae
 <400> 136
 40 Met Ile Glu Ala Ser Lys Leu Lys Ala Gly Met Thr Phe Glu Thr Ala
 1 5 10 15
 Asp Gly Lys Leu Ile Arg Val Leu Glu Ala Ser His His Lys Pro Gly
 20 25 30
 45 Lys Gly Asn Thr Ile Met Arg Met Lys Leu Arg Asp Val Arg Thr Gly
 35 40 45
 Ser Thr Phe Asp Thr Ser Tyr Arg Pro Glu Glu Lys Phe Glu Gln Ala
 50 55 60
 50 Ile Ile Glu Thr Val Pro Ala Gln Tyr Leu Tyr Lys Met Asp Asp Thr
 65 70 75 80
 55 Ala Tyr Phe Met Asn Thr Glu Thr Tyr Asp Gln Tyr Glu Ile Pro Val
 85 90 95
 Val Asn Val Glu Asn Glu Leu Leu Tyr Ile Leu Glu Asn Ser Asp Val

100 105 110
 Lys Ile Gln Phe Tyr Gly Thr Glu Val Ile Gly Val Thr Val Pro Thr
 115 120 125
 5 Thr Val Glu Leu Thr Val Ala Glu Thr Gln Pro Ser Ile Lys Gly Ala
 130 135 140
 10 Thr Val Thr Gly Ser Gly Lys Pro Ala Thr Met Glu Thr Gly Leu Val
 145 150 155 160
 Val Asn Val Pro Asp Phe Ile Glu Ala Gly Gln Lys Leu Val Ile Asn
 165 170 175
 15 Thr Ala Glu Gly Thr Tyr Val Ser Arg Ala
 180 185
 20 <210> 137
 <211> 523
 <212> PRT
 <213> Streptococcus pneumoniae
 25 <400> 137
 Met Ala Phe Glu Ser Leu Thr Glu Arg Leu Gln Asn Val Phe Lys Asn
 1 5 10 15
 30 Leu Arg Lys Lys Gly Lys Ile Ser Glu Ser Asp Val Gln Glu Ala Thr
 20 25 30
 Lys Glu Ile Arg Leu Ala Leu Leu Glu Ala Asp Val Ala Leu Pro Val
 35 40 45
 35 Val Lys Asp Phe Ile Lys Lys Val Arg Glu Arg Ala Val Gly His Glu
 50 55 60
 Val Ile Asp Thr Leu Asn Pro Ala Gln Gln Ile Ile Lys Ile Val Asp
 65 70 75 80
 40 Glu Glu Leu Thr Ala Val Leu Gly Ser Asp Thr Ala Glu Ile Ile Lys
 85 90 95
 45 Ser Pro Lys Ile Pro Thr Ile Ile Met Met Val Gly Leu Gln Gly Ala
 100 105 110
 Gly Lys Thr Thr Phe Ala Gly Lys Leu Ala Asn Lys Leu Lys Lys Glu
 115 120 125
 50 Glu Asn Ala Arg Pro Leu Met Ile Ala Ala Asp Ile Tyr Arg Pro Ala
 130 135 140
 Ala Ile Asp Gln Leu Lys Thr Leu Gly Gln Gln Ile Asp Val Pro Val
 145 150 155 160
 55 Phe Ala Leu Gly Thr Glu Val Pro Ala Val Glu Ile Val Arg Gln Gly
 165 170 175

Leu Glu Gln Ala Gln Thr Asn His Asn Asp Tyr Val Leu Ile Asp Thr
 180 185 190

5 Ala Gly Arg Leu Gln Ile Asp Glu Leu Leu Met Asn Glu Leu Arg Asp
 195 200 205

Val Lys Thr Leu Ala Gln Pro Asn Glu Ile Leu Leu Val Val Asp Ala
 210 215 220

10 Met Ile Gly Gln Glu Ala Ala Asn Val Ala Arg Glu Phe Asn Ala Gln
 225 230 235 240

15 Leu Glu Val Thr Gly Val Ile Leu Thr Lys Ile Asp Gly Asp Thr Arg
 245 250 255

Gly Gly Ala Ala Leu Ser Val Arg His Ile Thr Gly Lys Pro Ile Lys
 260 265 270

20 Phe Thr Gly Thr Gly Glu Lys Ile Thr Asp Ile Glu Thr Phe His Pro
 275 280 285

Asp Arg Met Ser Ser Arg Ile Leu Gly Met Gly Asp Met Leu Thr Leu
 290 295 300

25 Ile Glu Lys Ala Ser Gln Glu Tyr Asp Glu Gln Lys Ala Leu Glu Met
 305 310 315 320

30 Ala Glu Lys Met Arg Glu Asn Thr Phe Asp Phe Asn Asp Phe Ile Asp
 325 330 335

Gln Leu Asp Gln Val Gln Asn Met Gly Pro Met Glu Asp Leu Leu Lys
 340 345 350

35 Met Ile Pro Gly Met Ala Asn Asn Pro Ala Leu Gln Asn Met Lys Val
 355 360 365

Asp Glu Arg Gln Ile Ala Arg Lys Arg Ala Ile Val Ser Ser Met Thr
 370 375 380

40 Pro Glu Glu Arg Glu Asn Pro Asp Leu Leu Asn Pro Ser Arg Arg Arg
 385 390 395 400

45 Arg Ile Ala Ala Gly Ser Gly Asn Thr Phe Val Glu Val Asn Lys Phe
 405 410 415

Ile Lys Asp Phe Asn Gln Ala Lys Gln Leu Met Gln Gly Val Met Ser
 420 425 430

50 Gly Asp Met Asn Lys Met Met Lys Gln Met Gly Ile Asn Pro Asn Asn
 435 440 445

Leu Pro Lys Asn Met Pro Asn Met Gly Gly Met Asp Met Ser Ala Leu
 450 455 460

55 Glu Gly Met Met Gly Gln Gly Gly Met Pro Asp Leu Ser Ala Leu Gly
 465 470 475 480

Gly Ala Gly Met Pro Asp Met Ser Gln Met Phe Gly Gly Gly Leu Lys
 485 490 495
 5 Gly Lys Ile Gly Glu Phe Ala Met Lys Gln Ser Met Lys Arg Met Ala
 500 505 510
 Asn Lys Met Lys Lys Ala Lys Lys Lys Arg Lys
 515 520
 10
 <210> 138
 <211> 281
 <212> PRT
 15 <213> Streptococcus pneumoniae
 <400> 138
 Met Tyr Leu Ile Glu Ile Leu Lys Ser Ile Phe Phe Gly Ile Val Glu
 1 5 10 15
 20 Gly Ile Thr Glu Trp Leu Pro Ile Ser Ser Thr Gly His Leu Ile Leu
 20 25 30
 Ala Glu Glu Phe Ile Gln Tyr Gln Asn Gln Asn Glu Ala Phe Met Ser
 25 35 40 45
 Met Phe Asn Val Val Ile Gln Leu Gly Ala Ile Leu Ala Val Met Val
 50 55 60
 30 Ile Tyr Phe Asn Lys Leu Asn Pro Phe Lys Pro Thr Lys Asp Lys Gln
 65 70 75 80
 Glu Val Arg Lys Thr Trp Arg Leu Trp Leu Lys Val Leu Ile Ala Thr
 85 90 95
 35 Leu Pro Leu Leu Gly Val Phe Lys Phe Asp Asp Trp Phe Asp Thr His
 100 105 110
 Phe His Asn Met Val Ser Val Ala Leu Met Leu Ile Ile Tyr Gly Val
 40 115 120 125
 Ala Phe Ile Tyr Leu Glu Lys Arg Asn Lys Ala Arg Ala Ile Glu Pro
 130 135 140
 45 Ser Val Thr Glu Leu Asp Lys Leu Pro Tyr Thr Thr Ala Phe Tyr Ile
 145 150 155 160
 Gly Leu Phe Gln Val Leu Ala Leu Leu Pro Gly Thr Ser Arg Ser Gly
 165 170 175
 50 Ala Thr Ile Val Gly Gly Leu Leu Asn Gly Thr Ser Arg Ser Val Val
 180 185 190
 Thr Glu Phe Thr Phe Tyr Leu Gly Ile Pro Val Met Phe Gly Ala Ser
 55 195 200 205
 Ala Leu Lys Ile Phe Lys Phe Val Lys Ala Gly Glu Leu Leu Ser Phe

210 215 220
 Gly Gln Leu Phe Leu Leu Leu Val Ala Met Gly Val Ala Phe Ala Val
 225 230 235 240
 5 Ser Met Val Ala Ile Arg Phe Leu Thr Ser Tyr Val Lys Lys His Asp
 245 250 255
 10 Phe Thr Leu Phe Gly Lys Tyr Arg Ile Val Leu Gly Ser Val Leu Leu
 260 265 270
 Leu Tyr Ser Phe Val Arg Leu Phe Val
 275 280
 15
 <210> 139
 <211> 429
 <212> PRT
 <213> Streptococcus pneumoniae
 20
 <400> 139
 Met Gly Leu Phe Asp Arg Leu Phe Gly Lys Lys Glu Glu Pro Lys Ile
 1 5 10 15
 25 Glu Glu Val Val Lys Glu Ala Leu Glu Asn Leu Asp Leu Ser Glu Asp
 20 25 30
 Ile Glu Pro Ala Phe Thr Glu Ala Glu Glu Val Ser Gln Glu Glu Ala
 35 40 45
 30 Glu Val Glu Ser Ser Glu Glu Ser Val Phe Gln Glu Glu Asp Ser Gln
 50 55 60
 35 Asp Thr Val Glu Glu Asn Leu Asp Leu Glu Pro Val Val Glu Val Ser
 65 70 75 80
 Gln Glu Glu Val Glu Glu Phe Pro Asn Ser Gln Glu Val Thr Glu Glu
 85 90 95
 40 Glu Lys Leu Glu His Glu Gly Thr Val Glu Glu Asn Asn Phe Glu Val
 100 105 110
 Leu Glu Pro Glu Ala Pro Gln Thr Glu Glu Thr Val Gln Glu Lys Tyr
 115 120 125
 45 Asp Arg Ser Leu Lys Lys Thr Arg Thr Gly Phe Gly Ala Arg Leu Asn
 130 135 140
 50 Ala Phe Phe Ala Asn Phe Arg Ser Val Asp Glu Glu Phe Phe Glu Glu
 145 150 155 160
 Leu Glu Glu Leu Leu Ile Met Ser Asp Val Gly Val Gln Val Ala Ser
 165 170 175
 55 Asn Leu Thr Glu Glu Leu Arg Tyr Glu Ala Lys Leu Glu Asn Ala Lys
 180 185 190

Lys Pro Asp Ala Leu Arg Arg Val Ile Ile Glu Lys Leu Val Glu Leu
 195 200 205
 5 Tyr Glu Lys Asp Gly Ser Tyr Asp Glu Ser Ile His Phe Gln Asp Asn
 210 215 220
 Leu Thr Val Met Leu Phe Val Gly Val Asn Gly Val Gly Lys Thr Thr
 225 230 235 240
 10 Ser Ile Gly Lys Leu Ala His Arg Tyr Lys Arg Ala Gly Lys Lys Val
 245 250 255
 Met Leu Val Ala Ala Asp Thr Phe Arg Ala Gly Ala Val Ala Gln Leu
 260 265 270
 15 Ala Glu Trp Gly Arg Arg Val Asp Val Pro Val Val Thr Gly Pro Glu
 275 280 285
 Lys Ala Asp Pro Ala Ser Val Val Phe Asp Gly Met Glu Arg Ala Val
 290 295 300
 Ala Glu Gly Ile Asp Ile Leu Met Ile Asp Thr Ala Gly Arg Leu Gln
 305 310 315 320
 25 Asn Lys Asp Asn Leu Met Ala Glu Leu Glu Lys Ile Gly Arg Ile Ile
 325 330 335
 Lys Arg Val Val Pro Glu Ala Pro His Glu Thr Phe Leu Ala Leu Asp
 340 345 350
 30 Ala Ser Thr Gly Gln Asn Ala Leu Val Gln Ala Lys Glu Phe Ser Lys
 355 360 365
 Ile Thr Pro Leu Thr Gly Ile Val Leu Thr Lys Ile Asp Gly Thr Ala
 370 375 380
 Arg Gly Gly Val Val Leu Ala Ile Arg Glu Glu Leu Asn Ile Pro Val
 385 390 395 400
 40 Lys Leu Ile Gly Phe Gly Glu Lys Ile Asp Asp Ile Gly Glu Phe Asn
 405 410 415
 Ser Glu Asn Phe Met Lys Gly Leu Leu Glu Gly Leu Ile
 420 425
 45
 <210> 140
 <211> 165
 <212> PRT
 50 <213> Streptococcus pneumoniae
 <400> 140
 Met Tyr Ile Glu Met Val Asp Glu Thr Gly Gln Val Ser Lys Glu Met
 1 5 10 15
 55 Leu Gln Gln Thr Gln Glu Ile Leu Glu Phe Ala Ala Lys Lys Leu Gly
 20 25 30

Lys Glu Asp Lys Glu Met Ala Val Thr Phe Val Thr Asn Glu Arg Ser
 35 40 45
 5 His Glu Leu Asn Leu Glu Tyr Arg Asp Thr Asp Arg Pro Thr Asp Val
 50 55 60
 Ile Ser Leu Glu Tyr Lys Pro Glu Leu Glu Ile Ala Phe Asp Glu Glu
 65 70 75 80
 10 Asp Leu Leu Glu Asn Pro Glu Leu Ala Glu Met Met Ser Glu Phe Asp
 85 90 95
 15 Ala Tyr Ile Gly Glu Leu Phe Ile Ser Ile Asp Lys Ala His Glu Gln
 100 105 110
 Ala Glu Glu Tyr Gly His Ser Phe Glu Arg Glu Met Gly Phe Leu Ala
 115 120 125
 20 Val His Gly Phe Leu His Ile Asn Gly Tyr Asp His Tyr Thr Pro Glu
 130 135 140
 Glu Glu Ala Glu Met Phe Gly Leu Gln Glu Glu Ile Leu Thr Ala Tyr
 145 150 155 160
 25 Gly Leu Thr Arg Gln
 165
 30 <210> 141
 <211> 255
 <212> PRT
 <213> Streptococcus pneumoniae
 35 <400> 141
 Met Ser Ile Arg Val Ile Ile Ala Gly Phe Lys Gly Lys Met Gly Gln
 1 5 10 15
 40 Ala Ala Cys Gln Met Val Leu Thr Asp Pro Asp Leu Asp Leu Val Ala
 20 25 30
 Val Leu Asp Pro Phe Glu Ser Glu Ser Glu Trp Gln Gly Ile Pro Val
 35 40 45
 45 Phe Lys Asp Lys Ala Asp Leu Ala Gly Phe Glu Ala Asp Val Trp Val
 50 55 60
 Asp Phe Thr Thr Pro Ala Val Ala Tyr Glu Asn Thr Arg Phe Ala Leu
 65 70 75 80
 50 Glu Asn Gly Phe Ala Pro Val Val Gly Thr Thr Gly Phe Thr Ser Glu
 85 90 95
 55 Glu Ile Ala Glu Leu Lys Glu Phe Ser Arg Ala Gln Asp Leu Gly Gly
 100 105 110
 Leu Ile Ala Pro Asn Phe Ala Leu Gly Ala Val Leu Leu Met Gln Phe

115 120 125
 Ala Thr Gln Ala Ala Lys Tyr Phe Pro Asn Val Glu Ile Ile Glu Leu
 130 135 140
 5 His His Asp Lys Lys Lys Asp Ala Pro Ser Gly Thr Ala Ile Lys Thr
 145 150 155 160
 10 Ala Glu Leu Met Ala Glu Val Arg Glu Ser Ile Gln Gln Gly Ala Ala
 165 170 175
 Asp Glu Glu Glu Leu Ile Ala Gly Ala Arg Gly Ala Asp Phe Asp Gly
 180 185 190
 15 Met Arg Ile His Ser Val Arg Leu Pro Gly Leu Val Ala His Gln Glu
 195 200 205
 Val Ile Phe Gly Asn Gln Gly Glu Gly Leu Thr Leu Arg His Asp Ser
 210 215 220
 20 Tyr Asp Arg Ile Ser Phe Met Thr Gly Val Asn Leu Gly Ile Lys Glu
 225 230 235 240
 Val Val Lys Arg His Glu Leu Val Tyr Gly Leu Glu His Leu Leu
 245 250 255
 25
 <210> 142
 <211> 91
 30 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 142
 Met Ala Asn Lys Gln Asp Leu Ile Ala Lys Val Ala Glu Ala Thr Glu
 1 5 10 15
 Leu Thr Lys Lys Asp Ser Ala Ala Ala Val Glu Ala Val Phe Ala Ala
 20 25 30
 40 Val Ala Asp Tyr Leu Ala Ala Gly Glu Lys Val Gln Leu Ile Gly Phe
 35 40 45
 Ser Asn Phe Glu Val Arg Glu Arg Ala Glu Arg Lys Gly Arg Asn Pro
 50 55 60
 45 Gln Thr Gly Lys Glu Met Thr Ile Ala Ala Ser Lys Val Pro Ala Phe
 65 70 75 80
 Lys Ala Gly Lys Ala Leu Lys Asp Ala Val Lys
 85 90
 50
 <210> 143
 <211> 306
 55 <212> PRT
 <213> Streptococcus pneumoniae

<400> 143
 Met Thr Lys Thr Ala Phe Leu Phe Ala Gly Gln Gly Ala Gln Tyr Leu
 1 5 10 15
 5 Gly Met Gly Arg Asp Phe Tyr Asp Gln Tyr Pro Ile Val Lys Glu Thr
 20 25 30
 Ile Asp Arg Ala Ser Gln Val Leu Gly Tyr Asp Leu Arg Tyr Leu Ile
 35 40 45
 10 Asp Thr Glu Glu Asp Lys Leu Asn Gln Thr Arg Tyr Thr Gln Pro Ala
 50 55 60
 15 Ile Leu Ala Thr Ser Val Ala Ile Tyr Arg Leu Leu Gln Glu Lys Gly
 65 70 75 80
 Tyr Gln Pro Asp Met Val Ala Gly Leu Ser Leu Gly Glu Tyr Ser Ala
 85 90 95
 20 Leu Val Ala Ser Gly Ala Leu Asp Phe Glu Asp Ala Val Ala Leu Val
 100 105 110
 Ala Lys Arg Gly Ala Tyr Met Glu Glu Ala Ala Pro Ala Asp Ser Gly
 115 120 125
 25 Lys Met Val Ala Val Leu Asn Thr Pro Val Glu Val Ile Glu Glu Ala
 130 135 140
 30 Cys Gln Lys Ala Ser Glu Leu Gly Val Val Thr Pro Ala Asn Tyr Asn
 145 150 155 160
 Thr Pro Ala Gln Ile Val Ile Ala Gly Glu Val Val Ala Val Asp Arg
 165 170 175
 35 Ala Val Glu Leu Leu Gln Glu Ala Gly Ala Lys Arg Leu Ile Pro Leu
 180 185 190
 Lys Val Ser Gly Pro Phe His Thr Ala Leu Leu Glu Pro Ala Ser Gln
 195 200 205
 40 Lys Leu Ala Glu Thr Leu Ala Gln Val Ser Phe Ser Asp Phe Thr Cys
 210 215 220
 45 Pro Leu Val Gly Asn Thr Glu Ala Ala Val Met Gln Lys Glu Asp Ile
 225 230 235 240
 Ala Gln Leu Leu Thr Arg Gln Val Lys Glu Pro Val Arg Phe Tyr Glu
 245 250 255
 50 Ser Ile Gly Val Met Gln Glu Ala Gly Ile Ser Asn Phe Ile Glu Ile
 260 265 270
 Gly Pro Gly Lys Val Leu Ser Gly Phe Val Lys Lys Ile Asp Gln Thr
 275 280 285
 55 Ala His Leu Ala His Val Glu Asp Gln Ala Ser Leu Val Ala Leu Leu
 290 295 300

Glu Lys
305

5
<210> 144
<211> 243
<212> PRT
<213> Streptococcus pneumoniae

10
<400> 144
Met Lys Leu Glu His Lys Asn Ile Phe Ile Thr Gly Ser Ser Arg Gly
1 5 10 15

15
Ile Gly Leu Ala Ile Ala His Lys Phe Ala Gln Ala Gly Ala Asn Ile
20 25 30

Val Leu Asn Ser Arg Gly Ala Ile Ser Glu Glu Leu Leu Ala Glu Phe
35 40 45

20
Ser Asn Tyr Gly Ile Lys Val Val Pro Ile Ser Gly Asp Val Ser Asp
50 55 60

Phe Ala Asp Ala Lys Arg Met Ile Asp Gln Ala Ile Ala Glu Leu Gly
25 65 70 75 80

Ser Val Asp Val Leu Val Asn Asn Ala Gly Ile Thr Gln Asp Thr Leu
85 90 95

30
Met Leu Lys Met Thr Glu Ala Asp Phe Glu Lys Val Leu Lys Val Asn
100 105 110

Leu Thr Gly Ala Phe Asn Met Thr Gln Ser Val Leu Lys Pro Met Met
115 120 125

35
Lys Ala Arg Glu Gly Ala Ile Ile Asn Met Ser Ser Val Val Gly Leu
130 135 140

40
Met Gly Asn Ile Gly Gln Ala Asn Tyr Ala Ala Ser Lys Ala Gly Leu
145 150 155 160

Ile Gly Phe Thr Lys Ser Val Ala Arg Glu Val Ala Ser Arg Asn Ile
165 170 175

45
Arg Val Asn Val Ile Ala Pro Gly Met Ile Glu Ser Asp Met Thr Ala
180 185 190

Ile Leu Ser Asp Lys Ile Lys Glu Ala Thr Leu Ala Gln Ile Pro Met
195 200 205

50
Lys Glu Phe Gly Gln Ala Glu Gln Val Ala Asp Leu Thr Val Phe Leu
210 215 220

55
Ala Gly Gln Asp Tyr Leu Thr Gly Gln Val Val Ala Ile Asp Gly Gly
225 230 235 240

Leu Ser Met

5 <210> 145
 <211> 276
 <212> PRT
 <213> Streptococcus pneumoniae

 <400> 145
 10 Met Gly Val Lys Lys Lys Leu Lys Leu Thr Ser Leu Leu Gly Leu Ser
 1 5 10 15
 Leu Leu Ile Met Thr Ala Cys Ala Thr Asn Gly Val Thr Ser Asp Ile
 20 25 30
 15 Thr Ala Glu Ser Ala Asp Phe Trp Ser Lys Leu Val Tyr Phe Phe Ala
 35 40 45
 20 Glu Ile Ile Arg Phe Leu Ser Phe Asp Ile Ser Ile Gly Val Gly Ile
 50 55 60
 Ile Leu Phe Thr Val Leu Ile Arg Thr Val Leu Leu Pro Val Phe Gln
 65 70 75 80
 25 Val Gln Met Val Ala Ser Arg Lys Met Gln Glu Ala Gln Pro Arg Ile
 85 90 95
 Lys Ala Leu Arg Glu Gln Tyr Pro Gly Arg Asp Met Glu Ser Arg Thr
 100 105 110
 30 Lys Leu Glu Gln Glu Met Arg Lys Val Phe Lys Glu Met Gly Val Arg
 115 120 125
 Gln Ser Asp Ser Leu Trp Pro Ile Leu Ile Gln Met Pro Val Ile Leu
 35 130 135 140
 Ala Leu Phe Gln Ala Leu Ser Arg Val Asp Phe Leu Lys Thr Gly His
 145 150 155 160
 40 Phe Leu Trp Ile Asn Leu Gly Ser Val Asp Thr Thr Leu Val Leu Pro
 165 170 175
 Ile Leu Ala Ala Val Phe Thr Phe Leu Ser Thr Trp Leu Ser Asn Lys
 180 185 190
 45 Ala Leu Ser Glu Arg Asn Gly Ala Thr Thr Ala Met Met Tyr Gly Ile
 195 200 205
 Pro Val Leu Ile Phe Ile Phe Ala Val Tyr Ala Pro Gly Gly Val Ala
 50 210 215 220
 Leu Tyr Trp Thr Val Ser Asn Ala Tyr Gln Val Leu Gln Thr Tyr Phe
 225 230 235 240
 55 Leu Asn Asn Pro Phe Lys Ile Ile Ala Glu Arg Glu Ala Val Val Gln
 245 250 255

Ala Gln Lys Asp Leu Glu Asn Arg Lys Arg Lys Ala Lys Lys Lys Ala
 260 265 270

5 Gln Lys Thr Lys
 275

10 <210> 146
 <211> 409
 <212> PRT
 <213> Streptococcus pneumoniae

15 <400> 146
 Met Lys Ile Ser Lys Arg His Leu Leu Asn Tyr Ser Ile Leu Ile Pro
 1 5 10 15

Tyr Leu Leu Leu Ser Ile Leu Gly Leu Ile Val Val Tyr Ser Thr Thr
 20 25 30

20 Ser Ala Ile Leu Ile Glu Glu Gly Lys Ser Ala Leu Gln Leu Val Arg
 35 40 45

25 Asn Gln Gly Ile Phe Trp Ile Val Ser Leu Ile Leu Ile Ala Leu Ile
 50 55 60

Tyr Lys Leu Arg Leu Asp Phe Leu Arg Asn Glu Arg Leu Ile Ile Leu
 65 70 75 80

30 Val Ile Leu Ile Glu Met Leu Leu Leu Phe Leu Ala Arg Phe Ile Gly
 85 90 95

Ile Ser Val Asn Gly Ala Tyr Gly Trp Ile Ser Val Ala Gly Val Thr
 100 105 110

35 Ile Gln Pro Ala Glu Tyr Leu Lys Ile Ile Ile Ile Trp Tyr Leu Ala
 115 120 125

40 His Arg Phe Ser Lys Gln Gln Glu Glu Ile Ala Thr Tyr Asp Phe Gln
 130 135 140

Val Leu Thr Gln Asn Gln Trp Leu Pro Arg Ala Phe Asn Asp Trp Arg
 145 150 155 160

45 Phe Val Leu Leu Val Leu Ile Gly Ser Leu Gly Ile Phe Pro Asp Leu
 165 170 175

Gly Asn Ala Thr Ile Leu Val Leu Val Ser Leu Ile Met Tyr Thr Val
 180 185 190

50 Ser Gly Ile Ala Tyr Arg Trp Phe Ser Thr Ile Leu Ala Leu Val Ser
 195 200 205

Ala Thr Ser Val Phe Val Leu Thr Thr Ile Ser Leu Ile Gly Val Glu
 210 215 220

55 Thr Phe Ser Lys Ile Pro Val Phe Gly Tyr Val Ala Lys Arg Phe Ser
 225 230 235 240

Ala Phe Phe Asn Pro Phe Ala Asp Arg Ala Asp Ala Gly His Gln Leu
 245 250 255
 5 Ala Asn Ser Tyr Phe Ala Met Val Asn Gly Gly Trp Phe Gly Leu Gly
 260 265 270
 Leu Gly Asn Ser Ile Glu Lys Arg Gly Tyr Leu Pro Glu Ala His Thr
 275 280 285
 10 Asp Phe Val Phe Ser Ile Val Ile Glu Glu Phe Gly Phe Val Gly Ala
 290 295 300
 Ser Leu Ile Leu Ala Leu Leu Phe Phe Met Ile Leu Arg Ile Ile Leu
 15 305 310 315 320
 Val Gly Ile Arg Ala Glu Asn Pro Phe Asn Ala Met Val Ala Leu Gly
 325 330 335
 20 Val Gly Gly Met Met Leu Val Gln Val Phe Val Asn Ile Gly Gly Ile
 340 345 350
 Ser Gly Leu Ile Pro Ser Thr Gly Val Thr Phe Pro Phe Leu Ser Gln
 25 355 360 365
 Gly Gly Asn Ser Leu Leu Val Leu Ser Val Ala Val Ala Phe Val Leu
 370 375 380
 30 Asn Ile Asp Ala Ser Glu Lys Arg Ala Lys Leu Tyr Arg Glu Leu Glu
 385 390 395 400
 Asn Gln Pro Met Asn Leu Leu Leu Lys
 405
 35
 <210> 147
 <211> 419
 <212> PRT
 <213> Streptococcus pneumoniae
 40
 <400> 147
 Met Leu Gly Ile Leu Thr Phe Ile Leu Val Phe Gly Ile Ile Val Val
 1 5 10 15
 45 Val His Glu Phe Gly His Phe Tyr Phe Ala Lys Lys Ser Gly Ile Leu
 20 25 30
 Val Arg Glu Phe Ala Ile Gly Met Gly Pro Lys Ile Phe Ala His Ile
 35 40 45
 50 Gly Lys Asp Gly Thr Ala Tyr Thr Ile Arg Ile Leu Pro Leu Gly Gly
 50 55 60
 55 Tyr Val Arg Met Ala Gly Trp Gly Asp Asp Thr Thr Glu Ile Lys Thr
 65 70 75 80
 Gly Thr Pro Val Ser Leu Thr Leu Ala Asp Asp Gly Lys Val Lys Arg

	85	90	95
	Ile Asn Leu Ser Gly Lys Lys Leu Asp Gln Thr Ala Leu Pro Met Gln		
	100	105	110
5	Val Thr Gln Phe Asp Phe Glu Asp Lys Leu Phe Ile Lys Gly Leu Val		
	115	120	125
	Leu Glu Glu Glu Lys Thr Phe Ala Val Asp His Asp Ala Thr Val Val		
10	130	135	140
	Glu Ala Asp Gly Thr Glu Val Arg Ile Ala Pro Leu Asp Val Gln Tyr		
	145	150	155
	Gln Asn Ala Thr Ile Trp Gly Lys Leu Ile Thr Asn Phe Ala Gly Pro		
15	165	170	175
	Met Asn Asn Phe Ile Leu Gly Val Val Val Phe Trp Val Leu Ile Phe		
	180	185	190
20	Met Gln Gly Gly Val Arg Asp Val Asp Thr Asn Gln Phe His Ile Met		
	195	200	205
	Pro Gln Gly Ala Leu Ala Lys Val Gly Val Pro Glu Thr Ala Gln Ile		
25	210	215	220
	Thr Lys Ile Gly Ser His Glu Val Ser Asn Trp Glu Ser Leu Ile Gln		
	225	230	235
	Ala Val Glu Thr Glu Thr Lys Asp Lys Thr Ala Pro Thr Leu Asp Val		
30	245	250	255
	Thr Ile Ser Glu Lys Gly Ser Asp Lys Gln Val Thr Val Thr Pro Glu		
	260	265	270
35	Asp Ser Gln Gly Arg Tyr Leu Leu Gly Val Gln Pro Gly Val Lys Ser		
	275	280	285
	Asp Phe Leu Ser Met Phe Val Gly Gly Phe Thr Thr Ala Ala Asp Ser		
40	290	295	300
	Ala Leu Arg Ile Leu Ser Ala Leu Lys Asn Leu Ile Phe Gln Pro Asp		
	305	310	315
	Leu Asn Lys Leu Gly Gly Pro Val Ala Ile Phe Lys Ala Ser Ser Asp		
45	325	330	335
	Ala Ala Lys Asn Gly Ile Glu Asn Ile Leu Tyr Phe Leu Ala Met Ile		
	340	345	350
50	Ser Ile Asn Ile Gly Ile Phe Asn Leu Ile Pro Ile Pro Ala Leu Asp		
	355	360	365
	Gly Gly Lys Ile Val Leu Asn Ile Leu Glu Ala Ile Arg Arg Lys Pro		
55	370	375	380
	Leu Lys Gln Glu Ile Glu Thr Tyr Val Thr Leu Ala Gly Val Val Ile		

385 390 395 400

Met Val Val Leu Met Ile Ala Val Thr Trp Asn Asp Ile Met Arg Leu
 405 410 415

5 Phe Phe Arg

10 <210> 148
 <211> 197
 <212> PRT
 <213> Streptococcus pneumoniae

15 <400> 148
 Met Tyr Ala Tyr Leu Lys Gly Ile Ile Thr Lys Ile Thr Ala Lys Tyr
 1 5 10 15

20 Ile Val Leu Glu Thr Asn Gly Ile Gly Tyr Ile Leu His Val Ala Asn
 20 25 30

 Pro Tyr Ala Tyr Ser Gly Gln Val Asn Gln Glu Ala Gln Ile Tyr Val
 35 40 45

25 His Gln Val Val Arg Glu Asp Ala His Leu Leu Tyr Gly Phe Arg Ser
 50 55 60

 Glu Asp Glu Lys Lys Leu Phe Leu Ser Leu Ile Ser Val Ser Gly Ile
 65 70 75 80

30 Gly Pro Val Ser Ala Leu Ala Ile Ile Ala Ala Asp Asp Asn Ala Gly
 85 90 95

35 Leu Val Gln Ala Ile Glu Thr Lys Asn Ile Thr Tyr Leu Thr Lys Phe
 100 105 110

 Pro Lys Ile Gly Lys Lys Thr Ala Gln Gln Met Val Leu Asp Leu Glu
 115 120 125

40 Gly Lys Val Val Val Ala Gly Asp Asp Leu Pro Ala Lys Val Ala Val
 130 135 140

 Gln Ala Ser Ala Glu Asn Gln Glu Leu Glu Glu Ala Met Glu Ala Met
 145 150 155 160

45 Leu Ala Leu Gly Tyr Lys Ala Thr Glu Leu Lys Lys Ile Lys Lys Phe
 165 170 175

50 Phe Glu Gly Thr Thr Asp Thr Ala Glu Asn Tyr Ile Lys Ser Ala Leu
 180 185 190

 Lys Met Leu Val Lys
 195

55 <210> 149
 <211> 257

<212> PRT

<213> Streptococcus pneumoniae

<400> 149

5 Met Lys Asn Asn Arg Ile Leu Ala Leu Ser Gly Asn Asp Ile Phe Ser
 1 5 10 15
 Gly Gly Gly Leu Ser Ala Asp Leu Ala Thr Tyr Thr Leu Asn Gly Leu
 20 25 30
 10 His Gly Phe Val Ala Val Thr Cys Leu Thr Ala Leu Thr Glu Lys Gly
 35 40 45
 Phe Glu Val Phe Pro Thr Asp Asp Thr Ile Phe Gln His Glu Leu Asp
 15 50 55 60
 Ser Leu Arg Asp Val Glu Phe Gly Gly Ile Lys Ile Gly Leu Leu Pro
 65 70 75 80
 20 Thr Val Ser Val Ala Glu Lys Ala Leu Asp Phe Ile Lys Gln Arg Pro
 85 90 95
 Gly Val Pro Val Val Leu Asp Pro Val Leu Val Cys Lys Glu Thr His
 100 105 110
 25 Asp Val Ala Val Ser Glu Leu Cys Gln Glu Leu Ile Arg Phe Phe Pro
 115 120 125
 Tyr Val Ser Val Ile Thr Pro Asn Leu Pro Glu Ala Glu Leu Leu Ser
 30 130 135 140
 Gly Gln Glu Ile Lys Thr Leu Glu Asp Met Lys Thr Ala Ala Gln Lys
 145 150 155 160
 35 Leu His Asp Leu Gly Ala Pro Ala Val Ile Ile Lys Gly Gly Asn Arg
 165 170 175
 Leu Ser Gln Asp Lys Ala Val Asp Val Phe Tyr Asp Gly Gln Thr Phe
 180 185 190
 40 Thr Ile Leu Glu Asn Pro Val Ile Gln Gly Gln Asn Ala Gly Ala Gly
 195 200 205
 Cys Thr Phe Ala Ser Ser Ile Ala Ser His Leu Val Lys Gly Asp Lys
 45 210 215 220
 Phe Leu Pro Ala Val Glu Ser Ser Lys Ala Phe Val Tyr Arg Ala Ile
 225 230 235 240
 50 Ala Gln Ala Asp Gln Tyr Gly Val Arg Gln Tyr Glu Ala Asn Lys Asn
 245 250 255

Asn

55

<210> 150

<211> 412

<212> PRT

<213> Streptococcus pneumoniae

5 <400> 150
 Met Ile Glu Thr Glu Lys Lys Glu Glu Arg Val Leu Leu Ile Gly Val
 1 5 10 15

10 Glu Leu Gln Gly Met Asp Ser Phe Asp Leu Ser Met Glu Glu Leu Ala
 20 25 30

Ser Leu Ala Lys Thr Ala Gly Ala Val Val Val Asp Ser Tyr Arg Gln
 35 40 45

15 Lys Arg Glu Lys Tyr Asp Ser Lys Thr Phe Val Gly Ser Gly Lys Leu
 50 55 60

Glu Glu Ile Ala Leu Met Val Asp Ala Glu Glu Ile Thr Thr Val Ile
 65 70 75 80

20 Val Asn Asn Arg Leu Thr Pro Arg Gln Asn Val Asn Leu Glu Glu Val
 85 90 95

25 Leu Gly Val Lys Val Ile Asp Arg Met Gln Leu Ile Leu Asp Ile Phe
 100 105 110

Ala Met Arg Ala Arg Ser His Glu Gly Lys Leu Gln Val His Leu Ala
 115 120 125

30 Gln Phe Lys Tyr Leu Leu Pro Arg Leu Val Gly Gln Gly Ile Met Leu
 130 135 140

Ser Arg Gln Ala Gly Gly Ile Gly Ser Arg Gly Pro Gly Glu Ser Gln
 145 150 155 160

35 Leu Glu Leu Asn Arg Arg Ser Val Arg Asn Gln Ile Thr Asp Ile Glu
 165 170 175

40 Arg Gln Leu Lys Val Val Glu Lys Asn Arg Ala Thr Val Arg Glu Lys
 180 185 190

Arg Leu Glu Ser Ser Thr Phe Lys Ile Gly Leu Ile Gly Tyr Thr Asn
 195 200 205

45 Ala Gly Lys Ser Thr Ile Met Asn Ile Leu Thr Ser Lys Thr Gln Tyr
 210 215 220

Glu Ala Asp Glu Leu Phe Ala Thr Leu Asp Ala Thr Thr Lys Ser Ile
 225 230 235 240

50 His Leu Gly Gly Asn Leu Gln Val Thr Leu Thr Asp Thr Val Gly Phe
 245 250 255

55 Ile Gln Asp Leu Pro Thr Glu Leu Val Ser Ser Phe Lys Ser Thr Leu
 260 265 270

Glu Glu Ser Lys His Val Asp Leu Leu Val His Val Ile Asp Ala Ser

275 280 285
 Asn Pro Tyr His Glu Glu His Glu Lys Thr Val Leu Ser Ile Met Lys
 290 295 300
 5 Asp Leu Asp Met Glu Asp Ile Pro His Leu Thr Leu Tyr Asn Lys Ala
 305 310 315 320
 10 Asp Leu Val Glu Asp Phe Thr Pro Thr Gln Thr Pro Tyr Thr Leu Ile
 325 330 335
 Ser Ala Lys Ser Glu Asp Ser Arg Glu Asn Leu Gln Ala Leu Leu Leu
 340 345 350
 15 Asp Lys Ile Lys Glu Ile Phe Glu Ala Phe Thr Leu Arg Val Pro Phe
 355 360 365
 Ser Lys Ser Tyr Lys Ile His Asp Leu Glu Ser Val Ala Ile Leu Glu
 370 375 380
 20 Glu Arg Asp Tyr Gln Glu Asp Gly Glu Val Ile Thr Gly Tyr Ile Ser
 385 390 395 400
 25 Glu Lys Asn Lys Trp Arg Leu Glu Glu Phe Tyr Asp
 405 410
 <210> 151
 <211> 160
 30 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 151
 35 Met Ala Glu Lys Thr Tyr Pro Met Thr Leu Glu Glu Lys Glu Lys Leu
 1 5 10 15
 Glu Lys Glu Leu Glu Glu Leu Lys Leu Val Arg Arg Pro Glu Val Val
 20 25 30
 40 Glu Arg Ile Lys Ile Ala Arg Ser Tyr Gly Asp Leu Ser Glu Asn Ser
 35 40 45
 Glu Tyr Glu Ala Ala Lys Asp Glu Gln Ala Phe Val Glu Gly Gln Ile
 50 55 60
 45 Ser Ser Leu Glu Thr Lys Ile Arg Tyr Ala Glu Ile Val Asn Ser Asp
 65 70 75 80
 50 Ala Val Ala Gln Asp Glu Val Ala Ile Gly Lys Thr Val Thr Ile Gln
 85 90 95
 Glu Ile Gly Glu Asp Glu Glu Glu Val Tyr Ile Ile Val Gly Ser Ala
 100 105 110
 55 Gly Ala Asp Ala Phe Ala Gly Lys Val Ser Asn Glu Ser Pro Ile Gly
 115 120 125

Gln Ala Leu Ile Gly Lys Lys Thr Gly Asp Thr Ala Thr Ile Glu Thr
 130 135 140

5 Pro Val Gly Ser Tyr Asp Val Lys Ile Leu Lys Val Glu Lys Thr Ala
 145 150 155 160

10
 <210> 152
 <211> 189
 <212> PRT
 <213> Streptococcus pneumoniae

15
 <400> 152
 Met Thr Lys Leu Leu Val Gly Leu Gly Asn Pro Gly Asp Lys Tyr Phe
 1 5 10 15

20 Glu Thr Lys His Asn Val Gly Phe Met Leu Ile Asp Gln Leu Ala Lys
 20 25 30

Lys Gln Asn Val Thr Phe Thr His Asp Lys Ile Phe Gln Ala Asp Leu
 35 40 45

25 Ala Ser Phe Phe Leu Asn Gly Glu Lys Ile Tyr Leu Val Lys Pro Thr
 50 55 60

30 Thr Phe Met Asn Glu Ser Gly Lys Ala Val His Ala Leu Leu Thr Tyr
 65 70 75 80

Tyr Gly Leu Asp Ile Asp Asp Leu Leu Ile Ile Tyr Asp Asp Leu Asp
 85 90 95

35 Met Glu Val Gly Lys Ile Arg Leu Arg Ala Lys Gly Ser Ala Gly Gly
 100 105 110

His Asn Gly Ile Lys Ser Ile Ile Gln His Ile Gly Thr Gln Val Phe
 115 120 125

40 Asn Arg Val Lys Ile Gly Ile Gly Arg Pro Lys Asn Gly Met Ser Val
 130 135 140

45 Val His His Val Leu Ser Lys Phe Asp Arg Asp Glu Tyr Ile Gly Ile
 145 150 155 160

Leu Gln Ser Val Asp Lys Val Asp Asp Ser Val Asn Tyr Tyr Leu Gln
 165 170 175

50 Glu Lys Asn Phe Glu Lys Thr Met Gln Arg Tyr Asn Gly
 180 185

55
 <210> 153
 <211> 283
 <212> PRT
 <213> Streptococcus pneumoniae

<400> 153
 Met Ile Leu Ile Thr Gly Ala Asn Gly Gln Leu Gly Thr Glu Leu Arg
 1 5 10 15
 5 Tyr Leu Leu Asp Glu Arg Asn Glu Glu Tyr Val Ala Val Asp Val Ala
 20 25 30
 10 Lys Met Asp Ile Thr Asn Glu Glu Met Val Glu Lys Val Phe Glu Glu
 35 40 45
 Val Lys Pro Thr Leu Val Tyr His Cys Ala Ala Tyr Thr Ala Val Asp
 50 55 60
 15 Ala Ala Glu Asp Glu Gly Lys Glu Leu Asp Phe Ala Ile Asn Val Thr
 65 70 75 80
 Gly Thr Lys Asn Val Ala Lys Ala Ser Glu Lys His Gly Ala Thr Leu
 85 90 95
 20 Val Tyr Ile Ser Thr Asp Tyr Val Phe Asp Gly Lys Lys Pro Val Gly
 100 105 110
 25 Gln Glu Trp Glu Val Asp Asp Arg Pro Asp Pro Gln Thr Glu Tyr Gly
 115 120 125
 Arg Thr Lys Arg Met Gly Glu Leu Val Glu Lys His Val Ser Asn
 130 135 140
 30 Phe Tyr Ile Ile Arg Thr Ala Trp Val Phe Gly Asn Tyr Gly Lys Asn
 145 150 155 160
 Phe Val Phe Thr Met Gln Asn Leu Ala Lys Thr His Lys Thr Leu Thr
 165 170 175
 35 Val Val Asn Asp Gln Tyr Gly Arg Pro Thr Trp Thr Arg Thr Leu Ala
 180 185 190
 40 Glu Phe Met Thr Tyr Leu Ala Glu Asn Arg Lys Glu Phe Gly Tyr Tyr
 195 200 205
 His Leu Ser Asn Asp Ala Thr Glu Asp Thr Thr Trp Tyr Asp Phe Ala
 210 215 220
 45 Val Glu Ile Leu Lys Asp Thr Asp Val Glu Val Lys Pro Val Asp Ser
 225 230 235 240
 Ser Gln Phe Pro Ala Lys Ala Lys Arg Pro Leu Asn Ser Thr Met Ser
 245 250 255
 50 Leu Ala Lys Ala Lys Ala Thr Gly Phe Val Ile Pro Thr Trp Gln Asp
 260 265 270
 55 Ala Leu Gln Glu Phe Tyr Lys Gln Glu Val Arg
 275 280

<210> 154
 <211> 407
 5 <212> PRT
 <213> Streptococcus pneumoniae

 <400> 154
 10 Met Lys Arg Ser Leu Asp Ser Arg Val Asp Tyr Ser Leu Leu Leu Pro
 1 5 10 15
 Val Phe Phe Leu Leu Val Ile Gly Val Val Ala Ile Tyr Ile Ala Val
 20 25 30
 15 Ser His Asp Tyr Pro Asn Asn Ile Leu Pro Ile Leu Gly Gln Gln Val
 35 40 45
 Ala Trp Ile Ala Leu Gly Leu Val Ile Gly Phe Val Val Met Leu Phe
 50 55 60
 20 Asn Thr Glu Phe Leu Trp Lys Val Thr Pro Phe Leu Tyr Ile Leu Gly
 65 70 75 80
 Leu Gly Leu Met Ile Leu Pro Ile Val Phe Tyr Asn Pro Ser Leu Val
 25 85 90 95
 Ala Ser Thr Gly Ala Lys Asn Trp Val Ser Ile Asn Gly Ile Thr Leu
 100 105 110
 30 Phe Gln Pro Ser Glu Phe Met Lys Ile Ser Tyr Ile Leu Met Leu Ala
 115 120 125
 Arg Val Ile Val Gln Phe Thr Lys Lys His Lys Glu Trp Arg Arg Thr
 130 135 140
 35 Val Pro Leu Asp Phe Leu Leu Ile Phe Trp Met Ile Leu Phe Thr Ile
 145 150 155 160
 40 Pro Val Leu Val Leu Leu Ala Leu Gln Ser Asp Leu Gly Thr Ala Leu
 165 170 175
 Val Phe Val Ala Ile Phe Ser Gly Ile Val Leu Leu Ser Gly Val Ser
 180 185 190
 45 Trp Lys Ile Ile Ile Pro Val Phe Val Thr Ala Val Thr Gly Val Ala
 195 200 205
 Gly Phe Leu Ala Ile Phe Ile Ser Lys Asp Gly Arg Ala Phe Leu His
 210 215 220
 50 Gln Ile Gly Met Pro Thr Tyr Gln Ile Asn Arg Ile Leu Ala Trp Leu
 225 230 235 240
 55 Asn Pro Phe Glu Phe Ala Gln Thr Thr Thr Tyr Gln Gln Ala Gln Gly
 245 250 255
 Gln Ile Ala Ile Gly Ser Gly Gly Leu Phe Gly Gln Gly Phe Asn Ala

260 265 270
 Ser Asn Leu Leu Ile Pro Val Arg Glu Ser Asp Met Ile Phe Thr Val
 275 280 285
 5 Ile Ala Glu Asp Phe Gly Phe Ile Gly Ser Val Leu Val Ile Ala Leu
 290 295 300
 Tyr Leu Met Leu Ile Tyr Arg Met Leu Lys Ile Thr Leu Lys Ser Asn
 10 305 310 315 320
 Asn Gln Phe Tyr Thr Tyr Ile Ser Thr Gly Leu Ile Met Met Leu Leu
 325 330 335
 15 Phe His Ile Phe Glu Asn Ile Gly Ala Val Thr Gly Leu Leu Pro Leu
 340 345 350
 Thr Gly Ile Pro Leu Pro Phe Ile Ser Gln Gly Gly Ser Ala Ile Ile
 355 360 365
 20 Ser Asn Leu Ile Gly Val Gly Leu Leu Leu Ser Met Ser Tyr Gln Thr
 370 375 380
 Asn Leu Ala Glu Glu Lys Ser Gly Lys Val Pro Phe Lys Arg Lys Lys
 25 385 390 395 400
 Val Val Leu Lys Gln Ile Lys
 405
 30
 <210> 155
 <211> 202
 <212> PRT
 <213> Streptococcus pneumoniae
 35
 <400> 155
 Met Gly Lys Ile Ile Gly Ile Thr Gly Gly Ile Ala Ser Gly Lys Ser
 1 5 10 15
 40 Thr Val Thr Asn Phe Leu Lys His Gln Gly Leu Ser Ser Ser Gly Leu
 20 25 30
 Pro Thr Gln Cys Ser Thr Asn Tyr Arg Lys Pro Gly Gly Arg Leu Phe
 35 40 45
 45 Glu Ala Leu Val Gln His Phe Gly Gln Glu Ile Ile Leu Glu Asn Gly
 50 55 60
 Glu Leu Asn Arg Pro Leu Ile Ala Ser Leu Ile Phe Ser Asn Pro Glu
 50 65 70 75 80
 Glu Gln Lys Trp Ser Asn Gln Ile Gln Gly Glu Ile Ile Arg Glu Glu
 85 90 95
 55 Leu Ala Thr Leu Arg Glu Gln Leu Ala Gln Thr Glu Glu Ile Phe Phe
 100 105 110

Met Asp Ile Pro Leu Leu Phe Glu Gln Asp Tyr Ser Asp Trp Phe Ala
 115 120 125
 5 Glu Thr Trp Leu Val Tyr Val Asp Arg Asp Ala Gln Val Glu Arg Leu
 130 135 140
 Met Lys Arg Asp Gln Leu Ser Lys Asp Glu Ala Glu Ser Arg Met Ala
 145 150 155 160
 10 Ala Gln Trp Pro Leu Glu Lys Lys Lys Asp Leu Ala Ser Gln Val Leu
 165 170 175
 Asp Asn Asn Gly Asn Gln Asn Gln Leu Leu Asn Gln Val His Ile Leu
 180 185 190
 15 Leu Glu Gly Gly Arg Gln Asp Asp Arg Asp
 195 200
 20 <210> 156
 <211> 419
 <212> PRT
 <213> Streptococcus pneumoniae
 25 <400> 156
 Met Arg Lys Ile Val Ile Asn Gly Gly Leu Pro Leu Gln Gly Glu Ile
 1 5 10 15
 30 Thr Ile Ser Gly Ala Lys Asn Ser Val Val Ala Leu Ile Pro Ala Ile
 20 25 30
 Ile Leu Ala Asp Asp Val Val Thr Leu Asp Cys Val Pro Asp Ile Ser
 35 40 45
 35 Asp Val Ala Ser Leu Val Glu Ile Met Glu Leu Met Gly Ala Thr Val
 50 55 60
 Lys Arg Tyr Asp Asp Val Leu Glu Ile Asp Pro Arg Gly Val Gln Asn
 65 70 75 80
 40 Ile Pro Met Pro Tyr Gly Lys Ile Asn Ser Leu Arg Ala Ser Tyr Tyr
 85 90 95
 45 Phe Tyr Gly Ser Leu Leu Gly Arg Phe Gly Glu Ala Thr Val Gly Leu
 100 105 110
 Pro Gly Gly Cys Asp Leu Gly Pro Arg Pro Ile Asp Leu His Leu Lys
 115 120 125
 50 Ala Phe Glu Ala Met Gly Ala Thr Ala Ser Tyr Glu Gly Asp Asn Met
 130 135 140
 Lys Leu Ser Ala Lys Asp Thr Gly Leu His Gly Ala Ser Ile Tyr Met
 145 150 155 160
 55 Asp Thr Val Ser Val Gly Ala Thr Ile Asn Thr Met Ile Ala Ala Val
 165 170 175

Lys Ala Asn Gly Arg Thr Ile Ile Glu Asn Ala Ala Arg Glu Pro Glu
 180 185 190
 5 Ile Ile Asp Val Ala Thr Leu Leu Asn Asn Met Gly Ala His Ile Arg
 195 200 205
 Gly Ala Gly Thr Asn Ile Ile Ile Ile Asp Gly Val Glu Arg Leu His
 210 215 220
 10 Gly Thr Arg His Gln Val Ile Pro Asp Arg Ile Glu Ala Gly Thr Tyr
 225 230 235 240
 15 Ile Ser Leu Ala Ala Val Gly Lys Gly Ile Arg Ile Asn Asn Val
 245 250 255
 Leu Tyr Glu His Leu Glu Gly Phe Ile Ala Lys Leu Glu Glu Met Gly
 260 265 270
 20 Val Arg Met Thr Val Ser Glu Asp Ser Ile Phe Val Glu Glu Gln Ser
 275 280 285
 Asn Leu Lys Ala Ile Asn Ile Lys Thr Ala Pro Tyr Pro Gly Phe Ala
 290 295 300
 25 Thr Asp Leu Gln Gln Pro Leu Thr Pro Leu Leu Leu Arg Ala Asn Gly
 305 310 315 320
 30 Arg Gly Thr Ile Val Asp Thr Ile Tyr Glu Lys Arg Val Asn His Val
 325 330 335
 Phe Glu Leu Ala Lys Met Asp Ala Asp Ile Ser Thr Thr Asn Gly His
 340 345 350
 35 Ile Leu Tyr Thr Gly Gly Arg Asp Leu Arg Gly Ala Ser Val Lys Ala
 355 360 365
 Thr Asp Leu Arg Ala Gly Ala Ala Leu Val Ile Ala Gly Leu Met Ala
 370 375 380
 40 Glu Gly Lys Thr Glu Ile Thr Asn Ile Glu Phe Ile Leu Arg Gly Tyr
 385 390 395 400
 45 Ser Asp Ile Ile Glu Lys Leu Arg Asn Leu Gly Ala Asp Ile Arg Leu
 405 410 415
 Val Glu Asp
 50
 <210> 157
 <211> 231
 <212> PRT
 <213> Streptococcus pneumoniae
 55
 <400> 157
 Met Ser Arg Ile Glu Phe Ser Pro Ser Leu Met Thr Met Asp Leu Asp

1 5 10 15
 Lys Phe Lys Glu Gln Ile Thr Phe Leu Asn Asp Lys Val Ala Ser Tyr
 20 25 30
 5 His Ile Asp Ile Met Asp Gly His Phe Val Pro Asn Ile Thr Leu Ser
 35 40 45
 Pro Trp Phe Ile Gln Glu Val Gln Lys Ile Ser Asp Thr Pro Leu Ser
 10 50 55 60
 Val His Leu Met Val Thr Asp Pro Thr Phe Trp Val Asp Gln Val Leu
 65 70 75 80
 15 Asp Leu Gln Cys Glu Tyr Ile Cys Ile His Ala Glu Val Leu Asn Gly
 85 90 95
 Leu Ala Phe Arg Leu Ile Asp Lys Ile His Asp Ala Gly Leu Lys Ala
 100 105 110
 20 Gly Val Val Leu Asn Pro Glu Thr Pro Val Ser Thr Ile Phe Pro Tyr
 115 120 125
 Ile Asp Leu Leu Asp Lys Val Thr Ile Met Thr Val Asp Pro Gly Phe
 25 130 135 140
 Ala Gly Gln Arg Phe Leu Glu Ser Thr Leu Tyr Lys Ile Gln Glu Leu
 145 150 155 160
 30 Arg Gln Leu Arg Val Gln Asn Gly Tyr His Tyr Ile Ile Glu Met Asp
 165 170 175
 Gly Ser Ser Ser Arg Lys Thr Phe Lys Gln Ile Asp Val Ala Gly Pro
 180 185 190
 35 Asp Ile Tyr Val Ile Gly Arg Ser Gly Leu Phe Gly Leu Asp Asp Asp
 195 200 205
 40 Ile Ala Lys Ala Trp Asp Ile Cys Ser Arg Asp Tyr Glu Glu Met Thr
 210 215 220
 Gly Lys Thr Met Pro Ile Lys
 225 230
 45
 <210> 158
 <211> 374
 <212> PRT
 <213> Streptococcus pneumoniae
 50
 <400> 158
 Met Arg Asn Met Ala Leu Thr Ala Gly Ile Val Gly Leu Pro Asn Val
 1 5 10 15
 55 Gly Lys Ser Thr Leu Phe Asn Ala Ile Thr Lys Ala Gly Ala Glu Ala
 20 25 30

Ala Asn Tyr Pro Phe Ala Thr Ile Asp Pro Asn Val Gly Met Val Glu
 35 40 45
 5 Asp Pro Asp Glu Arg Leu Gln Lys Leu Thr Glu Met Ile Thr Pro Lys
 50 55 60
 Lys Thr Val Pro Thr Thr Phe Glu Phe Thr Asp Ile Ala Gly Ile Val
 65 70 75 80
 10 Lys Gly Ala Ser Lys Gly Glu Gly Leu Gly Asn Lys Phe Leu Ala Asn
 85 90 95
 Ile Arg Glu Val Asp Ala Ile Val His Val Val Arg Ala Phe Asp Asp
 100 105 110
 15 Glu Asn Val Met Arg Glu Gln Gly Arg Glu Asp Ala Phe Val Asp Pro
 115 120 125
 20 Leu Ala Asp Ile Asp Thr Ile Asn Leu Glu Leu Ile Leu Ala Asp Leu
 130 135 140
 Glu Ser Val Asn Lys Arg Tyr Ala Arg Val Glu Lys Met Ala Arg Thr
 145 150 155 160
 25 Gln Lys Asp Lys Glu Ser Val Ala Glu Phe Asn Val Leu Gln Lys Ile
 165 170 175
 Lys Pro Val Leu Glu Asp Gly Lys Ser Ala Arg Thr Ile Glu Phe Thr
 180 185 190
 30 Asp Glu Glu Gln Lys Val Val Lys Gly Leu Phe Leu Leu Thr Thr Lys
 195 200 205
 35 Pro Val Leu Tyr Val Ala Asn Val Asp Glu Asp Val Val Ser Glu Pro
 210 215 220
 Asp Ser Ile Asp Tyr Val Lys Gln Ile Arg Glu Phe Ala Ala Thr Glu
 225 230 235 240
 40 Asn Ala Glu Val Val Val Ile Ser Ala Arg Ala Glu Glu Glu Ile Ser
 245 250 255
 Glu Leu Asp Asp Glu Asp Lys Lys Glu Phe Leu Glu Ala Ile Gly Leu
 260 265 270
 45 Thr Glu Ser Gly Val Asp Lys Leu Thr Arg Ala Ala Tyr His Leu Leu
 275 280 285
 50 Gly Leu Gly Thr Tyr Phe Thr Ala Gly Glu Lys Glu Val Arg Ala Trp
 290 295 300
 Thr Phe Lys Arg Gly Met Lys Ala Pro Gln Ala Ala Gly Ile Ile His
 305 310 315 320
 55 Ser Asp Phe Glu Lys Gly Phe Ile Arg Ala Val Thr Met Ser Tyr Glu
 325 330 335

Asp Leu Val Lys Tyr Gly Ser Glu Lys Ala Val Lys Glu Ala Gly Arg
 340 345 350
 5 Leu Arg Glu Glu Gly Lys Glu Tyr Ile Val Gln Asp Gly Asp Ile Met
 355 360 365
 Glu Phe Arg Phe Asn Val
 370
 10
 <210> 159
 <211> 110
 <212> PRT
 <213> Streptococcus pneumoniae
 15
 <400> 159
 Met Glu Ile Glu Lys Thr Asn Arg Met Asn Ala Leu Phe Glu Phe Tyr
 1 5 10 15
 20 Ala Ala Leu Leu Thr Asp Lys Gln Met Asn Tyr Ile Glu Leu Tyr Tyr
 20 25 30
 Ala Asp Asp Tyr Ser Leu Ala Glu Ile Ala Glu Glu Phe Gly Val Ser
 35 40 45
 25 Arg Gln Ala Val Tyr Asp Asn Ile Lys Arg Thr Glu Lys Ile Leu Glu
 50 55 60
 30 Asp Tyr Glu Met Lys Leu His Met Tyr Ser Asp Tyr Ile Val Arg Ser
 65 70 75 80
 Gln Ile Phe Asp Gln Ile Leu Glu Arg Tyr Pro Lys Asp Asp Phe Leu
 85 90 95
 35 Gln Glu Gln Ile Glu Ile Leu Thr Ser Ile Asp Asn Arg Glu
 100 105 110
 40
 <210> 160
 <211> 223
 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 160
 45 Met Thr Leu Glu Trp Glu Glu Phe Leu Asp Pro Tyr Ile Gln Ala Val
 1 5 10 15
 Gly Glu Leu Lys Ile Lys Leu Arg Gly Ile Arg Lys Gln Tyr Arg Lys
 20 25 30
 50 Gln Asn Lys His Ser Pro Ile Glu Phe Val Thr Gly Arg Val Lys Pro
 35 40 45
 55 Ile Glu Ser Ile Lys Glu Lys Met Ala Arg Arg Gly Ile Thr Tyr Ala
 50 55 60
 Thr Leu Glu His Asp Leu Gln Asp Ile Ala Gly Leu Arg Val Met Val

101

Ser Leu Val Asp Leu Arg His Asp Pro Ser Ala Asp Asp Val Gln Met
 115 120 125
 Tyr Glu Phe Leu Lys Tyr Tyr Glu Ile Pro Val Ile Ile Val Ala Thr
 5 130 135 140
 Lys Ala Asp Lys Ile Pro Arg Gly Lys Trp Asn Lys His Glu Ser Ala
 145 150 155 160
 10 Ile Lys Lys Lys Leu Asn Phe Asp Pro Ser Asp Asp Phe Ile Leu Phe
 165 170 175
 Ser Ser Val Ser Lys Ala Gly Met Asp Glu Ala Trp Asp Ala Ile Leu
 180 185 190
 15 Glu Lys Leu
 195
 20 <210> 162
 <211> 97
 <212> PRT
 <213> Streptococcus pneumoniae
 25 <400> 162
 Met Lys Thr Arg Lys Ile Pro Leu Arg Lys Ser Val Val Ser Asn Glu
 1 5 10 15
 30 Val Ile Asp Lys Arg Asp Leu Leu Arg Ile Val Lys Asn Lys Glu Gly
 20 25 30
 Gln Val Phe Ile Asp Pro Thr Gly Lys Ala Asn Gly Arg Gly Ala Tyr
 35 40 45
 35 Ile Lys Leu Asp Asn Ala Glu Ala Leu Glu Ala Lys Lys Lys Lys Val
 50 55 60
 Phe Asn Arg Ser Phe Ser Met Glu Val Glu Glu Ser Phe Tyr Asp Glu
 65 70 75 80
 40 Leu Ile Ala Tyr Val Asp His Lys Val Lys Arg Arg Glu Leu Gly Leu
 85 90 95
 Glu
 45
 <210> 163
 <211> 103
 50 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 163
 Met Leu Lys Pro Ser Ile Asp Thr Leu Leu Asp Lys Val Pro Ser Lys
 55 1 5 10 15
 Tyr Ser Leu Val Ile Leu Glu Ala Lys Arg Ala His Glu Leu Glu Ala

20 25 30
 Gly Ala Pro Ala Thr Gln Gly Phe Lys Ser Glu Lys Ser Thr Leu Arg
 35 40 45
 5 Ala Leu Glu Glu Ile Glu Ser Gly Asn Val Thr Ile His Pro Asp Pro
 50 55 60
 10 Glu Gly Lys Arg Glu Ala Val Arg Arg Arg Ile Glu Glu Glu Lys Arg
 65 70 75 80
 Arg Lys Glu Glu Glu Glu Lys Lys Ile Lys Glu Gln Ile Ala Lys Glu
 85 90 95
 15 Lys Glu Asp Gly Glu Lys Ile
 100
 <210> 164
 20 <211> 103
 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 164
 25 Met Ser Leu Thr Ser Lys Gln Arg Ala Phe Leu Asn Ser Gln Ala His
 1 5 10 15
 Thr Leu Lys Pro Ile Ile Gln Ile Gly Lys Asn Gly Leu Asn Asp Gln
 20 25 30
 30 Ile Lys Thr Ser Val Arg Gln Ala Leu Asp Ala Arg Glu Leu Ile Lys
 35 40 45
 Val Thr Leu Leu Gln Asn Thr Asp Glu Asn Ile His Glu Val Ala Glu
 50 55 60
 Ile Leu Glu Glu Glu Ile Gly Val Asp Thr Val Gln Lys Ile Gly Arg
 65 70 75 80
 40 Ile Leu Ile Leu Phe Lys Gln Ser Ser Lys Lys Glu Asn Arg Lys Ile
 85 90 95
 Ser Lys Lys Val Lys Glu Ile
 100
 45
 <210> 165
 <211> 175
 <212> PRT
 50 <213> Streptococcus pneumoniae
 <400> 165
 Met Ala Ile Glu Asn Tyr Ile Pro Asp Phe Ala Val Glu Ala Val Tyr
 1 5 10 15
 55 Asp Leu Thr Val Pro Ser Leu Gln Ala Gln Gly Ile Lys Ala Val Leu
 20 25 30

Val Asp Leu Asp Asn Thr Leu Ile Ala Trp Asn Asn Pro Asp Gly Thr
 35 40 45
 5 Pro Glu Met Lys Gln Trp Leu His Asp Leu Arg Asp Ala Gly Ile Gly
 50 55 60
 Ile Ile Val Val Ser Asn Asn Thr Lys Lys Arg Val Gln Arg Ala Val
 65 70 75 80
 10 Glu Lys Phe Gly Ile Asp Tyr Val Tyr Trp Ala Leu Lys Pro Phe Thr
 85 90 95
 Phe Gly Ile Asp Arg Ala Met Lys Glu Phe His Tyr Asp Lys Lys Glu
 100 105 110
 15 Val Val Met Val Gly Asp Gln Leu Met Thr Asp Ile Arg Ala Ala His
 115 120 125
 20 Arg Ala Gly Ile Arg Ser Ile Leu Val Lys Pro Leu Val Gln His Asp
 130 135 140
 Ser Ile Lys Thr Gln Ile Asn Arg Thr Arg Glu Arg Arg Val Met Arg
 145 150 155 160
 25 Lys Ile Thr Glu Lys Tyr Gly Pro Ile Thr Tyr Lys Lys Gly Ile
 165 170 175
 30 <210> 166
 <211> 455
 <212> PRT
 <213> Streptococcus pneumoniae
 35 <400> 166
 Met Phe Arg Lys Ile Leu Ile Ala Asn Arg Gly Glu Ile Ala Val Arg
 1 5 10 15
 40 Ile Ile Arg Ala Ala Arg Glu Leu Gly Ile Ala Thr Val Ala Val Tyr
 20 25 30
 Ser Thr Ala Asp Lys Glu Ala Leu His Thr Leu Leu Ala Asp Glu Ala
 35 40 45
 45 Val Cys Ile Gly Pro Gly Lys Ala Thr Glu Ser Tyr Leu Asn Ile Asn
 50 55 60
 Ala Val Leu Ser Ala Ala Val Leu Thr Glu Ala Glu Ala Ile His Pro
 65 70 75 80
 50 Gly Phe Gly Phe Leu Ser Glu Asn Ser Lys Phe Ala Thr Met Cys Glu
 85 90 95
 55 Glu Ile Gly Ile Lys Phe Ile Gly Pro Ser Gly His Val Met Asp Met
 100 105 110
 Met Gly Asp Lys Ile Asn Ala Arg Ala Gln Met Ile Lys Ala Gly Val

	115	120	125
	Pro Val Ile Pro Gly Ser Asp Gly Glu Val His Asn Ser Glu Glu Ala		
	130	135	140
5	Leu Ile Val Ala Glu Lys Ile Gly Tyr Pro Val Met Leu Lys Ala Ser		
	145	150	155 160
10	Ala Gly Gly Gly Gly Lys Gly Ile Arg Lys Val Glu Lys Pro Asp Asp		
	165	170	175
	Leu Val Ser Ala Phe Glu Thr Ala Ser Ser Glu Ala Lys Ala Asn Tyr		
	180	185	190
15	Gly Asn Gly Ala Met Tyr Ile Glu Arg Val Ile Tyr Pro Ala Arg His		
	195	200	205
	Ile Glu Val Gln Ile Leu Gly Asp Glu His Gly His Val Ile His Leu		
20	210	215	220
	Gly Glu Arg Asp Cys Ser Leu Gln Arg Asn Asn Gln Lys Val Leu Glu		
	225	230	235 240
25	Glu Ser Pro Ser Ile Ala Ile Gly Lys Thr Leu Arg His Glu Ile Gly		
	245	250	255
	Ala Ala Ala Val Arg Ala Ala Glu Phe Val Gly Tyr Glu Asn Ala Gly		
	260	265	270
30	Thr Ile Glu Phe Leu Leu Asp Glu Ala Ser Ser Asn Phe Tyr Phe Met		
	275	280	285
	Glu Met Asn Thr Arg Val Gln Val Glu His Pro Val Thr Glu Phe Val		
35	290	295	300
	Ser Gly Val Asp Ile Val Lys Glu Gln Ile Cys Ile Ala Ala Gly Gln		
	305	310	315 320
40	Pro Leu Ser Val Lys Gln Glu Asp Ile Val Leu Arg Gly His Ala Ile		
	325	330	335
	Glu Cys Arg Ile Asn Ala Glu Asn Pro Ala Phe Asn Phe Ala Pro Ser		
	340	345	350
45	Pro Gly Lys Ile Thr Asn Leu Tyr Leu Pro Ser Gly Gly Val Gly Leu		
	355	360	365
	Arg Val Asp Ser Ala Val Tyr Pro Gly Tyr Thr Ile Pro Pro Tyr Tyr		
50	370	375	380
	Asp Ser Met Ile Ala Lys Ile Ile Val His Gly Glu Asn Arg Phe Asp		
	385	390	395 400
55	Ala Leu Met Lys Met Gln Arg Ala Leu Tyr Glu Leu Glu Ile Glu Gly		
	405	410	415
	Val Gln Thr Asn Ala Asp Phe Gln Leu Asp Leu Ile Ser Asp Arg Asn		

420 425 430
 Val Ile Ala Gly Asp Tyr Asp Thr Cys Phe Leu Met Glu Thr Phe Leu
 435 440 445
 5 Pro Lys Tyr Gln Glu Lys Glu
 450 455
 10 <210> 167
 <211> 77
 <212> PRT
 <213> Streptococcus pneumoniae
 15 <400> 167
 Met Ile Tyr Lys Val Phe Tyr Gln Glu Thr Lys Glu Arg Ser Pro Arg
 1 5 10 15
 20 Arg Glu Thr Thr Arg Ala Leu Tyr Leu Asp Ile Asp Thr Ser Ser Glu
 20 25 30
 Leu Glu Gly Arg Ile Thr Ala Arg Gln Leu Val Glu Glu Asn Arg Pro
 35 40 45
 25 Glu Tyr Asn Ile Glu Tyr Ile Glu Leu Leu Ser Asp Lys Leu Leu Asp
 50 55 60
 Tyr Glu Lys Glu Thr Gly Ala Phe Glu Ile Thr Glu Phe
 65 70 75
 30
 <210> 168
 <211> 336
 <212> PRT
 35 <213> Streptococcus pneumoniae
 <400> 168
 Met Lys Asp Arg Tyr Ile Leu Ala Phe Glu Thr Ser Cys Asp Glu Thr
 1 5 10 15
 40 Ser Val Ala Val Leu Lys Asn Asp Asp Glu Leu Leu Ser Asn Val Ile
 20 25 30
 45 Ala Ser Gln Ile Glu Ser His Lys Arg Phe Gly Gly Val Val Pro Glu
 35 40 45
 Val Ala Ser Arg His His Val Glu Val Ile Thr Ala Cys Ile Glu Glu
 50 55 60
 50 Ala Leu Ala Glu Ala Gly Ile Thr Glu Glu Asp Val Thr Ala Val Ala
 65 70 75 80
 Val Thr Tyr Gly Pro Gly Leu Val Gly Ala Leu Leu Val Gly Leu Ser
 85 90 95
 55 Ala Ala Lys Ala Phe Ala Trp Ala His Gly Leu Pro Leu Ile Pro Val
 100 105 110

Asn His Met Ala Gly His Leu Met Ala Ala Gln Ser Val Glu Pro Leu
 115 120 125
 5 Glu Phe Pro Leu Leu Ala Leu Leu Val Ser Gly Gly His Thr Glu Leu
 130 135 140
 Val Tyr Val Ser Glu Ala Gly Asp Tyr Lys Ile Val Gly Glu Thr Arg
 145 150 155 160
 10 Asp Asp Ala Val Gly Glu Ala Tyr Asp Lys Val Gly Arg Val Met Gly
 165 170 175
 Leu Thr Tyr Pro Ala Gly Arg Glu Ile Asp Glu Leu Ala His Gln Gly
 180 185 190
 15 Gln Asp Ile Tyr Asp Phe Pro Arg Ala Met Ile Lys Glu Asp Asn Leu
 195 200 205
 20 Glu Phe Ser Phe Ser Gly Leu Lys Ser Ala Phe Ile Asn Leu His His
 210 215 220
 Asn Ala Glu Gln Lys Gly Glu Ser Leu Ser Thr Glu Asp Leu Cys Ala
 225 230 235 240
 25 Ser Phe Gln Ala Ala Val Met Asp Ile Leu Met Ala Lys Thr Lys Lys
 245 250 255
 Ala Leu Glu Glu Tyr Pro Val Lys Thr Leu Phe Val Ala Gly Gly Val
 260 265 270
 30 Ala Ala Asn Lys Gly Leu Arg Glu Arg Leu Ala Ala Glu Ile Thr Asp
 275 280 285
 35 Val Lys Val Ile Ile Pro Pro Leu Arg Leu Cys Gly Asp Asn Ala Gly
 290 295 300
 Met Ile Ala Tyr Ala Ser Val Ser Glu Trp Asn Lys Glu Asn Phe Ala
 305 310 315 320
 40 Gly Trp Asp Leu Asn Ala Lys Pro Ser Leu Ala Phe Asp Thr Met Glu
 325 330 335
 45
 <210> 169
 <211> 602
 50 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 169
 Met Cys Gly Ile Val Gly Val Val Gly Asn Thr Asn Ala Thr Asp Ile
 55 1 5 10 15
 Leu Ile Gln Gly Leu Glu Lys Leu Glu Tyr Arg Gly Tyr Asp Ser Ala

20 25 30
 Gly Ile Phe Val Leu Asp Gly Ala Asp Asn His Leu Val Lys Ala Val
 35 40 45
 5 Gly Arg Ile Ala Glu Leu Ser Ala Lys Thr Ala Gly Val Glu Gly Thr
 50 55 60
 10 Thr Gly Ile Gly His Thr Arg Trp Ala Thr His Gly Lys Pro Thr Glu
 65 70 75 80
 Asp Asn Ala His Pro His Arg Ser Glu Thr Glu Arg Phe Val Leu Val
 85 90 95
 15 His Asn Gly Val Ile Glu Asn Tyr Leu Glu Ile Lys Glu Glu Tyr Leu
 100 105 110
 Ala Gly His His Phe Lys Gly Gln Thr Asp Thr Glu Ile Ala Val His
 115 120 125
 20 Leu Ile Gly Lys Phe Ala Glu Glu Glu Gly Leu Ser Val Leu Glu Ala
 130 135 140
 Phe Lys Lys Ala Leu His Ile Ile Arg Gly Ser Tyr Ala Phe Ala Leu
 145 150 155 160
 Ile Asp Ser Glu Asn Pro Asp Val Ile Tyr Val Ala Lys Asn Lys Ser
 165 170 175
 30 Pro Leu Leu Ile Gly Leu Gly Glu Gly Tyr Asn Met Val Cys Ser Asp
 180 185 190
 Ala Met Ala Met Ile Arg Glu Thr Asn Gln Tyr Met Glu Ile His Asp
 195 200 205
 35 Gln Glu Leu Val Ile Val Lys Ala Asp Ser Val Glu Val Gln Asp Tyr
 210 215 220
 Asp Gly Asn Ser Arg Glu Arg Ala Ser Tyr Thr Ala Glu Leu Asp Leu
 225 230 235 240
 Ser Asp Ile Gly Lys Gly Thr Tyr Pro Tyr Tyr Met Leu Lys Glu Ile
 245 250 255
 45 Asp Glu Gln Pro Thr Val Met Arg Lys Leu Ile Gln Ala Tyr Thr Asp
 260 265 270
 Asp Ala Gly Gln Val Val Val Ala Pro Ala Ile Ile Lys Ala Val Gln
 275 280 285
 50 Asp Ala Asp Arg Ile Tyr Ile Leu Ala Ala Gly Thr Ser Tyr His Ala
 290 295 300
 Gly Phe Ala Ser Lys Lys Met Leu Glu Glu Leu Thr Asp Thr Pro Val
 305 310 315 320
 55 Glu Leu Gly Ile Ser Ser Glu Trp Gly Tyr Gly Met Pro Leu Leu Ser

	325	330	335
	Lys Lys Pro Leu Phe Ile Phe Ile Ser Gln Ser Gly Glu Thr Ala Asp		
	340	345	350
5	Ser Arg Gln Val Leu Val Lys Ala Asn Glu Met Gly Ile Pro Ser Leu		
	355	360	365
10	Thr Val Thr Asn Val Pro Gly Ser Thr Leu Ser Arg Glu Ala Asn Tyr		
	370	375	380
	Thr Met Leu Leu His Ala Gly Pro Glu Ile Ala Val Ala Ser Thr Lys		
	385	390	395
15	Ala Tyr Thr Ala Gln Ile Ala Ala Leu Ala Phe Leu Ala Lys Ala Val		
	405	410	415
	Gly Glu Ala Asn Gly Asn Ala Lys Ala Gln Ala Phe Asp Leu Val His		
	420	425	430
20	Glu Leu Ser Ile Val Ala Gln Ser Ile Glu Ser Thr Leu Ser Glu Lys		
	435	440	445
	Glu Thr Ile Glu Ala Lys Val Arg Glu Leu Leu Glu Thr Thr Arg Asn		
25	450	455	460
	Ala Phe Tyr Ile Gly Arg Gly Gln Asp Tyr Tyr Val Ala Met Glu Ala		
	465	470	475
30	Ser Leu Lys Leu Lys Glu Ile Ser Tyr Ile Gln Cys Glu Gly Phe Ala		
	485	490	495
	Ala Gly Glu Leu Lys His Gly Thr Ile Ala Leu Ile Glu Glu Gly Thr		
	500	505	510
35	Pro Val Leu Ala Leu Leu Ser Asp Pro Val Leu Ala Asn His Thr Arg		
	515	520	525
	Gly Asn Ile Gln Glu Val Ala Ala Arg Gly Ala Lys Val Leu Thr Ile		
40	530	535	540
	Ala Glu Glu Asn Val Ala Lys Asp Thr Asp Asp Ile Val Leu Thr Thr		
	545	550	555
45	Val His Pro Tyr Leu Ser Pro Ile Ser Met Val Val Pro Thr Gln Leu		
	565	570	575
	Val Ala Tyr Phe Ala Thr Leu His Arg Gly Leu Asp Val Asp Lys Pro		
	580	585	590
50	Arg Asn Leu Ala Lys Ser Val Thr Val Glu		
	595	600	
55	<210> 170		
	<211> 240		
	<212> PRT		

<213> Streptococcus pneumoniae

<400> 170

5 Met Ile Arg Ile Glu Asn Leu Ser Val Ser Tyr Lys Glu Thr Leu Ala
1 5 10 15
Leu Lys Asp Ile Ser Leu Val Leu His Gly Pro Thr Ile Thr Gly Ile
20 25 30
10 Ile Gly Pro Asn Gly Ala Gly Lys Ser Thr Leu Leu Lys Gly Met Leu
35 40 45
Gly Ile Ile Pro His Gln Gly Gln Ala Phe Leu Asp Asp Lys Glu Val
50 55 60
15 Lys Lys Ser Leu His Arg Ile Ala Tyr Val Glu Gln Lys Ile Asn Ile
65 70 75 80
20 Asp Tyr Asn Phe Pro Ile Lys Val Lys Glu Cys Val Ser Leu Gly Leu
85 90 95
Phe Pro Ser Ile Pro Leu Phe Arg Ser Leu Lys Ala Lys His Trp Lys
100 105 110
25 Lys Val Gln Glu Ala Leu Glu Ile Val Gly Leu Ala Asp Tyr Ala Glu
115 120 125
Arg Gln Ile Ser Gln Leu Ser Gly Gly Gln Phe Gln Arg Val Leu Ile
130 135 140
30 Ala Arg Cys Leu Val Gln Glu Ala Asp Tyr Ile Leu Leu Asp Glu Pro
145 150 155 160
35 Phe Ala Gly Ile Asp Ser Val Ser Glu Glu Ile Ile Met Asn Thr Leu
165 170 175
Arg Asp Leu Lys Lys Ala Gly Lys Thr Val Leu Ile Val His His Asp
180 185 190
40 Leu Ser Lys Ile Pro His Tyr Phe Asp Gln Val Leu Leu Val Asn Arg
195 200 205
Glu Val Ile Ala Phe Gly Pro Thr Lys Glu Thr Phe Thr Glu Thr Asn
210 215 220
45 Leu Lys Glu Ala Tyr Gly Asn Gln Leu Phe Phe Asn Gly Gly Asp Leu
225 230 235 240
50

<210> 171

<211> 740

55 <212> PRT

<213> Streptococcus pneumoniae

<400> 171
 Met Pro Lys Glu Val Asn Leu Thr Gly Glu Glu Val Val Ala Leu Thr
 1 5 10 15
 5 Lys Glu Tyr Leu Thr Glu Glu Asp Val His Phe Val His Lys Ala Leu
 20 25 30
 Val Tyr Ala Val Glu Cys His Ser Gly Gln Tyr Arg Lys Ser Gly Glu
 35 40 45
 10 Pro Tyr Ile Ile His Pro Ile Gln Val Ala Gly Ile Leu Ala Lys Leu
 50 55 60
 15 Lys Leu Asp Ala Val Thr Val Ala Cys Gly Phe Leu His Asp Val Val
 65 70 75 80
 Glu Asp Thr Asp Ala Thr Leu Asp Asp Leu Glu Arg Glu Phe Gly Pro
 85 90 95
 20 Asp Val Arg Val Ile Val Asp Gly Val Thr Lys Leu Gly Lys Val Glu
 100 105 110
 Tyr Lys Ser Ile Glu Glu Gln Leu Ala Glu Asn His Arg Lys Met Leu
 115 120 125
 25 Met Ala Met Ser Glu Asp Ile Arg Val Ile Leu Val Lys Leu Ser Asp
 130 135 140
 30 Arg Leu His Asn Met Arg Thr Leu Lys His Leu Arg Lys Asp Lys Gln
 145 150 155 160
 Glu Arg Ile Ser Lys Glu Thr Met Glu Ile Tyr Ala Pro Leu Ala His
 165 170 175
 35 Arg Leu Gly Ile Ser Ser Val Lys Trp Glu Leu Glu Asp Leu Ser Phe
 180 185 190
 Arg Tyr Leu Asn Pro Thr Glu Phe Tyr Lys Ile Thr His Met Met Lys
 195 200 205
 40 Glu Lys Arg Arg Glu Arg Glu Ala Leu Val Asp Glu Val Val Thr Lys
 210 215 220
 45 Leu Glu Glu Tyr Thr Thr Glu Arg His Leu Lys Gly Lys Ile Tyr Gly
 225 230 235 240
 Arg Pro Lys His Ile Tyr Ser Ile Phe Arg Lys Met Gln Asp Lys Arg
 245 250 255
 50 Lys Arg Phe Glu Glu Ile Tyr Asp Leu Ile Ala Ile Arg Cys Ile Leu
 260 265 270
 Asp Thr Gln Ser Asp Val Tyr Ala Met Leu Gly Tyr Val His Glu Phe
 275 280 285
 55 Trp Lys Pro Met Pro Gly Arg Phe Lys Asp Tyr Ile Ala Asn Arg Lys
 290 295 300

Ala Asn Gly Tyr Gln Ser Ile His Thr Thr Val Tyr Gly Pro Lys Gly
 305 310 315 320
 5 Pro Ile Glu Phe Gln Ile Arg Thr Lys Glu Met His Glu Val Ala Glu
 325 330 335
 Tyr Gly Val Ala Ala His Trp Ala Tyr Lys Lys Gly Ile Lys Gly Gln
 340 345 350
 10 Val Asn Ser Lys Glu Ser Ala Ile Gly Met Asn Trp Ile Lys Glu Met
 355 360 365
 15 Met Glu Leu Gln Asp Gln Ala Asp Asp Ala Lys Glu Phe Val Asp Ser
 370 375 380
 Val Lys Glu Asn Tyr Leu Ala Glu Glu Ile Tyr Val Phe Thr Pro Asp
 385 390 395 400
 20 Gly Ala Val Arg Ser Leu Pro Lys Asp Ser Gly Pro Ile Asp Phe Ala
 405 410 415
 Tyr Glu Ile His Thr Lys Val Gly Glu Lys Ala Thr Gly Ala Lys Val
 420 425 430
 25 Asn Gly Arg Met Val Pro Leu Thr Thr Lys Leu Lys Thr Gly Asp Gln
 435 440 445
 30 Val Glu Ile Ile Ala Asn Pro Asn Ser Phe Gly Pro Ser Arg Asp Trp
 450 455 460
 Leu Asn Met Val Lys Thr Ser Lys Ala Arg Asn Lys Ile Arg Gln Phe
 465 470 475 480
 35 Phe Lys Asn Gln Asp Lys Glu Leu Ser Val Asn Lys Gly Arg Glu Met
 485 490 495
 Leu Met Ala Gln Phe Gln Glu Asn Gly Tyr Val Ala Asn Lys Phe Met
 500 505 510
 40 Asp Lys Arg His Met Asp Gln Val Leu Gln Lys Thr Ser Tyr Lys Thr
 515 520 525
 45 Glu Asp Ser Leu Phe Ala Ala Ile Gly Phe Gly Glu Ile Gly Ala Ile
 530 535 540
 Thr Val Phe Asn Arg Leu Thr Glu Lys Glu Arg Arg Glu Glu Glu Arg
 545 550 555 560
 50 Ala Lys Ala Lys Ala Glu Ala Glu Glu Leu Val Lys Gly Gly Glu Val
 565 570 575
 Lys Val Glu Asn Lys Glu Thr Leu Lys Val Lys His Glu Gly Gly Val
 580 585 590
 55 Val Ile Glu Gly Ala Ser Gly Leu Leu Val Arg Ile Ala Lys Cys Cys
 595 600 605

Asn Pro Val Pro Gly Asp Asp Ile Val Gly Tyr Ile Thr Lys Gly Arg
 610 615 620
 5 Gly Val Ala Ile His Arg Val Asp Cys Met Asn Leu Arg Ala Gln Glu
 625 630 635 640
 Asn Tyr Glu Gln Arg Leu Leu Asp Val Glu Trp Glu Asp Gln Tyr Ser
 645 650 655
 10 Ser Ser Asn Lys Glu Tyr Leu Ala His Ile Asp Ile Tyr Gly Leu Asn
 660 665 670
 Arg Thr Gly Leu Leu Asn Asp Val Leu Gln Val Leu Ser Asn Thr Thr
 675 680 685
 15 Lys Asn Ile Ser Thr Val Asn Ala Gln Pro Thr Lys Asp Met Lys Phe
 690 695 700
 20 Ala Asn Ile His Val Ser Phe Gly Ile Ala Asn Leu Ser Thr Leu Thr
 705 710 715 720
 Thr Val Val Asp Lys Ile Lys Ser Val Pro Glu Val Tyr Ser Val Lys
 725 730 735
 25 Arg Thr Asn Gly
 740
 30 <210> 172
 <211> 492
 <212> PRT
 <213> Streptococcus pneumoniae
 35 <400> 172
 Met Ser Asn Trp Asp Thr Lys Phe Leu Lys Lys Gly Phe Thr Phe Asp
 1 5 10 15
 40 Asp Val Leu Leu Ile Pro Ala Glu Ser His Val Leu Pro Asn Asp Ala
 20 25 30
 Asp Leu Thr Thr Lys Leu Ala Asp Asn Leu Thr Leu Asn Ile Pro Ile
 35 40 45
 45 Ile Thr Ala Ala Met Asp Thr Val Thr Glu Ser Gln Met Ala Ile Ala
 50 55 60
 Ile Ala Arg Ala Gly Gly Leu Gly Val Ile His Lys Asn Met Ser Ile
 65 70 75 80
 50 Ala Gln Gln Ala Asp Glu Val Arg Lys Val Lys Arg Ser Glu Asn Gly
 85 90 95
 55 Val Ile Ile Asp Pro Phe Phe Leu Thr Pro Glu His Thr Ile Ala Glu
 100 105 110
 Ala Asp Glu Leu Met Gly Arg Tyr Arg Ile Ser Gly Val Pro Val Val

	115	120	125
	Glu Thr Leu Glu Asn Arg Lys Leu Val Gly Ile Leu Thr Asn Arg Asp		
	130	135	140
5	Leu Arg Phe Ile Ser Asp Tyr Asn Gln Pro Ile Ser Asn His Met Thr		
	145	150	155 160
10	Ser Glu Asn Leu Val Thr Ala Pro Val Gly Thr Asp Leu Ala Thr Ala		
	165	170	175
	Glu Ser Ile Leu Gln Glu His Arg Ile Glu Lys Leu Pro Leu Val Asp		
	180	185	190
15	Glu Glu Gly Ser Leu Ser Gly Leu Ile Thr Ile Lys Asp Ile Glu Lys		
	195	200	205
	Val Ile Glu Phe Pro Asn Ala Ala Lys Asp Glu Phe Gly Arg Leu Leu		
	210	215	220
20	Val Ala Gly Ala Val Gly Val Thr Ser Asp Thr Phe Glu Arg Ala Glu		
	225	230	235 240
	Ala Leu Phe Glu Ala Gly Ala Asp Ala Ile Val Ile Asp Thr Ala His		
	245	250	255
25	Gly His Ser Ala Gly Val Leu Arg Lys Ile Ala Glu Ile Arg Ala His		
	260	265	270
30	Phe Pro Asp Arg Thr Leu Ile Ala Gly Asn Ile Ala Thr Ala Glu Gly		
	275	280	285
	Ala Arg Ala Leu Tyr Glu Ala Gly Val Asp Val Val Lys Val Gly Ile		
	290	295	300
35	Gly Pro Gly Ser Ile Cys Thr Thr Arg Val Ile Ala Gly Val Gly Val		
	305	310	315 320
40	Pro Gln Val Thr Ala Ile Tyr Asp Ala Ala Ala Val Ala Arg Glu Tyr		
	325	330	335
	Gly Lys Thr Ile Ile Ala Asp Gly Gly Ile Lys Tyr Ser Gly Asp Ile		
	340	345	350
45	Val Lys Ala Leu Ala Ala Gly Gly Asn Ala Val Met Leu Gly Ser Met		
	355	360	365
	Phe Ala Gly Thr Asp Glu Ala Pro Gly Glu Thr Glu Ile Phe Gln Gly		
	370	375	380
50	Arg Lys Phe Lys Thr Tyr Arg Gly Met Gly Ser Ile Ala Ala Met Lys		
	385	390	395 400
55	Lys Gly Ser Ser Asp Arg Tyr Phe Gln Gly Ser Val Asn Glu Ala Asn		
	405	410	415
	Lys Leu Val Pro Glu Gly Ile Glu Gly Arg Val Ala Tyr Lys Gly Ala		

420 425 430
 Ala Ala Asp Ile Val Phe Gln Met Ile Gly Gly Ile Arg Ser Gly Met
 435 440 445
 5 Gly Tyr Cys Gly Ala Ala Asn Leu Lys Glu Leu His Asp Asn Ala Gln
 450 455 460
 10 Phe Ile Glu Met Ser Gly Ala Gly Leu Lys Glu Ser His Pro His Asp
 465 470 475 480
 Val Gln Ile Thr Asn Glu Ala Pro Asn Tyr Ser Met
 485 490
 15
 <210> 173
 <211> 648
 <212> PRT
 <213> Streptococcus pneumoniae
 20
 <400> 173
 Met Thr Glu Glu Ile Lys Asn Leu Gln Ala Gln Asp Tyr Asp Ala Ser
 1 5 10 15
 25 Gln Ile Gln Val Leu Glu Gly Leu Glu Ala Val Arg Met Arg Pro Gly
 20 25 30
 Met Tyr Ile Gly Ser Thr Ser Lys Glu Gly Leu His His Leu Val Trp
 35 40 45
 30 Glu Ile Val Asp Asn Ser Ile Asp Glu Ala Leu Ala Gly Phe Ala Ser
 50 55 60
 35 His Ile Gln Val Phe Ile Glu Pro Asp Asp Ser Ile Thr Val Val Asp
 65 70 75 80
 Asp Gly Arg Gly Ile Pro Val Asp Ile Gln Glu Lys Thr Gly Arg Pro
 85 90 95
 40 Ala Val Glu Thr Val Phe Thr Val Leu His Ala Gly Gly Lys Phe Gly
 100 105 110
 Gly Gly Gly Tyr Lys Val Ser Gly Gly Leu His Gly Val Gly Ser Ser
 115 120 125
 45 Val Val Asn Ala Leu Ser Thr Gln Leu Asp Val His Val His Lys Asn
 130 135 140
 50 Gly Lys Ile His Tyr Gln Glu Tyr Arg Arg Gly His Val Val Ala Asp
 145 150 155 160
 Leu Glu Ile Val Gly Asp Thr Asp Lys Thr Gly Thr Thr Val His Phe
 165 170 175
 55 Thr Pro Asp Pro Lys Ile Phe Thr Glu Thr Thr Ile Phe Asp Phe Asp
 180 185 190

Lys Leu Asn Lys Arg Ile Gln Glu Leu Ala Phe Leu Asn Arg Gly Leu
 195 200 205
 5 Gln Ile Ser Ile Thr Asp Lys Arg Gln Gly Leu Glu Gln Thr Lys His
 210 215 220
 Tyr His Tyr Glu Gly Gly Ile Ala Ser Tyr Val Glu Tyr Ile Asn Glu
 225 230 235 240
 10 Asn Lys Asp Val Ile Phe Asp Thr Pro Ile Tyr Thr Asp Gly Glu Met
 245 250 255
 Asp Asp Ile Thr Val Glu Val Ala Met Gln Tyr Thr Thr Gly Tyr His
 260 265 270
 15 Glu Asn Val Met Ser Phe Ala Asn Asn Ile His Thr His Glu Gly Gly
 275 280 285
 Thr His Glu Gln Gly Phe Arg Thr Ala Leu Thr Arg Val Ile Asn Asp
 290 295 300
 Tyr Ala Arg Lys Asn Lys Leu Leu Lys Asp Asn Glu Asp Asn Leu Thr
 305 310 315 320
 25 Gly Glu Asp Val Arg Glu Gly Leu Thr Ala Val Ile Ser Val Lys His
 325 330 335
 Pro Asn Pro Gln Phe Glu Gly Gln Thr Lys Thr Lys Leu Gly Asn Ser
 340 345 350
 30 Glu Val Val Lys Ile Thr Asn Arg Leu Phe Ser Glu Ala Phe Ser Asp
 355 360 365
 Phe Leu Met Glu Asn Pro Gln Ile Ala Lys Arg Ile Val Glu Lys Gly
 370 375 380
 Ile Leu Ala Ala Lys Ala Arg Val Ala Ala Lys Arg Ala Arg Glu Val
 385 390 395 400
 40 Thr Arg Lys Lys Ser Gly Leu Glu Ile Ser Asn Leu Pro Gly Lys Leu
 405 410 415
 Ala Asp Cys Ser Ser Asn Asn Pro Ala Glu Thr Glu Leu Phe Ile Val
 420 425 430
 45 Glu Gly Asp Ser Ala Gly Gly Ser Ala Lys Ser Gly Arg Asn Arg Glu
 435 440 445
 Phe Gln Ala Ile Leu Pro Ile Arg Gly Lys Ile Leu Asn Val Glu Lys
 450 455 460
 Ala Ser Met Asp Lys Ile Leu Ala Asn Glu Glu Ile Arg Ser Leu Phe
 465 470 475 480
 55 Thr Ala Met Gly Thr Gly Phe Gly Ala Glu Phe Asp Val Ser Lys Ala
 485 490 495

Arg Tyr Gln Lys Leu Val Leu Met Thr Asp Ala Asp Val Asp Gly Ala
 500 505 510
 5 His Ile Arg Thr Leu Leu Leu Thr Leu Ile Tyr Arg Tyr Met Lys Pro
 515 520 525
 Ile Leu Glu Ala Gly Tyr Val Tyr Ile Ala Gln Pro Pro Ile Tyr Gly
 530 535 540
 10 Val Lys Val Gly Ser Glu Ile Lys Glu Tyr Ile Gln Pro Gly Ala Asp
 545 550 555 560
 Gln Glu Ile Lys Leu Gln Glu Ala Leu Ala Arg Tyr Ser Glu Gly Arg
 565 570 575
 15 Thr Lys Pro Thr Ile Gln Arg Tyr Lys Gly Leu Gly Glu Met Asp Asp
 580 585 590
 His Gln Leu Trp Glu Thr Thr Met Asp Pro Glu His Arg Leu Met Ala
 595 600 605
 Arg Val Ser Val Asp Asp Ala Ala Glu Ala Asp Lys Ile Phe Asp Met
 610 615 620
 25 Leu Met Gly Asp Arg Val Glu Pro Arg Arg Glu Phe Ile Glu Glu Asn
 625 630 635 640
 Ala Val Tyr Ser Thr Leu Asp Val
 645
 30
 <210> 174
 <211> 88
 <212> PRT
 35 <213> Streptococcus pneumoniae
 <400> 174
 Met Gly Phe Thr Glu Glu Thr Val Arg Phe Lys Leu Asp Asp Ser Asn
 1 5 10 15
 40 Lys Lys Glu Ile Ser Glu Thr Leu Thr Asp Val Tyr Ala Ser Leu Asn
 20 25 30
 Asp Lys Gly Tyr Asn Pro Ile Asn Gln Ile Val Gly Tyr Val Leu Ser
 35 40 45
 Gly Asp Pro Ala Tyr Val Pro Arg Tyr Asn Asn Ala Arg Asn Gln Ile
 50 55 60
 50 Arg Lys Tyr Glu Arg Asp Glu Ile Val Glu Glu Leu Val Arg Tyr Tyr
 65 70 75 80
 Leu Lys Gly Gln Gly Val Asp Leu
 85
 55
 <210> 175

<211> 198
 <212> PRT
 <213> Streptococcus pneumoniae

- 5 <400> 175
 Met Val Asn Tyr Pro His Lys Val Ser Ser Gln Asp Arg Gln Thr Ser
 1 5 10 15
- 10 Leu Ser Gln Pro Lys Asn Phe Ala Asn Arg Gly Met Ser Phe Glu Lys
 20 25 30
- Met Ile Asn Ala Thr Asn Asp Tyr Tyr Leu Ser Gln Gly Leu Ala Val
 35 40 45
- 15 Ile His Lys Lys Pro Thr Pro Ile Gln Ile Val Gln Val Asp Tyr Pro
 50 55 60
- Gln Arg Ser Arg Ala Lys Ile Val Glu Ala Tyr Phe Arg Gln Ala Ser
 65 70 75 80
- 20 Thr Thr Asp Tyr Ser Gly Val Tyr Asn Gly Tyr Tyr Ile Asp Phe Glu
 85 90 95
- 25 Val Lys Glu Thr Lys Gln Lys Arg Ala Ile Pro Met Lys Asn Phe His
 100 105 110
- Pro His Gln Ile Gln His Met Glu Gln Val Leu Ala Gln Gln Gly Ile
 115 120 125
- 30 Cys Phe Val Leu Leu His Phe Ser Ser Gln Gln Glu Thr Tyr Leu Leu
 130 135 140
- Pro Ala Phe Asp Leu Ile Arg Phe Tyr His Gln Asp Lys Gly Gln Lys
 145 150 155 160
- 35 Ser Met Pro Leu Glu Tyr Ile Arg Glu Tyr Gly Tyr Glu Ile Lys Ala
 165 170 175
- 40 Gly Ala Phe Pro Gln Ile Pro Tyr Leu Asn Val Ile Lys Glu His Leu
 180 185 190
- Leu Gly Gly Lys Thr Arg
 195
- 45 <210> 176
 <211> 288
 <212> PRT
 <213> Streptococcus pneumoniae
- 50 <400> 176
 Met Ala Leu Phe Ser Lys Lys Asp Lys Tyr Ile Arg Ile Asn Pro Asn
 1 5 10 15
- 55 Arg Ser Val Arg Glu Lys Pro Gln Ala Lys Pro Glu Val Pro Asp Glu
 20 25 30

Leu Phe Ser Gln Cys Pro Gly Cys Lys His Thr Ile Tyr Gln Lys Asp
 35 40 45
 5 Leu Gly Ser Glu Arg Ile Cys Pro His Cys Ser Tyr Thr Phe Arg Ile
 50 55 60
 Ser Ala Gln Glu Arg Leu Ala Leu Thr Ile Asp Met Gly Thr Phe Lys
 65 70 75 80
 10 Glu Leu Phe Thr Gly Ile Glu Ser Lys Asp Pro Leu His Phe Pro Gly
 85 90 95
 Tyr Gln Lys Lys Leu Ala Ser Met Arg Glu Lys Thr Gly Leu His Glu
 100 105 110
 15 Ala Val Val Thr Gly Thr Ala Leu Ile Lys Gly Gln Thr Val Ala Leu
 115 120 125
 Gly Ile Met Asp Ser Asn Phe Ile Met Ala Ser Met Gly Thr Val Val
 130 135 140
 Gly Glu Lys Ile Thr Arg Leu Phe Glu Tyr Ala Thr Val Glu Lys Leu
 145 150 155 160
 25 Pro Val Val Leu Phe Thr Ala Ser Gly Gly Ala Arg Met Gln Glu Gly
 165 170 175
 Ile Met Ser Leu Met Gln Met Ala Lys Ile Ser Ala Ala Val Lys Arg
 180 185 190
 30 His Ser Asn Ala Gly Leu Phe Tyr Leu Thr Ile Leu Thr Asp Pro Thr
 195 200 205
 Thr Gly Gly Val Thr Ala Ser Phe Ala Met Glu Gly Asp Ile Ile Leu
 210 215 220
 Ala Glu Pro Gln Ser Leu Val Gly Phe Ala Gly Arg Arg Val Ile Glu
 225 230 235 240
 40 Asn Thr Val Arg Glu Ser Leu Pro Glu Asp Phe Gln Lys Ala Glu Phe
 245 250 255
 Leu Leu Glu His Gly Phe Val Asp Ala Ile Val Lys Arg Arg Asp Leu
 260 265 270
 45 Pro Asp Thr Ile Ala Ser Leu Val Arg Leu His Gly Gly Ser Pro Arg
 275 280 285
 50
 <210> 177
 <211> 139
 55 <212> PRT
 <213> Streptococcus pneumoniae

<400> 177
 Met Arg Ile Met Gly Leu Asp Val Gly Ser Lys Thr Val Gly Val Ala
 1 5 10 15
 5 Ile Ser Asp Pro Leu Gly Phe Thr Ala Gln Gly Leu Glu Ile Ile Gln
 20 25 30
 Ile Asn Glu Glu Gln Gly Gln Phe Gly Ser Asp Arg Val Lys Glu Leu
 35 40 45
 10 Val Asp Thr Tyr Lys Val Glu Arg Phe Val Val Gly Leu Pro Lys Asn
 50 55 60
 15 Met Asn Asn Thr Ser Gly Pro Arg Val Glu Ala Ser Gln Ala Tyr Gly
 65 70 75 80
 Ala Lys Leu Glu Glu Phe Phe Gly Leu Pro Val Asp Tyr Gln Asp Glu
 85 90 95
 20 Arg Leu Thr Thr Val Ala Ala Glu Arg Met Leu Ile Glu Gln Ala Asp
 100 105 110
 Ile Ser Arg Asn Lys Arg Lys Lys Val Ile Asp Lys Leu Ala Ala Gln
 115 120 125
 25 Leu Ile Leu Gln Asn Tyr Leu Asp Arg Lys Phe
 130 135
 30 <210> 178
 <211> 398
 <212> PRT
 <213> Streptococcus pneumoniae
 35 <400> 178
 Met Ala Lys Leu Thr Val Lys Asp Val Asp Leu Lys Gly Lys Lys Val
 1 5 10 15
 40 Leu Val Arg Val Asp Phe Asn Val Pro Leu Lys Asp Gly Val Ile Thr
 20 25 30
 Asn Asp Asn Arg Ile Thr Ala Ala Leu Pro Thr Ile Lys Tyr Ile Ile
 35 40 45
 45 Glu Gln Gly Gly Arg Ala Ile Leu Phe Ser His Leu Gly Arg Val Lys
 50 55 60
 Glu Glu Ala Asp Lys Ala Gly Lys Ser Leu Ala Pro Val Ala Ala Asp
 65 70 75 80
 50 Leu Ala Ala Lys Leu Gly Gln Asp Val Val Phe Pro Gly Val Thr Arg
 85 90 95
 55 Gly Ala Glu Leu Glu Ala Ala Ile Asn Ala Leu Glu Asp Gly Gln Val
 100 105 110
 Leu Leu Val Glu Asn Thr Arg Tyr Glu Asp Val Asp Gly Lys Lys Glu

	115	120	125
5	Ser Lys Asn Asp Pro Glu Leu Gly Lys Tyr Trp Ala Ser Leu Gly Asp 130 135 140		
	Gly Ile Phe Val Asn Asp Ala Phe Gly Thr Ala His Arg Ala His Ala 145 150 155 160		
10	Ser Asn Val Gly Ile Ser Ala Asn Val Glu Lys Ala Val Ala Gly Phe 165 170 175		
	Leu Leu Glu Asn Glu Ile Ala Tyr Ile Gln Glu Ala Val Glu Thr Pro 180 185 190		
15	Glu Arg Pro Phe Val Ala Ile Leu Gly Gly Ser Lys Val Ser Asp Lys 195 200 205		
	Ile Gly Val Ile Glu Asn Leu Leu Glu Lys Ala Asp Lys Val Leu Ile 210 215 220		
20	Gly Gly Gly Met Thr Tyr Thr Phe Tyr Lys Ala Gln Gly Ile Glu Ile 225 230 235 240		
	Gly Asn Ser Leu Val Glu Glu Asp Lys Leu Asp Val Ala Lys Ala Leu 245 250 255		
25	Leu Glu Lys Ala Asn Gly Lys Leu Ile Leu Pro Val Asp Ser Lys Glu 260 265 270		
30	Ala Asn Ala Phe Ala Gly Tyr Thr Glu Val Arg Asp Thr Glu Gly Glu 275 280 285		
	Ala Val Ser Glu Gly Phe Leu Gly Leu Asp Ile Gly Pro Lys Ser Ile 290 295 300		
35	Ala Lys Phe Asp Glu Ala Leu Thr Gly Ala Lys Thr Val Val Trp Asn 305 310 315 320		
	Gly Pro Met Gly Val Phe Glu Asn Pro Asp Phe Gln Ala Gly Thr Ile 325 330 335		
40	Gly Val Met Asp Ala Ile Val Lys Gln Pro Gly Val Lys Ser Ile Ile 340 345 350		
45	Gly Gly Gly Asp Ser Ala Ala Ala Ile Asn Leu Gly Arg Ala Asp 355 360 365		
	Lys Phe Ser Trp Ile Ser Thr Gly Gly Gly Ala Ser Met Glu Leu Leu 370 375 380		
50	Glu Gly Lys Val Leu Pro Gln Leu Ala Ala Leu Thr Glu Lys 385 390 395		
55	<210> 179 <211> 165 <212> PRT		

<213> Streptococcus pneumoniae

<400> 179

5 Met Leu Lys Ser Glu Lys Gln Ser Arg Tyr Gln Met Leu Asn Glu Glu
 1 5 10 15
 Leu Ser Phe Leu Leu Glu Gly Glu Thr Asn Val Leu Ala Asn Leu Ser
 20 25 30
 10 Asn Ala Ser Ala Leu Ile Lys Ser Arg Phe Pro Asn Thr Val Phe Ala
 35 40 45
 Gly Phe Tyr Leu Phe Asp Gly Lys Glu Leu Val Leu Gly Pro Phe Gln
 50 55 60
 15 Gly Gly Val Ser Cys Ile Arg Ile Ala Leu Gly Lys Gly Val Cys Gly
 65 70 75 80
 Glu Ala Ala His Phe Gln Glu Thr Val Ile Val Gly Asp Val Thr Thr
 85 90 95
 Tyr Leu Asn Tyr Ile Ser Cys Asp Ser Leu Ala Lys Ser Glu Ile Val
 100 105 110
 25 Val Pro Met Met Lys Asn Gly Gln Leu Leu Gly Val Leu Asp Leu Asp
 115 120 125
 Ser Ser Glu Ile Glu Asp Tyr Asp Ala Met Asp Arg Asp Tyr Leu Glu
 130 135 140
 30 Gln Phe Val Ala Ile Leu Leu Glu Lys Thr Ala Trp Asp Phe Thr Met
 145 150 155 160
 35 Phe Glu Glu Lys Ser
 165

<210> 180

<211> 209

40 <212> PRT

<213> Streptococcus pneumoniae

<400> 180

45 Met Thr Ile Glu Leu Leu Thr Pro Phe Thr Lys Val Glu Leu Glu Pro
 1 5 10 15
 Glu Ile Lys Glu Lys Lys Arg Lys Gln Val Gly Ile Leu Gly Gly Asn
 20 25 30
 50 Phe Asn Pro Val His Asn Ala His Leu Ile Val Ala Asp Gln Val Arg
 35 40 45
 Gln Gln Leu Gly Leu Asp Gln Val Leu Leu Met Pro Glu Tyr Gln Pro
 50 55 60
 55 Pro His Val Asp Lys Lys Glu Thr Ile Pro Glu His His Arg Leu Lys
 65 70 75 80

Met Leu Glu Leu Ala Ile Glu Gly Ile Asp Gly Leu Val Ile Glu Thr
 85 90 95
 5 Ile Glu Leu Glu Arg Lys Gly Ile Ser Tyr Thr Tyr Asp Thr Met Lys
 100 105 110
 Ile Leu Thr Glu Lys Asn Pro Asp Thr Asp Tyr Tyr Phe Ile Ile Gly
 115 120 125
 10 Ala Asp Met Val Asp Tyr Leu Pro Lys Trp Tyr Arg Ile Asp Glu Leu
 130 135 140
 Val Asp Met Val Gln Phe Val Gly Val Gln Arg Pro Arg Tyr Lys Val
 15 145 150 155 160
 Gly Thr Ser Tyr Pro Val Ile Trp Val Asp Val Pro Leu Met Asp Ile
 165 170 175
 20 Ser Ser Ser Met Val Arg Ala Phe Leu Ala Gln Gly Arg Lys Pro Asn
 180 185 190
 Phe Leu Leu Pro Gln Pro Val Leu Asp Tyr Ile Glu Lys Glu Gly Leu
 25 195 200 205
 Tyr
 30 <210> 181
 <211> 255
 <212> PRT
 <213> Streptococcus pneumoniae
 35 <400> 181
 Met Asn Ile Ala Lys Ile Val Arg Glu Ala Arg Glu Gln Ser Arg Leu
 1 5 10 15
 Thr Thr Leu Asp Phe Ala Thr Gly Ile Phe Asp Glu Phe Ile Gln Leu
 40 20 25 30
 His Gly Asp Arg Ser Phe Arg Asp Asp Gly Ala Val Val Gly Gly Ile
 35 40 45
 45 Gly Trp Leu Gly Asp Gln Ala Val Thr Val Val Gly Ile Gln Lys Gly
 50 55 60
 Lys Ser Leu Gln Asp Asn Leu Lys Arg Asn Phe Gly Gln Pro His Pro
 50 65 70 75 80
 Glu Gly Tyr Arg Lys Ala Leu Arg Leu Met Lys Gln Ala Glu Lys Phe
 85 90 95
 55 Gly Arg Pro Val Val Thr Phe Ile Asn Thr Ala Gly Ala Tyr Pro Gly
 100 105 110
 Val Gly Ala Glu Glu Arg Gly Gln Gly Glu Ala Ile Ala Arg Asn Leu

115 120 125
 Met Glu Met Ser Asp Leu Lys Val Pro Ile Ile Ala Ile Ile Ile Gly
 130 135 140
 5 Glu Gly Gly Ser Gly Gly Ala Leu Ala Leu Ala Val Ala Asp Arg Val
 145 150 155 160
 10 Trp Met Leu Glu Asn Ser Ile Tyr Ala Ile Leu Ser Pro Glu Gly Phe
 165 170 175
 Ala Ser Ile Leu Trp Lys Asp Gly Thr Arg Ala Met Glu Ala Ala Glu
 180 185 190
 15 Leu Met Lys Ile Thr Ser His Glu Leu Leu Glu Met Asp Val Val Asp
 195 200 205
 Lys Val Ile Ser Glu Val Gly Leu Ser Ser Lys Glu Leu Ile Lys Ser
 210 215 220
 20 Val Lys Lys Glu Leu Gln Thr Glu Leu Ala Arg Leu Ser Gln Lys Pro
 225 230 235 240
 25 Leu Glu Glu Leu Leu Glu Glu Arg Tyr Gln Arg Phe Arg Lys Tyr
 245 250 255
 <210> 182
 <211> 169
 30 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 182
 35 Met Ile Ile Lys Val Glu Met Ala Asp Val Glu Val Leu Ala Lys Ile
 1 5 10 15
 Ala Lys Gln Thr Phe Arg Glu Thr Phe Ala Tyr Asp Asn Thr Glu Glu
 20 25 30
 40 Gln Leu Gln Glu Tyr Phe Glu Glu Ala Tyr Ser Leu Lys Thr Leu Ser
 35 40 45
 Thr Glu Leu Gly Asn Pro Asp Ser Glu Thr Tyr Phe Ile Met His Glu
 50 55 60
 45 Glu Glu Ile Ala Gly Phe Leu Lys Val Asn Trp Gly Ser Ala Gln Thr
 65 70 75 80
 50 Glu Arg Glu Leu Glu Asp Ala Phe Glu Ile Gln Arg Leu Tyr Val Leu
 85 90 95
 Gln Lys Phe Gln Gly Phe Gly Leu Gly Lys Gln Leu Phe Glu Phe Ala
 100 105 110
 55 Leu Glu Leu Ala Thr Lys Asn Ser Phe Ser Trp Ala Trp Leu Gly Val
 115 120 125

Trp Glu His Asn Thr Lys Ala Gln Ala Phe Tyr Asn Arg Tyr Gly Phe
 130 135 140
 5 Glu Lys Phe Ser Gln His His Phe Met Val Gly Gln Lys Val Asp Thr
 145 150 155 160
 Asp Trp Leu Leu Arg Lys Lys Leu Arg
 165
 10 <210> 183
 <211> 529
 <212> PRT
 <213> Streptococcus pneumoniae
 15 <400> 183
 Met Leu Arg Gly Thr Ala Leu Leu Thr Ala Ser Asn Phe Ile Ser Arg
 1 5 10 15
 20 Leu Leu Gly Ala Val Tyr Ile Ile Pro Trp Tyr Ile Trp Met Gly Ala
 20 25 30
 Tyr Ala Ala Lys Ala Asn Gly Leu Phe Thr Met Gly Tyr Thr Ile Tyr
 35 40 45
 25 Ala Trp Phe Leu Leu Val Ser Thr Ala Gly Ile Pro Val Ala Val Ala
 50 55 60
 30 Lys Gln Val Ala Lys Tyr Asn Thr Met Arg Glu Glu Glu His Ser Phe
 65 70 75 80
 Ala Leu Ile Arg Ser Phe Leu Gly Phe Met Thr Gly Leu Gly Leu Val
 85 90 95
 35 Phe Ala Leu Val Leu Tyr Val Phe Ala Pro Trp Leu Ala Asp Leu Ser
 100 105 110
 Gly Val Gly Lys Asp Leu Ile Pro Ile Met Gln Ser Leu Ala Trp Gly
 115 120 125
 40 Val Leu Ile Phe Pro Ser Met Ser Val Ile Arg Gly Phe Phe Gln Gly
 130 135 140
 45 Met Asn Asn Leu Lys Pro Tyr Ala Met Ser Gln Ile Ala Glu Gln Val
 145 150 155 160
 Ile Arg Val Ile Trp Met Leu Leu Ala Thr Phe Ile Ile Met Lys Leu
 165 170 175
 50 Gly Ser Gly Asp Tyr Leu Ala Ala Val Thr Gln Ser Thr Phe Ala Ala
 180 185 190
 Phe Val Gly Met Val Ala Ser Phe Ala Val Leu Ile Tyr Phe Leu Ala
 195 200 205
 55 Gln Glu Ser Ser Leu Lys Arg Val Phe Glu Thr Gly Asp Lys Ile Asn
 210 215 220

Ser Lys Arg Leu Leu Val Asp Thr Ile Lys Glu Ala Ile Pro Phe Ile
 225 230 235 240
 5 Leu Thr Gly Ser Ala Ile Gln Ile Phe Gln Ile Leu Asp Gln Leu Thr
 245 250 255
 Phe Ile Asn Ser Met Ser Trp Phe Thr Asn Tyr Ser Asn Glu Asp Leu
 260 265 270
 10 Val Val Met Phe Ser Tyr Phe Ser Ala Asn Pro Asn Lys Ile Thr Met
 275 280 285
 Ile Leu Ile Ser Val Gly Val Ser Ile Gly Ser Val Gly Leu Pro Leu
 290 295 300
 15 Leu Thr Glu Asn Tyr Val Lys Gly Asp Leu Lys Ala Ala Ser Arg Leu
 305 310 315 320
 20 Val Gln Asp Ser Leu Thr Leu Leu Phe Met Phe Leu Leu Pro Ala Thr
 325 330 335
 Val Gly Val Val Met Val Gly Glu Pro Leu Tyr Thr Val Phe Tyr Gly
 340 345 350
 25 Lys Pro Asp Ser Leu Ala Leu Gly Leu Phe Val Phe Ala Val Leu Gln
 355 360 365
 Ser Ile Ile Leu Gly Leu Tyr Met Val Leu Ser Pro Met Leu Gln Ala
 370 375 380
 30 Met Phe Arg Asn Arg Lys Ala Val Leu Tyr Phe Ile Tyr Gly Ser Ile
 385 390 395 400
 35 Ala Lys Leu Val Leu Gln Leu Pro Thr Ile Ala Leu Phe His Ser Tyr
 405 410 415
 Gly Pro Leu Ile Ser Thr Thr Ile Ala Leu Ile Ile Pro Asn Val Leu
 420 425 430
 40 Met Tyr Arg Asp Ile Cys Lys Val Thr Gly Val Lys Arg Lys Val Ile
 435 440 445
 Leu Lys Arg Thr Ile Leu Ile Ser Leu Leu Thr Leu Val Met Phe Leu
 450 455 460
 Leu Ile Gly Thr Ile Gln Trp Leu Leu Gly Phe Phe Phe Gln Pro Ser
 465 470 475 480
 50 Gly Arg Leu Trp Ser Phe Phe Tyr Val Ala Leu Val Gly Ala Met Gly
 485 490 495
 Gly Gly Leu Tyr Met Val Met Ser Leu Arg Thr Tyr Leu Leu Asp Lys
 500 505 510
 55 Val Ile Gly Lys Ala Gln Ala Asp Arg Leu Arg Ala Lys Phe Lys Leu
 515 520 525

Ser

- 5
 <210> 184
 <211> 155
 <212> PRT
 <213> Streptococcus pneumoniae
- 10
 <400> 184
 Met Ser Asp Lys Ile Gly Leu Phe Thr Gly Ser Phe Asp Pro Met Thr
 1 5 10 15
- 15 Asn Gly His Leu Asp Ile Ile Glu Arg Ala Ser Arg Leu Phe Asp Lys
 20 25 30
- Leu Tyr Val Gly Ile Phe Phe Asn Pro His Lys Gln Gly Phe Leu Pro
 35 40 45
- 20 Ile Glu Asn Arg Lys Arg Gly Leu Glu Lys Ala Leu Gly His Leu Glu
 50 55 60
- 25 Asn Val Glu Val Val Ala Ser His Asp Glu Leu Val Val Asp Val Ala
 65 70 75 80
- Lys Arg Leu Gly Ala Thr Cys Leu Val Arg Gly Leu Arg Asn Ala Ser
 85 90 95
- 30 Asp Leu Gln Tyr Glu Ala Ser Phe Asp Tyr Tyr Asn His Gln Leu Ser
 100 105 110
- Ser Asp Ile Glu Thr Ile Tyr Leu His Ser Arg Pro Glu His Leu Tyr
 115 120 125
- 35 Ile Ser Ser Ser Gly Val Arg Glu Leu Leu Lys Phe Gly Gln Asp Ile
 130 135 140
- 40 Ala Cys Tyr Val Pro Glu Ser Ile Trp Arg Lys
 145 150 155
- 45
 <210> 185
 <211> 143
 <212> PRT
 <213> Streptococcus pneumoniae
- <400> 185
 Met Thr Ile Leu Phe Val Val Ile Ser Ala Ser Phe Leu Tyr Met Val
 1 5 10 15
- Ser Leu Ser Met Lys Pro Tyr Gln Thr Ala Lys Ser Glu Gly Glu Lys
 20 25 30
- 55 Leu Ala Gln Gln Tyr Ala Gly Leu Glu Gln Ala Asp Gln Val Asp Leu
 35 40 45

Tyr Asn Gly Leu Glu Ser Tyr Tyr Ser Val Leu Gly Arg Asn Lys Gln
 50 55 60
 5 Gln Glu Ala Leu Ala Val Leu Ile Gly Lys Asp Asp His Lys Ile Tyr
 65 70 75 80
 Val Tyr Gln Leu Asn Gln Gly Val Ser Gln Glu Lys Ala Glu Thr Val
 85 90 95
 10 Ser Lys Glu Lys Gly Ala Gly Glu Ile Asp Lys Ile Ile Phe Gly Arg
 100 105 110
 Tyr Gln Asp Lys Pro Ile Trp Glu Val Lys Ser Gly Ser Asp Phe Tyr
 115 120 125
 15 Leu Val Asp Phe Glu Thr Gly Ala Leu Val Asn Lys Glu Gly Leu
 130 135 140
 20 <210> 186
 <211> 243
 <212> PRT
 <213> Streptococcus pneumoniae
 25 <400> 186
 Met Ile Asp Ile His Ser His Ile Val Phe Asp Val Asp Asp Gly Pro
 1 5 10 15
 30 Lys Ser Arg Glu Glu Ser Lys Ala Leu Leu Thr Glu Ala Tyr Arg Gln
 20 25 30
 Gly Val Arg Thr Ile Val Ser Thr Ser His Arg Arg Lys Gly Met Phe
 35 40 45
 35 Glu Thr Pro Glu Glu Lys Ile Ala Glu Asn Phe Leu Gln Val Arg Glu
 50 55 60
 Ile Ala Lys Glu Val Ala Ser Asp Leu Val Ile Ala Tyr Gly Ala Glu
 65 70 75 80
 40 Ile Tyr Tyr Thr Pro Asp Val Leu Asp Lys Leu Glu Asn Asn Arg Ile
 85 90 95
 45 Pro Thr Leu Asn Asn Ser Arg Tyr Ala Leu Ile Glu Phe Ser Met Asn
 100 105 110
 Thr Pro Tyr Arg Asp Ile His Ser Ala Leu Asn Lys Ile Leu Met Leu
 115 120 125
 50 Gly Ile Thr Pro Val Ile Ala His Ile Glu Arg Tyr Asp Val Leu Glu
 130 135 140
 Asn Asn Glu Lys Arg Val Arg Glu Leu Ile Asp Met Gly Cys Tyr Thr
 145 150 155 160
 55 Gln Ile Asn Ser Ser His Val Leu Lys Ser Lys Leu Phe Gly Glu Pro
 165 170 175

Tyr Lys Phe Met Lys Lys Arg Ala Gln Tyr Phe Leu Glu Arg Asp Leu
 180 185 190
 5 Val His Ile Ile Ala Ser Asp Met His Asn Val Asp Gly Arg Pro Pro
 195 200 205
 His Met Ala Glu Ala Tyr Asp Leu Val Ser Gln Lys Tyr Gly Glu Ala
 210 215 220
 10 Lys Ala Gln Glu Leu Phe Ile Asp Asn Pro Arg Lys Ile Val Met Asp
 225 230 235 240
 Gln Leu Ile
 15
 <210> 187
 <211> 308
 20 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 187
 25 Met Ser Thr Ile Asp Lys Glu Lys Phe Gln Phe Val Lys Arg Asp Asp
 1 5 10 15
 Phe Ala Ser Glu Thr Ile Asp Ala Pro Ala Tyr Ser Tyr Trp Lys Ser
 20 25 30
 30 Val Phe Lys Gln Phe Met Lys Lys Lys Ser Thr Val Val Met Leu Gly
 35 40 45
 Ile Leu Val Ala Ile Ile Leu Ile Ser Phe Ile Tyr Pro Met Phe Ser
 50 55 60
 35 Lys Phe Asp Phe Asn Asp Val Ser Lys Val Asn Asp Phe Ser Val Arg
 65 70 75 80
 40 Tyr Ile Lys Pro Asn Ala Glu His Trp Phe Gly Thr Asp Ser Asn Gly
 85 90 95
 Lys Ser Leu Phe Asp Gly Val Trp Phe Gly Ala Arg Asn Ser Ile Leu
 100 105 110
 45 Ile Ser Val Ile Ala Thr Val Ile Asn Leu Val Ile Gly Val Phe Val
 115 120 125
 Gly Gly Ile Trp Gly Ile Ser Lys Ser Val Asp Arg Val Met Met Glu
 130 135 140
 50 Val Tyr Asn Val Ile Ser Asn Ile Pro Pro Leu Leu Ile Val Ile Val
 145 150 155 160
 55 Leu Thr Tyr Ser Ile Gly Ala Gly Phe Trp Asn Leu Ile Phe Ala Met
 165 170 175
 Ser Val Thr Thr Trp Ile Gly Ile Ala Phe Met Ile Arg Val Gln Ile

180 185 190
 Leu Arg Tyr Arg Asp Leu Glu Tyr Asn Leu Ala Ser Arg Thr Leu Gly
 195 200 205
 5 Thr Pro Thr Leu Lys Ile Val Ala Lys Asn Ile Met Pro Gln Leu Val
 210 215 220
 10 Ser Val Ile Val Thr Thr Met Thr Gln Met Leu Pro Ser Phe Ile Ser
 225 230 235 240
 Tyr Glu Ala Phe Leu Ser Phe Phe Gly Leu Gly Leu Pro Ile Thr Val
 245 250 255
 15 Pro Ser Leu Gly Arg Leu Ile Ser Asp Tyr Ser Gln Asn Val Thr Thr
 260 265 270
 Asn Ala Tyr Leu Phe Trp Ile Pro Leu Thr Thr Leu Val Leu Val Ser
 275 280 285
 20 Leu Ser Leu Phe Val Val Gly Gln Asn Leu Ala Asp Ala Ser Asp Pro
 290 295 300
 25 Arg Thr His Arg
 305
 <210> 188
 <211> 77
 30 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 188
 35 Met Tyr Asn Leu Leu Leu Thr Ile Leu Leu Val Leu Ser Val Val Ile
 1 5 10 15
 Val Ile Ala Ile Phe Met Gln Pro Thr Lys Asn Gln Ser Ser Asn Val
 20 25 30
 40 Phe Asp Ala Ser Ser Gly Asp Leu Phe Glu Arg Ser Lys Ala Arg Gly
 35 40 45
 Phe Glu Ala Val Met Gln Arg Leu Thr Gly Ile Leu Val Phe Phe Trp
 50 55 60
 45 Leu Ala Ile Ala Leu Ala Leu Thr Val Leu Ser Ser Arg
 65 70 75
 50 <210> 189
 <211> 369
 <212> PRT
 <213> Streptococcus pneumoniae
 55 <400> 189
 Met Phe Arg Arg Asn Lys Leu Phe Phe Trp Thr Thr Glu Ile Leu Leu
 1 5 10 15

Leu Thr Ile Ile Phe Tyr Leu Trp Arg Gln Met Gly Ser Leu Ile Asn
 20 25 30
 5 Pro Phe Val Ser Val Leu Asn Thr Ile Met Ile Pro Phe Leu Leu Gly
 35 40 45
 Gly Phe Leu Tyr Tyr Leu Thr Asn Pro Ile Val Thr Phe Leu Asn Lys
 50 55 60
 10 Val Cys Lys Leu Asn Arg Leu Leu Gly Ile Leu Ile Thr Leu Cys Thr
 65 70 75 80
 15 Leu Val Trp Gly Met Val Ile Gly Val Val Tyr Leu Leu Pro Ile Leu
 85 90 95
 Ile Asn Gln Leu Ser Ser Leu Ile Ile Ser Ser Gln Thr Ile Tyr Ser
 100 105 110
 20 Arg Val Gln Asp Leu Ile Ile Asp Leu Ser Asn Tyr Pro Ala Leu Gln
 115 120 125
 Asn Leu Asp Val Glu Ala Thr Ile Gln Gln Leu Asn Leu Ser Tyr Val
 130 135 140
 25 Asp Ile Leu Gln Asn Ile Leu Asn Ser Val Ser Asn Ser Val Gly Ser
 145 150 155 160
 30 Val Leu Ser Ala Leu Ile Ser Thr Val Leu Ile Leu Ile Met Thr Pro
 165 170 175
 Val Phe Leu Val Tyr Phe Leu Leu Asp Gly His Lys Phe Leu Pro Met
 180 185 190
 35 Leu Glu Arg Thr Ile Leu Lys Arg Asp Arg Leu His Ile Ala Gly Leu
 195 200 205
 Leu Lys Asn Leu Asn Ala Thr Ile Ala Arg Tyr Ile Ser Gly Val Ser
 210 215 220
 40 Ile Asp Ala Ile Ile Ile Gly Cys Leu Ala Tyr Ile Gly Tyr Ser Ile
 225 230 235 240
 45 Ile Gly Leu Lys Tyr Ala Leu Val Phe Ala Ile Phe Ser Gly Val Ala
 245 250 255
 Asn Leu Ile Pro Tyr Val Gly Pro Ser Ile Gly Leu Ile Pro Met Ile
 260 265 270
 50 Ile Ala Asn Ile Phe Thr Val Pro His Arg Leu Leu Ile Ala Val Ile
 275 280 285
 Tyr Met Leu Val Val Gln Gln Val Asp Gly Asn Ile Leu Tyr Pro Arg
 290 295 300
 55 Ile Val Gly Ser Val Met Lys Val His Pro Ile Thr Ile Leu Val Leu
 305 310 315 320

Leu Leu Leu Ser Ser Asn Ile Tyr Gly Val Val Gly Met Ile Val Ala
 325 330 335
 5 Val Pro Thr Tyr Ser Ile Leu Lys Glu Ile Ser Lys Phe Leu Ser Arg
 340 345 350
 Leu Tyr Glu Asn His Lys Ile Met Lys Glu Arg Glu Arg Glu Leu Ala
 355 360 365
 10 Lys
 15 <210> 190
 <211> 451
 <212> PRT
 <213> Streptococcus pneumoniae
 20 <400> 190
 Met Tyr Gln Ala Leu Tyr Arg Lys Tyr Arg Ser Gln Asn Phe Ser Gln
 1 5 10 15
 Leu Val Gly Gln Glu Val Val Ala Lys Thr Leu Lys Gln Ala Val Glu
 25 20 25 30
 Gln Glu Lys Ile Ser His Ala Tyr Leu Phe Ser Gly Pro Arg Gly Thr
 35 40 45
 30 Gly Lys Thr Ser Val Ala Lys Ile Phe Ala Lys Ala Met Asn Cys Pro
 50 55 60
 Asn Gln Val Gly Gly Glu Pro Cys Asn Asn Cys Tyr Ile Cys Gln Ala
 65 70 75 80
 35 Val Thr Asp Gly Ser Leu Glu Asp Val Ile Glu Met Asp Ala Ala Ser
 85 90 95
 40 Asn Asn Gly Val Asp Glu Ile Arg Glu Ile Arg Asp Lys Ser Thr Tyr
 100 105 110
 Ala Pro Ser Leu Ala Arg Tyr Lys Val Tyr Ile Ile Asp Glu Val His
 115 120 125
 45 Met Leu Ser Thr Gly Ala Phe Asn Ala Leu Leu Lys Thr Leu Glu Glu
 130 135 140
 Pro Thr Gln Asn Val Val Phe Ile Leu Ala Thr Thr Glu Leu His Lys
 145 150 155 160
 50 Ile Pro Ala Thr Ile Leu Ser Arg Val Gln Arg Phe Glu Phe Lys Ser
 165 170 175
 55 Ile Lys Thr Gln Asp Ile Lys Glu His Ile His Tyr Ile Leu Glu Lys
 180 185 190
 Glu Asn Ile Ser Ser Glu Pro Glu Ala Val Glu Ile Ile Ala Arg Arg

	195	200	205
5	Ala Glu Gly Gly Met Arg Asp Ala Leu Ser Ile Leu Asp Gln Ala Leu 210 215 220		
	Ser Leu Thr Gln Gly Asn Glu Leu Thr Thr Ala Ile Ser Glu Glu Ile 225 230 235 240		
10	Thr Gly Thr Ile Ser Leu Ser Ala Leu Asp Asp Tyr Val Ala Ala Leu 245 250 255		
	Ser Gln Gln Asp Val Pro Lys Ala Leu Ser Cys Leu Asn Leu Leu Phe 260 265 270		
15	Asp Asn Gly Lys Ser Met Thr Arg Phe Val Thr Asp Leu Leu His Tyr 275 280 285		
	Leu Arg Asp Leu Leu Ile Val Gln Thr Gly Gly Glu Asn Thr His His 290 295 300		
20	Ser Ser Val Phe Val Glu Asn Leu Ala Leu Pro Gln Lys Asn Leu Phe 305 310 315 320		
	Glu Met Ile Arg Leu Ala Thr Val Asn Leu Ala Asp Ile Lys Ser Ser 325 330 335		
25	Leu Gln Pro Lys Ile Tyr Ala Glu Met Met Thr Val Arg Leu Ala Glu 340 345 350		
	Ile Lys Pro Glu Pro Ala Leu Ser Gly Ala Val Glu Asn Glu Ile Ala 355 360 365		
30	Thr Leu Arg Gln Glu Val Ala Arg Leu Lys Gln Glu Leu Ser Asn Ala 370 375 380		
35	Gly Ala Val Pro Lys Gln Val Ala Pro Ala Pro Ser Arg Pro Ala Thr 385 390 395 400		
	Gly Lys Thr Val Tyr Arg Val Asp Arg Asn Lys Val Gln Ser Ile Leu 405 410 415		
40	Gln Glu Ala Val Glu Asn Pro Asp Leu Thr Arg Gln Asn Leu Ile Arg 420 425 430		
	Leu Gln Asn Ala Trp Gly Glu Val Ile Glu Ser Leu Gly Gly Pro Asp 435 440 445		
45	Lys Leu Cys 450		
50			
	<210> 191		
	<211> 662		
	<212> PRT		
55	<213> Streptococcus pneumoniae		
	<400> 191		

Met Phe Arg Leu Thr Asn Lys Leu Ala Val Ser Asn Leu Ile Lys Asn
 1 5 10 15
 5 Arg Lys Leu Tyr Tyr Pro Phe Ala Leu Ala Val Leu Leu Ala Val Thr
 20 25 30
 Leu Thr Tyr Leu Phe Tyr Ser Leu Thr Phe Asn Pro Lys Ile Ala Glu
 35 40 45
 10 Ile Arg Gly Gly Thr Thr Ile Gln Ala Thr Leu Gly Phe Gly Met Phe
 50 55 60
 Val Val Thr Leu Ala Ser Ala Ile Ile Val Leu Tyr Ala Asn Ser Phe
 65 70 75 80
 15 Val Met Lys Lys Arg Ser Lys Glu Leu Gly Ile Tyr Gly Met Leu Gly
 85 90 95
 Leu Glu Lys Arg His Leu Ile Ser Met Thr Phe Lys Glu Leu Val Val
 100 105 110
 Phe Gly Ile Leu Thr Val Gly Ala Gly Ile Gly Ile Gly Ala Leu Phe
 115 120 125
 25 Asp Lys Leu Ile Phe Ala Phe Leu Leu Lys Leu Met Lys Leu Lys Val
 130 135 140
 Glu Leu Val Ala Thr Phe Gln Thr Lys Val Val Ile Thr Val Leu Val
 145 150 155 160
 30 Val Phe Gly Leu Ile Phe Leu Gly Leu Met Phe Leu Asn Ala Leu Arg
 165 170 175
 Ile Ala Arg Met Asn Ala Leu Gln Leu Ser Arg Glu Lys Ala Ser Gly
 180 185 190
 Glu Lys Lys Gly Arg Phe Leu Pro Leu Gln Thr Ile Leu Gly Ser Ile
 195 200 205
 40 Ser Leu Gly Ile Gly Tyr Tyr Leu Ala Leu Thr Val Lys Asp Pro Leu
 210 215 220
 Thr Ala Leu Thr Thr Phe Phe Ile Ala Val Leu Leu Val Ile Phe Gly
 225 230 235 240
 45 Thr Tyr Leu Leu Phe Asn Ala Gly Ile Thr Val Phe Leu Gln Ile Leu
 245 250 255
 Lys Lys Asn Lys Lys Tyr Tyr Tyr Gln Pro Asn Asn Leu Ile Ser Val
 260 265 270
 Ser Asn Leu Ile Phe Arg Met Lys Lys Asn Ala Val Gly Leu Ala Thr
 275 280 285
 55 Ile Ala Ile Leu Ser Thr Met Val Leu Val Thr Met Ser Ala Ala Thr
 290 295 300

Ser Ile Phe Asn Ser Ala Glu Ser Phe Lys Lys Val Leu Asn Pro His
 305 310 315 320
 5 Asp Phe Gly Val Ser Gly Gln Asn Val Glu Lys Glu Asp Leu Asp Lys
 325 330 335
 Leu Leu Ser Gln Phe Ala Ser Asp Asn Gly Tyr Lys Ile Lys Glu Lys
 340 345 350
 10 Glu Val Phe Arg Tyr Thr Tyr Phe Gly Val Ala Asn Gln Glu Gly Asn
 355 360 365
 Lys Leu Thr Phe Phe Glu Lys Gly Gln Asn Arg Val Gln Pro Thr Thr
 370 375 380
 15 Val Phe Met Val Phe Asp Gln Lys Asp Tyr Glu Asn Met Thr Gly Gln
 385 390 395 400
 Lys Leu Ser Leu Ser Gly Asn Glu Val Gly Leu Phe Ala Lys Asn Asp
 405 410 415
 Gly Leu Lys Gly Gln Lys Thr Leu Ile Leu Asn Asp His Gln Phe Ser
 420 425 430
 25 Val Lys Glu Glu Phe Asn Lys Asp Phe Ile Val Asn His Val Pro Asn
 435 440 445
 Gln Phe Asn Ile Leu Thr Ala Asp Tyr Asn Tyr Leu Val Val Pro Asp
 450 455 460
 30 Leu Gln Ala Phe Leu Asn Gln Phe Pro Asp Ser Asp Ile Tyr Asn Gln
 465 470 475 480
 Phe Tyr Gly Gly Met Asn Val Asn Val Ser Glu Glu Glu Gln Leu Lys
 485 490 495
 Val Ala Glu Glu Tyr Glu Asn Tyr Leu Asn Gln Phe Asn Ala Gln Leu
 500 505 510
 40 Asp Thr Glu Gly Ser Tyr Val Tyr Gly Ser Asn Leu Ala Asp Ala Ser
 515 520 525
 Ser Gln Met Ser Ala Leu Phe Gly Gly Val Phe Phe Ile Gly Ile Phe
 530 535 540
 45 Leu Ser Ile Ile Phe Met Val Gly Thr Val Leu Val Ile Tyr Tyr Lys
 545 550 555 560
 Gln Ile Ser Glu Gly Tyr Glu Asp Arg Glu Arg Phe Ile Ile Leu Gln
 565 570 575
 50 Lys Val Gly Leu Asp Gln Lys Gln Ile Lys Gln Thr Ile His Lys Gln
 580 585 590
 55 Val Leu Thr Val Phe Phe Leu Pro Leu Leu Phe Ala Phe Ile His Leu
 595 600 605

Ala Phe Ala Tyr His Met Leu Ser Leu Ile Leu Lys Val Ile Gly Val
 610 615 620
 5 Leu Asp Thr Thr Met Met Leu Ile Val Thr Leu Ser Ile Cys Ala Ile
 625 630 635 640
 Phe Leu Ile Ala Tyr Val Leu Ile Phe Met Ile Thr Ser Arg Ser Tyr
 645 650 655
 10 Arg Lys Ile Val Gln Met
 660
 <210> 192
 15 <211> 296
 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 192
 20 Met Lys Gln Asp Gln Leu Lys Ala Trp Gln Pro Ala Gln Phe Asp Arg
 1 5 10 15
 Phe Val Arg Ile Leu Glu Gln Asp Gln Leu Asn His Ala Tyr Leu Phe
 20 25 30
 25 Ser Gly Phe Phe Gly Ser Leu Glu Met Ala Gln Phe Leu Ala Lys Ser
 35 40 45
 30 Leu Phe Cys Thr Asp Lys Val Gly Val Leu Pro Cys Glu Lys Cys Arg
 50 55 60
 Ser Cys Lys Leu Ile Glu Gln Glu Glu Phe Pro Asp Val Thr Leu Ile
 65 70 75 80
 35 Lys Pro Val Asn Gln Val Ile Lys Thr Glu Arg Ile Arg Glu Leu Val
 85 90 95
 Gly Gln Phe Ser Gln Ala Gly Ile Glu Ser Gln Gln Gln Val Phe Ile
 100 105 110
 40 Ile Glu Gln Ala Asp Lys Met His Pro Asn Ala Ala Asn Ser Leu Leu
 115 120 125
 45 Lys Val Ile Glu Glu Pro Gln Ser Glu Val Tyr Ile Phe Phe Leu Thr
 130 135 140
 Ser Asp Glu Glu Lys Met Leu Pro Thr Ile Arg Ser Arg Thr Gln Ile
 145 150 155 160
 50 Phe His Phe Lys Lys Gln Glu Glu Lys Leu Ile Leu Leu Leu Glu Gln
 165 170 175
 Met Gly Leu Val Lys Lys Lys Ala Thr Leu Leu Ala Lys Phe Ser Gln
 180 185 190
 55 Ser Arg Ala Glu Ala Glu Lys Leu Ala Asn Gln Ala Ser Phe Trp Thr
 195 200 205

Leu Val Asp Glu Ser Glu Arg Leu Leu Thr Trp Leu Val Ala Lys Lys
 210 215 220
 5 Lys Glu Ser Tyr Leu Gln Val Ala Lys Leu Ala Asn Leu Ala Asp Asp
 225 230 235 240
 Lys Glu Lys Gln Asp Gln Val Leu Arg Ile Leu Glu Val Leu Cys Gly
 245 250 255
 10 Gln Asp Leu Leu Gln Val Arg Val Arg Val Ile Leu Gln Asp Leu Leu
 260 265 270
 15 Glu Ala Arg Lys Met Trp Gln Ala Asn Val Ser Phe Gln Asn Ala Met
 275 280 285
 Glu Tyr Leu Val Leu Lys Glu Ile
 290 295
 20
 <210> 193
 <211> 204
 <212> PRT
 <213> Streptococcus pneumoniae
 25
 <400> 193
 Met Asn Ser Phe Lys Asn Phe Leu Lys Glu Trp Gly Leu Phe Leu Leu
 1 5 10 15
 30 Ile Leu Ser Leu Leu Ala Leu Ser Arg Ile Phe Phe Trp Ser Asn Val
 20 25 30
 Arg Val Glu Gly His Ser Met Asp Pro Thr Leu Ala Asp Gly Glu Ile
 35 35 40 45
 Leu Phe Val Val Lys His Leu Pro Ile Asp Arg Phe Asp Ile Val Val
 50 55 60
 40 Ala His Glu Glu Asp Gly Asn Lys Asp Ile Val Lys Arg Val Ile Gly
 65 70 75 80
 Met Pro Gly Asp Thr Ile Arg Tyr Glu Asn Asp Lys Leu Tyr Ile Asn
 85 90 95
 45 Asp Lys Glu Thr Asp Glu Pro Tyr Leu Ala Asp Tyr Ile Lys Arg Phe
 100 105 110
 Lys Asp Asp Lys Leu Gln Ser Thr Tyr Ser Gly Lys Gly Phe Glu Gly
 115 120 125
 50 Asn Lys Gly Thr Phe Phe Arg Ser Ile Ala Gln Lys Ala Gln Ala Phe
 130 135 140
 55 Thr Val Asp Val Asn Tyr Asn Thr Asn Phe Ser Phe Thr Val Pro Glu
 145 150 155 160
 Gly Glu Tyr Leu Leu Leu Gly Asp Asp Arg Leu Val Ser Ser Asp Ser

165 170 175
 Arg His Val Gly Thr Phe Lys Ala Lys Asp Ile Thr Gly Glu Ala Lys
 180 185 190
 5 Phe Arg Phe Trp Pro Ile Thr Arg Ile Gly Thr Phe
 195 200
 10 <210> 194
 <211> 328
 <212> PRT
 <213> Streptococcus pneumoniae
 15 <400> 194
 Met Val Val Phe Thr Gly Ser Thr Val Glu Glu Ala Ile Gln Lys Gly
 1 5 10 15
 20 Leu Lys Glu Leu Asp Ile Pro Arg Met Lys Ala His Ile Lys Val Ile
 20 25 30
 Ser Arg Glu Lys Lys Gly Phe Leu Gly Leu Phe Gly Lys Lys Pro Ala
 35 40 45
 25 Gln Val Asp Ile Glu Ala Ile Ser Glu Thr Thr Val Val Lys Ala Asn
 50 55 60
 Gln Gln Val Val Lys Gly Val Pro Lys Lys Ile Asn Asp Leu Asn Glu
 65 70 75 80
 30 Pro Val Lys Thr Val Ser Glu Glu Thr Val Asp Leu Gly His Val Val
 85 90 95
 35 Asn Ala Ile Lys Lys Ile Glu Glu Glu Gly Gln Gly Ile Ser Asp Glu
 100 105 110
 Val Lys Ala Glu Ile Leu Lys His Glu Arg His Ala Ser Thr Ile Leu
 115 120 125
 40 Glu Glu Thr Gly His Ile Glu Ile Leu Asn Glu Leu Gln Ile Glu Glu
 130 135 140
 Ala Met Arg Glu Glu Ala Gly Ala Asp Asp Leu Glu Thr Glu Gln Asp
 145 150 155 160
 45 Gln Thr Glu Asn Gln Asp Leu Lys Glu Met Gly Leu Lys Val Glu Gln
 165 170 175
 50 Ser Tyr Asp Ile Ala Gln Val Ala Thr Asp Val Thr Ala Tyr Val Gln
 180 185 190
 Ala Ile Val Asp Asp Met Asp Val Glu Ala Thr Leu Ser Asn Asp Tyr
 195 200 205
 55 Asn Arg Arg Ser Ile Asn Leu Gln Ile Asp Thr Asn Glu Pro Gly Arg
 210 215 220

Ile Ile Gly Tyr His Gly Lys Val Leu Lys Ala Leu Gln Leu Leu Ala
 225 230 235 240
 5 Gln Asn Tyr Leu Tyr Asn Arg Tyr Ser Lys Thr Phe Tyr Val Thr Ile
 245 250 255
 Asn Val Asn Asp Tyr Val Glu His Arg Ala Glu Val Leu Gln Thr Tyr
 260 265 270
 10 Ala Gln Lys Leu Ala Asn Arg Val Leu Glu Glu Gly Arg Ser His Lys
 275 280 285
 Thr Asp Pro Met Ser Asn Ser Glu Arg Lys Ile Ile His Arg Ile Ile
 290 295 300
 15 Ser Arg Met Asp Gly Val Thr Ser Tyr Ser Glu Gly Asp Glu Pro Asn
 305 310 315 320
 20 Arg Tyr Val Val Val Asp Thr Glu
 325
 <210> 195
 <211> 460
 25 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 195
 30 Met Ser Asn Phe Ala Ile Ile Leu Ala Ala Gly Lys Gly Thr Arg Met
 1 5 10 15
 Lys Ser Asp Leu Pro Lys Val Leu His Lys Val Ala Gly Ile Ser Met
 20 25 30
 35 Leu Glu His Val Phe Arg Ser Val Gly Ala Ile Gln Pro Glu Lys Thr
 35 40 45
 Val Thr Val Val Gly His Lys Ala Glu Leu Val Glu Glu Val Leu Ala
 50 55 60
 40 Gly Gln Thr Glu Phe Val Thr Gln Ser Glu Gln Leu Gly Thr Gly His
 65 70 75 80
 45 Ala Val Met Met Thr Glu Pro Ile Leu Glu Gly Val Ser Gly His Thr
 85 90 95
 Leu Val Ile Ala Gly Asp Thr Pro Leu Ile Thr Gly Glu Ser Leu Lys
 100 105 110
 50 Asn Leu Ile Asp Phe His Ile Asn His Lys Asn Val Ala Thr Ile Leu
 115 120 125
 Thr Ala Glu Thr Asp Asn Pro Phe Gly Tyr Gly Arg Ile Val Arg Asn
 130 135 140
 55 Asp Asn Ala Glu Val Leu Arg Ser Leu Leu Ser Arg Arg Met Leu Gln
 145 150 155 160

Ile Leu Lys Ser Lys Ser Arg Lys Ser Thr Leu Val Thr Tyr Val Phe
 165 170 175
 5 Asp Asn Glu Arg Leu Phe Glu Ala Leu Lys Asn Ile Asn Thr Asn Asn
 180 185 190
 Ala Gln Gly Glu Tyr Tyr Ile Thr Asp Val Ile Gly Ile Phe Arg Glu
 195 200 205
 10 Thr Gly Glu Lys Val Gly Ala Tyr Thr Leu Lys Asp Phe Asp Glu Ser
 210 215 220
 Leu Gly Val Asn Asp Arg Val Ala Leu Ala Thr Ala Glu Ser Val Met
 15 225 230 235 240
 Arg Arg Arg Ile Asn His Lys His Met Val Asn Gly Val Ser Phe Val
 245 250 255
 20 Asn Pro Glu Ala Thr Tyr Ile Asp Ile Asp Val Glu Ile Ala Pro Glu
 260 265 270
 Val Gln Ile Glu Ala Asn Val Ile Leu Lys Gly Gln Thr Lys Ile Gly
 275 280 285
 25 Ala Glu Thr Val Leu Thr Asn Gly Thr Tyr Val Val Asp Ser Thr Ile
 290 295 300
 Gly Ala Gly Ala Val Ile Thr Asn Ser Met Ile Glu Glu Ser Ser Val
 30 305 310 315 320
 Ala Asp Gly Val Thr Val Gly Pro Tyr Ala His Ile Arg Pro Asn Ser
 325 330 335
 35 Ser Leu Gly Ala Gln Val His Ile Gly Asn Phe Val Glu Val Lys Gly
 340 345 350
 Ser Ser Ile Gly Glu Asn Thr Lys Ala Gly His Leu Thr Tyr Ile Gly
 355 360 365
 40 Asn Cys Glu Val Gly Ser Asn Val Asn Phe Gly Ala Gly Thr Ile Thr
 370 375 380
 Val Asn Tyr Asp Gly Lys Asn Lys Tyr Lys Thr Val Ile Gly Val Asn
 45 385 390 395 400
 Val Phe Val Gly Ser Asn Ser Thr Ile Ile Ala Pro Val Glu Leu Gly
 405 410 415
 50 Asp Asn Ser Leu Val Gly Ala Gly Ser Thr Ile Thr Lys Asp Val Pro
 420 425 430
 Ala Asp Ala Ile Ala Ile Gly Arg Gly Arg Gln Ile Asn Lys Asp Glu
 435 440 445
 55 Tyr Ala Thr Arg Leu Pro His His Pro Lys Asn Gln
 450 455 460

<210> 196
 <211> 311
 5 <212> PRT
 <213> Streptococcus pneumoniae

 <400> 196
 10 Met Ser Lys Ile Leu Val Phe Gly His Gln Asn Pro Asp Ser Asp Ala
 1 5 10 15
 Ile Gly Ser Ser Val Ala Phe Ala Tyr Leu Ala Lys Glu Ala Tyr Gly
 20 25 30
 15 Leu Asp Thr Glu Ala Val Ala Leu Gly Thr Pro Asn Glu Glu Thr Ala
 35 40 45
 Phe Val Leu Asn Tyr Phe Gly Val Glu Ala Pro Arg Val Ile Thr Ser
 50 55 60
 20 Ala Lys Ala Glu Gly Ala Glu Gln Val Ile Leu Thr Asp His Asn Glu
 65 70 75 80
 Phe Gln Gln Ser Val Ser Asp Ile Ala Glu Val Glu Val Tyr Gly Val
 25 85 90 95
 Val Asp His His Arg Val Ala Asn Phe Glu Thr Ala Ser Pro Leu Tyr
 100 105 110
 30 Met Arg Leu Glu Pro Val Gly Ser Ala Ser Ser Ile Val Tyr Arg Met
 115 120 125
 Phe Lys Glu His Gly Val Ala Val Pro Lys Glu Ile Ala Gly Leu Met
 35 130 135 140
 Leu Ser Gly Leu Ile Ser Asp Thr Leu Leu Leu Lys Ser Pro Thr Thr
 145 150 155 160
 40 His Pro Thr Asp Lys Ile Ile Ala Pro Glu Leu Ala Glu Leu Ala Gly
 165 170 175
 Val Asn Leu Glu Glu Tyr Gly Leu Ala Met Leu Lys Ala Gly Thr Asn
 180 185 190
 45 Leu Ala Ser Lys Ser Ala Glu Glu Leu Ile Asp Ile Asp Ala Lys Thr
 195 200 205
 Phe Glu Leu Asn Gly Asn Asn Val Arg Val Ala Gln Val Asn Thr Val
 50 210 215 220
 Asp Ile Ala Glu Val Leu Glu Arg Gln Ala Glu Ile Glu Ala Ala Met
 225 230 235 240
 55 Gln Ala Ala Asn Glu Ser Asn Gly Tyr Ser Asp Phe Val Leu Met Ile
 245 250 255
 Thr Asp Ile Val Asn Ser Asn Ser Glu Ile Leu Ala Leu Gly Ala Asn

142

Val Leu Val Asp Lys Ile Gln Ala Ile Lys Glu Val Leu His Val Ser
 210 215 220
 Lys
 5 225
 <210> 198
 <211> 161
 10 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 198
 15 Met Asn Leu Asn Asp Ile Lys Asp Leu Met Thr Gln Phe Asp Gln Ser
 1 5 10 15
 Ser Leu Arg Glu Phe Ser Tyr Lys Asn Gly Thr Asp Glu Leu Gln Phe
 20 20 25 30
 Ser Lys Asn Glu Ala Arg Pro Val Pro Glu Val Ala Thr Gln Val Ala
 35 40 45
 Pro Ala Pro Val Leu Ala Thr Pro Ser Pro Val Ala Pro Thr Ser Ala
 50 55 60
 25 Pro Ala Glu Thr Val Ala Glu Glu Val Pro Ala Pro Ala Glu Ala Ser
 65 70 75 80
 Val Ala Ser Glu Gly Asn Leu Val Glu Ser Pro Leu Val Gly Val Val
 30 85 90 95
 Tyr Leu Ala Ala Gly Pro Asp Lys Pro Ala Phe Val Thr Val Gly Asp
 100 105 110
 35 Ser Val Lys Lys Gly Gln Thr Leu Val Ile Ile Glu Ala Met Lys Val
 115 120 125
 Met Asn Glu Ile Pro Ala Pro Lys Asp Gly Val Val Thr Glu Ile Leu
 130 135 140
 40 Val Ser Asn Glu Glu Met Val Glu Phe Gly Lys Gly Leu Val Arg Ile
 145 150 155 160
 Lys
 45
 <210> 199
 <211> 411
 50 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 199
 55 Met Lys Leu Asn Arg Val Val Val Thr Gly Tyr Gly Val Thr Ser Pro
 1 5 10 15
 Ile Gly Asn Thr Pro Glu Glu Phe Trp Asn Ser Leu Ala Thr Gly Lys

20 25 30
 Ile Gly Ile Gly Gly Ile Thr Lys Phe Asp His Ser Asp Phe Asp Val
 35 40 45
 5 His Asn Ala Ala Glu Ile Gln Asp Phe Pro Phe Asp Lys Tyr Phe Val
 50 55 60
 10 Lys Lys Asp Thr Asn Arg Phe Asp Asn Tyr Ser Leu Tyr Ala Leu Tyr
 65 70 75 80
 Ala Ala Gln Glu Ala Val Asn His Ala Asn Leu Asp Val Glu Ala Leu
 85 90 95
 15 Asn Arg Asp Arg Phe Gly Val Ile Val Ala Ser Gly Ile Gly Gly Ile
 100 105 110
 Lys Glu Ile Glu Asp Gln Val Leu Arg Leu His Glu Lys Gly Pro Lys
 115 120 125
 20 Arg Val Lys Pro Met Thr Leu Pro Lys Ala Leu Pro Asn Met Ala Ser
 130 135 140
 Gly Asn Val Ala Met Arg Phe Gly Ala Asn Gly Val Cys Lys Ser Ile
 145 150 155 160
 Asn Thr Ala Cys Ser Ser Ser Asn Asp Ala Ile Gly Asp Ala Phe Arg
 165 170 175
 30 Ser Ile Lys Phe Gly Phe Gln Asp Val Met Leu Val Gly Gly Thr Glu
 180 185 190
 Ala Ser Ile Thr Pro Phe Ala Ile Ala Gly Phe Gln Ala Leu Thr Ala
 195 200 205
 35 Leu Ser Thr Thr Glu Asp Pro Thr Arg Ala Ser Ile Pro Phe Asp Lys
 210 215 220
 Asp Arg Asn Gly Phe Val Met Gly Glu Gly Ser Gly Met Leu Val Leu
 225 230 235 240
 Glu Ser Leu Glu His Ala Glu Lys Arg Gly Ala Thr Ile Leu Ala Glu
 245 250 255
 45 Val Val Gly Tyr Gly Asn Thr Cys Asp Ala Tyr His Met Thr Ser Pro
 260 265 270
 His Pro Glu Gly Gln Gly Ala Ile Lys Ala Ile Lys Leu Ala Leu Glu
 275 280 285
 50 Glu Ala Glu Ile Ser Pro Glu Gln Val Ala Tyr Val Asn Ala His Gly
 290 295 300
 Thr Ser Thr Pro Ala Asn Glu Lys Gly Glu Ser Gly Ala Ile Val Ala
 305 310 315 320
 55 Val Leu Gly Lys Glu Val Pro Val Ser Ser Thr Lys Ser Phe Thr Gly

145

Leu Lys Tyr Glu Ser Gly Ala His Arg Val Gln Arg Val Pro Val Thr
 180 185 190
 5 Glu Ser Gln Gly Arg Val His Thr Ser Thr Ala Thr Val Leu Val Met
 195 200 205
 Pro Glu Val Glu Glu Val Glu Tyr Asp Ile Asp Pro Lys Asp Leu Arg
 210 215 220
 10 Val Asp Ile Tyr His Ala Ser Gly Ala Gly Gly Gln Asn Val Asn Lys
 225 230 235 240
 Val Ala Thr Ala Val Arg Ile Val His Leu Pro Thr Asn Ile Lys Val
 245 250 255
 15 Glu Met Gln Glu Glu Arg Thr Gln Gln Lys Asn Arg Glu Lys Ala Met
 260 265 270
 20 Lys Ile Ile Arg Ala Arg Val Ala Asp His Phe Ala Gln Ile Ala Gln
 275 280 285
 Asp Glu Gln Asp Ala Glu Arg Lys Ser Thr Ile Gly Thr Gly Asp Arg
 290 295 300
 25 Ser Glu Arg Ile Arg Thr Tyr Asn Phe Pro Gln Asn Arg Val Thr Asp
 305 310 315 320
 His Arg Ile Gly Leu Thr Leu Gln Lys Leu Asp Thr Ile Leu Ser Gly
 325 330 335
 30 Lys Leu Asp Glu Val Val Asp Ala Leu Val Leu Tyr Asp Gln Thr Gln
 340 345 350
 35 Lys Leu Glu Glu Leu Asn Lys
 355
 <210> 201
 <211> 559
 40 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 201
 45 Met Ala Tyr Thr Leu Lys Pro Glu Glu Val Gly Val Phe Ala Ile Gly
 1 5 10 15
 Gly Leu Gly Glu Ile Gly Lys Asn Thr Tyr Gly Ile Glu Tyr Gln Asp
 20 25 30
 50 Glu Ile Ile Ile Val Asp Ala Gly Ile Lys Phe Pro Glu Asp Asp Leu
 35 40 45
 Leu Gly Ile Asp Tyr Val Ile Pro Asp Tyr Ser Tyr Ile Val Asp Asn
 50 55 60
 55 Ile Asp Arg Val Lys Ala Val Leu Ile Thr His Gly His Glu Asp His
 65 70 75 80

Ile Gly Gly Ile Pro Phe Leu Leu Lys Gln Ala Asn Val Pro Ile Tyr
 85 90 95
 5 Ala Gly Pro Leu Ala Leu Ala Leu Ile Arg Gly Lys Leu Glu Glu His
 100 105 110
 Gly Leu Leu Arg Asn Ala Lys Leu Tyr Glu Ile Asn His Asn Thr Glu
 115 120 125
 10 Leu Thr Phe Lys Asn Leu Lys Ala Thr Phe Phe Arg Thr Thr His Ser
 130 135 140
 15 Ile Pro Glu Pro Leu Gly Ile Val Ile His Thr Pro Gln Gly Lys Ile
 145 150 155 160
 Val Cys Thr Gly Asp Phe Lys Phe Asp Phe Thr Pro Val Gly Glu Pro
 165 170 175
 20 Ala Asp Leu His Arg Met Ala Ala Leu Gly Glu Glu Gly Val Leu Cys
 180 185 190
 Leu Leu Ser Asp Ser Thr Asn Ala Glu Val Pro Thr Phe Thr Asn Ser
 195 200 205
 25 Glu Lys Val Val Gly Gln Ser Ile Met Lys Ile Ile Gln Gly Ile Glu
 210 215 220
 30 Gly Arg Ile Ile Phe Ala Ser Phe Ala Ser Asn Ile Phe Arg Leu Gln
 225 230 235 240
 Gln Ala Thr Glu Ala Ala Val Lys Thr Gly Arg Lys Ile Ala Val Phe
 245 250 255
 35 Gly Arg Ser Met Glu Lys Ala Ile Val Asn Gly Ile Asp Leu Gly Tyr
 260 265 270
 Ile Lys Ala Pro Lys Gly Thr Phe Ile Glu Pro Asn Glu Ile Lys Asp
 275 280 285
 40 Tyr Pro Ala Gly Glu Val Leu Ile Leu Cys Thr Gly Ser Gln Gly Glu
 290 295 300
 45 Pro Met Ala Ala Leu Ser Arg Ile Ala Asn Gly Thr His Arg Gln Val
 305 310 315 320
 Gln Leu Gln Pro Gly Asp Thr Val Ile Phe Ser Ser Ser Pro Ile Pro
 325 330 335
 50 Gly Asn Thr Thr Ser Val Asn Lys Leu Ile Asn Ile Ile Ser Glu Ala
 340 345 350
 Gly Val Glu Val Ile His Gly Lys Val Asn Asn Ile His Thr Ser Gly
 355 360 365
 55 His Gly Gly Gln Gln Glu Gln Lys Leu Met Leu Cys Leu Ile Lys Pro
 370 375 380

Lys Tyr Phe Met Pro Val His Gly Glu Tyr Arg Met Gln Lys Val His
 385 390 395 400
 5 Ala Gly Leu Ala Val Asp Thr Gly Val Glu Lys Asp Asn Ile Phe Ile
 405 410 415
 Met Ser Asn Gly Asp Val Leu Ala Leu Thr Ala Asp Ser Ala Arg Ile
 420 425 430
 10 Ala Gly His Phe Asn Ala Gln Asp Ile Tyr Val Asp Gly Asn Arg Ile
 435 440 445
 Gly Glu Ile Gly Ala Ala Val Leu Lys Asp Arg Arg Asp Leu Ser Glu
 450 455 460
 15 Asp Gly Val Val Leu Ala Val Ala Thr Val Asp Phe Lys Ser Gln Met
 465 470 475 480
 20 Ile Leu Ser Gly Pro Asp Ile Leu Ser Arg Gly Phe Val Tyr Met Arg
 485 490 495
 Glu Ser Gly Asp Leu Ile Arg Gln Ser Gln Arg Ile Leu Phe Asn Ala
 500 505 510
 25 Ile Arg Ile Ala Leu Lys Asn Lys Asp Ala Ser Val Gln Ser Val Asn
 515 520 525
 Gly Ala Ile Val Asn Ala Ile Arg Pro Phe Leu Tyr Glu Asn Thr Glu
 530 535 540
 30 Arg Glu Pro Ile Ile Ile Pro Met Ile Leu Thr Pro Asp Glu Glu
 545 550 555
 35
 <210> 202
 <211> 450
 <212> PRT
 <213> Streptococcus pneumoniae
 40
 <400> 202
 Met Ala Glu Val Glu Glu Leu Arg Val Gln Pro Gln Asp Ile Leu Ala
 1 5 10 15
 45 Glu Gln Ser Val Leu Gly Ala Ile Phe Ile Asp Glu Ser Lys Leu Val
 20 25 30
 Phe Val Arg Glu Tyr Ile Glu Ser Arg Asp Phe Phe Lys Tyr Ala His
 35 40 45
 50 Arg Leu Ile Phe Gln Ala Met Val Asp Leu Ser Asp Arg Gly Asp Ala
 50 55 60
 55 Ile Asp Ala Thr Thr Val Arg Thr Ile Leu Asp Asn Gln Gly Asp Leu
 65 70 75 80
 Gln Asn Ile Gly Gly Leu Ser Tyr Leu Val Glu Ile Val Asn Ser Val

	85	90	95
	Pro Thr Ser Ala Asn Ala Glu Tyr Tyr Ala Lys Ile Val Ala Glu Lys		
	100	105	110
5	Ala Met Leu Arg Arg Leu Ile Ala Lys Leu Thr Glu Ser Val Asn Gln		
	115	120	125
10	Ala Tyr Glu Ala Ser Gln Pro Ala Asp Glu Ile Ile Ala Gln Ala Glu		
	130	135	140
	Lys Gly Leu Ile Asp Val Ser Glu Asn Ala Asn Arg Ser Gly Phe Lys		
	145	150	155
15	Asn Ile Arg Asp Val Leu Asn Leu Asn Phe Gly Asn Leu Glu Ala Arg		
	165	170	175
	Ser Gln Gln Thr Thr Asp Ile Thr Gly Ile Ala Thr Gly Tyr Arg Asp		
	180	185	190
20	Leu Asp His Met Thr Thr Gly Leu His Glu Glu Glu Leu Ile Ile Leu		
	195	200	205
	Ala Ala Arg Pro Ala Val Gly Lys Thr Ala Phe Ala Leu Asn Ile Ala		
25	210	215	220
	Gln Asn Ile Gly Thr Lys Leu Asp Lys Thr Val Ala Ile Phe Ser Leu		
	225	230	235
30	Glu Met Gly Ala Glu Ser Leu Val Asp Arg Met Leu Ala Ala Glu Gly		
	245	250	255
	Leu Val Glu Ser His Ser Ile Arg Thr Gly Gln Leu Thr Asp Glu Glu		
	260	265	270
35	Trp Gln Lys Tyr Thr Ile Ala Gln Gly Asn Leu Ala Asn Ala Ser Ile		
	275	280	285
	Tyr Ile Asp Asp Thr Pro Gly Ile Arg Ile Thr Glu Ile Arg Ser Arg		
40	290	295	300
	Ser Arg Lys Leu Ala Gln Glu Thr Gly Asn Leu Gly Leu Ile Val Ile		
	305	310	315
	Asp Tyr Leu Gln Leu Ile Thr Gly Thr Gly Arg Glu Asn Arg Gln Gln		
45	325	330	335
	Glu Val Ser Glu Ile Ser Arg Gln Leu Lys Ile Leu Ala Lys Glu Leu		
	340	345	350
50	Lys Val Pro Val Ile Ala Leu Ser Gln Leu Ser Arg Gly Val Glu Gln		
	355	360	365
	Arg Gln Asp Lys Arg Pro Val Leu Ser Asp Ile Arg Glu Ser Gly Ser		
55	370	375	380
	Ile Glu Gln Asp Ala Asp Ile Val Ala Phe Leu Tyr Arg Asp Asp Tyr		

385 390 395 400
 Tyr Glu Arg Gly Gly Glu Glu Glu Glu Gly Ile Pro Asn Asn Lys Val
 405 410 415
 5 Glu Val Ile Ile Glu Lys Asn Arg Ser Gly Ala Arg Gly Thr Val Glu
 420 425 430
 10 Leu Ile Val Gln Lys Glu Tyr Asn Lys Phe Ser Ser Ile Ser Lys Arg
 435 440 445
 Glu Ala
 450
 15
 <210> 203
 <211> 699
 <212> PRT
 <213> Streptococcus pneumoniae
 20
 <400> 203
 Met Ala Thr Ala Thr Lys Lys Lys Lys Ser Thr Val Lys Lys Asn Leu
 1 5 10 15
 25 Val Ile Val Glu Ser Pro Ala Lys Ala Lys Thr Ile Glu Lys Tyr Leu
 20 25 30
 Gly Arg Asn Tyr Lys Val Leu Ala Ser Val Gly His Ile Arg Asp Leu
 35 40 45
 30 Lys Lys Ser Ser Met Ser Val Asp Ile Glu Asn Asn Tyr Glu Pro Gln
 50 55 60
 35 Tyr Ile Asn Ile Arg Gly Lys Gly Pro Leu Ile Asn Asp Leu Lys Lys
 65 70 75 80
 Glu Ala Lys Lys Ala Asn Lys Val Phe Leu Ala Ser Asp Pro Asp Arg
 85 90 95
 40 Glu Gly Glu Ala Ile Ser Trp His Leu Ala His Ile Leu Asn Leu Asp
 100 105 110
 Glu Asn Asp Ala Asn Arg Val Val Phe Asn Glu Ile Thr Lys Asp Ala
 115 120 125
 45 Val Lys Asn Ala Phe Lys Glu Pro Arg Lys Ile Asp Met Asp Leu Val
 130 135 140
 50 Asp Ala Gln Gln Ala Arg Arg Ile Leu Asp Arg Leu Val Gly Tyr Ser
 145 150 155 160
 Ile Ser Pro Ile Leu Trp Lys Lys Val Lys Lys Gly Leu Ser Ala Gly
 165 170 175
 55 Arg Val Gln Ser Ile Ala Leu Lys Leu Ile Ile Asp Arg Glu Asn Glu
 180 185 190

Ile Asn Ala Phe Gln Pro Glu Glu Tyr Trp Thr Val Asp Ala Val Phe
 195 200 205
 5 Lys Lys Gly Thr Lys Gln Phe His Ala Ser Phe Tyr Gly Val Asp Gly
 210 215 220
 Lys Lys Met Lys Leu Thr Ser Asn Asn Glu Val Lys Glu Val Leu Ser
 225 230 235 240
 10 Arg Leu Thr Ser Lys Asp Phe Ser Val Asp Gln Val Asp Lys Lys Glu
 245 250 255
 Arg Lys Arg Asn Ala Pro Leu Pro Tyr Thr Thr Ser Ser Met Gln Met
 260 265 270
 15 Asp Ala Ala Asn Lys Ile Asn Phe Arg Thr Arg Lys Thr Met Met Val
 275 280 285
 Ala Gln Gln Leu Tyr Glu Gly Ile Asn Ile Gly Ser Gly Val Gln Gly
 290 295 300
 Leu Ile Thr Tyr Met Arg Thr Asp Ser Thr Arg Ile Ser Pro Val Ala
 305 310 315 320
 25 Gln Asn Glu Ala Ala Ser Phe Ile Thr Asp Arg Phe Gly Ser Lys Tyr
 325 330 335
 Ser Lys His Gly Ser Lys Val Lys Asn Ala Ser Gly Ala Gln Asp Ala
 340 345 350
 30 His Glu Ala Ile Arg Pro Ser Ser Val Phe Asn Thr Pro Glu Ser Ile
 355 360 365
 Ala Lys Tyr Leu Asp Lys Asp Gln Leu Lys Leu Tyr Thr Leu Ile Trp
 370 375 380
 Asn Arg Phe Val Ala Ser Gln Met Thr Ala Ala Val Phe Asp Thr Met
 385 390 395 400
 40 Ala Val Lys Leu Ser Gln Lys Gly Val Gln Phe Ala Ala Asn Gly Ser
 405 410 415
 Gln Val Lys Phe Asp Gly Tyr Leu Ala Ile Tyr Asn Asp Ser Asp Lys
 420 425 430
 45 Asn Lys Met Leu Pro Asp Met Val Val Gly Asp Val Val Lys Gln Val
 435 440 445
 Asn Ser Lys Pro Glu Gln His Phe Thr Gln Pro Pro Ala Arg Tyr Ser
 450 455 460
 Glu Ala Thr Leu Ile Lys Thr Leu Glu Glu Asn Gly Val Gly Arg Pro
 465 470 475 480
 55 Ser Thr Tyr Ala Pro Thr Ile Glu Thr Ile Gln Lys Arg Tyr Tyr Val
 485 490 495

Arg Leu Ala Ala Lys Arg Phe Glu Pro Thr Glu Leu Gly Glu Ile Val
 500 505 510
 5 sn Lys Leu Ile Val Glu Tyr Phe Pro Asp Ile Val Asn Val Thr Phe
 515 520 525
 Thr Ala Glu Met Glu Gly Lys Leu Asp Asp Val Glu Val Gly Lys Glu
 530 535 540
 10 Gln Trp Arg Arg Val Ile Asp Ala Phe Tyr Lys Pro Phe Ser Lys Glu
 545 550 555 560
 15 Val Ala Lys Ala Glu Glu Glu Met Glu Lys Ile Gln Ile Lys Asp Glu
 565 570 575
 Pro Ala Gly Phe Asp Cys Glu Val Cys Gly Ser Pro Met Val Ile Lys
 580 585 590
 20 Leu Gly Arg Phe Gly Lys Phe Tyr Ala Cys Ser Asn Phe Pro Asp Cys
 595 600 605
 Arg His Thr Gln Ala Ile Val Lys Glu Ile Gly Val Glu Cys Pro Ser
 610 615 620
 25 Cys His Gln Gly Gln Ile Ile Glu Arg Lys Thr Lys Arg Asn Arg Leu
 625 630 635 640
 30 Phe Tyr Gly Cys Asn Arg Tyr Pro Glu Cys Glu Phe Thr Ser Trp Asp
 645 650 655
 Lys Pro Val Gly Arg Asp Cys Pro Lys Cys Gly Asn Phe Leu Met Glu
 660 665 670
 35 Lys Lys Val Arg Gly Gly Gly Lys Gln Val Val Cys Ser Lys Gly Asp
 675 680 685
 Tyr Glu Glu Glu Lys Met Ala Leu Cys Gln Leu
 690 695
 40
 <210> 204
 <211> 326
 <212> PRT
 45 <213> Streptococcus pneumoniae
 <400> 204
 Met Phe Ile Ser Ile Ser Ala Gly Ile Val Thr Phe Leu Leu Thr Leu
 1 5 10 15
 50 Val Gly Ile Pro Ala Phe Ile Gln Phe Tyr Arg Lys Ala Gln Ile Thr
 20 25 30
 Gly Gln Gln Met His Glu Asp Val Lys Gln His Gln Ala Lys Ala Gly
 35 40 45
 55 Thr Pro Thr Met Gly Gly Leu Val Phe Leu Ile Thr Ser Val Leu Val

50 55 60
 Ala Phe Phe Phe Ala Leu Phe Ser Ser Gln Phe Ser Asn Asn Val Gly
 65 70 75 80
 5 Met Ile Leu Phe Ile Leu Val Leu Tyr Gly Leu Val Gly Phe Leu Asp
 85 90 95
 10 Asp Phe Leu Lys Val Phe Arg Lys Ile Asn Glu Gly Leu Asn Pro Lys
 100 105 110
 Gln Lys Leu Ala Leu Gln Leu Leu Gly Gly Val Ile Phe Tyr Leu Phe
 115 120 125
 15 Tyr Glu Arg Gly Gly Asp Met Leu Ser Val Phe Gly Tyr Gln Val His
 130 135 140
 Leu Gly Ile Phe Tyr Ile Val Phe Ala Leu Phe Trp Leu Val Gly Phe
 145 150 155 160
 20 Ser Asn Ala Val Asn Leu Thr Asp Gly Val Asp Gly Leu Ala Ser Ile
 165 170 175
 25 Ser Val Val Ile Ser Leu Ser Ala Tyr Gly Val Ile Ala Tyr Val Gln
 180 185 190
 Gly Gln Met Asp Ile Leu Leu Val Ile Leu Ala Met Ile Gly Gly Leu
 195 200 205
 30 Leu Ser Phe Phe Ile Phe Asn His Lys Pro Ala Lys Ile Phe Met Gly
 210 215 220
 Asp Val Gly Ser Leu Ala Leu Gly Gly Met Leu Ala Ala Ile Ser Met
 225 230 235 240
 35 Ala Leu His Gln Glu Trp Thr Leu Leu Ile Ile Gly Ile Val Tyr Val
 245 250 255
 40 Phe Glu Thr Thr Ser Val Met Met Gln Val Ser Tyr Phe Lys Leu Thr
 260 265 270
 Gly Gly Lys Arg Ile Phe Arg Met Thr Pro Val His His His Phe Glu
 275 280 285
 45 Leu Gly Gly Leu Ser Gly Lys Gly Asn Pro Trp Ser Glu Trp Lys Val
 290 295 300
 Asp Phe Phe Phe Trp Gly Val Gly Leu Leu Ala Ser Leu Leu Thr Leu
 305 310 315 320
 50 Ala Ile Leu Tyr Leu Met
 325
 55 <210> 205
 <211> 693
 <212> PRT

<213> Streptococcus pneumoniae

<400> 205

5 Met Ala Arg Glu Phe Ser Leu Glu Lys Thr Arg Asn Ile Gly Ile Met
 1 5 10 15
 Ala His Val Asp Ala Gly Lys Thr Thr Thr Thr Glu Arg Ile Leu Tyr
 20 25 30
 10 Tyr Thr Gly Lys Ile His Lys Ile Gly Glu Thr His Glu Gly Ala Ser
 35 40 45
 Gln Met Asp Trp Met Glu Gln Glu Gln Glu Arg Gly Ile Thr Ile Thr
 50 55 60
 15 Ser Ala Ala Thr Thr Ala Gln Trp Asn Asn His Arg Val Asn Ile Ile
 65 70 75 80
 Asp Thr Pro Gly His Val Asp Phe Thr Ile Glu Val Gln Arg Ser Leu
 85 90 95
 Arg Val Leu Asp Gly Ala Val Thr Val Leu Asp Ser Gln Ser Gly Val
 100 105 110
 25 Glu Pro Gln Thr Glu Thr Val Trp Arg Gln Ala Thr Glu Tyr Gly Val
 115 120 125
 Pro Arg Ile Val Phe Ala Asn Lys Met Asp Lys Ile Gly Ala Asp Phe
 130 135 140
 30 Leu Tyr Ser Val Ser Thr Leu His Asp Arg Leu Gln Ala Asn Ala His
 145 150 155 160
 Pro Ile Gln Leu Pro Ile Gly Ser Glu Asp Asp Phe Arg Gly Ile Ile
 165 170 175
 35 Asp Leu Ile Lys Met Lys Ala Glu Ile Tyr Thr Asn Asp Leu Gly Thr
 180 185 190
 40 Asp Ile Leu Glu Glu Asp Ile Pro Ala Glu Tyr Leu Asp Gln Ala Gln
 195 200 205
 Glu Tyr Arg Glu Lys Leu Ile Glu Ala Val Ala Glu Thr Asp Glu Glu
 210 215 220
 45 Leu Met Met Lys Tyr Leu Glu Gly Glu Glu Ile Thr Asn Glu Glu Leu
 225 230 235 240
 Lys Ala Gly Ile Arg Lys Ala Thr Ile Asn Val Glu Phe Phe Pro Val
 245 250 255
 50 Leu Cys Gly Ser Ala Phe Lys Asn Lys Gly Val Gln Leu Met Leu Asp
 260 265 270
 55 Ala Val Ile Asp Tyr Leu Pro Ser Pro Leu Asp Ile Pro Ala Ile Lys
 275 280 285

Gly Ile Asn Pro Asp Thr Asp Ala Glu Glu Ile Arg Pro Ala Ser Asp
 290 295 300
 5 Glu Glu Pro Phe Ala Ala Leu Ala Phe Lys Ile Met Thr Asp Pro Phe
 305 310 315 320
 Val Gly Arg Leu Thr Phe Phe Arg Val Tyr Ser Gly Val Leu Gln Ser
 325 330 335
 10 Gly Ser Tyr Val Leu Asn Thr Ser Lys Gly Lys Arg Glu Arg Ile Gly
 340 345 350
 Arg Ile Leu Gln Met His Ala Asn Ser Arg Gln Glu Ile Asp Thr Val
 355 360 365
 15 Tyr Ser Gly Asp Ile Ala Ala Ala Val Gly Leu Lys Asp Thr Thr Thr
 370 375 380
 20 Gly Asp Ser Leu Thr Asp Glu Lys Ala Lys Ile Ile Leu Glu Ser Ile
 385 390 395 400
 Asn Val Pro Glu Pro Val Ile Gln Leu Met Val Glu Pro Lys Ser Lys
 405 410 415
 25 Ala Asp Gln Asp Lys Met Gly Ile Ala Leu Gln Lys Leu Ala Glu Glu
 420 425 430
 Asp Pro Thr Phe Arg Val Glu Thr Asn Val Glu Thr Gly Glu Thr Val
 435 440 445
 30 Ile Ser Gly Met Gly Glu Leu His Leu Asp Val Leu Val Asp Arg Met
 450 455 460
 35 Arg Arg Glu Phe Lys Val Glu Ala Asn Val Gly Ala Pro Gln Val Ser
 465 470 475 480
 Tyr Arg Glu Thr Phe Arg Ala Ser Thr Gln Ala Arg Gly Phe Phe Lys
 485 490 495
 40 Arg Gln Ser Gly Gly Lys Gly Gln Phe Gly Asp Val Trp Ile Glu Phe
 500 505 510
 Thr Pro Asn Glu Glu Gly Lys Gly Phe Glu Phe Glu Asn Ala Ile Val
 515 520 525
 45 Gly Gly Val Val Pro Arg Glu Phe Ile Pro Ala Val Glu Lys Gly Leu
 530 535 540
 50 Val Glu Ser Met Ala Asn Gly Val Leu Ala Gly Tyr Pro Met Val Asp
 545 550 555 560
 Val Lys Ala Lys Leu Tyr Asp Gly Ser Tyr His Asp Val Asp Ser Ser
 565 570 575
 55 Glu Thr Ala Phe Lys Ile Ala Ala Ser Leu Ser Leu Lys Glu Ala Ala
 580 585 590

Lys Ser Ala Gln Pro Ala Ile Leu Glu Pro Met Met Leu Val Thr Ile
 595 600 605
 5 Thr Val Pro Glu Glu Asn Leu Gly Asp Val Met Gly His Val Thr Ala
 610 615 620
 Arg Arg Gly Arg Val Asp Gly Met Glu Ala His Gly Asn Ser Gln Ile
 625 630 635 640
 10 Val Arg Ala Tyr Val Pro Leu Ala Glu Met Phe Gly Tyr Ala Thr Val
 645 650 655
 Leu Arg Ser Ala Ser Gln Gly Arg Gly Thr Phe Met Met Val Phe Asp
 660 665 670
 15 His Tyr Glu Asp Val Pro Lys Ser Val Gln Glu Glu Ile Ile Lys Lys
 675 680 685
 20 Asn Lys Gly Glu Asp
 690
 <210> 206
 <211> 408
 25 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 206
 30 Met Pro Asn Tyr Asn Ile Pro Phe Ser Pro Pro Asp Ile Thr Glu Ala
 1 5 10 15
 Glu Ile Ala Glu Val Ala Asp Thr Leu Arg Ser Gly Trp Ile Thr Thr
 20 25 30
 35 Gly Pro Lys Thr Lys Glu Leu Glu Arg Arg Leu Ser Leu Tyr Thr Gln
 35 40 45
 Thr Pro Lys Thr Val Cys Leu Asn Ser Ala Thr Ala Ala Leu Glu Leu
 50 55 60
 40 Ile Leu Arg Val Leu Glu Val Gly Pro Gly Asp Glu Val Ile Val Pro
 65 70 75 80
 45 Ala Met Thr Tyr Thr Ala Ser Cys Ser Val Ile Thr His Val Gly Ala
 85 90 95
 Thr Pro Val Met Val Asp Ile Gln Ala Asp Thr Phe Glu Met Asp Tyr
 100 105 110
 50 Asp Leu Leu Glu Gln Ala Ile Thr Glu Lys Thr Lys Val Ile Ile Pro
 115 120 125
 Val Glu Leu Ala Gly Ile Val Cys Asp Tyr Asp Arg Leu Phe Gln Val
 130 135 140
 55 Val Glu Lys Lys Arg Asp Phe Phe Thr Ala Ser Ser Lys Trp Gln Lys
 145 150 155 160

Ala Phe Asn Arg Ile Val Ile Val Ser Asp Ser Ala His Ala Leu Gly
 165 170 175

5 Ser Thr Tyr Lys Gly Gln Pro Ser Gly Ser Ile Ala Asp Phe Thr Ser
 180 185 190

Phe Ser Phe His Ala Val Lys Asn Phe Thr Thr Ala Glu Gly Gly Ser
 195 200 205

10 Ala Thr Trp Lys Ala Asn Pro Val Ile Asp Asp Glu Glu Met Tyr Lys
 210 215 220

15 Glu Phe Gln Ile Leu Ser Leu His Gly Gln Thr Lys Asp Ala Leu Ala
 225 230 235 240

Lys Met Gln Leu Gly Ser Trp Glu Tyr Asp Ile Val Thr Pro Ala Tyr
 245 250 255

20 Lys Cys Asn Met Thr Asp Ile Met Ala Ser Leu Gly Leu Val Gln Leu
 260 265 270

Asp Arg Tyr Pro Ser Leu Leu Gln Arg Arg Lys Asp Ile Val Asp Arg
 275 280 285

25 Tyr Asp Ser Gly Phe Ala Gly Ser Arg Ile His Pro Leu Ala His Lys
 290 295 300

30 Thr Glu Thr Val Glu Ser Ser Arg His Leu Tyr Ile Thr Arg Val Glu
 305 310 315 320

Gly Ala Ser Leu Glu Glu Arg Ser Leu Ile Ile Gln Glu Leu Ala Lys
 325 330 335

35 Ala Gly Ile Ala Ser Asn Val His Tyr Lys Pro Leu Pro Leu Leu Thr
 340 345 350

Ala Tyr Lys Asn Leu Gly Phe Asp Met Thr Asn Tyr Pro Lys Ala Tyr
 355 360 365

40 Ala Phe Phe Glu Asn Glu Ile Thr Leu Pro Leu His Thr Lys Leu Ser
 370 375 380

45 Asp Glu Glu Val Asp Tyr Ile Ile Glu Thr Phe Lys Thr Val Ser Glu
 385 390 395 400

Lys Val Leu Thr Leu Ser Lys Lys
 405

50
 <210> 207
 <211> 325
 <212> PRT
 <213> Streptococcus pneumoniae

55
 <400> 207
 Met Thr Glu Pro Asp Phe Trp Asn Asp Asn Ile Ala Ala Gln Lys Thr

1 5 10 15
 Ser Gln Glu Leu Asn Val Phe Lys Asn Thr Tyr Asn Thr Phe His Lys
 20 25 30
 5 Met Glu Glu Leu Gln Asp Glu Val Glu Ile Leu Leu Asp Phe Leu Ala
 35 40 45
 10 Glu Asp Glu Ser Val His Asp Glu Leu Val Ala Gln Leu Ala Glu Leu
 50 55 60
 Asp Lys Ile Met Thr Ser Tyr Glu Met Thr Leu Leu Leu Ser Glu Pro
 65 70 75 80
 15 Tyr Asp His Asn Asn Ala Ile Leu Glu Ile His Pro Gly Ser Gly Gly
 85 90 95
 Thr Glu Ala Gln Asp Trp Gly Asp Met Leu Leu Arg Met Tyr Thr Arg
 100 105 110
 20 Tyr Gly Asn Ala Lys Gly Phe Lys Val Glu Val Leu Asp Tyr Gln Ala
 115 120 125
 25 Gly Asp Glu Ala Gly Ile Lys Ser Val Thr Leu Ser Phe Glu Gly Pro
 130 135 140
 Asn Ala Tyr Gly Leu Leu Lys Ser Glu Met Gly Val His Arg Leu Val
 145 150 155 160
 30 Arg Ile Ser Pro Phe Asp Ser Ala Lys Arg Arg His Thr Ser Phe Thr
 165 170 175
 Ser Val Glu Val Met Pro Glu Leu Asp Asp Thr Ile Glu Val Glu Ile
 180 185 190
 35 Arg Glu Asp Asp Ile Lys Met Asp Thr Phe Arg Ser Gly Gly Ala Gly
 195 200 205
 40 Gly Gln Asn Val Asn Lys Val Ser Thr Gly Val Arg Leu Thr His Ile
 210 215 220
 Pro Thr Gly Ile Val Val Gln Ser Thr Val Asp Arg Thr Gln Tyr Gly
 225 230 235 240
 45 Asn Arg Asp Arg Ala Met Lys Met Leu Gln Ala Lys Leu Tyr Gln Met
 245 250 255
 50 Glu Gln Glu Lys Lys Ala Ala Glu Val Asp Ser Leu Lys Gly Glu Lys
 260 265 270
 Lys Glu Ile Thr Trp Gly Ser Gln Ile Arg Ser Tyr Val Phe Thr Pro
 275 280 285
 55 Tyr Thr Met Val Lys Asp His Arg Thr Ser Phe Glu Val Ala Gln Val
 290 295 300
 Asp Lys Val Met Asp Gly Asp Leu Asp Gly Phe Ile Asp Ala Tyr Leu

305 310 315 320
 Lys Trp Arg Ile Ser
 325
 5
 <210> 208
 <211> 249
 <212> PRT
 10 <213> Streptococcus pneumoniae
 <400> 208
 Met Phe Tyr Thr Tyr Leu Arg Gly Leu Val Val Leu Leu Leu Trp Ser
 1 5 10 15
 15 Ile Asn Gly Asn Ala His Tyr His Asn Thr Asp Lys Ile Pro Asn Gln
 20 25 30
 20 Asp Glu Asn Tyr Ile Leu Val Ala Pro His Arg Thr Trp Trp Asp Pro
 35 40 45
 Val Tyr Met Ala Phe Ala Thr Lys Pro Lys Gln Phe Ile Phe Met Ala
 50 55 60
 25 Lys Lys Glu Leu Phe Thr Asn Arg Ile Phe Gly Trp Trp Ile Arg Met
 65 70 75 80
 Cys Gly Ala Phe Pro Ile Asp Arg Glu Asn Pro Ser Ala Ser Ala Ile
 85 90 95
 30 Lys Tyr Pro Ile Asn Val Leu Lys Lys Ser Asp Arg Ser Leu Ile Met
 100 105 110
 35 Phe Pro Ser Gly Ser Arg His Ser Asn Asp Val Lys Gly Gly Ala Ala
 115 120 125
 Leu Ile Ala Lys Met Ala Lys Val Arg Ile Met Pro Val Thr Tyr Thr
 130 135 140
 40 Gly Pro Met Thr Leu Lys Gly Leu Ile Ser Arg Glu Arg Val Asp Met
 145 150 155 160
 Asn Phe Gly Asn Pro Ile Asp Ile Ser Asp Ile Lys Lys Met Asn Asp
 165 170 175
 45 Glu Gly Ile Glu Thr Val Ala Asn Arg Ile Gln Thr Glu Phe Gln Arg
 180 185 190
 50 Leu Asp Glu Glu Thr Lys Gln Trp His Asn Asp Lys Lys Pro Asn Pro
 195 200 205
 Leu Trp Trp Phe Ile Arg Ile Pro Ala Leu Ile Leu Ala Ile Ile Leu
 210 215 220
 55 Ala Ile Leu Thr Ile Ile Phe Ser Phe Ile Ala Ser Phe Ile Trp Asn
 225 230 235 240

Pro Asp Lys Lys Arg Glu Glu Leu Ala
245

- 5 <210> 209
<211> 1033
<212> PRT
<213> Streptococcus pneumoniae
- 10 <400> 209
Met Ile Ala Gln Leu Asp Thr Lys Thr Val Tyr Ser Phe Met Glu Ser
1 5 10 15
Val Ile Ser Ile Glu Lys Tyr Val Arg Ala Ala Lys Glu Tyr Gly Tyr
15 20 25 30
Thr His Leu Ala Met Met Asp Ile Asp Asn Leu Tyr Gly Ala Phe Asp
35 40 45
20 Phe Leu Glu Ile Thr Lys Lys Tyr Gly Ile His Pro Leu Leu Gly Leu
50 55 60
Glu Met Thr Val Phe Val Asp Asp Gln Gly Val Asn Leu Arg Phe Leu
65 70 75 80
25 Ala Leu Ser Ser Val Gly Tyr Gln Gln Leu Met Lys Leu Ser Thr Ala
85 90 95
Lys Met Gln Gly Glu Lys Thr Trp Ser Val Leu Ser Gln Tyr Leu Glu
30 100 105 110
Asp Ile Ala Val Ile Val Pro Tyr Phe Asp Arg Val Glu Ser Leu Glu
115 120 125
35 Leu Gly Cys Asp Tyr Tyr Ile Gly Val Tyr Pro Glu Thr Leu Ala Ser
130 135 140
Glu Phe His His Pro Ile Leu Pro Leu Tyr Arg Val Asn Ala Phe Glu
145 150 155 160
40 Ser Arg Asp Arg Glu Val Leu Gln Val Leu Thr Ala Ile Lys Glu Asn
165 170 175
Leu Pro Leu Arg Glu Val Pro Leu Arg Ser Arg Gln Asp Val Phe Ile
45 180 185 190
Ser Ala Ser Ser Leu Glu Lys Leu Phe Gln Glu Arg Phe Pro Gln Ala
195 200 205
50 Leu Asp Asn Leu Glu Lys Leu Ile Ser Gly Ile Ser Tyr Asp Leu Asp
210 215 220
Thr Ser Leu Lys Leu Pro Arg Phe Asn Pro Ala Arg Pro Ala Val Glu
225 230 235 240
55 Glu Leu Arg Glu Arg Ala Glu Leu Gly Leu Val Gln Lys Gly Leu Thr
245 250 255

Ser Lys Glu Tyr Gln Asp Arg Leu Asp Gln Glu Leu Ser Val Ile His
 260 265 270
 5 Asp Met Gly Phe Asp Asp Tyr Phe Leu Val Val Trp Asp Leu Leu Arg
 275 280 285
 Phe Gly Arg Ser Asn Gly Tyr Tyr Met Gly Met Gly Arg Gly Ser Ala
 290 295 300
 10 Val Gly Ser Leu Val Ser Tyr Ala Leu Asp Ile Thr Gly Ile Asp Pro
 305 310 315 320
 Val Glu Lys Asn Leu Ile Phe Glu Arg Phe Leu Asn Arg Glu Arg Tyr
 15 325 330 335
 Thr Met Pro Asp Ile Asp Ile Asp Ile Pro Asp Ile Tyr Arg Pro Asp
 340 345 350
 20 Phe Ile Arg Tyr Val Gly Asn Lys Tyr Gly Ser Lys His Ala Ala Gln
 355 360 365
 Ile Val Thr Phe Ser Thr Phe Gly Ala Lys Gln Ala Leu Arg Asp Val
 370 375 380
 25 Leu Lys Arg Phe Gly Val Pro Glu Tyr Glu Leu Ser Ala Ile Thr Lys
 385 390 395 400
 Lys Ile Ser Phe Arg Asp Asn Leu Lys Ser Ala Tyr Glu Gly Asn Leu
 30 405 410 415
 Gln Phe Arg Gln Gln Ile Asn Ser Lys Leu Glu Tyr Gln Lys Ala Phe
 420 425 430
 35 Glu Ile Ala Cys Lys Ile Glu Gly Tyr Pro Arg Gln Thr Ser Val His
 435 440 445
 Ala Ala Gly Val Val Ile Ser Asp Gln Asp Leu Thr Asn Tyr Ile Pro
 40 450 455 460
 Leu Lys Tyr Gly Asp Glu Ile Pro Leu Thr Gln Tyr Asp Ala His Gly
 465 470 475 480
 45 Val Glu Ala Ser Gly Leu Leu Lys Met Asp Phe Leu Gly Leu Arg Asn
 485 490 495
 Leu Thr Phe Val Gln Lys Met Gln Glu Leu Leu Ala Glu Ile Glu Gly
 500 505 510
 50 Ile His Leu Lys Ile Glu Glu Ile Asp Leu Glu Asp Lys Glu Thr Leu
 515 520 525
 Asp Leu Phe Ala Ser Gly Asn Thr Lys Gly Ile Phe Gln Phe Glu Gln
 530 535 540
 55 Pro Gly Ala Ile Arg Leu Lys Arg Val Gln Pro Val Cys Phe Glu
 545 550 555 560

Asp Val Val Ala Thr Thr Ser Leu Asn Arg Pro Gly Ala Ser Asp Tyr
 565 570 575
 5 Ile Asn Asn Phe Val Ala Arg Lys His Gly Gln Glu Glu Val Thr Val
 580 585 590
 Leu Asp Pro Val Leu Glu Asp Ile Leu Ala Pro Thr Tyr Gly Ile Met
 595 600 605
 10 Leu Tyr Gln Glu Gln Val Met Gln Val Ala Gln Arg Phe Ala Gly Phe
 610 615 620
 Ser Leu Gly Lys Ala Asp Ile Leu Arg Arg Ala Met Gly Lys Lys Asp
 625 630 635 640
 15 Ala Ser Ala Met His Glu Met Arg Ala Ser Phe Ile Gln Gly Ser Leu
 645 650 655
 Glu Ala Gly His Thr Val Glu Lys Ala Glu Gln Val Phe Asp Val Met
 660 665 670
 20 Glu Lys Phe Ala Gly Tyr Gly Phe Asn Arg Ser His Ala Tyr Ala Tyr
 675 680 685
 25 Ser Ala Leu Ala Phe Gln Leu Ala Tyr Phe Lys Thr His Tyr Pro Ala
 690 695 700
 Ile Phe Tyr Gln Ile Met Leu Asn Ser Ala Asn Ser Asp Tyr Leu Ile
 705 710 715 720
 Asp Ala Leu Glu Ala Gly Phe Glu Val Ala Pro Leu Ser Ile Asn Thr
 725 730 735
 35 Ile Pro Tyr His Asp Lys Ile Ala Asn Lys Ala Ile Tyr Leu Gly Leu
 740 745 750
 Lys Ser Ile Lys Gly Val Ser Asn Asp Leu Ala Leu Trp Ile Ile Glu
 755 760 765
 40 His Arg Pro Tyr Ser Asn Ile Glu Asp Phe Ile Ala Lys Leu Pro Glu
 770 775 780
 Asn Tyr Leu Lys Leu Pro Leu Leu Glu Pro Leu Val Lys Val Gly Leu
 785 790 795 800
 Phe Asp Ser Phe Glu Lys Asn Arg Gln Lys Val Phe Asn Asn Leu Ala
 805 810 815
 50 Asn Leu Phe Glu Phe Val Lys Glu Leu Gly Ser Leu Phe Gly Asp Ala
 820 825 830
 Ile Tyr Ser Trp Gln Glu Ser Glu Asp Trp Thr Glu Gln Glu Lys Phe
 835 840 845
 55 Tyr Met Glu Gln Glu Leu Leu Gly Ile Gly Val Ser Lys His Pro Leu
 850 855 860

Gln Ala Ile Ala Ser Lys Ala Ile Tyr Pro Ile Thr Pro Ile Gly Asn
 865 870 875 880
 5 Leu Ser Glu Asn Ser Tyr Ala Ile Ile Leu Val Glu Val Gln Lys Ile
 885 890 895
 Lys Val Ile Arg Thr Lys Lys Gly Glu Asn Met Ala Phe Leu Gln Ala
 900 905 910
 10 Asp Asp Ser Lys Lys Lys Leu Asp Val Thr Leu Phe Ser Asp Leu Tyr
 915 920 925
 15 Arg Gln Val Gly Gln Glu Ile Lys Glu Gly Ala Phe Tyr Tyr Val Lys
 930 935 940
 Gly Lys Ile Gln Ser Arg Asp Gly Arg Leu Gln Met Ile Ala Gln Glu
 945 950 955 960
 20 Ile Arg Glu Ala Val Ala Glu Arg Phe Trp Ile Gln Val Lys Asn His
 965 970 975
 Glu Ser Asp Gln Glu Ile Ser Arg Ile Leu Glu Gln Phe Lys Gly Pro
 980 985 990
 25 Ile Pro Val Ile Ile Arg Tyr Glu Glu Glu Gln Lys Thr Ile Val Ser
 995 1000 1005
 30 Pro His His Phe Val Ala Lys Ser Asn Glu Leu Glu Glu Lys Leu Asn
 1010 1015 1020
 Glu Ile Val Met Lys Thr Ile Tyr Arg
 1025 1030
 35
 <210> 210
 <211> 306
 <212> PRT
 <213> Streptococcus pneumoniae
 40
 <400> 210
 Met Thr Asn Glu Phe Leu His Phe Glu Lys Ile Ser Arg Gln Thr Trp
 1 5 10 15
 45 Gln Ser Leu His Arg Lys Thr Thr Pro Pro Leu Thr Glu Glu Glu Leu
 20 25 30
 Glu Ser Ile Lys Ser Phe Asn Asp Gln Ile Ser Leu Gln Asp Val Thr
 35 40 45
 50 Asp Ile Tyr Leu Pro Leu Ala His Leu Ile Gln Ile Tyr Lys Arg Thr
 50 55 60
 55 Lys Glu Asp Leu Ala Phe Ser Lys Gly Ile Phe Leu Gln Arg Glu Ser
 65 70 75 80
 Lys Ser Gln Pro Phe Ile Ile Gly Val Ser Gly Ser Val Ala Val Gly

85 90 95

5 Lys Ser Thr Thr Ser Arg Leu Leu Gln Ile Leu Leu Ser Arg Thr Phe
100 105 110

Thr Asp Ala Thr Val Glu Leu Val Thr Thr Asp Gly Phe Leu Tyr Pro
115 120 125

10 Asn Gln Thr Leu Ile Glu Gln Gly Ile Leu Asn Arg Lys Gly Phe Pro
130 135 140

Glu Ser Tyr Asp Met Glu Ala Leu Leu Asn Phe Leu Asp Arg Ile Lys
145 150 155 160

15 Asn Gly Gln Asp Val Asp Ile Pro Val Tyr Ser His Glu Val Tyr Asp
165 170 175

Ile Val Pro Lys Lys Lys Gln Ser Val Lys Ala Ala Asp Phe Val Ile
180 185 190

20 Val Glu Gly Ile Asn Val Phe Gln Asn Pro Gln Asn Asp Arg Leu Tyr
195 200 205

Ile Thr Asp Phe Phe Asp Phe Ser Ile Tyr Val Asp Ala Gly Val Asp
210 215 220

25 Asp Ile Glu Ser Trp Tyr Leu Asp Arg Phe Leu Lys Met Leu Ser Leu
225 230 235 240

30 Ala Gln Asn Asp Pro Asp Ser Tyr Tyr Tyr Arg Phe Thr Gln Met Pro
245 250 255

Ile Gly Glu Val Glu Ser Phe Ala His Gln Val Trp Thr Ser Ile Asn
260 265 270

35 Leu Thr Asn Leu Gln Asn Tyr Ile Glu Pro Thr Arg Asn Arg Ala Glu
275 280 285

40 Val Ile Leu His Lys Ser Lys Asn His Glu Ile Asp Glu Ile Tyr Leu
290 295 300

Lys Lys
305

45 <210> 211
<211> 246
<212> PRT
<213> Streptococcus pneumoniae

50 <400> 211
Met Glu Ile Ser Leu Leu Thr Asp Val Gly Gln Lys Arg Thr Asn Asn
1 5 10 15

55 Gln Asp Tyr Val Asn His Tyr Val Asn Arg Ala Gly Arg Thr Met Ile
20 25 30

Ile Leu Ala Asp Gly Met Gly Gly His Arg Ala Gly Asn Ile Ala Ser
 35 40 45
 5 Glu Met Ala Val Thr Asp Leu Gly Val Ala Trp Val Asp Thr Gln Ile
 50 55 60
 Asp Thr Val Asn Glu Val Arg Glu Trp Phe Ala His Tyr Leu Glu Ile
 65 70 75 80
 10 Glu Asn Gln Lys Ile His Gln Leu Gly Gln Asp Glu Ala Tyr Arg Gly
 85 90 95
 Met Gly Thr Thr Leu Glu Val Leu Ala Ile Ile Asp Asn Gln Ala Ile
 100 105 110
 15 Tyr Ala His Ile Gly Asp Ser Arg Ile Gly Leu Ile Arg Gly Glu Glu
 115 120 125
 Tyr His Gln Leu Thr Ser Asp His Ser Leu Val Asn Glu Leu Leu Lys
 130 135 140
 Ala Gly Gln Leu Thr Pro Glu Glu Ala Glu Ala His Pro Gln Lys Asn
 145 150 155 160
 25 Ile Ile Thr Gln Ser Ile Gly Gln Lys Asp Glu Ile Gln Pro Asp Phe
 165 170 175
 Gly Thr Val Ile Leu Glu Ser Gly Asp Tyr Leu Leu Leu Asn Ser Asp
 180 185 190
 30 Gly Leu Thr Asn Met Ile Ser Gly Ser Glu Ile Arg Asp Ile Val Thr
 195 200 205
 Ser Asp Ile Pro Leu Ala Asp Lys Thr Glu Thr Leu Val Arg Phe Ala
 210 215 220
 Asn Asn Ala Gly Gly Leu Asp Asn Ile Thr Val Ala Leu Val Ser Met
 225 230 235 240
 40 Asn Glu Glu Asp Glu Glu
 245
 45 <210> 212
 <211> 276
 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 212
 50 Met Thr Ile Gln Met Lys Asn Thr Gly Lys Arg Ile Asp Leu Ile Ala
 1 5 10 15
 Asn Arg Lys Pro Gln Ser Gln Arg Val Leu Tyr Glu Leu Arg Asp Arg
 20 25 30
 55 Leu Lys Arg Asn Gln Phe Ile Leu Asn Asp Thr Asn Pro Asp Ile Val
 35 40 45

Ile Ser Ile Gly Gly Asp Gly Met Leu Leu Ser Ala Phe His Lys Tyr
 50 55 60
 5 Glu Asn Gln Leu Asp Lys Val Arg Phe Ile Gly Leu His Thr Gly His
 65 70 75 80
 Leu Gly Phe Tyr Thr Asp Tyr Arg Asp Phe Glu Leu Asp Lys Leu Val
 85 90 95
 10 Thr Asn Leu Gln Leu Asp Thr Gly Ala Arg Val Ser Tyr Pro Val Leu
 100 105 110
 15 Asn Val Lys Val Phe Leu Glu Asn Gly Glu Val Lys Ile Phe Arg Ala
 115 120 125
 Leu Asn Glu Ala Ser Ile Arg Arg Ser Asp Arg Thr Met Val Ala Asp
 130 135 140
 20 Ile Val Ile Asn Gly Val Pro Phe Glu Arg Phe Arg Gly Asp Gly Leu
 145 150 155 160
 Thr Val Ser Thr Pro Thr Gly Ser Thr Ala Tyr Asn Lys Ser Leu Gly
 165 170 175
 25 Gly Ala Val Leu His Pro Thr Ile Glu Ala Leu Gln Leu Thr Glu Ile
 180 185 190
 30 Ala Ser Leu Asn Asn Arg Val Tyr Arg Thr Leu Gly Ser Ser Ile Ile
 195 200 205
 Val Pro Lys Lys Asp Lys Ile Glu Leu Ile Pro Thr Arg Asn Asp Tyr
 210 215 220
 35 His Thr Ile Ser Val Asp Asn Ser Val Tyr Ser Phe Arg Asn Ile Glu
 225 230 235 240
 Arg Ile Glu Tyr Gln Ile Asp His His Lys Ile His Phe Val Ala Thr
 245 250 255
 40 Pro Ser His Thr Ser Phe Trp Asn Arg Val Lys Asp Ala Phe Ile Gly
 260 265 270
 45 Glu Val Asp Glu
 275
 <210> 213
 <211> 540
 50 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 213
 55 Met Ser Lys Glu Ile Lys Phe Ser Ser Asp Ala Arg Ser Ala Met Val
 1 5 10 15
 Arg Gly Val Asp Ile Leu Ala Asp Thr Val Lys Val Thr Leu Gly Pro

	20	25	30
	Lys Gly Arg Asn Val Val Leu Glu Lys Ser Phe Gly Ser Pro Leu Ile		
	35	40	45
5	Thr Asn Asp Gly Val Thr Ile Ala Lys Glu Ile Glu Leu Glu Asp His		
	50	55	60
10	Phe Glu Asn Met Gly Ala Lys Leu Val Ser Glu Val Ala Ser Lys Thr		
	65	70	75
	Asn Asp Ile Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Thr Gln		
	85	90	95
15	Ala Ile Val Arg Glu Gly Ile Lys Asn Val Thr Ala Gly Ala Asn Pro		
	100	105	110
	Ile Gly Ile Arg Arg Gly Ile Glu Thr Ala Val Ala Ala Val Glu		
	115	120	125
20	Ala Leu Lys Asn Asn Ala Ile Pro Val Ala Asn Lys Glu Ala Ile Ala		
	130	135	140
	Gln Val Ala Ala Val Ser Ser Arg Ser Glu Lys Val Gly Glu Tyr Ile		
25	145	150	155
	Ser Glu Ala Met Glu Lys Val Gly Lys Asp Gly Val Ile Thr Ile Glu		
	165	170	175
30	Glu Ser Arg Gly Met Glu Thr Glu Leu Glu Val Val Glu Gly Met Gln		
	180	185	190
	Phe Asp Arg Gly Tyr Leu Ser Gln Tyr Met Val Thr Asp Ser Glu Lys		
	195	200	205
35	Met Val Ala Asp Leu Glu Asn Pro Tyr Ile Leu Ile Thr Asp Lys Lys		
	210	215	220
	Ile Ser Asn Ile Gln Glu Ile Leu Pro Leu Leu Glu Ser Ile Leu Gln		
40	225	230	235
	Ser Asn Arg Pro Leu Leu Ile Ile Ala Asp Asp Val Asp Gly Glu Ala		
	245	250	255
45	Leu Pro Thr Leu Val Leu Asn Lys Ile Arg Gly Thr Phe Asn Val Val		
	260	265	270
	Ala Val Lys Ala Pro Gly Phe Gly Asp Arg Arg Lys Ala Met Leu Glu		
	275	280	285
50	Asp Ile Ala Ile Leu Thr Gly Gly Thr Val Ile Thr Glu Asp Leu Gly		
	290	295	300
	Leu Glu Leu Lys Asp Ala Thr Ile Glu Ala Leu Gly Gln Ala Ala Arg		
55	305	310	315
	Val Thr Val Asp Lys Asp Ser Thr Val Ile Val Glu Gly Ala Gly Asn		

	325	330	335
	Pro Glu Ala Ile Ser His Arg Val Ala Val Ile Lys Ser Gln Ile Glu		
	340	345	350
5	Thr Thr Thr Ser Glu Phe Asp Arg Glu Lys Leu Gln Glu Arg Leu Ala		
	355	360	365
10	Lys Leu Ser Gly Gly Val Ala Val Ile Lys Val Gly Ala Ala Thr Glu		
	370	375	380
	Thr Glu Leu Lys Glu Met Lys Leu Arg Ile Glu Asp Ala Leu Asn Ala		
	385	390	395
15	Thr Arg Ala Ala Val Glu Glu Gly Ile Val Ala Gly Gly Gly Thr Ala		
	405	410	415
	Leu Ala Asn Val Ile Pro Ala Val Ala Thr Leu Glu Leu Thr Gly Asp		
20	420	425	430
	Glu Ala Thr Gly Arg Asn Ile Val Leu Arg Ala Leu Glu Glu Pro Val		
	435	440	445
25	Arg Gln Ile Ala His Asn Ala Gly Phe Glu Gly Ser Ile Val Ile Asp		
	450	455	460
	Arg Leu Lys Asn Ala Glu Leu Gly Ile Gly Phe Asn Ala Ala Thr Gly		
	465	470	475
30	Glu Trp Val Asn Met Ile Asp Gln Gly Ile Ile Asp Pro Val Lys Val		
	485	490	495
	Ser Arg Ser Ala Leu Gln Asn Ala Ala Ser Val Ala Ser Leu Ile Leu		
35	500	505	510
	Thr Thr Glu Ala Val Val Ala Asn Lys Pro Glu Pro Val Ala Pro Ala		
	515	520	525
40	Pro Ala Met Asp Pro Ser Met Met Gly Gly Met Met		
	530	535	540
	<210> 214		
	<211> 481		
45	<212> PRT		
	<213> Streptococcus pneumoniae		
	<400> 214		
50	Met Ile Lys Ile Glu Thr Val Leu Asp Ile Leu Lys Lys Asp Gly Leu		
	1	5	10
	Phe Arg Glu Ile Ile Asp Gln Gly His Tyr His Tyr Asn Tyr Ser Lys		
	20	25	30
55	Val Ile Phe Asp Ser Ile Ser Tyr Asp Ser Arg Lys Val Thr Glu Asp		
	35	40	45

Thr Leu Phe Phe Ala Lys Gly Ala Ala Phe Lys Lys Glu Tyr Leu Leu
 50 55 60
 5 Ser Ala Ile Thr Gln Gly Leu Ala Trp Tyr Val Ala Glu Lys Asp Tyr
 65 70 75 80
 Glu Val Gly Ile Pro Val Ile Ile Val Asn Asp Ile Lys Lys Ala Met
 85 90 95
 10 Ser Leu Ile Ala Met Glu Phe Tyr Gly Asn Pro Gln Glu Lys Leu Lys
 100 105 110
 Leu Leu Ala Phe Thr Gly Thr Lys Gly Lys Thr Thr Ala Ala Tyr Phe
 115 120 125
 15 Ala Tyr Asn Ile Leu Ser Gln Gly His Arg Pro Ala Met Leu Ser Thr
 130 135 140
 20 Met Asn Thr Thr Leu Asp Gly Glu Thr Phe Phe Lys Ser Ala Leu Thr
 145 150 155 160
 Thr Pro Glu Ser Ile Asp Leu Phe Asp Met Met Asn Gln Ala Val Gln
 165 170 175
 25 Asn Asp Arg Thr His Leu Ile Met Glu Val Ser Ser Gln Ala Tyr Leu
 180 185 190
 Val Lys Arg Val Tyr Gly Leu Thr Phe Asp Val Gly Val Phe Leu Asn
 195 200 205
 30 Ile Ser Pro Asp His Ile Gly Pro Ile Glu His Pro Ser Phe Glu Asp
 210 215 220
 35 Tyr Phe Tyr His Lys Arg Leu Leu Met Glu Lys Ser Arg Ala Val Ile
 225 230 235 240
 Ile Asn Ser Asp Met Asp His Phe Ser Val Leu Lys Glu Gln Val Glu
 245 250 255
 40 Asp Gln Asp His Asp Phe Tyr Gly Ser Gln Phe Asp Asn Gln Ile Glu
 260 265 270
 Asn Ser Lys Ala Phe Ser Phe Ser Ala Thr Gly Lys Leu Ala Gly Asp
 275 280 285
 45 Tyr Asp Ile Gln Leu Ile Gly Asn Phe Asn Gln Glu Asn Ala Val Ala
 290 295 300
 50 Ala Gly Leu Ala Cys Leu Arg Leu Gly Ala Ser Leu Glu Asp Ile Lys
 305 310 315 320
 Lys Gly Ile Ala Ala Thr Arg Val Pro Gly Arg Met Glu Val Leu Thr
 325 330 335
 55 Gln Lys Asn Gly Ala Lys Val Phe Ile Asp Tyr Ala His Asn Gly Asp
 340 345 350

Ser Leu Lys Lys Leu Ile Asn Val Val Glu Thr His Gln Thr Gly Lys
 355 360 365
 5 Ile Ala Leu Val Leu Gly Ser Thr Gly Asn Lys Gly Glu Ser Arg Arg
 370 375 380
 Lys Asp Phe Gly Leu Leu Leu Asn Gln His Pro Glu Ile Gln Val Phe
 385 390 395 400
 10 Leu Thr Ala Asp Asp Pro Asn Tyr Glu Asp Pro Met Ala Ile Ala Asp
 405 410 415
 Glu Ile Ser Ser Tyr Ile Asn His Pro Val Glu Lys Ile Ala Asp Arg
 420 425 430
 15 Gln Glu Ala Ile Lys Ala Ala Met Ala Ile Thr Asn His Glu Leu Asp
 435 440 445
 Ala Val Ile Ile Ala Gly Lys Gly Ala Asp Cys Tyr Gln Ile Ile Gln
 20 450 455 460
 Gly Lys Lys Glu Ser Tyr Pro Gly Asp Thr Ala Val Ala Glu Asn Tyr
 465 470 475 480
 25 Leu
 30 <210> 215
 <211> 659
 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 215
 35 Met Ile Gln Ile Gly Lys Ile Phe Ala Gly Arg Tyr Arg Ile Val Lys
 1 5 10 15
 Gln Ile Gly Arg Gly Gly Met Ala Asp Val Tyr Leu Ala Lys Asp Leu
 20 25 30
 40 Ile Leu Asp Gly Glu Glu Val Ala Val Lys Val Leu Arg Thr Asn Tyr
 35 40 45
 45 Gln Thr Asp Pro Ile Ala Val Ala Arg Phe Gln Arg Glu Ala Arg Ala
 50 55 60
 Met Ala Asp Leu Asp His Pro His Ile Val Arg Ile Thr Asp Ile Gly
 65 70 75 80
 50 Glu Glu Asp Gly Gln Gln Tyr Leu Ala Met Glu Tyr Val Ala Gly Leu
 85 90 95
 Asp Leu Lys Arg Tyr Ile Lys Glu His Tyr Pro Leu Ser Asn Glu Glu
 100 105 110
 55 Ala Val Arg Ile Met Gly Gln Ile Leu Leu Ala Met Arg Leu Ala His
 115 120 125

Thr Arg Gly Ile Val His Arg Asp Leu Lys Pro Gln Asn Ile Leu Leu
 130 135 140

5 Thr Pro Asp Gly Thr Ala Lys Val Thr Asp Phe Gly Ile Ala Val Ala
 145 150 155 160

Phe Ala Glu Thr Ser Leu Thr Gln Thr Asn Ser Met Leu Gly Ser Val
 165 170 175

10 His Tyr Leu Ser Pro Glu Gln Ala Arg Gly Ser Lys Ala Thr Val Gln
 180 185 190

15 Ser Asp Ile Tyr Ala Met Gly Ile Ile Phe Tyr Glu Met Leu Thr Gly
 195 200 205

His Ile Pro Tyr Asp Gly Asp Ser Ala Val Thr Ile Ala Leu Gln His
 210 215 220

20 Phe Gln Lys Pro Leu Pro Ser Val Ile Ala Glu Asn Pro Ser Val Pro
 225 230 235 240

Gln Ala Leu Glu Asn Val Ile Ile Lys Ala Thr Ala Lys Lys Leu Thr
 245 250 255

25 Asn Arg Tyr Arg Ser Val Ser Glu Met Tyr Val Asp Leu Ser Ser Ser
 260 265 270

30 Leu Ser Tyr Asn Arg Arg Asn Glu Ser Lys Leu Ile Phe Asp Glu Thr
 275 280 285

Ser Lys Ala Asp Thr Lys Thr Leu Pro Lys Val Ser Gln Ser Thr Leu
 290 295 300

35 Thr Ser Ile Pro Lys Val Gln Ala Gln Thr Glu His Lys Ser Ile Lys
 305 310 315 320

Asn Pro Ser Gln Ala Val Thr Glu Glu Thr Tyr Gln Pro Gln Ala Pro
 325 330 335

40 Lys Lys His Arg Phe Lys Met Arg Tyr Leu Ile Leu Leu Ala Ser Leu
 340 345 350

45 Val Leu Val Ala Ala Ser Leu Ile Trp Ile Leu Ser Arg Thr Pro Ala
 355 360 365

Thr Ile Ala Ile Pro Asp Val Ala Gly Gln Thr Val Ala Glu Ala Lys
 370 375 380

50 Ala Thr Leu Lys Lys Ala Asn Phe Glu Ile Gly Glu Glu Lys Thr Glu
 385 390 395 400

Ala Ser Glu Lys Val Glu Glu Gly Arg Ile Ile Arg Thr Asp Pro Gly
 405 410 415

55 Ala Gly Thr Gly Arg Lys Glu Gly Thr Lys Ile Asn Leu Val Val Ser
 420 425 430

Ser Gly Lys Gln Ser Phe Gln Ile Ser Asn Tyr Val Gly Arg Lys Ser
 435 440 445
 5 Ser Asp Val Ile Ala Glu Leu Lys Glu Lys Lys Val Pro Asp Asn Leu
 450 455 460
 Ile Lys Ile Glu Glu Glu Glu Ser Asn Glu Ser Glu Ala Gly Thr Val
 465 470 475 480
 10 Leu Lys Gln Ser Leu Pro Glu Gly Thr Thr Tyr Asp Leu Ser Lys Ala
 485 490 495
 15 Thr Gln Ile Val Leu Thr Val Ala Lys Lys Ala Thr Thr Ile Gln Leu
 500 505 510
 Gly Asn Tyr Ile Gly Arg Asn Ser Thr Glu Val Ile Ser Glu Leu Lys
 515 520 525
 20 Gln Lys Lys Val Pro Glu Asn Leu Ile Lys Ile Glu Glu Glu Glu Ser
 530 535 540
 Ser Glu Ser Glu Pro Gly Thr Ile Met Lys Gln Ser Pro Gly Ala Gly
 545 550 555 560
 25 Thr Thr Tyr Asp Val Ser Lys Pro Thr Gln Ile Val Leu Thr Val Ala
 565 570 575
 Lys Lys Val Thr Ser Val Ala Met Pro Ser Tyr Ile Gly Ser Ser Leu
 580 585 590
 30 Glu Phe Thr Lys Asn Asn Leu Ile Gln Ile Val Gly Ile Lys Glu Ala
 595 600 605
 35 Asn Ile Glu Val Val Glu Val Thr Thr Ala Pro Ala Gly Ser Ala Glu
 610 615 620
 Gly Met Val Val Glu Gln Ser Pro Arg Ala Gly Glu Lys Val Asp Leu
 625 630 635 640
 40 Asn Lys Thr Arg Val Lys Ile Ser Ile Tyr Lys Pro Lys Thr Thr Ser
 645 650 655
 45 Ala Thr Pro
 <210> 216
 <211> 391
 50 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 216
 Met Lys His Phe Asp Thr Ile Val Ile Gly Gly Gly Pro Ala Gly Met
 55 1 5 10 15
 Met Ala Thr Ile Ser Ser Asn Phe Tyr Gly Gln Lys Thr Leu Leu Ile

	20	25	30
	Glu Lys Asn Arg Lys Leu Gly Lys Lys Leu Ala Gly Thr Gly Gly Gly		
	35	40	45
5	Arg Cys Asn Val Thr Asn Asn Gly Ser Leu Asp Asn Leu Leu Ala Gly		
	50	55	60
	Ile Pro Gly Asn Gly Arg Phe Leu Tyr Ser Val Phe Ser Gln Phe Asp		
10	65	70	75 80
	Asn His Asp Ile Ile Asn Phe Phe Thr Glu Asn Gly Val Lys Leu Lys		
	85	90	95
15	Val Glu Asp His Gly Arg Val Phe Pro Ala Ser Asp Lys Ser Arg Thr		
	100	105	110
	Ile Ile Glu Ala Leu Glu Lys Lys Ile Thr Glu Leu Gly Gly Gln Val		
	115	120	125
20	Ala Thr Gln Ile Glu Ile Val Ser Val Lys Lys Val Asp Asp Gln Phe		
	130	135	140
	Val Leu Lys Ser Ala Asp Gln Thr Phe Thr Cys Glu Lys Leu Ile Val		
25	145	150	155 160
	Thr Thr Gly Gly Lys Ser Tyr Pro Ser Thr Gly Ser Thr Gly Phe Gly		
	165	170	175
30	His Glu Ile Ala Arg His Phe Lys His Thr Ile Thr Asp Leu Glu Ala		
	180	185	190
	Ala Glu Ser Pro Leu Leu Thr Asp Phe Pro His Lys Ala Leu Gln Gly		
	195	200	205
35	Ile Ser Leu Asp Asp Val Thr Leu Ser Tyr Gly Lys His Val Ile Thr		
	210	215	220
	His Asp Leu Leu Phe Thr His Phe Gly Leu Ser Gly Pro Ala Ala Leu		
40	225	230	235 240
	Arg Met Ser Ser Phe Val Lys Gly Gly Glu Val Leu Ser Leu Asp Val		
	245	250	255
45	Leu Pro Gln Leu Ser Glu Lys Asp Leu Val Thr Phe Leu Glu Glu Asn		
	260	265	270
	Arg Glu Lys Ser Leu Lys Asn Ala Leu Lys Thr Leu Leu Pro Glu Arg		
	275	280	285
50	Leu Ala Glu Phe Phe Val Gln Gly Tyr Pro Glu Lys Val Lys Gln Leu		
	290	295	300
	Thr Glu Lys Glu Arg Glu Gln Leu Val Gln Ser Ile Lys Glu Leu Lys		
55	305	310	315 320
	Ile Pro Val Thr Gly Lys Met Ser Leu Ala Lys Ser Phe Val Thr Lys		

174

Ala Tyr Val Glu His Val Leu Pro Glu Lys Met Arg Tyr Asn Leu Ala
 195 200 205

5 Tyr Leu Arg Glu Phe Ser Phe Phe Gly Asp Ile Lys Ile Met Phe Gln
 210 215 220

Thr Val Phe Glu Val Leu Lys
 225 230

10 <210> 218
 <211> 140
 <212> PRT
 <213> Streptococcus pneumoniae

15 <400> 218
 Met Thr Ser Pro Leu Leu Glu Ser Arg Arg Gln Leu Arg Lys Cys Ala
 1 5 10 15

20 Phe Gln Ala Leu Met Ser Leu Glu Phe Gly Thr Asp Val Glu Thr Ala
 20 25 30

Cys Arg Phe Ala Tyr Thr His Asp Arg Glu Tyr Thr Asp Val Gln Leu
 35 40 45

25 Pro Ala Phe Leu Ile Asp Leu Val Ser Gly Val Gln Ala Lys Lys Glu
 50 55 60

30 Glu Leu Asp Lys Gln Ile Thr Gln His Leu Lys Ala Gly Trp Thr Ile
 65 70 75 80

Glu Arg Leu Thr Leu Val Glu Arg Asn Leu Leu Arg Leu Gly Val Phe
 85 90 95

35 Glu Ile Thr Ser Phe Asp Thr Pro Gln Leu Val Ala Val Asn Glu Ala
 100 105 110

Ile Glu Leu Ala Lys Asp Phe Ser Asp Gln Lys Ser Ala Arg Phe Ile
 115 120 125

40 Asn Gly Leu Leu Ser Gln Phe Val Thr Glu Glu Gln
 130 135 140

45 <210> 219
 <211> 1179
 <212> PRT
 <213> Streptococcus pneumoniae

50 <400> 219
 Met Tyr Leu Lys Glu Ile Glu Ile Gln Gly Phe Lys Ser Phe Ala Asp
 1 5 10 15

55 Lys Thr Lys Val Val Phe Asp Gln Gly Val Thr Ala Val Val Gly Pro
 20 25 30

Asn Gly Ser Gly Lys Ser Asn Ile Thr Glu Ser Leu Arg Trp Ala Leu

	35	40	45
	Gly Glu Ser Ser Val Lys Ser Leu Arg Gly Gly Lys Met Pro Asp Val		
	50	55	60
5	Ile Phe Ala Gly Thr Glu Ser Arg Lys Pro Leu Asn Tyr Ala Ser Val		
	65	70	75 80
10	Val Val Thr Leu Asp Asn His Asp Gly Phe Ile Lys Asp Ala Gly Gln		
	85	90	95
	Glu Ile Arg Val Glu Arg His Ile Tyr Arg Ser Gly Asp Ser Glu Tyr		
	100	105	110
15	Lys Ile Asp Gly Lys Lys Val Arg Leu Arg Asp Ile His Asp Leu Phe		
	115	120	125
20	Leu Asp Thr Gly Leu Gly Arg Asp Ser Phe Ser Ile Ile Ser Gln Gly		
	130	135	140
	Lys Val Glu Glu Ile Phe Asn Ser Lys Pro Glu Glu Arg Arg Ala Ile		
	145	150	155 160
25	Phe Glu Glu Ala Ala Gly Val Leu Lys Tyr Lys Thr Arg Arg Lys Glu		
	165	170	175
	Thr Glu Ser Lys Leu Gln Gln Thr Gln Asp Asn Leu Asp Arg Leu Glu		
	180	185	190
30	Asp Ile Ile Tyr Glu Leu Asp Asn Gln Ile Lys Pro Leu Glu Lys Gln		
	195	200	205
	Ala Glu Asn Ala Arg Lys Phe Leu Asp Leu Glu Gly Gln Arg Lys Ala		
	210	215	220
35	Ile Tyr Leu Asp Val Leu Val Ala Gln Ile Lys Glu Asn Lys Ala Glu		
	225	230	235 240
40	Leu Glu Ser Thr Glu Glu Glu Leu Ala Gln Val Gln Glu Leu Leu Met		
	245	250	255
	Ser Tyr Tyr Gln Lys Arg Glu Lys Leu Glu Glu Glu Asn Gln Thr Leu		
	260	265	270
45	Lys Lys Gln Arg Gln Asp Leu Gln Ala Glu Met Ala Lys Asp Gln Gly		
	275	280	285
	Ser Leu Met Asp Leu Thr Ser Leu Ile Ser Asp Leu Glu Arg Lys Leu		
	290	295	300
50	Ala Leu Ser Lys Leu Glu Ser Glu Gln Val Ala Leu Asn Gln Gln Glu		
	305	310	315 320
55	Ala Gln Ala Arg Leu Ala Ala Leu Glu Asp Lys Arg Asn Ser Leu Ser		
	325	330	335
	Lys Glu Lys Tyr Asp Lys Glu Ser Ser Leu Ala Leu Leu Glu Gly Asn		

	340	345	350
	Leu Val Gln Asn Asn Gln Lys	Leu Asn Arg Leu Glu Ala Glu Leu Leu	
	355	360	365
5	Ala Phe Ser Asp Asp Pro Asp Gln Met Ile Glu Leu Leu Arg Glu Arg		
	370	375	380
10	Phe Val Ala Leu Leu Gln Glu Glu Ala Asp Val Ser Asn Gln Leu Thr		
	385	390	395
	Arg Ile Glu Asn Glu Leu Glu Asn Ser Arg Gln Leu Ser Gln Lys Gln		
	405	410	415
15	Ala Asp Gln Leu Glu Lys Leu Lys Glu Gln Leu Ala Thr Ala Lys Glu		
	420	425	430
	Lys Ala Ser Gln Gln Lys Asp Glu Leu Glu Thr Ala Lys Val Gln Val		
	435	440	445
20	Gln Lys Leu Leu Ala Asp Tyr Gln Ala Ile Ala Lys Glu Gln Glu Glu		
	450	455	460
	Gln Lys Thr Ser Tyr Gln Ala Gln Gln Ser Gln Leu Phe Asp Arg Leu		
	465	470	475
25	Asp Ser Leu Lys Asn Lys Gln Ala Arg Ala Gln Ser Leu Glu Asn Ile		
	485	490	495
	Leu Arg Asn His Ser Asn Phe Tyr Ala Gly Val Lys Ser Val Leu Gln		
	500	505	510
	Glu Lys Asp Arg Leu Gly Gly Ile Ile Gly Ala Val Ser Glu His Leu		
	515	520	525
35	Thr Phe Asp Val Tyr Tyr Gln Thr Ala Leu Glu Ile Ala Leu Gly Ala		
	530	535	540
	Ser Ser Gln His Ile Ile Val Glu Asp Glu Glu Ser Ala Thr Lys Ala		
	545	550	555
40	Ile Asp Phe Leu Lys Arg Asn Arg Val Gly Arg Ala Thr Phe Leu Pro		
	565	570	575
	Leu Thr Thr Ile Lys Ala Arg Thr Ile Ser Ser Gln Asn Gln Asp Ala		
	580	585	590
	Ile Ala Val Ser Pro Gly Phe Leu Gly Met Ala Asp Glu Leu Val Thr		
	595	600	605
50	Phe Asp Thr Arg Leu Glu Ala Ile Phe Lys Asn Leu Leu Ala Thr Thr		
	610	615	620
	Ala Ile Phe Asp Thr Val Glu His Ala Arg Glu Ala Ala Arg Gln Val		
	625	630	635
55	Arg Tyr Gln Val Arg Met Val Thr Leu Asp Gly Thr Glu Leu Arg Thr		
			640

	645	650	655
	Gly Gly Ser Tyr Ala Gly Gly Ala Asn Arg Gln Asn Asn Ser Ile Phe		
	660	665	670
5	Ile Lys Pro Glu Leu Glu Gln Leu Gln Lys Glu Ile Ala Ala Asp Glu		
	675	680	685
10	Ala Ser Leu Gly Ser Glu Glu Ala Ala Leu Lys Thr Leu Gln Asp Gln		
	690	695	700
	Met Ala Ala Leu Thr Glu Arg Leu Glu Ala Ile Lys Ser Gln Gly Glu		
	705	710	715
15	Gln Ala Arg Ile Gln Glu Gln Gly Leu Ser Leu Ala Tyr Gln Gln Thr		
	725	730	735
	Ser Gln Gln Val Glu Glu Leu Glu Thr Leu Trp Lys Leu Gln Glu Glu		
	740	745	750
20	Glu Ile Asp Arg Leu Ser Glu Gly Asp Trp Gln Ala Asp Lys Glu Lys		
	755	760	765
25	Cys Gln Glu Ser Leu Ala Thr Ile Ala Ser Asp Lys Gln Asn Leu Glu		
	770	775	780
	Ala Glu Ile Glu Glu Ile Lys Ser Asn Lys Asn Ala Ile Gln Glu Arg		
	785	790	795
30	Tyr Gln Asn Leu Gln Glu Glu Val Ala Gln Ala Arg Leu Leu Lys Thr		
	805	810	815
	Lys Leu Gln Gly Gln Lys Arg Tyr Glu Val Ala Asp Ile Glu Arg Leu		
	820	825	830
35	Gly Lys Glu Leu Asp Asn Leu Asn Ile Glu Gln Glu Glu Ile Gln Arg		
	835	840	845
40	Met Leu Gln Glu Lys Val Asp Asn Leu Glu Lys Val Asp Thr Glu Leu		
	850	855	860
	Leu Ser Gln Gln Ala Glu Glu Ser Lys Thr Gln Lys Thr Asn Leu Gln		
	865	870	875
45	Gln Gly Leu Ile Arg Lys Gln Phe Glu Leu Asp Asp Ile Glu Gly Gln		
	885	890	895
	Leu Asp Asp Ile Ala Ser His Leu Asp Gln Ala Arg Gln Gln Asn Glu		
	900	905	910
50	Glu Trp Ile Arg Lys Gln Thr Arg Ala Glu Ala Lys Lys Glu Lys Val		
	915	920	925
55	Ser Glu Arg Leu Arg His Leu Gln Asn Gln Leu Thr Asp Gln Tyr Gln		
	930	935	940
	Ile Ser Tyr Thr Glu Ala Leu Glu Lys Ala His Glu Leu Glu Asn Leu		

945 950 955 960
 Asn Leu Ala Glu Gln Glu Val Gln Asp Leu Glu Lys Ala Ile Arg Ser
 965 970 975
 5 Leu Gly Pro Val Asn Leu Glu Ala Ile Asp Gln Tyr Glu Glu Val His
 980 985 990
 10 Asn Arg Leu Asp Phe Leu Asn Ser Gln Arg Asp Asp Ile Leu Ser Ala
 995 1000 1005
 Lys Asn Leu Leu Leu Glu Thr Ile Thr Glu Met Asn Asp Glu Val Lys
 1010 1015 1020
 15 Glu Arg Phe Lys Ser Thr Phe Glu Ala Ile Arg Glu Ser Phe Lys Val
 1025 1030 1035 1040
 Thr Phe Lys Gln Met Phe Gly Gly Gly Gln Ala Asp Leu Ile Leu Thr
 1045 1050 1055
 20 Glu Gly Asp Leu Leu Thr Ala Gly Val Glu Ile Ser Val Gln Pro Pro
 1060 1065 1070
 25 Gly Lys Lys Ile Gln Ser Leu Asn Leu Met Ser Gly Gly Glu Lys Ala
 1075 1080 1085
 Leu Ser Ala Leu Ala Leu Leu Phe Ser Ile Ile Arg Val Lys Thr Ile
 1090 1095 1100
 30 Pro Phe Val Ile Leu Asp Glu Val Glu Ala Ala Leu Asp Glu Ala Asn
 1105 1110 1115 1120
 Val Lys Arg Phe Gly Asp Tyr Leu Asn Arg Phe Asp Lys Asp Ser Gln
 1125 1130 1135
 35 Phe Ile Val Val Thr His Arg Lys Gly Thr Met Ala Ala Ala Asp Ser
 1140 1145 1150
 40 Ile Tyr Gly Val Thr Met Gln Glu Ser Gly Val Ser Lys Ile Val Ser
 1155 1160 1165
 Val Lys Leu Lys Asp Leu Glu Ser Ile Glu Gly
 1170 1175
 45 <210> 220
 <211> 447
 <212> PRT
 <213> Streptococcus pneumoniae
 50 <400> 220
 Met Thr Lys Arg Val Thr Ile Ile Asp Val Lys Asp Tyr Val Gly Gln
 1 5 10 15
 55 Glu Val Thr Ile Gly Ala Trp Val Ala Asn Lys Ser Gly Lys Gly Lys
 20 25 30

Ile Ala Phe Leu Gln Leu Arg Asp Gly Thr Ala Phe Phe Gln Gly Val
 35 40 45
 5 Ala Phe Lys Pro Asn Phe Val Glu Lys Phe Gly Glu Glu Val Gly Leu
 50 55 60
 Glu Lys Phe Asp Val Ile Lys Arg Leu Ser Gln Glu Thr Ser Val Tyr
 65 70 75 80
 10 Val Thr Gly Ile Val Lys Glu Asp Glu Arg Ser Lys Phe Gly Tyr Glu
 85 90 95
 Leu Asp Ile Thr Asp Ile Glu Val Ile Gly Glu Ser Gln Asp Tyr Pro
 100 105 110
 15 Ile Thr Pro Lys Glu His Gly Thr Asp Phe Leu Met Asp Asn Arg His
 115 120 125
 Leu Trp Leu Arg Ser Arg Lys Gln Val Ala Val Leu Gln Ile Arg Asn
 130 135 140
 Ala Ile Ile Tyr Ala Thr Tyr Glu Phe Phe Asp Lys Asn Gly Phe Met
 145 150 155 160
 25 Lys Phe Asp Ser Pro Ile Leu Ser Gly Asn Ala Ala Glu Asp Ser Thr
 165 170 175
 Glu Leu Phe Glu Thr Asp Tyr Phe Gly Thr Pro Ala Tyr Leu Ser Gln
 180 185 190
 30 Ser Gly Gln Leu Tyr Leu Glu Ala Gly Ala Met Ala Leu Gly Arg Val
 195 200 205
 Phe Asp Phe Gly Pro Val Phe Arg Ala Glu Lys Ser Lys Thr Arg Arg
 210 215 220
 His Leu Thr Glu Phe Trp Met Met Asp Ala Glu Tyr Ser Tyr Leu Thr
 225 230 235 240
 40 His Asp Glu Ser Leu Asp Leu Gln Glu Ala Tyr Val Lys Ala Leu Leu
 245 250 255
 Gln Gly Val Leu Asp Arg Ala Pro Gln Ala Leu Glu Thr Leu Glu Arg
 260 265 270
 45 Asp Thr Glu Leu Leu Lys Arg Tyr Ile Ala Glu Pro Phe Lys Arg Ile
 275 280 285
 Thr Tyr Asp Gln Ala Ile Asp Leu Leu Gln Glu His Glu Asn Asp Glu
 290 295 300
 Asp Ala Asp Tyr Glu His Leu Glu His Gly Asp Asp Phe Gly Ser Pro
 305 310 315 320
 55 His Glu Thr Trp Ile Ser Asn His Phe Gly Val Pro Thr Phe Val Met
 325 330 335

Asn Tyr Pro Ala Ala Ile Lys Ala Phe Tyr Met Lys Pro Val Pro Gly
 340 345 350
 5 Asn Pro Glu Arg Val Leu Cys Ala Asp Leu Leu Ala Pro Glu Gly Tyr
 355 360 365
 Gly Glu Ile Ile Gly Gly Ser Met Arg Glu Glu Asp Tyr Asp Ala Leu
 370 375 380
 10 Val Ala Lys Met Asp Glu Leu Gly Met Asp Arg Thr Glu Tyr Glu Phe
 385 390 395 400
 Tyr Leu Asp Leu Arg Lys Tyr Gly Thr Val Pro His Gly Gly Phe Gly
 405 410 415
 15 Ile Gly Ile Glu Arg Met Val Thr Phe Ala Ala Gly Thr Lys His Ile
 420 425 430
 20 Arg Glu Ala Ile Pro Phe Pro Arg Met Leu His Arg Ile Lys Pro
 435 440 445
 <210> 221
 <211> 308
 25 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 221
 30 Met Ser Glu Lys Leu Val Glu Ile Lys Asp Leu Glu Ile Ser Phe Gly
 1 5 10 15
 Glu Gly Ser Lys Lys Phe Val Ala Val Lys Asn Ala Asn Phe Phe Ile
 20 25 30
 35 Asn Lys Gly Glu Thr Phe Ser Leu Val Gly Glu Ser Gly Ser Gly Lys
 35 40 45
 Thr Thr Ile Gly Arg Ala Ile Ile Gly Leu Asn Asp Thr Ser Asn Gly
 50 55 60
 40 Asp Ile Ile Phe Asp Gly Gln Lys Ile Asn Gly Lys Lys Ser Arg Glu
 65 70 75 80
 Gln Ala Ala Glu Leu Ile Arg Arg Ile Gln Met Ile Phe Gln Asp Pro
 85 90 95
 45 Ala Ala Ser Leu Asn Glu Arg Ala Thr Val Asp Tyr Ile Ile Ser Glu
 100 105 110
 50 Gly Leu Tyr Asn His Arg Leu Phe Lys Asp Glu Glu Glu Arg Lys Glu
 115 120 125
 Lys Val Gln Asn Ile Ile Arg Glu Val Gly Leu Leu Ala Glu His Leu
 130 135 140
 55 Thr Arg Tyr Pro His Glu Phe Ser Gly Gly Gln Arg Gln Arg Ile Gly
 145 150 155 160

Ile Ala Arg Ala Leu Val Met Gln Pro Asp Phe Val Ile Ala Asp Glu
 165 170 175
 5 Pro Ile Ser Ala Leu Asp Val Ser Val Arg Ala Gln Val Leu Asn Leu
 180 185 190
 Leu Lys Lys Phe Gln Lys Glu Leu Gly Leu Thr Tyr Leu Phe Ile Ala
 195 200 205
 10 His Asp Leu Ser Val Val Arg Phe Ile Ser Asp Arg Ile Ala Val Ile
 210 215 220
 Tyr Lys Gly Val Ile Val Glu Val Ala Glu Thr Glu Glu Leu Phe Asn
 15 225 230 235 240
 Asn Pro Ile His Pro Tyr Thr Gln Ala Leu Leu Ser Ala Val Pro Ile
 245 250 255
 20 Pro Asp Pro Ile Leu Glu Arg Lys Lys Val Leu Lys Val Tyr Asp Pro
 260 265 270
 Ser Gln His Asp Tyr Glu Thr Asp Lys Pro Ser Met Val Glu Ile Arg
 275 280 285
 25 Pro Gly His Tyr Val Trp Ala Asn Gln Thr Glu Leu Ala Arg Tyr Gln
 290 295 300
 Lys Gly Leu Asn
 30 305
 <210> 222
 <211> 424
 35 <212> PRT
 <213> Streptococcus pneumoniae
 <400> 222
 Met Lys Ile Ser Trp Asn Gly Phe Ser Lys Lys Ser Tyr Gln Glu Arg
 40 1 5 10 15
 Leu Glu Leu Leu Lys Ala Gln Ala Leu Leu Ser Pro Glu Arg Gln Ala
 20 25 30
 45 Ser Leu Glu Lys Asp Glu Gln Met Ser Val Thr Val Ala Asp Gln Leu
 35 40 45
 Ser Glu Asn Val Val Gly Thr Phe Ser Leu Pro Tyr Ser Leu Val Pro
 50 55 60
 50 Glu Val Leu Val Asn Gly Gln Glu Tyr Thr Val Pro Tyr Val Thr Glu
 65 70 75 80
 Glu Pro Ser Val Val Ala Ala Ala Ser Tyr Ala Ser Lys Ile Ile Lys
 55 85 90 95
 Arg Ala Gly Gly Phe Thr Ala Gln Val His Gln Arg Gln Met Ile Gly

	100	105	110
	Gln Val Ala Leu Tyr Gln Ile Ala Asn Pro Lys Leu Ala Gln Glu Lys		
	115	120	125
5	Ile Ala Ser Lys Lys Ala Glu Leu Leu Glu Leu Ala Asn Gln Ala Tyr		
	130	135	140
10	Pro Ser Ile Val Lys Arg Gly Gly Gly Ala Arg Asp Leu His Val Glu		
	145	150	155
	Gln Ile Lys Gly Glu Pro Asp Phe Leu Val Val Tyr Ile His Val Asp		
	165	170	175
15	Thr Gln Glu Ala Met Gly Ala Asn Met Leu Asn Thr Met Leu Glu Ala		
	180	185	190
	Leu Lys Pro Val Leu Glu Glu Leu Ser Gln Gly Gln Ser Leu Met Gly		
20	195	200	205
	Ile Leu Ser Asn Tyr Ala Thr Asp Ser Leu Val Thr Ala Ser Cys Arg		
	210	215	220
25	Ile Ala Phe Arg Tyr Leu Ser Arg Gln Lys Asp Gln Gly Arg Glu Ile		
	225	230	235
	Ala Glu Lys Ile Ala Leu Ala Ser Gln Phe Ala Gln Ala Asp Pro Tyr		
	245	250	255
30	Arg Ala Ala Thr His Asn Lys Gly Ile Phe Asn Gly Ile Asp Ala Ile		
	260	265	270
	Leu Ile Ala Thr Gly Asn Asp Trp Arg Ala Ile Glu Ala Gly Ala His		
35	275	280	285
	Ala Phe Ala Ser Arg Asp Gly Arg Tyr Gln Gly Leu Ser Cys Trp Thr		
	290	295	300
40	Leu Asp Leu Glu Arg Glu Glu Leu Val Gly Glu Met Thr Leu Pro Met		
	305	310	315
	Pro Val Ala Thr Lys Gly Gly Ser Ile Gly Leu Asn Pro Arg Val Ala		
	325	330	335
45	Leu Ser His Asp Leu Leu Gly Asn Pro Ser Ala Arg Glu Leu Ala Gln		
	340	345	350
	Ile Ile Val Ser Ile Gly Leu Ala Gln Asn Phe Ala Ala Leu Lys Ala		
50	355	360	365
	Leu Val Ser Thr Gly Ile Gln Gln Gly His Met Lys Leu Gln Ala Lys		
	370	375	380
55	Ser Leu Ala Leu Leu Ala Gly Ala Ser Glu Ser Glu Val Ala Pro Leu		
	385	390	395
			400
	Val Glu Arg Leu Ile Ser Asp Lys Thr Phe Asn Leu Glu Thr Ala Gln		

405 410 415
 Arg Tyr Leu Glu Asn Leu Arg Ser
 420
 5
 <210> 223
 <211> 262
 <212> PRT
 10 <213> Streptococcus pneumoniae
 <400> 223
 Met Pro Ile Thr Ser Leu Glu Ile Lys Asp Lys Thr Phe Gly Thr Arg
 1 5 10 15
 15 Phe Arg Gly Phe Asp Pro Glu Glu Val Asp Glu Phe Leu Asp Ile Val
 20 25 30
 Val Arg Asp Tyr Glu Asp Leu Val Arg Ala Asn His Asp Lys Asn Leu
 20 35 40 45
 Arg Ile Lys Ser Leu Glu Glu Arg Leu Ser Tyr Phe Asp Glu Ile Lys
 50 55 60
 25 Asp Ser Leu Ser Gln Ser Val Leu Ile Ala Gln Asp Thr Ala Glu Arg
 65 70 75 80
 Val Lys Gln Ala Ala His Glu Arg Ser Asn Asn Ile Ile His Gln Ala
 85 90 95
 30 Glu Gln Asp Ala Gln Arg Leu Leu Glu Glu Ala Lys Tyr Lys Ala Asn
 100 105 110
 Glu Ile Leu Arg Gln Ala Thr Asp Asn Ala Lys Lys Val Ala Val Glu
 115 120 125
 35 Thr Glu Glu Leu Lys Asn Lys Ser Arg Val Phe His Gln Arg Leu Lys
 130 135 140
 40 Ser Thr Ile Glu Ser Gln Leu Ala Ile Val Glu Ser Ser Asp Trp Glu
 145 150 155 160
 Asp Ile Leu Arg Pro Thr Ala Thr Tyr Leu Gln Thr Ser Asp Glu Ala
 165 170 175
 45 Phe Lys Glu Val Val Ser Glu Val Leu Gly Glu Pro Ile Pro Ala Pro
 180 185 190
 50 Ile Glu Glu Glu Pro Ile Asp Met Thr Arg Gln Phe Ser Gln Ala Glu
 195 200 205
 Met Ala Glu Leu Gln Ala Arg Ile Glu Val Ala Asp Lys Glu Leu Ser
 210 215 220
 55 Glu Phe Glu Ala Gln Ile Lys Gln Glu Val Glu Ala Pro Thr Pro Val
 225 230 235 240

Val Ser Pro Gln Val Glu Glu Glu Pro Leu Leu Ile Gln Leu Ala Gln
245 250 255

5 Cys Met Lys Asn Gln Lys
260

10 <210> 224
<211> 575
<212> PRT
<213> Streptococcus pneumoniae

15 <400> 224
Met Ser Asn Gly Gln Leu Ile Tyr Leu Met Val Ala Ile Ala Val Ile
1 5 10 15

Leu Val Leu Ala Tyr Val Val Ala Ile Phe Leu Arg Lys Arg Asn Glu
20 25 30

20 Gly Arg Leu Glu Ala Leu Glu Glu Arg Lys Glu Glu Leu Tyr Asn Leu
35 40 45

Pro Val Asn Asp Glu Val Glu Ala Val Lys Asn Met His Leu Ile Gly
50 55 60

25 Gln Ser Gln Val Ala Phe Arg Glu Trp Asn Gln Lys Trp Val Asp Leu
65 70 75 80

30 Ser Leu Asn Ser Phe Ala Asp Ile Glu Asn Asn Leu Phe Glu Ala Glu
85 90 95

Gly Tyr Asn His Ser Phe Arg Phe Leu Lys Ala Ser His Gln Ile Asp
100 105 110

35 Gln Ile Glu Ser Gln Ile Thr Leu Ile Glu Glu Asp Ile Ala Ala Ile
115 120 125

Arg Asn Ala Leu Ala Asp Leu Glu Lys Gln Glu Ser Lys Asn Ser Gly
130 135 140

40 Arg Val Leu His Ala Leu Asp Leu Phe Glu Glu Leu Gln His Arg Val
145 150 155 160

45 Ala Glu Asn Ser Glu Gln Tyr Gly Gln Ala Leu Asp Glu Ile Glu Lys
165 170 175

Gln Leu Glu Asn Ile Gln Ser Glu Phe Ser Gln Phe Val Thr Leu Asn
180 185 190

50 Ser Ser Gly Asp Pro Val Glu Ala Ala Val Ile Leu Asp Asn Thr Glu
195 200 205

Asn His Ile Leu Ala Leu Ser His Ile Val Asp Arg Val Pro Ala Leu
210 215 220

55 Val Thr Thr Leu Ser Thr Glu Leu Pro Asp Gln Leu Gln Asp Leu Glu
225 230 235 240

Ala Gly Tyr Arg Lys Leu Ile Asp Ala Asn Tyr His Phe Val Glu Thr
 245 250 255
 5 Asp Ile Glu Ala Arg Phe His Leu Leu Tyr Glu Ala Phe Lys Lys Asn
 260 265 270
 Gln Glu Asn Ile Arg Gln Leu Glu Leu Asp Asn Ala Glu Tyr Glu Asn
 275 280 285
 10 Gly Gln Ala Gln Glu Glu Ile Asn Ala Leu Tyr Asp Ile Phe Thr Arg
 290 295 300
 Glu Ile Ala Ala Gln Lys Val Val Glu Asn Leu Leu Ala Thr Leu Pro
 15 305 310 315 320
 Thr Tyr Leu Gln His Met Lys Glu Asn Asn Thr Leu Leu Gly Glu Asp
 325 330 335
 20 Ile Ala Arg Leu Asn Lys Thr Tyr Leu Leu Pro Glu Thr Ala Ala Ser
 340 345 350
 His Val Arg Arg Ile Gln Thr Glu Leu Glu Ser Phe Glu Ala Ala Ile
 355 360 365
 25 Val Glu Val Thr Ser Asn Gln Glu Glu Pro Thr Gln Ala Tyr Ser Val
 370 375 380
 Leu Glu Glu Asn Leu Glu Asp Leu Gln Thr Gln Leu Lys Asp Ile Glu
 30 385 390 395 400
 Asp Glu Gln Ile Ser Val Ser Glu Arg Leu Thr Gln Ile Glu Lys Asp
 405 410 415
 35 Asp Ile Asn Ala Arg Gln Lys Ala Asn Val Tyr Val Asn Arg Leu His
 420 425 430
 Thr Ile Lys Arg Tyr Met Glu Lys Arg Asn Leu Pro Gly Ile Pro Gln
 435 440 445
 40 Thr Phe Leu Lys Leu Phe Phe Thr Ala Ser Asn Asn Thr Glu Asp Leu
 450 455 460
 Met Val Glu Leu Glu Gln Lys Met Ile Asn Ile Glu Ser Val Thr Arg
 45 465 470 475 480
 Val Leu Glu Ile Ala Thr Asn Asp Met Glu Ala Leu Glu Thr Glu Thr
 485 490 495
 50 Tyr Asn Ile Val Gln Tyr Ala Thr Leu Thr Glu Gln Leu Leu Gln Tyr
 500 505 510
 Ser Asn Arg Tyr Arg Ser Phe Asp Glu Arg Ile Gln Glu Ala Phe Asn
 515 520 525
 55 Glu Ala Leu Asp Ile Phe Glu Lys Glu Phe Asp Tyr His Ala Ser Phe
 530 535 540

Asp Lys Ile Ser Gln Ala Leu Glu Val Ala Glu Pro Gly Val Thr Asn
 545 550 555 560

5 Arg Phe Val Thr Ser Tyr Glu Lys Thr Arg Glu Thr Ile Arg Phe
 565 570 575

10 <210> 225
 <211> 800
 <212> PRT
 <213> Streptococcus pneumoniae

15 <400> 225
 Met Leu Ile Ser Tyr Lys Trp Leu Lys Glu Leu Val Asp Ile Asp Val
 1 5 10 15

20 Pro Ser Gln Glu Leu Ala Glu Lys Met Ser Thr Thr Gly Ile Glu Val
 20 25 30

25 Glu Gly Val Glu Ser Pro Ala Ala Gly Leu Ser Lys Ile Val Val Gly
 35 40 45

30 Glu Val Leu Ser Cys Glu Asp Val Pro Glu Thr His Leu His Val Cys
 50 55 60

35 Gln Val Asn Val Gly Glu Glu Glu Arg Gln Ile Val Cys Gly Ala Pro
 65 70 75 80

40 Asn Val Arg Ala Gly Ile Lys Val Met Val Ala Leu Pro Gly Ala Arg
 85 90 95

45 Ile Ala Asp Asn Tyr Lys Ile Lys Lys Gly Lys Ile Arg Gly Leu Glu
 100 105 110

50 Ser Leu Gly Met Ile Cys Ser Leu Gly Glu Leu Gly Ile Ser Asp Ser
 115 120 125

55 Val Val Pro Lys Glu Phe Ala Asp Gly Ile Gln Ile Leu Pro Glu Asp
 130 135 140

60 Ala Val Pro Gly Glu Glu Val Phe Ser Tyr Leu Asp Leu Asp Asp Glu
 145 150 155 160

65 Ile Ile Glu Leu Ser Ile Thr Pro Asn Arg Ala Asp Ala Leu Ser Met
 165 170 175

70 Cys Gly Val Ala His Glu Val Ala Ala Ile Tyr Asp Lys Ala Val Asn
 180 185 190

75 Phe Lys Glu Phe Thr Leu Thr Glu Thr Asn Glu Ala Ala Ala Asp Ala
 195 200 205

80 Leu Ser Val Ser Ile Glu Thr Asp Lys Ala Pro Tyr Tyr Ala Ala Arg
 210 215 220

85 Ile Leu Asp Asn Val Thr Ile Ala Pro Ser Pro Gln Trp Leu Gln Asn

188

530 535 540
 Asp Arg Ser Val Leu Arg Gln Asn Met Ile Ser Gly Ile Leu Asp Thr
 545 550 555 560
 5 Val Ala Tyr Asn Val Ala Arg Lys Asn Lys Asn Leu Ala Leu Tyr Glu
 565 570 575
 10 Ile Gly Lys Val Phe Glu Gln Thr Gly Asn Pro Lys Glu Glu Leu Pro
 580 585 590
 Asn Glu Ile Asn Ser Phe Ala Phe Ala Leu Thr Gly Leu Val Ala Glu
 595 600 605
 15 Lys Asp Phe Gln Thr Ala Ala Val Pro Val Asp Phe Phe Tyr Ala Lys
 610 615 620
 Gly Ile Leu Glu Ala Leu Phe Thr Arg Leu Gly Leu Gln Val Thr Tyr
 20 625 630 635 640
 Thr Ala Thr Ser Glu Ile Ala Ser Leu His Pro Gly Arg Thr Ala Val
 645 650 655
 25 Ile Ser Leu Gly Asp Gln Val Leu Gly Phe Leu Gly Gln Val His Pro
 660 665 670
 Val Thr Ala Lys Ala Tyr Asp Ile Pro Glu Thr Tyr Val Ala Glu Leu
 675 680 685
 30 Asn Leu Ser Ala Ile Glu Ala Ala Leu Gln Pro Ala Thr Pro Phe Val
 690 695 700
 Glu Ile Thr Lys Phe Pro Ala Val Ser Arg Asp Val Ala Leu Leu Leu
 35 705 710 715 720
 Lys Ala Glu Val Thr His Gln Glu Val Val Asp Ala Ile Gln Ala Ala
 725 730 735
 40 Gly Val Lys Arg Leu Thr Asp Ile Lys Leu Phe Asp Val Phe Ser Gly
 740 745 750
 Glu Lys Leu Gly Leu Gly Met Lys Ser Met Ala Tyr Ser Leu Thr Phe
 755 760 765
 45 Gln Asn Pro Glu Asp Ser Leu Thr Asp Glu Glu Val Ala Arg Tyr Met
 770 775 780
 Glu Lys Ile Gln Ala Ser Leu Glu Glu Lys Val Asn Ala Glu Val Arg
 50 785 790 795 800
 55 <210> 226
 <211> 180
 <212> PRT

<213> Streptococcus pneumoniae

<400> 226

5 Met Leu Glu Asn Asp Ile Lys Lys Val Leu Val Ser His Asp Glu Ile
 1 5 10 15
 Thr Glu Ala Ala Lys Lys Leu Gly Ala Gln Leu Thr Lys Asp Tyr Ala
 20 25 30
 10 Gly Lys Asn Pro Ile Leu Val Gly Ile Leu Lys Gly Ser Ile Pro Phe
 35 40 45
 Met Ala Glu Leu Val Lys His Ile Asp Thr His Ile Glu Met Asp Phe
 50 55 60
 15 Met Met Val Ser Ser Tyr His Gly Gly Thr Ala Ser Ser Gly Val Ile
 65 70 75 80
 20 Asn Ile Lys Gln Asp Val Thr Gln Asp Ile Lys Gly Arg His Val Leu
 85 90 95
 Phe Val Glu Asp Ile Ile Asp Thr Gly Gln Thr Leu Lys Asn Leu Arg
 100 105 110
 25 Asp Met Phe Lys Ala Arg Glu Ala Ala Ser Val Lys Ile Ala Thr Leu
 115 120 125
 Leu Asp Lys Pro Glu Gly Arg Val Val Glu Ile Glu Ala Asp Tyr Thr
 130 135 140
 30 Cys Phe Thr Ile Pro Asn Glu Phe Val Val Gly Tyr Gly Leu Asp Tyr
 145 150 155 160
 35 Lys Glu Asn Tyr Arg Asn Leu Pro Tyr Ile Gly Val Leu Lys Glu Glu
 165 170 175
 Val Tyr Ser Asn
 180

40